OBO_ID (LABEL):	CHEBI_27300 (vitamin D)

ARTICLE	ARTICLE DATE	SENTENCE NUM	SENTENCE	IGNORANCE CATEGORIES	NUM IGNORANCE CATEGORIES	OBO ID (LABEL)
PMC1361787	12/2005	S96-PMC1361787	['with the exception of Vitamin A, all of the deattenuated correlation coefficients for Nutrient intakes were greater than 0.50.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 22, 'vitamin A'), ('PR_000004370', 'asialoglycoprotein receptor 2', 30, 'A'), ('CHEBI_33284', 'nutrient', 86, 'nutrient')]
PMC1361787	12/2005	S100-PMC1361787	['the highest correlation for the hsffq was for calcium (0.47) and the lowest correlation was for Vitamin C (0.08); the correlations for the block ffq were very similar.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 96, 'vitamin C')]
PMC1481554	4/2006	S24-PMC1481554	['moreover, pregvit®contains higher doses of Vitamin C, which is also known to facilitate iron absorption (table1).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 43, 'vitamin C')]
PMC1533075	6/1998	S8-PMC1533075	['the composition of the various multivitamin Compounds taken also varied: the daily dose of Vitamin C ranged from 0 to 600 mg, Vitamin E ranged from 0 to 70 mg, Vitamin A ranged from 0 to 30,000 iu, and Folate ranged from 0 to 2000 micrograms.']	N/A	N/A	[('CHEBI_36357', 'polyatomic entity', 44, 'compounds'), ('CHEBI_27300', 'vitamin D', 91, 'vitamin C'), ('CHEBI_27300', 'vitamin D', 126, 'vitamin E'), ('CHEBI_27300', 'vitamin D', 160, 'vitamin A'), ('CHEBI_30863', '5-azaorotic acid', 202, 'folate')]
PMC1852384	1/2007	S48-PMC1852384	['all routine follow-up appointments included nutritional counseling and those after 2\xa0weeks included laboratory studies [Serum electrolytes, Glucose, hba1c, calcium, albumin, Lipid profile, Liver function tests, complete Blood count, Platelets, Serum Insulin, iron, ferritin, Vitamin B12, 25-Oh Vitamin D, and Thiamine (Vitamin B1)].']	N/A	N/A	[('UBERON_0001977', 'blood serum', 120, 'serum'), ('CHEBI_17234', 'glucose', 140, 'glucose'), ('CHEBI_18059', 'lipid', 174, 'lipid'), ('UBERON_0002107', 'liver', 189, 'liver'), ('UBERON_0000178', 'blood', 220, 'blood'), ('CL_0000233', 'platelet', 233, 'platelets'), ('UBERON_0001977', 'blood serum', 244, 'serum'), ('PR_000045358', 'insulin family protein', 250, 'insulin'), ('CHEBI_33279', 'vitamin D5', 275, 'vitamin B12'), ('PR_000004738', 'class E basic helix-loop-helix protein 22', 283, 'B12'), ('CHEBI_86198', '1,2-di-[(11Z)-eicosenoyl]-sn-glycero-3-phosphocholine', 288, '25-OH'), ('CHEBI_27300', 'vitamin D', 294, 'vitamin D'), ('CHEBI_26948', 'vitamin B1', 309, 'thiamine'), ('PR_000004483', 'V-type proton ATPase subunit C 1', 319, 'vitamin B1')]
PMC1888711	5/2007	S87-PMC1888711	['between iron and calcium, between iron and Vitamin A, and between p falciparum and Micronutrient deficiencies [13,27,28].']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 43, 'vitamin A'), ('CHEBI_33962', 'mu4-sulfido-quadro-tetracopper(6+)', 83, 'micronutrient')]
PMC2151954	10/2007	S193-PMC2151954	['Vitamin D, temperature).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 0, 'vitamin D')]
PMC2290997	4/2008	S6-PMC2290997	['both forms can damage collagen fibers, destroy Vitamin A in skin, accelerate aging of the skin, and increase the risk of skin cancers.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 47, 'vitamin A')]
PMC2290997	4/2008	S19-PMC2290997	['for most white People, a half-hour in the summer sun in a bathing suit can initiate the release of 50,000 iu (1.25 mg) Vitamin D into the circulation within 24 hours of exposure; this same amount of exposure yields 20,000–30,000 iu in tanned Individuals and 8,000–10,000 iu in dark-skinned People.']	N/A	N/A	[('NCBITaxon_10088', 'Mus <genus>', 15, 'people'), ('CHEBI_27300', 'vitamin D', 119, 'vitamin D'), ('NCBITaxon_1', 'root', 242, 'individuals'), ('NCBITaxon_10088', 'Mus <genus>', 290, 'people')]
PMC2290997	4/2008	S20-PMC2290997	['the initial Photosynthesis produces Vitamin D3, most of which undergoes additional transformations, starting with the production of 25-Hydroxyvitamin D (25[Oh]D), the major form of Vitamin D circulating in the Bloodstream and the form that is routinely measured to determine a Person’s Vitamin D status.']	N/A	N/A	[('GO_0006654', 'phosphatidic acid biosynthetic process', 12, 'photosynthesis'), ('CHEBI_33279', 'vitamin D5', 36, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 36, 'vitamin D3'), ('CHEBI_62218', '23,24-dihydrocucurbitacin D', 132, '25-hydroxyvitamin D'), ('CHEBI_15643', '(6R)-6-(L-erythro-1,2-dihydroxypropyl)-7,8-dihydro-6H-pterin', 153, '25[OH]D'), ('CHEBI_27300', 'vitamin D', 181, 'vitamin D'), ('UBERON_0001969', 'blood plasma', 210, 'bloodstream'), ('NCBITaxon_10088', 'Mus <genus>', 277, 'person'), ('CHEBI_27300', 'vitamin D', 286, 'vitamin D')]
PMC2290997	4/2008	S24-PMC2290997	['michael holick, a medical professor and director of the bone health care clinic at boston university medical center, says, “the primary physiologic function of Vitamin D is to maintain Serum calcium and Phosphorous levels within the normal physiologic range to support most Metabolic functions, Neuromuscular transmission, and bone mineralization.”\nwithout sufficient Vitamin D, Bones will not form properly.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 160, 'vitamin D'), ('UBERON_0001977', 'blood serum', 185, 'serum'), ('CHEBI_30207', 'phosphorus(.)', 203, 'phosphorous'), ('GO_0008152', 'metabolic process', 274, 'metabolic'), ('GO_0050905', 'neuromuscular process', 295, 'neuromuscular'), ('UBERON_0001016', 'nervous system', 295, 'neuromuscular'), ('CHEBI_27300', 'vitamin D', 368, 'vitamin D'), ('UBERON_0001474', 'bone element', 379, 'bones')]
PMC2290997	4/2008	S28-PMC2290997	['“low Vitamin D levels will precipitate and exacerbate osteoporosis in both men and women and cause the painful bone disease osteomalacia,” says holick.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 5, 'vitamin D')]
PMC2290997	4/2008	S103-PMC2290997	['additionally, solely Breastfed infants whose mothers were Vitamin D deficient during Pregnancy have smaller reserves of the Nutrient and are at greater risk of developing rickets.']	N/A	N/A	[('GO_0007567', 'parturition', 21, 'breastfed'), ('CHEBI_27300', 'vitamin D', 58, 'vitamin D'), ('GO_0007565', 'female pregnancy', 85, 'pregnancy'), ('CHEBI_33284', 'nutrient', 124, 'nutrient')]
PMC2290997	4/2008	S122-PMC2290997	['“without the sunscreen, this same Individual would be incurring substantially more damage to her skin but not further increasing her Vitamin D level,” she says.']	N/A	N/A	[('NCBITaxon_1', 'root', 34, 'individual'), ('CHEBI_27300', 'vitamin D', 133, 'vitamin D')]
PMC2290997	4/2008	S129-PMC2290997	['“the elderly [have a] declining capacity to make Vitamin D,” she says.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 49, 'vitamin D')]
PMC2290997	4/2008	S184-PMC2290997	['in sunlight-related research, there are two main exposures of interest: Vitamin D status, which is measured by the Serum 25(Oh)D level; and personal uvr dose, which involves three fundamental factors: ambient uvr (a function of latitude, altitude, atmospheric Ozone levels, pollution, and time of year), amount of skin exposed (a function of behavioral, cultural, and clothing practices), and skin pigmentation (with dark skin receiving a smaller effective dose to underlying structures than light skin).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 72, 'vitamin D'), ('UBERON_0001977', 'blood serum', 115, 'serum'), ('CHEBI_71657', 'versiconol acetate', 121, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 121, '25(OH ... D'), ('CHEBI_25812', 'ozone', 260, 'ozone')]
PMC2330139	3/2008	S5-PMC2330139	['the most commonly used Ds were: multivitamins (16%) and Vitamin C (6%).']	N/A	N/A	[('CHEBI_52029', 'dilC18(3) dye', 23, 'DS'), ('CHEBI_27300', 'vitamin D', 56, 'vitamin C')]
PMC2396486	6/2008	S33-PMC2396486	['methods\nto obtain Vitamin D3Depletion, female sprague-dawley Rats (herston Animal facility, queensland, australia) were kept on a Vitamin D deficient diet (dyets inc., pa, usa).']	N/A	N/A	[('CHEBI_61669', '2-methylbutanenitrile', 18, 'vitamin D3depletion'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 18, 'vitamin D3depletion'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 61, 'rats'), ('NCBITaxon_33208', 'Metazoa', 75, 'Animal'), ('CHEBI_27300', 'vitamin D', 130, 'vitamin D')]
PMC2396486	6/2008	S36-PMC2396486	['control Animals were kept under similar conditions except they received a Vitamin D replete diet (dyets, pa, usa and specialty foods, wa, australia) and were housed under standard lighting conditions.']	N/A	N/A	[('NCBITaxon_33208', 'Metazoa', 8, 'animals'), ('CHEBI_27300', 'vitamin D', 74, 'vitamin D')]
PMC2409299	5/2008	S58-PMC2409299	['there were no other observed associations between any Lymphocyte subpopulation and concurrent Plasma zinc, Retinol or Vitamin C concentration.']	N/A	N/A	[('CL_0000542', 'lymphocyte', 54, 'lymphocyte'), ('UBERON_0001969', 'blood plasma', 94, 'plasma'), ('CHEBI_26536', 'retinoic acid', 107, 'retinol'), ('CHEBI_27300', 'vitamin D', 118, 'vitamin C')]
PMC2409299	5/2008	S133-PMC2409299	['Plasma act and Vitamin C levels assay on a cobas-bio centrifugal analyser (f.hoffman-la-roche ltd, basel, switzerland).']	N/A	N/A	[('UBERON_0001969', 'blood plasma', 0, 'Plasma'), ('CHEBI_27300', 'vitamin D', 15, 'vitamin C')]
PMC2409299	5/2008	S134-PMC2409299	['prior to freezing, Plasma samples for Vitamin C analysis were mixed with an equal volume of 10% Metaphosphoric Acid in order to deproteinize the Plasma.']	N/A	N/A	[('UBERON_0001969', 'blood plasma', 19, 'plasma'), ('CHEBI_27300', 'vitamin D', 38, 'vitamin C'), ('CHEBI_25218', 'methacrylate', 96, 'metaphosphoric acid'), ('UBERON_0001969', 'blood plasma', 145, 'plasma')]
PMC2581757	11/2008	S177-PMC2581757	['no effect of Vitamins C and E, however, was observed on Gpx levels.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 13, 'vitamins C'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 28, 'E'), ('PR_000008210', 'glutathione peroxidase 1', 56, 'GPx')]
PMC2581757	11/2008	S178-PMC2581757	['Grx activity declined significantly (27%) in preeclamptics who had not consumed Vitamins C and E (group a), but its activity did not fall significantly (5.5%) in patients who had used these Vitamins regularly as mentioned above.']	N/A	N/A	[('PR_000008290', 'eukaryotic peptide chain release factor GTP-binding subunit ERF3A', 0, 'GRx'), ('CHEBI_27300', 'vitamin D', 80, 'vitamins C'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 95, 'E'), ('CHEBI_33277', 'gamma-tocotrienol', 190, 'vitamins')]
PMC2582131	11/2008	S69-PMC2582131	['women classified as being deficient for Vitamin D had a 3.7-fold increased subsequent risk of gdm, as compared with Vitamin D sufficient women (≥30 ng/ml) after adjustment for maternal age, race/ethnicity, first-degree family history of type 2 diabetes (adjusted or\u200a=\u200a3.74, 95% ci, 1.47–9.50).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 40, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 116, 'vitamin D')]
PMC2606998	6/2007	S4-PMC2606998	['absolute intakes were below recommended intake (ri) according to nnr for Folate, Vitamin D, Selenium, Vitamin E and iron both before and at mid-Gestation.']	N/A	N/A	[('CHEBI_30863', '5-azaorotic acid', 73, 'folate'), ('CHEBI_27300', 'vitamin D', 81, 'vitamin D'), ('CHEBI_27568', 'selenium atom', 92, 'selenium'), ('CHEBI_27300', 'vitamin D', 102, 'vitamin E'), ('GO_0007565', 'female pregnancy', 144, 'gestation')]
PMC2606998	6/2007	S6-PMC2606998	['twenty-three women were below li for Selenium before Pregnancy and five for each of Vitamin D and Selenium at mid-Gestation.']	N/A	N/A	[('CHEBI_27568', 'selenium atom', 37, 'selenium'), ('GO_0007565', 'female pregnancy', 53, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 84, 'vitamin D'), ('CHEBI_27568', 'selenium atom', 98, 'selenium'), ('GO_0007565', 'female pregnancy', 114, 'gestation')]
PMC2606998	6/2007	S7-PMC2606998	['when expressed as Nutrient densities (amount of Nutrient per energy unit), intakes were below nnr for Folate, Vitamin D and Selenium before Pregnancy, and for folate, Vitamin D and iron at mid-Gestation.']	N/A	N/A	[('CHEBI_33284', 'nutrient', 18, 'nutrient'), ('CHEBI_33284', 'nutrient', 48, 'nutrient'), ('CHEBI_30863', '5-azaorotic acid', 102, 'folate'), ('CHEBI_27300', 'vitamin D', 110, 'vitamin D'), ('CHEBI_27568', 'selenium atom', 124, 'selenium'), ('GO_0007565', 'female pregnancy', 140, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 167, 'vitamin D'), ('GO_0007565', 'female pregnancy', 193, 'gestation')]
PMC2606998	6/2007	S41-PMC2606998	['for example, for the women, the pearson correlation coefficient for Vitamin\u2009C was 0.51 (0.35–0.64), for Vitamin\u2009E 0.45 (0.28–0.60), for calcium 0.47 (0.30–0.61) and for iron 0.43 (0.24–0.57)13.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 68, 'vitamin C'), ('CHEBI_27300', 'vitamin D', 104, 'vitamin E')]
PMC2606998	6/2007	S75-PMC2606998	['intakes were also expressed as Nutrient densities (amount per mj) and were shown to be lower than ri for Folate, Vitamin\u2009D and Selenium in the Pregestational diet, and for Folate, Vitamin\u2009D and iron at mid-Gestation (table5).']	N/A	N/A	[('CHEBI_33284', 'nutrient', 31, 'nutrient'), ('CHEBI_30863', '5-azaorotic acid', 105, 'folate'), ('CHEBI_27300', 'vitamin D', 113, 'vitamin D'), ('CHEBI_27568', 'selenium atom', 127, 'selenium'), ('GO_0007565', 'female pregnancy', 143, 'pregestational'), ('CHEBI_30863', '5-azaorotic acid', 172, 'folate'), ('CHEBI_27300', 'vitamin D', 180, 'vitamin D'), ('GO_0007565', 'female pregnancy', 206, 'gestation')]
PMC2606998	6/2007	S89-PMC2606998	['at mid-Gestation five women were below li for Vitamin\u2009D and Selenium.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 7, 'gestation'), ('CHEBI_27300', 'vitamin D', 46, 'vitamin D'), ('CHEBI_27568', 'selenium atom', 60, 'selenium')]
PMC2606998	6/2007	S102-PMC2606998	['iron and Vitamin\u2009D).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 9, 'vitamin D')]
PMC2679409	5/2009	S489-PMC2679409	['caption (table-wrap): table 13\n\nimpact of Vitamin A/Β-Carotene supplementation on stillbirths and Perinatal mortalitysourcelocation and type of studyinterventionstillbirths/Perinatal outcomereviews and meta-analyses rumbold et al.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 42, 'vitamin A'), ('CHEBI_28064', 'cyanidin 3-O-rutinoside', 52, 'β-carotene'), ('GO_0036268', 'swimming', 98, 'perinatal'), ('UBERON_0012101', 'perinatal stage', 98, 'perinatal'), ('GO_0036268', 'swimming', 173, 'Perinatal'), ('UBERON_0012101', 'perinatal stage', 173, 'Perinatal')]
PMC2685863	5/2009	S16-PMC2685863	['[for more information on Vitamin D deficiency, see “benefits of sunlight: a bright spot for Human health,” ehp 116:a160–a167 (2008)].']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 25, 'vitamin D'), ('NCBITaxon_10088', 'Mus <genus>', 92, 'Human')]
PMC2716336	7/2009	S6-PMC2716336	['the ear cut-offs based on the chinese nutrition society dietary reference intakes (dris) were used to assess the prevalence of inadequate dietary intakes of energy, protein, calcium, zinc, riboflavin, Vitamin C and Folate.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 201, 'vitamin C'), ('CHEBI_30863', '5-azaorotic acid', 215, 'folate')]
PMC2716336	7/2009	S103-PMC2716336	['caption (table-wrap): table 3\n\nmedian Intake and percentage of inadequate Intake of selected Nutrients in rural shaanxi china 2004median intakeear*increment for Pregnancy<ear + increment (%)energy (kcal)2234.62100†20054protein (g)60.638‡1231calcium (mg)412.9525¶070zinc (mg)8.58.3591riboflavin (mg)0.881.00.4591vitamin C (mg)89.475-934folate (μg)244.232020097\n* estimated average requirement for non-Pregnant women aged above 18 with low physical activity, china nutrition society, 2001\n† ear for energy shown in the table is the figure rni for energy\n‡ the figure shown is the ear for protein for non-Pregnant women aged from 19–50 in usa with the addition of an increment for Pregnancy (ear for groups Food and nutrition board, institute of medicine, national academies)\n¶the figure shown is the ear for Calcium for non-Pregnant women aged 19–50 years in united kingdom with the addition of an increment for Pregnancy (ear; department of health, 1991)\nthe median intakes of energy, protein, calcium, iron, zinc, riboflavin, Vitamin C and Folate were compared between bmi and household wealth sub-groups (table4).']	N/A	N/A	[('GO_0007631', 'feeding behavior', 38, 'intake'), ('GO_0007631', 'feeding behavior', 74, 'intake'), ('CHEBI_33284', 'nutrient', 93, 'nutrients'), ('GO_0007565', 'female pregnancy', 161, 'pregnancy'), ('CHEBI_18245', 'carboxylato group', 319, 'C'), ('GO_0007565', 'female pregnancy', 400, 'pregnant'), ('GO_0007565', 'female pregnancy', 602, 'pregnant'), ('GO_0007565', 'female pregnancy', 678, 'pregnancy'), ('CHEBI_33290', 'food', 704, 'Food'), ('CHEBI_22313', 'alkaline earth metal atom', 806, 'calcium'), ('GO_0007565', 'female pregnancy', 822, 'pregnant'), ('GO_0007565', 'female pregnancy', 910, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 1026, 'vitamin C'), ('CHEBI_30863', '5-azaorotic acid', 1040, 'folate')]
PMC2716336	7/2009	S108-PMC2716336	['figure2demonstrates increased Vitamin C intake in summer and autumn (kruskal-wallis test p < 0.05).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 30, 'vitamin C')]
PMC2716336	7/2009	S112-PMC2716336	['caption (fig): figure 2\n\ncomparison of dietary intake of Vitamin C and iron across season of third trimester .']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 57, 'vitamin C')]
PMC2716336	7/2009	S113-PMC2716336	['comparison of dietary Intakes of Vitamin C (mg) and iron (mg) based on the Food frequency questionnaire by Pregnant women in rural shaanxi china 2004 by season of third Trimester.']	N/A	N/A	[('GO_0007631', 'feeding behavior', 22, 'intakes'), ('CHEBI_27300', 'vitamin D', 33, 'vitamin C'), ('CHEBI_33290', 'food', 75, 'food'), ('GO_0007565', 'female pregnancy', 107, 'pregnant'), ('GO_0009294', 'DNA mediated transformation', 169, 'trimester')]
PMC2716336	7/2009	S133-PMC2716336	['the study population also had higher intakes of total Vitamin A, Vitamin C and calcium.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 54, 'vitamin A'), ('CHEBI_27300', 'vitamin D', 65, 'vitamin C')]
PMC2779500	11/2009	S19-PMC2779500	['non-enzymatic antioxidants obtained directly from the diet (i.e., Glutathione, Vitamins A, c and e, and flavenoids) decrease oxygen concentrations, remove catalytic metal Ions and eliminate Radicals from the system [8,9].']	N/A	N/A	[('CHEBI_16856', 'glutathione', 66, 'glutathione'), ('CHEBI_27300', 'vitamin D', 79, 'vitamins A'), ('PR_000004370', 'asialoglycoprotein receptor 2', 88, 'A'), ('CHEBI_24870', 'ion', 171, 'ions'), ('CHEBI_26534', 'retinals', 190, 'radicals')]
PMC2779500	11/2009	S62-PMC2779500	['the latter hiv-positive group was divided into two subgroups: one subgroup of 15 patients received a placebo (hiv(+)p), while the other received a daily supplement of 5000 units of Vitamin A, 100 units of Vitamin E and 50 mg of Vitamin C (hiv(+)v).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 181, 'vitamin A'), ('CHEBI_27300', 'vitamin D', 205, 'vitamin E'), ('CHEBI_27300', 'vitamin D', 228, 'vitamin C'), ('PR_000004900', 'complement C3', 236, 'C')]
PMC2779500	11/2009	S193-PMC2779500	['in (a), a stable equilibrium results from a supplement of α = 2.0 × 1013molecules/( μ l day) which corresponds to 58 mg of daily Vitamin C supplementation.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 129, 'vitamin C')]
PMC2798111	12/2010	S3-PMC2798111	['as part of a larger ongoing Vitamin D rct trial of Lactating women, infants of mothers assigned to control received 1 drop of 400\u2009iu Vitamin D3/day starting at one month of age.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 28, 'vitamin D'), ('GO_0007594', 'puparial adhesion', 51, 'lactating'), ('CHEBI_33279', 'vitamin D5', 133, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 133, 'vitamin D3')]
PMC2798111	12/2010	S36-PMC2798111	['following written informed consent, mothers were randomized to one of three Vitamin D supplementation regimens: group 1: 400\u2009iu Vitamin D3/day (0\u2009iu vitamin D3—placebo and 1 Prenatal Vitamin containing 400\u2009iu Vitamin D3), group 2: 2,400\u2009iu Vitamin D3/day (2,000\u2009iu Vitamin D3And 1 Prenatal Vitamin containing 400\u2009iu Vitamin D3), or group 3: 6,400\u2009iu Vitamin D3/day (6,000\u2009iu Vitamin D3And 1 Prenatal Vitamin containing 400\u2009iu Vitamin D3).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 76, 'vitamin D'), ('CHEBI_33279', 'vitamin D5', 128, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 128, 'vitamin D3'), ('CHEBI_29238', 'tritium atom', 157, 'D3'), ('PR_000001177', 'D(2) dopamine receptor', 157, 'D3'), ('GO_0007565', 'female pregnancy', 174, 'prenatal'), ('CHEBI_33229', 'vitamin (role)', 183, 'vitamin'), ('CHEBI_33279', 'vitamin D5', 209, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 209, 'vitamin D3'), ('CHEBI_33279', 'vitamin D5', 240, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 240, 'vitamin D3'), ('CHEBI_61991', 'maltotriose trisaccharide', 265, 'vitamin D3and'), ('PR_000006317', 'mRNA-decapping enzyme 1A', 273, 'D3and'), ('GO_0007565', 'female pregnancy', 281, 'prenatal'), ('CHEBI_33229', 'vitamin (role)', 290, 'vitamin'), ('CHEBI_33279', 'vitamin D5', 316, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 316, 'vitamin D3'), ('CHEBI_33279', 'vitamin D5', 350, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 350, 'vitamin D3'), ('CHEBI_61991', 'maltotriose trisaccharide', 375, 'vitamin D3and'), ('PR_000027594', 'histone H3', 375, 'vitamin D3and'), ('GO_0007565', 'female pregnancy', 391, 'prenatal'), ('CHEBI_33229', 'vitamin (role)', 400, 'vitamin'), ('CHEBI_33279', 'vitamin D5', 426, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 426, 'vitamin D3')]
PMC2798111	12/2010	S40-PMC2798111	['the Vitamin D status of those infants in the control group who received 400\u2009iu/day Vitamin D3Was measured by circulating 25(Oh)D at 1, 4, and 7 months of age.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 4, 'vitamin D'), ('CHEBI_73754', 'thiosugar', 83, 'vitamin D3was'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 83, 'vitamin D3was'), ('CHEBI_71657', 'versiconol acetate', 121, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 121, '25(OH ... D')]
PMC2798111	12/2010	S44-PMC2798111	['each mother was to record any Vitamin D-free and/or regular formulas use during the study period.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 30, 'vitamin D')]
PMC2798111	12/2010	S75-PMC2798111	['results\nin this ongoing Vitamin D supplementation trial of Lactating women and their infants, 54 were enrolled in the study and were randomized to the control group in a blinded fashion.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 24, 'vitamin D'), ('GO_0007594', 'puparial adhesion', 59, 'lactating')]
PMC2798111	12/2010	S85-PMC2798111	['in addition, there were no adverse health effects attributed to Vitamin D supplementation.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 64, 'vitamin D')]
PMC2798111	12/2010	S86-PMC2798111	['when examining the 400\u2009iu Vitamin D/day dose on a weight basis, there was a significant change in iu/kg over the time for the 33 infants who completed the study: at visit 1, the infants were receiving 88.9 ± 10.5\u2009iu/kg; at visit 4, they were receiving 59.7 ± 6.6 iu/kg; and at visit 7, they were receiving 50.5 ± 6.0 iu/kg ( p< .0001).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 26, 'vitamin D')]
PMC2798111	12/2010	S94-PMC2798111	['there were no adverse events associated with the prescribed Vitamin D supplementation.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 60, 'vitamin D')]
PMC2821652	2/2010	S4-PMC2821652	['data were obtained from a Prenatal Vitamin D supplementation trial where subjects were stratified by race and randomized into three dosing groups: 400 (control), 2000, or 4000 iu Vitamin D3/day.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 26, 'prenatal'), ('CHEBI_27300', 'vitamin D', 35, 'vitamin D'), ('CHEBI_33279', 'vitamin D5', 179, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 179, 'vitamin D3')]
PMC2821652	2/2010	S15-PMC2821652	['the two main Human sources of Vitamin D are sunlight exposure, which converts 7-Dehydrocholesterol in the skin to Vitamin D3, and oral Intake.']	N/A	N/A	[('NCBITaxon_9606', 'Homo sapiens', 13, 'human'), ('CHEBI_27300', 'vitamin D', 30, 'vitamin D'), ('CHEBI_17500', '7alpha-hydroxycholesterol', 78, '7-dehydrocholesterol'), ('CHEBI_33279', 'vitamin D5', 114, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 114, 'vitamin D3'), ('GO_0007631', 'feeding behavior', 135, 'intake')]
PMC2821652	2/2010	S17-PMC2821652	['the amount of Vitamin D produced by a given amount of exposure is modified by skin pigmentation, with darkly-Pigmented populations producing significantly less Vitamin D than fair-skinned populations after exposure to similar conditions [3–7].']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 14, 'vitamin D'), ('CHEBI_26130', 'biological pigment', 109, 'pigmented'), ('CHEBI_27300', 'vitamin D', 160, 'vitamin D')]
PMC2821652	2/2010	S28-PMC2821652	['with respect to Vitamin D, the Placenta and/or Deciduas are active Extrarenal sites of conversion of 25(Oh)D as they contain 1 α -hydroxylase, providing a source of 1,25(Oh)2D for the fetus.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 16, 'vitamin D'), ('UBERON_0001987', 'placenta', 31, 'placenta'), ('UBERON_0002450', 'decidua', 47, 'deciduas'), ('UBERON_0001691', 'external ear', 67, 'extrarenal'), ('CHEBI_71657', 'versiconol acetate', 101, '25(OH)D'), ('CHEBI_37958', 'dye', 165, '1,'), ('CHEBI_66212', "5,7,3',4'-tetrahydroxy-2'-(3,3-dimethylallyl)isoflavone", 167, '25(OH)2D')]
PMC2821652	2/2010	S48-PMC2821652	['study design\ndata were obtained from a large nih-supported (#r01 hd043921) randomized, double-blind, Placebo-control trial of Vitamin D supplements in Pregnant women that took place at the medical university of south carolina (musc).']	N/A	N/A	[('CHEBI_26130', 'biological pigment', 101, 'placebo'), ('CHEBI_27300', 'vitamin D', 126, 'vitamin D'), ('GO_0007565', 'female pregnancy', 151, 'pregnant')]
PMC2821652	2/2010	S126-PMC2821652	['because maternal circulating 25(Oh)D is not affected by Gestational age per se, the stability of Vitamin D during Pregnancy allowed for analysis of adherence once steady state was achieved throughout Gestation [15,16].']	N/A	N/A	[('CHEBI_71657', 'versiconol acetate', 29, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 35, 'D'), ('GO_0007565', 'female pregnancy', 56, 'gestational'), ('CHEBI_27300', 'vitamin D', 97, 'vitamin D'), ('GO_0007565', 'female pregnancy', 114, 'pregnancy'), ('GO_0007565', 'female pregnancy', 200, 'gestation')]
PMC2841444	2/2010	S482-PMC2841444	['a 2007 cochrane review of very low Birth weight infants showed a significant but small reduction in death or oxygen use at one month [rr= 0.93; 95% ci 0.88, 0.99] in infants receiving intravenous Vitamin A compared to placebo [243].']	N/A	N/A	[('GO_0007567', 'parturition', 35, 'birth'), ('CHEBI_27300', 'vitamin D', 196, 'vitamin A')]
PMC2841444	2/2010	S505-PMC2841444	['assessment\nthe quality of the evidence for both Antenatal and Postnatal Vitamin K use is moderate.']	N/A	N/A	[('GO_0007567', 'parturition', 48, 'antenatal'), ('GO_0007567', 'parturition', 62, 'postnatal'), ('CHEBI_27300', 'vitamin D', 72, 'vitamin K')]
PMC2849017	9/2007	S62-PMC2849017	['in the hungarian study, women (n=4,156) without a previous ntd-affected Pregnancy and Planning to Become Pregnant again were randomly assigned to receive a multivitamin-Mineral supplement (including 0.8mg of Folic Acid) or a placebo (no Folic Acid but contained copper, manganese, zinc and Vitamin C) (czeizel, 1993).']	N/A	N/A	[('GO_0007565', 'female pregnancy', 72, 'pregnancy'), ('GO_0006260', 'DNA replication', 86, 'planning'), ('GO_0007567', 'parturition', 98, 'become'), ('GO_0007565', 'female pregnancy', 105, 'pregnant'), ('CHEBI_46662', 'mineral', 169, 'mineral'), ('CHEBI_30751', 'formic acid', 208, 'folic acid'), ('CHEBI_30751', 'formic acid', 237, 'folic acid'), ('CHEBI_27300', 'vitamin D', 290, 'vitamin C'), ('PR_000004900', 'complement C3', 298, 'C')]
PMC2872349	4/2010	S89-PMC2872349	['in this study 31% of the mothers had insufficient and 18% had deficient circulating concentrations of 25(Oh) Vitamin D during late Pregnancy (11–20 and <11 μg/l respectively).']	N/A	N/A	[('CHEBI_30778', 'gallic acid', 102, '25(OH)'), ('CHEBI_27300', 'vitamin D', 109, 'vitamin D'), ('GO_0007565', 'female pregnancy', 131, 'pregnancy')]
PMC2872349	4/2010	S95-PMC2872349	['circulating maternal 25(Oh) Vitamin D concentrations in this cohort were relatively high, and were not associated with childhood Skeletal measures.']	N/A	N/A	[('CHEBI_30778', 'gallic acid', 21, '25(OH)'), ('CHEBI_27300', 'vitamin D', 28, 'vitamin D'), ('UBERON_0004288', 'skeleton', 129, 'skeletal')]
PMC2874300	5/2010	S6-PMC2874300	['Vitamins C, d and e) protect against am.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 0, 'vitamins C')]
PMC2874518	6/2010	S58-PMC2874518	['dietary recall\nbased on midwife-administered 24-hour recall dietary assessment at 8–12 weeks of Gestation, women in our cohort had average dietary intakes from Food above the reference Nutrient intake values for most Vitamins and minerals21except Vitamin D, iron, Folate, Selenium and Iodine (table 2).']	N/A	N/A	[('GO_0007565', 'female pregnancy', 96, 'gestation'), ('CHEBI_33290', 'food', 160, 'food'), ('CHEBI_33284', 'nutrient', 185, 'nutrient'), ('CHEBI_33277', 'gamma-tocotrienol', 217, 'vitamins'), ('CHEBI_27300', 'vitamin D', 247, 'vitamin D'), ('CHEBI_30863', '5-azaorotic acid', 264, 'folate'), ('CHEBI_27568', 'selenium atom', 272, 'selenium'), ('CHEBI_24859', 'iodine atom', 285, 'iodine')]
PMC2874518	6/2010	S61-PMC2874518	['caption (table-wrap): table 2\n\naverage daily intakes of Vitamins and Minerals (from diet alone) based on 24-hour dietary recall at 8–12 weeks of Pregnancy, leeds, uk, 2003–06 ( n = 1257)Micronutrientmean (sd)rni*recommended increment to rni during Pregnancy**proportion of women with Intakes above the Pregnancy rni (95% ci)Thiamin (mg/day)2.4 (7.7)0.8+0.185 (83, 87)riboflavin (mg/day)1.7 (0.8)1.1+0.358 (55, 61)niacin (mg/day)20 (10)13–75 (72, 77)Vitamin B6 (mg/day)2.1 (1.0)1.2–85 (82, 86)Vitamin B12 (μg/day)3.9 (3.7)1.5–79 (77, 82)Folate (μg/day)257 (119)200+10032 (29, 35)vitamin c (μg/day)143 (129)40+1075 (73, 78)Vitamin A (μg Retinol equivalent/day)803 (665)600+10045 (42, 48)Vitamin D (μg/day)2.5 (2.7)–102 (1, 3)Vitamin E (mg/day)7.9 (5.4)–****–Calcium (mg/day)938 (471)700***65 (62, 68)Phosphorus (mg/day)1344 (501)550***98 (97, 99)magnesium (mg/day)283 (112)270***49 (46, 52)iron (mg/day)11.5 (5.3)14.8***20 (18, 23)Zinc (mg/day)8.6 (4.3)7***59 (56, 62)copper (mg/day)1.1 (0.6)1.2***32 (29, 35)Selenium (μg/day)58 (37)60***40 (38, 43)Iodine (μg/day)118 (82)140***28 (24, 29)\nreference Nutrient intakes (rni) for women aged 19–50 years in the uk.21\nreference Nutrient intakes for Pregnant women.21\nno increment.21\nsafe intake – above 3 mg/day for women.21\n\ntype of supplements\nwomen reported taking 22 different types of supplements including Folic Acid, iron, combined Folic Acid–iron preparations, multivitamin–Mineral preparations (six brands), evening primrose, cod Liver oil, Omega 3, Vitamin C, Vitamin B, Vitamin D, Vitamin E, Vitamin A, calcium, zinc, magnesium and Selenium preparations (table 3).']	N/A	N/A	[('CHEBI_33277', 'gamma-tocotrienol', 56, 'vitamins'), ('CHEBI_46751', 'quinolizidine', 69, 'minerals'), ('GO_0007565', 'female pregnancy', 145, 'pregnancy'), ('CHEBI_6923', 'miconazole', 186, 'MicronutrientMean'), ('GO_0007565', 'female pregnancy', 248, 'pregnancy'), ('GO_0007631', 'feeding behavior', 284, 'intakes'), ('GO_0007565', 'female pregnancy', 302, 'pregnancy'), ('CHEBI_9544', 'thiethylperazine', 324, 'Thiamin'), ('CHEBI_27306', 'vitamin B6', 449, 'Vitamin B6'), ('PR_000017269', 'ventral anterior homeobox 2', 449, 'Vitamin B6'), ('CHEBI_28334', 'malonamoyl-CoA', 492, 'Vitamin B12'), ('PR_000017279', 'testis-specific basic protein Y 1', 492, 'Vitamin B12'), ('CHEBI_81245', 'Vulpecholate', 536, 'Folate'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 621, 'Vitamin A'), ('CHEBI_26536', 'retinoic acid', 635, 'retinol'), ('CHEBI_28384', 'vitamin K', 685, 'Vitamin D'), ('CHEBI_28384', 'vitamin K', 723, 'Vitamin E'), ('CHEBI_31341', 'calcium dihydroxide', 756, 'Calcium'), ('CHEBI_30207', 'phosphorus(.)', 798, 'Phosphorus'), ('CHEBI_27377', "Unsym-bis(4'-chlorophenyl)ethylene", 929, 'Zinc'), ('CHEBI_27568', 'selenium atom', 1007, 'Selenium'), ('CHEBI_31719', 'ipriflavone', 1047, 'Iodine'), ('CHEBI_33284', 'nutrient', 1098, 'nutrient'), ('CHEBI_33284', 'nutrient', 1171, 'nutrient'), ('GO_0007565', 'female pregnancy', 1192, 'pregnant'), ('CHEBI_30751', 'formic acid', 1355, 'folic acid'), ('CHEBI_30751', 'formic acid', 1382, 'folic acid'), ('CHEBI_46662', 'mineral', 1425, 'mineral'), ('UBERON_0002107', 'liver', 1482, 'liver'), ('CHEBI_30823', 'oleate', 1493, 'omega'), ('CHEBI_27300', 'vitamin D', 1502, 'vitamin C'), ('CHEBI_27300', 'vitamin D', 1513, 'vitamin B'), ('CHEBI_27300', 'vitamin D', 1524, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 1535, 'vitamin E'), ('CHEBI_27300', 'vitamin D', 1546, 'vitamin A'), ('CHEBI_27568', 'selenium atom', 1586, 'selenium')]
PMC2874518	6/2010	S109-PMC2874518	['both brands included Folate and Vitamin C exceeding the current recommended minimum during Pregnancy (table 2).']	N/A	N/A	[('CHEBI_30863', '5-azaorotic acid', 21, 'folate'), ('CHEBI_27300', 'vitamin D', 32, 'vitamin C'), ('GO_0007565', 'female pregnancy', 91, 'pregnancy')]
PMC2889879	5/2010	S13-PMC2889879	['women in the highest compared with the lowest quartile of Vitamin D consumption experienced a 37% (95% ci, 22-50%) lower risk of psychotic-like symptoms.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 58, 'vitamin D')]
PMC2889879	5/2010	S40-PMC2889879	['the women were asked to fill in a paper questionnaire, including a Food frequency questionnaire (ffq), and levels of fish, Pufas and Vitamin D intake were evaluated.']	N/A	N/A	[('CHEBI_33290', 'food', 67, 'food'), ('CHEBI_86926', 'S a S b S', 123, 'PUFAs'), ('CHEBI_27300', 'vitamin D', 133, 'vitamin D')]
PMC2889879	5/2010	S80-PMC2889879	['the association between fish, Fatty Acids or Vitamin D and psychotic-like symptoms was summarized in terms of relative risk ratios (rrrs) and corresponding 95% confidence intervals, and it was evaluated by energy-adjusted multinomial logistic regression (polytomous logistic regression), for example: rrr = p(y = high level group; Fish Intake >2/week)/p(y = low level group; fish Intake >2/week)/p(y = high level group; no Fish Intake)/p(y = low level group; no Fish Intake).']	N/A	N/A	[('CHEBI_35366', 'fatty acid', 30, 'fatty acids'), ('CHEBI_27300', 'vitamin D', 45, 'vitamin D'), ('CHEBI_83324', 'pent-2-enoyl-CoA(4-)', 331, 'fish'), ('GO_0007631', 'feeding behavior', 336, 'intake'), ('GO_0007631', 'feeding behavior', 380, 'intake'), ('CHEBI_83324', 'pent-2-enoyl-CoA(4-)', 423, 'fish'), ('GO_0007631', 'feeding behavior', 428, 'intake'), ('CHEBI_83324', 'pent-2-enoyl-CoA(4-)', 462, 'fish'), ('GO_0007631', 'feeding behavior', 467, 'intake')]
PMC2889879	5/2010	S86-PMC2889879	['nutrient density was calculated by dividing the estimated intake of Fatty Acids, Vitamin D and other Nutrients by the total energy intake (i.e., the multivariate Nutrient density model) [28].']	N/A	N/A	[('CHEBI_35366', 'fatty acid', 68, 'fatty acids'), ('CHEBI_27300', 'vitamin D', 81, 'vitamin D'), ('CHEBI_33284', 'nutrient', 101, 'nutrients'), ('CHEBI_33284', 'nutrient', 162, 'nutrient')]
PMC2889879	5/2010	S87-PMC2889879	['the intake of Fatty Acids and Vitamin D was categorized into quartiles, with the lowest quartile as the reference category for comparison.']	N/A	N/A	[('CHEBI_35366', 'fatty acid', 14, 'fatty acids'), ('CHEBI_27300', 'vitamin D', 30, 'vitamin D')]
PMC2889879	5/2010	S111-PMC2889879	['(%) \u2003\u2003ever16 258 (88)12 614 (88)668 (82)\u2003\u2003never2 153 (12)1 781 (12)149 (18) dietary Intake, g/day, median (5-95%) of: \u2003\u2003Fatty Fish7 (0-21)7 (0-21)7 (0-28)\u2003\u2003meat76 (26-144)78 (22-149)77 (3-167)\u2003\u2003dairy products330 (20-831)331 (14-850)320 (4-857)\u2003\u2003vegetables79 (22-177)79 (21-186)80 (19-214)\u2003\u2003fruit107 (15-315)106 (11-311)102 (7-337)\u2003\u2003cereals125 (47-280)129 (47-288)129 (41-299)\u2003\u2003Saccharides (Sugar)20 (7-44)20 (7-45)21 (6-51)\u2003\u2003Alcohol2.5 (0-11)2.4 (0-11)1.8 (0-12)\u2003\u2003Marine Fatty Acidsc0.27 (0.07-0.6)0.27 (0.06-0.6)0.26 (0.05-0.7)\u2003\u2003Omega-3 Fatty Acidsd1.3 (0.6-2)1.3 (0.6-2)1.2 (0.6-2)\u2003\u2003Omega-6 Fatty Acidse4.8 (2-8)4.8 (2-8)4.7 (2-8)\u2003\u2003Vitamin D (μg/day)4.0 (1.8-7.1)3.9 (1.7-7.2)3.8 (1.4-7.1)total energy intake, kj/day, mean (sd)6 509 (1 801)6 626 (1 886)6 637 (1 986) proportion of total energy intake, % from: \u2003• fat313131\u2003• protein161616\u2003• Carbohydrate515151\u2003• alcohol111\naparticipants categorized into levels of psychotic-like symptoms; low, middle, high (see methods section)\nbage at the completeness of the follow-up questionnaire\ncsum of Eicosapentaenoic Acid (Epa), Docosahexaenoic Acid (Dha) and Docosapentaenoic Acid\ndsum of Eicosapentaenoic Acid (Epa), Docosahexaenoic Acid (Dha), Docosapentaenoic Acid and Α-Linolenic Acid\nesum of Arachidonic And Linoleic Acids\n\ndietary Intake of Fish and risk of positive psychotic-like symptoms\nthe risk of positive psychotic-like symptoms in relation to estimated dietary Intake of fish is shown in table2.']	N/A	N/A	[('GO_0007631', 'feeding behavior', 84, 'intake'), ('CHEBI_83230', 'pradimicin', 120, 'fatty fish7'), ('CHEBI_48438', 'pyrimidinecarboxamide', 377, 'saccharides'), ('CHEBI_24870', 'ion', 390, 'sugar'), ('CHEBI_30879', 'alcohol', 425, 'alcohol2'), ('CHEBI_6809', 'methamphetamine', 464, 'marine'), ('CHEBI_87207', 'pyrimidine fungicide', 471, 'fatty acidsc0'), ('CHEBI_30823', 'oleate', 530, 'omega'), ('CHEBI_37972', 'phosphorus-32 atom', 536, '3'), ('CHEBI_73926', '3alpha,12alpha-dihydroxy-5beta-chol-6-en-24-oic acid', 538, 'fatty acidsd1'), ('CHEBI_79370', 'ibho#10', 585, 'omega-6'), ('CHEBI_78197', '1-alkyl-2-acyl-glycero-3-phosphoethanolamine zwitterion', 593, 'fatty acidse4'), ('CHEBI_27300', 'vitamin D', 634, 'vitamin D'), ('CHEBI_58997', '(Z)-azobenzene', 843, 'carbohydrate515151'), ('CHEBI_36003', 'decenoic acid', 1045, 'eicosapentaenoic acid'), ('CHEBI_34733', 'EPN', 1068, 'EPA'), ('CHEBI_36003', 'decenoic acid', 1074, 'docosahexaenoic acid'), ('CHEBI_17874', 'dihydrozeatin', 1096, 'DHA'), ('CHEBI_61205', 'docosatetraenoic acid', 1105, 'docosapentaenoic acid'), ('CHEBI_36003', 'decenoic acid', 1135, 'eicosapentaenoic acid'), ('CHEBI_34733', 'EPN', 1158, 'EPA'), ('CHEBI_36003', 'decenoic acid', 1164, 'docosahexaenoic acid'), ('CHEBI_17874', 'dihydrozeatin', 1186, 'DHA'), ('CHEBI_61205', 'docosatetraenoic acid', 1192, 'docosapentaenoic acid'), ('CHEBI_86354', '2-hydroxyacrylic acid', 1218, 'α-linolenic acid'), ('CHEBI_36431', 'angelic acid', 1243, 'arachidonic and'), ('CHEBI_25048', 'linolenic acid', 1259, 'linoleic acids'), ('GO_0007631', 'feeding behavior', 1283, 'intake'), ('CHEBI_83324', 'pent-2-enoyl-CoA(4-)', 1293, 'fish'), ('GO_0007631', 'feeding behavior', 1421, 'intake')]
PMC2889879	5/2010	S119-PMC2889879	['dietary Intake of Omega-3, Omega-6 Fatty Acids, Vitamin D and risk of positive psychotic-like symptoms\nthe relative risk of positive psychotic-like symptoms by the level of Fatty Acids Intake is shown in table3.']	N/A	N/A	[('GO_0007631', 'feeding behavior', 8, 'intake'), ('CHEBI_79370', 'ibho#10', 18, 'omega-3'), ('CHEBI_75862', 'alpha-D-rhamnofuranose', 27, 'omega-6 fatty acids'), ('CHEBI_27300', 'vitamin D', 48, 'vitamin D'), ('CHEBI_35366', 'fatty acid', 173, 'fatty acids'), ('GO_0007631', 'feeding behavior', 185, 'intake')]
PMC2889879	5/2010	S126-PMC2889879	['for example, after multivariate adjustment, the risk of middle respective high level psychotic-like symptoms for Intake of Vitamin D were respectively 18% and 37% lower in the highest quartile compared to the lowest quartile of Intake.']	N/A	N/A	[('GO_0007631', 'feeding behavior', 113, 'intake'), ('CHEBI_27300', 'vitamin D', 123, 'vitamin D'), ('GO_0007631', 'feeding behavior', 228, 'intake')]
PMC2913107	8/2010	S34-PMC2913107	['clouds and rain retard Vitamin D-producing ultraviolet b light from penetrating the atmosphere.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 23, 'vitamin D')]
PMC2945165	10/2010	S40-PMC2945165	['all newborns were provided with powdered fortified Cow Milk (whole Bovine Milk homogenized and enriched with Vitamin C, iron, zinc, and copper) (purita fortificada; calo [central de abastecimiento del ministerio de salud de chile], osorno, chile) according to chilean government policy, which applies until a child reaches 6 years of age.']	N/A	N/A	[('NCBITaxon_33208', 'Metazoa', 51, 'cow'), ('UBERON_0001913', 'milk', 55, 'milk'), ('NCBITaxon_33208', 'Metazoa', 67, 'bovine'), ('UBERON_0001913', 'milk', 74, 'milk'), ('CHEBI_27300', 'vitamin D', 109, 'vitamin C')]
PMC2963768	10/2010	S5-PMC2963768	['the proportion of infants with Vitamin D deficiency defined by 25(Oh)D <25 nmol/l was 28% (95% ci 10-45), 59% (95% ci 40-78) had 25(Oh)D<40 nmol/l, and all were below 80 nmol/l.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 31, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 63, '25(OH)D'), ('PR_000009880', 'Lon protease, mitochondrial', 63, '25 ... OH ... D'), ('CHEBI_71657', 'versiconol acetate', 129, '25(OH)D')]
PMC2963768	10/2010	S44-PMC2963768	['estimates of the prevalence of Vitamin D deficiency were based on the proportion of participants with 25(Oh)D lower than pre-specified cut-offs (<25 nmol/l, <40 nmol/l, and <80 nmol/l).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 31, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 102, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 102, '25(OH ... D')]
PMC2963768	10/2010	S46-PMC2963768	['comparisons were made between groups of participants categorized by Vitamin D status using a 25-nmol/l cut-off.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 68, 'vitamin D')]
PMC2963768	10/2010	S50-PMC2963768	["other than age and 25(Oh)D, which were compared across groups by one-way analysis of variance, the statistical significance of bivariate associations between the Vitamin D status and the maternal, infant or household characteristics in the entire sample (n=74) was assessed by non-parametric tests, including chi-square tests, mann-u whitney tests, and spearman's rank correlation coefficient."]	N/A	N/A	[('CHEBI_71657', 'versiconol acetate', 19, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 19, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 162, 'vitamin D')]
PMC2963768	10/2010	S82-PMC2963768	['comparison of selected characteristics of infants and toddlers categorized by Vitamin D status in sylhet, bangladeshcharacteristics25(Oh)D <25 nmol/l25(Oh)d ≥25 nmol/lp valueno.2450mean 25(Oh)D±sd16.3±5.840.5±11.8<0.001age (mean days±sd)71.3±43.4136.6±126.7<0.001<6 months23 (96)39 (78)0.051boys21 (88)40 (80)0.427birth-order (median±iqr)2±4.52±50.455anthropometric indicators\xa0\xa0underweight11 (46)25 (48)0.861\xa0\xa0stunted10 (42)16 (32)0.415\xa0\xa0low body mass index14 (58)20 (40)0.138age of mothers (mean years±sd)23.7±5.624.8±5.30.410years of schooling of mother (median±iqr)1.5±6.55±60.613years of schooling of father (median±iqr)0±54±50.177family owns their own homestead14 (58)32 (64)0.638manufactured housing materials (i.e.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 78, 'vitamin D'), ('CHEBI_33010', 'chromide(1-)', 133, '(OH)D'), ('CHEBI_33310', 'neon atom', 151, '(OH)'), ('CHEBI_71657', 'versiconol acetate', 186, '25(OH)D')]
PMC2963768	10/2010	S121-PMC2963768	['frying) or processingintestinal Vitamin D absorption and storage\nnutrient-Nutrient interactions or competition, e.g.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 32, 'vitamin D'), ('CHEBI_33284', 'nutrient', 74, 'nutrient')]
PMC2992766	12/2010	S45-PMC2992766	['caption (table-wrap): table 1\n\ndiet composition per weight of Chow and per kcalcontrolcontrol+aoxwesternwestern+aoxprotein (% per 100 g)15.915.921.621.9protein (% per kcal)20.120.119.919.9Carbohydrate (% per 100 g)454550.250.2carbohydrate (% per kcal)56.756.746.346.3fat (% per 100 g)8.28.216.216.2fat (% per kcal)23.123.133.733.7total Vitamin A (iu/kg)4,60023,0008,900*32,000**total Vitamin E (iu/kg)86260118*360**total Vitamin C (g/kg)05.605.6total Selenium (mg/kg)0.1650.50.225*0.675**\n*indicates that this Vitamin or Mineral is present in the same absolute amount as the control on an energy basis (per kcal).']	N/A	N/A	[('CHEBI_33290', 'food', 62, 'chow'), ('CHEBI_35489', 'organic disulfide', 187, '9Carbohydrate'), ('CHEBI_27300', 'vitamin D', 336, 'vitamin A'), ('CHEBI_27300', 'vitamin D', 384, 'vitamin E'), ('CHEBI_27300', 'vitamin D', 421, 'vitamin C'), ('CHEBI_27568', 'selenium atom', 451, 'selenium'), ('CHEBI_33229', 'vitamin (role)', 510, 'vitamin'), ('CHEBI_46662', 'mineral', 521, 'mineral')]
PMC2996405	11/2010	S99-PMC2996405	["* fisher's exact test;§bonferroni adjusted p-value\n\ncaption (fig): figure 1\n\noverlaps among latitude, Vitamin D and schizophrenia related Genes ."]	N/A	N/A	[('CHEBI_27300', 'vitamin D', 102, 'vitamin D'), ('SO_0000704', 'gene', 138, 'genes')]
PMC2996405	11/2010	S104-PMC2996405	['to achieve this, we merged: a list of 6 Genes implied in the Metabolism Of Vitamin D obtained from reactome, a list of 26 Genes in the pathway of the Control Of the Expression by Vitamin D receptor from biocarta and a list of 911 Genes from a large-scale identification of 1,25(Oh)2D3Target Genes by wang and colleagues [38].']	N/A	N/A	[('SO_0000704', 'gene', 40, 'genes'), ('GO_0019458', 'methionine catabolic process via 2-oxobutanoate', 61, 'metabolism of vitamin D'), ('CHEBI_27300', 'vitamin D', 75, 'vitamin D'), ('SO_0000704', 'gene', 122, 'genes'), ('GO_0010468', 'regulation of gene expression', 150, 'control of ... expression'), ('CHEBI_27300', 'vitamin D', 179, 'vitamin D'), ('SO_0000704', 'gene', 230, 'genes'), ('CHEBI_32819', 'L-2-amino-4-chloropent-4-enoate', 278, 'OH)2D3target'), ('SO_0000704', 'gene', 291, 'genes')]
PMC2996405	11/2010	S154-PMC2996405	['we found among Vitamin D related Genes a significant enrichment for Genes latitude-related (figure1and additional file3).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 15, 'vitamin D'), ('SO_0000704', 'gene', 33, 'genes'), ('SO_0000704', 'gene', 68, 'genes')]
PMC2996405	11/2010	S166-PMC2996405	['the largest part of Vitamin D related Genes in our list is made by Genes differentially Expressed in Epithelial Cells after treatment with the biological active form of Vitamin D [56].']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 20, 'vitamin D'), ('SO_0000704', 'gene', 38, 'genes'), ('SO_0000704', 'gene', 67, 'genes'), ('GO_0010467', 'gene expression', 88, 'expressed'), ('CL_0000066', 'epithelial cell', 101, 'epithelial cells'), ('UBERON_0000483', 'epithelium', 101, 'epithelial'), ('CHEBI_27300', 'vitamin D', 169, 'vitamin D')]
PMC2996405	11/2010	S191-PMC2996405	['winac and Vitamin D Receptor are targeted to Vitamin D responsive Promoters in the absence of ligand to both positively and negatively regulated Genes.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 10, 'vitamin D'), ('PR_000001683', 'vasopressin V2 receptor', 10, 'vitamin D receptor'), ('CHEBI_27300', 'vitamin D', 45, 'vitamin D'), ('SO_0000167', 'promoter', 66, 'promoters'), ('SO_0000704', 'gene', 145, 'genes')]
PMC2996405	11/2010	S268-PMC2996405	['the second one was extracted from the biocarta\'s pathway "Control Of the Expression by Vitamin D receptor" (h_vdrpathway) as present on the cancer Genome anatomy projecthttp://cgap.nci.nih.gov/.']	N/A	N/A	[('GO_0010468', 'regulation of gene expression', 58, 'Control of ... expression'), ('CHEBI_27300', 'vitamin D', 87, 'vitamin D'), ('SO_0001026', 'genome', 147, 'Genome')]
PMC2996405	11/2010	S304-PMC2996405	['excel spreadsheet containing the list of Vitamin D related Genes.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 41, 'vitamin D'), ('SO_0000704', 'gene', 59, 'genes')]
PMC3004407	12/2010	S0-PMC3004407	['profound Vitamin D deficiency in a diverse group of women during Pregnancy living in a sun-rich environment at latitude 32°n\n\nabstract\nobjective : determine prevalence of Vitamin D deficiency (vdd) in a diverse group of women presenting for obstetrical care at two community health centers in south carolina at latitude 32°n.']	N/A	N/A	[('CHEBI_28384', 'vitamin K', 9, 'Vitamin D'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 9, 'Vitamin D'), ('GO_0007565', 'female pregnancy', 65, 'Pregnancy'), ('CHEBI_27300', 'vitamin D', 171, 'vitamin D')]
PMC3004407	12/2010	S3-PMC3004407	['a single Blood sample was taken to measure circulating 25(Oh)D as indicator of Vitamin D status [25(Oh)D < 20\u2009ng/ml (50\u2009nmol/l deficiency; <32\u2009ng/ml (80\u2009nmol/l) insufficiency].']	N/A	N/A	[('UBERON_0000178', 'blood', 9, 'blood'), ('CHEBI_71657', 'versiconol acetate', 55, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 55, '25(OH ... D'), ('CHEBI_27300', 'vitamin D', 79, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 97, '25(OH)D'), ('PR_000003010', 'moesin isoform 1', 99, '(OH ... D')]
PMC3004407	12/2010	S34-PMC3004407	['each woman had been prescribed a Prenatal Vitamin containing 400\u2009iu of Vitamin D at her first Prenatal visit; compliance with the Prenatal vitamin regimen at the time of the Blood sampling was also recorded.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 33, 'prenatal'), ('CHEBI_33229', 'vitamin (role)', 42, 'vitamin'), ('CHEBI_27300', 'vitamin D', 71, 'vitamin D'), ('GO_0007565', 'female pregnancy', 94, 'prenatal'), ('GO_0007565', 'female pregnancy', 130, 'prenatal'), ('UBERON_0000178', 'blood', 174, 'blood')]
PMC3004407	12/2010	S36-PMC3004407	['Blood was processed and Serum separated for later analysis for total circulating 25-Hydroxy-Vitamin D [25(Oh)D], Serum calcium, phosphorus, and creatinine, and intact Parathyroid hormone (pth).']	N/A	N/A	[('UBERON_0000178', 'blood', 0, 'Blood'), ('UBERON_0001977', 'blood serum', 24, 'serum'), ('CHEBI_70487', '(-)-sanguinolignan C', 81, '25-hydroxy-'), ('CHEBI_27300', 'vitamin D', 92, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 103, '25(OH)D'), ('UBERON_0001977', 'blood serum', 113, 'serum'), ('UBERON_0001132', 'parathyroid gland', 167, 'parathyroid')]
PMC3004407	12/2010	S51-PMC3004407	['this laboratory participated throughout the study in the deqas quarterly quality control program for Vitamin D. a priori , “deficiency” was defined as a concentration <20\u2009ng/ml (<50\u2009nmol/l) and “insufficiency” as a concentration between 20 and 32\u2009ng/ml (50–80\u2009nmol/l) [43].']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 101, 'vitamin D')]
PMC3004407	12/2010	S88-PMC3004407	['overall, 48% of the participants were Vitamin D deficient, with an additional 37.1% insufficient.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 38, 'vitamin D')]
PMC3004407	12/2010	S92-PMC3004407	['Vitamin D status as measured by 25(Oh)D was also analyzed by season: after controlling for race, there was no significant evidence of seasonal variation in the prevalence of Vitamin D insufficiency and/or deficiency in this population.']	N/A	N/A	[('CHEBI_28384', 'vitamin K', 0, 'Vitamin D'), ('CHEBI_71657', 'versiconol acetate', 32, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 174, 'vitamin D')]
PMC3004407	12/2010	S97-PMC3004407	['after controlling for race, Prenatal/multivitamin use (containing 400\u2009iu Vitamin D/day) was not associated with 25(Oh)D concentration ( p = .11).']	N/A	N/A	[('GO_0007565', 'female pregnancy', 28, 'prenatal'), ('CHEBI_27300', 'vitamin D', 73, 'vitamin D'), ('PR_000006444', 'diacylglycerol kinase delta', 81, 'D'), ('CHEBI_71657', 'versiconol acetate', 112, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 112, '25(OH)D')]
PMC3004407	12/2010	S105-PMC3004407	['in exploratory univariate analyses, Vitamin D concentrations differed significantly or nearly significantly between subgroups based on hypertension ( p = .055), diabetes ( p = .023), varicose Veins ( p = .056), and the presence of any std ( p< .001).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 36, 'vitamin D'), ('UBERON_0000964', 'cornea', 192, 'veins')]
PMC3004407	12/2010	S128-PMC3004407	['overall, 48% of the participants were Vitamin D deficient, with an additional 37% being insufficient.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 38, 'vitamin D')]
PMC3004407	12/2010	S148-PMC3004407	['at its most basic concentration, such a burden of deficiency sets the stage of subsequent deficiency for the neonate and infant whose stores of Vitamin D were set during Pregnancy.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 144, 'vitamin D'), ('GO_0007565', 'female pregnancy', 170, 'pregnancy')]
PMC3028947	11/2010	S30-PMC3028947	['the evolution of the modern diet can be traced back from the Primate evolution when the Primate biology lost the ability to synthesize Vitamin C consequent to the good consumption of fruits28.']	N/A	N/A	[('NCBITaxon_9986', 'Oryctolagus cuniculus', 61, 'primate'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 88, 'primate'), ('CHEBI_27300', 'vitamin D', 135, 'vitamin C')]
PMC3032617	5/2010	S0-PMC3032617	['regular Vitamin C supplementation during Pregnancy reduces hospitalization: outcomes of a ugandan rural cohort study\n\nabstract:executive-summary\n\nbackground\nvitamin c or Ascorbic Acid is a hydro-soluble Lactone (synthesized from Glucose) essential to Human body and available from diet.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 8, 'vitamin C'), ('GO_0007565', 'female pregnancy', 41, 'pregnancy'), ('CHEBI_22652', 'ascorbic acid', 170, 'ascorbic acid'), ('CHEBI_25000', 'lactone', 203, 'lactone'), ('CHEBI_17234', 'glucose', 229, 'glucose'), ('NCBITaxon_9606', 'Homo sapiens', 251, 'human')]
PMC3032617	5/2010	S4-PMC3032617	['methods\n384 Pregnant women met the inclusion criteria and were randomly assigned to receive either 400 mg of Vitamin C daily (187) or not (197) in addition to their standard Antenatal Vitamins until Delivery.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 12, 'pregnant'), ('CHEBI_27300', 'vitamin D', 109, 'vitamin C'), ('GO_0007567', 'parturition', 174, 'antenatal'), ('CHEBI_33277', 'gamma-tocotrienol', 184, 'vitamins'), ('GO_0007567', 'parturition', 199, 'delivery')]
PMC3032617	5/2010	S7-PMC3032617	['results\n42.2% women in the Vitamin C group and 27.9% in the control group were not hospitalized during Pregnancy; this difference was found statistically significant.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 27, 'vitamin C'), ('GO_0007565', 'female pregnancy', 103, 'pregnancy')]
PMC3032617	5/2010	S43-PMC3032617	['treatment consisted of a chewable tablet and this was the synthetic form of L-Ascorbic Acid or Vitamin C. each chewable tablet was of 100mg and patients were prescribed two tablets two times a day (2×2) and advised to take with a full glass of Water (200ml) regardless of meals but with at least eight hours distance between the Intakes.']	N/A	N/A	[('CHEBI_29073', 'L-ascorbic acid', 76, 'L-ascorbic acid'), ('CHEBI_27300', 'vitamin D', 95, 'vitamin C'), ('CHEBI_15377', 'water', 244, 'water'), ('GO_0007631', 'feeding behavior', 329, 'intakes')]
PMC3032617	5/2010	S48-PMC3032617	['as patients presented to the health centre, those who met the inclusion criteria were randomly assigned to receive either 400 mg of Vitamin C daily or not in addition to their standard Antenatal Vitamins.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 132, 'vitamin C'), ('GO_0007567', 'parturition', 185, 'antenatal'), ('CHEBI_33277', 'gamma-tocotrienol', 195, 'vitamins')]
PMC3032617	5/2010	S50-PMC3032617	['randomization was obtained by a computer-generated, block design sequence to receive Vitamin C or not in a 1:1 ratio.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 85, 'vitamin C')]
PMC3032617	5/2010	S63-PMC3032617	['fisher’s exact test was employed to compare the Vitamin C group vs. controls with respect to: need or not for hospitalization, term Pregnancy, preterm Delivery, Miscarriage and child low Birth weight.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 48, 'vitamin C'), ('GO_0007565', 'female pregnancy', 132, 'pregnancy'), ('GO_0007567', 'parturition', 151, 'delivery'), ('GO_0046660', 'female sex differentiation', 161, 'miscarriage'), ('GO_0007567', 'parturition', 187, 'birth')]
PMC3032617	5/2010	S73-PMC3032617	['results\nof the four hundred patients assessed and entered into the trial, sixteen were excluded from further analysis after randomization, thirteen in the Vitamin C group and three in the control group.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 155, 'vitamin C')]
PMC3032617	5/2010	S76-PMC3032617	['three hundred and eighty four evaluable patients of which (n=187) in the Vitamin C group and (n=197) in the control group were included in the analysis.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 73, 'vitamin C')]
PMC3032617	5/2010	S78-PMC3032617	['during Pregnancy, 79 out of 187 (42.2%) in the Vitamin C group and 55 out of 197 (27.9%) in the control group were not hospitalized and this difference was considered statistically significant.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 7, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 47, 'vitamin C')]
PMC3032617	5/2010	S79-PMC3032617	['term Pregnancy was achieved by 143 out of 187 women in the Vitamin C group and 152 out of 197 in the control group, the difference was considered not significant.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 5, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 59, 'vitamin C')]
PMC3032617	5/2010	S80-PMC3032617	['for the Preterm Delivery, 15 vs.18 in the Vitamin C group and in the control group respectively were recorded and no statistical difference was found.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 8, 'preterm'), ('GO_0007567', 'parturition', 16, 'delivery'), ('CHEBI_27300', 'vitamin D', 42, 'vitamin C')]
PMC3032617	5/2010	S81-PMC3032617	['29 women in the Vitamin C group and 27 in the control group experienced Miscarriage, there was no statistical significance found.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 16, 'vitamin C'), ('GO_0046660', 'female sex differentiation', 72, 'miscarriage')]
PMC3032617	5/2010	S84-PMC3032617	['average weight gain during Pregnancy was of 14kg in the Vitamin C group of women and 15 kg in the control group, this difference was found statistically not significant (table 1).']	N/A	N/A	[('GO_0007565', 'female pregnancy', 27, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 56, 'vitamin C')]
PMC3032617	5/2010	S86-PMC3032617	['from baseline to Delivery there was a significant increase in systolic Blood pressure both in the Vitamin C and control groups, (table 4).']	N/A	N/A	[('GO_0007567', 'parturition', 17, 'delivery'), ('UBERON_0000178', 'blood', 71, 'blood'), ('CHEBI_27300', 'vitamin D', 98, 'vitamin C')]
PMC3032617	5/2010	S126-PMC3032617	['however, three women in the Vitamin C group and four in the control group were admitted for acute gastroenteritis deemed as bacterial then treated with Antibiotics and parenteral fluids.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 28, 'vitamin C'), ('CHEBI_33282', 'antibacterial agent', 152, 'antibiotics')]
PMC3034879	12/2010	S9-PMC3034879	['results\nthe children were divided into two groups based on Vitamin D status during Pregnancy.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 59, 'vitamin D'), ('GO_0007565', 'female pregnancy', 83, 'pregnancy')]
PMC3034879	12/2010	S37-PMC3034879	['maternal Vitamin D status was assessed in communal Prenatal clinics during the first trimesters as part of normal follow-up.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 9, 'vitamin D'), ('GO_0007565', 'female pregnancy', 51, 'prenatal')]
PMC3034879	12/2010	S59-PMC3034879	['the total intake of Vitamin D included intake from diet and from supplements.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 20, 'vitamin D')]
PMC3034879	12/2010	S91-PMC3034879	['for data analysis, the participants were divided into two groups based on maternal Vitamin D status during Pregnancy.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 83, 'vitamin D'), ('GO_0007565', 'female pregnancy', 107, 'pregnancy')]
PMC3034879	12/2010	S96-PMC3034879	['dietary intakes of energy, protein, Vitamin D and calcium did not differ between the groups and all children had normal development.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 36, 'vitamin D')]
PMC3034879	12/2010	S107-PMC3034879	['squares indicate high d and circles indicate low d\n\ncaption (table-wrap): table\xa03\n\ndistribution of Vitamin D status in 1-year-old children and mean intake in each categorys-25-Ohd (nmol/l) n (%)total intake of Vitamin D (μg/day)auser of d2(%)b<37.52 (2.3)12.2 (4.0)10037.6–5016 (18.6)10.6 (3.1)10050.1–79.953 (61.6)12.4 (2.8)88.5≥8015 (17.4)13.1 (2.5)50total (n)868484\natotal Intake differed between categories of 25-Ohd (anova; p \u2009=\u20090.03)\nbdistribution of d2users differed between categories (chi square; p \u2009=\u20090.001)\n\nTibia bmc, csa and bmd\nbone measurements were successful in 68 of subjects (78%) at the 14-month visit.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 99, 'vitamin D'), ('CHEBI_72765', 'verruculogen', 173, '25-OHD'), ('CHEBI_27300', 'vitamin D', 210, 'vitamin D'), ('GO_0007631', 'feeding behavior', 376, 'intake'), ('CHEBI_72765', 'verruculogen', 414, '25-OHD'), ('UBERON_0000979', 'tibia', 519, 'Tibia')]
PMC3034879	12/2010	S139-PMC3034879	['firstly, distal Tibia csa remained larger at 14\xa0months in infants with higher maternal Vitamin D status during Pregnancy than in infants with lower maternal Vitamin D status.']	N/A	N/A	[('UBERON_0000979', 'tibia', 16, 'tibia'), ('CHEBI_27300', 'vitamin D', 87, 'vitamin D'), ('GO_0007565', 'female pregnancy', 111, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 157, 'vitamin D')]
PMC3034879	12/2010	S140-PMC3034879	['secondly, the increment in Tibial bmc from Birth to 14\xa0months was higher in those with inferior maternal Vitamin D status during Pregnancy.']	N/A	N/A	[('UBERON_0002101', 'limb', 27, 'tibial'), ('GO_0007567', 'parturition', 43, 'birth'), ('CHEBI_27300', 'vitamin D', 105, 'vitamin D'), ('GO_0007565', 'female pregnancy', 129, 'pregnancy')]
PMC3034879	12/2010	S151-PMC3034879	['maternal Vitamin D status Regulates Skeletal growth and Development during fetal Life [9,10,28].']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 9, 'vitamin D'), ('GO_0065007', 'biological regulation', 26, 'regulates'), ('GO_0001501', 'skeletal system development', 36, 'skeletal ... development'), ('UBERON_0004288', 'skeleton', 36, 'skeletal'), ('UBERON_0000104', 'life cycle', 81, 'life')]
PMC3034879	12/2010	S156-PMC3034879	['furthermore, Vitamin D stimulates Osteoblastogenesis in Human Mesenchymal Stem Cells and Production Of Igf-1 in Osteoblasts [14].']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 13, 'vitamin D'), ('GO_0001503', 'ossification', 34, 'osteoblastogenesis'), ('NCBITaxon_9606', 'Homo sapiens', 56, 'human'), ('CL_0000134', 'mesenchymal stem cell', 62, 'mesenchymal stem cells'), ('UBERON_0003104', 'mesenchyme', 62, 'mesenchymal'), ('GO_0006412', 'translation', 89, 'production of IGF-1'), ('PR_000008929', 'interferon-related developmental regulator 1', 103, 'IGF-1'), ('CL_0000062', 'osteoblast', 112, 'osteoblasts')]
PMC3034879	12/2010	S157-PMC3034879	['in infants with rickets Vitamin D supplementation increases Serum Igf-1 and accelerates linear growth [33].']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 24, 'vitamin D'), ('UBERON_0001977', 'blood serum', 60, 'serum'), ('PR_000008929', 'interferon-related developmental regulator 1', 66, 'IGF-1')]
PMC3034879	12/2010	S190-PMC3034879	['at the 14-month visit, 2.3%, 18.4% and 79.3% were defined as Vitamin D deficient, insufficient and sufficient, respectively [20].']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 61, 'vitamin D')]
PMC3039633	2/2011	S31-PMC3039633	['the search syntax included four key parts: 1) terms defining the population of interest (Pregnancy, Pregnant women, Prenatal, Perinatal, Antenatal); 2) terms for Micronutrients (supplement, Micronutrient, dietary supplement, Vitamin, Mineral, Folic Acid/Folate, iron, Iodine, b complex, b12, selenium, zinc, Vitamin A, Vitamin D); 3) terms for developmental outcomes (Infant Development, Child Development, Mental Development, Brain Development, Neurodevelopment, Cognitive Development, psychomotor, iq, behavior); and 4) terms for study design (rct, pseudo-experimental, clinical trial, longitudinal cohort).']	N/A	N/A	[('GO_0007565', 'female pregnancy', 89, 'pregnancy'), ('GO_0007565', 'female pregnancy', 100, 'pregnant'), ('GO_0007565', 'female pregnancy', 116, 'prenatal'), ('GO_0036268', 'swimming', 126, 'perinatal'), ('UBERON_0012101', 'perinatal stage', 126, 'perinatal'), ('GO_0007567', 'parturition', 137, 'antenatal'), ('CHEBI_33839', 'macromolecule', 162, 'micronutrients'), ('CHEBI_33962', 'mu4-sulfido-quadro-tetracopper(6+)', 190, 'micronutrient'), ('CHEBI_33229', 'vitamin (role)', 225, 'vitamin'), ('CHEBI_46662', 'mineral', 234, 'mineral'), ('CHEBI_30751', 'formic acid', 243, 'folic acid'), ('CHEBI_30863', '5-azaorotic acid', 254, 'folate'), ('CHEBI_24859', 'iodine atom', 268, 'iodine'), ('CHEBI_27300', 'vitamin D', 308, 'vitamin A'), ('CHEBI_27300', 'vitamin D', 319, 'vitamin D'), ('GO_0060119', 'inner ear receptor cell development', 368, 'infant development'), ('GO_0001410', 'chlamydospore formation', 388, 'child development'), ('GO_0030901', 'midbrain development', 407, 'mental development'), ('GO_0007420', 'brain development', 427, 'brain development'), ('UBERON_0000955', 'brain', 427, 'brain'), ('GO_0007399', 'nervous system development', 446, 'neurodevelopment'), ('GO_0050787', 'detoxification of mercury ion', 464, 'cognitive development')]
PMC3039633	2/2011	S71-PMC3039633	['[28]276 infants(rural indonesia)1,2(at 6 and 12 mo)bayley scales of infant developmentiron + Folic Acid + Vitamin A vs. Iron + Folic Acid vs. ld iron + ld Folic Acid20 weeks Gestation to Birth∅ 1, 214/21tamura et al.']	N/A	N/A	[('CHEBI_30751', 'formic acid', 93, 'folic acid'), ('CHEBI_27300', 'vitamin D', 106, 'vitamin A'), ('CHEBI_24870', 'ion', 120, 'iron'), ('CHEBI_30751', 'formic acid', 127, 'folic acid'), ('CHEBI_70616', '4-hydroxybenzoic acid 4-(6-O-sulfo)glucopyranoside', 155, 'folic acid20'), ('GO_0007565', 'female pregnancy', 174, 'gestation'), ('GO_0007567', 'parturition', 187, 'birth'), ('GO_0007567', 'parturition', 192, '∅')]
PMC3039633	2/2011	S99-PMC3039633	['[27]"Vitamin A"6000----------------mcgrath et al.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 5, 'vitamin A')]
PMC3039633	2/2011	S103-PMC3039633	['[28]"Iron + Folic Acid + Vitamin A"4800-----0.5---120------schmidt et al.']	N/A	N/A	[('CHEBI_24870', 'ion', 5, 'iron'), ('CHEBI_30751', 'formic acid', 12, 'folic acid'), ('CHEBI_27300', 'vitamin D', 25, 'vitamin A')]
PMC3039633	2/2011	S115-PMC3039633	['[27] - Vitamin A dose provided as 30 mg Beta-Carotene (4500 mcg rae) and 5000 iu (1500 mcg rae) preformed Vitamin A\netofail et al.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 7, 'vitamin A'), ('CHEBI_17579', 'beta-carotene', 40, 'beta-carotene'), ('CHEBI_27300', 'vitamin D', 106, 'vitamin A')]
PMC3075531	7/2010	S17-PMC3075531	['we included them if they had the following criteria: no known diseases related to Vitamin D deficiency such as rickets or Parathyroid diseases and no intake of Drug or supplement containing Vitamin D or calcium.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 82, 'vitamin D'), ('UBERON_0001132', 'parathyroid gland', 122, 'parathyroid'), ('CHEBI_23888', 'drug', 160, 'drug'), ('CHEBI_27300', 'vitamin D', 190, 'vitamin D')]
PMC3075531	7/2010	S20-PMC3075531	['in attention to exclusion criteria (not to give Blood sample or usage of Vitamin D supplement during the study period) none of the case and control populations were not excluded from our research.']	N/A	N/A	[('UBERON_0000178', 'blood', 48, 'blood'), ('CHEBI_27300', 'vitamin D', 73, 'vitamin D')]
PMC3075531	7/2010	S24-PMC3075531	['after gathering information, we divided all subjects into three categories on the base of their 25-Hydroxy Vitamin D Serum level as follows: Vitamin D deficient patients (Serum level below 25 nmol/l), Vitamin D insufficient cases (Serum level between 25 and 75 nmol/l) and subjects with normal or higher than normal Vitamin D level (Serum level higher than 75 nmol/l).']	N/A	N/A	[('CHEBI_43141', '3-hydroxypropoxy group', 96, '25-hydroxy'), ('CHEBI_27300', 'vitamin D', 107, 'vitamin D'), ('UBERON_0001977', 'blood serum', 117, 'serum'), ('CHEBI_27300', 'vitamin D', 141, 'vitamin D'), ('UBERON_0001977', 'blood serum', 171, 'serum'), ('CHEBI_27300', 'vitamin D', 201, 'vitamin D'), ('UBERON_0001977', 'blood serum', 231, 'serum'), ('CHEBI_27300', 'vitamin D', 316, 'vitamin D'), ('UBERON_0001977', 'blood serum', 333, 'serum')]
PMC3075531	7/2010	S25-PMC3075531	['the mean 25-Hydroxy Vitamin D levels in case and control groups were compared with independent t test.']	N/A	N/A	[('CHEBI_43141', '3-hydroxypropoxy group', 9, '25-hydroxy'), ('CHEBI_27300', 'vitamin D', 20, 'vitamin D')]
PMC3075531	7/2010	S26-PMC3075531	['the relationship of Vitamin D level with other factors was compared by chi-square test.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 20, 'vitamin D')]
PMC3075531	7/2010	S31-PMC3075531	['the mean levels of Vitamin D in the two groups are shown infigure 1.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 19, 'vitamin D')]
PMC3075531	7/2010	S33-PMC3075531	['the number of patients with Vitamin D deficiency, insufficiency and normal range in the case group were 15 (30%), 28 (56%) and 7 (14%), respectively.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 28, 'vitamin D')]
PMC3075531	7/2010	S36-PMC3075531	['Serum levels of Vitamin D in three categories in the two groups are shown infigure 2.']	N/A	N/A	[('UBERON_0001977', 'blood serum', 0, 'Serum'), ('CHEBI_27300', 'vitamin D', 16, 'vitamin D')]
PMC3075531	7/2010	S37-PMC3075531	['the mean levels of Vitamin D in the case group for deficient, insufficient and normal categories were 13.78, 49.14, and 116.81, respectively and these numbers for control group were 17.44, 53.34, and 93.97, respectively.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 19, 'vitamin D')]
PMC3075531	7/2010	S38-PMC3075531	['caption (fig): figure 1\n\nmean Serum levels of Vitamin D based on sex in the two groups.']	N/A	N/A	[('UBERON_0001977', 'blood serum', 30, 'serum'), ('CHEBI_27300', 'vitamin D', 46, 'vitamin D')]
PMC3075531	7/2010	S39-PMC3075531	['caption (fig): figure 2\n\nSerum levels of Vitamin D in three categories in case and control groups.']	N/A	N/A	[('UBERON_0001977', 'blood serum', 25, 'Serum'), ('CHEBI_27300', 'vitamin D', 41, 'vitamin D')]
PMC3075531	7/2010	S41-PMC3075531	['the primary form of Vitamin D, Colecalciferol (Vitamin D3), is available from two sources: skin exposure to ultraviolet b radiation (uvb) in sunlight and diet.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 20, 'vitamin D'), ('CHEBI_50553', 'mancude carbobicyclic parent', 31, 'colecalciferol'), ('CHEBI_33279', 'vitamin D5', 47, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 47, 'vitamin D3')]
PMC3103150	3/2011	S4-PMC3103150	['details of infants’ Feeding, Vitamin D supplementation, sunlight exposure and mothers’ Calcium and Vitamin D intake were recorded.']	N/A	N/A	[('GO_0007631', 'feeding behavior', 20, 'feeding'), ('CHEBI_27300', 'vitamin D', 29, 'vitamin D'), ('CHEBI_22313', 'alkaline earth metal atom', 87, 'calcium'), ('CHEBI_27300', 'vitamin D', 99, 'vitamin D')]
PMC3103150	3/2011	S25-PMC3103150	['enrollment of study participants:\nthe calculated sample size for an anticipated prevalence of Vitamin D deficiency of 80 per cent to fall within 10 per centof the true prevalence with 95 per centconfidence was 256.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 94, 'vitamin D')]
PMC3103150	3/2011	S32-PMC3103150	['clinical and anthropometric data:\ndetails regarding mode of Feeding of infant, supplementation of any Vitamin or Calcium to infant, mothers’ diet, Intake of Calcium and Vitamin D supplements during Pregnancy and after Delivery, education and profession, financial status of the family and usual duration and type of clothing worn during sunlight exposure for both infant and mother were recorded in a case record form.']	N/A	N/A	[('GO_0007631', 'feeding behavior', 60, 'feeding'), ('CHEBI_33229', 'vitamin (role)', 102, 'vitamin'), ('CHEBI_22313', 'alkaline earth metal atom', 113, 'calcium'), ('GO_0007631', 'feeding behavior', 147, 'intake'), ('CHEBI_22313', 'alkaline earth metal atom', 157, 'calcium'), ('CHEBI_27300', 'vitamin D', 169, 'vitamin D'), ('GO_0007565', 'female pregnancy', 198, 'pregnancy'), ('GO_0007567', 'parturition', 218, 'delivery')]
PMC3103150	3/2011	S45-PMC3103150	['the radiographs were interpreted by a single radiologist, experienced in reporting of paediatric radiographs, who was blinded to the biochemical Vitamin D status of the infants.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 145, 'vitamin D')]
PMC3103150	3/2011	S49-PMC3103150	['of Vitamin D deficiency and insufficiency was presented for the primary objective.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 3, 'vitamin D')]
PMC3103150	3/2011	S77-PMC3103150	['of Vitamin D deficiency and insufficiency (25Ohd < 20 ng/ml) in infants and mothers was 86.5 per cent (78.0, 92.6) and 92.6 per cent (85.4, 97.0), respectively.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 3, 'vitamin D'), ('CHEBI_72652', "7,2'-dihydroxy-4'-methoxyisoflavan-4-ylium cation", 43, '25OHD')]
PMC3103150	3/2011	S80-PMC3103150	['among infants and mothers with Vitamin D deficiency, hyperparathyroidism was present in 62.5 and 57.0 per cent, respectively.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 31, 'vitamin D')]
PMC3103150	3/2011	S81-PMC3103150	['amongst those with severe Vitamin D deficiency, hyperparathyroidism was present in 90.3 per cent infants and 73.1 per cent mothers.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 26, 'vitamin D')]
PMC3103150	3/2011	S101-PMC3103150	['the odds ratio (95% ci) for Vitamin D deficiency among infants Born to mothers with deficiency was 3.4 (1.2, 9.9) compared to those Born to mothers without deficiency.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 28, 'vitamin D'), ('GO_0007567', 'parturition', 63, 'born'), ('GO_0007567', 'parturition', 132, 'born')]
PMC3107676	4/2011	S9-PMC3107676	['supplemental Vitamin C, an Inhibitor Of Nitrosation, was not taken by 41.6% and 19.3% of Nitrosatable Drug users during the first and second months of Pregnancy, respectively.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 13, 'vitamin C'), ('CHEBI_52846', 'cycloalkane ring', 27, 'inhibitor of nitrosation'), ('CHEBI_7587', 'nitroalkane', 89, 'nitrosatable'), ('CHEBI_23888', 'drug', 102, 'drug'), ('GO_0007565', 'female pregnancy', 151, 'pregnancy')]
PMC3107676	4/2011	S107-PMC3107676	['caption (table-wrap): table 3\n\nvitamin c supplementationaamong Nitrosatable Drug users during the first three months of Pregnancy, national Birth defects prevention study control women, 1997–2005number (%) who took Supplement with Vitamin C in the first month postconceptionnumber (%) who took Supplement with Vitamin C in the second month Postconceptionnumber (%) who took supplement with Vitamin C in the third month Postconceptionnitrosatable Drug takennoneless than dailydailynoneless than dailydailynoneless than dailydailyany652 (41.6)311 (19.8)604 (38.5)303 (19.3)299 (19.1)965 (61.6)193 (12.3)125 (8.0)1249 (79.7)secondary Amine334 (40.4)165 (20.0)327 (39.6)158 (19.1)149 (18.0)519 (62.8)89 (10.8)71 (8.6)666 (80.6)tertiary Amine333 (40.8)175 (21.4)308 (37.7)139 (17.0)176 (21.6)501 (61.4)98 (12.0)67 (8.2)651 (79.8)Amide205 (40.0)107 (20.9)200 (39.1)93 (18.2)97 (18.9)322 (62.9)58 (11.3)37 (7.2)417 (81.4)\nsupplementation from single, Prenatal, or multi-vitamin preparations.']	N/A	N/A	[('CHEBI_35705', 'immunosuppressive agent', 63, 'Nitrosatable Drug'), ('GO_0007565', 'female pregnancy', 120, 'Pregnancy'), ('GO_0007567', 'parturition', 140, 'Birth'), ('CHEBI_16158', 'steroid sulfate', 215, 'supplement'), ('CHEBI_27300', 'vitamin D', 231, 'vitamin C'), ('CHEBI_16158', 'steroid sulfate', 294, 'supplement'), ('CHEBI_27300', 'vitamin D', 310, 'vitamin C'), ('GO_0001110', 'promoter clearance from RNA polymerase III promoter', 340, 'postconceptionNumber'), ('CHEBI_27300', 'vitamin D', 390, 'vitamin C'), ('GO_0042711', 'maternal behavior', 419, 'postconceptionNitrosatable'), ('CHEBI_23888', 'drug', 446, 'drug'), ('CHEBI_82784', 'PVP38-Ag NP', 631, 'amine334'), ('CHEBI_83325', 'beta-carboline alkaloid', 732, 'amine333'), ('CHEBI_52661', 'Alexa Fluor 488', 824, 'Amide205'), ('GO_0007565', 'female pregnancy', 944, 'prenatal')]
PMC3107676	4/2011	S145-PMC3107676	['a substantial proportion of women who took these Medications during the first Trimester did not take supplements containing Vitamin C on a daily basis until the third month of pregnancy.']	N/A	N/A	[('CHEBI_25441', 'mycothiols', 49, 'medications'), ('GO_0009294', 'DNA mediated transformation', 78, 'trimester'), ('CHEBI_27300', 'vitamin D', 124, 'vitamin C')]
PMC3119798	10/2010	S37-PMC3119798	['after the operation, patients received Prenatal Vitamins, Calcium supplements, Vitamin D, and Acid suppression medication.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 39, 'prenatal'), ('CHEBI_33277', 'gamma-tocotrienol', 48, 'vitamins'), ('CHEBI_22313', 'alkaline earth metal atom', 58, 'calcium'), ('CHEBI_27300', 'vitamin D', 79, 'vitamin D'), ('CHEBI_37527', 'acid', 94, 'acid')]
PMC3120196	7/2011	S62-PMC3120196	['these factors included bmi (<25, 25–29.9, or ≥30 kg/m2), physical activity (highest 2 quintiles vs. lowest 3), family history of diabetes (yes or no), current cigarette smoking (yes or no), and dietary Vitamin C (high vs. low).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 202, 'vitamin C'), ('PR_000004900', 'complement C3', 210, 'C')]
PMC3120196	7/2011	S90-PMC3120196	['the association did not vary by bmi, physical activity, family history of diabetes, or Vitamin C intake (data not shown).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 87, 'vitamin C')]
PMC3120197	7/2011	S86-PMC3120197	['caption (table-wrap): table 2\n\nrrs and 95% cis of gdm according to quartiles of dietary Heme and nonheme Iron Intake, seattle and tacoma, wa, omega cohort studydietary iron variablesmediangdm ( n )energy adjustedadjusted*adjusted†incidence (%)rr (95% ci)rr (95% ci)rr (95% ci)dietary Heme iron (mg per day)\u2003quartile 1 (<0.48)0.3033 (4.1)1.00 (referent)1.00 (referent)1.00 (referent)\u2003quartile 2 (0.48–0.75)0.6136 (4.7)1.22 (0.76–1.96)1.17 (0.73–1.89)1.27 (0.77–2.09)\u2003quartile 3 (0.76–1.11)0.9336 (4.5)1.28 (0.79–2.08)1.20 (0.73–1.95)1.41 (0.81–2.44)\u2003quartile 4 (≥1.12)1.4353 (6.7)2.12 (1.31–3.43)1.57 (0.95–2.61)2.15 (1.09–4.27) \u2003p for trend0.0030.090.04\u2003quartile 1 (<0.48)0.3033 (4.1)1.00 (referent)1.00 (referent)1.00 (referent)\u2003upper decile (≥1.52)1.8525 (7.8)3.32 (1.70–6.47)2.26 (1.09–4.69)3.31 (1.02–10.72)dietary nonheme iron (mg per day)\u2003quartile 1 (<9.10)7.1650 (6.4)1.00 (referent)1.00 (referent)1.00 (referent)\u2003quartile 2 (9.10–12.16)10.6544 (5.6)0.83 (0.54–1.28)0.85 (0.54–1.33)0.83 (0.53–1.31)\u2003quartile 3 (12.17–15.97)13.8133 (4.2)0.60 (0.36–1.00)0.63 (0.37–1.08)0.62 (0.36–1.06)\u2003quartile 4 (≥12.98)19.6031 (3.9)0.54 (0.29–0.99)0.61 (0.32–1.17)0.61 (0.31–1.18) \u2003p for trend0.030.080.08\u2003quartile 1 (<9.10)7.1650 (6.4)1.00 (referent)1.00 (referent)1.00 (referent)\u2003upper decile (≥21.13)25.1911 (3.5)0.29 (0.10–0.84)0.34 (0.10–1.10)0.30 (0.09–0.99)\n*adjusted for daily energy intake, maternal age, race/ethnicity, parity, physical activity, Prepregnancy bmi, dietary fiber, and Vitamin C intake.']	N/A	N/A	[('CHEBI_30413', 'heme', 88, 'heme'), ('CHEBI_24870', 'ion', 105, 'iron'), ('GO_0007631', 'feeding behavior', 110, 'intake'), ('CHEBI_30413', 'heme', 284, 'heme'), ('GO_0007565', 'female pregnancy', 1449, 'prepregnancy'), ('CHEBI_27300', 'vitamin D', 1486, 'vitamin C')]
PMC3120197	7/2011	S87-PMC3120197	['†adjusted for daily energy intake; maternal age; race/ethnicity; parity; physical activity; Prepregnancy bmi; and dietary fiber, Vitamin C, saturated fat, Cholesterol, and red and processed meat Intake.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 92, 'prepregnancy'), ('CHEBI_27300', 'vitamin D', 129, 'vitamin C'), ('CHEBI_16113', 'cholesterol', 155, 'cholesterol'), ('GO_0007631', 'feeding behavior', 195, 'intake')]
PMC3120197	7/2011	S96-PMC3120197	['caption (fig): figure 1\n\nrelationship between maternal dietary Heme iron Intake in early Pregnancy and risk of gdm (solid line) with 95% cis (dotted lines) after adjusting for daily energy intake; maternal age; race/ethnicity; parity; physical activity; Prepregnancy bmi; and dietary fiber, Vitamin C, Saturated Fat, Cholesterol, and red and processed meat intake.']	N/A	N/A	[('CHEBI_30413', 'heme', 63, 'heme'), ('GO_0007631', 'feeding behavior', 73, 'intake'), ('GO_0007565', 'female pregnancy', 89, 'pregnancy'), ('GO_0007565', 'female pregnancy', 254, 'prepregnancy'), ('CHEBI_27300', 'vitamin D', 291, 'vitamin C'), ('CHEBI_26710', 'sodium chloride', 302, 'saturated fat'), ('CHEBI_16113', 'cholesterol', 317, 'cholesterol')]
PMC3130670	6/2011	S61-PMC3130670	["the fchv has a number of specific responsibilities: facilitation of the mother's group, counselling on family planning and distribution of Contraceptives, contribution to the community component of the integrated management of childhood illness, health education, safer motherhood referral services, immunization with an emphasis on oral polio vaccine and tetanus Toxoid, distribution of Vitamin A, anthelminthics and Iron supplements, management of minor illnesses and injuries, and nutrition education [21]."]	N/A	N/A	[('CHEBI_35223', 'catalyst', 139, 'contraceptives'), ('CHEBI_29238', 'tritium atom', 364, 'toxoid'), ('CHEBI_27300', 'vitamin D', 388, 'vitamin A'), ('CHEBI_24870', 'ion', 418, 'iron')]
PMC3169551	9/2011	S136-PMC3169551	['promotion accounted for 11% of the non-supplement costs, training 6% , volunteer time 24%, temporary paid workers 10%, permanent, salaried staff 41%, and other 11% for Vitamin A.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 168, 'vitamin A')]
PMC3171895	9/2011	S37-PMC3171895	['for this paper, we included data and relevant information obtained through a search of the pubmed database using free text and medical subject headings terms for all articles published in english from 1971 through 2011 which included the term “selenium,” “zinc,” “copper,” “manganese,” “Vitamin E and C,” and one of the following: “Pregnancy,” “Preeclampsia,” or “fetal growth restriction.” we further included published and unpublished data from our own laboratories and an “in-house” library of relevant publications.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 287, 'vitamin E'), ('PR_000004900', 'complement C3', 301, 'C'), ('GO_0007565', 'female pregnancy', 332, 'pregnancy'), ('GO_0007128', 'meiotic prophase I', 345, 'preeclampsia')]
PMC3231892	4/2011	S88-PMC3231892	['twelve studies used multiple Micronutrient supplement formula called unimmap which consisted of 30 mg iron, 400 µg Folic Acid, 15 mg zinc, 2 mg copper, 65 µg Selenium, 800 µg re Vitamin A, 1.4 mg Vitamin B1, 1.4 mg Vitamin B2, 18 mg niacin, 1.9 mg Vitamin B6, 2.6 µg Vitamin B12, 70 mg Vitamin C, 5 µg Vitamin D, 10 mg Vitamin E and 150 µg Iodine.']	N/A	N/A	[('CHEBI_33962', 'mu4-sulfido-quadro-tetracopper(6+)', 29, 'micronutrient'), ('CHEBI_30751', 'formic acid', 115, 'folic acid'), ('CHEBI_27568', 'selenium atom', 158, 'selenium'), ('CHEBI_27300', 'vitamin D', 178, 'vitamin A'), ('PR_000004483', 'V-type proton ATPase subunit C 1', 196, 'vitamin B1'), ('CHEBI_33279', 'vitamin D5', 215, 'vitamin B2'), ('PR_000004481', 'V-type proton ATPase subunit B, kidney isoform', 215, 'vitamin B2'), ('CHEBI_33237', 'vitamin D4', 248, 'vitamin B6'), ('CHEBI_33279', 'vitamin D5', 267, 'vitamin B12'), ('CHEBI_27300', 'vitamin D', 286, 'vitamin C'), ('CHEBI_27300', 'vitamin D', 302, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 319, 'vitamin E'), ('CHEBI_24859', 'iodine atom', 340, 'iodine')]
PMC3231892	4/2011	S136-PMC3231892	['[26] had reported infant deaths (0 – 3 months) in the multiple Micronutrient recipients versus controls (receiving Vitamin A only) with a non-significant higher risk in the Micronutrient group (rr = 1.07; 95% ci: 0.75 – 1.58).']	N/A	N/A	[('CHEBI_33962', 'mu4-sulfido-quadro-tetracopper(6+)', 63, 'micronutrient'), ('CHEBI_27300', 'vitamin D', 115, 'vitamin A'), ('CHEBI_33962', 'mu4-sulfido-quadro-tetracopper(6+)', 173, 'micronutrient')]
PMC3231910	4/2011	S130-PMC3231910	['of studies (ref)designlimitationsconsistencygeneralizability to population of interestgeneralizability to intervention of interestrelative risk ( 95 % ci)Stillbirth: low outcome specific quality 13rctmethods of sequence generation and allocation concealment were not explicitly described in few of the studiesheterogeneity in the pooled data was not significant (i2=38%)all included studies from developing countriesnine studies used unimmap formulation (30 mg iron, 400 µg Folic Acid, 15 mg zinc, 2 mg copper, 65 µg Selenium, 800 µg re vitamin a, 1.4 mg vitamin b1, 1.4 mg Vitamin B2, 18 mg niacin, 1.9 mg Vitamin B6, 2.6 µg Vitamin B12, 70 mg Vitamin C, 5 µg Vitamin D, 10 mg Vitamin E and 150 µg Iodine)0.98 (0.88-1.10)a peri-Natal mortality: low outcome specific quality 11rctmethods of sequence generation and allocation concealment were not explicitly described in few of the studiessignificant heterogeneity (i2=56%).']	N/A	N/A	[('GO_0001967', 'suckling behavior', 154, 'Stillbirth'), ('CHEBI_30751', 'formic acid', 474, 'folic acid'), ('CHEBI_27568', 'selenium atom', 517, 'selenium'), ('CHEBI_33279', 'vitamin D5', 574, 'vitamin B2'), ('CHEBI_33237', 'vitamin D4', 607, 'vitamin B6'), ('CHEBI_33279', 'vitamin D5', 626, 'vitamin B12'), ('PR_000004738', 'class E basic helix-loop-helix protein 22', 634, 'B12'), ('CHEBI_27300', 'vitamin D', 645, 'vitamin C'), ('CHEBI_27300', 'vitamin D', 661, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 678, 'vitamin E'), ('CHEBI_24859', 'iodine atom', 699, 'iodine'), ('GO_0007567', 'parturition', 729, 'natal')]
PMC3231910	4/2011	S131-PMC3231910	['random models usedall included studies from developing countriesnine studies used unimmap formulation (30 mg iron, 400 µg Folic Acid, 15 mg zinc, 2 mg copper, 65 µg Selenium, 800 µg re Vitamin A, 1.4 mg Vitamin B1, 1.4 mg Vitamin B2, 18 mg niacin, 1.9 mg Vitamin B6, 2.6 µg Vitamin B12, 70 mg Vitamin C, 5 µg Vitamin D, 10 mg Vitamin E and 150 µg Iodine)1.07 (0.92 –1.25)a\na: generic inverse variance\n\ndiscussion\nevidence from a cochrane review by lumley et al.']	N/A	N/A	[('CHEBI_30751', 'formic acid', 122, 'folic acid'), ('CHEBI_27568', 'selenium atom', 165, 'selenium'), ('CHEBI_27300', 'vitamin D', 185, 'vitamin A'), ('PR_000004483', 'V-type proton ATPase subunit C 1', 203, 'vitamin B1'), ('CHEBI_33279', 'vitamin D5', 222, 'vitamin B2'), ('PR_000004481', 'V-type proton ATPase subunit B, kidney isoform', 222, 'vitamin B2'), ('CHEBI_33237', 'vitamin D4', 255, 'vitamin B6'), ('CHEBI_33279', 'vitamin D5', 274, 'vitamin B12'), ('CHEBI_27300', 'vitamin D', 293, 'vitamin C'), ('CHEBI_27300', 'vitamin D', 309, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 326, 'vitamin E'), ('CHEBI_24859', 'iodine atom', 347, 'iodine')]
PMC3235789	12/2011	S64-PMC3235789	['(1) Vitamin D\nPlasma 25-Oh-D concentration, the major circulating form of Vitamin D, was assayed using a commercially available elisa kit (immunodiagnostic systems, fountain hills, az), the range of detection for which is 2–120\u2009ng/ml.']	N/A	N/A	[('CHEBI_28384', 'vitamin K', 4, 'Vitamin D'), ('UBERON_0001969', 'blood plasma', 14, 'Plasma'), ('CHEBI_46744', 'DDT-2,3-dihydrodiol', 21, '25-OH-D'), ('CHEBI_27300', 'vitamin D', 74, 'vitamin D')]
PMC3235789	12/2011	S65-PMC3235789	['analyses were performed at the Vitamin D and bone research laboratory at emory university school of medicine, which participates in the Vitamin D external quality assessment scheme (http://www.deqas.org/) and in the national institutes of health/national institute of standards and technology (nih/nist) Vitamin D metabolites quality assurance program (vitdqap) to ensure accuracy of the 25-Oh-D measurements.']	N/A	N/A	[('CHEBI_28384', 'vitamin K', 31, 'Vitamin D'), ('CHEBI_27300', 'vitamin D', 136, 'vitamin D'), ('CHEBI_28384', 'vitamin K', 304, 'Vitamin D'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 304, 'Vitamin D'), ('CHEBI_46744', 'DDT-2,3-dihydrodiol', 388, '25-OH-D')]
PMC3257641	3/2010	S11-PMC3257641	['still within the skin, Previtamin D3Undergoes a chemical rearrangement to form Vitamin D3(Cholecalciferol) that is taken up into the circulation largely bound to the Vitamin D binding protein [1].']	N/A	N/A	[('PR_000013199', 'prolargin', 23, 'previtamin D3undergoes'), ('CHEBI_50837', 'estrogen antagonist', 34, 'D3undergoes'), ('CHEBI_33279', 'vitamin D5', 79, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 79, 'vitamin D3'), ('CHEBI_52550', 'theopalauamide', 90, 'cholecalciferol'), ('CHEBI_27300', 'vitamin D', 166, 'vitamin D')]
PMC3257641	3/2010	S14-PMC3257641	['both sunlight-derived (Vitamin D3) or Ingested (Vitamin D2Or Vitamin D3) Vitamin D are transported to the Liver where 25-hydroxylase enzymes catalyze conversion to the primary storage form (and the usual Serum measure of Vitamin D status), 25-Hydroxyvitamin D (25(Oh)D) [4].']	N/A	N/A	[('CHEBI_33279', 'vitamin D5', 23, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 23, 'vitamin D3'), ('GO_0007631', 'feeding behavior', 38, 'ingested'), ('CHEBI_27329', 'xanthosine phosphate', 48, 'vitamin D2or'), ('PR_000017209', 'utrophin', 48, 'vitamin D2or'), ('CHEBI_33279', 'vitamin D5', 61, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 61, 'vitamin D3'), ('CHEBI_27300', 'vitamin D', 73, 'vitamin D'), ('UBERON_0002107', 'liver', 106, 'liver'), ('UBERON_0001977', 'blood serum', 204, 'serum'), ('CHEBI_27300', 'vitamin D', 221, 'vitamin D'), ('CHEBI_62218', '23,24-dihydrocucurbitacin D', 240, '25-hydroxyvitamin D'), ('CHEBI_71657', 'versiconol acetate', 261, '25(OH)D')]
PMC3257641	3/2010	S130-PMC3257641	['in experimental studies, Rats deprived of Vitamin D Prenatally had enlarged Lateral Ventricles, decreased Cortical thickness and heavier and longer Brains, and altered patterns of Apoptosis [70,71].']	N/A	N/A	[('NCBITaxon_9986', 'Oryctolagus cuniculus', 25, 'rats'), ('CHEBI_27300', 'vitamin D', 42, 'vitamin D'), ('GO_0019230', 'proprioception', 52, 'prenatally'), ('UBERON_0002285', 'telencephalic ventricle', 76, 'lateral ventricles'), ('UBERON_0001851', 'cortex', 106, 'cortical'), ('UBERON_0000955', 'brain', 148, 'brains'), ('GO_0006915', 'apoptotic process', 180, 'apoptosis')]
PMC3271033	1/2012	S3-PMC3271033	['among 38 infants who completed a 3 month Vitamin D supplementation intervention, provision of 400 iu/day of Vitamin D increased final 25(Oh)D to a higher level in non-hispanic caucasian compared to hispanic infants.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 41, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 108, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 134, '25(OH)D'), ('PR_000009880', 'Lon protease, mitochondrial', 134, '25 ... OH ... D')]
PMC3271033	1/2012	S4-PMC3271033	['there was no significant relationship between Cord Serum 25(Oh)D and bmc or bmd in the first week of Life (n = 49) or after 3 months of Vitamin D supplementation.']	N/A	N/A	[('UBERON_0002240', 'spinal cord', 46, 'cord'), ('UBERON_0001977', 'blood serum', 51, 'serum'), ('CHEBI_71657', 'versiconol acetate', 57, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 57, '25(OH)D'), ('UBERON_0000104', 'life cycle', 101, 'life'), ('CHEBI_27300', 'vitamin D', 136, 'vitamin D')]
PMC3271033	1/2012	S19-PMC3271033	['due to the guidelines for providing Vitamin D supplements to all Breast-Fed infants, it is not ethically possible to conduct a placebo-controlled study of vitamin d supplementation in the united states.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 36, 'vitamin D'), ('GO_0007567', 'parturition', 65, 'breast'), ('UBERON_0000310', 'breast', 65, 'breast'), ('GO_0007631', 'feeding behavior', 72, 'fed')]
PMC3271033	1/2012	S23-PMC3271033	['the latitude of houston, tx is 29 degrees, more southern than the typically used latitude cutoff of atlanta, georgia of 33 degrees for sunlight exposure to lead to Vitamin D formation in the Dermis to occur throughout the year.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 164, 'vitamin D'), ('UBERON_0002067', 'dermis', 191, 'dermis')]
PMC3271033	1/2012	S29-PMC3271033	['one week later, subjects returned to the research facility for whole body dual-energy x-ray absorptiometry (dxa) measurements and to receive the Vitamin D supplements (400 iu/ml) with instructions to give daily by mouth until the final study visit.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 145, 'vitamin D')]
PMC3271033	1/2012	S33-PMC3271033	['a brief questionnaire on Prenatal Vitamins, including name and frequency, and intake of Vitamin D rich Foods was completed.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 25, 'prenatal'), ('CHEBI_33277', 'gamma-tocotrienol', 34, 'vitamins'), ('CHEBI_27300', 'vitamin D', 88, 'vitamin D'), ('CHEBI_33290', 'food', 103, 'foods')]
PMC3271033	1/2012	S61-PMC3271033	['to convert Serum Vitamin D levels from ng/ml to nmol/l, multiply by 2.5.']	N/A	N/A	[('UBERON_0001977', 'blood serum', 11, 'serum'), ('CHEBI_27300', 'vitamin D', 17, 'vitamin D')]
PMC3271033	1/2012	S78-PMC3271033	['none of the mothers reported taking additional Vitamin D supplements separate from their Prenatal Vitamins.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 47, 'vitamin D'), ('GO_0007565', 'female pregnancy', 89, 'prenatal'), ('CHEBI_33277', 'gamma-tocotrienol', 98, 'vitamins')]
PMC3271033	1/2012	S80-PMC3271033	['average maternal intake of Vitamin D from Foods and Prenatal supplements was 439 ± 94 iu/day.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 27, 'vitamin D'), ('CHEBI_33290', 'food', 42, 'foods'), ('GO_0007565', 'female pregnancy', 52, 'prenatal')]
PMC3271033	1/2012	S81-PMC3271033	['results at 3 months\noverall compliance with the Vitamin D drops was excellent with 90% of the drops given overall based on measurement of the volume of returned droppers.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 48, 'vitamin D')]
PMC3271033	1/2012	S158-PMC3271033	['improvement occurred with Vitamin D supplementation and was not related to changes in bone Mineral content.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 26, 'vitamin D'), ('CHEBI_46662', 'mineral', 91, 'mineral')]
PMC3272870	12/2011	S49-PMC3272870	['the active Metabolite of Vitamin D, 1,25-Dihydroxyvitamin D [1,25(Oh)2D] increases Intestinal calcium absorption and decreases Renal calcium Excretion, thus increasing the pool of calcium available both for mother and foetus.']	N/A	N/A	[('CHEBI_39382', 'flufenoxuron', 11, 'metabolite'), ('CHEBI_27300', 'vitamin D', 25, 'vitamin D'), ('CHEBI_67472', '15-epi-lupulin B', 36, '1,25-dihydroxyvitamin D'), ('CHEBI_82784', 'PVP38-Ag NP', 61, '1,25(OH)2D'), ('UBERON_0000160', 'intestine', 83, 'intestinal'), ('UBERON_0002113', 'kidney', 127, 'renal'), ('GO_0007588', 'excretion', 141, 'excretion')]
PMC3274449	12/2011	S51-PMC3274449	['each mms capsule contained 150 μg i (Potassium Iodide); 15 mg Zn (Sulfate); 65 μg Se (Sodium Selenite); 2 mg Cu (Sulfate); 800 μg retinyl acetate (re) Vitamin A; 1.4 mg Thiamine Mononitrate; 1.4 mg Vitamin riboflavin; 18 mg Vitamin B-3 (niacin); 1.9 mg Vitamin B-6 (Pyridoxine Hydrochloride); 2.6 μg Vitamin B-12 (Cyanocobalmin); 70 mg Vitamin C; 200 iu Vitamin D (Vitamin D3); 10 μg Vitamin E (Α- Tocopherol Acetate); 30 mg Fe (Fumarate); and, 400 μg Folate.']	N/A	N/A	[('CHEBI_8346', 'potassium iodide', 37, 'potassium iodide'), ('CHEBI_16159', 'sulochrin', 62, 'Zn (sulfate'), ('CHEBI_37972', 'phosphorus-32 atom', 82, 'Se'), ('CHEBI_77773', 'sodium selenide', 86, 'sodium selenite'), ('CHEBI_34656', 'cumene', 109, 'Cu (sulfate'), ('CHEBI_27300', 'vitamin D', 151, 'vitamin A'), ('CHEBI_9561', 'thiopental sodium', 169, 'thiamine mononitrate'), ('CHEBI_33229', 'vitamin (role)', 198, 'vitamin'), ('CHEBI_27300', 'vitamin D', 224, 'vitamin B'), ('CHEBI_27300', 'vitamin D', 253, 'vitamin B'), ('PR_000017255', 'Vang-like protein 1', 253, 'vitamin B-6'), ('CHEBI_16410', 'pyridoxamine', 266, 'pyridoxine'), ('CHEBI_17883', 'hydrogen chloride', 277, 'hydrochloride'), ('CHEBI_27300', 'vitamin D', 300, 'vitamin B'), ('PR_000017269', 'ventral anterior homeobox 2', 300, 'vitamin B-12'), ('CHEBI_38262', 'allothreonine', 314, 'cyanocobalmin'), ('CHEBI_27300', 'vitamin D', 336, 'vitamin C'), ('CHEBI_27300', 'vitamin D', 354, 'vitamin D'), ('CHEBI_33279', 'vitamin D5', 365, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 365, 'vitamin D3'), ('CHEBI_27300', 'vitamin D', 384, 'vitamin E'), ('CHEBI_19480', '2-bromomaleylacetate', 395, 'α- tocopherol acetate'), ('CHEBI_33290', 'food', 425, 'Fe'), ('CHEBI_16136', 'hydrogen sulfide', 429, 'fumarate'), ('CHEBI_30863', '5-azaorotic acid', 452, 'folate')]
PMC3277098	12/2011	S24-PMC3277098	['this resulted in a dramatic and overt rise in Vitamin D deficiency as rickets became endemic during this period.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 46, 'vitamin D')]
PMC3277098	12/2011	S49-PMC3277098	['one of the factors shown to enhance Treg Proliferation is the presence of the active form of Vitamin D, 1Α,25(Oh)2D3, which binds to the Retinoic Acid receptor of Naive T Cells, inducing Treg differentiation [30].']	N/A	N/A	[('CL_0000901', 'Tr1 cell', 36, 'Treg'), ('GO_0008283', 'cell proliferation', 41, 'proliferation'), ('CHEBI_27300', 'vitamin D', 93, 'vitamin D'), ('CHEBI_23995', 'N-ethyl-N-nitrosourea', 104, '1α,'), ('CHEBI_73394', 'Ala-Ser', 107, '25(OH)2D3'), ('CHEBI_26536', 'retinoic acid', 137, 'retinoic acid'), ('CL_0000898', 'naive T cell', 163, 'naive T cells'), ('CL_0000901', 'Tr1 cell', 187, 'Treg')]
PMC3277098	12/2011	S74-PMC3277098	['Nuclear actions of Vitamin D\nthe Vitamin D Receptor (Vdr), encoded by the vdr Gene [37], is a member of the Nuclear receptor family subgroup nr1i [38].']	N/A	N/A	[('GO_0005634', 'nucleus', 0, 'Nuclear'), ('CHEBI_28384', 'vitamin K', 19, 'Vitamin D'), ('CHEBI_27300', 'vitamin D', 33, 'vitamin D'), ('PR_000001683', 'vasopressin V2 receptor', 33, 'vitamin D receptor'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 53, 'VDR'), ('SO_0000704', 'gene', 78, 'gene'), ('GO_0005634', 'nucleus', 108, 'nuclear')]
PMC3277098	12/2011	S88-PMC3277098	['another Gene of interest is Vdbp encoding for the Vitamin D-Binding Protein (Vdbp).']	N/A	N/A	[('SO_0000704', 'gene', 8, 'gene'), ('PR_000017279', 'testis-specific basic protein Y 1', 28, 'VDBP'), ('CHEBI_27300', 'vitamin D', 50, 'vitamin D'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 50, 'vitamin D-binding protein'), ('PR_000017279', 'testis-specific basic protein Y 1', 77, 'VDBP')]
PMC3277098	12/2011	S92-PMC3277098	['in their review on the Vitamin D axis in Lung disease chisimba et al.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 23, 'vitamin D'), ('UBERON_0002048', 'lung', 41, 'lung')]
PMC3277098	12/2011	S106-PMC3277098	['Pregnancy\nduring Pregnancy the foetus is exposed to Vitamin D through Cord Blood supply and the ability of 25(Oh)D and 24,25(Oh)d to cross the Placenta [23].']	N/A	N/A	[('GO_0007565', 'female pregnancy', 0, 'Pregnancy'), ('GO_0007565', 'female pregnancy', 17, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 52, 'vitamin D'), ('UBERON_0002240', 'spinal cord', 70, 'cord'), ('UBERON_0000178', 'blood', 75, 'blood'), ('CHEBI_71657', 'versiconol acetate', 107, '25(OH)D'), ('CHEBI_51686', 'haematoxylin', 124, '(OH'), ('UBERON_0001987', 'placenta', 143, 'placenta')]
PMC3277098	12/2011	S127-PMC3277098	['there was no association between Vitamin D intake from diet or Supplements during Pregnancy, with the risk of eczema in infants at 12 months of age.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 33, 'vitamin D'), ('CHEBI_33341', 'titanium atom', 63, 'supplements'), ('GO_0007565', 'female pregnancy', 82, 'pregnancy')]
PMC3296991	2/2012	S11-PMC3296991	['secondary hyperparathyroidism is a classic sign of Vitamin D deficiency, where low Ionized calcium concentrations trigger a sensor in the Parathyroid Glands to increase pth secretion.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 51, 'vitamin D'), ('CHEBI_16397', 'formamide', 83, 'ionized'), ('UBERON_0001132', 'parathyroid gland', 138, 'parathyroid glands')]
PMC3296991	2/2012	S26-PMC3296991	['no routine Vitamin D screening was provided during Antenatal care at the clinic or hospital.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 11, 'vitamin D'), ('GO_0007567', 'parturition', 51, 'antenatal')]
PMC3296991	2/2012	S30-PMC3296991	['average daily dietary intake of Vitamin D was calculated from Food frequency using Food composition data from the united states department of agriculture national Nutrient database [16].']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 32, 'vitamin D'), ('CHEBI_33290', 'food', 62, 'food'), ('CHEBI_33290', 'food', 83, 'food'), ('CHEBI_33284', 'nutrient', 163, 'Nutrient')]
PMC3296991	2/2012	S31-PMC3296991	['in an interviewer-administered questionnaire, participants were asked to estimate frequency and quantity of the main dietary sources of Vitamin D (fatty fish, milk, breakfast cereals, fortified orange Juice, eggs, and meat) Consumed in the month prior to the interview.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 136, 'vitamin D'), ('CHEBI_37958', 'dye', 201, 'juice'), ('GO_0007631', 'feeding behavior', 224, 'consumed')]
PMC3296991	2/2012	S50-PMC3296991	['infants included in this analysis did not differ significantly from those who underwent dxa scans but were not included or who were eligible but did not return for the dxa visit in gender, maternal age, body mass index, l*, parity, or maternal or cord Vitamin D status.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 252, 'vitamin D')]
PMC3296991	2/2012	S66-PMC3296991	['none of the measured indices differed significantly by infant sex or by use of maternal Vitamin D supplements during Pregnancy.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 88, 'vitamin D'), ('GO_0007565', 'female pregnancy', 117, 'pregnancy')]
PMC3296991	2/2012	S72-PMC3296991	['caption (table-wrap): table 2\n\ncharacteristics of african american and non–african american participants.african american ( n = 40)non–african american ( n = 40) p –valuemean (sd)1rangemean (sd)1rangegestational age at Birth (weeks)39.7 (1.6)37.1–42.039.4 (1.1)37.1–41.3nsbirth weight (g)3429 (512)2372–45323419 (526)2290–4460nsage at dxa scan (days)12.8 (3.4)8–2113.4 (3.5)9–21nsmaternal parity2.1 (1.2)1–51.8 (0.8)1–3nsmaternal age (years)25.4 (5.2)18–3928.3 (5.6)18–380.02maternal bmi (kg/m2)132.2 (29.6, 35.0)18.8–49.930.9 (28.3, 33.7)20.5–66.0nsmaternal total Vitamin D intake (iu/days)698 (246)0–1326684 (253)184–1316nsmaternal 25(Oh)D (nmol/l)69.1 (26.1)33.5–118.582.3 (30.3)20.8–151.70.04cord 25(Oh)D1,2(nmol/l)36.0 (31.7, 40.8)16.7–87.548.2 (41.4, 56.1)14.1–157.50.004maternal pth (pg/ml)129.4 (24.9, 34.8)9.5–66.129.3 (23.6, 36.4)6.2–102.0Nscord pth (pg/ml)1,26.1 (4.6, 8.0)2.0–50.73.7 (2.8, 4.7)2.0–82.50.009cord Balp (u/l)1123.9 (112.2, 137.1)71.4–272.5107.7 (98.4, 117.9)58.3–197.80.04wbbmc (g)61.3 (13.1)38.3–95.961.9 (12.1)35.4–83.3nswbbmc (g per (kg^1.31))10.9 (0.9)9.1–12.711.4 (1.0)8.9–14.90.06 n % n % p –valuesexns\xa0\xa0\xa0male22551845\xa0\xa0\xa0female18452255racen/a\xa0\xa0\xa0african american401000–\xa0\xa0\xa0hispanic0–1230\xa0\xa0\xa0asian0–820\xa0\xa0\xa0caucasian0–410\xa0\xa0\xa0mixed/other0–1640maternal Vitamin D supplementationns\xa0\xa0\xa0<400 iu/day717.51127.5\xa0\xa0\xa0≥400 iu/day3382.52972.5feedingns\xa0\xa0\xa0exclusively Breast Fed1127.51947.5\xa0\xa0\xa0exclusively formula Fed1332.5615.0\xa0\xa0\xa0mixed1640.001537.5\n1geometric means and 95% confidence intervals are presented for variables requiring log transformation to conform to normal distribution;2undetectable samples assigned as 2/3 detection limit.']	N/A	N/A	[('GO_0007567', 'parturition', 219, 'birth'), ('CHEBI_27300', 'vitamin D', 565, 'vitamin D'), ('CHEBI_17792', 'organohalogen compound', 637, 'OH'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 640, 'D'), ('CHEBI_73281', '(2S)-versicolorone(1-)', 701, '25(OH)D1'), ('UBERON_0002328', 'notochord', 848, '0NSCord'), ('SO_0000153', 'BAC', 924, 'BALP'), ('CHEBI_27300', 'vitamin D', 1275, 'vitamin D'), ('UBERON_0000310', 'breast', 1377, 'breast'), ('GO_0032304', 'negative regulation of icosanoid secretion', 1384, 'fed1127'), ('GO_0044347', 'cell wall polysaccharide catabolic process', 1422, 'fed1332')]
PMC3296991	2/2012	S84-PMC3296991	['none of the measured indices differed significantly in the maternal or Cord Blood of women who did or did not take daily Prenatal Vitamins containing 400 iu Vitamin D. the Food and nutrition board recommendation for Vitamin D intake by Pregnant women was raised in 2010 from 200 to 600 iu/day [22].']	N/A	N/A	[('UBERON_0002240', 'spinal cord', 71, 'cord'), ('UBERON_0000178', 'blood', 76, 'blood'), ('GO_0007565', 'female pregnancy', 121, 'prenatal'), ('CHEBI_33277', 'gamma-tocotrienol', 130, 'vitamins'), ('CHEBI_27300', 'vitamin D', 157, 'vitamin D'), ('CHEBI_33290', 'food', 172, 'Food'), ('CHEBI_27300', 'vitamin D', 216, 'vitamin D'), ('GO_0007565', 'female pregnancy', 236, 'pregnant')]
PMC3313761	3/2012	S16-PMC3313761	['the child was treated with 600,000 iu of oral Vitamin D and discharged on maintenance doses of Calcium Gluconate and 800 iu of oral Vitamin D daily for 3 months.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 46, 'vitamin D'), ('CHEBI_3310', 'calcium acetate', 95, 'calcium gluconate'), ('CHEBI_27300', 'vitamin D', 132, 'vitamin D')]
PMC3338544	4/2012	S3-PMC3338544	['dvd deficiency was established by Feeding female c57bl/6j Mice a Vitamin D-deficient diet from four weeks of age.']	N/A	N/A	[('GO_0007631', 'feeding behavior', 34, 'feeding'), ('NCBITaxon_10088', 'Mus <genus>', 58, 'mice'), ('CHEBI_27300', 'vitamin D', 65, 'vitamin D')]
PMC3338544	4/2012	S4-PMC3338544	['after six weeks on the diet, Vitamin D-deficient and control females were Mated with Vitamin D-normal males and upon Birth of the pups, all dams were returned to a diet containing Vitamin D. the Adult offspring were tested on a range of Cognitive behavioural tests, including the five-choice serial reaction task (5c-srt) and five-choice continuous performance test (5c-cpt), as well as latent inhibition using a Fear Conditioning paradigm.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 29, 'vitamin D'), ('GO_0007618', 'mating', 74, 'mated'), ('CHEBI_27300', 'vitamin D', 85, 'vitamin D'), ('GO_0007567', 'parturition', 117, 'birth'), ('CHEBI_27300', 'vitamin D', 180, 'vitamin D'), ('UBERON_0007023', 'adult organism', 195, 'adult'), ('GO_0050890', 'cognition', 237, 'cognitive'), ('GO_0009566', 'fertilization', 413, 'fear conditioning')]
PMC3338544	4/2012	S185-PMC3338544	['briefly, female Mice were Fed on a diet free of Vitamin D (Vitamin D deficient ain93g Rodent diet, specialty feeds, wa, australia) from 4 weeks of age.']	N/A	N/A	[('NCBITaxon_10088', 'Mus <genus>', 16, 'mice'), ('GO_0007631', 'feeding behavior', 26, 'fed'), ('CHEBI_27300', 'vitamin D', 48, 'vitamin D'), ('CHEBI_28384', 'vitamin K', 59, 'Vitamin D'), ('NCBITaxon_10088', 'Mus <genus>', 86, 'Rodent')]
PMC3338544	4/2012	S186-PMC3338544	['control Animals were housed in the same conditions as Vitamin D-deficient Animals, but were given a standard Vitamin D-containing diet (standard ain93g Rodent diet, specialty feeds, wa, australia).']	N/A	N/A	[('NCBITaxon_33208', 'Metazoa', 8, 'animals'), ('CHEBI_27300', 'vitamin D', 54, 'vitamin D'), ('NCBITaxon_33208', 'Metazoa', 74, 'animals'), ('CHEBI_27300', 'vitamin D', 109, 'vitamin D'), ('NCBITaxon_10088', 'Mus <genus>', 152, 'Rodent')]
PMC3338544	4/2012	S187-PMC3338544	['at 10 weeks of age, all females were Mated with Vitamin D normal males by pairing one male with 2 females for 7 days.']	N/A	N/A	[('GO_0007618', 'mating', 37, 'mated'), ('CHEBI_27300', 'vitamin D', 48, 'vitamin D')]
PMC3338544	4/2012	S189-PMC3338544	['Pregnant dams were checked every 12 h for pups and the Food of dams on the Vitamin D-deplete diet was replaced with control Food within 12 h of Birth.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 0, 'Pregnant'), ('CHEBI_33290', 'food', 55, 'food'), ('CHEBI_27300', 'vitamin D', 75, 'vitamin D'), ('CHEBI_33290', 'food', 124, 'food'), ('GO_0007567', 'parturition', 144, 'birth')]
PMC3338544	4/2012	S190-PMC3338544	['offspring were weaned 21 days after Birth, and were provided with Water and standard Vitamin D containing Mouse pellets (feeder and grower diet, specialty feeds, wa, australia) for the remainder of the experiment.']	N/A	N/A	[('GO_0007567', 'parturition', 36, 'birth'), ('CHEBI_15377', 'water', 66, 'water'), ('CHEBI_27300', 'vitamin D', 85, 'vitamin D'), ('NCBITaxon_10088', 'Mus <genus>', 106, 'mouse')]
PMC3347007	4/2012	S2-PMC3347007	['in 68,447 danish Pregnant women the mean ± sd for Vitamin D intake was 9.23 ± 5.60 µg per day (diet: 3.56 ± 2.05 µg per day, supplements: 5.67 ± 5.20 µg per day).']	N/A	N/A	[('GO_0007565', 'female pregnancy', 17, 'pregnant'), ('CHEBI_27300', 'vitamin D', 50, 'vitamin D')]
PMC3347007	4/2012	S4-PMC3347007	['supplements were the primary source of Vitamin D for the two higher quartiles of total Vitamin D intake, with diet being the primary source for the two lower quartiles.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 39, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 87, 'vitamin D')]
PMC3347007	4/2012	S5-PMC3347007	['determinants of sufficient total Vitamin D intake were: high maternal age, nulliparity, non-smoking, and filling out of the Food frequency questionnaire (ffq) during summer or fall.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 33, 'vitamin D'), ('CHEBI_33290', 'food', 124, 'Food')]
PMC3347007	4/2012	S26-PMC3347007	['for instance in norway, 63% of Pregnant women consumed <10 µg per day of Vitamin D [17], in finland the prevalence was 85% [18], and 50% in the united states [19].']	N/A	N/A	[('GO_0007565', 'female pregnancy', 31, 'pregnant'), ('CHEBI_27300', 'vitamin D', 73, 'vitamin D')]
PMC3347007	4/2012	S60-PMC3347007	['these calculations led to the creation of a data set with information for all participants ( n = 68,447) on mean daily Vitamin D intake from supplements calculated from the ffq and mean daily Vitamin D intake from supplements per Gestational week from the interviews.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 119, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 192, 'vitamin D'), ('GO_0007565', 'female pregnancy', 230, 'gestational')]
PMC3347007	4/2012	S66-PMC3347007	['insufficient total Vitamin D intake was performed by t -test for normally distributed continuous variables.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 19, 'vitamin D')]
PMC3347007	4/2012	S68-PMC3347007	['univariate and multivariate logistic regression was employed to estimate the association between total Vitamin D intake and socio-demographic, Gestational, and Life-style characteristics.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 103, 'vitamin D'), ('GO_0007565', 'female pregnancy', 143, 'gestational'), ('UBERON_0000104', 'life cycle', 160, 'life')]
PMC3347007	4/2012	S76-PMC3347007	['results\nmean dietary Vitamin D intake was 3.56 ± 2.05 µg per day, mean Vitamin D intake from supplements was 5.67 ± 5.20 µg per day, and mean total intake of Vitamin D was 9.23 ± 5.60 µg per day.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 21, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 71, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 158, 'vitamin D')]
PMC3347007	4/2012	S78-PMC3347007	['44.4% had sufficient total Vitamin D intake.nutrients-04-00259-t001_table 1\n\ncaption (table-wrap): table 1\n\nintake of Vitamin D Supplements in the danish national Birth cohort during Gestational weeks 21–25 ( n = 68,447) *.daily Vitamin D dosen (%)0 µg22,214 (32.5)women who took Vitamin D supplements46,233 (67.5)>0 µg and ≤2.5 µg1020 (1.5)>2.5 µg and <5 µg2110 (3.1)≥5 µg and <7.5 µg16,710 (24.4)≥7.5 µg and <10 µg1114 (1.6)≥10 µg25,279 (36.9)\n* based on information from the Food frequency questionnaire.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 27, 'vitamin D'), ('CHEBI_33229', 'vitamin (role)', 118, 'vitamin'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 126, 'D'), ('CHEBI_33341', 'titanium atom', 128, 'supplements'), ('GO_0007567', 'parturition', 163, 'Birth'), ('GO_0007565', 'female pregnancy', 183, 'gestational'), ('CHEBI_27300', 'vitamin D', 229, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 280, 'vitamin D'), ('CHEBI_33290', 'food', 478, 'food')]
PMC3347007	4/2012	S80-PMC3347007	['the most common dose was 10 µg per day (31.5%) followed by 5 µg per day (22.2%) (data not shown).figure 2shows the proportion of women reporting use of Vitamin D supplements ≥10 µg per day per Gestational week based on the results from dnbc interview 2 and 3.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 152, 'vitamin D'), ('GO_0007565', 'female pregnancy', 193, 'gestational')]
PMC3347007	4/2012	S81-PMC3347007	['from Gestational week 7 onwards, more than 20% of the women reported use of Vitamin D supplements ≥10 µg per day with a maximum proportion of 31.7% in Gestational week 30.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 5, 'gestational'), ('CHEBI_27300', 'vitamin D', 76, 'vitamin D'), ('GO_0007565', 'female pregnancy', 151, 'gestational')]
PMC3347007	4/2012	S83-PMC3347007	['the proportion of women reporting use of Vitamin D supplements ≥10 µg per day found in the ffq was of 36.9%.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 41, 'vitamin D')]
PMC3347007	4/2012	S84-PMC3347007	['from Gestational week 30, the proportion of women who reported sufficient use of Vitamin D supplements decreased.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 5, 'gestational'), ('CHEBI_27300', 'vitamin D', 81, 'vitamin D')]
PMC3347007	4/2012	S88-PMC3347007	['the dietary Intake of Vitamin D from different Food groups for each quartile of dietary Vitamin D intake is presented intable 3.']	N/A	N/A	[('GO_0007631', 'feeding behavior', 12, 'intake'), ('CHEBI_27300', 'vitamin D', 22, 'vitamin D'), ('CHEBI_33290', 'food', 47, 'food'), ('CHEBI_27300', 'vitamin D', 88, 'vitamin D')]
PMC3347007	4/2012	S91-PMC3347007	['the main sources of dietary Vitamin D for all quartiles were fish and seafood, followed by low fat dairy products and eggs.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 28, 'vitamin D')]
PMC3347007	4/2012	S92-PMC3347007	['the higher the dietary Vitamin D intake, the higher amount of Vitamin D consumed from fish and seafood.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 23, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 62, 'vitamin D')]
PMC3347007	4/2012	S94-PMC3347007	['the contribution of Vitamin D from pork, beef/Veal, and processed meat was the same for all quartiles of dietary Vitamin D intake.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 20, 'vitamin D'), ('NCBITaxon_9606', 'Homo sapiens', 46, 'veal'), ('CHEBI_27300', 'vitamin D', 113, 'vitamin D')]
PMC3347007	4/2012	S101-PMC3347007	['before adjustment for relevant covariates, the or for sufficient total Vitamin D intake was significantly lower for partly Planned or non-planned Pregnancies than for Planned Pregnancies.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 71, 'vitamin D'), ('GO_0007565', 'female pregnancy', 123, 'planned'), ('GO_0007565', 'female pregnancy', 146, 'pregnancies'), ('GO_0007565', 'female pregnancy', 167, 'planned'), ('GO_0007565', 'female pregnancy', 175, 'pregnancies')]
PMC3347007	4/2012	S102-PMC3347007	['the or for sufficient total Vitamin D intake was significantly higher for mothers filling out the ffq during summer or fall.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 28, 'vitamin D')]
PMC3347007	4/2012	S125-PMC3347007	['insufficient total intake of Vitamin D are shown intable 5.nutrients-04-00259-t005_table 5\n\ncaption (table-wrap): table 5\n\nintakes of energy, Macronutrients and Food groups among women with sufficient total Vitamin D intake (≥10 µg per day) vs .']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 29, 'vitamin D'), ('CHEBI_33839', 'macromolecule', 142, 'macronutrients'), ('CHEBI_33290', 'food', 161, 'food'), ('CHEBI_27300', 'vitamin D', 207, 'vitamin D')]
PMC3347007	4/2012	S126-PMC3347007	['insufficient total Vitamin D intake (<10 µg per day) in Gestational weeks 21–25 ( n = 68,447) *.sufficient total Vitamin D intake ( n = 30,357)insufficient total Vitamin D intake ( n = 38,090) p -valuetotal energy (kj)10,042.6 (2439.8)9852.0 (2365.4)<0.0001†protein (% of energy)15.2 (2.4)15.0 (2.3)0.002†Carbohydrate (% of energy)54.5 (5.8)54.3 (5.9)0.1†fat (% of energy)29.8 (5.9)30.3 (6.0)0.03†Alcohol (% of energy)0.27 (0, 0.6)0.29 (0, 0.7)<0.0001‡dietary variables (g/mj)dairy products606.2 (359.7, 842.4)611.4 (366.1, 846.8)0.02‡fruit130.5 (67.5, 231.9)116.6 (65.2, 222.1)<0.0001‡vegetables113.2 (75.1, 168.2)102.7 (67.0, 152.8)<0.0001‡meat72.7 (31.1)72.9 (31.1)0.9†fish17.6 (9.3, 29.7)14.6 (7.9, 24.2)<0.0001‡poultry24.0 (13.2, 35.3)19.4 (11.2, 31.4)<0.0001‡cereals24.4 (5.5, 48.0)23.6 (5.2, 48.4)0.2‡potatoes115.9 (80.7, 165.8)120.1 (82.7, 173.0)<0.0001‡fats18.9 (11.1, 29.6)20.1 (11.5, 31.4)<0.0001‡\ndata are presented as mean (standard deviation) or median (25th percentile, 75th percentile).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 19, 'vitamin D'), ('GO_0007565', 'female pregnancy', 56, 'gestational'), ('CHEBI_27300', 'vitamin D', 113, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 162, 'vitamin D'), ('CHEBI_16646', 'carbohydrate', 305, 'Carbohydrate'), ('CHEBI_30879', 'alcohol', 397, 'Alcohol')]
PMC3347007	4/2012	S130-PMC3347007	['discussion\ndietary Vitamin D intake was very low in the study population.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 19, 'vitamin D')]
PMC3347007	4/2012	S142-PMC3347007	['the main source of Vitamin D was supplements for the two higher quartiles of total Vitamin D intake, and diet for the two lower quartiles.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 19, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 83, 'vitamin D')]
PMC3347007	4/2012	S143-PMC3347007	['both absolute dietary Vitamin D and Vitamin D from supplements increased with quartile of total Vitamin D intake.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 22, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 36, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 96, 'vitamin D')]
PMC3347007	4/2012	S167-PMC3347007	['women with sufficient total Vitamin D intake were found to have significantly higher intakes of total energy, protein, fruit, vegetables, poultry and fish, and significantly lower intakes of fat, dairy products, and potatoes, compared to women with insufficient total Vitamin D intake.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 28, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 268, 'vitamin D')]
PMC3347007	4/2012	S188-PMC3347007	['the main source of Vitamin D was supplements for the two higher quartiles of total Vitamin D intake, and diet for the two lower quartiles.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 19, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 83, 'vitamin D')]
PMC3347007	4/2012	S189-PMC3347007	['determinants of sufficient total Vitamin D intake were high maternal age, Giving Birth during fall or winter, nulliparity, and low number of daily cigarettes use during Pregnancy.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 33, 'vitamin D'), ('GO_0007567', 'parturition', 74, 'giving birth'), ('GO_0007565', 'female pregnancy', 169, 'pregnancy')]
PMC3347028	3/2012	S33-PMC3347028	['caption (fig): figure 1\n\nHuman Vitamin D Synthesis pathways.']	N/A	N/A	[('NCBITaxon_10088', 'Mus <genus>', 25, 'Human'), ('CHEBI_27300', 'vitamin D', 31, 'vitamin D'), ('GO_0042368', 'vitamin D biosynthetic process', 31, 'vitamin D synthesis')]
PMC3347028	3/2012	S37-PMC3347028	['following its synthesis, Vitamin D binds to Vitamin D Binding Protein (Vdbp) and finds its ways into the circulation.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 25, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 44, 'vitamin D'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 44, 'vitamin D binding protein'), ('PR_000017279', 'testis-specific basic protein Y 1', 71, 'VDBP')]
PMC3347028	3/2012	S74-PMC3347028	['the Vitamin D receptor (vdr) is found on Activated (but not resting) Human T- and B-Lymphocytes.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 4, 'vitamin D'), ('CL_0002627', 'mature astrocyte', 41, 'activated'), ('NCBITaxon_9606', 'Homo sapiens', 69, 'human'), ('CL_0000918', 'Tc2 cell', 75, 'T- ...'), ('CL_0000236', 'B cell', 82, 'B-lymphocytes')]
PMC3347028	3/2012	S84-PMC3347028	['in Individuals who have Vitamin D deficiency, the body increases Production Of Pth to maintain 1,25(Oh)2D and Calcium Homeostasis.']	N/A	N/A	[('NCBITaxon_1', 'root', 3, 'individuals'), ('CHEBI_27300', 'vitamin D', 24, 'vitamin D'), ('GO_0006560', 'proline metabolic process', 65, 'production of PTH'), ('CHEBI_82784', 'PVP38-Ag NP', 95, '1,25(OH)2D'), ('GO_0055073', 'cadmium ion homeostasis', 110, 'calcium homeostasis')]
PMC3347028	3/2012	S85-PMC3347028	['if Vitamin D deficiency is sustained, secondary hyperparathyroidism will result.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 3, 'vitamin D')]
PMC3347028	3/2012	S114-PMC3347028	['[65], and the nichd Vitamin D supplementation trial [70,71] was the high incidence of Vitamin D deficiency during early Pregnancy in women with darker pigmentation.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 20, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 86, 'vitamin D'), ('GO_0007565', 'female pregnancy', 120, 'pregnancy')]
PMC3347028	3/2012	S134-PMC3347028	['the Adipose Tissue serves as a repository for Vitamin D that does not get into the circulation.']	N/A	N/A	[('UBERON_0001013', 'adipose tissue', 4, 'adipose tissue'), ('CHEBI_27300', 'vitamin D', 46, 'vitamin D'), ('PR_000006444', 'diacylglycerol kinase delta', 54, 'D')]
PMC3347028	3/2012	S159-PMC3347028	['during Pregnancy, supplementation with the current standard amount of Vitamin D in Prenatal Vitamins—400 iu (10 μg) Vitamin D/day—has minimal effect on circulating 25(Oh)D concentrations in the mother and her infant at term [6,124].']	N/A	N/A	[('GO_0007565', 'female pregnancy', 7, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 70, 'vitamin D'), ('GO_0007565', 'female pregnancy', 83, 'prenatal'), ('CHEBI_33277', 'gamma-tocotrienol', 92, 'vitamins'), ('CHEBI_27300', 'vitamin D', 116, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 164, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 170, 'D')]
PMC3347028	3/2012	S175-PMC3347028	['there is a safety mechanism in place with sunlight: sunlight-derived Vitamin D triggers downregulation of certain enzyme systems and upregulation of others in the body to dispose of any Vitamin D and its Metabolites not needed by the body.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 69, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 186, 'vitamin D'), ('CHEBI_25212', 'metabolite', 204, 'metabolites')]
PMC3347028	3/2012	S197-PMC3347028	['there were no adverse events associated with Vitamin D supplementation [148].']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 45, 'vitamin D')]
PMC3347028	3/2012	S198-PMC3347028	['preliminary analysis of the two concurrent Vitamin D Pregnancy nichd ( n = 350) and thrasher research fund ( n = 157) trials was undertaken to assess the health characteristics and outcomes of this larger, combined group using a common data dictionary [150].']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 43, 'vitamin D'), ('GO_0007565', 'female pregnancy', 53, 'pregnancy')]
PMC3347028	3/2012	S206-PMC3347028	['no differences were noted between groups in baseline 25(Oh)D ( p = 0.24), but differences between groups were noted in Vitamin D status within one month of Delivery ( p< 0.0001) and in Cord Blood ( p = 0.0001), with improved status in the 4000-iu group overall.']	N/A	N/A	[('CHEBI_71657', 'versiconol acetate', 53, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 53, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 119, 'vitamin D'), ('GO_0007567', 'parturition', 156, 'delivery'), ('UBERON_0002240', 'spinal cord', 185, 'cord'), ('UBERON_0000178', 'blood', 190, 'blood')]
PMC3348565	4/2012	S10-PMC3348565	['there was no significant difference between the incidence of first or only pneumonia between the Vitamin D (0·145 per child per year, 95% ci 0·129–0·164) and the placebo group (0.137, 0·121–0·155); the incidence rate ratio was 1·06 (95% ci 0·89–1·27).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 97, 'vitamin D')]
PMC3348565	4/2012	S20-PMC3348565	['the binding of this to Vitamin D receptors in turn results in increased Intracellular Formation Of Antimicrobial Compounds, such as cathelicidins.5the generation of Intracellular Antimicrobial Compounds is impaired in patients who are Vitamin D deficient (ie, low Serum concentrations of Calcifediol).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 23, 'vitamin D'), ('GO_0005622', 'intracellular anatomical structure', 72, 'intracellular'), ('GO_0006260', 'DNA replication', 72, 'intracellular'), ('GO_0007631', 'feeding behavior', 86, 'formation of ...'), ('CHEBI_33656', 'antiaromatic compound', 99, 'antimicrobial compounds'), ('GO_0005622', 'intracellular anatomical structure', 165, 'intracellular'), ('CHEBI_33656', 'antiaromatic compound', 179, 'antimicrobial compounds'), ('CHEBI_27300', 'vitamin D', 235, 'vitamin D'), ('UBERON_0001977', 'blood serum', 264, 'serum'), ('CHEBI_22975', 'cadinane sesquiterpenoid', 288, 'calcifediol')]
PMC3348565	4/2012	S24-PMC3348565	['in afghanistan, dietary intake of Vitamin D is low10and exposure of women to sunlight is limited by the widespread use of the burqa.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 34, 'vitamin D')]
PMC3348565	4/2012	S29-PMC3348565	['we selected infants from inner-city kabul because we knew the prevalence of Vitamin D deficiency12and incidence of pneumonia3,15were high.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 76, 'vitamin D')]
PMC3348565	4/2012	S38-PMC3348565	['our exclusion criteria were families expecting to move to another town within 18 months, diagnosis of rickets or treatment with Vitamin D in the previous 3 months, and clinical diagnosis of kwashiorkor or marasmus.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 128, 'vitamin D')]
PMC3348565	4/2012	S46-PMC3348565	['fieldworkers allocated children to randomisation groups during recruitment and gave Vitamin D or placebo.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 84, 'vitamin D')]
PMC3348565	4/2012	S63-PMC3348565	['this was to ascertain Calcifediol Serum concentrations 1 week after giving the first dose in the placebo group (a baseline value for the whole population) as well as early concentrations after the first Vitamin D supplementation in the intervention group (70 in placebo and 69 in intervention groups).']	N/A	N/A	[('CHEBI_22975', 'cadinane sesquiterpenoid', 22, 'calcifediol'), ('UBERON_0001977', 'blood serum', 34, 'serum'), ('CHEBI_27300', 'vitamin D', 203, 'vitamin D')]
PMC3348565	4/2012	S87-PMC3348565	['the mortality rate in our study cohort was 4·2 per 1000 child years (95% ci 2·4–6·7): 4·2 per 1000 child years (2·4–6·7; ten cases) in our Vitamin D group and 3·4 per 1000 child years (1·3–7·1; seven cases) in our Placebo group.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 139, 'vitamin D'), ('CHEBI_26130', 'biological pigment', 214, 'placebo')]
PMC3348565	4/2012	S89-PMC3348565	['six children in the Vitamin D and four in the placebo group died of septicaemia or pneumonia.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 20, 'vitamin D')]
PMC3348565	4/2012	S97-PMC3348565	['the incidence rate of repeat episodes of all type pneumonia was significantly higher in the Vitamin D group (table 3).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 92, 'vitamin D')]
PMC3348565	4/2012	S98-PMC3348565	['restricting the definition of pneumonia confirmed with Chest radiography to consolidation only, gave a rate of 0·011 per child per year (95% ci 0·008–0·017) in the Vitamin D group and 0·008 (0·005–0·013) in the placebo group; this difference was not significant rr 1·44 (0·76–2·72).']	N/A	N/A	[('UBERON_0001443', 'chest', 55, 'chest'), ('CHEBI_27300', 'vitamin D', 164, 'vitamin D')]
PMC3355895	1/2011	S83-PMC3355895	['in this study around 31% of the mothers had insufficient and 18% had deficient circulating concentrations of 25(oh)-Vitamin D during late Pregnancy (11–20 and <11\u2009μg/l respectively).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 116, 'vitamin D'), ('GO_0007565', 'female pregnancy', 138, 'pregnancy')]
PMC3355895	1/2011	S90-PMC3355895	['circulating maternal 25(oh)-Vitamin D concentrations in this cohort were relatively high, and were not associated with childhood Skeletal measures.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 28, 'vitamin D'), ('UBERON_0004288', 'skeleton', 129, 'skeletal')]
PMC3355895	1/2011	S131-PMC3355895	['thus in the hertfordshire cohort study there was no significant association between either Vitamin D receptor (vdr) genotype and Adult bmd in the cohort as a whole (dennison et al.,2001).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 91, 'vitamin D'), ('UBERON_0007023', 'adult organism', 129, 'adult')]
PMC3356951	4/2012	S40-PMC3356951	['[2933–35] wearing a sunscreen with a sun protection factor of 30 reduces Vitamin D Synthesis in the skin by more than 95%.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 73, 'vitamin D'), ('GO_0042368', 'vitamin D biosynthetic process', 73, 'vitamin D synthesis')]
PMC3356951	4/2012	S58-PMC3356951	['older adults\nolder Adults are at high risk of developing Vitamin D insufficiency because of Aging.']	N/A	N/A	[('UBERON_0007023', 'adult organism', 19, 'adults'), ('CHEBI_27300', 'vitamin D', 57, 'vitamin D'), ('GO_0007568', 'aging', 92, 'aging')]
PMC3356951	4/2012	S62-PMC3356951	['[23] intake of rda levels of Vitamin D from foods and/or supplements will provide adequate amounts of this Nutrient to these Individuals.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 29, 'vitamin D'), ('CHEBI_33284', 'nutrient', 107, 'nutrient'), ('NCBITaxon_1', 'root', 125, 'individuals')]
PMC3356951	4/2012	S63-PMC3356951	["People with dark skin\nlarger amounts of the Pigment Melanin in the Epidermal Layer result in darker skin and reduce the skin's ability to produce Vitamin D from sunlight."]	N/A	N/A	[('NCBITaxon_10088', 'Mus <genus>', 0, 'People'), ('CHEBI_26130', 'biological pigment', 44, 'pigment'), ('CHEBI_25179', 'melanins', 52, 'melanin'), ('UBERON_0007383', 'enveloping layer of ectoderm', 67, 'epidermal layer'), ('CHEBI_27300', 'vitamin D', 146, 'vitamin D')]
PMC3356951	4/2012	S65-PMC3356951	['intake of rda levels of Vitamin D from Foods and/or supplements will provide adequate amounts of this Nutrient to these Individuals.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 24, 'vitamin D'), ('CHEBI_33290', 'food', 39, 'foods'), ('CHEBI_33284', 'nutrient', 102, 'nutrient'), ('NCBITaxon_1', 'root', 120, 'individuals')]
PMC3356951	4/2012	S77-PMC3356951	['[133]\n\nphysiological actions of Vitamin D\nVitamin D is a fat-soluble Vitamin that acts as a Steroid hormone.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 32, 'vitamin D'), ('CHEBI_28384', 'vitamin K', 42, 'Vitamin D'), ('CHEBI_33229', 'vitamin (role)', 69, 'vitamin'), ('CHEBI_35341', 'steroid', 92, 'steroid')]
PMC3356951	4/2012	S78-PMC3356951	['in Humans, the primary source of Vitamin D is uvb-induced conversion Of 7-Dehydrocholesterol to Vitamin D in the skin [figure 1].']	N/A	N/A	[('NCBITaxon_9606', 'Homo sapiens', 3, 'humans'), ('CHEBI_27300', 'vitamin D', 33, 'vitamin D'), ('GO_0007608', 'sensory perception of smell', 69, 'of ... dehydrocholesterol'), ('CHEBI_17500', '7alpha-hydroxycholesterol', 72, '7-dehydrocholesterol'), ('CHEBI_27300', 'vitamin D', 96, 'vitamin D')]
PMC3356951	4/2012	S91-PMC3356951	['Corticosteroids can reduce calcium absorption, which results in impaired Vitamin D Metabolism.']	N/A	N/A	[('CHEBI_36961', 'chalcocarbonic acid', 0, 'Corticosteroids'), ('CHEBI_27300', 'vitamin D', 73, 'vitamin D'), ('GO_0008152', 'metabolic process', 83, 'metabolism')]
PMC3356951	4/2012	S93-PMC3356951	['[9] Phenobarbital and Phenytoin increase the Hepatic Metabolism Of Vitamin D to inactive Compounds and decrease calcium absorption, which also impairs Vitamin D Metabolism.']	N/A	N/A	[('CHEBI_8069', 'phenobarbital', 4, 'Phenobarbital'), ('CHEBI_8107', 'phenytoin', 22, 'phenytoin'), ('UBERON_0002107', 'liver', 45, 'hepatic'), ('GO_0019458', 'methionine catabolic process via 2-oxobutanoate', 53, 'metabolism of vitamin D'), ('CHEBI_27300', 'vitamin D', 67, 'vitamin D'), ('CHEBI_36357', 'polyatomic entity', 89, 'compounds'), ('CHEBI_27300', 'vitamin D', 151, 'vitamin D'), ('GO_0042359', 'vitamin D metabolic process', 151, 'vitamin D metabolism')]
PMC3356951	4/2012	S96-PMC3356951	['a variety of options are available for individual Vitamin D supplements, including capsules, chewable tablets, Liquids, and drops.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 50, 'vitamin D'), ('CHEBI_37759', 'hydridoborate(2-)', 111, 'liquids')]
PMC3356951	4/2012	S97-PMC3356951	['Cod Liver oil is a good source of Vitamin D, but in large doses there is a risk of Vitamin A toxicity.']	N/A	N/A	[('CHEBI_33290', 'food', 0, 'Cod'), ('UBERON_0002107', 'liver', 4, 'liver'), ('CHEBI_27300', 'vitamin D', 34, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 83, 'vitamin A')]
PMC3356951	4/2012	S105-PMC3356951	['[17] in the framingham Heart study, patients with low Vitamin D concentrations (<15 ng/ml) had a 60% higher risk of Heart disease than those with higher concentrations.']	N/A	N/A	[('UBERON_0000948', 'heart', 23, 'Heart'), ('CHEBI_27300', 'vitamin D', 54, 'vitamin D'), ('UBERON_0000948', 'heart', 116, 'heart')]
PMC3356951	4/2012	S135-PMC3356951	['[96] in a japanese randomized, controlled trial, children given a daily Vitamin D supplement of 1200 iu had a 40% lower rate of influenza type a compared with those given placebo; there was no significant difference in rates of influenza type B.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 72, 'vitamin D'), ('PR_000000037', 'BMP receptor type-2', 243, 'B')]
PMC3356951	4/2012	S154-PMC3356951	['natural analogs of Vitamin D\n\nVitamin D1Is a Molecular Compound of Ergocalciferol (d2) with Lumisterol in a 1:1 ratio.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 19, 'vitamin D'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 30, 'Vitamin D1is'), ('CHEBI_23888', 'drug', 38, 'D1is'), ('CHEBI_33664', 'monocyclic hydrocarbon', 45, 'molecular compound'), ('CHEBI_4910', 'etomidate', 67, 'ergocalciferol'), ('CHEBI_66555', 'laurinterol', 92, 'lumisterol')]
PMC3365381	3/2011	S83-PMC3365381	['other Molecules (Benzpyrene, Vitamins A and D) also can imprint the Brain, is manifested in the change of biogenic amine levels of the Brain and csf (tekes et al.2007a,b,2009a,b,c).']	N/A	N/A	[('CHEBI_36357', 'polyatomic entity', 6, 'molecules'), ('CHEBI_29865', 'benzo[a]pyrene', 17, 'benzpyrene'), ('CHEBI_27300', 'vitamin D', 29, 'vitamins A'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 44, 'D'), ('UBERON_0000955', 'brain', 68, 'brain'), ('UBERON_0000955', 'brain', 135, 'brain')]
PMC3366289	7/2011	S35-PMC3366289	['at Delivery, all women received systematically Vitamin A (200,000\xa0iu) in the form of Retinyl Palmitate and Thiamine (7\xa0×\xa0100\xa0mg/week) was still provided for Postpartum women.']	N/A	N/A	[('GO_0007567', 'parturition', 3, 'delivery'), ('CHEBI_27300', 'vitamin D', 47, 'vitamin A'), ('CHEBI_84054', 'resveratrol glucuronide sulfate 2', 85, 'retinyl palmitate'), ('CHEBI_26948', 'vitamin B1', 107, 'thiamine'), ('GO_0007565', 'female pregnancy', 157, 'postpartum')]
PMC3376765	6/2012	S34-PMC3376765	['and Vitamin B-12 (16.8\u2009 μ g for the weekly arms or 2.4\u2009 μ g for the daily arms).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 4, 'vitamin B'), ('PR_000017269', 'ventral anterior homeobox 2', 4, 'vitamin B-12')]
PMC3376765	6/2012	S108-PMC3376765	['in a trial in nepal [25], 4926 Pregnant women were allocated at random to five regimens: daily supplements of Fa, ifa, ifa with zinc, multiple Micronutrients, or Vitamin A alone (control).']	N/A	N/A	[('GO_0007565', 'female pregnancy', 31, 'pregnant'), ('CHEBI_30751', 'formic acid', 110, 'FA'), ('CHEBI_33839', 'macromolecule', 143, 'micronutrients'), ('CHEBI_27300', 'vitamin D', 162, 'vitamin A')]
PMC3376765	6/2012	S142-PMC3376765	['the supplements also contained Vitamin B-12.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 31, 'vitamin B'), ('PR_000017269', 'ventral anterior homeobox 2', 31, 'vitamin B-12')]
PMC3385441	2/2012	S70-PMC3385441	['fish is high in protein and low in saturated fats and contains a number of other healthful Nutrients such as Vitamin D, Selenium, and Iodine.']	N/A	N/A	[('CHEBI_33284', 'nutrient', 91, 'nutrients'), ('CHEBI_27300', 'vitamin D', 109, 'vitamin D'), ('CHEBI_27568', 'selenium atom', 120, 'selenium'), ('CHEBI_24859', 'iodine atom', 134, 'iodine')]
PMC3395583	7/2012	S37-PMC3395583	["average predicted uvb exposure as well as Vitamin D status during the first, second and third Trimesters of Gestation were calculated for each month of Birth and tested for correlation with risk of id (monthly or) using the spearman's correlation coefficient."]	N/A	N/A	[('CHEBI_27300', 'vitamin D', 42, 'vitamin D'), ('GO_0043033', 'isoamylase complex', 94, 'trimesters'), ('GO_0007565', 'female pregnancy', 108, 'gestation'), ('GO_0007567', 'parturition', 152, 'birth')]
PMC3406997	5/2012	S54-PMC3406997	['caption (table-wrap): table 1\n\ncomposition of diet administered to Pigs during the study\xa0sows14–27\u2009day of Life28–42\u2009day of Life7–12\u2009week of Life13–19\u2009week of Lifefrom 20\u2009week of Life ingredient \xa0\xa0\xa0\xa0\xa0\xa0wheat middlings (%)35.047.045.040.030.025.0barley middlings (%)35.020.036.035.530.030.0soybean meal (%)15.018.010.017.515.010.0rye middlings (%)10.5–––22.032.5sauen-profi1* (%)3.5–––––ferkel-profi2* (%)–4.04.04.0––Josamin3* (%)––––3.02.5megajoule* (%)–5.02.02.5––cytromin duo* (%)0.51.01.00.5––trilac* (%)–5.02.0–––Limestone (%)0.3–––––Soybean oil (%)0.7––––– composition \xa0\xa0\xa0\xa0\xa0\xa0dry matter (%)88.4589.3288.8188.6488.3087.25crude protein (%)16.3519.3115.5317.7716.8015.18me (mj/kg)12.9613.2112.8912.9412.9913.07crude fibre (%)3.563.413.433.683.503.34crude fat (%)2.353.062.292.371.661.68ash (%)5.436.105.505.704.764.22starch (%)45.8240.8546.6643.9846.7249.42ca (%)0.810.840.800.810.750.63p (%)0.600.580.530.560.470.44available p (%)0.160.150.150.150.140.13na (%)0.170.220.210.210.170.15mg (%)0.170.190.190.190.190.17Carbohydrates (%)3.904.984.854.403.543.50lys (%)0.911.311.041.200.990.83met (%)0.280.440.380.400.310.28met\u2009+\u2009cys (%)0.590.780.690.740.630.57trp (%)0.200.270.210.230.200.18thr (%)0.580.840.680.780.630.55vitamin A (ie)18,00065,00038,00030,00012,00010,000vitamin D3(ie)1,5007,8004,3203,6501,9801,650vitamin E (mg)90307202145180150vitamin c (mg)30.038.035.033.0––Vitamin K (mg)2.12.52.52.51.401.20vitamin b1(mg)2.12.52.52.51.401.20Vitamin B2(mg)4.46.56.56.54.243.52vitamin B6(mg)4.25.05.05.04.23.5vitamin B12(μg)14.038.035.035.035.030.0\n1the Vitamin-Mineral concentrate contained per 1\u2009kg of diet: l-lysine 6.0\u2009%, methionine 1.0\u2009%, threonine 0.5\u2009%, Ca 20.0\u2009%, P 7.5\u2009%, Na 5.0\u2009%, Mg 2.5\u2009%, Vitamin a 600,000\u2009iu, Vitamin D350,000\u2009iu, Vitamin E 3,000\u2009mg, Vitanin C 1,000\u2009mg, Vitamin K3100\u2009mg, Vitamin b190\u2009mg, Vitamin B2200\u2009mg, Vitamin b6180, vitamin b121,330\u2009μg, niacin 1,200, Pantothenic Acid 660\u2009mg, Folic Acid 50\u2009mg, Choline Chloride 15,000\u2009mg, Biotin 4,000\u2009μg, Cu 875\u2009mg, zn 5,250\u2009mg, Mn 3,000\u2009mg, fe 4,000\u2009mg, j 75\u2009mg, co 10\u2009mg, Se 10\u2009mg.\n2the Vitamin-Mineral Concentrate contained per 1\u2009kg of diet: l-lysine 10.0\u2009%, methionine 3.3\u2009%, threonine 4.2\u2009%, Tryptophan 0.2\u2009%, ca 15.0\u2009%, p 4.0\u2009%, Na 4.5\u2009%, Vitamin A 500,000\u2009iu, Vitamin D350,000\u2009iu, Vitamin E 3,300\u2009mg, Vitanin C 4,000\u2009mg, Vitamin K3125\u2009mg, Vitamin B170\u2009mg, Vitamin B2150\u2009mg, vitamin b6130, vitamin b121,700\u2009μg, niacin 1,700, Pantothenic Acid 500\u2009mg, Folic Acid 40\u2009mg, Choline Chloride 17,500\u2009mg, Biotin 6,000\u2009μg, phytase 12,500 u, Cu 400\u2009mg, zn 1,000\u2009mg, Mn 500\u2009mg, Fe 800\u2009mg, j 55\u2009mg, Co 10\u2009mg, Se 10\u2009mg.\n3the Vitamin-Mineral concentrate contained per 1\u2009kg of diet: l-lysine 8.0\u2009%, methionine 2.0\u2009%, threonine 2.0\u2009%, Ca 21.0\u2009%, p 3.0\u2009%, Na 5.0\u2009%, Mg 2.0\u2009%, Vitamin A 400,000\u2009iu, Vitamin D366,000\u2009iu, Vitamin E 6,000\u2009mg, vitamin k375\u2009mg, Vitamin B170\u2009mg, Vitamin B2150\u2009mg, vitamin b6130, vitamin b121,000\u2009μg, niacin 900, Pantothenic Acid 500\u2009mg, Folic Acid 40\u2009mg, Choline Chloride 12,000\u2009mg, Biotin 2,500\u2009μg, phytase 10,000 u, Cu 160\u2009mg, zn 660\u2009mg, Mn 160\u2009mg, Fe 748\u2009mg, j 50\u2009mg, Co 11\u2009mg, Se 13\u2009mg.\n*josera erbacher gmbh & co., kleinheubach, germany.']	N/A	N/A	[('NCBITaxon_10088', 'Mus <genus>', 67, 'pigs'), ('UBERON_0007118', 'umbilicus', 106, 'life28'), ('UBERON_0000104', 'life cycle', 123, 'life7'), ('UBERON_0007118', 'umbilicus', 140, 'life13'), ('UBERON_0006376', 'premacula segment of distal straight tubule', 158, 'lifeFrom'), ('UBERON_0000104', 'life cycle', 178, 'life'), ('PR_000009682', 'ceramide synthase 6', 414, 'Josamin3'), ('CHEBI_18131', 'licodione', 515, 'Limestone'), ('CHEBI_36945', 'sulfaniumyl group', 536, 'Soybean'), ('CHEBI_33807', 'penturonic acid', 1012, '17Carbohydrates'), ('PR_000004370', 'asialoglycoprotein receptor 2', 1224, 'A'), ('PR_000001177', 'D(2) dopamine receptor', 1274, 'D3'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 1318, 'E'), ('CHEBI_28384', 'vitamin K', 1373, 'Vitamin K'), ('PR_000011032', 'neutrophil cytosol factor 4', 1439, '20Vitamin B2'), ('PR_000004690', 'B-cell lymphoma/leukemia 11A', 1483, 'B6'), ('CHEBI_27778', 'abequose', 1515, 'B12'), ('PR_000004738', 'class E basic helix-loop-helix protein 22', 1515, 'B12'), ('CHEBI_33229', 'vitamin (role)', 1552, 'vitamin'), ('CHEBI_46662', 'mineral', 1560, 'mineral'), ('CHEBI_32588', 'potassium chloride', 1659, 'Ca'), ('CHEBI_53758', 'PAP', 1670, 'P'), ('CHEBI_25614', 'nylons', 1679, 'Na'), ('CHEBI_34829', 'Medrysone', 1689, 'Mg'), ('CHEBI_33229', 'vitamin (role)', 1699, 'vitamin'), ('CHEBI_52330', 'glycerophosphatidylethanolamine', 1721, 'vitamin D350'), ('CHEBI_27300', 'vitamin D', 1742, 'vitamin E'), ('CHEBI_66356', 'Verrucoside', 1762, 'vitanin C'), ('CHEBI_85626', 'N-hydroxyhexadecenoylsphingosine-1-phosphocholine', 1782, 'vitamin K3100'), ('CHEBI_33229', 'vitamin (role)', 1800, 'vitamin'), ('CHEBI_72759', 'N-(pentadecanoyl)sphinganine-1-phosphocholine', 1817, 'vitamin B2200'), ('CHEBI_33229', 'vitamin (role)', 1835, 'vitamin'), ('CHEBI_7916', 'pantothenic acid', 1885, 'pantothenic acid'), ('CHEBI_30751', 'formic acid', 1910, 'folic acid'), ('CHEBI_133341', 'choline chloride', 1928, 'choline chloride'), ('CHEBI_15956', 'biotin', 1956, 'biotin'), ('CHEBI_17996', 'chloride', 1973, 'Cu'), ('CHEBI_25614', 'nylons', 1997, 'Mn'), ('CHEBI_37972', 'phosphorus-32 atom', 2042, 'Se'), ('CHEBI_33229', 'vitamin (role)', 2057, 'vitamin'), ('CHEBI_36134', 'glutaconate(2-)', 2065, 'mineral concentrate'), ('CHEBI_86267', 'nitrotyrosine', 2165, 'Tryptophan'), ('CHEBI_25614', 'nylons', 2203, 'Na'), ('CHEBI_27300', 'vitamin D', 2213, 'vitamin A'), ('CHEBI_52330', 'glycerophosphatidylethanolamine', 2235, 'vitamin D350'), ('CHEBI_27300', 'vitamin D', 2256, 'vitamin E'), ('CHEBI_66356', 'Verrucoside', 2276, 'vitanin C'), ('CHEBI_85626', 'N-hydroxyhexadecenoylsphingosine-1-phosphocholine', 2296, 'vitamin K3125'), ('CHEBI_72759', 'N-(pentadecanoyl)sphinganine-1-phosphocholine', 2314, 'vitamin B170'), ('CHEBI_52359', "tris(4,4'-diphenyl-2,2'-bipyridine)ruthenium(II) chloride", 2331, 'vitamin B2150'), ('CHEBI_7916', 'pantothenic acid', 2399, 'pantothenic acid'), ('CHEBI_30751', 'formic acid', 2424, 'folic acid'), ('CHEBI_133341', 'choline chloride', 2442, 'choline chloride'), ('CHEBI_15956', 'biotin', 2470, 'biotin'), ('CHEBI_17996', 'chloride', 2505, 'Cu'), ('CHEBI_25614', 'nylons', 2529, 'Mn'), ('CHEBI_33290', 'food', 2540, 'Fe'), ('CHEBI_33290', 'food', 2560, 'Co'), ('CHEBI_37972', 'phosphorus-32 atom', 2570, 'Se'), ('CHEBI_27300', 'vitamin D', 2585, 'vitamin-'), ('CHEBI_46662', 'mineral', 2593, 'mineral'), ('CHEBI_32588', 'potassium chloride', 2692, 'Ca'), ('CHEBI_25614', 'nylons', 2712, 'Na'), ('CHEBI_34829', 'Medrysone', 2722, 'Mg'), ('CHEBI_27300', 'vitamin D', 2732, 'vitamin A'), ('CHEBI_33739', 'di-mu-sulfido-diiron(0)', 2754, 'vitamin D366'), ('CHEBI_27300', 'vitamin D', 2775, 'vitamin E'), ('CHEBI_72759', 'N-(pentadecanoyl)sphinganine-1-phosphocholine', 2812, 'vitamin B170'), ('CHEBI_52359', "tris(4,4'-diphenyl-2,2'-bipyridine)ruthenium(II) chloride", 2829, 'vitamin B2150'), ('CHEBI_7916', 'pantothenic acid', 2895, 'pantothenic acid'), ('CHEBI_30751', 'formic acid', 2920, 'folic acid'), ('CHEBI_133341', 'choline chloride', 2938, 'choline chloride'), ('CHEBI_15956', 'biotin', 2966, 'biotin'), ('CHEBI_17996', 'chloride', 3001, 'Cu'), ('CHEBI_25614', 'nylons', 3023, 'Mn'), ('CHEBI_33290', 'food', 3034, 'Fe'), ('CHEBI_33290', 'food', 3054, 'Co'), ('CHEBI_37972', 'phosphorus-32 atom', 3064, 'Se')]
PMC3407995	7/2012	S3-PMC3407995	['reports were selected if they included benefits and harms of maternal supplementation of Dha, Vitamin D, Folic Acid or Iodine supplementation during Pregnancy and/or Lactation.']	N/A	N/A	[('CHEBI_17874', 'dihydrozeatin', 89, 'DHA'), ('CHEBI_27300', 'vitamin D', 94, 'vitamin D'), ('CHEBI_30751', 'formic acid', 105, 'folic acid'), ('CHEBI_24859', 'iodine atom', 119, 'iodine'), ('GO_0007565', 'female pregnancy', 149, 'pregnancy'), ('GO_0007595', 'lactation', 166, 'lactation')]
PMC3407995	7/2012	S14-PMC3407995	['a systematic search was performed in medline for english-language articles published between january 2000 and february 2012 using broad search criteria including dha and Pregnancy , dha and Lactation , Docosahexaenoic Acid and Pregnancy , Docosahexaenoic Acid and Lactation , Vitamin D and Pregnancy , Vitamin D and Lactation , Folic Acid and Pregnancy , Folic Acid and Lactation , Iodine and Pregnancy and Iodine and Lactation .']	N/A	N/A	[('GO_0007565', 'female pregnancy', 170, 'pregnancy'), ('GO_0007595', 'lactation', 190, 'lactation'), ('CHEBI_36003', 'decenoic acid', 202, 'docosahexaenoic acid'), ('GO_0007565', 'female pregnancy', 227, 'pregnancy'), ('CHEBI_36003', 'decenoic acid', 239, 'docosahexaenoic acid'), ('GO_0007595', 'lactation', 264, 'lactation'), ('CHEBI_27300', 'vitamin D', 276, 'vitamin D'), ('GO_0007565', 'female pregnancy', 290, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 302, 'vitamin D'), ('GO_0007595', 'lactation', 316, 'lactation'), ('CHEBI_30751', 'formic acid', 328, 'folic acid'), ('GO_0007565', 'female pregnancy', 343, 'pregnancy'), ('CHEBI_30751', 'formic acid', 355, 'folic acid'), ('GO_0007595', 'lactation', 370, 'lactation'), ('CHEBI_24859', 'iodine atom', 382, 'iodine'), ('GO_0007565', 'female pregnancy', 393, 'pregnancy'), ('CHEBI_24859', 'iodine atom', 407, 'iodine'), ('GO_0007595', 'lactation', 418, 'lactation')]
PMC3407995	7/2012	S86-PMC3407995	['supplement use contributed 6%–47% of the average Vitamin D intake in some countries.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 49, 'vitamin D')]
PMC3407995	7/2012	S95-PMC3407995	['maintain Pregnancy—the circulating concentration of maternal active Vitamin D rises in the first trimester and doubles by the end of the third trimester [53].']	N/A	N/A	[('GO_0007565', 'female pregnancy', 9, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 68, 'vitamin D')]
PMC3407995	7/2012	S267-PMC3407995	['intakes of Folate, iron, Vitamin D, Potassium, Iodine and Selenium were lower than uk recommendations during and after Pregnancy ( p< 0.05) [143].']	N/A	N/A	[('CHEBI_30863', '5-azaorotic acid', 11, 'folate'), ('CHEBI_27300', 'vitamin D', 25, 'vitamin D'), ('CHEBI_22314', 'alkali metal atom', 36, 'potassium'), ('CHEBI_24859', 'iodine atom', 47, 'iodine'), ('CHEBI_27568', 'selenium atom', 58, 'selenium'), ('GO_0007565', 'female pregnancy', 119, 'pregnancy')]
PMC3407995	7/2012	S270-PMC3407995	['a cross-sectional study in iran included 147 Pregnant women whose Serum status of Vitamin D, a, and e were assessed at 5–9 months of Pregnancy.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 45, 'pregnant'), ('UBERON_0001977', 'blood serum', 66, 'serum'), ('CHEBI_27300', 'vitamin D', 82, 'vitamin D'), ('GO_0007565', 'female pregnancy', 133, 'pregnancy')]
PMC3407995	7/2012	S271-PMC3407995	['the prevalence of Vitamin D deficiency was 95.8% [133].']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 18, 'vitamin D')]
PMC3407995	7/2012	S272-PMC3407995	['the prevalence of Vitamin D deficiency was determined in a diverse group of 559 women in south carolina, usa at latitude 32°n.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 18, 'vitamin D')]
PMC3407995	7/2012	S276-PMC3407995	['forty-eight percent were Vitamin D deficient, an additional 37% insufficient.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 25, 'vitamin D')]
PMC3407995	7/2012	S279-PMC3407995	['a cross-sectional study including 50 women in labour with a singleton term Pregnancy in pakistan measured Vitamin D status in maternal Blood before Delivery and Cord Blood at Delivery.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 75, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 106, 'vitamin D'), ('UBERON_0000178', 'blood', 135, 'blood'), ('GO_0007567', 'parturition', 148, 'delivery'), ('UBERON_0002240', 'spinal cord', 161, 'cord'), ('UBERON_0000178', 'blood', 166, 'blood'), ('GO_0007567', 'parturition', 175, 'delivery')]
PMC3407995	7/2012	S285-PMC3407995	['bone health\ndoctors in leicester city, uk reported that a significant number of south asian mothers visiting their clinic had Vitamin D deficiency at the end of Pregnancy.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 126, 'vitamin D'), ('GO_0007565', 'female pregnancy', 161, 'pregnancy')]
PMC3407995	7/2012	S308-PMC3407995	['maternal Vitamin D was measured at the 24th and 34th weeks of Pregnancy and at Delivery and infant Vitamin D was measured in Umbilical Blood at Birth and on the sixth day following Birth.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 9, 'vitamin D'), ('GO_0007565', 'female pregnancy', 62, 'pregnancy'), ('GO_0007567', 'parturition', 79, 'delivery'), ('CHEBI_27300', 'vitamin D', 99, 'vitamin D'), ('UBERON_0007118', 'umbilicus', 125, 'umbilical'), ('UBERON_0000178', 'blood', 135, 'blood'), ('GO_0007567', 'parturition', 144, 'birth'), ('GO_0007567', 'parturition', 181, 'birth')]
PMC3407995	7/2012	S314-PMC3407995	['bone health\na prospective partially randomised study of Vitamin D supplementation during Pregnancy included indian subjects (known to be Vitamin D deficient) randomised in the second Trimester to receive either one oral dose of 1500 μg Vitamin D (group 1, n = 48) or two doses of 3000 μg Vitamin D each in the second and third Trimesters (group 2, n = 49) [151].']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 56, 'vitamin D'), ('GO_0007565', 'female pregnancy', 89, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 137, 'vitamin D'), ('GO_0009294', 'DNA mediated transformation', 183, 'trimester'), ('CHEBI_27300', 'vitamin D', 236, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 288, 'vitamin D'), ('GO_0043033', 'isoamylase complex', 327, 'trimesters')]
PMC3407995	7/2012	S330-PMC3407995	['intakes of Folate, iron, Vitamin D, Potassium, Iodine and Selenium were lower than uk recommendations during and after Pregnancy ( p< 0.05) [143].']	N/A	N/A	[('CHEBI_30863', '5-azaorotic acid', 11, 'folate'), ('CHEBI_27300', 'vitamin D', 25, 'vitamin D'), ('CHEBI_22314', 'alkali metal atom', 36, 'potassium'), ('CHEBI_24859', 'iodine atom', 47, 'iodine'), ('CHEBI_27568', 'selenium atom', 58, 'selenium'), ('GO_0007565', 'female pregnancy', 119, 'pregnancy')]
PMC3407995	7/2012	S437-PMC3407995	['the review included five trials involving 623 women comparing the effects of Vitamin D alone versus no supplementation/placebo and one trial with 400 women comparing the effects of Vitamin D and Calcium versus no supplementation.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 77, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 181, 'vitamin D'), ('CHEBI_22313', 'alkaline earth metal atom', 195, 'calcium')]
PMC3407995	7/2012	S441-PMC3407995	['there were no significant differences in adverse side effects including nephritic syndrome, stillbirths or neonatal deaths between women who received Vitamin D supplements relative to women who received no treatment or placebo.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 150, 'vitamin D')]
PMC3407995	7/2012	S448-PMC3407995	['not a single adverse event was attributed to Vitamin D supplementation or circulating 25(Oh)D levels.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 45, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 86, '25(OH)D'), ('PR_000012046', 'oxysterol-binding protein-related protein 11', 89, 'OH ... D')]
PMC3424155	8/2012	S1-PMC3424155	['methods\nthis work studied the first two generations of offspring (f1 and f2) of swiss Mice from mothers Fed one of two diets: sc (standard Chow) or vitd- (Vitamin D-deficient).']	N/A	N/A	[('NCBITaxon_10088', 'Mus <genus>', 86, 'mice'), ('GO_0007631', 'feeding behavior', 104, 'fed'), ('CHEBI_33290', 'food', 139, 'chow'), ('CHEBI_27300', 'vitamin D', 155, 'vitamin D')]
PMC3424155	8/2012	S11-PMC3424155	['introduction\nadolescent and Adult women of Childbearing age in the united states of america have a high prevalence of Vitamin D insufficiency[1],[2].']	N/A	N/A	[('UBERON_0007023', 'adult organism', 28, 'adult'), ('GO_0007129', 'homologous chromosome pairing at meiosis', 43, 'childbearing'), ('CHEBI_27300', 'vitamin D', 118, 'vitamin D')]
PMC3424155	8/2012	S28-PMC3424155	['experimental design\nsix-week-old, female, virgin swiss webster Mice (n\u200a=\u200a20, obtained from oswaldo cruz institute foundation, rio de janeiro, rj, brazil) were allocated to one of two groups for six weeks: sc (standard Chow, Fed a diet made according to the ain93g protocol, including 1,000.0 iu/kg of Vitamin D3)[14]or vitd- (Vitamin D restricted, Fed the same ain93g diet but without Vitamin D3).']	N/A	N/A	[('NCBITaxon_10088', 'Mus <genus>', 63, 'mice'), ('CHEBI_33290', 'food', 218, 'chow'), ('GO_0007631', 'feeding behavior', 224, 'fed'), ('CHEBI_33279', 'vitamin D5', 301, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 301, 'vitamin D3'), ('CHEBI_27300', 'vitamin D', 326, 'vitamin D'), ('GO_0007631', 'feeding behavior', 348, 'fed'), ('CHEBI_33279', 'vitamin D5', 385, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 385, 'vitamin D3')]
PMC3424155	8/2012	S29-PMC3424155	['the Vitamin D was added separately only to the sc diet, and the Vitamin Mixture added to both the sc and vitd- diets did not contain Vitamin D.table 1shows the nutritional components in each diet, including the dietary composition of Vitamin D. the recommended minimum dietary requirement of Pregnant Mice for Vitamin D, according to the ain93g, is 1,000.0 iu/kg of diet.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 4, 'vitamin D'), ('CHEBI_33229', 'vitamin (role)', 64, 'vitamin'), ('CHEBI_60004', 'mixture', 72, 'mixture'), ('CHEBI_27300', 'vitamin D', 133, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 234, 'vitamin D'), ('GO_0007565', 'female pregnancy', 292, 'pregnant'), ('NCBITaxon_10088', 'Mus <genus>', 301, 'mice'), ('CHEBI_27300', 'vitamin D', 310, 'vitamin D')]
PMC3424155	8/2012	S30-PMC3424155	['the sc diet contained 400,000 iu of Vitamin D3/g or 0.250 g of Vitamin D3/kg of the feed Mix, which supplied the recommended levels of Vitamin D.10.1371/journal.pone.0041740.t001\n\ncaption (table-wrap): table 1\ncomposition of the diets.Nutrient (g/kg)dietsscvitd−corn Starch397.50397.50casein200.00200.00starch Dextrinated132.00132.00sucrose100.00100.00soya bean oil70.0070.00fiber50.0050.00l-Cystine3.003.00choline2.502.50mineral Mix35.0035.00calcium Carbonate357.00357.00vitamin Mix10.0010.00vitamin D30.250.00\nall the Nutrients corresponded to the recommendations of ain93g for rodents.']	N/A	N/A	[('CHEBI_33279', 'vitamin D5', 36, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 36, 'vitamin D3'), ('CHEBI_33279', 'vitamin D5', 63, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 63, 'vitamin D3'), ('CHEBI_60004', 'mixture', 89, 'mix'), ('CHEBI_27300', 'vitamin D', 135, 'vitamin D'), ('CHEBI_33284', 'nutrient', 235, 'Nutrient'), ('CHEBI_66439', 'sciscllascilloside E-1', 267, 'starch397'), ('CHEBI_85139', 'beta-amino acid ester', 310, 'dextrinated132'), ('PR_000005959', 'cysteine and glycine-rich protein 2', 392, 'cystine3'), ('CHEBI_85365', 'deuterated chloroform', 430, 'mix35'), ('CHEBI_85585', 'phosphatidylcholine O-42:3', 451, 'carbonate357'), ('CHEBI_53756', 'HIV-1 reverse transcriptase inhibitor', 480, 'mix10'), ('PR_000002019', 'MHC class II histocompatibility antigen beta chain DRB1', 501, 'D30'), ('CHEBI_33284', 'nutrient', 520, 'nutrients')]
PMC3424155	8/2012	S31-PMC3424155	['abbreviations: sc, standard Chow; vitd−, Vitamin D restricted diet.']	N/A	N/A	[('CHEBI_33290', 'food', 28, 'chow'), ('CHEBI_27300', 'vitamin D', 41, 'vitamin D')]
PMC3424155	8/2012	S176-PMC3424155	['in three different moments of Post-Natal Life (Birth, 10-days and 3 months of age), Bm was not affected by the maternal diet restricted in Vitamin D. at weaning and at six months of age, the vitd- offspring were heavier than the sc offspring in both the f1 and f2 generations.']	N/A	N/A	[('GO_0007567', 'parturition', 30, 'post'), ('GO_0007567', 'parturition', 35, 'natal'), ('UBERON_0000104', 'life cycle', 41, 'life'), ('GO_0007567', 'parturition', 47, 'birth'), ('UBERON_0005401', 'cerebral hemisphere gray matter', 84, 'BM'), ('CHEBI_27300', 'vitamin D', 139, 'vitamin D')]
PMC3427192	4/2012	S2-PMC3427192	['Vitamin D is of particular interest in asthma since Vitamin D concentrations decrease with increased time spent indoors, decreased exposure to sunlight, less exercise, obesity, and inadequate Calcium intake.']	N/A	N/A	[('CHEBI_28384', 'vitamin K', 0, 'Vitamin D'), ('CHEBI_27300', 'vitamin D', 52, 'vitamin D'), ('CHEBI_22313', 'alkaline earth metal atom', 192, 'calcium')]
PMC3427192	4/2012	S12-PMC3427192	['searches were made for “Vitamin D” and “asthma,” excluding in vitro and Animal studies.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 24, 'vitamin D'), ('NCBITaxon_33208', 'Metazoa', 72, 'animal')]
PMC3427250	8/2012	S9-PMC3427250	['the risk of Vitamin D deficiency (25-(Oh)D <20 ng/ml) was significantly higher for less educated women and women who reported not going on holidays to sunny climates.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 12, 'vitamin D'), ('CHEBI_72657', '19,20-DiHDPA', 34, '25-(OH)D')]
PMC3427250	8/2012	S10-PMC3427250	['the risk of severe Vitamin D deficiency (25-(Oh)D <10 ng/ml) decreased for women who reported Alcohol consumption during Pregnancy, decreased with more frequent use of sunscreen Lotion and increased for smokers and women who reported preference for shadow.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 19, 'vitamin D'), ('CHEBI_72657', '19,20-DiHDPA', 41, '25-(OH)D'), ('CHEBI_30879', 'alcohol', 94, 'alcohol'), ('GO_0007565', 'female pregnancy', 121, 'pregnancy'), ('CHEBI_75903', 'arsenic(1-) sulfides', 178, 'lotion')]
PMC3427250	8/2012	S19-PMC3427250	['Humans get Vitamin D (Cholecalciferol) from exposure to sunlight, diet and dietary supplements.']	N/A	N/A	[('NCBITaxon_10088', 'Mus <genus>', 0, 'Humans'), ('CHEBI_27300', 'vitamin D', 11, 'vitamin D'), ('CHEBI_52550', 'theopalauamide', 22, 'cholecalciferol')]
PMC3427250	8/2012	S20-PMC3427250	['as few Food items contain or are fortified with Vitamin D (such as Liver, fatty fish, eggs, milk and dairy products, soy milk, butter, margarines), the skin Synthesis Of Vitamin D induced by ultraviolet b radiation (uvb) is the main determinant of Vitamin D status in the population[23].']	N/A	N/A	[('CHEBI_33290', 'food', 7, 'food'), ('CHEBI_27300', 'vitamin D', 48, 'vitamin D'), ('UBERON_0002107', 'liver', 67, 'liver'), ('GO_0030474', 'spindle pole body duplication', 157, 'synthesis of vitamin D'), ('CHEBI_27300', 'vitamin D', 170, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 248, 'vitamin D')]
PMC3427250	8/2012	S24-PMC3427250	['several modifications of Vitamin D Metabolism occur during Pregnancy.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 25, 'vitamin D'), ('GO_0042359', 'vitamin D metabolic process', 25, 'vitamin D metabolism'), ('GO_0007565', 'female pregnancy', 59, 'pregnancy')]
PMC3427250	8/2012	S55-PMC3427250	['the odds of having a Serum 25-(Oh)D concentration lower than 20 ng/ml (Vitamin D deficiency) versus a non deficient Vitamin D status were estimated through multiple logistic regressions while entering the following variables as predictors in the model: season, age, Trimester Of Pregnancy, region, bmi, smoking behaviour, alcohol Consumption, use of Vitamin D-containing Food supplements, fish Consumption, milk and dairy product Consumption, education level, ethnicity, parity, exposure to sunlight during weekdays, exposure to sunlight during weekend days, use of sunscreen Lotion, use of solarium, shadow or sun preference and sometimes going on holidays to sunny climates (yes/no question).']	N/A	N/A	[('UBERON_0001977', 'blood serum', 21, 'serum'), ('CHEBI_72657', '19,20-DiHDPA', 27, '25-(OH)D'), ('CHEBI_27300', 'vitamin D', 71, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 116, 'vitamin D'), ('GO_0009294', 'DNA mediated transformation', 266, 'trimester of pregnancy'), ('GO_0007631', 'feeding behavior', 330, 'consumption'), ('CHEBI_27300', 'vitamin D', 350, 'vitamin D'), ('CHEBI_33290', 'food', 371, 'food'), ('GO_0007631', 'feeding behavior', 394, 'consumption'), ('GO_0007631', 'feeding behavior', 430, 'consumption'), ('CHEBI_75903', 'arsenic(1-) sulfides', 576, 'lotion')]
PMC3427250	8/2012	S56-PMC3427250	['in addition the odds of having a Serum 25-(Oh)D concentration lower than 10 ng/ml (severe Vitamin D deficiency) versus a non severe deficient Vitamin D status were estimated through multiple logistic regressions while entering the same predictors in the model.']	N/A	N/A	[('UBERON_0001977', 'blood serum', 33, 'serum'), ('CHEBI_72657', '19,20-DiHDPA', 39, '25-(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 46, 'D'), ('CHEBI_27300', 'vitamin D', 90, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 142, 'vitamin D')]
PMC3427250	8/2012	S61-PMC3427250	['for 1 hospital (n\u200a=\u200a23 women) certain questions (mainly nationality, ethnicity, education level) needed to be omitted from the questionnaire upon decision of the ethical committee of this particular hospital.10.1371/journal.pone.0043868.g001\n\ncaption (fig): figure 1\ngeographical distribution of the 55 hospitals visited in belgium and the number of Pregnant women (n\u200a=\u200a1311) investigated by site (national survey on Vitamin D status of Pregnant women belgium 2010–2011).10.1371/journal.pone.0043868.t001\n\ncaption (table-wrap): table 1\nnumber of Pregnant women by region, trimester and age (national survey on Vitamin D status among Pregnant women belgium, 2010–2011).regionsbrussels**flanders**walloniaage(years )1sttrimester3rdtrimester1sttrimester3rdtrimester1sttrimester3rdtrimester15–20721110211721–2534277751567326–304139108149765831–3534536975494536–4014142319132441–45231332total132138289307218219\n6 missing data for age.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 350, 'pregnant'), ('CHEBI_27300', 'vitamin D', 417, 'vitamin D'), ('GO_0007565', 'female pregnancy', 437, 'pregnant'), ('GO_0007565', 'female pregnancy', 546, 'pregnant'), ('CHEBI_27300', 'vitamin D', 610, 'vitamin D'), ('GO_0007565', 'female pregnancy', 633, 'pregnant')]
PMC3427250	8/2012	S75-PMC3427250	['of all women, 74.1% (95%ci\u200a=\u200a71.8–76.5%) were Vitamin D insufficient (25-(Oh)d concentration <30 ng/ml) and 44.6% (95%ci\u200a=\u200a41.9–47.3%) of the Pregnant women were Vitamin D deficient (25-(Oh)D concentration <20 ng/ml), while 12.1% (95%ci\u200a=\u200a10.3–13.8%) of the women were severely Vitamin D deficient (25-(Oh)D concentration <10 ng/ml).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 46, 'vitamin D'), ('CHEBI_30254', 'sulfidocarbon(.1+)', 70, '25-(OH)'), ('GO_0007565', 'female pregnancy', 142, 'pregnant'), ('CHEBI_27300', 'vitamin D', 162, 'vitamin D'), ('CHEBI_72657', '19,20-DiHDPA', 183, '25-(OH)D'), ('CHEBI_27300', 'vitamin D', 278, 'vitamin D'), ('CHEBI_72657', '19,20-DiHDPA', 299, '25-(OH)D')]
PMC3427250	8/2012	S76-PMC3427250	['the percentage of women with Vitamin D insufficiency and deficiency was higher in the first than in the third Trimester of Pregnancy but the prevalence of severe Vitamin D deficiency was higher in the third trimester (table 3).10.1371/journal.pone.0043868.t003\n\ncaption (table-wrap): table 3\nSerum 25-(Oh)D concentration in Pregnant women (n\u200a=\u200a1311) (belgian national survey on Vitamin D status in Pregnant women, 2010–2011).all womenwalloniaflanders1sttrimester3rdtrimestern1300453633633665age28.5±5.127.9±5.528.8±4.728.3±5.128.8±5.1gestational weeks22.2±12.522.1±12.822.4±12.39.9±2.834.1±3.625-(oh)d(ng/ml)median21.220.922.320.422.7*iqr13.8–30.013.5–29.114.6–30.613.6–26.714.3–34.195% ci20.5–22.219.8–22.321.2–23.219.3–21.121.6–24.4% <10 ng/ml12.112.310.911.612.6% <20 ng/ml44.645.742.347.042.3% <30 ng/ml74.176.372.582.266.7\ndifferent from first Trimester Pregnant women, p<0.001.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 29, 'vitamin D'), ('GO_0009294', 'DNA mediated transformation', 110, 'trimester'), ('GO_0007565', 'female pregnancy', 123, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 162, 'vitamin D'), ('UBERON_0001977', 'blood serum', 292, 'Serum'), ('CHEBI_72657', '19,20-DiHDPA', 298, '25-(OH)D'), ('GO_0007565', 'female pregnancy', 324, 'pregnant'), ('CHEBI_27300', 'vitamin D', 378, 'vitamin D'), ('GO_0007565', 'female pregnancy', 398, 'pregnant'), ('GO_0009294', 'DNA mediated transformation', 849, 'trimester'), ('GO_0007565', 'female pregnancy', 859, 'pregnant')]
PMC3427250	8/2012	S78-PMC3427250	['women of other ethnic origins were Vitamin D deficient (25-(Oh)D concentration <20 ng/ml) all year round, except during summer for third trimester women (figure 2).10.1371/journal.pone.0043868.g002\n\ncaption (fig): figure 2\nSerum 25-(Oh)d concentrations over the different seasons, by Trimester of Pregnancy and ethnicity (national survey on Vitamin D status among Pregnant women in belgium, 2010–2011).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 35, 'vitamin D'), ('CHEBI_72657', '19,20-DiHDPA', 56, '25-(OH)D'), ('UBERON_0001977', 'blood serum', 223, 'Serum'), ('CHEBI_30254', 'sulfidocarbon(.1+)', 229, '25-(OH)'), ('GO_0009294', 'DNA mediated transformation', 284, 'trimester'), ('GO_0007565', 'female pregnancy', 297, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 341, 'vitamin D'), ('GO_0007565', 'female pregnancy', 364, 'pregnant')]
PMC3427250	8/2012	S80-PMC3427250	['for 62.0% of them the multivitamin contained Vitamin D. in the first and third Trimester of Pregnancy the percentage of women taking a multivitamin containing vitamin d was 52.6% and 72.3% respectively.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 45, 'vitamin D'), ('GO_0009294', 'DNA mediated transformation', 79, 'trimester'), ('GO_0007565', 'female pregnancy', 92, 'pregnancy')]
PMC3427250	8/2012	S82-PMC3427250	['the risk of Vitamin D deficiency (25-(Oh)D <20 ng/ml) increased significantly with bmi and was significantly higher for women who reported not taking Vitamin D-containing multivitamins (table 4).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 12, 'vitamin D'), ('CHEBI_72657', '19,20-DiHDPA', 34, '25-(OH)D'), ('CHEBI_27300', 'vitamin D', 150, 'vitamin D')]
PMC3427250	8/2012	S83-PMC3427250	['in addition the risk of Vitamin D deficiency was threefold higher among women of asiatic descent, six fold higher for north african women and five fold higher for women of hispanic descent compared to caucasians.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 24, 'vitamin D')]
PMC3427250	8/2012	S84-PMC3427250	['the risk of Vitamin D insufficiency was significantly lower for more educated women and for Persons reporting going on holidays to sunny climates.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 12, 'vitamin D'), ('NCBITaxon_10088', 'Mus <genus>', 92, 'persons')]
PMC3427250	8/2012	S88-PMC3427250	['the risk of severe Vitamin D deficiency (25-(Oh)D <10 ng/ml) was significantly lower among third than first Trimester Pregnant women (table 5).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 19, 'vitamin D'), ('CHEBI_72657', '19,20-DiHDPA', 41, '25-(OH)D'), ('GO_0009294', 'DNA mediated transformation', 108, 'trimester'), ('GO_0007565', 'female pregnancy', 118, 'pregnant')]
PMC3427250	8/2012	S89-PMC3427250	['in addition risk of severe Vitamin D deficiency increased for women who reported not taking Vitamin D containing multivitamins, who were of non caucasian origin and who reported smoking during Pregnancy.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 27, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 92, 'vitamin D'), ('GO_0007565', 'female pregnancy', 193, 'pregnancy')]
PMC3427250	8/2012	S92-PMC3427250	['exposure to the sun during week and weekend days, and Consumption Of Milk and dairy Products were not associated with either severe or normal Vitamin D deficiency.10.1371/journal.pone.0043868.t005\n\ncaption (table-wrap): table 5\nrisk of severe Vitamin D deficiency during Pregnancy in belgium (25-(oh)d <10 ng/ml) (n\u200a=\u200a1121), results of multiple logistic regressions.n of subjectsn of severe deficient casesor[95% conf interval]p trimester of Pregnancy first trimester633741.000third trimester665841.7511.1282.7190.013 season winter470891.000spring384350.2830.1680.477<0.001summer930autumn351340.3240.1910.551<0.001 smoking yes219331.000no10781250.4630.2680.8010.006 Alcohol Consumption yes264131.000no10221432.3701.1624.8340.018 use of multivitamins containing Vitamin D no4891151.000yes809430.1210.0750.193<0.001 ethnicity caucasian, white955691.000asiatic3396.6562.41318.359<0.001african, black64132.6051.1515.8960.022african, north174638.1744.71214.177<0.001 frequency Fatty Fish Consumption never192181.000less than once a month188242.2051.0104.8160.0471–3 days a month498591.4810.7552.9040.2541 day per week291351.3910.6712.8850.3752–4 days a week or more frequent128221.5130.6593.4720.328 use of sunscreen Lotion yes, much of the time644361.000yes, sometimes281342.0871.1713.7220.013no368883.2631.9355.504<0.001 preference sun/shadow sun476531.000shadow497701.9831.2253.2100.005does not matter321351.2060.6912.1040.510\nor odds ratio.']	N/A	N/A	[('GO_0070817', 'P-TEFb-cap methyltransferase complex localization', 54, 'consumption of milk'), ('GO_0060208', 'proestrus', 84, 'products'), ('CHEBI_27300', 'vitamin D', 142, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 243, 'vitamin D'), ('GO_0007565', 'female pregnancy', 271, 'pregnancy'), ('GO_0007565', 'female pregnancy', 442, 'pregnancy'), ('CHEBI_30879', 'alcohol', 666, 'Alcohol'), ('GO_0007631', 'feeding behavior', 674, 'consumption'), ('CHEBI_27300', 'vitamin D', 761, 'vitamin D'), ('CHEBI_38677', 'famphur', 972, 'fatty fish'), ('GO_0007631', 'feeding behavior', 983, 'consumption'), ('CHEBI_75903', 'arsenic(1-) sulfides', 1212, 'lotion')]
PMC3427250	8/2012	S94-PMC3427250	['the prevalence of severe Vitamin D deficiency was 12% during the first trimester and was slightly higher, 13%, during the third Trimester of Pregnancy.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 25, 'vitamin D'), ('GO_0009294', 'DNA mediated transformation', 128, 'trimester'), ('GO_0007565', 'female pregnancy', 141, 'pregnancy')]
PMC3427250	8/2012	S100-PMC3427250	['similarly as in our Pregnant women population, in the Adult population the risk of Vitamin D deficiency was higher in winter than in summer and increased with bmi[36],[37],[44],[45],[46].']	N/A	N/A	[('GO_0007565', 'female pregnancy', 20, 'pregnant'), ('UBERON_0007023', 'adult organism', 54, 'adult'), ('CHEBI_27300', 'vitamin D', 83, 'vitamin D')]
PMC3427250	8/2012	S104-PMC3427250	['in belgium, Pregnant women of different ethnic origins had substantially lower Vitamin D concentrations than caucasian women and were Vitamin D deficient all year long except during summer for third Trimester women.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 12, 'pregnant'), ('CHEBI_27300', 'vitamin D', 79, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 134, 'vitamin D'), ('GO_0009294', 'DNA mediated transformation', 199, 'trimester')]
PMC3427250	8/2012	S113-PMC3427250	['in belgium, Pregnant women who reported going on holidays to sunny climates had a lower risk of Vitamin D deficiency and women who reported using sunscreen Lotion had a lower risk of severe Vitamin D deficiency.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 12, 'pregnant'), ('CHEBI_27300', 'vitamin D', 96, 'vitamin D'), ('CHEBI_75903', 'arsenic(1-) sulfides', 156, 'lotion'), ('CHEBI_27300', 'vitamin D', 190, 'vitamin D')]
PMC3427250	8/2012	S115-PMC3427250	['women who reported a preference for shadow had a higher risk of severe Vitamin D deficiency in our study.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 71, 'vitamin D')]
PMC3458940	9/2012	S1-PMC3458940	['most functions of Vitamin A are mediated by its main active form, All- Trans Retinoic Acid (Tra), which binds Retinoic Acid receptors (rars) to Modulate Gene Expression.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 18, 'vitamin A'), ('CHEBI_35589', '9H-purine', 66, 'all- trans'), ('CHEBI_26536', 'retinoic acid', 77, 'retinoic acid'), ('CHEBI_37972', 'phosphorus-32 atom', 92, 'tRA'), ('CHEBI_26536', 'retinoic acid', 110, 'retinoic acid'), ('GO_0065007', 'biological regulation', 144, 'modulate'), ('GO_0010467', 'gene expression', 153, 'gene expression'), ('SO_0000704', 'gene', 153, 'gene')]
PMC3458940	9/2012	S34-PMC3458940	['in cells, All- Trans Retinol (trol), i.e., Vitamin A, is oxidized reversibly to All- Trans Retinaldehyde (tral), catalyzed by the enzymes Retinol dehydrogenases (rdhs) or Alcohol dehydrogenases (adhs).']	N/A	N/A	[('CHEBI_31137', '5-Methyl-pyrrole-2-carboxyl-[pcp]', 10, 'all- trans retinol'), ('CHEBI_27300', 'vitamin D', 43, 'vitamin A'), ('CHEBI_55365', 'alpha-hexylcinnamaldehyde', 80, 'all- trans retinaldehyde'), ('CHEBI_26536', 'retinoic acid', 138, 'retinol'), ('CHEBI_30879', 'alcohol', 171, 'alcohol')]
PMC3465343	10/2012	S3-PMC3465343	['thirty two female Rats were randomized into two groups: control group, which was Fed a normal diet; Vitamin A deficient group, which were given Vitamin A-deficient diet from at least 2 weeks before Mating till delivery.']	N/A	N/A	[('NCBITaxon_9986', 'Oryctolagus cuniculus', 18, 'rats'), ('GO_0007631', 'feeding behavior', 81, 'fed'), ('CHEBI_27300', 'vitamin D', 100, 'vitamin A'), ('CHEBI_27300', 'vitamin D', 144, 'vitamin A'), ('GO_0007618', 'mating', 198, 'mating')]
PMC3465343	10/2012	S5-PMC3465343	['female Rats were Fed an ain-93g diet sufficient in Vitamin A to Feed the rest of neonates for two weeks until euthanasia.']	N/A	N/A	[('NCBITaxon_9986', 'Oryctolagus cuniculus', 7, 'rats'), ('GO_0007631', 'feeding behavior', 17, 'fed'), ('CHEBI_27300', 'vitamin D', 51, 'vitamin A'), ('GO_0007631', 'feeding behavior', 64, 'feed')]
PMC3465343	10/2012	S6-PMC3465343	['Serum levels of Vitamin A were assessed in the Adult and filial Rats.']	N/A	N/A	[('UBERON_0001977', 'blood serum', 0, 'Serum'), ('CHEBI_27300', 'vitamin D', 16, 'vitamin A'), ('UBERON_0007023', 'adult organism', 47, 'adult'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 64, 'rats')]
PMC3465343	10/2012	S10-PMC3465343	['the incidence of congenital scoliosis was 13.79% (8/58) in the filial Rats of Vitamin A deficiency group and 0% in the control group.']	N/A	N/A	[('NCBITaxon_9986', 'Oryctolagus cuniculus', 70, 'rats'), ('CHEBI_27300', 'vitamin D', 78, 'vitamin A')]
PMC3465343	10/2012	S11-PMC3465343	['furthermore, Vitamin A deficiency negatively regulate the Liver and verterbral body mrna levels of Raldh1, Raldh2, Raldh3, Rar-Α, Rar-Β and Rar-γ.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 13, 'vitamin A'), ('UBERON_0002107', 'liver', 58, 'liver'), ('PR_000013779', 'histone-binding protein RBBP7', 99, 'RALDH1'), ('PR_000013779', 'histone-binding protein RBBP7', 107, 'RALDH2'), ('PR_000013779', 'histone-binding protein RBBP7', 115, 'RALDH3'), ('PR_000013672', 'DNA repair protein RAD51 homolog 1', 123, 'RAR-α'), ('PR_000013672', 'DNA repair protein RAD51 homolog 1', 130, 'RAR-β'), ('PR_000013644', 'Ras-related protein Rab-9A', 140, 'RAR')]
PMC3465343	10/2012	S140-PMC3465343	['Teratogenic targets of Vitamin A excess were the Heart, the Skull, Skeleton, Limbs, Brain, Eyes, Cns, as well as craniofacial structures[32].']	N/A	N/A	[('CHEBI_73676', '3-deoxychenodeoxycholic acid', 0, 'Teratogenic'), ('CHEBI_27300', 'vitamin D', 23, 'vitamin A'), ('UBERON_0000948', 'heart', 49, 'heart'), ('UBERON_0003129', 'skull', 60, 'skull'), ('UBERON_0004288', 'skeleton', 67, 'skeleton'), ('UBERON_0002101', 'limb', 77, 'limbs'), ('UBERON_0000955', 'brain', 84, 'brain'), ('UBERON_0000970', 'eye', 91, 'eyes'), ('UBERON_0001017', 'central nervous system', 97, 'CNS')]
PMC3465343	10/2012	S174-PMC3465343	['in their study, the Birds were not severely deficient in Vitamin A because the investigators used Corn oil as the source of dietary Lipid[28].']	N/A	N/A	[('NCBITaxon_33208', 'Metazoa', 20, 'birds'), ('CHEBI_27300', 'vitamin D', 57, 'vitamin A'), ('CHEBI_33306', 'carbon group element atom', 98, 'corn'), ('CHEBI_18059', 'lipid', 132, 'lipid')]
PMC3465343	10/2012	S196-PMC3465343	['vad group (n\u200a=\u200a24) were Fed a modified ain-93g diet without any source of Vitamin A (table 4; research diets,usa); control group (n\u200a=\u200a8) received an ain-93g diet sufficient in Vitamin A (4 Retinol equivalents(re)/g diet).']	N/A	N/A	[('GO_0007631', 'feeding behavior', 24, 'fed'), ('CHEBI_27300', 'vitamin D', 74, 'vitamin A'), ('CHEBI_27300', 'vitamin D', 176, 'vitamin A'), ('CHEBI_26536', 'retinoic acid', 189, 'retinol')]
PMC3465343	10/2012	S198-PMC3465343	['Plasma levels were analyzed by hplc in a random sample of Animals to verity deficiency (<2 µg of Vitamin A per 100 ml, 0.74 µmol/l) as previously descibed[33].']	N/A	N/A	[('UBERON_0001969', 'blood plasma', 0, 'Plasma'), ('NCBITaxon_33208', 'Metazoa', 58, 'animals'), ('CHEBI_27300', 'vitamin D', 97, 'vitamin A')]
PMC3465343	10/2012	S199-PMC3465343	['then the Animals were Mated with normal males between 6 and 10 p.m. during Gestation, the vad group were Fed a modified ain-93g diet without any source of Vitamin A and the control group received an ain-93g diet sufficient in Vitamin A (4 Retinol equivalents (re)/g diet)[45].']	N/A	N/A	[('NCBITaxon_33208', 'Metazoa', 9, 'animals'), ('GO_0007618', 'mating', 22, 'mated'), ('GO_0007565', 'female pregnancy', 75, 'gestation'), ('GO_0007631', 'feeding behavior', 105, 'fed'), ('CHEBI_27300', 'vitamin D', 155, 'vitamin A'), ('CHEBI_27300', 'vitamin D', 226, 'vitamin A'), ('CHEBI_26536', 'retinoic acid', 239, 'retinol')]
PMC3465343	10/2012	S202-PMC3465343	['after Parturition, the two groups of female Rats were Fed an ain-93g diet sufficient in Vitamin A (4 Retinol equivalents (re)/g diet) to Feed the rest of neonates for two weeks until being killed.10.1371/journal.pone.0046565.t004\n\ncaption (table-wrap): table 4\nformulation of modified ain-93g Growing Rodent diet without added Vitamin A.ingredientamountgm/kgcasein, Lactic, 30 mesh200l-cystine3corn starch397.486maltodextrin 10132sucrose100cellulose,bw20050cottonseed oil70t-Butylhydroquinone0.014mineral Mix s10022g35vitamin Mix s1300210choline bitartrate2.5\n\nSerum Vitamin A measurement\nthe Tail Blood of female Rats was collected for detecting Serum Retinol level before Mating and after Parturition.']	N/A	N/A	[('GO_0019230', 'proprioception', 6, 'parturition'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 44, 'rats'), ('GO_0007631', 'feeding behavior', 54, 'fed'), ('CHEBI_27300', 'vitamin D', 88, 'vitamin A'), ('CHEBI_26536', 'retinoic acid', 101, 'retinol'), ('GO_0007631', 'feeding behavior', 137, 'feed'), ('GO_0040007', 'growth', 293, 'growing'), ('NCBITaxon_33208', 'Metazoa', 301, 'rodent'), ('CHEBI_27300', 'vitamin D', 327, 'vitamin A'), ('CHEBI_35571', 'mancude organic heterocyclic parent', 366, 'lactic'), ('CHEBI_28224', 'Peptidyl-L-arginine', 475, 'butylhydroquinone0'), ('CHEBI_60004', 'mixture', 505, 'mix'), ('CHEBI_60004', 'mixture', 526, 'mix'), ('UBERON_0001977', 'blood serum', 561, 'Serum'), ('CHEBI_27300', 'vitamin D', 567, 'vitamin A'), ('UBERON_0002415', 'tail', 593, 'tail'), ('UBERON_0000178', 'blood', 598, 'blood'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 614, 'rats'), ('UBERON_0001977', 'blood serum', 647, 'serum'), ('CHEBI_26536', 'retinoic acid', 653, 'retinol'), ('GO_0007618', 'mating', 674, 'mating'), ('GO_0019230', 'proprioception', 691, 'parturition')]
PMC3465343	10/2012	S205-PMC3465343	['all Serum Vitamin A measurements were carried out within 2 weeks after obtaining the samples.']	N/A	N/A	[('UBERON_0001977', 'blood serum', 4, 'serum'), ('CHEBI_27300', 'vitamin D', 10, 'vitamin A')]
PMC3465343	10/2012	S207-PMC3465343	['to minimize Photoisomerization Of Vitamin A, the Plasma was taken under reduced yellow light and frozen in the dark at −80°c until determination of Retinol concentrations.']	N/A	N/A	[('GO_0042461', 'photoreceptor cell development', 12, 'photoisomerization of vitamin A'), ('CHEBI_27300', 'vitamin D', 34, 'vitamin A'), ('UBERON_0001969', 'blood plasma', 49, 'plasma'), ('CHEBI_26536', 'retinoic acid', 148, 'retinol')]
PMC3465343	10/2012	S208-PMC3465343	['Serum Vitamin A concentration was measured using high performance liquid chromatography (150×4.6×5 mm; aglilent techologies,santa clara,ca) as previously described[46].']	N/A	N/A	[('UBERON_0001977', 'blood serum', 0, 'Serum'), ('CHEBI_27300', 'vitamin D', 6, 'vitamin A')]
PMC3470091	9/2012	S4-PMC3470091	['the ig received an im injection of 300,000 iu of Vitamin D, whereas cg did not.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 49, 'vitamin D')]
PMC3470091	9/2012	S8-PMC3470091	['of the patients, 79.2% of ig and 81.9% of cg suffered to some degree from Vitamin D deficiency.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 74, 'vitamin D')]
PMC3470091	9/2012	S14-PMC3470091	['during Pregnancy and Lactation outstanding changes occur in mother’s Vitamin D Metabolism.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 7, 'pregnancy'), ('GO_0007595', 'lactation', 21, 'lactation'), ('CHEBI_27300', 'vitamin D', 69, 'vitamin D'), ('GO_0007601', 'visual perception', 69, 'vitamin D'), ('GO_0008152', 'metabolic process', 79, 'metabolism')]
PMC3470091	9/2012	S29-PMC3470091	['the exclusion criteria included changing the routine treatment as well as taking Vitamin D, Ca, and multivitamin supplements.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 81, 'vitamin D'), ('CHEBI_32588', 'potassium chloride', 92, 'Ca')]
PMC3470091	9/2012	S32-PMC3470091	['the ig was given intramuscular 300,000 iu of Vitamin D, while the cg was not.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 45, 'vitamin D')]
PMC3470091	9/2012	S44-PMC3470091	['dose and follow-up\nthe administered Vitamin D was Vitamin D3, which were kept from light, frozen, and stored at 15 to 30oc during the study.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 36, 'vitamin D'), ('CHEBI_33279', 'vitamin D5', 50, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 50, 'vitamin D3')]
PMC3470091	9/2012	S45-PMC3470091	['patients’ Vitamin D status was determined by measuring Serum 25(Oh) Vitamin D3 concentration.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 10, 'vitamin D'), ('UBERON_0001977', 'blood serum', 55, 'serum'), ('CHEBI_30778', 'gallic acid', 61, '25(OH)'), ('CHEBI_33279', 'vitamin D5', 68, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 68, 'vitamin D3')]
PMC3470091	9/2012	S59-PMC3470091	['caption (table-wrap): table 2:\n\nthe Serum concentrations of Vitamin D (25(Oh) D3), Parathyroid hormone (pth), Calcium and phosphorus, and body mass index (bmi) of subjects in the intervention group (ig) and control group (cg)variablesigcgp value25(Oh)D3 (nmol/l)before24.25(13.3-202.4)δ25.30(12.8-137.2)0.44after62.10(31.7-278.9)24.10(18.0-191.7)<0.001p value<0.0010.02pth pmol/l)before3.42±1.083.6±1.050.6after2.88±1.064.78±2.400.003p value0.0010.1serum Calcium (mg/dl)before9.01±0.28.9±0.100.1after9.17±0.359.12±0.450.7p value0.070.013serum Phosphor (mg/dl)before3.37±0.453.61±0.390.07after3.25±0.33.41±0.360.3p value0.50.5bmi (kg/m2)before29.15±527.9±3.60.4after29.0±5.627.4±3.70.1p value0.350.25hba1c (%)before5.48±0.65.20±0.730.1after5.58±125.21±0.520.2p value0.730.67\n™: median (min-max)\nnone of the groups had severe Vitamin D deficiency before the intervention.']	N/A	N/A	[('UBERON_0001977', 'blood serum', 36, 'serum'), ('CHEBI_27300', 'vitamin D', 60, 'vitamin D'), ('CHEBI_62946', 'ammonium sulfate', 71, '25(OH) D3'), ('UBERON_0001132', 'parathyroid gland', 83, 'parathyroid'), ('CHEBI_22313', 'alkaline earth metal atom', 110, 'calcium'), ('CHEBI_32029', 'potassium acetate', 247, '(OH)D3'), ('PR_000011622', 'S-acyl fatty acid synthase thioesterase, medium chain', 248, 'OH)D3'), ('CHEBI_31341', 'calcium dihydroxide', 455, 'Calcium'), ('CHEBI_30207', 'phosphorus(.)', 543, 'Phosphor'), ('CHEBI_27300', 'vitamin D', 824, 'vitamin D')]
PMC3470091	9/2012	S60-PMC3470091	['fifteen (62.5%) of the subjects in the ig were suffering from a moderate Vitamin D deficiency, which decreased to zero after the intervention (table 3).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 73, 'vitamin D')]
PMC3470091	9/2012	S62-PMC3470091	['four (16.7%) of the subjects in the ig were suffering from a mild Vitamin D deficiency, which was reduced to one (4.2%) after the intervention.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 66, 'vitamin D')]
PMC3470091	9/2012	S64-PMC3470091	['if Vitamin D deficiency is regarded as 25-Oh Vitamin D3 lower than 35 nmol/l,1279.2% of patients from ig and 81.9% from cg suffered to some degrees from Vitamin D deficiency prior to the intervention.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 3, 'vitamin D'), ('CHEBI_86198', '1,2-di-[(11Z)-eicosenoyl]-sn-glycero-3-phosphocholine', 39, '25-OH'), ('CHEBI_33279', 'vitamin D5', 45, 'vitamin D3'), ('CHEBI_27300', 'vitamin D', 153, 'vitamin D')]
PMC3470091	9/2012	S68-PMC3470091	['twelve weeks after the administration of a single dose of 300,000 iu of Vitamin D, this figure was 4.2% and 71.4% for the ig and cg, respectively.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 72, 'vitamin D')]
PMC3471827	10/2012	S0-PMC3471827	['the Α-Tocopherol transfer protein is essential for Vertebrate Embryogenesis\n\nabstract\nthe Hepatic α-Tocopherol transfer protein (ttp) is required for optimal Α-Tocopherol bioavailability in Humans; mutations in the Human Ttpa Gene result in the heritable disorder ataxia with Vitamin E deficiency (aved, omim #277460).']	N/A	N/A	[('CHEBI_27725', 'butin', 4, 'α-Tocopherol'), ('GO_0030730', 'sequestering of triglyceride', 51, 'Vertebrate'), ('GO_0009790', 'embryo development', 62, 'Embryogenesis'), ('UBERON_0002107', 'liver', 90, 'hepatic'), ('CHEBI_27013', 'tocopherol', 100, 'tocopherol'), ('CHEBI_27725', 'butin', 158, 'α-tocopherol'), ('NCBITaxon_9606', 'Homo sapiens', 190, 'humans'), ('NCBITaxon_9606', 'Homo sapiens', 215, 'human'), ('PR_000016770', 'testis-specific serine/threonine-protein kinase 1', 221, 'TTPA'), ('SO_0000704', 'gene', 226, 'gene'), ('CHEBI_27300', 'vitamin D', 276, 'vitamin E')]
PMC3471827	10/2012	S13-PMC3471827	['Humans with Ttpa Gene mutations demonstrate a heritable disorder: ataxia with Vitamin E deficiency (aved, omim #277460), which manifests in infancy and childhood.']	N/A	N/A	[('NCBITaxon_10088', 'Mus <genus>', 0, 'Humans'), ('PR_000016770', 'testis-specific serine/threonine-protein kinase 1', 12, 'TTPA'), ('SO_0000704', 'gene', 17, 'gene'), ('CHEBI_27300', 'vitamin D', 78, 'vitamin E')]
PMC3472720	8/2012	S25-PMC3472720	['f0female c57bl/6 Mice were Fed a Vitamin D-free diet before and during Pregnancy.']	N/A	N/A	[('NCBITaxon_10088', 'Mus <genus>', 17, 'mice'), ('GO_0007631', 'feeding behavior', 27, 'fed'), ('CHEBI_27300', 'vitamin D', 33, 'vitamin D'), ('GO_0007565', 'female pregnancy', 71, 'pregnancy')]
PMC3472720	8/2012	S27-PMC3472720	['a Vitamin D-containing diet was provided to all Animals, before, during and after Pregnancy.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 2, 'vitamin D'), ('NCBITaxon_33208', 'Metazoa', 48, 'animals'), ('GO_0007565', 'female pregnancy', 82, 'pregnancy')]
PMC3472720	8/2012	S68-PMC3472720	['being Born in the fall means that, during the third Trimester of Pregnancy, the fetus developed in a supposedly Vitamin D optimal environment.']	N/A	N/A	[('GO_0007567', 'parturition', 6, 'born'), ('GO_0009294', 'DNA mediated transformation', 52, 'trimester'), ('GO_0007565', 'female pregnancy', 65, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 112, 'vitamin D')]
PMC3472720	8/2012	S78-PMC3472720	['Serum Vitamin D depletion was assessed six weeks later using a commercial ria (diasorin, stillwater, mn, usa) for 25-Hydroxyvitamin D3.']	N/A	N/A	[('UBERON_0001977', 'blood serum', 0, 'Serum'), ('CHEBI_27300', 'vitamin D', 6, 'vitamin D'), ('CHEBI_63991', '15-epi-lipoxin B4', 114, '25-hydroxyvitamin D3'), ('PR_000001177', 'D(2) dopamine receptor', 132, 'D3')]
PMC3475131	6/2012	S113-PMC3475131	['the dose and duration of Vitamin A supplementation varied from 2,400–60,000\u2009μg/day, and between 6–28\u2009weeks.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 25, 'vitamin A')]
PMC3476426	8/2012	S6-PMC3476426	['results\nautistic children had significantly lower Serum levels of 25-Hydroxy Vitamin D than healthy children ( p< 0.001) with 40% and 48% being Vitamin D deficient and insufficient, respectively.']	N/A	N/A	[('UBERON_0001977', 'blood serum', 50, 'serum'), ('CHEBI_62218', '23,24-dihydrocucurbitacin D', 66, '25-hydroxy vitamin D'), ('CHEBI_27300', 'vitamin D', 144, 'vitamin D')]
PMC3476426	8/2012	S13-PMC3476426	['the main source of Vitamin D is the conversion of 7-Dehydrocholesterol to pre-Vitamin D3 in the skin, by means of solar ultraviolet b radiation, and a lesser amount of Vitamin D is obtained from Food.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 19, 'vitamin D'), ('CHEBI_17500', '7alpha-hydroxycholesterol', 50, '7-dehydrocholesterol'), ('CHEBI_33279', 'vitamin D5', 78, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 78, 'vitamin D3'), ('CHEBI_27300', 'vitamin D', 168, 'vitamin D'), ('CHEBI_33290', 'food', 195, 'food')]
PMC3476426	8/2012	S14-PMC3476426	['Vitamin D3 undergoes a 25-hydroxylation in the Liver, with the resulting product, 25-Hydroxy Vitamin D or Calcidiol, being the main circulating form of Vitamin D. therefor, 25-Hydroxy Vitamin D levels are used to determine the Vitamin D status of a given Individual [1,2].']	N/A	N/A	[('CHEBI_33237', 'vitamin D4', 0, 'Vitamin D3'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 0, 'Vitamin D3'), ('UBERON_0002107', 'liver', 47, 'liver'), ('CHEBI_43141', '3-hydroxypropoxy group', 82, '25-hydroxy'), ('CHEBI_27300', 'vitamin D', 93, 'vitamin D'), ('PR_000006444', 'diacylglycerol kinase delta', 101, 'D'), ('CHEBI_17933', 'calcidiol', 106, 'calcidiol'), ('CHEBI_27300', 'vitamin D', 152, 'vitamin D'), ('CHEBI_62218', '23,24-dihydrocucurbitacin D', 173, '25-hydroxy vitamin D'), ('CHEBI_27300', 'vitamin D', 227, 'vitamin D'), ('NCBITaxon_1', 'root', 255, 'individual')]
PMC3476426	8/2012	S15-PMC3476426	['the fully active form 1, 25 Dihydroxy Vitamin D3, is synthesized in the Kidneys by the 25-Hydroxy Vitamin D-1A hydroxylase, an enzyme which is mainly induced by the Parathyroid hormone (pth).']	N/A	N/A	[('CHEBI_50341', '1-hydroxyethyl group', 22, '1, 25 dihydroxy'), ('CHEBI_33279', 'vitamin D5', 38, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 38, 'vitamin D3'), ('UBERON_0002113', 'kidney', 72, 'kidneys'), ('CHEBI_43141', '3-hydroxypropoxy group', 87, '25-hydroxy'), ('CHEBI_27300', 'vitamin D', 98, 'vitamin D'), ('PR_000017255', 'Vang-like protein 1', 98, 'vitamin D-1a'), ('UBERON_0001132', 'parathyroid gland', 165, 'parathyroid')]
PMC3476426	8/2012	S17-PMC3476426	['deficient levels of Vitamin D promote Pth Synthesis that results in Bone Resorption.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 20, 'vitamin D'), ('GO_0046463', 'acylglycerol biosynthetic process', 38, 'PTH synthesis'), ('GO_0045453', 'bone resorption', 68, 'bone resorption')]
PMC3476426	8/2012	S42-PMC3476426	['all studied children had not received Calcium and/or Vitamin D therapy in the past 6 months.']	N/A	N/A	[('CHEBI_22313', 'alkaline earth metal atom', 38, 'calcium'), ('CHEBI_27300', 'vitamin D', 53, 'vitamin D')]
PMC3476426	8/2012	S68-PMC3476426	['results\n\nSerum levels of 25-Hydroxy Vitamin D in autistic patients and healthy children\nautistic children had significantly lower Serum levels of 25-Hydroxy Vitamin D (median (iqr) = 18.5 (14) ng/ml) than healthy children (median (iqr) = 33 (11) ng/ml), p< 0.001 (figure1), with 40% and 48% being Vitamin D deficient and insufficient, respectively.']	N/A	N/A	[('UBERON_0001977', 'blood serum', 9, 'Serum'), ('CHEBI_62218', '23,24-dihydrocucurbitacin D', 25, '25-hydroxy vitamin D'), ('UBERON_0001977', 'blood serum', 130, 'serum'), ('CHEBI_62218', '23,24-dihydrocucurbitacin D', 146, '25-hydroxy vitamin D'), ('CHEBI_27300', 'vitamin D', 297, 'vitamin D')]
PMC3476426	8/2012	S69-PMC3476426	['none of the healthy children was Vitamin D deficient, but 20% were Vitamin D insufficient (table1).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 33, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 67, 'vitamin D')]
PMC3476426	8/2012	S70-PMC3476426	['caption (fig): figure 1\n\nSerum levels of 25-Hydroxy Vitamin D in the studied children.']	N/A	N/A	[('UBERON_0001977', 'blood serum', 25, 'Serum'), ('CHEBI_43141', '3-hydroxypropoxy group', 41, '25-hydroxy'), ('CHEBI_27300', 'vitamin D', 52, 'vitamin D')]
PMC3476426	8/2012	S74-PMC3476426	['Serum 25-Hydroxy Vitamin D had no significant correlations with the age of autistic children ( p = 0.83).']	N/A	N/A	[('UBERON_0001977', 'blood serum', 0, 'Serum'), ('CHEBI_43141', '3-hydroxypropoxy group', 6, '25-hydroxy'), ('CHEBI_27300', 'vitamin D', 17, 'vitamin D')]
PMC3476426	8/2012	S103-PMC3476426	['Vitamin D receptors and Vitamin D Metabolizing enzymes are present in Cns.']	N/A	N/A	[('CHEBI_28384', 'vitamin K', 0, 'Vitamin D'), ('CHEBI_27300', 'vitamin D', 24, 'vitamin D'), ('GO_0043181', 'vacuolar sequestering', 24, 'vitamin D metabolizing'), ('UBERON_0001017', 'central nervous system', 70, 'CNS')]
PMC3476426	8/2012	S146-PMC3476426	['three treatment modalities exist for Vitamin D deficiency which include; sunlight, artificial ultraviolet b radiation, and Vitamin D3 supplementation.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 37, 'vitamin D'), ('CHEBI_33279', 'vitamin D5', 123, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 123, 'vitamin D3')]
PMC3485340	10/2012	S17-PMC3485340	['within the Brain, the hippocampus has one of the highest vitc concentrations[10]–[12]and a corresponding high level of the vitc transporter–the sodium Dependent Vitamin C Co-Transporter 2 (Svct2)[13],[14].']	N/A	N/A	[('UBERON_0000955', 'brain', 11, 'brain'), ('PR_000014924', 'solute carrier family 12 member 1', 151, 'dependent vitamin C co-transporter 2'), ('CHEBI_27300', 'vitamin D', 161, 'vitamin C'), ('PR_000015393', 'suppressor of cytokine signaling 2', 189, 'SVCT2')]
PMC3485340	10/2012	S34-PMC3485340	['group high (n\u200a=\u200a30) was assigned to a diet containing 900 mg of Vitamin C per kg diet and group low (n\u200a=\u200a50) received a diet containing 100 mg of Vitamin C per kg.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 64, 'vitamin C'), ('CHEBI_27300', 'vitamin D', 146, 'vitamin C'), ('PR_000004900', 'complement C3', 154, 'C')]
PMC3485340	10/2012	S126-PMC3485340	['closed circles (•) represent high and open circles (○) represent low Postnatal Vitamin C. at p10 and p27 there is a significant difference between Prenatal diet group by two-way anova, and by student’s t-test at p70.']	N/A	N/A	[('GO_0007567', 'parturition', 69, 'postnatal'), ('CHEBI_27300', 'vitamin D', 79, 'vitamin C'), ('GO_0007565', 'female pregnancy', 147, 'prenatal')]
PMC3485340	10/2012	S151-PMC3485340	['closed circles (•) represent high and open circles (○) represent low Postnatal Vitamin C. n\u200a=\u200a7–11 per treatment group.']	N/A	N/A	[('GO_0007567', 'parturition', 69, 'postnatal'), ('CHEBI_27300', 'vitamin D', 79, 'vitamin C')]
PMC3488410	10/2012	S127-PMC3488410	['Prenatal Vitamin D deficiency reduced Cell Proliferation in the subgranular zone.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 0, 'Prenatal'), ('CHEBI_27300', 'vitamin D', 9, 'vitamin D'), ('GO_0008283', 'cell proliferation', 38, 'cell proliferation')]
PMC3488410	10/2012	S131-PMC3488410	['in Vitamin D-deficient Mice, the deficiency-induced reduction of Cell Proliferation was completely normalized by Haloperidol resulting in a mitotic activity adequate to the untreated control level.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 3, 'vitamin D'), ('NCBITaxon_10088', 'Mus <genus>', 23, 'mice'), ('GO_0008283', 'cell proliferation', 65, 'cell proliferation'), ('CHEBI_5613', 'haloperidol', 113, 'haloperidol')]
PMC3501517	11/2012	S4-PMC3501517	['at 8 weeks of age, Vitamin D deficient and sufficient Mice received 2.5 g/kg of Lps or saline intratracheal.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 19, 'vitamin D'), ('NCBITaxon_10088', 'Mus <genus>', 54, 'mice'), ('CHEBI_16412', 'lipopolysaccharide', 80, 'LPS')]
PMC3501517	11/2012	S9-PMC3501517	['Leukocytes were mildly decreased in the Bronchoalveolar Fluid of Vitamin D deficient Mice at 1 day.']	N/A	N/A	[('CL_0000346', 'hair follicle dermal papilla cell', 0, 'Leukocytes'), ('UBERON_0012128', 'nose tip', 40, 'bronchoalveolar fluid'), ('CHEBI_27300', 'vitamin D', 65, 'vitamin D'), ('NCBITaxon_10088', 'Mus <genus>', 85, 'mice')]
PMC3501517	11/2012	S10-PMC3501517	['ex-vivo , Neutrophils from Vitamin D deficient Mice showed impaired Chemotaxis to Kc but not to C5A.']	N/A	N/A	[('CL_0000775', 'neutrophil', 10, 'neutrophils'), ('CHEBI_27300', 'vitamin D', 27, 'vitamin D'), ('NCBITaxon_10088', 'Mus <genus>', 47, 'mice'), ('GO_0006935', 'chemotaxis', 68, 'chemotaxis'), ('PR_000009255', 'potassium voltage-gated channel subfamily E member 1', 82, 'KC'), ('PR_000002319', 'catenin beta-1 isoform 1', 96, 'C5a')]
PMC3501517	11/2012	S20-PMC3501517	['Macrophage Release Of Cathelicidin, an Antimicrobial peptide required for efficient Macrophage Killing of mtb , in response to toll-like receptor activation requires co-activation of the Vitamin D receptor[19],[20].']	N/A	N/A	[('CL_0000235', 'macrophage', 0, 'Macrophage'), ('GO_0046661', 'male sex differentiation', 0, 'Macrophage'), ('GO_1990864', 'response to growth hormone-releasing hormone', 11, 'release of cathelicidin'), ('CHEBI_3364', 'Canthiumine', 22, 'cathelicidin'), ('PR_000006009', 'alpha-catulin', 22, 'cathelicidin'), ('CHEBI_65381', 'albizoside C', 39, 'antimicrobial'), ('CL_0000235', 'macrophage', 84, 'macrophage'), ('GO_0007601', 'visual perception', 95, 'killing'), ('CHEBI_27300', 'vitamin D', 187, 'vitamin D')]
PMC3501517	11/2012	S32-PMC3501517	['materials and methods\n\ngeneration and characterization of Vitamin D sufficient (vds) and Vitamin D deficient (vdd) Mice\nthe university of washington office of Animal welfare approved these experiments.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 58, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 89, 'vitamin D'), ('NCBITaxon_10088', 'Mus <genus>', 115, 'mice'), ('NCBITaxon_33208', 'Metazoa', 159, 'Animal')]
PMC3501517	11/2012	S34-PMC3501517	['when female breeder Mice were visibly Pregnant, they were either placed in Vitamin D sufficient or deficient housing.']	N/A	N/A	[('NCBITaxon_10088', 'Mus <genus>', 20, 'mice'), ('GO_0007565', 'female pregnancy', 38, 'pregnant'), ('CHEBI_27300', 'vitamin D', 75, 'vitamin D')]
PMC3501517	11/2012	S35-PMC3501517	['Vitamin D deficient housing included a diet that was absent of Vitamin D and contained 1% calcium (harlan, madison, wi).']	N/A	N/A	[('CHEBI_28384', 'vitamin K', 0, 'Vitamin D'), ('CHEBI_27300', 'vitamin D', 63, 'vitamin D')]
PMC3501517	11/2012	S36-PMC3501517	['the cages were wrapped in ultraviolet blocking film (uv process supply, chicago, il) to prevent any cutaneous conversion of Vitamin D. the Vitamin D sufficient Mice were exposed to normal vivarium lighting and received an identical diet to the deficient Mice with an additional 1000 iu/kg of Cholecalciferol (harlan, madison, wi).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 124, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 139, 'vitamin D'), ('NCBITaxon_10088', 'Mus <genus>', 160, 'mice'), ('NCBITaxon_10088', 'Mus <genus>', 254, 'mice'), ('CHEBI_52550', 'theopalauamide', 292, 'cholecalciferol')]
PMC3501517	11/2012	S83-PMC3501517	['to evaluate Cxcr2 Expression, Neutrophils isolated from the Bone Marrow of Vitamin D –sufficient and –deficient Mice were washed in facs buffer (pbs+0.5% bsa), blocked with Rat anti-Mouse cd16/32 (fc block, bdbiosciences), incubated with either pe-conjugated Rat anti-Mouse Cxcr2 or Rat isotype control Igg2Aantibody (r&d systems), washed, and analyzed in a guava benchtop flow cytometer (millipore, billerica, ma).']	N/A	N/A	[('PR_000001209', 'C-X-C chemokine receptor type 5', 12, 'CXCR2'), ('GO_0010467', 'gene expression', 18, 'expression'), ('CL_0000775', 'neutrophil', 30, 'neutrophils'), ('UBERON_0002371', 'bone marrow', 60, 'bone marrow'), ('CHEBI_27300', 'vitamin D', 75, 'vitamin D'), ('NCBITaxon_10088', 'Mus <genus>', 112, 'mice'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 173, 'rat'), ('NCBITaxon_10088', 'Mus <genus>', 182, 'mouse'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 259, 'rat'), ('NCBITaxon_10088', 'Mus <genus>', 268, 'mouse'), ('PR_000001209', 'C-X-C chemokine receptor type 5', 274, 'CXCR2'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 283, 'rat'), ('GO_0071736', 'IgG immunoglobulin complex, circulating', 303, 'IgG2Aantibody')]
PMC3501517	11/2012	S103-PMC3501517	['( a ) mean body fat in Vitamin D sufficient (vds, n\u200a=\u200a23) and Vitamin D deficient (vdd, n\u200a=\u200a19) Mice of both genders as determined by quantitative magnetic resonance.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 23, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 62, 'vitamin D'), ('NCBITaxon_10088', 'Mus <genus>', 96, 'mice')]
PMC3501517	11/2012	S134-PMC3501517	['400× magnfication of Hematoxylin and eosin stained sections of Right Lung Lobes collected from Vitamin D sufficient (vds) and deficient (vdd) Mice after exposure to pbs or to Lps for varying lengths of time.']	N/A	N/A	[('CHEBI_51686', 'haematoxylin', 21, 'hematoxylin'), ('UBERON_0006518', 'right lung lobe', 63, 'right lung lobes'), ('CHEBI_27300', 'vitamin D', 95, 'vitamin D'), ('NCBITaxon_10088', 'Mus <genus>', 142, 'mice'), ('CHEBI_16412', 'lipopolysaccharide', 175, 'LPS')]
PMC3501517	11/2012	S170-PMC3501517	['Neutrophils were isolated from Vitamin D-sufficient (vds) or –deficient (vdd) Mouse Bone Marrow for Chemotaxis measurement and flow cytometry.']	N/A	N/A	[('CL_0000775', 'neutrophil', 0, 'Neutrophils'), ('CHEBI_27300', 'vitamin D', 31, 'vitamin D'), ('NCBITaxon_10088', 'Mus <genus>', 78, 'mouse'), ('UBERON_0002371', 'bone marrow', 84, 'bone marrow'), ('GO_0006935', 'chemotaxis', 100, 'chemotaxis')]
PMC3501517	11/2012	S193-PMC3501517	['specifically, tem identification of Extravascular Erythrocytes, Fibroblast count, collagen bundles, Perivascular Mast Cells, Eosinophil count, and intra-Alveolar debris were all lower 8 and 12 weeks after radiation injury in the Rats given supplemental Vitamin D. Neutrophil count was lower at 8 weeks and Macrophage count was lower at 12 weeks in supplemented Rats, as well.']	N/A	N/A	[('GO_0043265', 'ectoplasm', 36, 'extravascular'), ('CL_0000232', 'erythrocyte', 50, 'erythrocytes'), ('CL_0000057', 'fibroblast', 64, 'fibroblast'), ('UBERON_0014930', 'perivascular space', 100, 'perivascular'), ('CL_0000097', 'mast cell', 113, 'mast cells'), ('CL_0000771', 'eosinophil', 125, 'eosinophil'), ('UBERON_0003215', 'alveolus', 153, 'alveolar'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 229, 'rats'), ('CHEBI_27300', 'vitamin D', 253, 'vitamin D'), ('CL_0000775', 'neutrophil', 264, 'Neutrophil'), ('CL_0000235', 'macrophage', 306, 'macrophage'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 361, 'rats')]
PMC3509518	11/2012	S10-PMC3509518	['there were no relationships between Β-Carotene, Vitamin E or zinc and any allergic outcomes.']	N/A	N/A	[('CHEBI_28064', 'cyanidin 3-O-rutinoside', 36, 'β-carotene'), ('CHEBI_27300', 'vitamin D', 48, 'vitamin E')]
PMC3509518	11/2012	S45-PMC3509518	['reported Vitamin and Mineral supplement intakes (brand, dose and frequency) was converted into daily Β-Carotene, Vitamin C, e, zinc and copper intakes, using dosage information provided at the packaging.']	N/A	N/A	[('CHEBI_33229', 'vitamin (role)', 9, 'vitamin'), ('CHEBI_46662', 'mineral', 21, 'mineral'), ('CHEBI_28064', 'cyanidin 3-O-rutinoside', 101, 'β-carotene'), ('CHEBI_27300', 'vitamin D', 113, 'vitamin C')]
PMC3509518	11/2012	S92-PMC3509518	['no statistically significant exposure-response associations were observed between maternal dietary intakes of Β-Carotene, Vitamin E or zinc and the risk of developing early allergic outcomes (table 4).']	N/A	N/A	[('CHEBI_28064', 'cyanidin 3-O-rutinoside', 110, 'β-carotene'), ('CHEBI_27300', 'vitamin D', 122, 'vitamin E')]
PMC3513049	2/2012	S5-PMC3513049	['household Pets were assessed during Pregnancy and Serum level of 25 (Oh)D (25-Hydroxyvitamin D) in Cord Blood was used as the measure of Vitamin D and a marker of maternal level.']	N/A	N/A	[('NCBITaxon_10088', 'Mus <genus>', 10, 'pets'), ('GO_0007565', 'female pregnancy', 36, 'pregnancy'), ('UBERON_0001977', 'blood serum', 50, 'serum'), ('CHEBI_71657', 'versiconol acetate', 65, '25 (OH)D'), ('CHEBI_62218', '23,24-dihydrocucurbitacin D', 75, '25-hydroxyvitamin D'), ('UBERON_0002240', 'spinal cord', 99, 'cord'), ('UBERON_0000178', 'blood', 104, 'blood'), ('CHEBI_27300', 'vitamin D', 137, 'vitamin D')]
PMC3515553	12/2012	S40-PMC3515553	['out of these 331, a total of 310 (149 girls, 161 boys) had Plasma concentrations of Vitamin B-12 determined using a Colistin Sulfate-resistant strain of lactobacillus leichmanii [21],[22].']	N/A	N/A	[('UBERON_0001969', 'blood plasma', 59, 'plasma'), ('CHEBI_27300', 'vitamin D', 84, 'vitamin B'), ('PR_000017269', 'ventral anterior homeobox 2', 84, 'vitamin B-12'), ('CHEBI_59675', 'colistin B sulfate', 116, 'colistin sulfate'), ('PR_000005693', 'collagen alpha-1(X) chain', 116, 'colistin')]
PMC3515553	12/2012	S41-PMC3515553	['the coefficient of variation for Vitamin B-12 was 7% based on control samples run with every assay.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 33, 'vitamin B'), ('PR_000017269', 'ventral anterior homeobox 2', 33, 'vitamin B-12')]
PMC3515553	12/2012	S44-PMC3515553	['assessment of maternal Vitamin B-12 dietary intake\nmaternal Vitamin B-12 intake was assessed in the whole cohort at 32 weeks of Pregnancy using a Food frequency questionnaire (ffq).']	N/A	N/A	[('PR_000017269', 'ventral anterior homeobox 2', 23, 'Vitamin B-12'), ('CHEBI_27300', 'vitamin D', 60, 'vitamin B'), ('PR_000017269', 'ventral anterior homeobox 2', 60, 'vitamin B-12'), ('GO_0007565', 'female pregnancy', 128, 'pregnancy'), ('CHEBI_33290', 'food', 146, 'food')]
PMC3515553	12/2012	S47-PMC3515553	['the ffq was used to calculate approximate energy and Nutrient Intakes by multiplying the weekly frequency of Consumption of each Food/Food group by the Nutrient content (for this specific study Vitamin B-12) of a standard portion of that Food (the portion sizes were suitable for women of Childbearing age).']	N/A	N/A	[('CHEBI_33284', 'nutrient', 53, 'nutrient'), ('GO_0007631', 'feeding behavior', 62, 'intakes'), ('GO_0007631', 'feeding behavior', 109, 'consumption'), ('CHEBI_33290', 'food', 129, 'food'), ('CHEBI_33290', 'food', 134, 'food'), ('CHEBI_33284', 'nutrient', 152, 'nutrient'), ('CHEBI_27300', 'vitamin D', 194, 'vitamin B'), ('PR_000017269', 'ventral anterior homeobox 2', 194, 'vitamin B-12'), ('CHEBI_33290', 'food', 238, 'food'), ('GO_0007129', 'homologous chromosome pairing at meiosis', 289, 'childbearing')]
PMC3515553	12/2012	S64-PMC3515553	['statistical analysis\nmaternal dietary Vitamin B-12 intake and Cord Vitamin B-12 measures were log transformed because they were positively skewed.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 38, 'vitamin B'), ('PR_000017269', 'ventral anterior homeobox 2', 38, 'vitamin B-12'), ('CHEBI_37983', 'sulfur-35 atom', 48, '12'), ('UBERON_0002240', 'spinal cord', 62, 'cord'), ('CHEBI_27300', 'vitamin D', 67, 'vitamin B'), ('PR_000017269', 'ventral anterior homeobox 2', 67, 'vitamin B-12')]
PMC3515553	12/2012	S66-PMC3515553	['linear regression was also used in the analysis of the association of maternal dietary Intake, Cord Blood Vitamin B-12 and genotypes with offspring iq.']	N/A	N/A	[('GO_0007631', 'feeding behavior', 87, 'intake'), ('UBERON_0002240', 'spinal cord', 95, 'cord'), ('UBERON_0000178', 'blood', 100, 'blood'), ('CHEBI_27300', 'vitamin D', 106, 'vitamin B'), ('PR_000017269', 'ventral anterior homeobox 2', 106, 'vitamin B-12')]
PMC3515553	12/2012	S70-PMC3515553	['n\u200a=\u200a4787 with complete data on exposure, outcome and covariables in any model.mean difference in child iq per doubling of maternal Vitamin B-12 intake95% cip-valuemodel 12.01.3, 2.8<0.001model 20.7−0.04, 1.40.06model 30.5−0.2, 1.20.15\nmodel 1: adjusted for offspring sex and age at time of iq assessment, and maternal Energy Intake.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 131, 'vitamin B'), ('PR_000017269', 'ventral anterior homeobox 2', 131, 'vitamin B-12'), ('CHEBI_37983', 'sulfur-35 atom', 141, '12'), ('GO_0050998', 'nitric-oxide synthase binding', 318, 'energy intake')]
PMC3515553	12/2012	S81-PMC3515553	['in these analyses we stratified maternal-offspring pairs by whether the maternal Intake was below the recommended daily amount (rda) for Vitamin B-12 for pregnant women (2.6 µg) or at or above this value.']	N/A	N/A	[('GO_0007631', 'feeding behavior', 81, 'intake'), ('CHEBI_27300', 'vitamin D', 137, 'vitamin B'), ('PR_000017269', 'ventral anterior homeobox 2', 137, 'vitamin B-12')]
PMC3515553	12/2012	S102-PMC3515553	['n corresponds to the number of mothers with available genotype data for both Snps (n\u200a=\u200a5866), whose children had Vitamin B-12 measured in Cord blood (n\u200a=\u200a202), or whose children had been iq tested (n\u200a=\u200a3429).']	N/A	N/A	[('SO_0000694', 'SNP', 77, 'SNPs'), ('CHEBI_27300', 'vitamin D', 113, 'vitamin B'), ('PR_000017269', 'ventral anterior homeobox 2', 113, 'vitamin B-12'), ('UBERON_0002240', 'spinal cord', 138, 'cord')]
PMC3515553	12/2012	S115-PMC3515553	['fifteen percent of mothers Consumed less than the rda for Vitamin B-12 dietary intake.']	N/A	N/A	[('GO_0007631', 'feeding behavior', 27, 'consumed'), ('CHEBI_27300', 'vitamin D', 58, 'vitamin B'), ('PR_000017269', 'ventral anterior homeobox 2', 58, 'vitamin B-12')]
PMC3515553	12/2012	S123-PMC3515553	['genotypes and Haplotypes\nall Vitamin B-12 Snps were in hardy-weinberg equilibrium in mothers and children (all p-values >0.05).']	N/A	N/A	[('SO_0001024', 'haplotype', 14, 'Haplotypes'), ('CHEBI_27300', 'vitamin D', 29, 'vitamin B'), ('PR_000017269', 'ventral anterior homeobox 2', 29, 'vitamin B-12'), ('SO_0000694', 'SNP', 42, 'SNPs')]
PMC3515553	12/2012	S173-PMC3515553	['supporting information\n\ncaption (supplementary-material): table s1\n\nrepresentativeness of the sub-sample of children with Cord Blood Vitamin B-12 levels, and the sample used for iq analysis, with respect to the full alspac sample.']	N/A	N/A	[('UBERON_0002240', 'spinal cord', 122, 'cord'), ('UBERON_0000178', 'blood', 127, 'blood'), ('CHEBI_27300', 'vitamin D', 133, 'vitamin B'), ('PR_000017269', 'ventral anterior homeobox 2', 133, 'vitamin B-12')]
PMC3515553	12/2012	S185-PMC3515553	['caption (supplementary-material): table s7\n\nassociation between maternal Vitamin B-12 daily intake and potential covariables.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 73, 'vitamin B'), ('PR_000017269', 'ventral anterior homeobox 2', 73, 'vitamin B-12')]
PMC3515887	11/2012	S145-PMC3515887	['[62] openly gave 19 Adults with asd 0.93\u2009g/day of Epa+Dha and 5\u2009mg/day of Vitamin E and observed 6 more weeks.']	N/A	N/A	[('UBERON_0007023', 'adult organism', 20, 'adults'), ('CHEBI_34733', 'EPN', 50, 'EPA'), ('CHEBI_17874', 'dihydrozeatin', 54, 'DHA'), ('CHEBI_27300', 'vitamin D', 74, 'vitamin E')]
PMC3521768	12/2012	S38-PMC3521768	['Pregnant women were classified based on their Prenatal Serum zinc and Vitamin A statuses and followed until Birth.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 0, 'Pregnant'), ('GO_0007565', 'female pregnancy', 46, 'prenatal'), ('UBERON_0001977', 'blood serum', 55, 'serum'), ('CHEBI_27300', 'vitamin D', 70, 'vitamin A'), ('GO_0007567', 'parturition', 108, 'birth')]
PMC3521768	12/2012	S47-PMC3521768	['study subjects\nPregnant women whose zinc and Vitamin A statuses were determined at their second or third Trimester and who later gave singleton live-Births were eligible for the study.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 15, 'Pregnant'), ('CHEBI_27300', 'vitamin D', 45, 'vitamin A'), ('GO_0009294', 'DNA mediated transformation', 105, 'trimester'), ('GO_0007567', 'parturition', 149, 'births')]
PMC3521768	12/2012	S56-PMC3521768	['as a result, 97 Vitamin A deficient and non-deficient, and 165 zinc deficient and non-deficient subjects would have been sufficient for the study.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 16, 'vitamin A')]
PMC3521768	12/2012	S136-PMC3521768	['maternal zinc and Vitamin A statuses and lbw\nstandard cutoff points were applied to define Prenatal zd (Serum zinc <7.6 µmol/l[29]) and vad (Serum Retinol <0.7 µmol/l[30]).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 18, 'vitamin A'), ('GO_0007565', 'female pregnancy', 91, 'prenatal'), ('UBERON_0001977', 'blood serum', 104, 'serum'), ('UBERON_0001977', 'blood serum', 141, 'serum'), ('CHEBI_26536', 'retinoic acid', 147, 'retinol')]
PMC3521768	12/2012	S137-PMC3521768	['using independent t-test analysis, statistically significant 82 g (95% ci: 9–150 g) and 76 g (95% ci: 6–145 g) decrease on Birthweight was observed in babies Born to women who had Prenatal Vitamin A and zinc deficiencies, respectively.']	N/A	N/A	[('GO_0007596', 'blood coagulation', 123, 'birthweight'), ('GO_0007567', 'parturition', 158, 'born'), ('GO_0007565', 'female pregnancy', 180, 'prenatal'), ('CHEBI_27300', 'vitamin D', 189, 'vitamin A')]
PMC3521768	12/2012	S208-PMC3521768	['Prenatal Vitamin A and zinc deficiencies occurring in the second or third trimesters were not associated with increased risk of lbw.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 0, 'Prenatal'), ('CHEBI_27300', 'vitamin D', 9, 'vitamin A')]
PMC3534321	12/2012	S116-PMC3534321	['antioxidants\nsome antioxidants such as Vitamins C and e act as Free Radical cleaners.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 39, 'vitamins C'), ('CHEBI_26519', 'radical', 63, 'free radical')]
PMC3544621	11/2012	S77-PMC3544621	['Prenatal Vitamin A improved infant Birth weight (wmd 89.78, 95% ci 84.73-94.83), but had no effect on stillbirth rate (rr 0.99, 95% ci 0.68-1.43) or ptd (rr 0.88, 95% ci 0.65-1.19).rumbold et al .']	N/A	N/A	[('GO_0007565', 'female pregnancy', 0, 'Prenatal'), ('CHEBI_27300', 'vitamin D', 9, 'vitamin A'), ('GO_0007567', 'parturition', 35, 'birth')]
PMC3552819	12/2012	S24-PMC3552819	['all participants in this study received a dose of Vitamin D (70,000 iu) at baseline.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 50, 'vitamin D')]
PMC3552819	12/2012	S25-PMC3552819	['primary pk analyses involved participants who did not receive any additional Vitamin D throughout follow-up (“single-dose group”).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 77, 'vitamin D')]
PMC3552819	12/2012	S37-PMC3552819	['participants were advised not to take other Vitamin D-containing supplements during the study period, but were permitted to take other Micronutrient supplements (including calcium).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 44, 'vitamin D'), ('CHEBI_33962', 'mu4-sulfido-quadro-tetracopper(6+)', 135, 'micronutrient')]
PMC3552819	12/2012	S204-PMC3552819	['this was not due to Vitamin D toxicity because her [25(Oh)D] at the time was 47 nmol/l and the [Ca] rapidly and spontaneously normalized.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 20, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 52, '25(OH)D'), ('CHEBI_32588', 'potassium chloride', 96, 'Ca')]
PMC3585741	1/2013	S76-PMC3585741	['for example, if information on Vitamin D supplement intake was collected at each trimester (i.e., three times), then the total amount consumed was divided by three; if information was collected at only two times, then the total was divided by two.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 31, 'vitamin D')]
PMC3586494	2/2013	S117-PMC3586494	['a Human study determined Vitamin A, c, and e levels in the Umbilical Cord Blood of term and preterm infants and the Blood of their mothers taken at the time of Delivery [52].']	N/A	N/A	[('NCBITaxon_9606', 'Homo sapiens', 2, 'human'), ('CHEBI_27300', 'vitamin D', 25, 'vitamin A'), ('UBERON_0002331', 'umbilical cord', 59, 'umbilical cord'), ('UBERON_0000178', 'blood', 74, 'blood'), ('UBERON_0000178', 'blood', 116, 'blood'), ('GO_0007567', 'parturition', 160, 'delivery')]
PMC3586494	2/2013	S119-PMC3586494	['contrary to Vitamins A and E, cord Vitamin C levels were higher than maternal levels, and no significant correlation between Cord and maternal Vitamin C levels was present.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 12, 'vitamins A'), ('PR_000004370', 'asialoglycoprotein receptor 2', 21, 'A'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 27, 'E'), ('CHEBI_27300', 'vitamin D', 35, 'vitamin C'), ('PR_000004900', 'complement C3', 43, 'C'), ('UBERON_0002240', 'spinal cord', 125, 'cord'), ('CHEBI_27300', 'vitamin D', 143, 'vitamin C')]
PMC3586494	2/2013	S123-PMC3586494	['levels of Malondialdehyde were significantly higher, and Vitamin A and e levels were significantly lower in all diabetic women than controls.']	N/A	N/A	[('CHEBI_16480', 'nitric oxide', 10, 'malondialdehyde'), ('CHEBI_27300', 'vitamin D', 57, 'vitamin A')]
PMC3613945	2/2013	S9-PMC3613945	['introduction\n\ndbp structure and function\nthe Vitamin D Binding Protein (dbp), originally known as the group-specific component (gc-Globulin), is a 51–58\u2009kda multifunctional Serum Glycoprotein synthesized in large quantities by Hepatic Parenchymal Cells and Secreted into the circulation as a monomeric mature peptide of 458 residues and three structural Domains1–3.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 45, 'vitamin D'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 45, 'vitamin D binding protein'), ('PR_000002193', 'apoptosis regulator BAX', 130, '-globulin'), ('PR_000014450', 'histone deacetylase complex subunit SAP30L', 173, 'serum glycoprotein'), ('UBERON_0001977', 'blood serum', 173, 'serum'), ('CHEBI_17089', 'glycoprotein', 179, 'glycoprotein'), ('CL_0002184', 'basal proper cell of olfactory epithelium', 227, 'hepatic parenchymal cells'), ('UBERON_0001281', 'hepatic sinusoid', 227, 'hepatic parenchymal'), ('GO_0046903', 'secretion', 257, 'secreted'), ('SO_0000417', 'polypeptide_domain', 354, 'domains1')]
PMC3613945	2/2013	S10-PMC3613945	['two binding regions are well characterized – a Vitamin D/Fatty Acid binding Domain located between residues 35–49, and an actin binding Domain positioned between residues 350–403.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 47, 'vitamin D'), ('CHEBI_35366', 'fatty acid', 57, 'fatty acid'), ('SO_0000417', 'polypeptide_domain', 76, 'domain'), ('SO_0000417', 'polypeptide_domain', 136, 'domain')]
PMC3613945	2/2013	S21-PMC3613945	['Genetic variants of the Vitamin D-Binding Protein Gene ( gc ).']	N/A	N/A	[('SO_0000704', 'gene', 0, 'Genetic'), ('CHEBI_27300', 'vitamin D', 24, 'vitamin D'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 24, 'vitamin D-binding protein'), ('SO_0000704', 'gene', 50, 'gene')]
PMC3613945	2/2013	S162-PMC3613945	['Calcium and Vitamin D intake) is common.']	N/A	N/A	[('CHEBI_22313', 'alkaline earth metal atom', 0, 'calcium'), ('CHEBI_27300', 'vitamin D', 12, 'vitamin D')]
PMC3613945	2/2013	S179-PMC3613945	['in the same study, homozygous t436 subjects were found to have a 25% reduction in Vitamin D Serum levels ( p \u2009<\u20090.0001) and were enriched amongst the copd patient population (or\u2009=\u20092.11; ci\u2009=\u20091.20–3.71).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 82, 'vitamin D'), ('UBERON_0001977', 'blood serum', 92, 'serum')]
PMC3613945	2/2013	S278-PMC3613945	['oral supplementation of Vitamin D given to tuberculosis contacts enhanced immunity towards the mycobacterium205.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 24, 'vitamin D')]
PMC3616124	4/2013	S4-PMC3616124	['this is a secondary analysis of a randomized controlled trial in which 10,154 low-risk women received daily Vitamin C and E, or placebo, from 9-16 weeks Gestation until Delivery.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 108, 'vitamin C'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 122, 'E'), ('GO_0007565', 'female pregnancy', 153, 'gestation'), ('GO_0007567', 'parturition', 169, 'delivery')]
PMC3616124	4/2013	S55-PMC3616124	['materials and methods\n\npopulation\nthis was a secondary analysis of a eunice kennedy shriver national institute of child health and Human development maternal-fetal medicine units network double-blind, multicenter rct (nct 00135707) in which 10,154 nulliparous, low risk women received daily doses of 400 iu of Vitamin E and 1000 mg of Vitamin C, or placebo, from 9-16 weeks Gestation until Delivery.']	N/A	N/A	[('NCBITaxon_10088', 'Mus <genus>', 131, 'Human'), ('CHEBI_27300', 'vitamin D', 310, 'vitamin E'), ('CHEBI_27300', 'vitamin D', 335, 'vitamin C'), ('GO_0007565', 'female pregnancy', 374, 'gestation'), ('GO_0007567', 'parturition', 390, 'delivery')]
PMC3616124	4/2013	S135-PMC3616124	['increased Preeclampsia risk in hispanic Hp 2-2 women was specific to the large quantities of Vitamins C and E in study Supplements.']	N/A	N/A	[('GO_0007128', 'meiotic prophase I', 10, 'preeclampsia'), ('PR_000008443', 'huntingtin-associated protein 1', 40, 'Hp 2'), ('CHEBI_27300', 'vitamin D', 93, 'vitamins C'), ('PR_000004900', 'complement C3', 102, 'C'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 108, 'E'), ('CHEBI_33341', 'titanium atom', 119, 'supplements')]
PMC3616124	4/2013	S151-PMC3616124	['moreover, daily Vitamin C and e supplementation did not prevent the primary outcome or Preeclampsia in women of any hp phenotype.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 16, 'vitamin C'), ('GO_0007128', 'meiotic prophase I', 87, 'preeclampsia')]
PMC3616124	4/2013	S188-PMC3616124	['Coronary Artery diameter increased following Vitamin C and e supplementation in hp 1-1 post-menopausal women with Coronary Artery disease.']	N/A	N/A	[('UBERON_0001621', 'coronary artery', 0, 'Coronary artery'), ('CHEBI_27300', 'vitamin D', 45, 'vitamin C'), ('UBERON_0001621', 'coronary artery', 114, 'coronary artery')]
PMC3629265	4/2013	S6-PMC3629265	['results\nsevere Vitamin D deficiency was diagnosed in six formula-Fed infants over a two-and-a-half year period.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 15, 'vitamin D'), ('GO_0007631', 'feeding behavior', 65, 'fed')]
PMC3629265	4/2013	S19-PMC3629265	['one-hundred-and-four cases of Vitamin D deficiency rickets were reported over a 2-year period in infants and toddlers, 96.2% of whom had been Breast-Fed.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 30, 'vitamin D'), ('GO_0007567', 'parturition', 142, 'breast'), ('GO_0007631', 'feeding behavior', 149, 'fed')]
PMC3629265	4/2013	S20-PMC3629265	['86.5% of these infants had not received Vitamin D supplementation.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 40, 'vitamin D')]
PMC3629265	4/2013	S22-PMC3629265	['from may 2003 to march 2005, we diagnosed Vitamin D deficiency in 6 exclusively formula-Fed first nation infants presenting with hypocalcaemic seizures.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 42, 'vitamin D'), ('GO_0007631', 'feeding behavior', 88, 'fed')]
PMC3629265	4/2013	S28-PMC3629265	["they were all exclusively Fed a Vitamin D fortified Cow's milk-based infant formula and were gaining weight appropriately."]	N/A	N/A	[('GO_0007631', 'feeding behavior', 26, 'fed'), ('CHEBI_27300', 'vitamin D', 32, 'vitamin D'), ('NCBITaxon_33208', 'Metazoa', 52, 'cow')]
PMC3629265	4/2013	S31-PMC3629265	['caption (table-wrap): table i\n\nclinical presentation and Serum biochemistry profiles at presentation of 6 confirmed cases of severe Vitamin D deficiencycaseage at diagnosis (day)presentationcalcium (mmol/l); total/ionisedphosphate (mmol/l)alp (iu/l)pth (ng/l)25-Vitamin D (nmol/l)gendermonth of presentationmaternal 25-Vitamin D (nmol/l)149focal seizures1.54/0.972.23675266<15malemarchn/a26focal to generalised seizures1.47/0.953.554355225femalejanuary1635generalised seizures1.35/na3.293101616malejune<15442focal seizures1.57/0.99*3.263273<15malenovembern/a542generalised seizures1.55/na1.87586175<15femalejanuaryn/a635focal seizures1.52/0.842.81573184<15femalemayn/a\nalp=alkaline phosphatase, pth=Parathyroid hormone.']	N/A	N/A	[('UBERON_0001977', 'blood serum', 57, 'serum'), ('CHEBI_27300', 'vitamin D', 132, 'vitamin D'), ('CHEBI_18323', 'anserine', 259, '25-'), ('CHEBI_28384', 'vitamin K', 262, 'Vitamin D'), ('CHEBI_18323', 'anserine', 316, '25-'), ('CHEBI_27300', 'vitamin D', 319, 'vitamin D'), ('UBERON_0001132', 'parathyroid gland', 699, 'parathyroid')]
PMC3629265	4/2013	S33-PMC3629265	['normal values: total calcium (2.10–2.60 mmol/l); ionised calcium (>1.0 mmol/l); Phosphate (1.28–2.26 mmol/l); alp (117–352 iu/l); pth (7–50 ng/l), 25-Vitamin D (75–200 nmol/l).']	N/A	N/A	[('CHEBI_18367', 'phosphate(3-)', 80, 'phosphate'), ('CHEBI_27300', 'vitamin D', 150, 'vitamin D')]
PMC3629265	4/2013	S36-PMC3629265	['the 25-Vitamin D level was low in all infants.']	N/A	N/A	[('CHEBI_18323', 'anserine', 4, '25-'), ('CHEBI_27300', 'vitamin D', 7, 'vitamin D')]
PMC3629265	4/2013	S37-PMC3629265	['the 25-Vitamin D levels were available in the mothers of infant no.']	N/A	N/A	[('CHEBI_18323', 'anserine', 4, '25-'), ('CHEBI_27300', 'vitamin D', 7, 'vitamin D')]
PMC3629265	4/2013	S44-PMC3629265	['cases 3 and 5 were treated with Cholecalciferol and Calcium supplements in hospital and then discharged home on Vitamin D 2000 iu/day.']	N/A	N/A	[('CHEBI_52550', 'theopalauamide', 32, 'cholecalciferol'), ('CHEBI_22313', 'alkaline earth metal atom', 52, 'calcium'), ('CHEBI_27300', 'vitamin D', 112, 'vitamin D')]
PMC3629265	4/2013	S48-PMC3629265	['all presented in the late autumn, winter or early spring when cutaneous Synthesis Of Vitamin D would be minimal.']	N/A	N/A	[('GO_0030474', 'spindle pole body duplication', 72, 'synthesis of vitamin D'), ('CHEBI_27300', 'vitamin D', 85, 'vitamin D')]
PMC3629265	4/2013	S53-PMC3629265	["the infants in this series were exclusively bottle Fed a Cow's milk-based formula fortified with 400 iu/l of Vitamin D. they differ from the infants with Vitamin D deficiency in the cpsp study, 96.2% of whom were Breast Fed (13)."]	N/A	N/A	[('GO_0007631', 'feeding behavior', 51, 'fed'), ('NCBITaxon_33208', 'Metazoa', 57, 'cow'), ('CHEBI_27300', 'vitamin D', 109, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 154, 'vitamin D'), ('GO_0007567', 'parturition', 213, 'breast'), ('UBERON_0000310', 'breast', 213, 'breast'), ('GO_0007631', 'feeding behavior', 220, 'fed')]
PMC3629265	4/2013	S55-PMC3629265	['in the cpsp study, 34 out of 104 children with Vitamin D deficiency presented under 1 year of age.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 47, 'vitamin D')]
PMC3629265	4/2013	S69-PMC3629265	['none of these infants were receiving daily Vitamin D supplementation.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 43, 'vitamin D')]
PMC3629265	4/2013	S72-PMC3629265	['transplacental Transfer Of Vitamin D Stores from the mother to foetus occur during the third trimester.']	N/A	N/A	[('GO_0035147', 'branch fusion, open tracheal system', 15, 'transfer of vitamin D stores'), ('CHEBI_27300', 'vitamin D', 27, 'vitamin D')]
PMC3641012	4/2013	S6-PMC3641012	['in the Vitamin D group, 95% of neonates and 100% of mothers attained 25(Oh)D\u2009>50\xa0nmol/l, versus 21% mothers and 19% of neonates in the placebo group.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 7, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 69, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 69, '25(OH ... D')]
PMC3641012	4/2013	S44-PMC3641012	['participants were advised to discontinue all other supplements containing Vitamin D, and were offered Prenatal iron and Folic Acid supplements (66\xa0mg elemental iron and 350 mcg/day Folic Acid per day), routine Antenatal monitoring, and obstetric care free of charge.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 74, 'vitamin D'), ('GO_0007565', 'female pregnancy', 102, 'prenatal'), ('CHEBI_30751', 'formic acid', 120, 'folic acid'), ('CHEBI_30751', 'formic acid', 181, 'folic acid'), ('GO_0007567', 'parturition', 210, 'antenatal')]
PMC3641012	4/2013	S48-PMC3641012	['Venous Blood specimens were collected at baseline and once between Gestational weeks 30 and 37 (the specific week was randomly varied among participants); these specimens were drawn immediately preceding the weekly Vitamin D dose administration; a third specimen was collected around the time of Delivery, irrespective of when the last Vitamin D dose was received.']	N/A	N/A	[('UBERON_0001638', 'vein', 0, 'Venous'), ('UBERON_0000178', 'blood', 7, 'blood'), ('GO_0007565', 'female pregnancy', 67, 'gestational'), ('CHEBI_27300', 'vitamin D', 215, 'vitamin D'), ('GO_0007567', 'parturition', 296, 'delivery'), ('CHEBI_27300', 'vitamin D', 336, 'vitamin D')]
PMC3641012	4/2013	S73-PMC3641012	['the upper limit of the Serum calcium reference range used for safety monitoring was 2.60\xa0mmol/l, which was conservative relative to the threshold for defining hypercalcemia used by the iom in setting the 1997 dris for Vitamin D (2.75\xa0mmol/l) [10], and the threshold cited by the iom committee in its 2010 revision of the Vitamin D dris (2.63\xa0mmol/l) [7].']	N/A	N/A	[('UBERON_0001977', 'blood serum', 23, 'serum'), ('CHEBI_27300', 'vitamin D', 218, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 321, 'vitamin D')]
PMC3641012	4/2013	S95-PMC3641012	['as a per-protocol sensitivity analysis, change in mean 25(Oh)D over time was modeled as a function of cumulative dose (micrograms) of Vitamin D actually administered.']	N/A	N/A	[('CHEBI_71657', 'versiconol acetate', 55, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 55, '25(OH ... D'), ('CHEBI_27300', 'vitamin D', 134, 'vitamin D')]
PMC3641012	4/2013	S107-PMC3641012	['results\nof the 160 participants recruited and randomly assigned to either Vitamin D (35,000\xa0iu/week) or placebo, 13 were lost to follow-up prior to Delivery (6 in the placebo group and 7 in the Vitamin D group), all because of having left the dhaka area (figure\xa01).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 74, 'vitamin D'), ('GO_0007567', 'parturition', 148, 'delivery'), ('CHEBI_28384', 'vitamin K', 194, 'Vitamin D')]
PMC3641012	4/2013	S108-PMC3641012	['Serum specimens were available for all participants at baseline and for 130 (81.3%) participants (63 placebo, 67 Vitamin D) at Delivery.']	N/A	N/A	[('UBERON_0001977', 'blood serum', 0, 'Serum'), ('CHEBI_27300', 'vitamin D', 113, 'vitamin D'), ('GO_0007567', 'parturition', 127, 'delivery')]
PMC3641012	4/2013	S109-PMC3641012	['Cord Blood specimens were collected from 67 and 65 mother-infant pairs in the Placebo and Vitamin D groups, respectively.']	N/A	N/A	[('UBERON_0000948', 'heart', 0, 'Cord'), ('UBERON_0000178', 'blood', 5, 'blood'), ('CHEBI_26130', 'biological pigment', 78, 'placebo'), ('CHEBI_27300', 'vitamin D', 90, 'vitamin D')]
PMC3641012	4/2013	S114-PMC3641012	['in longitudinal analyses, 74 participants in the placebo group and 77 participants in the Vitamin D group contributed at least one biochemical value beyond baseline.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 90, 'vitamin D')]
PMC3641012	4/2013	S119-PMC3641012	['caption (table-wrap): table 3\n\nsupplementation duration and adherenceadherenceplacebovitamin dpmean\u2009±\u2009sdmedianrange (min, max)mean\u2009±\u2009sdmedianrange (min, max)time on study, weeks 9.7\u2009±\u20093.510.5(0, 18)9.8\u2009±\u20093.310(0, 18)0.871total supplement doses administered 10.5\u2009±\u20093.511(1, 19)10.6\u2009±\u20093.311(1, 17)0.83 total Vitamin D administered, mcg ---9469\u2009±\u200924249625(875, 14000)- adherence, %299.2\u2009±\u20092.7100(84.6, 100)99.4\u2009±\u20092.9100(80, 100)0.79 participants who received 100% of scheduled doses, n (%)3\xa068 (91.9%)\xa0\xa069 (94.5%)\xa00.533\n1p-value for student’s t -test for equality of means.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 306, 'vitamin D')]
PMC3641012	4/2013	S121-PMC3641012	['analysis shown included participants who contributed 25(Oh)D measurements beyond baseline (n\u2009=\u200974 and n\u2009=\u200973 in Placebo and Vitamin D groups, respectively).']	N/A	N/A	[('CHEBI_71657', 'versiconol acetate', 53, '25(OH)D'), ('PR_000005060', 'calpastatin', 53, '25 ...'), ('PR_000006444', 'diacylglycerol kinase delta', 59, 'D'), ('CHEBI_26130', 'biological pigment', 112, 'placebo'), ('CHEBI_27300', 'vitamin D', 124, 'vitamin D')]
PMC3641012	4/2013	S123-PMC3641012	['with respect to longitudinal analyses of changes in 25(Oh)D over time, 206/219 Serum specimens (93.5%) in the Vitamin D group and 201/213 (94.4%) specimens in the placebo group were preceded by 100% dose adherence.']	N/A	N/A	[('CHEBI_71657', 'versiconol acetate', 52, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 52, '25(OH ... D'), ('UBERON_0001977', 'blood serum', 79, 'serum'), ('CHEBI_27300', 'vitamin D', 110, 'vitamin D')]
PMC3641012	4/2013	S124-PMC3641012	['3proportions shown were calculated among participants who contributed 25(Oh)D measurements beyond baseline (74 in placebo group or 73 in the Vitamin D group); p value for chi-square test for proportions.']	N/A	N/A	[('CHEBI_71657', 'versiconol acetate', 70, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 141, 'vitamin D')]
PMC3641012	4/2013	S130-PMC3641012	['the highest 25(Oh)D value in any participant was 200\xa0nmol/l, observed in a Vitamin D group participant at Delivery; concurrently, her other biochemistry were normal (adj-ca, 2.47\xa0mmol/l; Urine ca:cr, 0.23\xa0mmol/mmol).']	N/A	N/A	[('CHEBI_71657', 'versiconol acetate', 12, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 18, 'D'), ('CHEBI_27300', 'vitamin D', 75, 'vitamin D'), ('GO_0007567', 'parturition', 106, 'delivery'), ('UBERON_0001088', 'urine', 187, 'urine')]
PMC3641012	4/2013	S134-PMC3641012	['caption (table-wrap): table 4\n\nbiochemical measures for maternal baseline, maternal Delivery, and Cord Blood specimens, by supplementation groupbiomarker (units)placebovitamin dgroup difference1group-by-time effect2(n\u2009=\u200980)(n\u2009=\u200980)mean95% cimean95% ci25(Oh)D (nmol/l) \xa0\xa0\xa0\xa0\xa0\xa0\u2003\u2003\xa0baseline344.0\u2009±\u200920.945.4\u2009±\u200918.41.4[−4.8, 7.5]––\u2003\u2003\xa0Delivery (n\u2009=\u2009130)438.4\u2009±\u200918.1134.4\u2009±\u200930.796.0***[87.6, 104.8]94.6***[85.0, 104.1]\u2003\u2003\xa0Cord (n\u2009=\u2009132)539.0\u2009±\u200918.7102.8\u2009±\u200928.663.9***[55.8, 72.0]–– Calcium (mmol/l) \xa0\xa0\xa0\xa0\xa0\xa0\u2003\u2003\xa0baseline2.27\u2009±\u20090.092.25\u2009±\u20090.09−0.02[−0.04, 0.01]––\u2003\u2003\xa0Delivery (n\u2009=\u2009130)2.31\u2009±\u20090.112.32\u2009±\u20090.100.02[−0.02, 0.05]0.03[−0.01, 0.07]albumin-adjusted calcium (mmol/l) \xa0\xa0\xa0\xa0\xa0\xa0\u2003\u2003\xa0baseline2.36\u2009±\u20090.072.35\u2009±\u20090.07−0.01[−0.03, 0.01]––\u2003\u2003\xa0Delivery (n\u2009=\u2009130)2.40\u2009±\u20090.082.43\u2009±\u20090.090.03*[0.00, 0.06]0.04*[0.01, 0.07]pth (pmol/l)6\xa0\xa0\xa0\xa0\xa0\xa0\u2003\u2003\xa0baseline2.7 (0.3, 9.3)2.9 (0.5, 9.4)0.02[−0.7, -0.2]––\u2003\u2003\xa0Delivery (n\u2009=\u2009129)73.9 (0.3, 20.5)2.3 (0.3, 9.8)−0.51***[−0.8, -0.3]−0.53***[−0.8, -0.3]Urinary calcium-Creatinine ratio (mmol/mmol)8\xa0\xa0\xa0\xa0\xa0\xa0\u2003\u2003\xa0baseline0.24 (0.0, 0.68)0.22 (0.0, 0.88)−0.01[−0.07, 0.05]––\u2003\u2003\xa02\xa0weeks (n\u2009=\u2009151)90.26 (0.0, 1.11)0.26 (0.0, 1.25)0.03[−0.04, 0.10]––\u2003\u2003\xa0Delivery (n\u2009=\u2009125)100.13 (0.0, 1.26)0.20 (0.0, 2.26)0.04[−0.05, 0.14]0.07[−0.03, 0.16]\n1mean difference [95% ci] between the Placebo and Vitamin D group at a given time, by ordinary least square estimation.']	N/A	N/A	[('GO_0007567', 'parturition', 84, 'delivery'), ('UBERON_0002240', 'spinal cord', 98, 'cord'), ('UBERON_0000178', 'blood', 103, 'blood'), ('CHEBI_33010', 'chromide(1-)', 253, '(OH)D'), ('GO_0007586', 'digestion', 327, 'Delivery'), ('UBERON_0000948', 'heart', 412, 'Cord'), ('CHEBI_31341', 'calcium dihydroxide', 472, 'Calcium'), ('GO_0007586', 'digestion', 551, 'Delivery'), ('GO_0007586', 'digestion', 721, 'Delivery'), ('GO_0007586', 'digestion', 874, 'Delivery'), ('UBERON_0001088', 'urine', 962, 'Urinary'), ('CHEBI_16737', 'creatinine', 978, 'creatinine'), ('GO_0007586', 'digestion', 1151, 'Delivery'), ('CHEBI_26130', 'biological pigment', 1276, 'placebo'), ('CHEBI_27300', 'vitamin D', 1288, 'vitamin D')]
PMC3641012	4/2013	S137-PMC3641012	['4delivery specimens were those collected within +/−1\xa0day of Delivery; n\u2009=\u200963 and n\u2009=\u200967 in the Placebo and Vitamin D groups, respectively;\n5cord Serum available for n\u2009=\u200967 in the Placebo and n\u2009=\u200965 in the Vitamin D group.']	N/A	N/A	[('GO_0007567', 'parturition', 60, 'delivery'), ('CHEBI_26130', 'biological pigment', 95, 'placebo'), ('CHEBI_27300', 'vitamin D', 107, 'vitamin D'), ('UBERON_0001977', 'blood serum', 145, 'serum'), ('CHEBI_26130', 'biological pigment', 179, 'placebo'), ('CHEBI_27300', 'vitamin D', 205, 'vitamin D')]
PMC3641012	4/2013	S141-PMC3641012	['7Pth concentration at Delivery available for n\u2009=\u200963 in placebo group and n\u2009=\u200966 in the Vitamin D group.']	N/A	N/A	[('CHEBI_53233', '3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide', 0, '7PTH'), ('GO_0007567', 'parturition', 22, 'delivery'), ('CHEBI_27300', 'vitamin D', 87, 'vitamin D')]
PMC3641012	4/2013	S145-PMC3641012	['10delivery Urine samples were taken day of Delivery, +/−1\xa0day, n\u2009=\u200960 and n\u2009=\u200965 in the Placebo and Vitamin D groups, respectively.']	N/A	N/A	[('UBERON_0001088', 'urine', 11, 'urine'), ('GO_0007567', 'parturition', 43, 'delivery'), ('CHEBI_26130', 'biological pigment', 88, 'placebo'), ('CHEBI_27300', 'vitamin D', 100, 'vitamin D')]
PMC3641012	4/2013	S157-PMC3641012	['point (nmol/l) 45.5[41.0, 49.9]44.4[39.7, 49.1]42.1[39.1, 45.1]difference in 25(Oh)D between groups at day 0 (nmol/l) –1.1[−5.3, 7.6]– decay rate (days-1or mcg-1) 0.04[0.03, 0.05]0.04[0.03, 0.05]0.0003[0.0002, 0.0004]δ25(Oh)D at steady-state in Placebo group (nmol/l) –−7.1[−12.3, -1.9]– effect of Vitamin D on δ25(Oh)D at steady-state (nmol/l) 94.4[83.9, 104.9]101.6[89.7, 113.4]398.3[88.7, 107.9]attained steady-state 25(Oh)D (nmol/l) 139.9[130.1, 149.6]138.8[127.4, 150.2]140.4[131.2, 149.6]adjusted r20.720.750.75 aic –3907.23904.4\n180 participants in the Vitamin D group, contributing 220 specimens.']	N/A	N/A	[('CHEBI_71657', 'versiconol acetate', 77, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 77, '25(OH ... D'), ('CHEBI_72805', '2-alkyl-sn-glycero-3-phosphocholine', 221, 'OH)D'), ('CHEBI_26130', 'biological pigment', 245, 'placebo'), ('CHEBI_27300', 'vitamin D', 298, 'vitamin D'), ('CHEBI_33010', 'chromide(1-)', 314, '(OH)D'), ('CHEBI_17792', 'organohalogen compound', 423, 'OH'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 426, 'D'), ('CHEBI_27300', 'vitamin D', 560, 'vitamin D')]
PMC3641012	4/2013	S158-PMC3641012	['negative exponential model (Vitamin D group): [25( Oh ) D]t\u2009=\u2009[25( Oh ) D]t \u2009=\u20090\u2009+\u2009 a1(1\u2009−\u2009 e−\u2009 kt); where t is time, a is the δ25(Oh)D (where δ is the change from baseline) at steady-state in the Placebo group, and k is the decay rate to the asymptote.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 28, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 47, '25( OH ) D'), ('CHEBI_71657', 'versiconol acetate', 63, '25( OH ) D'), ('CHEBI_33010', 'chromide(1-)', 130, '(OH)D'), ('CHEBI_26130', 'biological pigment', 197, 'placebo')]
PMC3641012	4/2013	S160-PMC3641012	['negative exponential model (both groups):\n[25( Oh ) D]t\u2009=\u2009[25( Oh ) D]t \u2009=\u20090\u2009+\u2009 β \u2009g\u2009+\u2009( gd \u2009+\u2009 a0)(1\u2009−\u2009 e−\u2009 kt); where t is time, a is the δ25(Oh)D at steady-state in the Placebo group, k is the decay rate to asymptote, g is group assignment and d is the difference in δ25(Oh)D between groups at steady-state,\n3difference in δ25(Oh)D between Placebo and Vitamin D groups at modeled steady-state.']	N/A	N/A	[('CHEBI_71657', 'versiconol acetate', 43, '25( OH ) D'), ('CHEBI_71657', 'versiconol acetate', 59, '25( OH ) D'), ('CHEBI_33010', 'chromide(1-)', 143, '(OH)D'), ('CHEBI_26130', 'biological pigment', 172, 'placebo'), ('CHEBI_33010', 'chromide(1-)', 273, '(OH)D'), ('CHEBI_33010', 'chromide(1-)', 329, '(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 333, 'D'), ('CHEBI_26130', 'biological pigment', 343, 'placebo'), ('CHEBI_27300', 'vitamin D', 355, 'vitamin D')]
PMC3641012	4/2013	S167-PMC3641012	['the mean adj-ca at Delivery and the change in this parameter from baseline to Delivery were slightly but significantly greater in the Vitamin D group versus placebo (table\xa04; figure\xa05).']	N/A	N/A	[('GO_0007567', 'parturition', 19, 'delivery'), ('GO_0007567', 'parturition', 78, 'delivery'), ('CHEBI_27300', 'vitamin D', 134, 'vitamin D')]
PMC3641012	4/2013	S170-PMC3641012	['one participant in the Vitamin D group exhibited an isolated adj-ca value of 2.62\xa0mmol/l at the time of Delivery, in the context of an acute diarrheal illness.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 23, 'vitamin D'), ('GO_0007567', 'parturition', 104, 'delivery')]
PMC3641012	4/2013	S177-PMC3641012	['( a ) knot was placed at day 60, and the change in slope at that point was statistically significant in the Vitamin D group (p < 0.01), but not in the placebo group.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 108, 'vitamin D')]
PMC3641012	4/2013	S178-PMC3641012	['associations: before knot in Vitamin D group = 0.044 mmol/l per month, (p < 0.001); after knot in Vitamin D group = −0.028 mmol/l per month, (p = 0.141); before knot in the Placebo group = 0.017 mmol/l per month, (p < 0.01); after knot in the placebo group = 0.000 mmol/l per month, (p = 0.997).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 29, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 98, 'vitamin D'), ('CHEBI_26130', 'biological pigment', 173, 'placebo')]
PMC3641012	4/2013	S180-PMC3641012	['a knot was placed at day 14, where the change in slope was statistically significant in the Vitamin D group (p < 0.01), but not in the placebo group.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 92, 'vitamin D')]
PMC3641012	4/2013	S181-PMC3641012	['associations: before knot in the Vitamin D group = 0.147 mmol/mmol per month, (p < 0.05); after knot in vitamin d group = −0.042 mmol/mmol per month, (p < 0.05); before knot in placebo group = 0.052 mmol/mmol per month, (p = 0.311); after knot in placebo group = −0.048 mmol/mmol per month, (p < 0.01).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 33, 'vitamin D')]
PMC3641012	4/2013	S184-PMC3641012	['there was a significant increase over time in the placebo group (0.01 log-pmol/l [95% ci: 0.003, 0.008] for each day increase in follow-up time; p < 0.001), but the slope of the Vitamin D group was significantly attenuated (0.007 log-pmol/l [95% ci: -0.01, -0.004] lower than in the Placebo group; p < 0.001).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 178, 'vitamin D'), ('CHEBI_26130', 'biological pigment', 283, 'placebo')]
PMC3641012	4/2013	S192-PMC3641012	['hypercalciuria, defined a priori as ca:cr\u2009>1.0\xa0mmol/mmol on 2 consecutive separate occasions, occurred in one participant in the Vitamin D group, at 29\xa0weeks Gestation on day 14 of follow-up.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 129, 'vitamin D'), ('GO_0007565', 'female pregnancy', 158, 'gestation')]
PMC3641012	4/2013	S193-PMC3641012	['ca:cr was 1.08\xa0mmol/mmol on day 14 and 1.11\xa0mmol/mmol on day 16, but was normal at Delivery (0.23\xa0mmol/mmol) after continuation of Vitamin D supplementation for a total of 10\xa0weeks (cumulative dose of 9625 mcg).']	N/A	N/A	[('GO_0007567', 'parturition', 83, 'delivery'), ('CHEBI_27300', 'vitamin D', 131, 'vitamin D')]
PMC3641012	4/2013	S196-PMC3641012	['transient hypercalciuria, defined as one ca:cr measurement above 1.0\xa0mmol/mmol, was observed in 3 (4.1%) participants in the Placebo group and 4 (5.5%) in the Vitamin D group ( p \u2009=\u20090.72 for between-group difference).']	N/A	N/A	[('CHEBI_26130', 'biological pigment', 125, 'placebo'), ('CHEBI_27300', 'vitamin D', 159, 'vitamin D')]
PMC3641012	4/2013	S208-PMC3641012	['7birth weight was missing for 2 infants in the placebo group and 1 in the Vitamin D group.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 74, 'vitamin D')]
PMC3641012	4/2013	S209-PMC3641012	['8n = 137 (69 in placebo, 68 in the Vitamin D group).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 35, 'vitamin D')]
PMC3641012	4/2013	S210-PMC3641012	['9n = 132 (65 in Placebo, 67 in Vitamin D group).']	N/A	N/A	[('CHEBI_26130', 'biological pigment', 16, 'placebo'), ('CHEBI_27300', 'vitamin D', 31, 'vitamin D')]
PMC3641012	4/2013	S213-PMC3641012	['discussion\namong Pregnant women with relatively low average baseline Vitamin D status in dhaka, 3rd-Trimester Vitamin D3 supplementation (35,000\xa0iu/week) significantly raised maternal and neonatal (Cord Blood) Serum 25(Oh)D concentrations above the iom cut-off for sufficiency (50\xa0nmol/l) in virtually all participants without inducing hypercalcemia or other apparent short-term clinical adverse effects.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 17, 'pregnant'), ('CHEBI_27300', 'vitamin D', 69, 'vitamin D'), ('GO_0009294', 'DNA mediated transformation', 100, 'trimester'), ('CHEBI_33279', 'vitamin D5', 110, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 110, 'vitamin D3'), ('UBERON_0002240', 'spinal cord', 198, 'cord'), ('UBERON_0000178', 'blood', 203, 'blood'), ('UBERON_0001977', 'blood serum', 210, 'serum'), ('CHEBI_71657', 'versiconol acetate', 216, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 216, '25(OH ... D')]
PMC3651971	5/2013	S1-PMC3651971	['design\nfollow-up assessment of Children Born to women randomly assigned by a village to receive either supplemental Vitamin A (7000\u2005µg Retinol equivalents) or placebo weekly during a continuous 3.5-year period from 1994–1997.']	N/A	N/A	[('GO_0050890', 'cognition', 31, 'children'), ('GO_0007567', 'parturition', 40, 'born'), ('CHEBI_27300', 'vitamin D', 116, 'vitamin A'), ('CHEBI_26536', 'retinoic acid', 135, 'retinol')]
PMC3651971	5/2013	S8-PMC3651971	['results\nthere were no differences in unit (79.61±5.99 vs 80.69±6.71) or mabc (2.64±0.07 vs 2.49±0.09) test scores in children whose mothers were exposed to Vitamin A vs placebo (mean differences: −1.07, 95% ci −7.10 to 9.26, p=0.78; 0.15, 95% ci 0.43 to −0.08, p=0.15), respectively.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 156, 'vitamin A')]
PMC3651971	5/2013	S9-PMC3651971	['more children in the placebo group had repeated a grade in school (28% of placebo vs 16.7% of Vitamin A, p=0.01).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 94, 'vitamin A')]
PMC3651971	5/2013	S10-PMC3651971	['conclusions\nPreconceptional to Postpartum maternal Vitamin A supplementation, in an undernourished setting, does not improve Cognition or motor Development at ages 10–13\u2005years.']	N/A	N/A	[('GO_0019230', 'proprioception', 12, 'Preconceptional'), ('GO_0007565', 'female pregnancy', 31, 'postpartum'), ('CHEBI_27300', 'vitamin D', 51, 'vitamin A'), ('GO_0050890', 'cognition', 125, 'cognition'), ('GO_0008289', 'lipid binding', 144, 'development')]
PMC3651971	5/2013	S12-PMC3651971	['the participants were Born to women who participated in a randomised, placebo-controlled Vitamin A supplementation trial before, during and after Pregnancy.']	N/A	N/A	[('GO_0007567', 'parturition', 22, 'born'), ('CHEBI_27300', 'vitamin D', 89, 'vitamin A'), ('GO_0007565', 'female pregnancy', 146, 'pregnancy')]
PMC3651971	5/2013	S21-PMC3651971	['the participants were exposed to Vitamin A deficiency or supplementation during a developmental critical window.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 33, 'vitamin A')]
PMC3651971	5/2013	S30-PMC3651971	['the women received weekly, oral doses of Vitamin A (23\u2005300\u2005iu or 7000\u2005μg Retinol equivalents) as Retinyl Palmitate, 42\u2005mg of all- trans Β-Carotene (∼7000\u2005μg Retinol equivalents at a 6\u2009:\u20091 conversion ratio), arithmetically equivalent to a daily recommended dietary allowance,28or a placebo.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 41, 'vitamin A'), ('CHEBI_26536', 'retinoic acid', 73, 'retinol'), ('CHEBI_84054', 'resveratrol glucuronide sulfate 2', 97, 'retinyl palmitate'), ('CHEBI_28064', 'cyanidin 3-O-rutinoside', 136, 'β-carotene'), ('CHEBI_26536', 'retinoic acid', 157, 'retinol')]
PMC3651971	5/2013	S34-PMC3651971	['participants in the current follow-up study were drawn from 12 wards, 6 each from the Vitamin A and placebo groups in two of the three substudy vdcs (haripur and netragunj).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 86, 'vitamin A')]
PMC3651971	5/2013	S36-PMC3651971	['the children studied were exposed in utero and Postnatally through Breast Milk Intake to a weekly supplemental supply of Vitamin A, calculated to meet maternal dietary recommendations during Pregnancy and Lactation,29or to placebo (serving as controls).']	N/A	N/A	[('GO_0007565', 'female pregnancy', 47, 'postnatally'), ('UBERON_0001348', 'brown adipose tissue', 67, 'breast milk'), ('GO_0007631', 'feeding behavior', 79, 'intake'), ('CHEBI_27300', 'vitamin D', 121, 'vitamin A'), ('GO_0007565', 'female pregnancy', 191, 'pregnancy'), ('GO_0007595', 'lactation', 205, 'lactation')]
PMC3651971	5/2013	S56-PMC3651971	['the sample included all resident children (n=47) in the 12-ward substudy area whose mothers were documented to have had night blindness, a clinical symptom of moderate Vitamin A deficiency, during the original trial.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 168, 'vitamin A')]
PMC3651971	5/2013	S71-PMC3651971	["analysis\nthe child's height-for-age z-score (haz) and body mass index (bmi)-for-age z-score were calculated using the who national center for health statistics (nchs) 2006 growth reference.35\nwe compared characteristics between Vitamin A and placebo groups using χ2tests or one-way analysis of variance with two-sided p values."]	N/A	N/A	[('CHEBI_27300', 'vitamin D', 228, 'vitamin A')]
PMC3651971	5/2013	S72-PMC3651971	['we compared the cluster-summarised test scores for Vitamin A and placebo group children.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 51, 'vitamin A')]
PMC3651971	5/2013	S78-PMC3651971	['results\n\ncomparisons related to follow-up\nduring the nnips-2 trial, 751 children were Born to Vitamin A and placebo-recipient mothers in the 12 substudy wards in haripur and netragunj.']	N/A	N/A	[('GO_0007567', 'parturition', 86, 'born'), ('CHEBI_27300', 'vitamin D', 94, 'vitamin A')]
PMC3651971	5/2013	S82-PMC3651971	['caption (fig): figure\xa01\n\nthe study sample showing children from the Vitamin A and placebo groups in haripur and netragunj village development committees, starting with children alive and accounted for in 2007.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 68, 'vitamin A')]
PMC3651971	5/2013	S90-PMC3651971	['the children in the Placebo group also had more missing maternal (50.6% vs 40%, p=0.04) and neonatal anthropometry (31.6% vs 18.8%, p<0.01) data than in the Vitamin A group (table 1).']	N/A	N/A	[('CHEBI_26130', 'biological pigment', 20, 'placebo'), ('CHEBI_27300', 'vitamin D', 157, 'vitamin A')]
PMC3651971	5/2013	S94-PMC3651971	['‡n=53 missing, 27 Vitamin A, 26 placebo.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 18, 'vitamin A')]
PMC3651971	5/2013	S98-PMC3651971	['the comparable proportions of children in the Vitamin A and Placebo groups came from two-parent families (94.2% vs 90.8%, respectively), and started school on time (59.4% vs 60.3%, respectively).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 46, 'vitamin A'), ('CHEBI_26130', 'biological pigment', 60, 'placebo')]
PMC3651971	5/2013	S99-PMC3651971	['a higher proportion of children in the Placebo group had ever repeated a grade (28%) than children Born to Vitamin A-recipient mothers (16.7%, p=0.01).']	N/A	N/A	[('CHEBI_26130', 'biological pigment', 39, 'placebo'), ('GO_0007567', 'parturition', 99, 'born'), ('CHEBI_27300', 'vitamin D', 107, 'vitamin A')]
PMC3651971	5/2013	S102-PMC3651971	['at the time of testing, control children were also younger than those in the Vitamin A group (52.3% vs 62.3% were >12\u2005years, p<0.01).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 77, 'vitamin A')]
PMC3651971	5/2013	S105-PMC3651971	['†p≤0.01 χ2test with 1 degree of freedom comparing Vitamin A with placebo.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 50, 'vitamin A')]
PMC3651971	5/2013	S106-PMC3651971	['‡p≤0.01 χ2test with 2 degrees of freedom comparing Vitamin A with placebo.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 51, 'vitamin A')]
PMC3651971	5/2013	S113-PMC3651971	['§§n=23 missing, 14 Vitamin A and 9 placebo.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 19, 'vitamin A')]
PMC3651971	5/2013	S123-PMC3651971	['similarly, in regression analysis, which controlled for imbalances between treatment groups (age, anaemia, Water source, household Salt Iodine and test season), there was no difference in the unit adjusted mean residual (difference −1.59 points, 95%ci −10.96 to 7.79, p=0.72) or the residual transformed mabc score (difference 0.06 transformed units, 95%ci −0.29 to 0.17, p=0.59) in children Born to Vitamin A versus placebo supplemented mothers (table 3).']	N/A	N/A	[('CHEBI_15377', 'water', 107, 'water'), ('CHEBI_24866', 'salt', 131, 'salt'), ('CHEBI_24859', 'iodine atom', 136, 'iodine'), ('GO_0007567', 'parturition', 392, 'born'), ('CHEBI_27300', 'vitamin D', 400, 'vitamin A')]
PMC3651971	5/2013	S124-PMC3651971	['caption (table-wrap): table\xa03\n\nthe average cluster-summarised unit and mabc scores and cluster-summarised residuals from a regression controlling for possible confoundersvitamin aplaceboeffect estimate*95% cip valuenumber of clusters66unit test\u2003number of participants207174\u2003mean of cluster mean unit scores79.6180.69−1.07(−7.10 to 9.26)0.78\u2003adjusted mean residual11.21−0.37−1.59(−10.96 to 7.79)0.72mabc test\u2003number of participants205173\u2003mean of cluster mean √(mabc score+1)2.642.460.18(−0.08 to 0.43)0.15\u2003adjusted mean residuals†0.005−0.050.06(−0.29 to 0.17)0.59\n*the effect estimate is the difference in scores or adjusted residuals comparing Vitamin A with placebo.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 644, 'vitamin A')]
PMC3651971	5/2013	S132-PMC3651971	['there was no difference in the unit scores between Vitamin A and placebo group children regardless of whether or not they repeated a grade (table 4).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 51, 'vitamin A')]
PMC3651971	5/2013	S133-PMC3651971	['however, among the children who never repeated a grade, children in the Placebo group scored better than those in the Vitamin A group on mabc by 0.36 transformed points, equivalent to 44% of sd (95%ci 0.05 to 0.67, p=0.03).']	N/A	N/A	[('CHEBI_26130', 'biological pigment', 72, 'placebo'), ('CHEBI_27300', 'vitamin D', 118, 'vitamin A')]
PMC3651971	5/2013	S138-PMC3651971	['discussion\nin this rural, undernourished setting of southern nepal, we observed no effect of weekly maternal Vitamin A receipt before, during and after Pregnancy on Cognitive or Motor Skill development among 10-year-old to 13-year-old offspring.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 109, 'vitamin A'), ('GO_0007565', 'female pregnancy', 152, 'pregnancy'), ('GO_0050890', 'cognition', 165, 'cognitive'), ('GO_0065007', 'biological regulation', 178, 'motor skill')]
PMC3653849	5/2013	S135-PMC3653849	[': 1.5 mg; Vitamin E: 720 mg; Menadione: 30 mg; Vitamin B-1: 30 mg; Vitamin B-2: 120 mg; Vitamin B-6: 60 mg; Vitamin B-12: 360 mg; niacin: 600 mg; Pantothenate: 300 mg; Folate: 6 mg; Manganese Sulfate: 1.0 g; Zinc Oxide: 2.5 g; Iron Sulfate: 4 g; Copper Sulfate: 4 g; Sodium Selenite: 6 mg; calcium: 150 g; Phosphorus: 15 g; Sodium Chloride: 40 g.\nprotein-to-Carbohydrate ratio based on n-free extracts/cp.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 10, 'vitamin E'), ('CHEBI_25179', 'melanins', 29, 'menadione'), ('CHEBI_27300', 'vitamin D', 47, 'vitamin B'), ('PR_000004480', 'V-type proton ATPase catalytic subunit A', 47, 'vitamin B-1'), ('CHEBI_27300', 'vitamin D', 67, 'vitamin B'), ('PR_000017279', 'testis-specific basic protein Y 1', 67, 'vitamin B-2'), ('CHEBI_27300', 'vitamin D', 88, 'vitamin B'), ('PR_000017255', 'Vang-like protein 1', 88, 'vitamin B-6'), ('CHEBI_27300', 'vitamin D', 108, 'vitamin B'), ('PR_000017269', 'ventral anterior homeobox 2', 108, 'vitamin B-12'), ('CHEBI_16454', 'pantothenate', 146, 'pantothenate'), ('CHEBI_30863', '5-azaorotic acid', 168, 'folate'), ('CHEBI_33310', 'neon atom', 182, 'manganese sulfate'), ('CHEBI_33110', 'diarsane', 208, 'zinc oxide'), ('CHEBI_53438', 'iron(3+) sulfate', 227, 'iron sulfate'), ('CHEBI_23414', 'copper(II) sulfate', 246, 'copper sulfate'), ('CHEBI_77773', 'sodium selenide', 267, 'sodium selenite'), ('CHEBI_35885', 'secondary phosphine', 306, 'phosphorus'), ('CHEBI_26710', 'sodium chloride', 324, 'sodium chloride'), ('CHEBI_16730', 'chloramphenicol 3-acetate', 358, 'carbohydrate')]
PMC3659910	1/2013	S28-PMC3659910	['however, these children represent a small proportion of the Individuals with a suboptimal Vitamin D status in the population.']	N/A	N/A	[('NCBITaxon_1', 'root', 60, 'individuals'), ('CHEBI_27300', 'vitamin D', 90, 'vitamin D')]
PMC3659910	1/2013	S40-PMC3659910	['[9] the actions of 1,25(Oh) 2D are mediated through specific, high affinity binding to the Vitamin D Receptor (Vdr), which is present in multiple Tissues.']	N/A	N/A	[('CHEBI_82784', 'PVP38-Ag NP', 19, '1,25(OH) 2D'), ('CHEBI_27300', 'vitamin D', 91, 'vitamin D'), ('PR_000001683', 'vasopressin V2 receptor', 91, 'vitamin D receptor'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 111, 'VDR'), ('UBERON_0000479', 'tissue', 146, 'tissues')]
PMC3659910	1/2013	S41-PMC3659910	['important changes occur in the maternal concentration of Vitamin D and in Calcium Metabolism to provide the calcium needed for fetal bone Mineral accretion during Pregnancy.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 57, 'vitamin D'), ('GO_0050817', 'coagulation', 74, 'calcium'), ('GO_0008152', 'metabolic process', 82, 'metabolism'), ('CHEBI_46662', 'mineral', 138, 'mineral'), ('GO_0007565', 'female pregnancy', 163, 'pregnancy')]
PMC3659910	1/2013	S54-PMC3659910	['[11] roles of Vitamin D are to maintain Skeletal calcium balance by promoting calcium absorption in the Intestines, promoting bone resobption by increasing Osteoclast number, maintaining calcium and Phosphate levels for bone formation, and allowing proper functioning of Parathyroid hormone to maintain Serum calcium levels.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 14, 'vitamin D'), ('UBERON_0004288', 'skeleton', 40, 'skeletal'), ('UBERON_0000160', 'intestine', 104, 'intestines'), ('CL_0000092', 'osteoclast', 156, 'osteoclast'), ('CHEBI_18367', 'phosphate(3-)', 199, 'phosphate'), ('UBERON_0001132', 'parathyroid gland', 271, 'parathyroid'), ('UBERON_0001977', 'blood serum', 303, 'serum')]
PMC3659910	1/2013	S63-PMC3659910	['dietary sources of Vitamin D include: fatty fish species, such as Catfish, salmon, mackerel, Tuna etc., egg, beef and fish Liver oils.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 19, 'vitamin D'), ('NCBITaxon_10088', 'Mus <genus>', 66, 'Catfish'), ('NCBITaxon_10088', 'Mus <genus>', 93, 'Tuna'), ('UBERON_0002107', 'liver', 123, 'liver')]
PMC3659910	1/2013	S72-PMC3659910	['certain Medications like Steroids, anti-epileptic medications, Cholesterol-lowering Drugs, and some Diuretics reduce absorption of Vitamin D from the Intestines.']	N/A	N/A	[('CHEBI_25441', 'mycothiols', 8, 'medications'), ('CHEBI_35341', 'steroid', 25, 'steroids'), ('CHEBI_16113', 'cholesterol', 63, 'cholesterol'), ('CHEBI_23888', 'drug', 84, 'drugs'), ('CHEBI_35498', 'diuretic', 100, 'diuretics'), ('CHEBI_27300', 'vitamin D', 131, 'vitamin D'), ('UBERON_0000160', 'intestine', 150, 'intestines')]
PMC3659910	1/2013	S86-PMC3659910	['a study in Human subjects involved the administration of 100,000 iu Vitamin D per day (2.5 mg/day) throughout Pregnancy to hypoparathyroid women to maintain Serum calcium with no fatal outcome.']	N/A	N/A	[('NCBITaxon_9606', 'Homo sapiens', 11, 'human'), ('CHEBI_27300', 'vitamin D', 68, 'vitamin D'), ('GO_0007565', 'female pregnancy', 110, 'pregnancy'), ('UBERON_0001977', 'blood serum', 157, 'serum')]
PMC3659910	1/2013	S91-PMC3659910	['hypercalciuria due to excessive Vitamin D intakes is always accompanied by circulating 25(Oh) D concentrations >250nmol/l (100 ng/ml).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 32, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 87, '25(OH) D'), ('PR_000006444', 'diacylglycerol kinase delta', 94, 'D')]
PMC3659910	1/2013	S100-PMC3659910	['Pregnancy does not exacerbate hypocalcaemia and secondary hyperparathyroidism in People with pre-existing Vitamin D deficiency.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 0, 'Pregnancy'), ('NCBITaxon_10088', 'Mus <genus>', 81, 'people'), ('CHEBI_27300', 'vitamin D', 106, 'vitamin D')]
PMC3659910	1/2013	S108-PMC3659910	['in an uncontrolled trial, supplementation with a multivitamin/Mineral supplement and halibut Liver oil (containing 900 iu/d Vitamin D) provided at 20 wk Gestation reduced the odds of preeclampsia by 32% (95% ci, 11-47%).']	N/A	N/A	[('CHEBI_46662', 'mineral', 62, 'mineral'), ('UBERON_0002107', 'liver', 93, 'liver'), ('CHEBI_27300', 'vitamin D', 124, 'vitamin D'), ('GO_0007565', 'female pregnancy', 153, 'gestation')]
PMC3659910	1/2013	S123-PMC3659910	['the cochrane library issued a review of Vitamin D supplementation during Pregnancy and identified 7 relevant studies.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 40, 'vitamin D'), ('GO_0007565', 'female pregnancy', 73, 'pregnancy')]
PMC3659910	1/2013	S151-PMC3659910	['a study in Pregnant women in south india assessed maternal Vitamin D status by measuring Serum 25-Hydroxyvitamin D in stored Serum samples.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 11, 'pregnant'), ('CHEBI_27300', 'vitamin D', 59, 'vitamin D'), ('UBERON_0001977', 'blood serum', 89, 'serum'), ('CHEBI_62218', '23,24-dihydrocucurbitacin D', 95, '25-hydroxyvitamin D'), ('UBERON_0001977', 'blood serum', 125, 'serum')]
PMC3659910	1/2013	S156-PMC3659910	['the us preventive services task force does not comment for or against routine screening for Vitamin D deficiency in Pregnant women.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 92, 'vitamin D'), ('GO_0007565', 'female pregnancy', 116, 'pregnant')]
PMC3660294	5/2013	S160-PMC3660294	['among breastfed infants, 23.3% were given no supplements (including Vitamin D).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 68, 'vitamin D')]
PMC3662163	3/2013	S92-PMC3662163	['† users of only Folic Acid and/or Vitamin D are excluded.']	N/A	N/A	[('CHEBI_30751', 'formic acid', 16, 'Folic acid'), ('CHEBI_27300', 'vitamin D', 34, 'vitamin D')]
PMC3668200	5/2013	S6-PMC3668200	['Previtamin D3 then binds to the Vitamin D-binding protein and is transported to the Liver, where it is converted to 25-Hydroxyvitamin D (25[Oh]D) by 25-Hydroxylase.']	N/A	N/A	[('CHEBI_34939', 'prostaglandin D3', 0, 'Previtamin D3'), ('PR_000013347', 'pregnancy-specific beta-1-glycoprotein 1', 0, 'Previtamin D3'), ('CHEBI_27300', 'vitamin D', 32, 'vitamin D'), ('UBERON_0002107', 'liver', 84, 'liver'), ('CHEBI_62218', '23,24-dihydrocucurbitacin D', 116, '25-hydroxyvitamin D'), ('CHEBI_23995', 'N-ethyl-N-nitrosourea', 140, 'OH]D'), ('CHEBI_17816', '1D-myo-inositol 1,4-bisphosphate', 149, '25-hydroxylase')]
PMC3668200	5/2013	S7-PMC3668200	['in the Kidney, 25(Oh)D, the nutritional indicator of Vitamin D, is hydroxylated into 1,25-Dihydroxyvitamin D (1,25-Oh2-d).']	N/A	N/A	[('UBERON_0002113', 'kidney', 7, 'kidney'), ('CHEBI_71657', 'versiconol acetate', 15, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 53, 'vitamin D'), ('CHEBI_67472', '15-epi-lupulin B', 85, '1,25-dihydroxyvitamin D'), ('CHEBI_16412', 'lipopolysaccharide', 115, 'OH2')]
PMC3668200	5/2013	S17-PMC3668200	['Human can take Vitamin D through fatty fish, certain fish oils, Animal Liver, aquatic Mammal fat and Egg Yolks of Vitamin D-Fed chickens.']	N/A	N/A	[('NCBITaxon_10088', 'Mus <genus>', 0, 'Human'), ('CHEBI_27300', 'vitamin D', 15, 'vitamin D'), ('NCBITaxon_33208', 'Metazoa', 64, 'animal'), ('UBERON_0002107', 'liver', 71, 'liver'), ('NCBITaxon_40674', 'Mammalia', 86, 'mammal'), ('UBERON_0005079', 'eggshell', 101, 'egg yolks'), ('CHEBI_27300', 'vitamin D', 114, 'vitamin D'), ('GO_0007631', 'feeding behavior', 124, 'fed')]
PMC3668200	5/2013	S18-PMC3668200	["Human Breast Milk contains little Vitamin D. the watersoluble fraction of Cow's Milk and Human Milk did not possess significant antirachitic activity."]	N/A	N/A	[('NCBITaxon_10088', 'Mus <genus>', 0, 'Human'), ('UBERON_0000310', 'breast', 6, 'breast'), ('UBERON_0001913', 'milk', 13, 'milk'), ('CHEBI_27300', 'vitamin D', 34, 'vitamin D'), ('NCBITaxon_33208', 'Metazoa', 74, 'cow'), ('UBERON_0001913', 'milk', 80, 'milk'), ('NCBITaxon_9606', 'Homo sapiens', 89, 'human'), ('UBERON_0001913', 'milk', 95, 'milk')]
PMC3668200	5/2013	S19-PMC3668200	['whole Human Milk contains a Vitamin D concentration of 15.26 iu/l, of which 12 iu is derived from the Lipid fraction.']	N/A	N/A	[('NCBITaxon_9606', 'Homo sapiens', 6, 'human'), ('UBERON_0001913', 'milk', 12, 'milk'), ('CHEBI_27300', 'vitamin D', 28, 'vitamin D'), ('CHEBI_18059', 'lipid', 102, 'lipid')]
PMC3668200	5/2013	S22-PMC3668200	['in the study of choi et al.1), 17.5% of the formula-Fed infants were Vitamin D deficient.']	N/A	N/A	[('GO_0007631', 'feeding behavior', 52, 'fed'), ('CHEBI_27300', 'vitamin D', 69, 'vitamin D')]
PMC3668200	5/2013	S34-PMC3668200	['in their study, choi et al.1)made no mention of whether the mothers took Vitamin D supplements or ate Vitamin-rich Food during their pregnancy.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 73, 'vitamin D'), ('CHEBI_33229', 'vitamin (role)', 102, 'vitamin'), ('CHEBI_33290', 'food', 115, 'food')]
PMC3668200	5/2013	S35-PMC3668200	['when large amounts of Vitamin D (1,000 iu/day) are supplemented during the last trimester to achieve 25(Oh)D concentrations of 50 nmol/l in Pregnant woman, the Vitamin D concentration in the Cord Blood is consequently increased.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 22, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 101, '25(OH)D'), ('GO_0007565', 'female pregnancy', 140, 'pregnant'), ('CHEBI_27300', 'vitamin D', 160, 'vitamin D'), ('UBERON_0002240', 'spinal cord', 191, 'cord'), ('UBERON_0000178', 'blood', 196, 'blood')]
PMC3672018	5/2013	S6-PMC3672018	['additionally, a validated method will be used to determine neonatal Vitamin D status using stored dried Blood spots (dbs) from Individuals who developed the aforementioned disease entities as Adults and their time and gender-matched controls.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 68, 'vitamin D'), ('UBERON_0000178', 'blood', 104, 'blood'), ('NCBITaxon_1', 'root', 127, 'individuals'), ('UBERON_0007023', 'adult organism', 192, 'adults')]
PMC3672018	5/2013	S53-PMC3672018	['additionally, a validated method will be used to determine neonatal Vitamin D status using stored dried Blood spots (dbs) from Individuals who develop the aforementioned disease entities as Adults and their time and gender-matched controls.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 68, 'vitamin D'), ('UBERON_0000178', 'blood', 104, 'blood'), ('NCBITaxon_1', 'root', 127, 'individuals'), ('UBERON_0007023', 'adult organism', 190, 'adults')]
PMC3672018	5/2013	S55-PMC3672018	['methods/design\n\nstudy populations\nin denmark, from 1961 to 1985 Vitamin D fortification of Margarine was mandatory (1.25ὕμg/100ὕg), and from 1972 to 1976 fortification of low fat milk (2.5-3.8ὕμg/100ὕgὕmilk) was permitted.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 64, 'vitamin D'), ('CHEBI_6784', 'mestranol', 91, 'margarine')]
PMC3672018	5/2013	S59-PMC3672018	['the Birth (grey boxes with allowance for short “wash-out period” in between) and follow-up years (arrows) of Individuals from subgroups exposed before and after Birth are given in relation to initiation or termination of Vitamin D fortification.']	N/A	N/A	[('GO_0007567', 'parturition', 4, 'birth'), ('NCBITaxon_1', 'root', 109, 'individuals'), ('GO_0007567', 'parturition', 161, 'birth'), ('CHEBI_27300', 'vitamin D', 221, 'vitamin D')]
PMC3672018	5/2013	S93-PMC3672018	['Perinatal exposure\ndevelopment of the disease outcomes will be compared for children Born around the time when mandatory Vitamin D fortification was initiated and terminated.']	N/A	N/A	[('GO_0036268', 'swimming', 0, 'Perinatal'), ('UBERON_0012101', 'perinatal stage', 0, 'Perinatal'), ('GO_0007567', 'parturition', 85, 'born'), ('CHEBI_27300', 'vitamin D', 121, 'vitamin D')]
PMC3672018	5/2013	S98-PMC3672018	['seasonal variation in Vitamin D exposure\nthe extra Vitamin D from fortification is expected to be of particular relevance when stores are low [9].']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 22, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 51, 'vitamin D')]
PMC3672018	5/2013	S147-PMC3672018	['when the previous 6\u2009months of uvb radiation from sun exposure in denmark was too weak to induce Vitamin D conversion in the skin [30].']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 96, 'vitamin D')]
PMC3672018	5/2013	S152-PMC3672018	['we do not collect any individual data on Vitamin D intake.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 41, 'vitamin D')]
PMC3672018	5/2013	S157-PMC3672018	['in breast feeding, fortified infant formulas, sun exposure) are independent of the Vitamin D intervention.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 83, 'vitamin D')]
PMC3679329	6/2013	S70-PMC3679329	['among Pregnant women, the proportion of women with an Intake of Vitamin C (from diet alone) below the ear was lower among Supplement users (44%) than among non-users (68%) ( p< 0.05).']	N/A	N/A	[('GO_0007565', 'female pregnancy', 6, 'pregnant'), ('GO_0007631', 'feeding behavior', 54, 'intake'), ('CHEBI_27300', 'vitamin D', 64, 'vitamin C'), ('CHEBI_16158', 'steroid sulfate', 122, 'supplement')]
PMC3685533	6/2013	S13-PMC3685533	['Vitamin D3 is the main source of Vitamin D for Humans.']	N/A	N/A	[('CHEBI_33237', 'vitamin D4', 0, 'Vitamin D3'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 0, 'Vitamin D3'), ('CHEBI_27300', 'vitamin D', 33, 'vitamin D'), ('NCBITaxon_9606', 'Homo sapiens', 47, 'humans')]
PMC3685533	6/2013	S28-PMC3685533	['dark-skinned Individuals require a greater duration of exposure (4–5 times) than their light-skinned counterparts to synthesise comparable amounts of Vitamin D [16].']	N/A	N/A	[('NCBITaxon_1', 'root', 13, 'individuals'), ('CHEBI_27300', 'vitamin D', 150, 'vitamin D')]
PMC3685533	6/2013	S53-PMC3685533	['all mothers were considered adequately supplemented, with an intake of 400 iu Vitamin D per day as recommended by the institute of medicine.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 78, 'vitamin D')]
PMC3685533	6/2013	S54-PMC3685533	['all mothers had used daily a standard Prenatal multivitamin containing 400 iu of Vitamin D (Vitamin D3), except for 4 mothers (2 times per day).']	N/A	N/A	[('GO_0007565', 'female pregnancy', 38, 'prenatal'), ('CHEBI_27300', 'vitamin D', 81, 'vitamin D'), ('CHEBI_33279', 'vitamin D5', 92, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 92, 'vitamin D3')]
PMC3685533	6/2013	S55-PMC3685533	['pure Vitamin D preparations were not used in any case.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 5, 'vitamin D')]
PMC3685533	6/2013	S57-PMC3685533	['the average daily Vitamin D intake was 420 iu\u2009±\u200980 iu/d and the average duration of supplementation was 117\u2009±\u200930 days.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 18, 'vitamin D')]
PMC3685533	6/2013	S62-PMC3685533	['the liaison 25 Oh Vitamin D total assay uses chemiluminescent immunoassay (clia) technology for the quantitative determination of 25Ohd and other hydroxylated Vitamin D Metabolites in Human serum.']	N/A	N/A	[('CHEBI_63058', '(2R,3S)-EHNA', 12, '25 OH'), ('CHEBI_28384', 'vitamin K', 18, 'Vitamin D'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 18, 'Vitamin D'), ('CHEBI_72652', "7,2'-dihydroxy-4'-methoxyisoflavan-4-ylium cation", 130, '25OHD'), ('CHEBI_27300', 'vitamin D', 159, 'vitamin D'), ('CHEBI_25212', 'metabolite', 169, 'metabolites'), ('NCBITaxon_9606', 'Homo sapiens', 184, 'human')]
PMC3685533	6/2013	S70-PMC3685533	['results\nthe mean Vitamin D levels in all subjects were 21.4\u2009±\u200911 ng/ml on Cord Blood and 14.9\u2009±\u20097 ng/ml in neonatal Serum.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 17, 'vitamin D'), ('UBERON_0002240', 'spinal cord', 74, 'cord'), ('UBERON_0000178', 'blood', 79, 'blood'), ('UBERON_0001977', 'blood serum', 116, 'serum')]
PMC3685533	6/2013	S74-PMC3685533	['in Cord Blood, 25Ohd values were <20 ng/ml in 30 cases (55.5%): 18 (33.3%) had mild Vitamin D deficiency (between 10 and 20 ng/ml) and 12 (22.2%) had severe deficiency (<10 ng/ml).']	N/A	N/A	[('UBERON_0002240', 'spinal cord', 3, 'cord'), ('UBERON_0000178', 'blood', 8, 'blood'), ('CHEBI_72652', "7,2'-dihydroxy-4'-methoxyisoflavan-4-ylium cation", 15, '25OHD'), ('CHEBI_27300', 'vitamin D', 84, 'vitamin D')]
PMC3685533	6/2013	S97-PMC3685533	['Gestational age not correlated with Cord Blood Vitamin D or neonatal Serum levels.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 0, 'Gestational'), ('UBERON_0002240', 'spinal cord', 36, 'cord'), ('UBERON_0000178', 'blood', 41, 'blood'), ('CHEBI_27300', 'vitamin D', 47, 'vitamin D'), ('UBERON_0001977', 'blood serum', 69, 'serum')]
PMC3685533	6/2013	S105-PMC3685533	['the two major sources of Vitamin D in the body are diet and the skin.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 25, 'vitamin D')]
PMC3691177	6/2013	S2-PMC3691177	['methods\nwe randomised 180 Pregnant women at 27 weeks Gestation to either no Vitamin D, 800 iu Ergocalciferol daily until Delivery or single oral bolus of 200,000 iu Cholecalciferol, in an ethnically stratified, randomised controlled trial.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 26, 'pregnant'), ('GO_0007565', 'female pregnancy', 53, 'gestation'), ('CHEBI_27300', 'vitamin D', 76, 'vitamin D'), ('CHEBI_4910', 'etomidate', 94, 'ergocalciferol'), ('GO_0007567', 'parturition', 121, 'delivery'), ('CHEBI_52550', 'theopalauamide', 165, 'cholecalciferol')]
PMC3691177	6/2013	S3-PMC3691177	['supplementation improved but did not optimise Vitamin D status.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 46, 'vitamin D')]
PMC3691177	6/2013	S10-PMC3691177	['we found no difference between supplemented and control groups in risk of wheeze [no Vitamin D: 14/50 (28%); any Vitamin D: 26/108 (24%) (risk ratio 0.86; 95% confidence interval 0.49, 1.50; p\u200a=\u200a0.69)].']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 85, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 113, 'vitamin D')]
PMC3691177	6/2013	S51-PMC3691177	['statistical analysis\nin the original study it was calculated that at least eight women in each ethnic group for each arm of treatment would be needed to demonstrate a significant difference in Vitamin D levels at Delivery in the no treatment group vs. the supplemented groups (power 90%, test of significance at 5% level).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 193, 'vitamin D'), ('GO_0007567', 'parturition', 213, 'delivery')]
PMC3691177	6/2013	S55-PMC3691177	['for primary analyses, bolus and daily Vitamin D supplemented groups were analysed together and compared with the control group.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 38, 'vitamin D')]
PMC3691177	6/2013	S56-PMC3691177	['we also report separate analyses of bolus and daily groups versus control, and of children Born to mothers with Vitamin D deficiency at enrolment (defined as 25(Oh)D <25 nmol/l).']	N/A	N/A	[('GO_0007567', 'parturition', 91, 'born'), ('CHEBI_27300', 'vitamin D', 112, 'vitamin D'), ('CHEBI_72805', '2-alkyl-sn-glycero-3-phosphocholine', 161, 'OH)D')]
PMC3691177	6/2013	S76-PMC3691177	['effect of Prenatal Vitamin D supplementation on parent reported wheezing, allergic disease and respiratory infections\nwe found no significant difference in the primary outcome of ‘wheeze ever’ between treatment groups (any Vitamin D vs. controltable 2, daily vs. controltable 3, bolus vs. controltable 4).']	N/A	N/A	[('GO_0007565', 'female pregnancy', 10, 'Prenatal'), ('CHEBI_28384', 'vitamin K', 19, 'Vitamin D'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 19, 'Vitamin D'), ('CHEBI_27300', 'vitamin D', 223, 'vitamin D')]
PMC3691177	6/2013	S80-PMC3691177	['combined Vitamin D groups versus control.controlcombined vitamin drror p aor† p (%)(%)(95% ci)(95% ci)(95% ci)wheeze ever14/50 (28)26/108 (24)0.86 (0.49, 1.50)0.82 (0.38, 1.74)0.600.73 (0.33, 1.65)0.45recurrent wheezing7/50 (14)17/108 (16)1.12 (0.50, 2.54)1.15 (0.44, 2.97)0.771.14 (0.42, 3.13)0.80wheezing in the last year8/50 (16)17/108 (16)0.98 (0.46, 2.13)0.98 (0.39, 2.45)0.970.95 (0.36, 2.51)0.92wheeze with positive api7/50 (15)15/107 (14)1.00 (0.44, 2.30)1.00 (0.38, 2.64)1.001.06 (0.37, 3.02)0.91any Bronchodilator use4/49 (8)24/104 (23)2.83 (1.04, 7.71)3.37 (1.10, 10.34)0.03*3.14 (0.96, 10.28)0.06*eczema ever15/49 (31)30/102 (29)0.96 (0.57, 1.61)0.75 (0.35, 1.62)0.470.72 (0.32, 1.61)0.42eczema in the last year7/49 (14)20/103 (19)1.36 (0.62, 3.00)1.34 (0.52, 3.47)0.551.52 (0.55, 4.21)0.42atopy7/27(26)11/68 (16)0.62 (0.27, 1.44)0.56 (0.19, 1.66)0.300.29 (0.07, 1.16)0.08allergic rhinitis7/49 (14)11/101 (12)0.76 (0.31, 1.85)0.63 (0.22, 1.78)0.380.69 (0.22, 2.13)0.52food allergy diagnosis3/49 (6)12/102 (12)1.92 (0.57, 6.50)1.81 (0.48, 6.85)0.381.93 (0.45, 8.29)0.38>4 urti/year7/50 (14)20/103 (19)1.39 (0.63, 3.06)1.43 (0.55, 3.68)0.461.34 (0.49, 3.68)0.57lrti ever11/50 (22)31/101 (31)1.40 (0.77, 2.54)1.47 (0.64, 3.37)0.371.60 (0.67, 3.85)0.29primary health care recordsrecurrent wheeze3/31 (10)10/70 (14)1.48 (0.44, 5.00)1.56 (0.40, 6.10)0.521.47 (0.33, 6.55)0.61eczema6/31 (19)10/70 (14)0.74 (0.29, 1.85)0.46 (0.23, 2.12)0.520.63 (0.18, 2.16)0.46food allergy2/31 (6)2/70 (3)0.44 (0.07, 3.00)0.43 (0.06, 3.18)0.580.14 (0.00, 4.39)0.26\nrr\u200a=\u200arisk ratio, or\u200a=\u200aunadjusted odds ratio, aor\u200a=\u200a adjusted odds ratio, api\u200a=\u200aasthma predictive index, urti\u200a=\u200aUpper Respiratory Tract infection, lrti\u200a=\u200aLower Respiratory Tract infection.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 9, 'vitamin D'), ('CHEBI_60874', 'phenylacetylglycine(1-)', 509, 'bronchodilator'), ('UBERON_0001557', 'upper respiratory tract', 1664, 'upper respiratory tract'), ('UBERON_0004905', 'articulation', 1706, 'lower respiratory tract')]
PMC3691177	6/2013	S84-PMC3691177	['daily Vitamin D versus control.controldaily Vitamin drror p aor† p (%)(%)(95% ci)(95% ci)(95% ci)wheeze ever14/50 (28)11/56 (20)0.70 (0.35, 1.40)0.63 (0.26, 1.55)0.310.56 (0.20, 1.57)0.27recurrent wheezing7/50 (14)8/56 (14)1.02 (0.40, 2.61)1.02 (0.34, 3.06)0.971.11 (0.32, 3.92)0.87wheezing in the last year8/50 (16)8/56 (14)0.89 (0.36, 2.20)0.88 (0.30, 2.54)0.810.88 (0.27, 2.90)0.84wheeze with positive api7/50 (14)6/56 (11)0.77 (0.28, 2.13)0.74 (0.23, 2.36)0.610.65 (0.15, 2.82)0.57any Bronchodilator use4/49 (8)10/56 (18)2.23 (0.75, 6.67)2.45 (0.72, 8.37)0.152.24 (0.54, 9.33)0.27eczema ever15/49 (31)15/54 (28)0.91 (0.50, 1.66)0.87 (0.37, 2.04)0.750.61 (0.23, 1.67)0.34eczema in the last year7/49 (14)11/55 (20)1.40 (0.59, 3.33)1.50 (0.53, 4.23)0.441.31 (0.38, 4.54)0.67atopy7/27 (26)4/36 (11)0.41 (0.13, 1.27)0.36 (0.09, 1.38)0.130.36 (0.05, 2.94)0.34allergic rhinitis7/49 (14)7/55 (13)0.89 (0.34, 2.36)0.88 (0.28, 2.70)0.820.63 (0.17, 2.36)0.49food allergy diagnosis3/49 (6)8/55 (15)2.38 (0.67, 8.46)2.61 (0.65, 10.45)0.164.53 (0.52, 39.33)0.17>4 urti/year7/50 (14)11/55 (20)1.43 (0.60, 3.40)1.54 (0.55, 4.33)0.421.39 (0.41, 4.68)0.60lrti ever11/50 (22)14/54 (26)1.18 (0.59, 2.35)1.24 (0.50, 3.07)0.641.00 (0.35, 2.91)1.00primary health care recordsrecurrent wheeze3/31 (10)4/36 (11)1.15 (0.28, 4.74)1.17 (0.24, 5.67)0.851.43 (0.21, 9.89)0.71eczema6/31 (19)5/36 (14)0.72 (0.24, 2.12)0.67 (0.18, 2.46)0.550.61 (0.13, 2.86)0.53food allergy2/31 (7)2/36 (6)0.86 (0.13, 5.76)0.85 (0.11, 6.44)0.88 --\nrr\u200a=\u200arisk ratio, or\u200a=\u200aunadjusted odds ratio, aor\u200a=\u200a adjusted odds ratio, api\u200a=\u200aasthma predictive index, urti\u200a=\u200aUpper Respiratory Tract infection, lrti\u200a=\u200aLower Respiratory Tract infection.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 6, 'vitamin D'), ('CHEBI_33229', 'vitamin (role)', 44, 'Vitamin'), ('CHEBI_60874', 'phenylacetylglycine(1-)', 489, 'bronchodilator'), ('UBERON_0001557', 'upper respiratory tract', 1613, 'upper respiratory tract'), ('UBERON_0004905', 'articulation', 1655, 'lower respiratory tract')]
PMC3691177	6/2013	S85-PMC3691177	['model adjusted for mother’s ethnic group, presence of household smokers, maternal smoking in Pregnancy, exclusive breast-feeding to four months, any parental allergic history, any child vitamin supplementation, number of children in the household, age mother left full-time education and baseline concentration of 25(Oh)D in maternal Blood.10.1371/journal.pone.0066627.t004\n\ncaption (table-wrap): table 4\nclinical outcomes at age three years.controlbolus Vitamin drror p aor† p (%)(%)(95% ci)(95% ci)(95% ci)wheeze ever14/50 (28)15/52 (29)1.03 (0.56, 1.91)1.04 (0.44, 2.47)0.931.17 (0.44, 3.10)0.75recurrent wheezing7/50 (14)9/52 (17)1.24 (0.50 (3.07)1.29 (0.44, 3.77)0.651.91 (0.53, 6.75)0.31wheezing in the last year8/50 (16)9/52 (17)1.08 (0.45, 2.58)1.10 (0.39, 3.12)0.861.29 (0.40, 4.15)0.66wheeze with positive api7/50 (14)9/51 (18)1.26 (0.51, 3.12)1.32 (0.45, 3.86)0.622.01 (0.58, 6.99)0.27any Bronchodilator use4/49 (8)14/48 (29)3.57 (1.27, 10.09)4.63 (1.40, 15.34)0.008*5.43 (1.39, 21.20)0.02*eczema ever15/49 (31)15/48 (31)1.02 (0.56, 1.85)1.03 (0.44, 2.44)0.950.86 (0.32, 2.28)0.76eczema in the last year7/49 (14)9/48 (19)1.31 (0.53, 3.24)1.39 (0.47, 4.08)0.551.97 (0.47, 8.27)0.36atopy7/27 (26)7/32 (22)0.84 (0.34, 2.11)0.80 (0.24, 2.66)0.720.31 (0.05, 1.83)0.20allergic rhinitis7/49 (14)4/46 (9)0.61 (0.19, 1.94)0.57 (0.16, 2.10)0.400.91 (0.20, 4.11)0.90food allergy diagnosed3/49 (6)4/47 (9)1.36 (0.32, 5.78)1.43 (0.30, 6.75)0.651.31 (0.24, 7.18)0.76>4 urti/year7/50 (14)9/48 (19)1.34 (0.54, 3.31)1.42 (0.48, 4.17)0.531.72 (0.49, 6.04)0.39lrti ever11/50 (22)17/47 (36)1.64 (0.86, 3.14)2.01 (0.82, 4.92)0.122.87 (1.03, 8.03)0.05*primary health care recordrecurrent wheeze3/31 (10)6/34 (18)1.82 (0.50, 6.68)2.00 (0.46, 8.80)0.351.85 (0.36, 9.66)0.47eczema6/31 (19)5/34 (15)0.76 (0.26, 2.24)0.72 (0.20, 2.64)0.620.63 (0.11, 3.59)0.60food allergy2/31 (7)0/34 (0)0.0 (-, -) ----\nbolus Vitamin D versus control.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 93, 'pregnancy'), ('CHEBI_71657', 'versiconol acetate', 314, '25(OH)D'), ('UBERON_0000178', 'blood', 334, 'blood'), ('CHEBI_33229', 'vitamin (role)', 455, 'Vitamin'), ('CHEBI_60874', 'phenylacetylglycine(1-)', 900, 'bronchodilator'), ('CHEBI_27300', 'vitamin D', 1893, 'vitamin D')]
PMC3691177	6/2013	S96-PMC3691177	['we found no significant difference between groups in baseline Respiratory resistance at 10 or 20 hz, resonant frequency, area under the reactance curve or percentage response of these parameters to bronchodilator, when data were analysed for the two forms of Prenatal Vitamin D supplementation combined (table s6 infile s1), or separately (figures 2and3).10.1371/journal.pone.0066627.g002\n\ncaption (fig): figure 2\nbaseline Respiratory resistance at 10 hz (r10, a), 20 hz (r20, b), resonant frequency (fres, c) and area under the reactance curve (ax, d) for control (n\u200a=\u200a13), daily (n\u200a=\u200a18), and bolus (n\u200a=\u200a20) Vitamin D groups at age three years.']	N/A	N/A	[('GO_0045333', 'cellular respiration', 62, 'respiratory'), ('UBERON_0001004', 'respiratory system', 62, 'respiratory'), ('GO_0007565', 'female pregnancy', 259, 'prenatal'), ('CHEBI_27300', 'vitamin D', 268, 'vitamin D'), ('UBERON_0001004', 'respiratory system', 423, 'respiratory'), ('CHEBI_27300', 'vitamin D', 610, 'vitamin D')]
PMC3691177	6/2013	S98-PMC3691177	['no significant difference between groups.10.1371/journal.pone.0066627.g003\n\ncaption (fig): figure 3\nbronchodilator response for respiratory resistance at 10 hz (r10, a), 20 hz (r20, b), resonant frequency (fres, c) and area under the reactance curve (ax, d) for control (n\u200a=\u200a10), daily (n\u200a=\u200a15), and bolus (n\u200a=\u200a14) Vitamin D groups at age three years.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 315, 'vitamin D')]
PMC3691177	6/2013	S102-PMC3691177	['we found no significant difference between groups in these outcomes assessed at age 3, when analysed for the two forms of Prenatal Vitamin D supplementation combined (table s7 infile s1) or analysed separately (figure 4).10.1371/journal.pone.0066627.g004\n\ncaption (fig): figure 4\nmeasures of allergic inflammation at age three years.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 122, 'prenatal'), ('CHEBI_27300', 'vitamin D', 131, 'vitamin D')]
PMC3691177	6/2013	S104-PMC3691177	['control versus daily and bolus Vitamin D. horizontal bars represent means.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 31, 'vitamin D')]
PMC3691177	6/2013	S119-PMC3691177	['fourth, women from four ethnic groups were enrolled in this study, with significant differences in baseline Vitamin D levels between caucasian women and all other ethnic groups (data not shown).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 108, 'vitamin D')]
PMC3691177	6/2013	S122-PMC3691177	['fifth, supplementation with Vitamin D only started at 27 weeks of Gestation.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 28, 'vitamin D'), ('GO_0007565', 'female pregnancy', 66, 'gestation')]
PMC3691177	6/2013	S135-PMC3691177	['the doses of supplementation were chosen pragmatically, were not stratified based on individual Vitamin D status or genotype, and response to treatment was not monitored before Delivery.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 96, 'vitamin D'), ('GO_0007567', 'parturition', 177, 'delivery')]
PMC3695234	7/2013	S29-PMC3695234	['method\nfor analysis of Vitamin D in Serum, we used liquid-liquid extraction (lle) and solid phase extraction (spe).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 23, 'vitamin D'), ('UBERON_0001977', 'blood serum', 36, 'serum')]
PMC3695234	7/2013	S37-PMC3695234	['statistical analysis\nthe Vitamin D levels among ad severity levels according to the scorad index were compared by anova.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 25, 'vitamin D')]
PMC3698442	7/2013	S41-PMC3698442	['all diets contained the same amount of Vitamin E to provide sufficient antioxidant capacity at the highest level of fo intake.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 39, 'vitamin E')]
PMC3702245	6/2013	S8-PMC3702245	['very few Food items, including fatty fish, fortified dairy products, and Egg Yolk, contain Vitamin D.9,10when exposure to sunlight is limited, Individuals depend on dietary sources or Vitamin D supplements to maintain adequate Vitamin D status.']	N/A	N/A	[('CHEBI_33290', 'food', 9, 'food'), ('UBERON_0007378', 'egg yolk', 73, 'egg yolk'), ('CHEBI_27300', 'vitamin D', 91, 'vitamin D'), ('NCBITaxon_1', 'root', 143, 'individuals'), ('CHEBI_27300', 'vitamin D', 184, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 227, 'vitamin D')]
PMC3702245	6/2013	S11-PMC3702245	['when Serum Vitamin D and calcium concentrations are low, there is increased Synthesis Of Parathyroid Hormone which further stimulates Synthesis Of 1,25- Dihydroxyvitamin D [1,25(Oh)2D] to correct calcium deficits through increased Intestinal calcium absorption and mobilization of calcium from bone.']	N/A	N/A	[('UBERON_0001977', 'blood serum', 5, 'serum'), ('CHEBI_27300', 'vitamin D', 11, 'vitamin D'), ('GO_0006523', 'alanine biosynthetic process', 76, 'synthesis of ... hormone'), ('UBERON_0001132', 'parathyroid gland', 89, 'parathyroid'), ('GO_0007608', 'sensory perception of smell', 134, 'synthesis of ...'), ('CHEBI_67472', '15-epi-lupulin B', 147, '1,25- dihydroxyvitamin D'), ('CHEBI_66212', "5,7,3',4'-tetrahydroxy-2'-(3,3-dimethylallyl)isoflavone", 175, '25(OH)2D'), ('UBERON_0000160', 'intestine', 231, 'intestinal')]
PMC3702245	6/2013	S12-PMC3702245	['restoration of Vitamin D status and calcium balance allows calcium accretion in the Bones.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 15, 'vitamin D'), ('UBERON_0001474', 'bone element', 84, 'bones')]
PMC3702245	6/2013	S66-PMC3702245	['these subjects with very low Vitamin D status were started on 800 iu/day of Vitamin D, increased to 1600 iu/day at 36 weeks’ Gestation if Serum 25(Oh)D was still low.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 29, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 76, 'vitamin D'), ('GO_0007565', 'female pregnancy', 125, 'gestation'), ('UBERON_0001977', 'blood serum', 138, 'serum'), ('CHEBI_71657', 'versiconol acetate', 144, '25(OH)D')]
PMC3702245	6/2013	S85-PMC3702245	['similarly, 82%, 71%, and 50%, respectively, of the mothers on 4000 iu, 2000 iu, and 400 iu of Vitamin D daily achieved a Serum 25(Oh)D concentration >80 nmol/l ( p = 0.0001).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 94, 'vitamin D'), ('UBERON_0001977', 'blood serum', 121, 'serum'), ('CHEBI_71657', 'versiconol acetate', 127, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 127, '25(OH)D')]
PMC3702245	6/2013	S90-PMC3702245	['there were no adverse events related to Vitamin D supplementation during the study.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 40, 'vitamin D')]
PMC3702339	6/2013	S101-PMC3702339	['prevalence of Vitamin A deficiency\nthe mean Serum Retinol level was 0.84±0.41 µmol/l (95% ci 0.81-0.87).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 14, 'vitamin A'), ('UBERON_0001977', 'blood serum', 44, 'serum'), ('CHEBI_26536', 'retinoic acid', 50, 'retinol')]
PMC3702339	6/2013	S107-PMC3702339	['prevalence of Vitamin A deficiency among Pregnant women in rural sidama, southern ethiopia, february 2011\nabout 59 (8.4%) of the Blood samples were positive for crp (crp ≥5 mg/dl).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 14, 'vitamin A'), ('GO_0007565', 'female pregnancy', 41, 'pregnant'), ('UBERON_0000178', 'blood', 129, 'blood')]
PMC3702339	6/2013	S136-PMC3702339	['a quarter—24.9% (95% ci 21.7-28.1)—of the subjects had both of the deficiencies, and about two-thirds—65.6% (95% ci 59.9-71.4)—of the Vitamin A-deficient subjects were zinc-deficient.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 134, 'vitamin A')]
PMC3702339	6/2013	S200-PMC3702339	['distance from the nearby health facility, Prenatal nutrition education/counselling, and frequency of anc were not associated with Vitamin A status.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 42, 'prenatal'), ('CHEBI_27300', 'vitamin D', 130, 'vitamin A')]
PMC3705146	5/2013	S218-PMC3705146	['any Genetic polymorphism that enhances the ability of Vitamin D to be generated from light would have been advantageous in low-light regimes, except when Vitamin D was easily obtained from the diet.']	N/A	N/A	[('SO_0000704', 'gene', 4, 'genetic'), ('CHEBI_27300', 'vitamin D', 54, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 154, 'vitamin D')]
PMC3705320	3/2013	S36-PMC3705320	['participants were advised not to take other Vitamin D-containing supplements during the study period.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 44, 'vitamin D')]
PMC3705320	3/2013	S41-PMC3705320	[', preceding the administration of a second Vitamin D dose) [13].']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 43, 'vitamin D')]
PMC3705320	3/2013	S117-PMC3705320	['there was no significant association between baseline Vitamin D status and ∆[25(Oh)D] (data not shown).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 54, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 77, '25(OH)D')]
PMC3705320	3/2013	S134-PMC3705320	['her albumin-adjusted [ca] of 2.61 mmol/l declined to 2.39 mmol/l in a repeat specimen on the same day, the illness was self-limited, and there was no other biochemical or clinical evidence of Vitamin D toxicity; furthermore, the participant continued to receive the supplement and had increasing [25(Oh)D] (range, 52 to 98 nmol/l during follow-up) but did not develop any further episodes of hypercalcemia or elevations in Urine ca:cr.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 192, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 297, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 303, 'D'), ('UBERON_0001088', 'urine', 423, 'urine')]
PMC3705320	3/2013	S164-PMC3705320	['this population was more Vitamin D-replete at baseline (mean [25(Oh)D] = 60 nmol/l) compared to the present study.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 25, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 62, '25(OH)D')]
PMC3705320	3/2013	S203-PMC3705320	[', 4000 iu/day for Vitamin D, as established by the institute of medicine [1]).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 18, 'vitamin D')]
PMC3708703	6/2013	S80-PMC3708703	['Serum 25(Oh) Vitamin D concentration and Urinary Iodine concentration were measured at 32 wk Gestation.']	N/A	N/A	[('UBERON_0001977', 'blood serum', 0, 'Serum'), ('CHEBI_30778', 'gallic acid', 6, '25(OH)'), ('CHEBI_27300', 'vitamin D', 13, 'vitamin D'), ('UBERON_0001088', 'urine', 41, 'urinary'), ('CHEBI_24859', 'iodine atom', 49, 'iodine'), ('GO_0007565', 'female pregnancy', 93, 'gestation')]
PMC3708703	6/2013	S111-PMC3708703	['five millilitres of maternal Venous Blood was collected for iron indices (Ferritin and Transferrin Receptor) and Serum Folate, Vitamin B12, and Vitamin D levels; maternal Urine was collected for Urinary Iodine concentration at 32 wk Gestation; and 1 ml of infant Venous Blood was collected for Serum ferritin.']	N/A	N/A	[('UBERON_0001638', 'vein', 29, 'venous'), ('UBERON_0000178', 'blood', 36, 'blood'), ('PR_000007309', 'fatty acid-binding protein, liver', 74, 'ferritin'), ('PR_000001679', 'trace amine-associated receptor 5', 87, 'transferrin receptor'), ('UBERON_0001977', 'blood serum', 113, 'serum'), ('CHEBI_30863', '5-azaorotic acid', 119, 'folate'), ('CHEBI_33279', 'vitamin D5', 127, 'vitamin B12'), ('PR_000004481', 'V-type proton ATPase subunit B, kidney isoform', 127, 'vitamin B12'), ('CHEBI_27300', 'vitamin D', 144, 'vitamin D'), ('UBERON_0001088', 'urine', 171, 'urine'), ('UBERON_0001088', 'urine', 195, 'urinary'), ('CHEBI_24859', 'iodine atom', 203, 'iodine'), ('GO_0007565', 'female pregnancy', 233, 'gestation'), ('UBERON_0001638', 'vein', 263, 'venous'), ('UBERON_0000178', 'blood', 270, 'blood'), ('UBERON_0001977', 'blood serum', 294, 'serum')]
PMC3708703	6/2013	S114-PMC3708703	['a waters tqd mass spectrometer was used to quantify 25(Oh) Vitamin D concentration.']	N/A	N/A	[('CHEBI_30778', 'gallic acid', 52, '25(OH)'), ('CHEBI_27300', 'vitamin D', 59, 'vitamin D'), ('PR_000006444', 'diacylglycerol kinase delta', 67, 'D')]
PMC3708703	6/2013	S117-PMC3708703	['definitions of deficiency for maternal samples were as follows: anemia, hb<110 g/l; iron deficiency, Serum ferritin <15 µg/l; vitamin B12 deficiency, Serum B12<150 pmol/l; Folate deficiency, Serum Folate <10 nmol/l[2],[28]; iron deficiency anemia, hb<110 g/l and ferritin <15 µg/l[2]; high ferritin, ferritin >41 µg/l[13]; hemoconcentration, hb>130 g/l[12]; Iodine deficiency, Urinary Iodine <150 µg/l[27]; and Vitamin D insufficiency, Serum 25(Oh) Vitamin D<75 nmol/l[29].']	N/A	N/A	[('UBERON_0001977', 'blood serum', 101, 'serum'), ('CHEBI_27778', 'abequose', 134, 'B12'), ('PR_000004738', 'class E basic helix-loop-helix protein 22', 134, 'B12'), ('UBERON_0001977', 'blood serum', 150, 'serum'), ('CHEBI_27778', 'abequose', 156, 'B12'), ('PR_000004738', 'class E basic helix-loop-helix protein 22', 156, 'B12'), ('CHEBI_30863', '5-azaorotic acid', 172, 'folate'), ('UBERON_0001977', 'blood serum', 191, 'serum'), ('CHEBI_30863', '5-azaorotic acid', 197, 'folate'), ('CHEBI_24859', 'iodine atom', 358, 'iodine'), ('UBERON_0001088', 'urine', 377, 'urinary'), ('CHEBI_24859', 'iodine atom', 385, 'iodine'), ('CHEBI_27300', 'vitamin D', 411, 'vitamin D'), ('UBERON_0001977', 'blood serum', 436, 'serum'), ('CHEBI_33310', 'neon atom', 444, '(OH)'), ('CHEBI_27300', 'vitamin D', 449, 'vitamin D')]
PMC3708703	6/2013	S193-PMC3708703	['at 32 wk Gestation, the prevalence of other Micronutrient deficiencies was 92.5% for Iodine, 8.5% for B12, 2.4% for Folate, and 60.6% for Vitamin D insufficiency (table 5).']	N/A	N/A	[('GO_0007565', 'female pregnancy', 9, 'gestation'), ('CHEBI_33962', 'mu4-sulfido-quadro-tetracopper(6+)', 44, 'micronutrient'), ('CHEBI_24859', 'iodine atom', 85, 'iodine'), ('CHEBI_27778', 'abequose', 102, 'B12'), ('CHEBI_30863', '5-azaorotic acid', 116, 'folate'), ('CHEBI_27300', 'vitamin D', 138, 'vitamin D')]
PMC3710934	7/2013	S379-PMC3710934	['those with the highest Heme iron intake (≥2.44 mg/day) and the highest Vitamin C supplement intake (>700 mg/day) had rr=8.97 (95% ci: 1.29–62.51) for Lung cancer compared to those with lowest Heme Iron intake (≤0.77 mg/day).']	N/A	N/A	[('CHEBI_30413', 'heme', 23, 'heme'), ('CHEBI_27300', 'vitamin D', 71, 'vitamin C'), ('UBERON_0002048', 'lung', 150, 'lung'), ('CHEBI_36084', 'dihydroxybenzoate', 192, 'heme iron')]
PMC3713405	7/2013	S52-PMC3713405	['the dvd-deficient rat model of schizophrenia\ndvd-deficient offspring are produced by Feeding female sprague-dawley Rats a diet that lacks Vitamin D but contains normal Calcium and Phosphorous.']	N/A	N/A	[('GO_0007631', 'feeding behavior', 85, 'feeding'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 115, 'rats'), ('CHEBI_27300', 'vitamin D', 138, 'vitamin D'), ('CHEBI_22313', 'alkaline earth metal atom', 168, 'calcium'), ('CHEBI_30207', 'phosphorus(.)', 180, 'phosphorous')]
PMC3713405	7/2013	S54-PMC3713405	['Vitamin D deficient dams are maintained on the Vitamin D depleted diet until the Birth of pups.']	N/A	N/A	[('CHEBI_28384', 'vitamin K', 0, 'Vitamin D'), ('CHEBI_27300', 'vitamin D', 47, 'vitamin D'), ('GO_0007567', 'parturition', 81, 'birth')]
PMC3713405	7/2013	S164-PMC3713405	['furthermore, when no ligand is present the rxr increases the Nuclear accumulation of vdr by slowing Nuclear Export whereas, when bound to Vitamin D, the vdr Regulates the Import Of the rxr Into the Nucleus (prufer and barsony, 2002).']	N/A	N/A	[('GO_0005634', 'nucleus', 61, 'nuclear'), ('GO_0005634', 'nucleus', 100, 'nuclear'), ('GO_0051168', 'nuclear export', 100, 'nuclear export'), ('CHEBI_27300', 'vitamin D', 138, 'vitamin D'), ('GO_0065007', 'biological regulation', 157, 'regulates'), ('GO_0006955', 'immune response', 171, 'import of ... into ... nucleus'), ('GO_0005634', 'nucleus', 198, 'nucleus')]
PMC3717170	5/2013	S25-PMC3717170	['caption (fig): figure 1\n\nGenomic mechanism of Vitamin D action.']	N/A	N/A	[('SO_0001026', 'genome', 25, 'Genomic'), ('CHEBI_27300', 'vitamin D', 46, 'vitamin D')]
PMC3717170	5/2013	S28-PMC3717170	['after interaction with the vdre (Vitamin D Response Element), transcription proceeds through the interaction of the vdr with coactivators and with the transcription machinery.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 33, 'vitamin D'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 33, 'vitamin D response element')]
PMC3717170	5/2013	S35-PMC3717170	['second, Antigen cells from the innate Immune System, such as Macrophages or Dendritic Cells (Dcs), also Express the Vitamin D activation enzyme 1α-hydroxylase, also known as Cyp27B1.']	N/A	N/A	[('CHEBI_59132', 'antigen', 8, 'antigen'), ('UBERON_0002405', 'immune system', 38, 'immune system'), ('CL_0000235', 'macrophage', 61, 'macrophages'), ('CL_0000451', 'dendritic cell', 76, 'dendritic cells'), ('CL_0000990', 'conventional dendritic cell', 93, 'DCs'), ('GO_0010467', 'gene expression', 104, 'express'), ('CHEBI_27300', 'vitamin D', 116, 'vitamin D'), ('PR_000006101', 'cytochrome P450 1A1', 174, 'CYP27B1')]
PMC3717170	5/2013	S36-PMC3717170	['as such, these cells are able to convert precursor 25(Oh)D3, the major circulating form of Vitamin D, to active 1,25(Oh)2D3That can then induce responses in the cells by binding to their vdrs and promoting transcriptional Regulation.']	N/A	N/A	[('CHEBI_62946', 'ammonium sulfate', 51, '25(OH)D3'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 51, '25(OH'), ('PR_000001177', 'D(2) dopamine receptor', 57, 'D3'), ('CHEBI_27300', 'vitamin D', 91, 'vitamin D'), ('CHEBI_63936', 'alpha1B-adrenoceptor antagonist', 117, 'OH)2D3that'), ('GO_0065007', 'biological regulation', 222, 'regulation')]
PMC3717170	5/2013	S93-PMC3717170	['caption (fig): figure 2\n\nbody-weight gain in Mice Fed high-fat diets with increased levels of Ca and Vitamin D. weight matched Mice were randomly assigned to the experimental high-fat (hf) diets containing 60% energy as fat (the normal control diet contained 10% energy as fat).']	N/A	N/A	[('NCBITaxon_10088', 'Mus <genus>', 45, 'mice'), ('GO_0007631', 'feeding behavior', 50, 'fed'), ('CHEBI_32588', 'potassium chloride', 94, 'Ca'), ('CHEBI_27300', 'vitamin D', 101, 'vitamin D'), ('NCBITaxon_10088', 'Mus <genus>', 127, 'mice')]
PMC3717170	5/2013	S107-PMC3717170	['the study group comprised 57% males, with mean age 65 ± 9 years, mean fev1 47.2 ± 17.9% predicted, mean fvc 94.6 ± 20.6% predicted, and mean dlco 53.2 ± 19.7% predicted; 58% of the patients were vitamin d deficient (Vitamin D concentration <20 ng/ml).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 216, 'vitamin D')]
PMC3717170	5/2013	S113-PMC3717170	['caption (fig): figure 3\n\nLung function and Plasma Vitamin D levels in a group of 151 copd patients.']	N/A	N/A	[('UBERON_0002048', 'lung', 25, 'Lung'), ('UBERON_0001969', 'blood plasma', 43, 'plasma'), ('CHEBI_27300', 'vitamin D', 50, 'vitamin D')]
PMC3739737	8/2013	S2-PMC3739737	['methods\nten-week old male sprague-dawley Rats were Fed a control or Vitamin D deficient diet for 6 weeks prior to, and during behavioural testing.']	N/A	N/A	[('NCBITaxon_9986', 'Oryctolagus cuniculus', 41, 'rats'), ('GO_0007631', 'feeding behavior', 51, 'fed'), ('CHEBI_27300', 'vitamin D', 68, 'vitamin D')]
PMC3739737	8/2013	S18-PMC3739737	['Prenatally Vitamin D-deficient neonates had increased Cell Proliferation and reduced Apoptosis[9].']	N/A	N/A	[('GO_0019230', 'proprioception', 0, 'Prenatally'), ('CHEBI_27300', 'vitamin D', 11, 'vitamin D'), ('GO_0008283', 'cell proliferation', 54, 'cell proliferation'), ('GO_0006915', 'apoptotic process', 85, 'apoptosis')]
PMC3739737	8/2013	S19-PMC3739737	['behaviourally, the Adult offspring of Prenatally Vitamin D deficient dams exhibit transient “hyperlocomotion”[10]–[12], enhanced Locomotor responses to Psychomimetic Drugs, such as mk-801[13]and Amphetamine[14], and impaired responses on Cognitive tasks assessing latent inhibition[15]and response inhibition[16].']	N/A	N/A	[('UBERON_0007023', 'adult organism', 19, 'adult'), ('GO_0019230', 'proprioception', 38, 'prenatally'), ('CHEBI_27300', 'vitamin D', 49, 'vitamin D'), ('GO_0040011', 'locomotion', 129, 'locomotor'), ('CHEBI_64709', 'organic acid', 152, 'psychomimetic'), ('CHEBI_23888', 'drug', 166, 'drugs'), ('CHEBI_2687', 'amsacrine', 195, 'amphetamine'), ('GO_0050890', 'cognition', 238, 'cognitive')]
PMC3739737	8/2013	S28-PMC3739737	['we selected Adult Rats (10 weeks of age) and maintained them on a diet free from Vitamin D but with normal calcium levels for 6 weeks to induce Vitamin D deficiency.']	N/A	N/A	[('UBERON_0007023', 'adult organism', 12, 'adult'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 18, 'rats'), ('CHEBI_27300', 'vitamin D', 81, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 144, 'vitamin D')]
PMC3739737	8/2013	S151-PMC3739737	['early Postnatal Vitamin D supplementation increased hva level in the Adult Forebrain[29].']	N/A	N/A	[('GO_0007567', 'parturition', 6, 'postnatal'), ('CHEBI_27300', 'vitamin D', 16, 'vitamin D'), ('UBERON_0007023', 'adult organism', 69, 'adult'), ('UBERON_0001890', 'forebrain', 75, 'forebrain')]
PMC3739737	8/2013	S166-PMC3739737	['for example, Vitamin D is a potent inducer of Nerve Growth Factor (Ngf)[36],[37].']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 13, 'vitamin D'), ('PR_000011193', 'ephexin-1', 46, 'nerve growth factor'), ('UBERON_0001021', 'nerve', 46, 'nerve'), ('PR_000011159', 'nexilin', 67, 'NGF')]
PMC3760821	9/2013	S13-PMC3760821	['conclusion\nin t1dm Pregnancy, low Vitamin D levels persist throughout Gestation and post-Delivery.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 19, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 34, 'vitamin D'), ('GO_0007565', 'female pregnancy', 70, 'gestation'), ('GO_0007567', 'parturition', 89, 'delivery')]
PMC3760821	9/2013	S23-PMC3760821	['during Pregnancy, 25Ohd diffuses across the Placental barrier, meaning the Foetus relies entirely on the Vitamin D status of the mother[9].']	N/A	N/A	[('GO_0007565', 'female pregnancy', 7, 'pregnancy'), ('CHEBI_72652', "7,2'-dihydroxy-4'-methoxyisoflavan-4-ylium cation", 18, '25OHD'), ('UBERON_0001987', 'placenta', 44, 'placental'), ('UBERON_0000376', 'hindlimb stylopod', 75, 'foetus'), ('CHEBI_27300', 'vitamin D', 105, 'vitamin D')]
PMC3760821	9/2013	S77-PMC3760821	['Methanol was added to precipitate proteins, followed by Hexane to extract Vitamin D. samples were vortex-mixed for 30 seconds and centrifuged for 5 minutes at 13,000 g. the Organic layer was transferred into maximum recovery vials (waters, uk), evaporated under nitrogen gas, and reconstituted in 75 µl of 70% (v/v) Methanol in Water.']	N/A	N/A	[('CHEBI_17790', 'methanol', 0, 'Methanol'), ('CHEBI_29021', 'hexane', 56, 'hexane'), ('CHEBI_27300', 'vitamin D', 74, 'vitamin D'), ('CHEBI_77514', '6-phenylundecane', 173, 'organic'), ('CHEBI_17790', 'methanol', 316, 'methanol'), ('CHEBI_15377', 'water', 328, 'water')]
PMC3760821	9/2013	S107-PMC3760821	['this information is presented to indicate the prevalence of Vitamin D deficiency (insufficiency) in control and t1dm women according to stage of Pregnancy.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 60, 'vitamin D'), ('GO_0007565', 'female pregnancy', 145, 'pregnancy')]
PMC3760821	9/2013	S132-PMC3760821	['correlations between maternal Serum Vitamin D levels and maternal and neonatal outcomes\ntable 3 shows correlations between maternal Serum 25Ohd levels and maternal and neonatal outcomes.']	N/A	N/A	[('UBERON_0001977', 'blood serum', 30, 'serum'), ('CHEBI_27300', 'vitamin D', 36, 'vitamin D'), ('UBERON_0001977', 'blood serum', 132, 'serum'), ('CHEBI_72652', "7,2'-dihydroxy-4'-methoxyisoflavan-4-ylium cation", 138, '25OHD')]
PMC3760821	9/2013	S143-PMC3760821	['obese bmi >30 kg/m2) on maternal and cord Vitamin D levels in the t1dm women was examined.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 42, 'vitamin D')]
PMC3760821	9/2013	S148-PMC3760821	['maternal age at Delivery, Subscapular Skinfold, Triceps Skinfold, sds bmi and sds height did not impact significantly on Cord Blood Vitamin D levels.']	N/A	N/A	[('GO_0007567', 'parturition', 16, 'delivery'), ('UBERON_0007191', 'anterior paracentral gyrus', 26, 'subscapular skinfold'), ('UBERON_0005299', 'prepuce of clitoris', 48, 'triceps skinfold'), ('UBERON_0002240', 'spinal cord', 121, 'cord'), ('UBERON_0000178', 'blood', 126, 'blood'), ('CHEBI_27300', 'vitamin D', 132, 'vitamin D')]
PMC3773018	4/2013	S3-PMC3773018	['we defined fs as specific Ige ≥0.35kua/l to any of eight common Food Allergens; and persistently low Vitamin D status as Cord Blood 25(Oh)D <11ng/ml and Postnatal 25(Oh)D <30ng/ml.']	N/A	N/A	[('GO_0071743', 'IgE immunoglobulin complex, circulating', 26, 'IgE'), ('CHEBI_33290', 'food', 64, 'food'), ('CHEBI_33663', 'cyclic hydrocarbon', 69, 'allergens'), ('CHEBI_27300', 'vitamin D', 101, 'vitamin D'), ('UBERON_0002240', 'spinal cord', 121, 'cord'), ('UBERON_0000178', 'blood', 126, 'blood'), ('CHEBI_33010', 'chromide(1-)', 134, '(OH)D'), ('GO_0007567', 'parturition', 153, 'postnatal'), ('CHEBI_71657', 'versiconol acetate', 163, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 169, 'D')]
PMC3773018	4/2013	S5-PMC3773018	['there was no association between low Vitamin D status and fs at any single time point alone.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 37, 'vitamin D')]
PMC3773018	4/2013	S36-PMC3773018	['persistently low Vitamin D status was defined as having low levels at both time points.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 17, 'vitamin D')]
PMC3773018	4/2013	S43-PMC3773018	['among children whose follow-up measurement was obtained within one year of age, Vitamin D levels were dramatically increased (n=232, black curve: 35.63 ± 11.43 ng/ml).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 80, 'vitamin D')]
PMC3773018	4/2013	S45-PMC3773018	['similarly, the proportions of children with low Vitamin D status at Birth (i.e., <11ng/ml), <1year, 1–2 years, and 2–3 years (i.e., <30ng/ml) were 38%, 29%, 36%, and 40%, respectively; and the correlation coefficients between Cord Blood 25(Oh)D concentrations and 25(Oh)D measures up to age 1 year, 1–2 years, and 2–3 years were 0.28, 0.39, and 0.63, respectively.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 48, 'vitamin D'), ('GO_0007567', 'parturition', 68, 'birth'), ('UBERON_0009472', 'axilla', 226, 'cord blood'), ('CHEBI_71657', 'versiconol acetate', 237, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 237, '25(OH ... D'), ('CHEBI_71657', 'versiconol acetate', 264, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 264, '25(OH ... D')]
PMC3773018	4/2013	S52-PMC3773018	['individually, neither Cord Blood nor Postnatal low Vitamin D status was significantly associated with any fs (table 3).']	N/A	N/A	[('UBERON_0002240', 'spinal cord', 22, 'cord'), ('UBERON_0000178', 'blood', 27, 'blood'), ('GO_0007567', 'parturition', 37, 'postnatal'), ('CHEBI_27300', 'vitamin D', 51, 'vitamin D')]
PMC3773449	8/2013	S131-PMC3773449	['maternal low protein diet, Vitamin A deficiency and maternal iron deficiency, Uterine Arteries ligation, maternal Gestational administration of Glucocorticoids, or other Drugs (Antibiotics) lead in most cases to iugr and to a reduced Nephron number by an average of 20%–50%.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 27, 'vitamin A'), ('UBERON_0001225', 'cortex of kidney', 78, 'uterine arteries'), ('GO_0007565', 'female pregnancy', 114, 'gestational'), ('CHEBI_36597', 'phthalazine', 144, 'glucocorticoids'), ('CHEBI_23888', 'drug', 170, 'drugs'), ('CHEBI_33282', 'antibacterial agent', 177, 'antibiotics'), ('UBERON_0001285', 'nephron', 234, 'nephron')]
PMC3798907	8/2013	S6-PMC3798907	['in conclusion, in vitro Vitamin E and C supplementation of cbmc modifies neonatal Immune function, but not in a manner predicted by observational epidemiological studies.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 24, 'vitamin E'), ('CHEBI_18245', 'carboxylato group', 38, 'C'), ('UBERON_0002405', 'immune system', 82, 'immune')]
PMC3798907	8/2013	S13-PMC3798907	['moreover for Vitamin E Th-Cells from younger subjects are more responsive to Vitamin E and naïve (Cd45Ra(+)) Th-Cells are more responsive to Vitamin E than Th Cells with a Memory/activated phenotype (Cd45Ro(+)) [4,8].']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 13, 'vitamin E'), ('CL_0000545', 'T-helper 1 cell', 23, 'Th-cells'), ('CHEBI_27300', 'vitamin D', 77, 'vitamin E'), ('PR_000005164', 'CD2 cytoplasmic tail-binding protein 2', 98, 'CD45RA'), ('CL_0000545', 'T-helper 1 cell', 109, 'Th-cells'), ('CHEBI_27300', 'vitamin D', 141, 'vitamin E'), ('CL_0000545', 'T-helper 1 cell', 156, 'Th cells'), ('GO_0007613', 'memory', 172, 'memory'), ('PR_000005170', 'CD37 molecule', 200, 'CD45RO')]
PMC3798907	8/2013	S24-PMC3798907	['for comparison, we included control cultures supplemented with a second antioxidant, Vitamin C, for which there is no evidence of any associations between maternal intake, maternal Blood levels, cbmc responses and childhood wheeze/asthma [9,10,11].']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 85, 'vitamin C'), ('UBERON_0000178', 'blood', 181, 'blood')]
PMC3798907	8/2013	S37-PMC3798907	['cell cultures were supplemented with either no antioxidant (controls), natural Α-Tocopherol (Vitamin E), or Ascorbic Acid (Vitamin C) (both sigma, gillingham, uk).']	N/A	N/A	[('CHEBI_27725', 'butin', 79, 'α-tocopherol'), ('CHEBI_27300', 'vitamin D', 93, 'vitamin E'), ('CHEBI_22652', 'ascorbic acid', 108, 'ascorbic acid'), ('CHEBI_27300', 'vitamin D', 123, 'vitamin C')]
PMC3798907	8/2013	S63-PMC3798907	['caption (fig): figure 1\n\nresponses of 70 Cord Blood Mononuclear Cell (Cbmc) samples to control stimuli and Allergens, with or without supplementation with Vitamin E. responses are expressed as stimulation index.']	N/A	N/A	[('CL_0000849', 'crypt olfactory receptor neuron', 41, 'cord blood mononuclear cell'), ('UBERON_0009472', 'axilla', 41, 'cord blood'), ('GO_0031097', 'medial cortex', 52, 'mononuclear'), ('CL_0002062', 'type I pneumocyte', 70, 'CBMC'), ('CHEBI_33663', 'cyclic hydrocarbon', 107, 'allergens'), ('CHEBI_27300', 'vitamin D', 155, 'vitamin E')]
PMC3798907	8/2013	S76-PMC3798907	['caption (fig): figure 2\n\nresponses of 18 pbmc samples to control stimuli and Allergens, with or without supplementation with Vitamin E. reponses are expressed as stimulation index.']	N/A	N/A	[('CHEBI_33663', 'cyclic hydrocarbon', 77, 'allergens'), ('CHEBI_27300', 'vitamin D', 125, 'vitamin E')]
PMC3798907	8/2013	S79-PMC3798907	['caption (fig): figure 3\n\nresponses of 51 cbmc samples to control stimuli and Allergens, with or without supplementation with Vitamin C. reponses are expressed as stimulation index.']	N/A	N/A	[('CHEBI_33663', 'cyclic hydrocarbon', 77, 'allergens'), ('CHEBI_27300', 'vitamin D', 125, 'vitamin C')]
PMC3798907	8/2013	S87-PMC3798907	['caption (fig): figure 4\n\nresponses of 18 pbmc samples to control stimuli and Allergens, with or without supplementation with Vitamin C. reponses are expressed as stimulation index.']	N/A	N/A	[('CHEBI_33663', 'cyclic hydrocarbon', 77, 'allergens'), ('CHEBI_27300', 'vitamin D', 125, 'vitamin C')]
PMC3809191	1/2013	S6-PMC3809191	['the mean Serum Vitamin D levels in gdm group were significantly lower than in non-gdm subjects (p=0.07).']	N/A	N/A	[('UBERON_0001977', 'blood serum', 9, 'serum'), ('CHEBI_27300', 'vitamin D', 15, 'vitamin D')]
PMC3809191	1/2013	S8-PMC3809191	['there was no significant association between Vitamin D levels and fasting Glucose, Insulin and hba1c.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 45, 'vitamin D'), ('CHEBI_17234', 'glucose', 74, 'glucose'), ('PR_000045358', 'insulin family protein', 83, 'insulin')]
PMC3827489	10/2013	S1-PMC3827489	['hypovitaminosis D (Vitamin D insufficiency or deficiency) is observed not only in Adults but also in infants, children, and adolescents.']	N/A	N/A	[('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 16, 'D'), ('CHEBI_27300', 'vitamin D', 19, 'vitamin D'), ('UBERON_0007023', 'adult organism', 82, 'adults')]
PMC3827489	10/2013	S9-PMC3827489	['ultraviolet b wavelengths in sunlight trigger Vitamin D synthesis in the skin by converting 7-Dehydrocholesterol to Cholecalciferol (Vitamin D3), which enters the circulation1).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 46, 'vitamin D'), ('CHEBI_17500', '7alpha-hydroxycholesterol', 92, '7-dehydrocholesterol'), ('CHEBI_52550', 'theopalauamide', 116, 'cholecalciferol'), ('CHEBI_33279', 'vitamin D5', 133, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 133, 'vitamin D3')]
PMC3827489	10/2013	S11-PMC3827489	['the major dietary sources of Vitamin D are oily fish, dairy products, eggs, and meat.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 29, 'vitamin D')]
PMC3827489	10/2013	S15-PMC3827489	['further, 1,25(Oh)2D acts by binding to the Nuclear Vitamin D receptor (vdr) within cells (fig.']	N/A	N/A	[('CHEBI_82784', 'PVP38-Ag NP', 9, '1,25(OH)2D'), ('GO_0005634', 'nucleus', 43, 'nuclear'), ('CHEBI_27300', 'vitamin D', 51, 'vitamin D')]
PMC3827489	10/2013	S26-PMC3827489	['epidemiology of Vitamin D status\n\n1.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 16, 'vitamin D')]
PMC3827489	10/2013	S38-PMC3827489	['predictors of Vitamin D insufficiency or deficiency\nthe main risk factors for Vitamin D insufficiency or deficiency in the pediatric population are season (winter), insufficient time spent outdoors, non-white ethnicity, older age, more advanced stage of puberty, obesity, low milk consumption, low socioeconomic status, and female gender19).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 14, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 78, 'vitamin D')]
PMC3829803	11/2013	S166-PMC3829803	['in mexican children receiving Vitamin A supplements, the incidence of norovirus diarrhea was reduced but Gut Viral titres and the period of Virus shedding in these children were both significantly increased [64].']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 30, 'vitamin A'), ('UBERON_0001555', 'digestive tract', 105, 'gut'), ('NCBITaxon_1', 'root', 109, 'viral'), ('NCBITaxon_1', 'root', 140, 'virus')]
PMC3829803	11/2013	S203-PMC3829803	['Retinol (Roh) is the form of Vitamin A found in the circulation at concentrations up to 2 μm [79].']	N/A	N/A	[('CHEBI_27810', 'resorcinol', 0, 'Retinol'), ('CHEBI_82003', 'R1128C', 9, 'ROH'), ('CHEBI_27300', 'vitamin D', 29, 'vitamin A')]
PMC3873449	12/2013	S6-PMC3873449	['the prevalence of Vitamin D deficiency (25(Oh)D < 50 nmol/l) was 96.8% and almost half (44.8%) of women were severely Vitamin D deficiency (25(Oh)D < 25 nmol/l).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 18, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 40, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 118, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 140, '25(OH)D')]
PMC3873449	12/2013	S52-PMC3873449	['the Vitamin supplements used were most commonly Pregnancy-specific multivitamins, containing relatively low doses of Vitamin D (between 5 and 12·5 μg/d).']	N/A	N/A	[('CHEBI_33229', 'vitamin (role)', 4, 'vitamin'), ('GO_0007565', 'female pregnancy', 48, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 117, 'vitamin D')]
PMC3873449	12/2013	S90-PMC3873449	['Serum 25(Oh)D levels and prevalence of Vitamin D deficiency or insufficiency in Pregnant women\nthe mean Serum 25(Oh)D concentration of women (n 125) was 28.4 ± 9.5; (range 15.1 - 57.1) nmol/l.']	N/A	N/A	[('UBERON_0001977', 'blood serum', 0, 'Serum'), ('CHEBI_71657', 'versiconol acetate', 6, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 39, 'vitamin D'), ('GO_0007565', 'female pregnancy', 80, 'pregnant'), ('UBERON_0001977', 'blood serum', 104, 'serum'), ('CHEBI_71657', 'versiconol acetate', 110, '25(OH)D')]
PMC3873449	12/2013	S91-PMC3873449	['the percentage of Vitamin D deficiency or insufficiency is shown intable 1.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 18, 'vitamin D')]
PMC3873449	12/2013	S95-PMC3873449	['age, Gestational age, weight, height, pre-Pregnant bmi, income, duration of walking and duration of computer usage were not different between the two groups.10.1371/journal.pone.0085081.t002\n\ncaption (table-wrap): table 2\nmaternal characteristics of all subjects by Vitamin D group.descriptivewomen with 25(Oh)D<25 nmol/lwomen with 25(Oh)D≥25 nmol/lpnumber (n, %)56 (44.8)69 (55.2)___age (years, sd)28.1 (2.67)28.7 (3.02)p = 0.206gestational age (weeks, sd)17.0 (1.26)16.8 (1.11)p = 0.239height (cm, sd)161.9 (3.26)161.2 (4.03)p = 0.326weight (kg, sd)58.3 (8.37)57.6 (7.62)p = 0.616pre-Pregnant weight (kg, sd)53.4 (6.81)52.9 (6.65)p = 0.648pre-Pregnant bmi (kg/m2, sd)20.4 (2.49)20.3 (2.34)p = 0.902assoc.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 5, 'gestational'), ('GO_0007565', 'female pregnancy', 42, 'pregnant'), ('CHEBI_27300', 'vitamin D', 266, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 304, '25(OH)D'), ('CHEBI_71657', 'versiconol acetate', 332, '25(OH)D'), ('GO_0007565', 'female pregnancy', 586, 'pregnant'), ('GO_0007565', 'female pregnancy', 645, 'pregnant')]
PMC3873449	12/2013	S97-PMC3873449	['the percentage of severe Vitamin D deficiency was much higher in women with shorter duration of sun exposure (≤ 0.5 h/day; 58.3%) than that of women with longer duration of sun exposure (> 0.5 h/day; 36.4%).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 25, 'vitamin D')]
PMC3873449	12/2013	S105-PMC3873449	['the amount of Vitamin D contained in multivitamin supplements consumed ranged from 5 to 12.5 μg.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 14, 'vitamin D')]
PMC3873449	12/2013	S106-PMC3873449	['amongst Supplement users, 13/58 (22.4%) were severely Vitamin D deficient vs. 43/67(64.2%) of non-users ( p< 0·001).']	N/A	N/A	[('CHEBI_16158', 'steroid sulfate', 8, 'supplement'), ('CHEBI_27300', 'vitamin D', 54, 'vitamin D')]
PMC3873449	12/2013	S110-PMC3873449	['the percentage of severe Vitamin D deficiency was much lower in better educated women (38/97, 39.2 %) than that in less educated women (18/28, 64.3%).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 25, 'vitamin D')]
PMC3873449	12/2013	S116-PMC3873449	['over 90% of women had Vitamin D deficiency (< 50nmol/l) and none of them reached normal 25(Oh)D concentrations (≥ 75 nmol/l).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 22, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 88, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 88, '25(OH)D')]
PMC3873449	12/2013	S121-PMC3873449	['of all subjects, 8% of western People and most non-western subjects (59%-84%) had Vitamin D deficiency [21].']	N/A	N/A	[('NCBITaxon_10088', 'Mus <genus>', 31, 'people'), ('CHEBI_27300', 'vitamin D', 82, 'vitamin D')]
PMC3873449	12/2013	S126-PMC3873449	['the major source of Vitamin D for Humans is exposure of the skin to sunlight [17].']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 20, 'vitamin D'), ('NCBITaxon_9606', 'Homo sapiens', 34, 'humans')]
PMC3873449	12/2013	S129-PMC3873449	['women with duration of sun exposure less than 0.5 h/day had higher rates of severe Vitamin D deficiency.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 83, 'vitamin D')]
PMC3873449	12/2013	S175-PMC3873449	['in canada, the adequate intake for Vitamin D in Pregnancy is 5 μg/d [38], while in the uk the reference Nutrient intake is set at 10 μg/day [39].']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 35, 'vitamin D'), ('GO_0007565', 'female pregnancy', 48, 'pregnancy'), ('CHEBI_33284', 'nutrient', 104, 'nutrient')]
PMC3873449	12/2013	S185-PMC3873449	['there is no regular Vitamin D supplementation in china at this time.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 20, 'vitamin D')]
PMC3873449	12/2013	S190-PMC3873449	['in the present study, no women intended to use Vitamin D and only 46.4% of women reported taking Pregnancy-specific Multivitamin Supplements.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 47, 'vitamin D'), ('GO_0007565', 'female pregnancy', 97, 'pregnancy'), ('CHEBI_7025', 'mupirocin', 116, 'multivitamin'), ('CHEBI_33341', 'titanium atom', 129, 'supplements')]
PMC3873449	12/2013	S193-PMC3873449	['better educated women had higher Serum 25(Oh)D concentrations and lower rates of severe Vitamin D deficiency.']	N/A	N/A	[('UBERON_0001977', 'blood serum', 33, 'serum'), ('CHEBI_71657', 'versiconol acetate', 39, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 45, 'D'), ('CHEBI_27300', 'vitamin D', 88, 'vitamin D')]
PMC3882256	1/2014	S67-PMC3882256	['a binary variable for dietary Vitamin C intake was created using the uk reference Nutrient intake cut-off of 50 mg/day and used to test for interaction[39].']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 30, 'vitamin C'), ('CHEBI_33284', 'nutrient', 82, 'Nutrient')]
PMC3882256	1/2014	S90-PMC3882256	['95% confidence intervals.10.1371/journal.pone.0084684.t002\n\ncaption (table-wrap): table 2\nsample characteristics by dietary iron intake as assessed by Food frequency questionnaire at 32 weeks Gestation (n\u200a=\u200a2958 for all, except where Cord ferritin data is used: n\u200a=\u200a795).dietary iron intake≥14.8 mg/day#(n\u200a=\u200a319)<14.8 mg/day (n\u200a=\u200a2,639)p value* dietary iron intake ## (mg/day) (m, sd ** ) 16.9 (1.9 )10.1 (2.5)– dietary Vitamin C intake ## (mg/day) (m, sd) 119.3 (35.6)81.8 (32.1)<0.001 age of mother (yrs) (m, sd) 30.0 (4.2)29.5 (4.2)0.02 pre-Pregnancy bmi (kg/m2) (m, sd) 21.7 (2.5)22.9 (3.6)<0.001 total energy Intake (kj) (m, sd) 10,100 (1,921)7,167 (1,645)<0.001 smoking in Pregnancy (%, 95% ci *** ) 10.7 (7.5, 14.6)15.0 (14.6, 14.4)0.001 caucasian (%, 95% ci) 98.1 (96.0, 99.3)99.0 (98.4, 99.3)0.2 university degree (%, 95% ci) 27.0 (22.2, 32.2)17.6 (16.2, 19.1)<0.001 vegetarian (%, 95% ci) 11.9 (8.3, 16.6)5.5 (4.6, 6.4)<0.001 primigravida (%, 95% ci) 48.0 (42.4, 53.6)51.0 (47.0, 50.9)0.8 early Pregnancy maternal anemia (<11 g/dl) (%, 95% ci) 6.6 (4.1, 9.9)4.1 (3.4, 4.9)0.04 report taking Iron supplements before 32 wks Gestation (%, 95% ci) 48.3 (42.7, 53.9)44.5 (42.6, 46.4)0.2 Cord Ferritin (µg/l) (m,sd) 151.9 (104.8) (n\u200a=\u200a−83)165.4 (123.6) (n\u200a=\u200a712)0.3 child systolic Blood pressure (mmhg) (m, sd) 103.9 (8.7)103.6 (8.8)0.5 child diastolic Blood pressure (mmhg) (m, sd) 60.3 (7.3)59.5 (7.8)0.08 child pulse wave velocity (m/s) (m, sd) 7.7 (1.3)7.5 (1.2)0.1 child flow mediated dilatation (%) (m, sd) 8.3 (3.5)8.0 (3.4)0.1 child body mass index (kg/m2) (m, sd) 17.9 (2.7)18.1 (3.0)0.2 child gender (male) (%, 95% ci) 55.2 (49.5, 60.7)50.3 (48.3, 52.2)0.1 Birthweight (g) (m, sd) 3,439 (486)3,450 (500)0.7 Gestational age (wks) (m, sd) 39.5 (1.6)39.6 (1.6)0.3\n#reference Nutrient intake (rni) for iron for women aged 19–50 years in the uk.']	N/A	N/A	[('CHEBI_33290', 'food', 151, 'food'), ('GO_0007565', 'female pregnancy', 192, 'gestation'), ('UBERON_0002240', 'spinal cord', 234, 'cord'), ('CHEBI_27300', 'vitamin D', 420, 'vitamin C'), ('PR_000004900', 'complement C3', 428, 'C'), ('GO_0007565', 'female pregnancy', 544, 'pregnancy'), ('GO_0007631', 'feeding behavior', 614, 'intake'), ('GO_0007565', 'female pregnancy', 679, 'pregnancy'), ('GO_0007565', 'female pregnancy', 1005, 'pregnancy'), ('CHEBI_24870', 'ion', 1101, 'iron'), ('GO_0007565', 'female pregnancy', 1132, 'gestation'), ('UBERON_0000948', 'heart', 1192, 'Cord'), ('CHEBI_5018', 'ferreirin', 1197, 'ferritin'), ('UBERON_0000178', 'blood', 1285, 'blood'), ('UBERON_0000178', 'blood', 1357, 'blood'), ('GO_0007608', 'sensory perception of smell', 1671, 'Birthweight'), ('GO_0007565', 'female pregnancy', 1721, 'Gestational'), ('CHEBI_33284', 'nutrient', 1786, 'nutrient')]
PMC3888066	12/2012	S13-PMC3888066	['the frequency of defects was concentrated among babies Born to women who had Consumed high levels of Vitamin A before the seventh week of Gestation.']	N/A	N/A	[('GO_0007567', 'parturition', 55, 'born'), ('GO_0007631', 'feeding behavior', 77, 'consumed'), ('CHEBI_27300', 'vitamin D', 101, 'vitamin A'), ('GO_0007565', 'female pregnancy', 138, 'gestation')]
PMC3888066	12/2012	S38-PMC3888066	['fortified foods\nmany cereals, dairy products, and soups are fortified with Vitamin A.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 75, 'vitamin A')]
PMC3888066	12/2012	S40-PMC3888066	['non-fortified foods\nLiver is the Food source with the highest quantity of Vitamin A by weight.']	N/A	N/A	[('UBERON_0002107', 'liver', 20, 'Liver'), ('CHEBI_33290', 'food', 33, 'food'), ('CHEBI_27300', 'vitamin D', 74, 'vitamin A')]
PMC3901983	1/2013	S96-PMC3901983	['furthermore, Vitamin A deficiency also impairs iron status, increases susceptibility to Respiratory infections and diarrhea, and increases morbidity and mortality.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 13, 'vitamin A'), ('UBERON_0001004', 'respiratory system', 88, 'respiratory')]
PMC3901983	1/2013	S101-PMC3901983	['an additional benefit of Vitamin A supplementation in Pregnant women is increasing hemoglobin concentrations [20].']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 25, 'vitamin A'), ('GO_0007565', 'female pregnancy', 54, 'pregnant')]
PMC3925765	9/2013	S167-PMC3925765	['under normal circumstances ros/rns are continually produced by pro-oxidant mechanisms(39,42) balanced by removal by antioxidant defenses - Superoxide dismutase, catalase and gpx, and scavenger Molecules - Vitamins E and C and melatonin(39).']	N/A	N/A	[('CHEBI_18421', 'superoxide', 139, 'superoxide'), ('CHEBI_36357', 'polyatomic entity', 193, 'molecules'), ('CHEBI_27300', 'vitamin D', 205, 'vitamins E'), ('CHEBI_18245', 'carboxylato group', 220, 'C'), ('PR_000004900', 'complement C3', 220, 'C')]
PMC3926113	1/2014	S8-PMC3926113	['the foetal Brain is susceptible to oxidative stress imposed by Vitamin C deficiency.']	N/A	N/A	[('UBERON_0000955', 'brain', 11, 'brain'), ('CHEBI_27300', 'vitamin D', 63, 'vitamin C'), ('PR_000004900', 'complement C3', 71, 'C')]
PMC3926113	1/2014	S25-PMC3926113	['due to its one Electron reduction potential, vitc effectively inhibits Lipid peroxidation and scavenges several reactive oxidizing Compounds such as Superoxide, Hydrogen Peroxide and Hydroxyl Radicals as well as enabling the recycling of other antioxidant Compounds such as Vitamin E[7,20,30,49].']	N/A	N/A	[('CHEBI_10545', 'electron', 15, 'electron'), ('CHEBI_18059', 'lipid', 71, 'lipid'), ('CHEBI_36357', 'polyatomic entity', 131, 'compounds'), ('CHEBI_18421', 'superoxide', 149, 'superoxide'), ('CHEBI_16240', 'hydrogen peroxide', 161, 'hydrogen peroxide'), ('CHEBI_24680', 'hydroxybiphenyl', 183, 'hydroxyl radicals'), ('CHEBI_36357', 'polyatomic entity', 256, 'compounds'), ('CHEBI_27300', 'vitamin D', 274, 'vitamin E')]
PMC3930526	2/2014	S101-PMC3930526	['they are Vitamin A (800 µg), Vitamin E (10 mg), Vitamin D (5 µg), vitamin b1 (1.4 mg), Vitamin B2 (1.4 mg), niacin (18 mg), Vitamin B6 (1.9 mg), Vitamin B12 (2.6 µg), Folic Acid (400 µg), Vitamin C (70 mg), iron (30 mg), zinc (15 mg), copper (2 mg), Selenium (65 µg), and Iodine (150 µg);\nthere were six intervention groups including unimmap, fe60f, fe30f plus early or usual Food invitation.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 9, 'vitamin A'), ('CHEBI_27300', 'vitamin D', 29, 'vitamin E'), ('CHEBI_27300', 'vitamin D', 48, 'vitamin D'), ('CHEBI_33279', 'vitamin D5', 87, 'vitamin B2'), ('CHEBI_33237', 'vitamin D4', 124, 'vitamin B6'), ('CHEBI_33279', 'vitamin D5', 145, 'vitamin B12'), ('PR_000004738', 'class E basic helix-loop-helix protein 22', 153, 'B12'), ('CHEBI_30751', 'formic acid', 167, 'folic acid'), ('CHEBI_27300', 'vitamin D', 188, 'vitamin C'), ('CHEBI_27568', 'selenium atom', 250, 'selenium'), ('CHEBI_24859', 'iodine atom', 272, 'iodine'), ('CHEBI_33290', 'food', 376, 'food')]
PMC3933411	12/2013	S106-PMC3933411	['the most popular Vitamin and Mineral supplements contain iron, Folic Acid and Vitamin D [12,28].']	N/A	N/A	[('CHEBI_33229', 'vitamin (role)', 17, 'vitamin'), ('CHEBI_46662', 'mineral', 29, 'mineral'), ('CHEBI_30751', 'formic acid', 63, 'folic acid'), ('CHEBI_27300', 'vitamin D', 78, 'vitamin D')]
PMC3970319	5/2013	S24-PMC3970319	['in this latter trial, there was also no impact of maternal iron, zinc, and Folate supplementation on offspring Blood Pressure compared with Vitamin A supplementation (11).']	N/A	N/A	[('CHEBI_30863', '5-azaorotic acid', 75, 'folate'), ('UBERON_0013756', 'venous blood', 111, 'blood pressure'), ('CHEBI_27300', 'vitamin D', 140, 'vitamin A')]
PMC3973641	4/2014	S173-PMC3973641	['this Vitamin B and Choline deficient diet creates a significant Methyl Group deficit in the fetus.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 5, 'vitamin B'), ('CHEBI_15354', 'choline', 19, 'choline'), ('CHEBI_32875', 'methyl group', 64, 'methyl group')]
PMC3991049	11/2013	S6-PMC3991049	['weekly oral Vitamin D (50,000 iu) were prescribed after an initial testing for Serum level of 25-Hydroxyvitamin D, Parathyroid hormone, calcium, Phosphorus, total protein and Albumin.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 12, 'vitamin D'), ('UBERON_0001977', 'blood serum', 79, 'serum'), ('CHEBI_62218', '23,24-dihydrocucurbitacin D', 94, '25-hydroxyvitamin D'), ('UBERON_0001132', 'parathyroid gland', 115, 'parathyroid'), ('CHEBI_35885', 'secondary phosphine', 145, 'phosphorus'), ('PR_000005908', 'alpha-crystallin B chain', 175, 'albumin')]
PMC3991049	11/2013	S9-PMC3991049	['Umbilical Cords Vitamin D levels were determined at Birth.']	N/A	N/A	[('UBERON_0002331', 'umbilical cord', 0, 'Umbilical cords'), ('CHEBI_27300', 'vitamin D', 16, 'vitamin D'), ('GO_0007567', 'parturition', 52, 'birth')]
PMC3991049	11/2013	S12-PMC3991049	['the mean level of Vitamin D level in the first trimester and prior to starting Vitamin D supplementation was 17.15\xa0ng/ml, 29.08\xa0ng/ml in the second trimester, 27.3\xa0ng/ml in third trimester and 22.36\xa0ng/ml in newborns.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 18, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 79, 'vitamin D')]
PMC3991049	11/2013	S13-PMC3991049	['there were no toxic levels of Vitamin D in any of the women at the second or third trimesters or in the newborns.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 30, 'vitamin D')]
PMC3991049	11/2013	S14-PMC3991049	['the mean levels of Vitamin D in the second and third Trimester were not significantly different in those women who were taking multivitamin supplementation and those who were not.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 19, 'vitamin D'), ('GO_0009294', 'DNA mediated transformation', 53, 'trimester')]
PMC3991049	11/2013	S44-PMC3991049	['there was no difference in the Vitamin D levels between the qatari and the residents living in qatar.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 31, 'vitamin D')]
PMC3991049	11/2013	S48-PMC3991049	['a Vitamin D level of less than 10\xa0ng/ml was considered as deficiency and levels of more than 30\xa0ng/ml were considered as insufficiency.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 2, 'vitamin D')]
PMC3991049	11/2013	S49-PMC3991049	['sixty-six patients (66/97) were found to have Vitamin D levels of less than 20\xa0ng/ml (58%), thirty one (31/97) 31.9% had levels less than 10\xa0ng/ml.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 46, 'vitamin D')]
PMC3991049	11/2013	S50-PMC3991049	['during the first trimester, the lowest mean level of Vitamin D was 3\xa0ng/ml and the highest level was 48\xa0ng/ml with a mean level of Vitamin D level of 17.15\xa0ng/ml.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 53, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 131, 'vitamin D')]
PMC3991049	11/2013	S52-PMC3991049	['at the second trimester, the lowest Vitamin D level was 5\xa0ng/ml and highest was 70\xa0ng/ml with a mean level of 29.08\xa0ng/ml.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 36, 'vitamin D')]
PMC3991049	11/2013	S54-PMC3991049	['the range of Vitamin D level in 61 Umbilical Cord Blood samples of the newborns was 3 and 59\xa0ng/ml with a mean level of 22.36\xa0ng/ml (table 1).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 13, 'vitamin D'), ('UBERON_0002331', 'umbilical cord', 35, 'umbilical cord'), ('UBERON_0000178', 'blood', 50, 'blood')]
PMC3991049	11/2013	S57-PMC3991049	['her Vitamin D level in the first trimester was 3\xa0ng/ml and pth was 191\xa0ng/ml, Vitamin D level was 5\xa0ng/ml and pth level was 152\xa0ng/ml in the second trimester and in third trimester Vitamin D was 4\xa0ng/ml with a pth level of 290\xa0ng/ml, with normal level of calcium and alkaline phosphatase.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 4, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 78, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 181, 'vitamin D')]
PMC3991049	11/2013	S59-PMC3991049	["both groups had no significant differences in the level of Vitamin D in the second and third trimester and in the newborns' Vitamin D levels."]	N/A	N/A	[('CHEBI_27300', 'vitamin D', 59, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 124, 'vitamin D')]
PMC3991049	11/2013	S64-PMC3991049	['in african-american women, Vitamin D deficiency occurred in 29.2% and insufficiency in 54.1%, compared with 5% and 42.1% of caucasian Pregnant women.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 27, 'vitamin D'), ('GO_0007565', 'female pregnancy', 134, 'pregnant')]
PMC3991049	11/2013	S73-PMC3991049	['the highest dose of Vitamin D studied during Pregnancy was given to 15 hypoparathyroid women who received 100,000 iu/day in order to maintain Serum calcium.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 20, 'vitamin D'), ('GO_0007565', 'female pregnancy', 45, 'pregnancy'), ('UBERON_0001977', 'blood serum', 142, 'serum')]
PMC3991049	11/2013	S75-PMC3991049	['routine supplementation of Pregnant mothers with 50,000 iu Vitamin D per week resulted in improvement of Vitamin D levels.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 27, 'pregnant'), ('CHEBI_27300', 'vitamin D', 59, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 105, 'vitamin D')]
PMC3991049	11/2013	S77-PMC3991049	['at the present time Vitamin D supplementation is not part of Antenatal Care program in qatar.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 20, 'vitamin D'), ('GO_0007608', 'sensory perception of smell', 61, 'antenatal care')]
PMC3994635	8/2010	S125-PMC3994635	['significant group differences were observed at 13 wk Postpartum in Urinary Mineral outputs and Plasma concentrations of Vitamin D Metabolites, other calciotropic hormones, and bone turnover markers.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 53, 'postpartum'), ('UBERON_0001088', 'urine', 67, 'urinary'), ('CHEBI_46662', 'mineral', 75, 'mineral'), ('UBERON_0001969', 'blood plasma', 95, 'plasma'), ('CHEBI_27300', 'vitamin D', 120, 'vitamin D'), ('CHEBI_25212', 'metabolite', 130, 'metabolites')]
PMC4045304	2/2014	S194-PMC4045304	['active Vitamin D (1, 25-Dihydroxy Vitamin D), like other hormones, acts as a molecular switch, activating many target Genes via the Vitamin D receptor (vdr).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 7, 'vitamin D'), ('CHEBI_50341', '1-hydroxyethyl group', 18, '1, 25-dihydroxy'), ('CHEBI_27300', 'vitamin D', 34, 'vitamin D'), ('SO_0000704', 'gene', 118, 'genes'), ('CHEBI_27300', 'vitamin D', 132, 'vitamin D')]
PMC4045304	2/2014	S222-PMC4045304	['in a randomized controlled trial in Humans, 800 iu of Vitamin D increased the levels of Bax, which helps to stop mutations by promoting Apoptosis [98].']	N/A	N/A	[('NCBITaxon_9606', 'Homo sapiens', 36, 'humans'), ('CHEBI_27300', 'vitamin D', 54, 'vitamin D'), ('PR_000002193', 'apoptosis regulator BAX', 88, 'Bax'), ('GO_0006915', 'apoptotic process', 136, 'apoptosis')]
PMC4045304	2/2014	S242-PMC4045304	['in a study of nonautistic children with 25-Hydroxy D levels below 10\u2009ng/ml (poor Vitamin D status), Insulin resistance was 7 times higher than that in children with Vitamin D levels above 30\u2009ng/ml [103].']	N/A	N/A	[('CHEBI_52306', "2',7'-difluorofluorescein", 40, '25-hydroxy D'), ('CHEBI_27300', 'vitamin D', 81, 'vitamin D'), ('PR_000045358', 'insulin family protein', 100, 'insulin'), ('CHEBI_27300', 'vitamin D', 165, 'vitamin D')]
PMC4072587	6/2014	S7-PMC4072587	['infants Born to women with 25-Ohd deficiency (<37.5 nmol/l) had reduced developmental Language scores compared to those Born to women who were Vitamin D replete (≥75 nmol/l) (mean difference (md) −3.48, 95% confidence interval (ci) −5.67 to −1.28).']	N/A	N/A	[('GO_0007567', 'parturition', 8, 'born'), ('CHEBI_72765', 'verruculogen', 27, '25-OHD'), ('GO_0006266', 'DNA ligation', 86, 'language'), ('GO_0007567', 'parturition', 120, 'born'), ('CHEBI_27300', 'vitamin D', 143, 'vitamin D')]
PMC4072587	6/2014	S28-PMC4072587	['our main exposure of interest was maternal Vitamin D concentration at 32 weeks Gestation.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 43, 'vitamin D'), ('GO_0007565', 'female pregnancy', 79, 'gestation')]
PMC4072587	6/2014	S64-PMC4072587	['Serum samples were frozen at −20°c and transported to the alfred hospital, melbourne, and analysis for Vitamin D was performed on those with a sufficient volume of Blood.']	N/A	N/A	[('UBERON_0001977', 'blood serum', 0, 'Serum'), ('CHEBI_27300', 'vitamin D', 103, 'vitamin D'), ('UBERON_0000178', 'blood', 164, 'blood')]
PMC4072587	6/2014	S88-PMC4072587	['sixty percent (582/960) of women had Vitamin D concentrations less than 75 nmol/l in late Pregnancy.figure 2shows the distribution of Vitamin D concentration among Pregnant women at 32 weeks Gestation.10.1371/journal.pone.0099005.g002\n\ncaption (fig): figure 2\nmaternal 25(oh)-Vitamin D concentration (nmol/l) at 32 weeks Gestation.10.1371/journal.pone.0099005.t001\n\ncaption (table-wrap): table 1\nscreening, eligibility and enrolment, of trial participants.screened from commune lists2161 not Pregnant13Miscarried before enrollment42complicated Pregnancy/sickness12over eligible Gestational age (>16 weeks)628absent at enrollment time51migrated from province after screening31 eligible population1384 excluded at enrolmentwork commitments, could not commit to trial protocol90refused36 enrolled1258 10.1371/journal.pone.0099005.t002\n\ncaption (table-wrap): table 2\ndistribution of baseline maternal sociodemographic, anthropometric characteristics, and maternal Serum 25-Ohd concentration (nmol/l) at 32 weeks Gestation.maternal characteristicnumber (%)mean maternal Serum 25-Ohd concentration nmol/l [sd]overall960 (100)70.5 [22.2]maternal age at enrolment (years)<2037 (3.9)70.2 [21.4]20–24298 (31)72.3 [21.9]25–29400 (41.7)69.1 [21.5]30–34152 (15.8)69.5 [21.0]≥3573 (7.6)72.6 [29.4]maternal height≥145 cm930 (97.0)70.3 [22.2]<145 cm (short maternal stature)29 (3.0)75.8 [24.4]maternal body mass indexunderweight (<18.5 kg/m2)251 (26.2)70.7 [22.4]normal (18.5–25 kg/m2)655 (68.3)69.8 [21.4]overweight (>25 kg/m2)53 (5.5)77.4 [29.7]educational levelprimary school146 (15.2)73.0 [23.5]secondary school643 (67.0)70.9 [22.3]university/college171 (17.8)66.4 [20.2]occupationfarmer/housewife509 (53.0)74.1 [22.6]factory worker/trader324 (33.8)66.6 [22.1]government official/clerk127 (13.2)65.9 [18.4]gravidityprimigravida296 (30.8)67.7 [21.3]multigravida664 (69.2)71.7 [22.5]type of Supplement taken during Pregnancydaily ifa supplements327 (34.1)67.8 [21.5]twice weekly ifa supplements340 (35.4)68.0 [21.5]mmn supplements293 (30.5)76.3[23.8]\nifa\u200a=\u200airon Folic Acid, mmn\u200a=\u200amultiple Micronutrients, sd\u200a=\u200astandard deviation.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 37, 'vitamin D'), ('GO_0007565', 'female pregnancy', 90, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 134, 'vitamin D'), ('GO_0007565', 'female pregnancy', 164, 'pregnant'), ('GO_0007565', 'female pregnancy', 191, 'gestation'), ('CHEBI_28384', 'vitamin K', 276, 'Vitamin D'), ('GO_0007565', 'female pregnancy', 321, 'gestation'), ('GO_0016042', 'lipid catabolic process', 492, 'pregnant13Miscarried'), ('GO_0007565', 'female pregnancy', 544, 'pregnancy'), ('GO_0007565', 'female pregnancy', 578, 'gestational'), ('UBERON_0001977', 'blood serum', 960, 'serum'), ('CHEBI_72765', 'verruculogen', 966, '25-OHD'), ('GO_0007565', 'female pregnancy', 1008, 'gestation'), ('UBERON_0001977', 'blood serum', 1065, 'serum'), ('CHEBI_72765', 'verruculogen', 1071, '25-OHD'), ('CHEBI_16158', 'steroid sulfate', 1877, 'supplement'), ('GO_0007608', 'sensory perception of smell', 1901, 'pregnancyDaily'), ('CHEBI_30751', 'formic acid', 2048, 'folic acid'), ('CHEBI_33839', 'macromolecule', 2075, 'micronutrients')]
PMC4072587	6/2014	S92-PMC4072587	['(%)mean difference1,3or odds ratio2,3(95% ci)p valuemean difference1,4or odds ratio2,4(95% ci)p valuemean difference1,5or odds ratio2,5(95% ci)p valuebirth weight (g)3168.6 [392.3]−11.9 (−40.0 to 16.3)0.41−21.01(−51.2 to 9.3)0.17−18.9 (−49.0 to 11.3)0.22birth length (cm)49.1 [2.61]−0.05 (−0.34 to 0.24)0.73−0.081(−0.44 to 0.27)0.64−0.07 (−0.43 to 0.29)0.70head circumference (cm)32.7 [2.12]−0.27 (−0.49 to −0.03) 0.03 −0.381(−0.64 to −0.12) 0.01 −0.35 (−0.62 to −0.09) 0.01 low Birth weight (<2500 g)27 (2.8%)1.03 (0.67 to 1.59)0.891.112(0.77 to 1.61)0.571.15 (0.74 to 1.80)0.54gestational age (weeks)39.2 [1.87]0.07 (−0.06 to 0.20)0.310.08 (−0.09 to 0.25)0.380.07 (−0.10 to 0.24)0.42preterm Delivery (<37 weeks)103 (10.7%)0.78 (0.61 to 1.00)0.0540.602(0.57 to 1.05)0.090.77 (0.57 to 1.05)0.09small for Gestational age50 (5.3)1.24 (0.91 to 1.68)0.171.33 (0.94 to 1.87)0.111.37 (0.98 to 1.91)0.07\nvalues are estimated mean difference for each outcome associated with a 25 nmol/l increase in Vitamin D concentration (95% confidence interval).']	N/A	N/A	[('GO_0007567', 'parturition', 479, 'birth'), ('GO_0007567', 'parturition', 693, 'delivery'), ('GO_0007565', 'female pregnancy', 804, 'gestational'), ('CHEBI_27300', 'vitamin D', 991, 'vitamin D')]
PMC4072587	6/2014	S93-PMC4072587	['values are relative changes in the odds for each outcome associated with a 25 nmol/l increase in Vitamin D concentration (95% confidence interval).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 97, 'vitamin D')]
PMC4072587	6/2014	S96-PMC4072587	['model adjusted for maternal age, education, month of sampling of maternal Vitamin D, Micronutrient intervention, maternal body mass index, gravidity, and clustering at commune level.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 74, 'vitamin D'), ('CHEBI_33962', 'mu4-sulfido-quadro-tetracopper(6+)', 85, 'micronutrient')]
PMC4072587	6/2014	S98-PMC4072587	['maternal Vitamin D concentration and infant development at 6 months of age\nno association between overall maternal Vitamin D concentration and developmental composite scores was observed (table 4).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 9, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 115, 'vitamin D')]
PMC4072587	6/2014	S103-PMC4072587	['model adjusted for maternal age, education, month of sampling of maternal Vitamin D, Micronutrient.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 74, 'vitamin D'), ('CHEBI_33962', 'mu4-sulfido-quadro-tetracopper(6+)', 85, 'micronutrient')]
PMC4072587	6/2014	S107-PMC4072587	['model adjusted for maternal age, education, month of sampling of maternal Vitamin D, Micronutrient intervention, maternal body mass index, gravidity, maternal depression and clustering.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 74, 'vitamin D'), ('CHEBI_33962', 'mu4-sulfido-quadro-tetracopper(6+)', 85, 'micronutrient')]
PMC4072587	6/2014	S109-PMC4072587	['values are relative changes in the odds for each outcome associated with a 25 nmol/l increase in Vitamin D concentration (95% confidence interval).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 97, 'vitamin D')]
PMC4072587	6/2014	S111-PMC4072587	['model adjusted for maternal age, education, month of sampling of maternal Vitamin D, Micronutrient intervention, maternal body mass index, gravidity, and clustering.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 74, 'vitamin D'), ('CHEBI_33962', 'mu4-sulfido-quadro-tetracopper(6+)', 85, 'micronutrient')]
PMC4072587	6/2014	S117-PMC4072587	['in this study, Vitamin D concentration was measured early, at 18 weeks Gestation, and receptive language was assessed using the peabody picture vocabulary test.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 15, 'vitamin D'), ('GO_0007565', 'female pregnancy', 71, 'gestation')]
PMC4072587	6/2014	S118-PMC4072587	['gale et al., measured maternal Vitamin D concentration during the third trimester and assessed infants using the weschler abbreviated scale of Intelligence (n\u200a=\u200a178), and found no association between maternal Vitamin D levels and full scale, verbal or performance iq at 9 years of age[38].']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 31, 'vitamin D'), ('GO_0036155', 'acylglycerol acyl-chain remodeling', 143, 'Intelligence'), ('CHEBI_27300', 'vitamin D', 209, 'vitamin D')]
PMC4074693	3/2014	S58-PMC4074693	['the most commonly used was Vitamin C.\n\ncaption (table-wrap): table 2\n\nfactors associated with dietary Supplement use\namongst the students who are dietary Supplement users in the past 12 months, most of them (63%) were occasional or once in a while users.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 27, 'vitamin C'), ('CHEBI_16158', 'steroid sulfate', 102, 'supplement'), ('CHEBI_16158', 'steroid sulfate', 154, 'supplement')]
PMC4113768	7/2014	S3-PMC4113768	['thirty international experts in the field of clinical Vitamin D research presented talks organised into a programme spanning the Human Life Course.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 54, 'vitamin D'), ('NCBITaxon_9606', 'Homo sapiens', 129, 'human'), ('UBERON_0001281', 'hepatic sinusoid', 135, 'life course')]
PMC4113768	7/2014	S8-PMC4113768	['the anticipation of results from very large ( n> 5000) randomised controlled trials of Vitamin D supplementation (“mega-trials”) and individual patient data (ipd) meta-analyses were hot topics of discussion.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 87, 'vitamin D')]
PMC4113768	7/2014	S22-PMC4113768	['results: median (25th–75th percentiles) Vitamin D status was 64(52–72) nmol/l.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 40, 'vitamin D')]
PMC4113768	7/2014	S130-PMC4113768	['in asians there was no significant correlation between Vitamin D status and any Tibial bone parameter ( p> 0.05).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 55, 'vitamin D'), ('UBERON_0002101', 'limb', 80, 'tibial')]
PMC4113768	7/2014	S154-PMC4113768	['participants completed a sleep questionnaire (the pittsburgh sleep quality index; psqi n = 27 c; n = 13 a), and gave fasted Blood samples for hplc measurement of 25-Hydroxy Vitamin D (25(Oh)D) ( n = 27 c; n = 14 a).']	N/A	N/A	[('UBERON_0000178', 'blood', 124, 'blood'), ('CHEBI_43141', '3-hydroxypropoxy group', 162, '25-hydroxy'), ('CHEBI_27300', 'vitamin D', 173, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 184, '25(OH)D')]
PMC4113768	7/2014	S171-PMC4113768	['method: using terms for Vitamin D and Colorectal cancer, the medline, embase and web of science databases were systematically searched for studies published, in any language, until march 2013.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 24, 'vitamin D'), ('UBERON_0012652', 'colorectum', 38, 'colorectal')]
PMC4113768	7/2014	S172-PMC4113768	['random effects meta-analyses were used to calculate pooled hazard ratios (hr) and 95% confidence intervals (ci) for the association between Vitamin D measures and Colorectal cancer-specific survival and overall survival.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 140, 'vitamin D'), ('UBERON_0012652', 'colorectum', 163, 'colorectal')]
PMC4113768	7/2014	S177-PMC4113768	['no significant associations were observed between total Vitamin D intake and disease-free survival ( n = 1 prospective study), between supplemental Vitamin D intake and Colorectal cancer mortality ( n = 2 randomised controlled trials, where Colorectal cancer mortality was a secondary outcome), or between Vitamin D related polymorphisms (Bsml and fokl) and Colorectal cancer specific survival ( n = 1 prospective study).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 56, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 148, 'vitamin D'), ('UBERON_0012652', 'colorectum', 169, 'colorectal'), ('UBERON_0012652', 'colorectum', 241, 'colorectal'), ('CHEBI_28384', 'vitamin K', 306, 'Vitamin D'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 306, 'Vitamin D'), ('PR_000004775', 'BMP-binding endothelial regulator protein', 339, 'Bsml'), ('UBERON_0012652', 'colorectum', 358, 'colorectal')]
PMC4113768	7/2014	S217-PMC4113768	['at each visit, Blood was taken for Serum 25(Oh)D and Vitamin D binding protein quantification, full Blood count, whole-Blood immunophenotyping by flow cytometry and in vitro Infection with hiv-1, followed by functional flow cytometry.']	N/A	N/A	[('UBERON_0000178', 'blood', 15, 'blood'), ('UBERON_0001977', 'blood serum', 35, 'serum'), ('CHEBI_71657', 'versiconol acetate', 41, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 41, '25(OH ... D'), ('CHEBI_27300', 'vitamin D', 53, 'vitamin D'), ('UBERON_0000178', 'blood', 100, 'blood'), ('UBERON_0000178', 'blood', 119, 'blood'), ('GO_0007586', 'digestion', 174, 'infection')]
PMC4113768	7/2014	S238-PMC4113768	['the adjusted rr of lrti for Individuals with Vitamin D deficiency (25(Oh)D < 25 nmol/l) in comparison to the referent category (>50 nmol/l) was 1.32 (95% confidence interval (ci) 1.00,1.73).']	N/A	N/A	[('NCBITaxon_1', 'root', 28, 'individuals'), ('CHEBI_27300', 'vitamin D', 45, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 67, '25(OH)D')]
PMC4113768	7/2014	S240-PMC4113768	['the adjusted rr was 1.68 (95% ci 0.98, 2.86) using a priori defined cutpoints, 1.91 (95% ci 1.10, 3.32) for the lowest vs highest Vitamin D quartiles and 1.59 (95% ci 0.95, 2.67) in the lowest quartile in the season standardized model.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 130, 'vitamin D')]
PMC4113768	7/2014	S255-PMC4113768	['methods: this prospective controlled study enrolled 28 subjects with low Plasma Vitamin D (Vitamin D) (<20 ng/l, 50 micromol/l) comprising 17 hiv+ patients (11 on haart, 6 treatment naive) and 11 healthy controls.']	N/A	N/A	[('UBERON_0001969', 'blood plasma', 73, 'plasma'), ('CHEBI_27300', 'vitamin D', 80, 'vitamin D'), ('CHEBI_28384', 'vitamin K', 91, 'Vitamin D')]
PMC4113768	7/2014	S277-PMC4113768	['results: pain in Muscles and/or Joints and balance problems were more frequent in patients with Vitamin D deficiency.']	N/A	N/A	[('UBERON_0005090', 'muscle structure', 17, 'muscles'), ('UBERON_0004905', 'articulation', 32, 'joints'), ('CHEBI_27300', 'vitamin D', 96, 'vitamin D')]
PMC4113768	7/2014	S358-PMC4113768	['method: identified as high risk low Vitamin D community we engaged with massey university’s research into Vitamin D deficiency in preschool children in nz.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 36, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 106, 'vitamin D')]
PMC4113768	7/2014	S359-PMC4113768	['47 children had their Vitamin D levels measured within our practice in august and september 2012.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 22, 'vitamin D')]
PMC4113768	7/2014	S360-PMC4113768	['primary and secondary medical service contacts were compared between those children who had a Vitamin D level <25 nmol/l and those >25 nmol/l over a 2 years period.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 94, 'vitamin D')]
PMC4113768	7/2014	S380-PMC4113768	['Serum 25(Oh)D concentrations (measured via lc-tandem ms) was the primary outcome and Serum Ca, pth, 1,25(Oh)2D, 24,25(Oh)2D, Vitamin D binding protein and free 25(Oh)D were exploratory outcomes.']	N/A	N/A	[('UBERON_0001977', 'blood serum', 0, 'Serum'), ('CHEBI_71657', 'versiconol acetate', 6, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 12, 'D'), ('UBERON_0001977', 'blood serum', 85, 'serum'), ('CHEBI_32588', 'potassium chloride', 91, 'Ca'), ('CHEBI_63056', 'zinc cation', 102, '25(OH'), ('CHEBI_66526', 'strongylin A', 108, '2D'), ('CHEBI_66212', "5,7,3',4'-tetrahydroxy-2'-(3,3-dimethylallyl)isoflavone", 115, '25(OH)2D'), ('CHEBI_27300', 'vitamin D', 125, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 160, '25(OH)D')]
PMC4113768	7/2014	S464-PMC4113768	['Retinoid formation from carotinoids is self-Regulated and avoids Vitamin A toxicity.']	N/A	N/A	[('CHEBI_35341', 'steroid', 0, 'Retinoid'), ('GO_0065007', 'biological regulation', 44, 'regulated'), ('CHEBI_27300', 'vitamin D', 65, 'vitamin A')]
PMC4113768	7/2014	S469-PMC4113768	['results: Retinol does not affect Vitamin D Metabolism directly.']	N/A	N/A	[('CHEBI_27810', 'resorcinol', 9, 'Retinol'), ('CHEBI_27300', 'vitamin D', 33, 'vitamin D'), ('GO_0042359', 'vitamin D metabolic process', 33, 'vitamin D metabolism')]
PMC4113768	7/2014	S474-PMC4113768	['for example: Vitamin D-induced calcium absorption by the Gut is reduced by Vitamin A in fish, Animals and Humans.']	N/A	N/A	[('CHEBI_28384', 'vitamin K', 13, 'Vitamin D'), ('UBERON_0001555', 'digestive tract', 57, 'gut'), ('CHEBI_27300', 'vitamin D', 75, 'vitamin A'), ('NCBITaxon_33208', 'Metazoa', 94, 'animals'), ('NCBITaxon_9606', 'Homo sapiens', 106, 'humans')]
PMC4113768	7/2014	S513-PMC4113768	['methods: we conducted a multi-centre double-blind randomised placebo-controlled trial of Vitamin D supplementation in Adults with Inhaled Corticosteroid (ics)-treated asthma in london, uk.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 89, 'vitamin D'), ('UBERON_0007023', 'adult organism', 118, 'adults'), ('CHEBI_38959', 'diphenyl sulfide', 130, 'inhaled'), ('CHEBI_36916', 'cation', 138, 'corticosteroid')]
PMC4113768	7/2014	S523-PMC4113768	['the effect of the intervention on co-primary outcomes did not differ according to baseline Vitamin D status.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 91, 'vitamin D')]
PMC4113768	7/2014	S524-PMC4113768	['conclusions: intermittent bolus-dose Vitamin D supplementation significantly improved Vitamin D status but did not influence time to exacerbation or time to uri in a population of adults with ics-treated asthma and a high prevalence of Vitamin D deficiency at baseline.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 37, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 86, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 236, 'vitamin D')]
PMC4113768	7/2014	S536-PMC4113768	['results: of the 115 vd deficient subjects enrolled at baseline, 42 were lost to follow-up (47% in Vitamin D alone vs. 52% in vitamin along with physical activity group).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 98, 'vitamin D')]
PMC4113768	7/2014	S547-PMC4113768	['we used liaison 25-Oh Vitamin D (diasorin®) immunoassay to measure Serum concentration of 25-Oh Vitamin D. the patients were followed for major outcomes after one year: weaning from mechanical ventilation and death.']	N/A	N/A	[('CHEBI_86198', '1,2-di-[(11Z)-eicosenoyl]-sn-glycero-3-phosphocholine', 16, '25-OH'), ('CHEBI_28384', 'vitamin K', 22, 'Vitamin D'), ('UBERON_0001977', 'blood serum', 67, 'serum'), ('CHEBI_86198', '1,2-di-[(11Z)-eicosenoyl]-sn-glycero-3-phosphocholine', 90, '25-OH'), ('CHEBI_27300', 'vitamin D', 96, 'vitamin D')]
PMC4113768	7/2014	S550-PMC4113768	['patients with enteral tube Feeding had significantly higher levels of Vitamin D than patients with oral Food Intake (42 ± 16 ng/ml vs. 33 ± 20 ng/ml, p< 0.005).']	N/A	N/A	[('GO_0007631', 'feeding behavior', 27, 'feeding'), ('CHEBI_27300', 'vitamin D', 70, 'vitamin D'), ('CHEBI_33290', 'food', 104, 'food'), ('GO_0007631', 'feeding behavior', 104, 'food intake')]
PMC4113768	7/2014	S567-PMC4113768	['results: 260 Pregnant women were randomised to placebo ( n = 87), lower dose ( n = 87) or higher dose ( n = 86) vitamin D. in comparison with placebo, Serum 25(Oh)D concentrations were higher during Pregnancy and infancy in both the lower and higher dose Vitamin D groups.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 13, 'pregnant'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 120, 'D'), ('UBERON_0001977', 'blood serum', 151, 'serum'), ('CHEBI_71657', 'versiconol acetate', 157, '25(OH)D'), ('PR_000011614', 'opioid growth factor receptor', 160, 'OH'), ('PR_000006444', 'diacylglycerol kinase delta', 163, 'D'), ('GO_0007565', 'female pregnancy', 199, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 255, 'vitamin D')]
PMC4113768	7/2014	S571-PMC4113768	['in comparison with placebo, the proportion of children prescribed Antibiotics at any acute primary care visit did not differ for the lower dose Vitamin D group (85% vs. 77%, p = 0.24) but was smaller in the higher dose group (85% vs. 71%, p = 0.04).']	N/A	N/A	[('CHEBI_33282', 'antibacterial agent', 66, 'antibiotics'), ('CHEBI_27300', 'vitamin D', 144, 'vitamin D')]
PMC4113768	7/2014	S581-PMC4113768	['methods: the project was based on the danish Vitamin D fortification programs (mandatory fortification of Margarine 1961–1985 and voluntary fortification of low fat milk 1972–1976).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 45, 'vitamin D'), ('CHEBI_6784', 'mestranol', 106, 'margarine')]
PMC4113768	7/2014	S672-PMC4113768	['habitual physical activity and health-related quality of life (hrqol) were assessed via interview, during which use of Vitamin D-containing supplements or medications was checked and recorded.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 119, 'vitamin D')]
PMC4113768	7/2014	S678-PMC4113768	['of those taking Vitamin D, 49% took high oral doses ≥25 µg (1000 iu) Vitamin D daily equivalent, and 5 Individuals took >50 µg (2000 iu) equivalent daily dose.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 16, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 69, 'vitamin D'), ('NCBITaxon_1', 'root', 103, 'individuals')]
PMC4113768	7/2014	S697-PMC4113768	['the mean 25(Oh) Vitamin D was 65.7 ± 35.1 nmol/l, with a range of 15.8–140.0 nmol/l, which is within the range of published values.']	N/A	N/A	[('CHEBI_30778', 'gallic acid', 9, '25(OH)'), ('CHEBI_27300', 'vitamin D', 16, 'vitamin D')]
PMC4113768	7/2014	S698-PMC4113768	['29 children had a 25(Oh) Vitamin D level defined as deficient or insufficient ( i.e.']	N/A	N/A	[('CHEBI_30778', 'gallic acid', 18, '25(OH)'), ('CHEBI_27300', 'vitamin D', 25, 'vitamin D')]
PMC4113768	7/2014	S735-PMC4113768	['mrna was extracted and relative mrna Expression of Vitamin D Metabolizing enzymes were investigated using real time-pcr.']	N/A	N/A	[('GO_0010467', 'gene expression', 37, 'expression'), ('CHEBI_27300', 'vitamin D', 51, 'vitamin D'), ('GO_0006312', 'mitotic recombination', 59, 'D metabolizing')]
PMC4113768	7/2014	S744-PMC4113768	['background: laboratory measurement of Serum 25-Hydroxy Vitamin D [25(Oh)D] concentration is used to assess an Individual’s Vitamin D status.']	N/A	N/A	[('UBERON_0001977', 'blood serum', 38, 'serum'), ('CHEBI_62218', '23,24-dihydrocucurbitacin D', 44, '25-hydroxy vitamin D'), ('CHEBI_71657', 'versiconol acetate', 66, '25(OH)D'), ('NCBITaxon_1', 'root', 110, 'individual'), ('CHEBI_27300', 'vitamin D', 123, 'vitamin D')]
PMC4113768	7/2014	S754-PMC4113768	['eight national surveys from australia, canada, germany, ireland, mexico, korea, uk and usa are participating in an effort to characterize Vitamin D status around the world.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 138, 'vitamin D')]
PMC4113768	7/2014	S765-PMC4113768	['methods: Serum 25-Hydroxy Vitamin D (25(Oh)D) was quantified by hplc-ms/ms at 5–7 weeks of age in 253 hiv-infected and 948 hiv-exposed (uninfected) infants enrolled in a randomized trial of multivitamins (not including Vitamin D) conducted in tanzania during 2004–2007.']	N/A	N/A	[('UBERON_0001977', 'blood serum', 9, 'Serum'), ('CHEBI_62218', '23,24-dihydrocucurbitacin D', 15, '25-hydroxy vitamin D'), ('CHEBI_71657', 'versiconol acetate', 37, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 219, 'vitamin D')]
PMC4113768	7/2014	S790-PMC4113768	['methods: a549 cells were cultured and mono-layers were pre-treated with 25-Hydroxy Vitamin D (25(Oh)D), 1,25-Dihydroxy Vitamin D (1,25(Oh)2D) or vehicle (0.1% Ethanol) at a concentration of 10−7m for 48 h. cells were then stimulated with media, rhinovirus-16 (moi 1), filtered rv-16 or uv-inactivated rv-16 for 6 h. supernatants were collected for analysis by multiplex elisa, and cells were Lysed for mrna analysis by rt-pcr.']	N/A	N/A	[('CHEBI_62218', '23,24-dihydrocucurbitacin D', 72, '25-hydroxy vitamin D'), ('CHEBI_71657', 'versiconol acetate', 94, '25(OH)D'), ('CHEBI_50050', 'cystinyl group', 108, '-dihydroxy'), ('CHEBI_27300', 'vitamin D', 119, 'vitamin D'), ('CHEBI_82784', 'PVP38-Ag NP', 130, '1,25(OH)2D'), ('CHEBI_16236', 'ethanol', 159, 'ethanol'), ('GO_0019835', 'cytolysis', 392, 'lysed')]
PMC4113768	7/2014	S821-PMC4113768	['; embleton, n.d.\nackground: in the uk, over 50% of whites and 90% of south asians have insufficient Vitamin D levels.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 100, 'vitamin D')]
PMC4113768	7/2014	S831-PMC4113768	['results: Postnatal mothers: less than half the women surveyed were given information after Vitamin D supplementation during Pregnancy.']	N/A	N/A	[('GO_0007567', 'parturition', 9, 'Postnatal'), ('CHEBI_27300', 'vitamin D', 91, 'vitamin D'), ('GO_0007565', 'female pregnancy', 124, 'pregnancy')]
PMC4113768	7/2014	S833-PMC4113768	['no-one had been given information and advice about Vitamin D supplements whilst breastfeeding and only 20% breastfeeding mothers were planning to start Supplements (all as part of healthy start or Pregnancy multivitamin).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 51, 'vitamin D'), ('CHEBI_33341', 'titanium atom', 152, 'supplements'), ('GO_0007565', 'female pregnancy', 197, 'pregnancy')]
PMC4113768	7/2014	S868-PMC4113768	['various therapeutic regimens were used to replenish Vitamin D levels to ≥56 nmol/l by the end of the study.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 52, 'vitamin D')]
PMC4113768	7/2014	S872-PMC4113768	['also used jumping mechanography to demonstrate a 5% increase in the efficiency of movement in those who received Vitamin D (ward, k.a., et al.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 113, 'vitamin D')]
PMC4113768	7/2014	S897-PMC4113768	['however patients with low Vitamin D but few painful crises had normal vertebral morphology.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 26, 'vitamin D')]
PMC4113768	7/2014	S959-PMC4113768	['methods: we conducted a cross-sectional study in 278 copd patients aged 40–85 years who were screened for enrolment in a clinical trial of Vitamin D supplementation conducted in london, uk.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 139, 'vitamin D')]
PMC4113768	7/2014	S964-PMC4113768	['results: mean Serum 25(Oh)D concentration was 45.4 nmol/l (sd 25.3), and 171/278 (61.5%) participants were Vitamin D deficient.']	N/A	N/A	[('UBERON_0001977', 'blood serum', 14, 'serum'), ('CHEBI_71657', 'versiconol acetate', 20, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 20, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 107, 'vitamin D')]
PMC4113768	7/2014	S967-PMC4113768	['none of the 37 Snps investigated independently associated with Vitamin D deficiency.']	N/A	N/A	[('SO_0000694', 'SNP', 15, 'SNPs'), ('CHEBI_27300', 'vitamin D', 63, 'vitamin D')]
PMC4113768	7/2014	S1016-PMC4113768	['there were no associations between maternal Serum 25(Oh)D or maternal or infant Vitamin D supplementation and any of the gross motor outcomes specified.']	N/A	N/A	[('UBERON_0001977', 'blood serum', 44, 'serum'), ('CHEBI_71657', 'versiconol acetate', 50, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 50, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 80, 'vitamin D')]
PMC4113768	7/2014	S1029-PMC4113768	['information on Birth outcomes and maternal health during Pregnancy, including bacterial and Viral infections and the use of Vitamin D supplementation was obtained from medical records, “maternity logbooks” filled in during visits to Prenatal care clinics, or through a retrospective structured questionnaire sent to the mother after Birth.']	N/A	N/A	[('GO_0007567', 'parturition', 15, 'birth'), ('GO_0007565', 'female pregnancy', 57, 'pregnancy'), ('NCBITaxon_1', 'root', 92, 'viral'), ('CHEBI_27300', 'vitamin D', 124, 'vitamin D'), ('GO_0007565', 'female pregnancy', 233, 'prenatal'), ('GO_0007567', 'parturition', 333, 'birth')]
PMC4113768	7/2014	S1031-PMC4113768	['results: from the mothers, 24.9% took single Vitamin D preparations (>3000 iu/week) with additional 4.7% taking multivitamins containing lower dosages of Vitamin D (100–400 iu/day).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 45, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 154, 'vitamin D')]
PMC4113768	7/2014	S1047-PMC4113768	['methods: 25(Oh) Vitamin D, calcium (ca), Osteocalcin (Bone Gla Protein, Bglap), a specific marker of bone formation reflecting Osteoblastic activity, and β-crosslaps (β-ctx) a marker of Bone Resorption were measured in 2798 ten-year-old children from the german Birth cohorts giniplus and lisaplus.']	N/A	N/A	[('CHEBI_30778', 'gallic acid', 9, '25(OH)'), ('CHEBI_27300', 'vitamin D', 16, 'vitamin D'), ('PR_000011634', 'oxidized low-density lipoprotein receptor 1', 41, 'osteocalcin'), ('PR_000014408', 'protein S100-A16', 54, 'bone Gla protein'), ('PR_000004706', 'Bcl-2-associated transcription factor 1', 72, 'BGLAP'), ('CL_0000062', 'osteoblast', 127, 'osteoblastic'), ('GO_0045453', 'bone resorption', 186, 'bone resorption'), ('GO_0007567', 'parturition', 262, 'birth')]
PMC4113768	7/2014	S1049-PMC4113768	['linear regression was used to determine the association between bone turnover markers and Vitamin D levels in Serum.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 90, 'vitamin D'), ('UBERON_0001977', 'blood serum', 110, 'serum')]
PMC4113768	7/2014	S1090-PMC4113768	['case reporting criteria: any child < 16 years of age with a suspected seizure in the presence of a Serum corrected calcium < 2.0 mmol/l and a Serum 25-Hydroxy Vitamin D < 50 nmol/l.']	N/A	N/A	[('UBERON_0001977', 'blood serum', 99, 'serum'), ('UBERON_0001977', 'blood serum', 142, 'serum'), ('CHEBI_43141', '3-hydroxypropoxy group', 148, '25-hydroxy'), ('CHEBI_27300', 'vitamin D', 159, 'vitamin D')]
PMC4113768	7/2014	S1123-PMC4113768	['d-cure®consists of an ampoule containing an oily Solution of 25,000 iu Vitamin D for oral use.']	N/A	N/A	[('CHEBI_75958', 'solution', 49, 'solution'), ('CHEBI_27300', 'vitamin D', 71, 'vitamin D')]
PMC4113768	7/2014	S1124-PMC4113768	['three dosing schedules were compared: subjects received a loading dose of 50,000, 100,000 or 200,000 iu of Vitamin D according to their group at week 0, followed by 25,000, 50,000 or 100,000 at week 4 and week 8.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 107, 'vitamin D')]
PMC4113768	7/2014	S1138-PMC4113768	['starting the treatment with a high loading dose allows faster correction of the Vitamin D deficiency.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 80, 'vitamin D')]
PMC4113768	7/2014	S1149-PMC4113768	['there was no association between Vitamin D and age, month/season of Birth, iq, subcategories of asd, or ados score.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 33, 'vitamin D'), ('GO_0007567', 'parturition', 68, 'birth')]
PMC4113768	7/2014	S1157-PMC4113768	['; de jongh, r.t.; den heijer, m.; visser, m.; merlijn, t.; lips, p.; van schoor, n.m.\nbackground: Vitamin D status is currently diagnosed by measuring Serum 25-Hydroxy Vitamin D (25(Oh)D).']	N/A	N/A	[('CHEBI_28384', 'vitamin K', 98, 'Vitamin D'), ('UBERON_0001977', 'blood serum', 151, 'serum'), ('CHEBI_43141', '3-hydroxypropoxy group', 157, '25-hydroxy'), ('CHEBI_27300', 'vitamin D', 168, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 179, '25(OH)D')]
PMC4113768	7/2014	S1278-PMC4113768	['conclusion: one year treatment with high dose Vitamin D had no effect on muscular strength and balance in Postmenopausal women with osteopenia or osteoporosis as compared to a standard dose.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 46, 'vitamin D'), ('GO_0007595', 'lactation', 106, 'postmenopausal')]
PMC4113768	7/2014	S1286-PMC4113768	['in the delhi infant Vitamin D supplementation study (divids) we randomized 2079 neonates to weekly Vitamin D or placebo until age 6 months.']	N/A	N/A	[('CHEBI_28384', 'vitamin K', 20, 'Vitamin D'), ('CHEBI_27300', 'vitamin D', 99, 'vitamin D')]
PMC4113768	7/2014	S1292-PMC4113768	['results: demographic characteristics did not differ at follow-up between children in the Vitamin D and placebo groups.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 89, 'vitamin D')]
PMC4113768	7/2014	S1293-PMC4113768	['qus z scores for radius were mean −0.72 (95% ci −0.82 to −0.62, n = 398) for the Vitamin D group and mean −0.60 (95% ci −0.70 to −0.50, n = 397) for the placebo group; p = 0.11.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 81, 'vitamin D')]
PMC4113768	7/2014	S1294-PMC4113768	['for Tibia, values for the Vitamin D group were mean −0.57 (95% ci −0.67 to −0.47, n = 398) and for the Placebo group mean −0.53 (95% ci −0.63 to −0.43, n = 398); p = 0.62.']	N/A	N/A	[('UBERON_0000979', 'tibia', 4, 'tibia'), ('CHEBI_27300', 'vitamin D', 26, 'vitamin D'), ('CHEBI_26130', 'biological pigment', 103, 'placebo')]
PMC4113768	7/2014	S1298-PMC4113768	['conclusions: in a large randomized controlled trial, Vitamin D supplementation in infancy did not affect bone structure and strength in childhood.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 53, 'vitamin D')]
PMC4113768	7/2014	S1308-PMC4113768	['we carried out a 1-year randomized controlled trial in 300 Postmenopausal women (age 60–70 years) using two doses of Vitamin D (macdonald, h.m, et al .']	N/A	N/A	[('GO_0007595', 'lactation', 59, 'postmenopausal'), ('CHEBI_27300', 'vitamin D', 117, 'vitamin D')]
PMC4113768	7/2014	S1322-PMC4113768	['we reported no effect on bone turnover markers, but Vitamin D treatment resulted in a reduction in pth and a small increase in Serum calcium (the latter only with 1000 iu).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 52, 'vitamin D'), ('UBERON_0001977', 'blood serum', 127, 'serum')]
PMC4113768	7/2014	S1337-PMC4113768	['of 35 patients who took Vitamin D at the start of their cancer diagnosis, 23 are still alive, 12 have died.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 24, 'vitamin D')]
PMC4113768	7/2014	S1344-PMC4113768	['most of the cancer patients tested at the start of their diagnosis were severely Vitamin D deficient.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 81, 'vitamin D')]
PMC4113768	7/2014	S1355-PMC4113768	['they were randomly assigned at a ratio of 3 to 2 to 60 days of administration with Vitamin D or placebo, respectively, and followed up for 120 days after administration.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 83, 'vitamin D')]
PMC4113768	7/2014	S1381-PMC4113768	['mean total Vitamin D concentration was 32.2 nmol/l.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 11, 'vitamin D')]
PMC4113768	7/2014	S1382-PMC4113768	['thirty (33%) were deficient (<25 nmol/l), 43 (47%) insufficient (26–50 nmol/l) and 19 (20%) adequate (>50 nmol/l) in Vitamin D. pearson’s correlation coefficients for Vitamin D and gir step 1 were −0.003 ( p = 0.98), gir step 2 –0.036 ( p = 0.73) and homa-ir −0.163 ( p = 0.13).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 117, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 167, 'vitamin D')]
PMC4113768	7/2014	S1385-PMC4113768	['conclusions: using gold standard techniques this cross-sectional analysis did not reveal a significant association between Vitamin D and measures of Whole-Body, Peripheral or Hepatic Insulin resistance in healthy overweight Individuals at high risk of Cardiovascular disease.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 123, 'vitamin D'), ('UBERON_0000468', 'multicellular organism', 149, 'whole-body'), ('UBERON_0003060', 'pronephric duct', 161, 'peripheral ...'), ('UBERON_0002107', 'liver', 175, 'hepatic'), ('PR_000045358', 'insulin family protein', 183, 'insulin'), ('NCBITaxon_1', 'root', 224, 'individuals'), ('UBERON_0004535', 'cardiovascular system', 252, 'cardiovascular')]
PMC4113768	7/2014	S1520-PMC4113768	['methods: we used data from the Vitamin D study, a double-blinded, randomized placebo-controlled intervention trial with healthy danish families ( n = 782).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 31, 'vitamin D')]
PMC4113768	7/2014	S1549-PMC4113768	['total Vitamin D measurements were made on 1908 Serum samples, via lc-ms methodology in a deqas-accredited clinical biochemistry lab.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 6, 'vitamin D'), ('UBERON_0001977', 'blood serum', 47, 'serum')]
PMC4113768	7/2014	S1554-PMC4113768	['results: unadjusted mean levels of Vitamin D for south-asian and afro-caribbean participants were 9.6 and 14.3 ng/ml, respectively.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 35, 'vitamin D')]
PMC4113768	7/2014	S1580-PMC4113768	['patients with at least one 25-Hydroxy Vitamin D measurement taken between 1 january 2008 and 31 december 2012, who had an hiv viral load >50 copies/ml and were not receiving art at the time of Vitamin D measurement were included in this study.']	N/A	N/A	[('CHEBI_62218', '23,24-dihydrocucurbitacin D', 27, '25-hydroxy vitamin D'), ('CHEBI_27300', 'vitamin D', 193, 'vitamin D')]
PMC4113768	7/2014	S1581-PMC4113768	['absolute cd4+ Cell count, cd4% and hiv viral load are measured 3–6 monthly and will be collected from the time of Vitamin D measurement until the 31st december 2013.']	N/A	N/A	[('CL_0000573', 'retinal cone cell', 14, 'cell'), ('CHEBI_27300', 'vitamin D', 114, 'vitamin D')]
PMC4113768	7/2014	S1583-PMC4113768	['a proportional hazards model will be constructed to identify the hazard of an Individual’s decrease in cd4+ cell count to <350 cells/ul for those with Vitamin D insufficiency.']	N/A	N/A	[('NCBITaxon_1', 'root', 78, 'individual'), ('CHEBI_27300', 'vitamin D', 151, 'vitamin D')]
PMC4113768	7/2014	S1585-PMC4113768	['results: of those Individuals with a Vitamin D measurement, 312 were found to have an hiv viral load >50 copies/ml and not receiving Antiretroviral therapy.']	N/A	N/A	[('NCBITaxon_1', 'root', 18, 'individuals'), ('CHEBI_27300', 'vitamin D', 37, 'vitamin D'), ('CHEBI_65417', '(+)-aplysinillin', 133, 'antiretroviral')]
PMC4113768	7/2014	S1586-PMC4113768	['characteristics of participants included in this study: baseline characteristics n = 312*; age, years 34(10); male sex 290 (93%); europid country of birth 222 (71%); Cd4 (cells/µl) 516 (254); Cd4 (% of T-Lymphocytes) 25 (8); Cd4<200 21 (7%); cd4<350 81 (26%); antiretroviral naïve 144 (46%); season of Vitamin D measurement:winter 113 (36%); spring 94 (30%); summer 62 (20%); autumn 43 (14%); Vitamin D (nmol/l) 57 (28); Vitamin D ≥ 75 nmol/l 75 (24%); Vitamin D < 50 nmol/l 142 (45%); Vitamin D < 25 nmol/l 29 (9%); *mean(sd) or n (%).']	N/A	N/A	[('PR_000001204', 'C-C chemokine receptor type 8', 166, 'CD4'), ('PR_000001204', 'C-C chemokine receptor type 8', 192, 'CD4'), ('CL_0000084', 'T cell', 202, 'T-lymphocytes'), ('PR_000001204', 'C-C chemokine receptor type 8', 225, 'CD4'), ('CHEBI_27300', 'vitamin D', 302, 'vitamin D'), ('CHEBI_28384', 'vitamin K', 393, 'Vitamin D'), ('CHEBI_28384', 'vitamin K', 421, 'Vitamin D'), ('CHEBI_28384', 'vitamin K', 453, 'Vitamin D'), ('CHEBI_28384', 'vitamin K', 486, 'Vitamin D')]
PMC4113768	7/2014	S1609-PMC4113768	['eighty-five (53%) were Vitamin D deficient (defined as <50 nmol/l).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 23, 'vitamin D')]
PMC4113768	7/2014	S1610-PMC4113768	['a linear regression model was constructed which included an interaction term between Vitamin D deficiency and previous tdf use.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 85, 'vitamin D')]
PMC4113768	7/2014	S1661-PMC4113768	['concentrations of 25-Hydroxy Vitamin D (25(Oh)D), 1Α,25-Dihydroxy Vitamin D (1,25(Oh)2D), 24r,25-Dihydroxy Vitamin D (24,25(Oh)2D) and 4Β,25-Dihydroxy Vitamin D (4,25(Oh)2d) were determined in Serum samples collected at follow-up and at the time of tb diagnosis.']	N/A	N/A	[('CHEBI_62218', '23,24-dihydrocucurbitacin D', 18, '25-hydroxy vitamin D'), ('CHEBI_71657', 'versiconol acetate', 40, '25(OH)D'), ('CHEBI_50341', '1-hydroxyethyl group', 50, '1α,25-dihydroxy'), ('CHEBI_27300', 'vitamin D', 66, 'vitamin D'), ('CHEBI_66212', "5,7,3',4'-tetrahydroxy-2'-(3,3-dimethylallyl)isoflavone", 79, '25(OH)2D'), ('CHEBI_43141', '3-hydroxypropoxy group', 94, '25-dihydroxy'), ('CHEBI_27300', 'vitamin D', 107, 'vitamin D'), ('CHEBI_66212', "5,7,3',4'-tetrahydroxy-2'-(3,3-dimethylallyl)isoflavone", 121, '25(OH)2D'), ('CHEBI_83121', 'decyl hydrogen sulfate', 135, '4β,25-dihydroxy'), ('CHEBI_27300', 'vitamin D', 151, 'vitamin D'), ('CHEBI_51686', 'haematoxylin', 166, '(OH'), ('UBERON_0001977', 'blood serum', 193, 'serum')]
PMC4113768	7/2014	S1683-PMC4113768	[', 50.6% and 45.1% patients had Vitamin D insufficiency.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 31, 'vitamin D')]
PMC4113768	7/2014	S1714-PMC4113768	['results: the prevalence of Vitamin D deficiency (Serum 25-Hydroxy Vitamin D concentration [25(Oh)D]<50 nmol/l) was 54%; median Serum 25(Oh)D concentration was 47 nmol/l.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 27, 'vitamin D'), ('UBERON_0001977', 'blood serum', 49, 'serum'), ('CHEBI_62218', '23,24-dihydrocucurbitacin D', 55, '25-hydroxy vitamin D'), ('CHEBI_71657', 'versiconol acetate', 91, '25(OH)D'), ('UBERON_0001977', 'blood serum', 127, 'serum'), ('CHEBI_71657', 'versiconol acetate', 133, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 133, '25(OH)D')]
PMC4113768	7/2014	S1763-PMC4113768	['levels >50 nmol/l were obtained by 18.6%, among which 72% had taken a Vitamin D injection between 6–48 months prior to the examination.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 70, 'vitamin D')]
PMC4113768	7/2014	S1889-PMC4113768	['this has spurred discussion on the best way to improve the Vitamin D status of children.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 59, 'vitamin D')]
PMC4113768	7/2014	S1897-PMC4113768	['canada has mandatory fortification of Vitamin D to Cow’s milk.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 38, 'vitamin D'), ('NCBITaxon_33208', 'Metazoa', 51, 'cow')]
PMC4113768	7/2014	S1900-PMC4113768	['in the uk Cows’ milk contains trace amounts of Vitamin D whilst Growing-up Milk (gum) contains around 1.7 µg/100 ml.']	N/A	N/A	[('NCBITaxon_33208', 'Metazoa', 10, 'cows'), ('CHEBI_27300', 'vitamin D', 47, 'vitamin D'), ('GO_0040007', 'growth', 64, 'growing-'), ('UBERON_0001913', 'milk', 75, 'milk')]
PMC4113768	7/2014	S1907-PMC4113768	['mean intakes of Vitamin D were 1.82 ± 0.28 µg/day (mean ± sem) for Cows’ milk consumers aged 18–24 m, and 1.71 ± 0.15 µg/day for Cows’ milk consumers aged 24–36 m. this corresponds to 4.1% of the 18–24 m having intakes of Vitamin D at or above the rni, and 2.8% of the 24–36 m. after replacement from Cows’ Milk by gum at observed Consumption (scenario 1), mean Intakes respectively corresponded to 48.1% and 43.0% of the children having intakes of Vitamin D at or above the rni.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 16, 'vitamin D'), ('NCBITaxon_33208', 'Metazoa', 67, 'cows'), ('NCBITaxon_33208', 'Metazoa', 129, 'cows'), ('CHEBI_27300', 'vitamin D', 222, 'vitamin D'), ('NCBITaxon_33208', 'Metazoa', 301, 'cows'), ('UBERON_0001913', 'milk', 307, 'milk'), ('GO_0007631', 'feeding behavior', 331, 'consumption'), ('GO_0007631', 'feeding behavior', 362, 'intakes'), ('CHEBI_27300', 'vitamin D', 449, 'vitamin D')]
PMC4113768	7/2014	S1923-PMC4113768	['mean level of Vitamin D was lower in patients with Neurologic disorders with respect to patients with osteoarticular disorders (18.0 ± 11.7 ng/ml vs. 21.8 ± 13.9 ng/ml; p = 0.001).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 14, 'vitamin D'), ('UBERON_0001016', 'nervous system', 51, 'neurologic')]
PMC4113768	7/2014	S1950-PMC4113768	['background: the main source of Vitamin D for People is exposure to sunlight (holick, m.f.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 31, 'vitamin D'), ('NCBITaxon_10088', 'Mus <genus>', 45, 'people')]
PMC4113768	7/2014	S1972-PMC4113768	['the intake of Vitamin D was calculated based with a dietary questionnaire.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 14, 'vitamin D')]
PMC4113768	7/2014	S1992-PMC4113768	['the population attributable risks of Vitamin D deficiency was 24.1% for death from clrd, 16.4% from total Respiratory disease, 7.4% from cvd, and 7.3% from all-cause mortality.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 37, 'vitamin D'), ('UBERON_0001004', 'respiratory system', 106, 'respiratory')]
PMC4113768	7/2014	S1998-PMC4113768	['Vitamin D receptors and Vitamin D Metabolizing enzymes are present in the Brain and in the Central Nervous System at sites responsible for Regulation Of Emotions and Behaviour.']	N/A	N/A	[('CHEBI_28384', 'vitamin K', 0, 'Vitamin D'), ('CHEBI_27300', 'vitamin D', 24, 'vitamin D'), ('GO_0043181', 'vacuolar sequestering', 24, 'vitamin D metabolizing'), ('UBERON_0000955', 'brain', 74, 'brain'), ('UBERON_0001017', 'central nervous system', 91, 'central nervous system'), ('GO_2000250', 'negative regulation of actin cytoskeleton reorganization', 139, 'regulation of emotions ... behaviour')]
PMC4113768	7/2014	S2003-PMC4113768	['Serum 25(Oh) Vitamin D concentrations were measured on fasting Blood samples by either hplc or a chemiluminescence immunoassay.']	N/A	N/A	[('UBERON_0001977', 'blood serum', 0, 'Serum'), ('CHEBI_30778', 'gallic acid', 6, '25(OH)'), ('CHEBI_27300', 'vitamin D', 13, 'vitamin D'), ('UBERON_0000178', 'blood', 63, 'blood')]
PMC4113768	7/2014	S2011-PMC4113768	['results: median Serum 25(Oh) Vitamin D concentrations were 70.3, 41.9, and 51.0 nmol/l in the health2008, health2006, and inter99 study populations, respectively.']	N/A	N/A	[('UBERON_0001977', 'blood serum', 16, 'serum'), ('CHEBI_30778', 'gallic acid', 22, '25(OH)'), ('CHEBI_27300', 'vitamin D', 29, 'vitamin D')]
PMC4113768	7/2014	S2014-PMC4113768	['the odds ratio (or) and 95% confidence interval (ci) per 10 nmol/l Serum Vitamin D were 0.97 (0.93–1.01) for depression ( p = 0.10), and 1.01(0.97–1.05) for anxiety ( p = 0.56).']	N/A	N/A	[('UBERON_0001977', 'blood serum', 67, 'serum'), ('CHEBI_27300', 'vitamin D', 73, 'vitamin D')]
PMC4113768	7/2014	S2057-PMC4113768	['Vitamin D Endocrine system was evaluated in all children: 25-Oh-D (25-Oh-d125i ria kit, diasorin), 1,25-Dihydroxy-Vitamin D (1,25-Oh2-D) (1,25-Oh-d125i ria kit, diasorin), parathormone (pth) (n-tact pth sp irma kit, diasorin®), calcium and Phosphorus levels were measured following Blood withdrawal.']	N/A	N/A	[('CHEBI_28384', 'vitamin K', 0, 'Vitamin D'), ('UBERON_0002049', 'vasculature', 10, 'endocrine'), ('CHEBI_46744', 'DDT-2,3-dihydrodiol', 58, '25-OH-D'), ('CHEBI_75393', 'Y-27632', 67, '25-OH-'), ('CHEBI_67814', 'Neurosporaside peracetate', 104, 'dihydroxy-'), ('CHEBI_27300', 'vitamin D', 114, 'vitamin D'), ('CHEBI_78731', '9(R)-HPETE', 126, ',25-OH2-D'), ('CHEBI_17996', 'chloride', 139, ','), ('CHEBI_75393', 'Y-27632', 140, '25-OH-'), ('CHEBI_35885', 'secondary phosphine', 240, 'phosphorus'), ('UBERON_0000178', 'blood', 282, 'blood')]
PMC4113768	7/2014	S2078-PMC4113768	['Serum 25Ohd concentrations were measured in 10,181 samples using the elecsys Vitamin D total automated competitive binding protein assay (roche®diagnostics).']	N/A	N/A	[('UBERON_0001977', 'blood serum', 0, 'Serum'), ('CHEBI_72652', "7,2'-dihydroxy-4'-methoxyisoflavan-4-ylium cation", 6, '25OHD'), ('CHEBI_27300', 'vitamin D', 77, 'vitamin D')]
PMC4113768	7/2014	S2120-PMC4113768	['information on use of Vitamin D supplements and oral Contraceptives was obtained in computer-assisted personal interviews.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 22, 'vitamin D'), ('CHEBI_35223', 'catalyst', 53, 'contraceptives')]
PMC4113768	7/2014	S2122-PMC4113768	['a Vitamin D intake index was constructed from ffq information.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 2, 'vitamin D')]
PMC4113768	7/2014	S2126-PMC4113768	['determinants of Vitamin D status were analyzed in gender-specific multiple linear regression models.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 16, 'vitamin D')]
PMC4113768	7/2014	S2148-PMC4113768	['results: total Protein Degradation as measured by the release of tyrosine from muscle was significantly increased in the deficient group than the controls.Urinary Excretion of the amino Acid 3-Methylhistidine, an in vivo index for muscle Protein Degradation was also increased in the Vitamin D deficient group compared to Vitamin D sufficient group.']	N/A	N/A	[('GO_0030163', 'protein catabolic process', 15, 'protein degradation'), ('GO_0036268', 'swimming', 155, 'Urinary'), ('UBERON_0001088', 'urine', 155, 'Urinary'), ('GO_0007588', 'excretion', 163, 'excretion'), ('CHEBI_2485', 'adenylyl selenate', 186, 'acid 3-methylhistidine'), ('GO_0030163', 'protein catabolic process', 238, 'protein degradation'), ('CHEBI_27300', 'vitamin D', 284, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 322, 'vitamin D')]
PMC4113768	7/2014	S2149-PMC4113768	['Type Ii Fibre area was decreased in Vitamin D deficient muscle and this was reversed upon rehabilitation with Vitamin D. the 20s Proteasomal enzyme activities namely chymotrypsin-like (Ch-L), Trypsin-Like (T-L) and Caspase-Like (Cp-L) were significantly increased in the deficient muscle than the control muscle.']	N/A	N/A	[('CL_0002212', 'type II muscle cell', 0, 'Type II fibre'), ('CHEBI_27300', 'vitamin D', 36, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 110, 'vitamin D'), ('GO_0000502', 'proteasome complex', 129, 'proteasomal'), ('PR_000006000', 'carboxy-terminal domain RNA polymerase II polypeptide A small phosphatase 2', 185, 'Ch-L'), ('PR_000016755', 'tetraspanin-9', 192, 'trypsin-like'), ('PR_000016493', 'TNFAIP3-interacting protein 2', 206, 'T-L'), ('PR_000002118', 'voltage-dependent P/Q-type calcium channel subunit alpha-1A', 215, 'caspase-like'), ('PR_000004968', 'calretinin', 229, 'Cp-L')]
PMC4113768	7/2014	S2153-PMC4113768	['both rescue with Vitamin D and supplementation with high calcium diets corrected all the muscle changes observed.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 17, 'vitamin D')]
PMC4113768	7/2014	S2164-PMC4113768	['interventions included activated Vitamin D, unactivated Vitamin D2And D3And Vitamin D analogues including paricalcitol.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 33, 'vitamin D'), ('CHEBI_10124', 'zolmitriptan', 56, 'vitamin D2and'), ('PR_000027594', 'histone H3', 56, 'vitamin D2and D3and'), ('CHEBI_27300', 'vitamin D', 76, 'vitamin D'), ('PR_000006444', 'diacylglycerol kinase delta', 84, 'D')]
PMC4113768	7/2014	S2190-PMC4113768	['Left Ventricular mass index was measured in a subgroup ( n = 25); no reduction was seen with Vitamin D treatment (adjusted treatment effect +4 g/m2, 95% ci 0 to +7, p = 0.04).']	N/A	N/A	[('UBERON_0002084', 'heart left ventricle', 0, 'Left ventricular'), ('CHEBI_27300', 'vitamin D', 93, 'vitamin D')]
PMC4113768	7/2014	S2205-PMC4113768	['treatment with Vitamin D did not improve pulse wave velocity at 6 months (adjusted treatment effect 0.0 m/s; 95% ci −0.6 to 0.6; p = 0.93).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 15, 'vitamin D')]
PMC4113768	7/2014	S2290-PMC4113768	['a total of 256 subjects filled a general questionnaire, height and weight were measured and Blood extracted ascertaining total 25-Hydroxy Vitamin D, calcium, Phosphorous and alkaline phophatase from a Vitamin D external quality assessment (deqas)-certified laboratory.']	N/A	N/A	[('UBERON_0000178', 'blood', 92, 'blood'), ('CHEBI_43141', '3-hydroxypropoxy group', 127, '25-hydroxy'), ('CHEBI_27300', 'vitamin D', 138, 'vitamin D'), ('CHEBI_30207', 'phosphorus(.)', 158, 'phosphorous'), ('CHEBI_27300', 'vitamin D', 201, 'vitamin D')]
PMC4113768	7/2014	S2305-PMC4113768	['anthropometrics were obtained and fasting Blood samples were taken for ascertaining Lipid and Thyroid profile, as well as measuring pth, 25(Oh) Vitamin D and calcium.']	N/A	N/A	[('UBERON_0000178', 'blood', 42, 'blood'), ('CHEBI_18059', 'lipid', 84, 'lipid'), ('UBERON_0002046', 'thyroid gland', 94, 'thyroid'), ('CHEBI_30778', 'gallic acid', 137, '25(OH)'), ('CHEBI_27300', 'vitamin D', 144, 'vitamin D')]
PMC4113768	7/2014	S2347-PMC4113768	['methods: a total of 47 volunteers (21 males, 26 females) out of the initial 95 subjects were given verbal advice to expose themselves to sunlight for 5–30 min twice weekly and were encouraged to increase their intake of Vitamin D–rich foods.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 220, 'vitamin D')]
PMC4113768	7/2014	S2349-PMC4113768	['results: a significant decrease in the prevalence of Vitamin D deficiency was observed (44% to 27%) after one year follow-up ( p = 0.025).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 53, 'vitamin D')]
PMC4113768	7/2014	S2364-PMC4113768	['results: age- and bmi-matched mean 25(Oh) Vitamin D levels from the winter group were significantly higher than those of the summer group ( p< 0.001).']	N/A	N/A	[('CHEBI_30778', 'gallic acid', 35, '25(OH)'), ('CHEBI_27300', 'vitamin D', 42, 'vitamin D')]
PMC4113768	7/2014	S2426-PMC4113768	['methods: the 25(Oh)D (Vitamin D) level of tb patients diagnosed at two south london hospitals between 2004 and 2012 was collected retrospectively from electronic hospital records ( n = 728).']	N/A	N/A	[('CHEBI_71657', 'versiconol acetate', 13, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 22, 'vitamin D')]
PMC4113768	7/2014	S2453-PMC4113768	['body surface exposure and dietary Vitamin D intake were assessed by questionnaire.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 34, 'vitamin D')]
PMC4113768	7/2014	S2455-PMC4113768	['total Vitamin D was taken as the sum of sunlight-derived (calculated from sed, corrected for skin type and body surface area exposed) and dietary vitamin d intake.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 6, 'vitamin D')]
PMC4113768	7/2014	S2462-PMC4113768	['when comparing skin types ii and iii with skin type iv to vi, there was no difference in sed or dietary Vitamin D intake.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 104, 'vitamin D')]
PMC4113768	7/2014	S2464-PMC4113768	['seasonsun iudiet iutotal iu% sun/totalspring 77(190)91(112)233(241)61(48) summer 235(311)81(88)323(319)74(28) autumn 22(36)75(118)91(123)23(34)\nthere was sporadic use of Vitamin D supplements ( n = 6 in spring; n = 7 for summer and autumn; with Supplements providing between 57 iu and 5714 iu Vitamin D daily).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 170, 'vitamin D'), ('CHEBI_33341', 'titanium atom', 245, 'supplements'), ('CHEBI_27300', 'vitamin D', 293, 'vitamin D')]
PMC4113768	7/2014	S2477-PMC4113768	['of the total study population, 17.8% had Vitamin D deficiency (≤50 nmol/l) and a further 6.67% had Vitamin D insufficiency (≤75 nmol/l).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 41, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 99, 'vitamin D')]
PMC4113768	7/2014	S2548-PMC4113768	['results: Serum Calcium concentrations increased with 0.0008 mmol/l per increment of 1000 iu/day Vitamin D ( p -value < 0.008) and with 0.0001 mmol/l per increase of 1 nmol/l 25(Oh)D ( p -value < 0.001).']	N/A	N/A	[('UBERON_0001977', 'blood serum', 9, 'Serum'), ('CHEBI_22313', 'alkaline earth metal atom', 15, 'calcium'), ('CHEBI_27300', 'vitamin D', 96, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 174, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 174, '25(OH)D')]
PMC4113768	7/2014	S2564-PMC4113768	['methods: this study used data from a pilot randomised controlled trial of Vitamin D supplementation (pilot d-health) in which 644 australian Adults aged 60–84 years were randomly assigned to receive monthly doses of placebo or 30,000 iu or 60,000 iu Vitamin D3(Cholecalciferol) for 12 months.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 74, 'vitamin D'), ('UBERON_0007023', 'adult organism', 141, 'adults'), ('CHEBI_33279', 'vitamin D5', 250, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 250, 'vitamin D3'), ('CHEBI_52550', 'theopalauamide', 261, 'cholecalciferol')]
PMC4113768	7/2014	S2569-PMC4113768	['results: this analysis included 385 of the 430 participants randomised to one of the two Vitamin D doses who provided post-supplementation Blood samples and had adequate snp data.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 89, 'vitamin D'), ('UBERON_0000178', 'blood', 139, 'blood')]
PMC4113768	7/2014	S2585-PMC4113768	['the main source of Vitamin D is its synthesis in the skin due to exposure to sunlight.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 19, 'vitamin D')]
PMC4113768	7/2014	S2596-PMC4113768	['individuals Born in two years after milk fortification start were considered as exposed to Vitamin D fortification during Gestation; Individuals Born in two years before milk fortification end were considered as unexposed.']	N/A	N/A	[('GO_0007567', 'parturition', 12, 'born'), ('CHEBI_27300', 'vitamin D', 91, 'vitamin D'), ('GO_0007565', 'female pregnancy', 122, 'gestation'), ('NCBITaxon_1', 'root', 133, 'individuals'), ('GO_0007567', 'parturition', 145, 'born')]
PMC4113768	7/2014	S2600-PMC4113768	['results: there were no statistically significant differences in seasonality of month of Birth in t1d in Individuals exposed or unexposed to Vitamin D fortified milk during Gestation.']	N/A	N/A	[('GO_0007567', 'parturition', 88, 'birth'), ('NCBITaxon_1', 'root', 104, 'individuals'), ('CHEBI_27300', 'vitamin D', 140, 'vitamin D'), ('GO_0007565', 'female pregnancy', 172, 'gestation')]
PMC4113768	7/2014	S2623-PMC4113768	['there were no differences between the Placebo and Vitamin D groups for hba1c (hba1c difference: d2vs.']	N/A	N/A	[('CHEBI_26130', 'biological pigment', 38, 'placebo'), ('CHEBI_27300', 'vitamin D', 50, 'vitamin D')]
PMC4113768	7/2014	S2670-PMC4113768	['mean (sd) 25(Oh)D changed from 73 (22) nmol/l at baseline to 124(28) nmol/l at 18-months in the Vitamin D group, and from 71(22) to 56(22) nmol/l in the placebo group.']	N/A	N/A	[('CHEBI_71657', 'versiconol acetate', 10, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 96, 'vitamin D')]
PMC4113768	7/2014	S2672-PMC4113768	['the mean change (95% confidence interval) in bp from baseline in the Vitamin D group compared with placebo group: at 5-months was −2.3(−4.3, −0.3) mmhg for systolic ( p = 0.021) and −0.6(−2.8, 1.6) mmhg for diastolic ( p = 0.61); and at 18-months was −0.6(−2.8, 1.6) mmhg for systolic ( p = 0.61) and 0.5 (−1.1, 2.2) mmhg for diastolic ( p = 0.53).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 69, 'vitamin D')]
PMC4113768	7/2014	S2679-PMC4113768	['background: in 2011 we introduced a direct-to-the-public Vitamin D testing service using dried Blood Spots (dbs).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 57, 'vitamin D'), ('UBERON_0001969', 'blood plasma', 95, 'blood spots')]
PMC4113768	7/2014	S2705-PMC4113768	['background: in 2011 we introduced a direct-to-the-public Vitamin D testing service using dried Blood Spots (dbs).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 57, 'vitamin D'), ('UBERON_0001969', 'blood plasma', 95, 'blood spots')]
PMC4113768	7/2014	S2713-PMC4113768	['one had been prescribed Vitamin D, the other was taking up to 100,000 iu/day against the advice of her consultant.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 24, 'vitamin D')]
PMC4113768	7/2014	S2761-PMC4113768	['background: the Vitamin D Metabolites are transported in the circulation by Vitamin D-Binding Protein (dbp) which is a Water-soluble carrier-protein.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 16, 'vitamin D'), ('CHEBI_25212', 'metabolite', 26, 'metabolites'), ('CHEBI_27300', 'vitamin D', 76, 'vitamin D'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 76, 'vitamin D-binding protein'), ('CHEBI_15377', 'water', 119, 'water')]
PMC4113768	7/2014	S2797-PMC4113768	['Cathelicidin mrna (a Vitamin D responsive Antimicrobial peptide; hcap-18/Ll37) was undetectable in both cell lines, but was induced by 1,25(Oh)2D3And 25(oh)d3in rt4 cells (6–24 h; p< 0.05).']	N/A	N/A	[('PR_000004907', 'complement component C7', 0, 'Cathelicidin'), ('CHEBI_27300', 'vitamin D', 21, 'vitamin D'), ('CHEBI_65381', 'albizoside C', 42, 'antimicrobial'), ('PR_000009801', 'DNA ligase 3', 73, 'LL37'), ('CHEBI_74895', '(223)RaCl2', 139, '(OH)2D3and')]
PMC4113768	7/2014	S2812-PMC4113768	['ajcn 1997, 65 , s1240–s1245), uv-b intensity is insufficient to synthesise Vitamin D for 6 months of the year, spanning october-march.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 75, 'vitamin D')]
PMC4113768	7/2014	S2822-PMC4113768	['the ffq was composed of 17 questions to document the habitual frequency of Consumption and portion size of foods known to be sources of Vitamin D (including natural sources, fortified foods and dietary supplements).']	N/A	N/A	[('GO_0007631', 'feeding behavior', 75, 'consumption'), ('CHEBI_27300', 'vitamin D', 136, 'vitamin D')]
PMC4113768	7/2014	S2826-PMC4113768	['the mean daily total Vitamin D intake reported (Food + supplements) using the ffq was 8.04 µg (range 1.0–36.1 µg), and that from the wfr was 5.64 µg (range 0.4–31.7 µg).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 21, 'vitamin D'), ('CHEBI_33290', 'food', 48, 'food')]
PMC4113768	7/2014	S2830-PMC4113768	['the mean difference between the Vitamin D intake quantified from the wfr and ffq equalled +1.62 (sd 3.86).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 32, 'vitamin D')]
PMC4113768	7/2014	S2855-PMC4113768	['25(Oh)D3Serum levels were evaluated by radioimmunoassay: Vitamin D concentrations were classified as normal (>30 ng/ml), insufficient (30 < 25(Oh)D3< 10 ng/ml) or deficient (<10 ng/ml) (holick, m.f.']	N/A	N/A	[('CHEBI_77855', '3-chlorolactic acid', 0, '25(OH)D3serum'), ('PR_000012979', 'DNA-directed DNA/RNA polymerase mu', 6, 'D3serum'), ('CHEBI_27300', 'vitamin D', 57, 'vitamin D'), ('CHEBI_31948', 'Oxoassoanine', 143, 'OH)D3'), ('PR_000011622', 'S-acyl fatty acid synthase thioesterase, medium chain', 143, 'OH)D3')]
PMC4113768	7/2014	S2919-PMC4113768	['Vitamin D acts through the Vitamin D receptor to promote Cellular Differentiation and inhibit Proliferation and inflammation.']	N/A	N/A	[('CHEBI_28384', 'vitamin K', 0, 'Vitamin D'), ('CHEBI_27300', 'vitamin D', 27, 'vitamin D'), ('GO_0030154', 'cell differentiation', 57, 'cellular differentiation'), ('GO_0008283', 'cell proliferation', 94, 'proliferation')]
PMC4113768	7/2014	S2925-PMC4113768	['results: the percentage of hgd lesions in the large Airways was reduced in the Vitamin D sufficient Mice (Sn) (8.72%, p< 0.05), sn + Calcitriol (sn + c) (6.59%, p< 0.05) and the Vitamin D deficient + Calcitriol (dn + c) (12.3%, p< 0.05) groups compared to the dn (22.67%) group after 15 w of ntcu.']	N/A	N/A	[('UBERON_0001005', 'respiratory airway', 52, 'airways'), ('CHEBI_27300', 'vitamin D', 79, 'vitamin D'), ('NCBITaxon_10088', 'Mus <genus>', 100, 'mice'), ('UBERON_0001322', 'sciatic nerve', 106, 'SN'), ('CHEBI_17823', 'calcitriol', 133, 'calcitriol'), ('CHEBI_27300', 'vitamin D', 178, 'vitamin D'), ('CHEBI_17823', 'calcitriol', 200, 'calcitriol')]
PMC4113768	7/2014	S2967-PMC4113768	['routine treatment includes phosphate restriction ± binding agents and Vitamin D Receptor activators (Vdra) such as Calcitriol [1,25(Oh)D], Alfacalcidol or paricalcitol.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 70, 'vitamin D'), ('PR_000001683', 'vasopressin V2 receptor', 70, 'vitamin D receptor'), ('PR_000017279', 'testis-specific basic protein Y 1', 101, 'VDRa'), ('CHEBI_17823', 'calcitriol', 115, 'calcitriol'), ('CHEBI_82678', '3beta-hydroxy-7-oxo-5beta-cholan-24-oic acid', 127, '1,25(OH)D'), ('CHEBI_31186', 'alfacalcidol', 139, 'alfacalcidol')]
PMC4113768	7/2014	S2975-PMC4113768	['at this point the patient’s Vitamin D status was assessed as insufficient and Vitamin D3Supplementation commenced.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 28, 'vitamin D'), ('CHEBI_52915', 'phosphatediyl group', 78, 'vitamin D3supplementation')]
PMC4113768	7/2014	S2995-PMC4113768	['; petchey, m.; higgins, r.; fletcher, s.; zehnder, d.; bland, r.\nbackground: supplementation with Calcitriol (1,25-Dihydroxy Vitamin D; or analogue) is used routinely in patients with chronic Kidney disease (ckd).']	N/A	N/A	[('CHEBI_17823', 'calcitriol', 98, 'calcitriol'), ('CHEBI_50050', 'cystinyl group', 114, '-dihydroxy'), ('CHEBI_27300', 'vitamin D', 125, 'vitamin D'), ('UBERON_0002113', 'kidney', 192, 'kidney')]
PMC4113768	7/2014	S3045-PMC4113768	['among the 42% of women who took a Vitamin D-containing supplement at 15 weeks Gestation, 31 and 72% of the Cords were <30 and 50 nmol/l, respectively.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 34, 'vitamin D'), ('GO_0007565', 'female pregnancy', 78, 'gestation'), ('UBERON_0005297', 'testis sex cord', 107, 'cords')]
PMC4113768	7/2014	S3072-PMC4113768	['conclusions: high dose Vitamin D supplementations do not improve the glycaemic indices or the Cardiovascular risk factors in a population with prediabetes.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 23, 'vitamin D'), ('UBERON_0004535', 'cardiovascular system', 94, 'cardiovascular')]
PMC4113768	7/2014	S3081-PMC4113768	['methods: we randomised 180 Pregnant women at 27 weeks Gestation to either no Vitamin D, 800 iu Ergocalciferol daily until Delivery or single oral bolus of 200,000 iu Cholecalciferol, in an ethnically stratified, randomised controlled trial.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 27, 'pregnant'), ('GO_0007565', 'female pregnancy', 54, 'gestation'), ('CHEBI_27300', 'vitamin D', 77, 'vitamin D'), ('CHEBI_4910', 'etomidate', 95, 'ergocalciferol'), ('GO_0007567', 'parturition', 122, 'delivery'), ('CHEBI_52550', 'theopalauamide', 166, 'cholecalciferol')]
PMC4113768	7/2014	S3082-PMC4113768	['supplementation improved but did not optimise Vitamin D status.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 46, 'vitamin D')]
PMC4113768	7/2014	S3089-PMC4113768	['we found no difference between supplemented and control groups in risk of wheeze (no Vitamin D: 14/50 (28%); any Vitamin D: 26/108 (24%) (risk ratio 0.86; 95% confidence interval 0.49, 1.50; p = 0.69)).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 85, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 113, 'vitamin D')]
PMC4113768	7/2014	S3137-PMC4113768	['methods: published literature was searched for relevant articles of 10 mcg (400 iu) Vitamin D supplementation or fortification.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 84, 'vitamin D')]
PMC4113768	7/2014	S3138-PMC4113768	['exclusion criteria were: Nonhuman studies (cell, Animal); review articles; studies lacking Blood level data pre- and post-treatment; no control group; bolus treatments (weekly, monthly, yearly); Vitamin D < 5 mcg (200 iu) or >20 mcg (800 iu); baseline 25(Oh)d > 75 nmol/l; patient studies (e.g., diabetes, cancer, cvd); studies < 2 months; age < 19 years.']	N/A	N/A	[('NCBITaxon_33208', 'Metazoa', 25, 'nonhuman'), ('NCBITaxon_33208', 'Metazoa', 49, 'animal'), ('UBERON_0000178', 'blood', 91, 'blood'), ('CHEBI_27300', 'vitamin D', 195, 'vitamin D'), ('CHEBI_63056', 'zinc cation', 252, '25(OH')]
PMC4113768	7/2014	S3187-PMC4113768	['the significant predictors of lower Vitamin D status identified using multivariable logistic regression model were: urban setting, female sex, high maternal education, greater Triceps skinfold thickness, less sun exposure, less body surface area exposed, having television/computer in the home, and high socioeconomic status [aor(2.74–19.57): 95% ci (1.23, 69.21)].']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 36, 'vitamin D'), ('UBERON_0001509', 'triceps brachii', 176, 'triceps')]
PMC4113768	7/2014	S3197-PMC4113768	['season of Blood sampling, health, lifestyle, socio-economic and anthropometric data were collected and included as potential predictors of Vitamin D status in regression models.']	N/A	N/A	[('UBERON_0000178', 'blood', 10, 'blood'), ('CHEBI_27300', 'vitamin D', 139, 'vitamin D')]
PMC4113768	7/2014	S3199-PMC4113768	['the prevalence of Vitamin D deficiency (Serum 25(Oh)D < 30 nmol/l) varied significantly with season with 51% and 23% of participants deficient during spring and autumn respectively ( p< 0.001).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 18, 'vitamin D'), ('UBERON_0001977', 'blood serum', 40, 'serum'), ('CHEBI_71657', 'versiconol acetate', 46, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 46, '25(OH)D')]
PMC4113768	7/2014	S3269-PMC4113768	['methods: we conducted a multi-centre double-blind randomised placebo-controlled trial of Vitamin D supplementation in Adults with gold stage i-iv copd in london, uk.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 89, 'vitamin D'), ('UBERON_0007023', 'adult organism', 118, 'adults')]
PMC4113768	7/2014	S3341-PMC4113768	['Vitamin D inadequate (Serum 25Ohd of 30~50 nmol/l) accounted for 35.9% of all Pregnant women, and only 24.0% of Pregnant women were Vitamin D sufficient.']	N/A	N/A	[('CHEBI_28384', 'vitamin K', 0, 'Vitamin D'), ('UBERON_0001977', 'blood serum', 22, 'serum'), ('CHEBI_72652', "7,2'-dihydroxy-4'-methoxyisoflavan-4-ylium cation", 28, '25OHD'), ('GO_0007565', 'female pregnancy', 78, 'pregnant'), ('GO_0007565', 'female pregnancy', 112, 'pregnant'), ('CHEBI_27300', 'vitamin D', 132, 'vitamin D')]
PMC4113768	7/2014	S3342-PMC4113768	['moreover, in the winter, most (58.7%) of Pregnant women were the deficiency of Vitamin D, and only 7.5% of the Pregnant women were adequate to Vitamin D. of the 32 newborns, all were deficient in Vitamin D. (2) maternal Vitamin D levels among different seasons were significant different (χ2= 326.15, p< 0.001), and the lowest level of Vitamin D was in the winter, and the highest was in the summer.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 41, 'pregnant'), ('CHEBI_27300', 'vitamin D', 79, 'vitamin D'), ('GO_0007565', 'female pregnancy', 111, 'pregnant'), ('CHEBI_27300', 'vitamin D', 143, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 196, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 220, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 336, 'vitamin D')]
PMC4113768	7/2014	S3343-PMC4113768	['(3) among different age groups of Pregnant women, Vitamin D levels had significant difference (χ2= 11.82, p = 0.003).']	N/A	N/A	[('GO_0007565', 'female pregnancy', 34, 'pregnant'), ('CHEBI_27300', 'vitamin D', 50, 'vitamin D')]
PMC4113768	7/2014	S3344-PMC4113768	['the Vitamin D level in 30~35 age group of Pregnant women (median: 36.2 nmol/l, range: 13.8~108.7 nmol/l) was higher than that in the 25~30 age group (median: 35.9 nmol/l, range: 10.4~89.8 nmol/l) and the 18~25 age group (median: 33.3 nmol/l, range: 10.1~85.2 nmol/l).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 4, 'vitamin D'), ('GO_0007565', 'female pregnancy', 42, 'pregnant')]
PMC4113768	7/2014	S3368-PMC4113768	['methods: we first performed a Genome-wide methylation scan using the illumina Human methylation 27 bead-chip on Leukocyte dna of 11 young african american males with severe Vitamin D deficiency (25(Oh)D ≤ 10 ng/ml) and 11 matched controls (25(Oh)D ≥ 30 ng/ml).']	N/A	N/A	[('SO_0001026', 'genome', 30, 'genome'), ('NCBITaxon_10088', 'Mus <genus>', 78, 'Human'), ('CL_0000738', 'leukocyte', 112, 'leukocyte'), ('CHEBI_27300', 'vitamin D', 173, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 195, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 201, 'D'), ('CHEBI_71657', 'versiconol acetate', 240, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 246, 'D')]
PMC4113768	7/2014	S3369-PMC4113768	['then, we conducted a 16-weeks randomized, placebo controlled clinical trial of Vitamin D supplementation (nct01583621).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 79, 'vitamin D')]
PMC4113768	7/2014	S3370-PMC4113768	['a total of 65 young overweight and obese african americans with Vitamin D deficiency (25(Oh)D) ≤20 ng/ml were randomly assigned to receive a supervised monthly oral Vitamin D3Dose of placebo ( n = 16), 18,000 iu (~600 iu/day, the current rda; n = 15), 60,000 iu (~2000 iu/day; n = 17), or 120,000 iu (~4000 iu/day, the deemed tolerable upper Intake level; n = 17).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 64, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 86, '25(OH)D'), ('CHEBI_27353', 'xylulose', 165, 'vitamin D3dose'), ('GO_0007631', 'feeding behavior', 342, 'intake')]
PMC4142706	7/2014	S139-PMC4142706	['there was no significant effect of intervention with a Mix of Selenium, Retinol, Β-Carotene, Vitamin C, and Vitamin E for 6 weeks (caple et al., 2010), nor after a broccoli-rich diet for 10 days in a crossover trial (riso et al., 2010).']	N/A	N/A	[('CHEBI_60004', 'mixture', 55, 'mix'), ('CHEBI_27568', 'selenium atom', 62, 'selenium'), ('CHEBI_26536', 'retinoic acid', 72, 'retinol'), ('CHEBI_28064', 'cyanidin 3-O-rutinoside', 81, 'β-carotene'), ('CHEBI_27300', 'vitamin D', 93, 'vitamin C'), ('CHEBI_27300', 'vitamin D', 108, 'vitamin E')]
PMC4160835	9/2014	S63-PMC4160835	['overall Food pattern was described as scores on a principal component denoted as a ‘health and sustainability component’, derived by principal component analysis and ranked into tertiles.33dietary Supplement use reported in the Food frequency questionnaire was computed as a categorical variable with three categories: no Supplement use, use of any Supplement without Vitamin D and use of a Vitamin D containing supplement.']	N/A	N/A	[('CHEBI_33290', 'food', 8, 'food'), ('CHEBI_16158', 'steroid sulfate', 197, 'supplement'), ('CHEBI_33290', 'food', 228, 'food'), ('CHEBI_16158', 'steroid sulfate', 322, 'supplement'), ('CHEBI_16158', 'steroid sulfate', 349, 'supplement'), ('CHEBI_27300', 'vitamin D', 368, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 391, 'vitamin D')]
PMC4169453	9/2014	S29-PMC4169453	['higher Serum 25(Oh)D levels, prevalence of Vitamin D sufficiency, fat mass loss as well as a lower prevalence of Vitamin D deficiency and decrease of bone mass are expected in Lactating women.']	N/A	N/A	[('UBERON_0001977', 'blood serum', 7, 'serum'), ('CHEBI_71657', 'versiconol acetate', 13, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 43, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 113, 'vitamin D'), ('GO_0007594', 'puparial adhesion', 176, 'lactating')]
PMC4169453	9/2014	S30-PMC4169453	['materials and methods\n\nstudy design\nthe study was designed as a prospective, double-blinded, randomized, controlled trial of Vitamin D supplementation during Lactation.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 125, 'vitamin D'), ('GO_0007595', 'lactation', 158, 'lactation')]
PMC4169453	9/2014	S67-PMC4169453	['the cross-reactivity with other Vitamin D Metabolites and detection limit (4 ng/ml) was provided by the manufacturer (liaison, diasorin, sallugia, italy).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 32, 'vitamin D'), ('CHEBI_25212', 'metabolite', 42, 'metabolites')]
PMC4169453	9/2014	S79-PMC4169453	['dietary Vitamin D intake\ninfant dietary Vitamin D intake was calculated at all visits using a questionnaire that assessed the type of Feeding (exclusive breastfeeding, partial breastfeeding), daily volume of infant formula consumed, or complementary Food Ingested during the study period.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 8, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 40, 'vitamin D'), ('GO_0007631', 'feeding behavior', 134, 'feeding'), ('CHEBI_33290', 'food', 250, 'food'), ('GO_0007631', 'feeding behavior', 255, 'ingested')]
PMC4169453	9/2014	S80-PMC4169453	['the Vitamin D concentration per 100 ml of infant formula or complementary Food was obtained from the manufacturers.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 4, 'vitamin D'), ('CHEBI_33290', 'food', 74, 'food')]
PMC4169453	9/2014	S81-PMC4169453	['mean daily dietary Vitamin D intake was a product of the mean daily volume consumed during the study period and the Vitamin D concentration of the formula.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 19, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 116, 'vitamin D')]
PMC4169453	9/2014	S82-PMC4169453	['a precise calculation of Vitamin D intake from Breast Milk was not possible.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 25, 'vitamin D'), ('UBERON_0001348', 'brown adipose tissue', 47, 'breast milk')]
PMC4169453	9/2014	S94-PMC4169453	['a two-factor repeated-measures anova (with box-cox transformation for baseline maternal 25(Oh)D level and infants’ 25(Oh)D levels at Birth, and at 3 and 6 months of age) with time and Vitamin D dose (group) as factors was used to analyze maternal and infants’ Serum 25(Oh)D levels.']	N/A	N/A	[('CHEBI_71657', 'versiconol acetate', 88, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 88, '25(OH)D'), ('CHEBI_71657', 'versiconol acetate', 115, '25(OH)D'), ('GO_0007567', 'parturition', 133, 'birth'), ('CHEBI_27300', 'vitamin D', 184, 'vitamin D'), ('UBERON_0001977', 'blood serum', 260, 'serum'), ('CHEBI_71657', 'versiconol acetate', 266, '25(OH)D'), ('PR_000009880', 'Lon protease, mitochondrial', 266, '25 ... OH ... D')]
PMC4169453	9/2014	S111-PMC4169453	['the groups were similar in all baseline characteristics, including Vitamin D status (fig.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 67, 'vitamin D')]
PMC4169453	9/2014	S115-PMC4169453	['percentage of participants with Serum 25(Oh)D level <20 ng/ml, 20–29.9 ng/ml and >30 ng/ml in both study groups (maternal Vitamin D intake 400 iu/d vs. 1200 iu/d).']	N/A	N/A	[('UBERON_0001977', 'blood serum', 32, 'serum'), ('CHEBI_71657', 'versiconol acetate', 38, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 38, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 122, 'vitamin D')]
PMC4169453	9/2014	S116-PMC4169453	['significant ( p<0.05 ) differences between the study groups are shown on the figures.10.1371/journal.pone.0107708.g003\n\ncaption (fig): figure 3\nmaternal (a) and infants’ (b) Serum 25(Oh)D concentrations at baseline and during Vitamin D supplementation in the study groups (maternal Vitamin D dose: 400 iu/d vs. 1200 iu/d).']	N/A	N/A	[('UBERON_0001977', 'blood serum', 174, 'serum'), ('CHEBI_71657', 'versiconol acetate', 180, '25(OH)D'), ('PR_000009880', 'Lon protease, mitochondrial', 180, '25 ... OH ... D'), ('CHEBI_27300', 'vitamin D', 226, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 282, 'vitamin D')]
PMC4169453	9/2014	S121-PMC4169453	['the study visits: v0- the baseline visit, v3, v6 – the visits after 3 and 6 months of Vitamin D supplementation.10.1371/journal.pone.0107708.t001\n\ncaption (table-wrap): table 1\nsociodemographic and clinical characteristics of the mothers and infants at study enrollment based on vitamin d supplementation group.parameter400 iu/d group1200 iu/d group p -value between groups mathers n\u200a=\u200a67n\u200a=\u200a70age, years30 (27–33)30 (26–34)0.89baseline bmi, kg/m224.4 (22.1–27.3)23.8 (22.1–26.8)0.49bmi>30, n (%)8 (12%)5 (7%)0.34weight before Delivery, kg77.4 (69–86)74 (67–83)0.26season at Delivery, n (%)june–october25 (37%)22 (31%)0.47november–may42 (63%)48 (69%)education, n (%)>high school5 (8%)5 (7%)0.04high school27 (41%)15 (21%)college or more34 (52%)50 (71%)monthly income, n (%)<250 euro/capita16 (24%)16 (23%)0.59250–750 euro/capita32 (49%)37 (54%)>750 euro/capita18 (27%)16 (23%)Vitamin D during Pregnancy,n (%)46 (69%)50 (71%)0.73daily dose, iu/d400 (200–800)400 (200–800)0.70duration, months7 (6–9)7 (5–9)0.87 infants n\u200a=\u200a67n\u200a=\u200a70age at baseline visit, days18 (14–22)15 (13–20)0.09boys, n (%)29 (44%)27 (38%)0.48birth weight, g3500 (3200–3815)3480 (3280–3640)0.80birth length, cm55 (53–57)55 (53–56)0.25\ndata are presented as median and interquartile range (q1–q3) or number and (%).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 86, 'vitamin D'), ('GO_0007567', 'parturition', 527, 'delivery'), ('GO_0007567', 'parturition', 575, 'delivery'), ('CHEBI_28384', 'vitamin K', 876, 'Vitamin D'), ('GO_0007565', 'female pregnancy', 893, 'pregnancy')]
PMC4169453	9/2014	S127-PMC4169453	['the mean maternal 25(Oh)D increment was 5.5±8.4 ng/ml in the 400 iu/d group and 10.8±9.4 ng/ml in the 1200 iu/d group ( p \u200a=\u200a0.0009) after 6 months of Vitamin D supplementation.']	N/A	N/A	[('CHEBI_71657', 'versiconol acetate', 18, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 18, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 151, 'vitamin D')]
PMC4169453	9/2014	S129-PMC4169453	['the prevalence of maternal Vitamin D deficiency was significantly higher in the 400 iu/d group at v3 (25.4% vs.8.6%; p \u200a=\u200a0.009) and v6 (29.9% vs. 14.3%; p \u200a=\u200a0.028) (fig.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 27, 'vitamin D')]
PMC4169453	9/2014	S137-PMC4169453	['the prevalence of infants’ Vitamin D deficiency and sufficiency was also comparable across the study groups (fig.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 27, 'vitamin D')]
PMC4169453	9/2014	S143-PMC4169453	['maternal and infant dietary Vitamin D intake, sun exposure, and compliance are presented intable 3.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 28, 'vitamin D')]
PMC4169453	9/2014	S175-PMC4169453	['more than 60% of mothers and newborns were Vitamin D-deficient, and less than 10% of mothers and newborns had 25(Oh)D >30 ng/ml.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 43, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 110, '25(OH)D'), ('PR_000005506', 'Cbp/p300-interacting transactivator 2', 110, '25('), ('PR_000006444', 'diacylglycerol kinase delta', 116, 'D')]
PMC4169453	9/2014	S176-PMC4169453	['fortunately, as early as 3 months after implementing Vitamin D supplementation, 25(Oh)D levels increased.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 53, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 80, '25(OH)D')]
PMC4169453	9/2014	S207-PMC4169453	['we observed a slightly higher maternal 25(Oh)D increment during Vitamin D supplementation (5.5 ng/ml in the 400 iu/d group and 11 ng/ml in the 1200 iu/d) due to additional input from diet and endogenous Skin Synthesis[37],[43].']	N/A	N/A	[('CHEBI_71657', 'versiconol acetate', 39, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 45, 'D'), ('CHEBI_27300', 'vitamin D', 64, 'vitamin D'), ('GO_0009697', 'salicylic acid biosynthetic process', 203, 'skin synthesis')]
PMC4169453	9/2014	S242-PMC4169453	['furthermore, maternal Vitamin D3 supplementation during Lactation at a dose up to 1200 iu/d had no influence on maternal and infant body composition or infant Vitamin D status.']	N/A	N/A	[('CHEBI_33279', 'vitamin D5', 22, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 22, 'vitamin D3'), ('GO_0007595', 'lactation', 56, 'lactation'), ('CHEBI_27300', 'vitamin D', 159, 'vitamin D')]
PMC4171568	9/2014	S71-PMC4171568	['in a double-blind rct, 40 patients with schizophrenia were tested for Serum Malondialdehyde (Mda; a marker of Lipid peroxidation) and Plasma Ascorbic Acid at baseline and eight weeks following supplementations with Vitamin C [46].']	N/A	N/A	[('UBERON_0001977', 'blood serum', 70, 'serum'), ('CHEBI_16480', 'nitric oxide', 76, 'malondialdehyde'), ('CHEBI_34840', 'methyl methacrylate', 93, 'MDA'), ('CHEBI_18059', 'lipid', 110, 'lipid'), ('UBERON_0001969', 'blood plasma', 134, 'plasma'), ('CHEBI_22652', 'ascorbic acid', 141, 'ascorbic acid'), ('CHEBI_27300', 'vitamin D', 215, 'vitamin C')]
PMC4172095	8/2014	S137-PMC4172095	['such Foods include dark leafy greens, which contain high levels of b vitamins, iron, magnesium and Vitamin A, Legumes, such as beans and Lentils, which are a good source of Folate, iron, and magnesium, as well as whole unrefined grains, which contain b Vitamins and magnesium (kaiser et al., 2002).']	N/A	N/A	[('CHEBI_33290', 'food', 5, 'foods'), ('CHEBI_27300', 'vitamin D', 99, 'vitamin A'), ('NCBITaxon_7955', 'Danio rerio', 110, 'legumes'), ('NCBITaxon_7955', 'Danio rerio', 137, 'lentils'), ('CHEBI_30863', '5-azaorotic acid', 173, 'folate'), ('CHEBI_33277', 'gamma-tocotrienol', 253, 'vitamins')]
PMC4176103	10/2013	S151-PMC4176103	['they also had significantly higher intakes of dietary fibre (20.3\xa0g vs. 18.8\xa0g, p\u2009<\u20090.01 ), Vitamin A (949.6\xa0μg vs. 896.8\xa0μg, p\u2009<\u20090.05 ) and magnesium (265.8\xa0mg vs. 249.3\xa0mg, p\u2009<\u20090.001 ) at trimester 3 (data not presented).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 92, 'vitamin A')]
PMC4188019	1/2010	S3-PMC4188019	['method : from august 1 2009 until november 30 2009 we systematically determined 25-Hydroxy Vitamin D (25-Oh Vitamin D) in each Blood sample taken from Pregnant women visiting the Antenatal clinic.']	N/A	N/A	[('CHEBI_62218', '23,24-dihydrocucurbitacin D', 80, '25-hydroxy vitamin D'), ('CHEBI_86198', '1,2-di-[(11Z)-eicosenoyl]-sn-glycero-3-phosphocholine', 102, '25-OH'), ('CHEBI_27300', 'vitamin D', 108, 'vitamin D'), ('UBERON_0000178', 'blood', 127, 'blood'), ('GO_0007565', 'female pregnancy', 151, 'pregnant'), ('GO_0007567', 'parturition', 179, 'antenatal')]
PMC4188019	1/2010	S6-PMC4188019	['the mean value of 25-Oh Vitamin D was 28\u2008ng/ml.']	N/A	N/A	[('CHEBI_86198', '1,2-di-[(11Z)-eicosenoyl]-sn-glycero-3-phosphocholine', 18, '25-OH'), ('CHEBI_27300', 'vitamin D', 24, 'vitamin D')]
PMC4188019	1/2010	S9-PMC4188019	['there were significantly more covered than non-covered women with a Vitamin D concentration lower than 30\u2008ng/ml (or6.2; 95% ci: 1,8-21,7; p\u2008<\u20080,05).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 68, 'vitamin D')]
PMC4188019	1/2010	S10-PMC4188019	['there was no effect of Gestational age, maternal age, gravidity, parity and intake of supplements on Vitamin D levels.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 23, 'gestational'), ('CHEBI_27300', 'vitamin D', 101, 'vitamin D')]
PMC4188019	1/2010	S15-PMC4188019	['in the Liver, Vitamin D is hydroxylated to 25-Hydroxyvitamin D. subsequent hydroxylation in the Kidney forms the active Metabolite, 1,25-Oh vitamin D.\nin Pregnancy, there is a 2-fold higher concentration of 1,25-Oh Vitamin D in maternal Serum due to activity of Placental 1-α-hydroxylase (novakovic et al., 2009).']	N/A	N/A	[('UBERON_0002107', 'liver', 7, 'liver'), ('CHEBI_27300', 'vitamin D', 14, 'vitamin D'), ('CHEBI_62218', '23,24-dihydrocucurbitacin D', 43, '25-hydroxyvitamin D'), ('UBERON_0002113', 'kidney', 96, 'kidney'), ('CHEBI_39382', 'flufenoxuron', 120, 'metabolite'), ('CHEBI_86198', '1,2-di-[(11Z)-eicosenoyl]-sn-glycero-3-phosphocholine', 134, '25-OH'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 148, 'D'), ('GO_0007565', 'female pregnancy', 154, 'pregnancy'), ('CHEBI_72639', '13-HODE', 207, '1,25-OH'), ('CHEBI_27300', 'vitamin D', 215, 'vitamin D'), ('UBERON_0001977', 'blood serum', 237, 'serum'), ('UBERON_0001987', 'placenta', 262, 'placental')]
PMC4188019	1/2010	S24-PMC4188019	['results of Vitamin D status in the Pregnant flemish population have never been published before.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 11, 'vitamin D'), ('GO_0007565', 'female pregnancy', 35, 'pregnant')]
PMC4188019	1/2010	S27-PMC4188019	['in each Blood sample that was taken from Pregnant women consulting the Antenatal clinic, we determined 25-Oh Vitamin D. the nurse taking the Blood samples put every patient in a category according to their sun exposure.']	N/A	N/A	[('UBERON_0000178', 'blood', 8, 'blood'), ('GO_0007565', 'female pregnancy', 41, 'pregnant'), ('GO_0007567', 'parturition', 71, 'antenatal'), ('CHEBI_86198', '1,2-di-[(11Z)-eicosenoyl]-sn-glycero-3-phosphocholine', 103, '25-OH'), ('CHEBI_27300', 'vitamin D', 109, 'vitamin D'), ('UBERON_0000178', 'blood', 141, 'blood')]
PMC4188019	1/2010	S36-PMC4188019	['normality was tested with the kolmogorov-smirnov test, the means of Vitamin D between all three groups were compared with anova-analysis.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 68, 'vitamin D')]
PMC4188019	1/2010	S41-PMC4188019	['the odd’s ratio between covered and non-covered women with Vitamin D levels lower than 30\u2008ng/ml was calculated, and 95% confidence intercal group were also compared using the chi squared test.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 59, 'vitamin D')]
PMC4188019	1/2010	S47-PMC4188019	['they all used the same brand containing 10\u2008microgram (400\u2008iu) of Vitamin D. in the entire population the mean 25-Oh Vitamin D value was 28\u2008±\u200812,4 (sd) ng/ml.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 65, 'vitamin D'), ('CHEBI_86198', '1,2-di-[(11Z)-eicosenoyl]-sn-glycero-3-phosphocholine', 110, '25-OH'), ('CHEBI_27300', 'vitamin D', 116, 'vitamin D')]
PMC4188019	1/2010	S48-PMC4188019	['there was no effect of age, gravidity, parity, Intake of Supplements nor Gestational age on the Vitamin D level.']	N/A	N/A	[('GO_0007631', 'feeding behavior', 47, 'intake'), ('CHEBI_33341', 'titanium atom', 57, 'supplements'), ('GO_0007565', 'female pregnancy', 73, 'gestational'), ('CHEBI_27300', 'vitamin D', 96, 'vitamin D')]
PMC4188019	1/2010	S50-PMC4188019	['the mean Vitamin D value of women taking Supplements was 28,5\u2008±\u200812,5 (sd) ng/ml, the group without Supplements had a mean of 27,9\u2008±\u200812,5 (sd) ng/ml.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 9, 'vitamin D'), ('CHEBI_33341', 'titanium atom', 41, 'supplements'), ('CHEBI_33341', 'titanium atom', 99, 'supplements')]
PMC4188019	1/2010	S54-PMC4188019	['the mean 25-Oh Vitamin D value in the non-covered group was 29,5\u2008±\u200812,2 (sd) ng/ml.']	N/A	N/A	[('CHEBI_86198', '1,2-di-[(11Z)-eicosenoyl]-sn-glycero-3-phosphocholine', 9, '25-OH'), ('CHEBI_27300', 'vitamin D', 15, 'vitamin D')]
PMC4188019	1/2010	S55-PMC4188019	['there was a significant difference in Vitamin D level between the three groups (anova, p\u2008=\u20080,001) (fig.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 38, 'vitamin D')]
PMC4188019	1/2010	S62-PMC4188019	['discussion\nthe mean Vitamin D value of our population, 28\u2008ng/ml, was below the reference range used in our laboratory.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 20, 'vitamin D')]
PMC4188019	1/2010	S68-PMC4188019	['we found no effect of maternal age, Gestational age, parity, gravidity and intake of supplements on the Vitamin D level.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 36, 'gestational'), ('CHEBI_27300', 'vitamin D', 104, 'vitamin D')]
PMC4188019	1/2010	S71-PMC4188019	['the most commonly prescribed multivitamin preparation in belgium, only contains 10\u2008µg (400\u2008iu) of Vitamin D, a value that will not suffice to maintain or build sufficient levels.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 98, 'vitamin D'), ('PR_000006444', 'diacylglycerol kinase delta', 106, 'D')]
PMC4192458	9/2014	S50-PMC4192458	['dietary Intake data were converted into uniform units when inconsistently reported across studies (kcal/day for total energy intake; mg/day for Calcium, Vitamin C, and Sodium; g/day for N-3 Fatty Acids and mcg/day for Vitamin D).']	N/A	N/A	[('GO_0007631', 'feeding behavior', 8, 'intake'), ('CHEBI_22313', 'alkaline earth metal atom', 144, 'calcium'), ('CHEBI_27300', 'vitamin D', 153, 'vitamin C'), ('CHEBI_52632', 'potassium-39 atom', 168, 'sodium'), ('CHEBI_35418', 'N-acetylneuraminate', 186, 'n-3 fatty acids'), ('CHEBI_27300', 'vitamin D', 218, 'vitamin D')]
PMC4194375	10/2014	S124-PMC4194375	['these women also increased their Consumption of Vitamin A, Vitamin C and Folate overall, compared with women in the standard care group (table\xa03).']	N/A	N/A	[('GO_0007631', 'feeding behavior', 33, 'consumption'), ('CHEBI_27300', 'vitamin D', 48, 'vitamin A'), ('CHEBI_27300', 'vitamin D', 59, 'vitamin C'), ('CHEBI_30863', '5-azaorotic acid', 73, 'folate')]
PMC4196482	11/2014	S4-PMC4196482	['treatment snacks contained 0.69 mj of energy (controls: 0.37 mj) and 10–23% of who reference Nutrient intakes of β-Carotene, riboflavin, Folate, Vitamin B-12, Calcium, and iron (controls: 0–7%).']	N/A	N/A	[('CHEBI_33284', 'nutrient', 93, 'Nutrient'), ('CHEBI_23042', 'carotene', 115, 'carotene'), ('CHEBI_30863', '5-azaorotic acid', 137, 'folate'), ('CHEBI_27300', 'vitamin D', 145, 'vitamin B'), ('PR_000004770', 'Polycomb complex protein BMI-1', 153, 'B-12'), ('CHEBI_22313', 'alkaline earth metal atom', 159, 'calcium')]
PMC4221707	11/2014	S6-PMC4221707	['results\nintake of Folate and Vitamin D from Foods was generally low for both groups.']	N/A	N/A	[('CHEBI_30863', '5-azaorotic acid', 18, 'folate'), ('CHEBI_27300', 'vitamin D', 29, 'vitamin D'), ('CHEBI_33290', 'food', 44, 'foods')]
PMC4221707	11/2014	S89-PMC4221707	['thus, the following additions were made: calcium, 200\xa0mg; iron, 18\xa0mg; Vitamin D, 7.5\xa0μg; Vitamin B12, 2.5\xa0μg; and Folate, 200\xa0μg.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 71, 'vitamin D'), ('CHEBI_33279', 'vitamin D5', 90, 'vitamin B12'), ('PR_000004738', 'class E basic helix-loop-helix protein 22', 98, 'B12'), ('CHEBI_30863', '5-azaorotic acid', 115, 'folate')]
PMC4221707	11/2014	S128-PMC4221707	['calcium 200\xa0mg, iron 18\xa0mg, Vitamin D 7.5\xa0μg, Folate 200\xa0μg as Folic Acid, and Vitamin B12 2.5\xa0μg.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 28, 'vitamin D'), ('CHEBI_30863', '5-azaorotic acid', 46, 'folate'), ('CHEBI_30751', 'formic acid', 63, 'folic acid'), ('CHEBI_33279', 'vitamin D5', 79, 'vitamin B12'), ('PR_000004481', 'V-type proton ATPase subunit B, kidney isoform', 79, 'vitamin B12')]
PMC4221707	11/2014	S147-PMC4221707	['both groups reported a low Intake from Foods of Folate and Vitamin D compared to the nnr.']	N/A	N/A	[('GO_0007631', 'feeding behavior', 27, 'intake'), ('CHEBI_33290', 'food', 39, 'foods'), ('CHEBI_30863', '5-azaorotic acid', 48, 'folate'), ('CHEBI_27300', 'vitamin D', 59, 'vitamin D')]
PMC4224012	11/2014	S22-PMC4224012	["gross domestic product is us$35·81 billion and per Person income is $1160 (at purchasing power parity), which places nepal 103rd in terms of wealth.22,23the Human Development index is 0·458, ranked 157th worldwide.23\nthe trial has been described previously.71200 women attending janakpur zonal hospital for Antenatal care were randomly allocated to receive either a multivitamin supplement (containing 800 μg Vitamin A, 10 mg Vitamin E, 5 μg Vitamin D, 1·4 mg vitamin b1, 1·4 mg Vitamin B2, 18 mg niacin, 1·9 mg Vitamin B6, 2·6 μg vitamin b12, 400 μg Folic Acid, 70 mg Vitamin C, 30 mg iron, 15 mg zinc, 2 mg copper, 65 μg Selenium, and 150 μg Iodine) or a control supplement of 60 mg Iron and 400 μg Folic Acid.6supplements were taken every day from 12 to 20 weeks' Gestation (average 15·9 weeks) until Delivery, and women were assessed every 2 weeks."]	N/A	N/A	[('NCBITaxon_10088', 'Mus <genus>', 51, 'person'), ('GO_0060976', 'coronary vasculature development', 157, 'Human Development'), ('NCBITaxon_10088', 'Mus <genus>', 157, 'Human'), ('GO_0007567', 'parturition', 307, 'antenatal'), ('CHEBI_27300', 'vitamin D', 409, 'vitamin A'), ('PR_000004370', 'asialoglycoprotein receptor 2', 417, 'A'), ('CHEBI_27300', 'vitamin D', 426, 'vitamin E'), ('CHEBI_27300', 'vitamin D', 442, 'vitamin D'), ('PR_000006444', 'diacylglycerol kinase delta', 450, 'D'), ('CHEBI_33279', 'vitamin D5', 479, 'vitamin B2'), ('CHEBI_33237', 'vitamin D4', 512, 'vitamin B6'), ('CHEBI_30751', 'formic acid', 551, 'folic acid'), ('CHEBI_27300', 'vitamin D', 569, 'vitamin C'), ('CHEBI_27568', 'selenium atom', 623, 'selenium'), ('CHEBI_24859', 'iodine atom', 644, 'iodine'), ('CHEBI_24870', 'ion', 685, 'iron'), ('CHEBI_30751', 'formic acid', 701, 'folic acid'), ('GO_0007565', 'female pregnancy', 767, 'gestation'), ('GO_0007567', 'parturition', 804, 'delivery')]
PMC4231606	10/2013	S6-PMC4231606	['children underwent a Blood draw for Vitamin D (25(Oh)D), calcium, Parathyroid hormone, and albumin levels.']	N/A	N/A	[('UBERON_0000178', 'blood', 21, 'blood'), ('CHEBI_27300', 'vitamin D', 36, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 47, '25(OH)D'), ('UBERON_0001132', 'parathyroid gland', 66, 'parathyroid')]
PMC4231606	10/2013	S29-PMC4231606	['there are two main sources of obtaining Vitamin D: endogenous synthesis and exogenous attainment from diet and supplementation [15,16].']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 40, 'vitamin D')]
PMC4231606	10/2013	S51-PMC4231606	['assays for 25(Oh)D, the main circulating form of Vitamin D, were conducted by the hospitals in common laboratory (hicl) at mount sinai hospital in toronto, canada using chemiluminescence immunoassay.']	N/A	N/A	[('CHEBI_71657', 'versiconol acetate', 11, '25(OH)D'), ('PR_000011040', 'nuclear receptor coactivator 1', 13, '(OH'), ('PR_000006444', 'diacylglycerol kinase delta', 17, 'D'), ('CHEBI_27300', 'vitamin D', 49, 'vitamin D')]
PMC4231606	10/2013	S57-PMC4231606	['multiple regression analysis was performed for mean 25(Oh)D including independent variables significantly associated with Vitamin D levels on bivariate analysis or known to influence Vitamin D status.']	N/A	N/A	[('CHEBI_71657', 'versiconol acetate', 52, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 58, 'D'), ('CHEBI_27300', 'vitamin D', 122, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 183, 'vitamin D')]
PMC4231606	10/2013	S76-PMC4231606	['a total of 136 children (52.1%) had levels\u2009<\u200975\xa0nmol/l, indicating suboptimal Vitamin D while 43 children (16.5%) had inadequate Vitamin D (< 50\xa0nmol/l).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 78, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 129, 'vitamin D')]
PMC4231606	10/2013	S77-PMC4231606	['additionally, 16 (6.1%) had deficient Vitamin D concentrations (< 35\xa0nmol/l).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 38, 'vitamin D')]
PMC4231606	10/2013	S78-PMC4231606	['more frequent intake of foods containing or fortified with Vitamin D (e.g.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 59, 'vitamin D')]
PMC4231606	10/2013	S81-PMC4231606	['those presently taking Vitamin D drops also had higher 25(Oh)D levels (92.2\u2009±\u200934.6\xa0nmol/l vs. 72.2\u2009±\u200928.2, p\u2009<\u20090.001).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 23, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 55, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 55, '25(OH)D')]
PMC4231606	10/2013	S88-PMC4231606	['there was no significant difference between the two groups with respect to premature Birth (p\u2009=\u20090.88), whether mothers took Vitamin D supplements during Pregnancy (p\u2009=\u20090.92), or Maternal milk intake during Pregnancy (p\u2009=\u20090.56) (data not shown).']	N/A	N/A	[('GO_0007567', 'parturition', 85, 'birth'), ('CHEBI_27300', 'vitamin D', 124, 'vitamin D'), ('GO_0007565', 'female pregnancy', 153, 'pregnancy'), ('GO_0007618', 'mating', 178, 'maternal'), ('GO_0007565', 'female pregnancy', 206, 'pregnancy')]
PMC4231606	10/2013	S95-PMC4231606	['those in the s-ecc group were found to have relatively poor Vitamin D status compared to caries-free children.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 60, 'vitamin D')]
PMC4231606	10/2013	S100-PMC4231606	['there was no association between the education level of the primary caregiver and the child’s Vitamin D status with respect to both the mean levels and the proportion with levels\u2009≥\u200975\xa0nmol/l (p\u2009=\u20090.74 and p\u2009=\u20090.35, respectively).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 94, 'vitamin D')]
PMC4231606	10/2013	S109-PMC4231606	['caption (table-wrap): table 3\n\nmultiple regression for mean Vitamin D levelvariableunstandardized regression coefficient (b)± 95%confidence intervalp value intercept71.01//s-ecc (reference\u2009=\u2009yes)5.331.24, 9.420.01regular milk drinker (reference\u2009=\u2009yes)-6.60-13.16, -0.030.05season (reference\u2009=\u2009winter)5.221.37, 9.060.008vitamin D drop user (reference\u2009=\u2009yes)-2.172.01, -6.130.28yearly income (reference\u2009=\u2009< 28\xa0k)2.732.06, -1.320.19\ns-ecc\u2009=\u2009severe early Childhood caries.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 60, 'vitamin D'), ('PR_000006444', 'diacylglycerol kinase delta', 327, 'D'), ('GO_0007605', 'sensory perception of sound', 451, 'Childhood')]
PMC4237823	8/2014	S54-PMC4237823	['abbreviations: dhfr, Dihydrofolate reductase; Dhf, Dihydrofolate; Thf, Tetrahydrofolate; shmt, serine-hydroxymethyltransferase; 5,10-Methenyl- Thf, 5,10-Methenyl-Tetrahydrofolate; mthfr, 5,10-Methylenetetrahydrofolate reductase; 5-methyl thf, 5-Methyltetrahydrofolate; ms, methionine synthase; B12, Vitamin B-12; sam, S -Adenosylmethionine; sah, S -Adenosylhomocysteine; dnmt, dna methyltransferase; mt, methyltransferases.']	N/A	N/A	[('CHEBI_36263', 'hydrogenmolybdate', 21, 'dihydrofolate'), ('CHEBI_42098', 'digoxigenin', 46, 'DHF'), ('CHEBI_36263', 'hydrogenmolybdate', 51, 'dihydrofolate'), ('CHEBI_17038', 'fecosterol', 66, 'THF'), ('CHEBI_67016', 'tetrahydrofolate', 71, 'tetrahydrofolate'), ('CHEBI_52555', 'm-tolyl group', 128, '5,10-methenyl'), ('CHEBI_17038', 'fecosterol', 143, 'THF'), ('CHEBI_18123', 'N-methylnicotinate', 150, '10-methenyl-tetrahydrofolate'), ('CHEBI_20612', '5-methyltetrahydrofolate', 187, '5,10-methylenetetrahydrofolate'), ('CHEBI_20612', '5-methyltetrahydrofolate', 243, '5-methyltetrahydrofolate'), ('CHEBI_27778', 'abequose', 294, 'B12'), ('PR_000004738', 'class E basic helix-loop-helix protein 22', 294, 'B12'), ('CHEBI_27300', 'vitamin D', 299, 'vitamin B'), ('PR_000017269', 'ventral anterior homeobox 2', 299, 'vitamin B-12'), ('CHEBI_37983', 'sulfur-35 atom', 309, '12'), ('CHEBI_50770', 'N,N-dihydroxypentahomomethionine', 318, 'S -adenosylmethionine'), ('CHEBI_17575', 'S-(5-deoxy-D-ribos-5-yl)-L-homocysteine', 346, 'S -adenosylhomocysteine')]
PMC4251419	12/2014	S18-PMC4251419	['the Synthesis Of Vitamin D following uvb irradiation Of The Skin\nuvb Photons are absorbed by 7-Dehydrocholestrol in the Epidermis and are converted into pre-Vitamin D which undergoes a thermal isomerisation to Formvitamin D. this then undergoes two Hydroxylation reactions, first in the Liver to form 25-Hydroxyvitamin D (25(Oh)D) and then in the Kidney to form the active Metabolite, 1,25-Dihydroxyvitamin D (1,25(Oh)2D).']	N/A	N/A	[('GO_0030474', 'spindle pole body duplication', 4, 'synthesis of vitamin D'), ('CHEBI_27300', 'vitamin D', 17, 'vitamin D'), ('GO_0001554', 'luteolysis', 53, 'of     skin'), ('CHEBI_30212', 'photon', 69, 'photons'), ('CHEBI_17500', '7alpha-hydroxycholesterol', 93, '7-dehydrocholestrol'), ('UBERON_0007376', 'outer epithelium', 120, 'epidermis'), ('CHEBI_27300', 'vitamin D', 157, 'vitamin D'), ('CHEBI_72459', 'Dig-Cy5', 210, 'formvitamin D'), ('GO_0044444', 'cytoplasmic part', 249, 'hydroxylation'), ('UBERON_0002107', 'liver', 287, 'liver'), ('CHEBI_62218', '23,24-dihydrocucurbitacin D', 301, '25-hydroxyvitamin D'), ('CHEBI_63056', 'zinc cation', 322, '25(OH'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 328, 'D'), ('UBERON_0002113', 'kidney', 347, 'kidney'), ('CHEBI_39382', 'flufenoxuron', 373, 'metabolite'), ('CHEBI_67472', '15-epi-lupulin B', 385, '1,25-dihydroxyvitamin D'), ('CHEBI_82784', 'PVP38-Ag NP', 410, '1,25(OH)2D')]
PMC4251419	12/2014	S19-PMC4251419	['Serum 25(Oh)D levels are used to determine Vitamin D status.']	N/A	N/A	[('UBERON_0001977', 'blood serum', 0, 'Serum'), ('CHEBI_71657', 'versiconol acetate', 6, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 43, 'vitamin D')]
PMC4251419	12/2014	S20-PMC4251419	['Vdr, Vitamin D Receptor.']	N/A	N/A	[('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 0, 'VDR'), ('CHEBI_27300', 'vitamin D', 5, 'vitamin D'), ('PR_000001683', 'vasopressin V2 receptor', 5, 'vitamin D receptor')]
PMC4251419	12/2014	S66-PMC4251419	['cells from Individuals with various Vitamin D-Binding Protein (Vdbp) variants were studied and for Individuals with the strong 25(Oh)D binding variant, the availability of 25(Oh)D to Dendritic Cells was restricted, resulting in less Dendritic Cell-T Cell interaction.']	N/A	N/A	[('NCBITaxon_1', 'root', 11, 'individuals'), ('CHEBI_27300', 'vitamin D', 36, 'vitamin D'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 36, 'vitamin D-binding protein'), ('PR_000017279', 'testis-specific basic protein Y 1', 63, 'VDBP'), ('NCBITaxon_1', 'root', 99, 'individuals'), ('CHEBI_71657', 'versiconol acetate', 127, '25(OH)D'), ('PR_000005506', 'Cbp/p300-interacting transactivator 2', 127, '25'), ('PR_000006444', 'diacylglycerol kinase delta', 133, 'D'), ('CHEBI_71657', 'versiconol acetate', 172, '25(OH)D'), ('CL_0000451', 'dendritic cell', 183, 'dendritic cells'), ('CL_0000451', 'dendritic cell', 233, 'dendritic cell'), ('GO_0030425', 'dendrite', 233, 'dendritic'), ('CL_0000084', 'T cell', 248, 'T cell')]
PMC4251419	12/2014	S92-PMC4251419	['transcription of the Camp , the Gene encoding Cathelicidin, is Regulated by the Vitamin D receptor through 1,25(Oh)2D in Humans, but not rodents [58].']	N/A	N/A	[('PR_000004968', 'calretinin', 21, 'CAMP'), ('SO_0000704', 'gene', 32, 'gene'), ('PR_000006009', 'alpha-catulin', 46, 'cathelicidin'), ('GO_0065007', 'biological regulation', 63, 'regulated'), ('CHEBI_27300', 'vitamin D', 80, 'vitamin D'), ('CHEBI_82784', 'PVP38-Ag NP', 107, '1,25(OH)2D'), ('NCBITaxon_9606', 'Homo sapiens', 121, 'humans')]
PMC4256222	12/2014	S15-PMC4256222	['during Pregnancy Vitamin D is transported from the mother to the fetus through the Placenta in the form of 25-Hydroxyvitamin D (25(Oh)D), and at Birth the concentration in Umbilical Cord Blood is around 80% of maternal Blood concentration[2].']	N/A	N/A	[('GO_0007565', 'female pregnancy', 7, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 17, 'vitamin D'), ('UBERON_0001987', 'placenta', 83, 'placenta'), ('CHEBI_62218', '23,24-dihydrocucurbitacin D', 107, '25-hydroxyvitamin D'), ('CHEBI_71657', 'versiconol acetate', 128, '25(OH)D'), ('GO_0007567', 'parturition', 145, 'birth'), ('UBERON_0002331', 'umbilical cord', 172, 'umbilical cord'), ('UBERON_0000178', 'blood', 187, 'blood'), ('UBERON_0000178', 'blood', 219, 'blood')]
PMC4256222	12/2014	S44-PMC4256222	['for our exposure measure we classified the women according to their concentration of total Vitamin D: deficiency <25 nmol/l, insufficiency\u200a=\u200a25–49.9 nmol/l (deficiency and insufficiency were classified together), sufficiency\u200a=\u200a50–74.9 nmol/l, optimal level 75–125 nmol/l, and high level >125 nmol/l.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 91, 'vitamin D')]
PMC4256222	12/2014	S57-PMC4256222	['statistical methods\ncox proportional hazard model was used to investigate the association between total Vitamin D status in Pregnancy and first time bone fracture risk.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 104, 'vitamin D'), ('GO_0007565', 'female pregnancy', 124, 'pregnancy')]
PMC4256222	12/2014	S66-PMC4256222	['based on accessibility and current knowledge about Vitamin D and fracture risk, the following variables were included as covariates: mother’s age (continuous), pre-Pregnancy body mass index (bmi) (continuous), smoking in Pregnancy (yes, no), parity (nulliparous, 1 child, 2+children) and sex (girl, boy).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 51, 'vitamin D'), ('GO_0007565', 'female pregnancy', 164, 'pregnancy'), ('GO_0007565', 'female pregnancy', 221, 'pregnancy')]
PMC4256222	12/2014	S69-PMC4256222	['results\nSerum samples were available from 88% of the women in the cohort, which in total provided 850 mother and child pairs with a maternal Vitamin D status from Gestation week 30.']	N/A	N/A	[('UBERON_0001977', 'blood serum', 8, 'Serum'), ('CHEBI_27300', 'vitamin D', 141, 'vitamin D'), ('GO_0007565', 'female pregnancy', 163, 'gestation')]
PMC4256222	12/2014	S71-PMC4256222	['the median (5–95 percentile) total Vitamin D status among the 850 Pregnant women was 76.2 (23.0–152.1) nmol/l.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 35, 'vitamin D'), ('GO_0007565', 'female pregnancy', 66, 'pregnant')]
PMC4256222	12/2014	S72-PMC4256222	['in our study population, 6.3% had Vitamin D deficiency (<25 nmol/l), 74.5% reached sufficient status (≥50 nmol/l), 37.8% were at the optimal level (75–125 nmol/l) and 13.4% had high status of Vitamin D (>125 nmol/l).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 34, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 192, 'vitamin D')]
PMC4256222	12/2014	S75-PMC4256222	['background characteristics of the mothers according to Vitamin D status are shown intable 1.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 55, 'vitamin D')]
PMC4256222	12/2014	S83-PMC4256222	['in our data there was no overall association between total Vitamin D status and first time bone fracture (table 2).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 59, 'vitamin D')]
PMC4256222	12/2014	S88-PMC4256222	['adjustment for status of Vitamin D did not attenuate the association (hr\u200a=\u200a1.82, 95%ci: 1.12–2.97).10.1371/journal.pone.0114334.t002\n\ncaption (table-wrap): table 2\nthe association (hazard ratios and 95% confidence interval) between maternal Vitamin D status in Gestation week 30 and offspring bone fractures in childhood and adolescence among 850 mother and child pairs from the dafo88 cohort in aarhus city, denmark.crudeadjusted*ncaseshr (95% ci)hr (95% ci)all ages, 0–18 y<50 nmol/l)217781.13 (0.84–1.51)1.17 (0.87–1.57)50–75 nmol/l)199741.20 (0.89–1.62)1.19 (0.88–1.61)≥75–125 nmol/l)3211031.001.00>125 nmol/l)113391.09 (0.75–1.58)1.10 (0.76–1.59) p -valuea0.320.27childhood, 0–10 y<50 nmol/l)217391.04 (0.69–1.57)1.07 (0.70–1.62)50–75 nmol/l)199421.25 (0.84–1.87)1.26 (0.84–1.89)≥75–125 nmol/l)321551.001.00>125 nmol/l)113201.06 (0.64–1.78)1.09 (0.65–1.91) p -valuea0.590.53adolescence, 11–18 y<50 nmol/l)178391.23 (0.81–1.88)1.29 (0.84–1.99)50–75 nmol/l)157321.13 (0.72–1.77)1.11 (0.71–1.74)≥75–125 nmol/l)266481.001.00>125 nmol/l)93191.12 (0.66–1.91)1.13 (0.66–1.93) p -valuea0.370.35\n*adjusted for maternal age, pre-Pregnancy bmi, smoking, parity and sex.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 25, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 241, 'vitamin D'), ('GO_0007565', 'female pregnancy', 261, 'gestation'), ('GO_0007565', 'female pregnancy', 1124, 'pregnancy')]
PMC4256222	12/2014	S89-PMC4256222	['continuous values of Vitamin D status in the cox regression model.10.1371/journal.pone.0114334.t003\n\ncaption (table-wrap): table 3\nthe association (hazard ratios and 95% confidence interval) between season in Gestation week 30 and offspring bone fractures in childhood and Adolescence among 850 mother and child pairs from the dafo88 cohort in aarhus city, denmark.adjusted*+ vitamin d¤ncaseshr (95% ci)hr (95% ci)all ages, 0–18 ymar/apr/may113351.06 (0.71–1.59)1.05 (0.69–1.59)jun/jul/aug247761.001.00sep/oct/nov3001101.26 (0.94–1.69)1.24 (0.90–1.71)dec/jan/feb190731.39 (1.01–1.92)1.36 (0.96–1.93)childhood, 0–10 ymar/apr/may113211.37 (0.79–2.37)1.42 (0.80–2.50)jun/jul/aug247341.001.00sep/oct/nov300581.45 (0.95–2.22)1.51 (0.95–2.40)dec/jan,/feb190431.75 (1.11–2.74)1.82 (1.12–2.97)adolescence, 11–18 ymar/apr/may92140.82 (0.44–1.50)0.77 (0.41–1.43)jun/jul/aug213421.001.00sep/oct/nov242521.10 (0.73–1.66)1.02 (0.65–1.59)dec/jan,/feb147301.08 (0.67–1.73)0.99 (0.60–1.65)\n*adjusted for maternal age, pre-Pregnancy bmi, smoking, parity and sex.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 21, 'vitamin D'), ('GO_0007565', 'female pregnancy', 209, 'gestation'), ('GO_0048848', 'neurohypophysis morphogenesis', 273, 'adolescence'), ('GO_0007565', 'female pregnancy', 1006, 'pregnancy')]
PMC4256222	12/2014	S90-PMC4256222	['adjusted for maternal age, pre-Pregnancy bmi, smoking, parity, sex and maternal Vitamin D status in Gestational week 30.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 31, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 80, 'vitamin D'), ('GO_0007565', 'female pregnancy', 100, 'gestational')]
PMC4256222	12/2014	S95-PMC4256222	['when we adjusted for maternal status of Vitamin D a significantly higher hr for dec/jan/feb persisted (hr\u200a=\u200a2.17, 95%ci: 1.07–4.39).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 40, 'vitamin D')]
PMC4256222	12/2014	S96-PMC4256222	['discussion\noverall, there was no significant association between maternal Vitamin D status in Gestation week 30 and offspring bone fractures from Birth until 18 years of age in the dafo88 cohort.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 74, 'vitamin D'), ('GO_0007565', 'female pregnancy', 94, 'gestation'), ('GO_0007567', 'parturition', 146, 'birth')]
PMC4256222	12/2014	S123-PMC4256222	['[9]reported 38.7% in their study population to have a Vitamin D status below 50 nmol/l.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 54, 'vitamin D')]
PMC4258799	11/2014	S105-PMC4258799	['caption (table-wrap): table 1\n\nstudy outcomes involvingin vitrosupplementation of various Antioxidants during art protocolantioxidantstudy typepatient populationintervention (therapeutic approach)control group (daily dose)outcome/effect of intervention/effect on parametersreference Vitamin E prospectivesperm from normozoospermic and asthenozoospermic men5\xa0mm Vitamin E added to cryoprotective media prior to freeze-thaw procedure1.']	N/A	N/A	[('CHEBI_60641', 'methyl 5-aminolevulinate hydrochloride', 90, 'antioxidants'), ('CHEBI_28384', 'vitamin K', 283, 'Vitamin E'), ('PR_000017279', 'testis-specific basic protein Y 1', 283, 'Vitamin E'), ('CHEBI_27300', 'vitamin D', 361, 'vitamin E')]
PMC4258799	11/2014	S108-PMC4258799	['improvement in dna integrity Vitamin E prospectivesperm from normozoospermic men and men with abnormal Sperm parameters100\xa0μmol or 200\xa0μmol Vitamin E added to cryopreservation mediaimproved post-thaw motility of cryopreserved Sperm from men with both normal and abnormal Sperm parameterstaylor et al.']	N/A	N/A	[('CHEBI_28384', 'vitamin K', 29, 'Vitamin E'), ('CL_0000019', 'sperm', 103, 'sperm'), ('CHEBI_27300', 'vitamin D', 140, 'vitamin E'), ('CL_0000019', 'sperm', 226, 'sperm'), ('CL_0000019', 'sperm', 271, 'sperm')]
PMC4258799	11/2014	S112-PMC4258799	['increased Sperm viability vitamin c prospectivesperm from male volunteers with teratozoospermia (n\u2009=\u200915)Sperm prepared by Swim up incubated with 600\xa0μmol Vitamin C added to media x 1\xa0hour1.']	N/A	N/A	[('CL_0000019', 'sperm', 10, 'sperm'), ('CL_0000019', 'sperm', 104, 'Sperm'), ('GO_0036268', 'swimming', 122, 'swim'), ('CHEBI_27300', 'vitamin D', 154, 'vitamin C')]
PMC4258799	11/2014	S189-PMC4258799	['caption (table-wrap): table 2\n\nstudy outcomes involving oral supplementation of various Antioxidants in menantioxidantstudy typepatient populationintervention (daily dose x duration)control group (daily dose)study outcome (effect on Sperm parameters)reference Vitamin E double blind, placebo cross-over, rcthealthy men with high seminal Ros levels (n\u2009=\u200930)600\xa0mg Vitamin E x 3\xa0months (n\u2009=\u200915)placebo (n\u2009=\u200915)improved in vitro Sperm function (improved Zona-binding assay)kessopoulou et al.']	N/A	N/A	[('CHEBI_60641', 'methyl 5-aminolevulinate hydrochloride', 88, 'antioxidants'), ('CL_0000019', 'sperm', 233, 'sperm'), ('CHEBI_28384', 'vitamin K', 260, 'Vitamin E'), ('PR_000017279', 'testis-specific basic protein Y 1', 260, 'Vitamin E'), ('CHEBI_8756', 'RNA (poly(A))', 337, 'ROS'), ('CHEBI_27300', 'vitamin D', 363, 'vitamin E'), ('CL_0000019', 'sperm', 426, 'sperm'), ('UBERON_0001460', 'arm', 451, 'zona')]
PMC4258799	11/2014	S190-PMC4258799	['[101]Vitamin E double blind, placebo-controlledmen with (n\u2009=\u2009110) asthenozoospermia or oligoasthenozoospermia300\xa0mg Vitamin E x 6\xa0months (n\u2009=\u200952)placebo (n\u2009=\u200955)1.']	N/A	N/A	[('CHEBI_28384', 'vitamin K', 5, 'Vitamin E'), ('PR_000017279', 'testis-specific basic protein Y 1', 5, 'Vitamin E'), ('CHEBI_27300', 'vitamin D', 116, 'vitamin E')]
PMC4258799	11/2014	S194-PMC4258799	['20% of those on therapy achieved Pregnancy Vitamin E\u2009+\u2009anti-estrogen (Clomiphene Citrate) prospective, placebo-controlled rctinfertile men with idiopathic oligozoospermia (n\u2009=\u200960)400\xa0mg Vitamin E +25\xa0mg Clomiphene Citrate x 6\xa0months (n\u2009=\u200930)placebo (n\u2009=\u200930)1.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 33, 'pregnancy'), ('CHEBI_28384', 'vitamin K', 43, 'Vitamin E'), ('PR_000017279', 'testis-specific basic protein Y 1', 43, 'Vitamin E'), ('CHEBI_3755', 'clomipramine hydrochloride', 70, 'Clomiphene citrate'), ('CHEBI_27300', 'vitamin D', 186, 'vitamin E'), ('CHEBI_3753', 'clomiphene citrate', 203, 'clomiphene citrate')]
PMC4258799	11/2014	S197-PMC4258799	['partners had higher incidence of Pregnancy Vitamin E\u2009+\u2009Selenium open, randomizedvolunteers and infertile men (n\u2009=\u200954)400\xa0mg Vitamin E +225\xa0μg Selenium x 3\xa0months (n\u2009=\u200928)4.5\xa0g Vitamin B x 3\xa0months (n\u2009=\u200926)1.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 33, 'pregnancy'), ('CHEBI_28384', 'vitamin K', 43, 'Vitamin E'), ('PR_000017279', 'testis-specific basic protein Y 1', 43, 'Vitamin E'), ('CHEBI_27568', 'selenium atom', 55, 'selenium'), ('CHEBI_27300', 'vitamin D', 124, 'vitamin E'), ('CHEBI_27568', 'selenium atom', 142, 'selenium'), ('CHEBI_27300', 'vitamin D', 176, 'vitamin B'), ('PR_000000037', 'BMP receptor type-2', 184, 'B')]
PMC4258799	11/2014	S200-PMC4258799	['improved Sperm Motility Vitamin E\u2009+\u2009Selenium observational studyinfertile men with idiopathic asthenozoospermia (n\u2009=\u2009690)400\xa0iu Vitamin E +200\xa0μg Selenium x 100\xa0daysnone1.']	N/A	N/A	[('CL_0000019', 'sperm', 9, 'sperm'), ('GO_0065007', 'biological regulation', 15, 'motility'), ('CHEBI_28384', 'vitamin K', 24, 'Vitamin E'), ('CHEBI_27568', 'selenium atom', 36, 'selenium'), ('CHEBI_27300', 'vitamin D', 128, 'vitamin E'), ('CHEBI_27568', 'selenium atom', 146, 'selenium')]
PMC4258799	11/2014	S202-PMC4258799	['increased spontaneous Pregnancy rates (11%) Vitamin E\u2009+\u2009vitamin C double blind, placebo-controlled, rctmen (n\u2009=\u200931) with asthenozoospermia or moderate oligoasthenozoospermia1000\xa0mg Vitamin C +800\xa0mg Vitamin E x 8\xa0weeks (n\u2009=\u200915)placebo (n\u2009=\u200916)no improvement in Sperm parametersrolf et al.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 22, 'pregnancy'), ('CHEBI_28384', 'vitamin K', 44, 'Vitamin E'), ('PR_000004900', 'complement C3', 64, 'C'), ('CHEBI_27300', 'vitamin D', 181, 'vitamin C'), ('PR_000004900', 'complement C3', 189, 'C'), ('CHEBI_27300', 'vitamin D', 199, 'vitamin E'), ('CL_0000019', 'sperm', 261, 'sperm')]
PMC4258799	11/2014	S203-PMC4258799	['[106]no improvement in 24\xa0h Sperm survival rate Vitamin E\u2009+\u2009vitamin c observational study, double-blindmen with elevated Sperm Dna Fragmentation (≥15%) who have unexplained infertility1000\xa0mg Vitamin C +1000\xa0mg Vitamin E x 2\xa0months (n\u2009=\u200932)placebo (n\u2009=\u200932)reduced percentage of dna-fragmented Sperm (tunel test)greco et al.']	N/A	N/A	[('CL_0000019', 'sperm', 28, 'sperm'), ('CHEBI_28384', 'vitamin K', 48, 'Vitamin E'), ('PR_000017279', 'testis-specific basic protein Y 1', 48, 'Vitamin E'), ('CL_0000019', 'sperm', 121, 'sperm'), ('GO_0006306', 'DNA methylation', 127, 'DNA fragmentation'), ('CHEBI_27300', 'vitamin D', 192, 'vitamin C'), ('CHEBI_27300', 'vitamin D', 211, 'vitamin E'), ('CL_0000019', 'sperm', 293, 'sperm')]
PMC4258799	11/2014	S204-PMC4258799	['[107]Vitamin E\u2009+\u2009vitamin c observational study involving assisted Conception treatmentmen with elevated Sperm Dna Fragmentation (≥15%) who failed their 1sticsi attempt1000\xa0mg Vitamin C +1000\xa0mg Vitamin E x 2\xa0months (n\u2009=\u200938)none1.']	N/A	N/A	[('CHEBI_28384', 'vitamin K', 5, 'Vitamin E'), ('PR_000017279', 'testis-specific basic protein Y 1', 5, 'Vitamin E'), ('GO_0007620', 'copulation', 66, 'conception'), ('CL_0000019', 'sperm', 104, 'sperm'), ('GO_0006306', 'DNA methylation', 110, 'DNA fragmentation'), ('CHEBI_27300', 'vitamin D', 175, 'vitamin C'), ('CHEBI_27300', 'vitamin D', 194, 'vitamin E')]
PMC4258799	11/2014	S207-PMC4258799	['marked improvement in Implantation and clinical Pregnancy rates in the 2ndicsi attempt vs 1stattempt vitamin c men with Sperm agglutination (>25%) (n\u2009=\u200930)200\xa0mg Vitamin C or 1000\xa0mg Vitamin Cplaceboimproved Sperm Motility, viability, morphology after 4\xa0weeks (more prominent improvement in 1000\xa0mg Vitamin C vs. 200\xa0mg Vitamin c)dawson et al.']	N/A	N/A	[('GO_0007566', 'embryo implantation', 22, 'implantation'), ('GO_0007565', 'female pregnancy', 48, 'pregnancy'), ('CL_0000019', 'sperm', 120, 'sperm'), ('CHEBI_27300', 'vitamin D', 162, 'vitamin C'), ('CHEBI_35447', 'biphenyl-4-yl group', 183, 'vitamin CPlaceboImproved'), ('CL_0000019', 'sperm', 208, 'sperm'), ('GO_0065007', 'biological regulation', 214, 'motility'), ('CHEBI_27300', 'vitamin D', 299, 'vitamin C'), ('CHEBI_33229', 'vitamin (role)', 320, 'vitamin')]
PMC4258799	11/2014	S208-PMC4258799	['[109]vitamin c men who are heavy smokers (n\u2009=\u200975) with normal Reproductive function200\xa0mg Vitamin C or 1000\xa0mg Vitamin Cplacebo1.']	N/A	N/A	[('GO_0000003', 'reproduction', 62, 'reproductive'), ('CHEBI_27300', 'vitamin D', 90, 'vitamin C'), ('CHEBI_86960', 'veratrone acetate', 111, 'vitamin CPlacebo1')]
PMC4258799	11/2014	S243-PMC4258799	['no significant increase in Implantation and Pregnancy rates vitamin c prospectivewomen undergoing ivf-et (n\u2009=\u200976)500\xa0mg Vitamin C/day (slow release) to women smokers (n\u2009=\u200919) and women non-smokers (n\u2009=\u200919)placebowomen non-smokers had higher Pregnancy rates than women smokerscrha et al.']	N/A	N/A	[('GO_0007566', 'embryo implantation', 27, 'implantation'), ('GO_0007565', 'female pregnancy', 44, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 120, 'vitamin C'), ('GO_0007565', 'female pregnancy', 241, 'pregnancy')]
PMC4258799	11/2014	S298-PMC4258799	['following antioxidant therapy with Vitamin E, these men also experienced lower Lipid peroxidation levels in their Spermatozoa [150].']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 35, 'vitamin E'), ('CHEBI_18059', 'lipid', 79, 'lipid'), ('CL_0000019', 'sperm', 114, 'spermatozoa')]
PMC4258799	11/2014	S314-PMC4258799	['in a large, placebo-controlled, double blind rct, Vitamin C supplementation for a period of 14\xa0days starting on the day of follicle aspiration in women undergoing ivf-et showed no improvement in clinical Pregnancy or Implantation rates [125].']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 50, 'vitamin C'), ('GO_0007565', 'female pregnancy', 204, 'pregnancy'), ('GO_0007566', 'embryo implantation', 217, 'implantation')]
PMC4258799	11/2014	S316-PMC4258799	['addition of Vitamin C in cryomedia improved motility [62] and reduced dna damage [61] in post-thaw Spermatozoa.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 12, 'vitamin C'), ('CL_0000019', 'sperm', 99, 'spermatozoa')]
PMC4258799	11/2014	S317-PMC4258799	['similarly, Vitamin C supplemented culture media reduced Lipid peroxidation and dna damage, while improving Spermatozoa motility and viability [60].']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 11, 'vitamin C'), ('CHEBI_18059', 'lipid', 56, 'lipid'), ('CL_0000019', 'sperm', 107, 'spermatozoa')]
PMC4258799	11/2014	S327-PMC4258799	['in infertile women with pcos undergoing Ovulation induction for ivf/icsi, oral therapy of myo-inositol (a component of the Vitamin B family) and Folic Acid reduced the number of immature Oocytes during pick up [126,127].']	N/A	N/A	[('GO_0030728', 'ovulation', 40, 'ovulation'), ('CHEBI_27300', 'vitamin D', 123, 'vitamin B'), ('CHEBI_5054', 'Fibrin', 145, 'folic'), ('CHEBI_37527', 'acid', 151, 'acid'), ('CL_0000023', 'oocyte', 187, 'oocytes')]
PMC4263713	12/2014	S3-PMC4263713	['Vitamin A-deficient Pregnant Rats or their offspring were administered a low-dose of Vitamin A daily for 7 days starting on Gestational day 14 or Postnatal day 1, day 14 or day 28.']	N/A	N/A	[('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 0, 'Vitamin A'), ('GO_0007565', 'female pregnancy', 20, 'pregnant'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 29, 'rats'), ('CHEBI_27300', 'vitamin D', 85, 'vitamin A'), ('GO_0007565', 'female pregnancy', 124, 'gestational'), ('GO_0007567', 'parturition', 146, 'postnatal')]
PMC4263713	12/2014	S4-PMC4263713	['Serum Retinol concentrations increased significantly in all four groups that received Vitamin A supplementation, as determined by high-performance liquid chromatography.']	N/A	N/A	[('UBERON_0001977', 'blood serum', 0, 'Serum'), ('CHEBI_26536', 'retinoic acid', 6, 'retinol'), ('CHEBI_27300', 'vitamin D', 86, 'vitamin A')]
PMC4263713	12/2014	S5-PMC4263713	['the Intestinal levels of secretory Immunoglobulin a and Polymeric Immunoglobulin receptor increased significantly with Lipopolysaccharide challenge in the Rats that received Vitamin A supplementation starting on Postnatal day 1.']	N/A	N/A	[('UBERON_0000160', 'intestine', 4, 'intestinal'), ('GO_0019814', 'immunoglobulin complex', 35, 'immunoglobulin'), ('CHEBI_33839', 'macromolecule', 56, 'polymeric'), ('GO_0019814', 'immunoglobulin complex', 66, 'immunoglobulin'), ('CHEBI_16412', 'lipopolysaccharide', 119, 'lipopolysaccharide'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 155, 'rats'), ('CHEBI_27300', 'vitamin D', 174, 'vitamin A'), ('GO_0007567', 'parturition', 212, 'postnatal')]
PMC4263713	12/2014	S7-PMC4263713	['additionally, Vitamin A supplementation during late Gestation increased the numbers of Cd8+Intestinal Intraepithelial lymphocytes and decreased the numbers of B Lymphocytes in the Mesenteric Lymph Nodes.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 14, 'vitamin A'), ('GO_0007565', 'female pregnancy', 52, 'gestation'), ('PR_000005170', 'CD37 molecule', 87, 'CD8'), ('UBERON_0000160', 'intestine', 91, 'intestinal'), ('UBERON_0004821', 'pulmonary alveolus epithelium', 102, 'intraepithelial'), ('CL_0000236', 'B cell', 159, 'B lymphocytes'), ('UBERON_0002509', 'mesenteric lymph node', 180, 'mesenteric lymph nodes')]
PMC4263713	12/2014	S205-PMC4263713	['in the current study, Pregnant vad Rats or their vad offspring received a low-dose of Vitamin A daily for 7 days[19].']	N/A	N/A	[('GO_0007565', 'female pregnancy', 22, 'pregnant'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 35, 'rats'), ('CHEBI_27300', 'vitamin D', 86, 'vitamin A')]
PMC4268639	11/2014	S18-PMC4268639	['this included assessment of Vitamin D, Carnitine, iron, zinc, and mthfr polymorphism status in the first trimester prior to supplementation.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 28, 'vitamin D'), ('CHEBI_17126', 'carnitine', 39, 'carnitine')]
PMC4275595	9/2014	S17-PMC4275595	['in 1942 the vitamin welfare scheme was extended to include expectant and nursing mothers (and children under five), allowing them free or inexpensive orange juice, cod Liver oil or Vitamin A and d tablets.']	N/A	N/A	[('UBERON_0002107', 'liver', 168, 'liver'), ('CHEBI_27300', 'vitamin D', 181, 'vitamin A')]
PMC4277121	12/2015	S261-PMC4277121	['lastly, clinical trials with Vitamin E failed to prevent Cognitive decline (see the following sections).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 29, 'vitamin E'), ('GO_0050890', 'cognition', 57, 'cognitive')]
PMC4289064	1/2015	S49-PMC4289064	['this comparison was made for five age categories (children 1 to less than 4 years, children 4 to less than 9 years, women 19 to less than 51 years who were not Pregnant or Lactating, Lactating women 19 to less than 51 years, and Pregnant women 19 to less than 51 years) in each of four countries (bangladesh, mozambique, uganda, and zambia) across five Nutrients (Vitamin A, Calcium, Folate, iron, zinc).']	N/A	N/A	[('GO_0007565', 'female pregnancy', 160, 'pregnant'), ('GO_0007594', 'puparial adhesion', 172, 'lactating'), ('GO_0007594', 'puparial adhesion', 183, 'lactating'), ('GO_0007565', 'female pregnancy', 229, 'pregnant'), ('CHEBI_33284', 'nutrient', 353, 'nutrients'), ('CHEBI_27300', 'vitamin D', 364, 'vitamin A'), ('CHEBI_22313', 'alkaline earth metal atom', 375, 'calcium'), ('CHEBI_30863', '5-azaorotic acid', 384, 'folate')]
PMC4289064	1/2015	S52-PMC4289064	['full pollination scenario\nfirst, we calculated the total daily intake of Vitamin A, Calcium, Folate, iron, and zinc by Individual and day for each of the four countries in the full Pollination scenario, by summing the Nutrients in the Foods consumed by each Individual in a day.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 73, 'vitamin A'), ('CHEBI_22313', 'alkaline earth metal atom', 84, 'calcium'), ('CHEBI_30863', '5-azaorotic acid', 93, 'folate'), ('NCBITaxon_1', 'root', 119, 'individual'), ('GO_0009856', 'pollination', 181, 'pollination'), ('CHEBI_33284', 'nutrient', 218, 'nutrients'), ('CHEBI_33290', 'food', 235, 'foods'), ('NCBITaxon_1', 'root', 258, 'individual')]
PMC4289064	1/2015	S98-PMC4289064	['for example, if an Individual Consumed 100 grams of Mango, which included 38 milligrams of Vitamin A, we reduced the amount consumed to 35 grams of mango and 13.3 milligrams of Vitamin A because the percent yield of mangoes due to pollinators was assumed to be 65 percent.']	N/A	N/A	[('NCBITaxon_1', 'root', 19, 'individual'), ('GO_0007631', 'feeding behavior', 30, 'consumed'), ('CHEBI_33284', 'nutrient', 52, 'mango'), ('CHEBI_27300', 'vitamin D', 91, 'vitamin A'), ('PR_000004370', 'asialoglycoprotein receptor 2', 99, 'A'), ('CHEBI_27300', 'vitamin D', 177, 'vitamin A')]
PMC4289064	1/2015	S124-PMC4289064	['for comparison, results for women aged 19 to 50 are presented ins1,s2,s3 figs., and ins3 table.10.1371/journal.pone.0114805.g002\n\ncaption (fig): figure 2\naverage proportion of dietary intake of Vitamin A from different sources for children 1 to 3 years old.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 194, 'vitamin A'), ('PR_000004370', 'asialoglycoprotein receptor 2', 202, 'A')]
PMC4289064	1/2015	S136-PMC4289064	['for Vitamin A in uganda and mozambique, this increase was substantial (15% and 56%, respectively) and statistically significant (p<0.05,fig.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 4, 'vitamin A')]
PMC4289064	1/2015	S145-PMC4289064	['for example, for uganda, 39 percent of the population received equal to or less than the ear for Vitamin A in the no pollinator scenario (x) while 24 percent of the population received equal to or less than the ear in the full pollinator scenario (y).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 97, 'vitamin A'), ('PR_000004370', 'asialoglycoprotein receptor 2', 105, 'A')]
PMC4289064	1/2015	S150-PMC4289064	['n\u200a=\u200a451 for all Nutrients except Vitamin A where n\u200a=\u200a440.']	N/A	N/A	[('CHEBI_33284', 'nutrient', 16, 'nutrients'), ('CHEBI_27300', 'vitamin D', 33, 'vitamin A')]
PMC4289064	1/2015	S158-PMC4289064	['in bangladesh, for example, removal of pollinators had little effect on the risk of Vitamin A deficiency because most Individuals were already malnourished (fig.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 84, 'vitamin A'), ('NCBITaxon_1', 'root', 118, 'individuals')]
PMC4289064	1/2015	S190-PMC4289064	['supporting information\n\ncaption (supplementary-material): s1 fig\n\naverage proportion of dietary intake of Vitamin A from different sources for women 19 to 50 years old (including Pregnant and Lactating women).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 106, 'vitamin A'), ('GO_0007565', 'female pregnancy', 179, 'pregnant'), ('GO_0007594', 'puparial adhesion', 192, 'lactating')]
PMC4292819	1/2015	S31-PMC4292819	['meat contains several Nutrients (Vitamin D, iron, and zinc).']	N/A	N/A	[('CHEBI_33284', 'nutrient', 22, 'nutrients'), ('CHEBI_27300', 'vitamin D', 33, 'vitamin D')]
PMC4302429	1/2015	S86-PMC4302429	['after 6\xa0weeks of Feeding, a diet containing low Vitamin D concentrations (l-vitd) resulted in Serum 25-Oh Vitamin D3 concentrations significantly lower than those in s-vitd or h-vitd diet-Fed Mice (mean\u2009±\u2009sd: 5.9\u2009±\u20092.6 versus 30.4\u2009±\u20094.0 and 172.4\u2009±\u200926.1\xa0ng/ml, p \u2009<\u20090.05 for all group comparisons).']	N/A	N/A	[('GO_0007631', 'feeding behavior', 17, 'feeding'), ('CHEBI_27300', 'vitamin D', 48, 'vitamin D'), ('UBERON_0001977', 'blood serum', 94, 'serum'), ('CHEBI_86198', '1,2-di-[(11Z)-eicosenoyl]-sn-glycero-3-phosphocholine', 100, '25-OH'), ('CHEBI_33279', 'vitamin D5', 106, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 106, 'vitamin D3'), ('GO_0007631', 'feeding behavior', 188, 'fed'), ('NCBITaxon_10088', 'Mus <genus>', 192, 'mice')]
PMC4302429	1/2015	S90-PMC4302429	['at this time, Vitamin D-deficient Mice (l-vitd) had higher clinical scores than the two other groups (* p \u2009<\u20090.05; kruskal-wallis test, correction for repeated testing with the bonferroni method, figure\xa01c).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 14, 'vitamin D'), ('NCBITaxon_10088', 'Mus <genus>', 34, 'mice')]
PMC4302429	1/2015	S94-PMC4302429	['(a) survival, (b) weight loss, and (c) clinical score of Mice Fed diets containing different amounts of Vitamin D3 (low (l-vitd), standard (s-vitd) or high (h-vitd) Vitamin D supplementation).']	N/A	N/A	[('NCBITaxon_10088', 'Mus <genus>', 57, 'mice'), ('GO_0007631', 'feeding behavior', 62, 'fed'), ('CHEBI_33279', 'vitamin D5', 104, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 104, 'vitamin D3'), ('CHEBI_27300', 'vitamin D', 165, 'vitamin D')]
PMC4302429	1/2015	S106-PMC4302429	['(e) the mean numbers of Chloroacetate-esterase-stained Leukocytes per area in Brain sections of Mice Fed a diet containing different amounts of Vitamin D (low (l-vitd), standard (s-vitd) or high (h-vitd) Vitamin D supplementation), which were killed after 20\xa0h of E. Coli meningoencephalitis ( n \u2009≥\u200915).']	N/A	N/A	[('CHEBI_23123', 'chloroacetate', 24, 'chloroacetate'), ('CL_0000738', 'leukocyte', 55, 'leukocytes'), ('UBERON_0000955', 'brain', 78, 'brain'), ('NCBITaxon_10088', 'Mus <genus>', 96, 'mice'), ('GO_0007631', 'feeding behavior', 101, 'fed'), ('CHEBI_27300', 'vitamin D', 144, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 204, 'vitamin D'), ('NCBITaxon_10088', 'Mus <genus>', 264, 'E. coli')]
PMC4302429	1/2015	S122-PMC4302429	['caption (table-wrap): table 1\n\nsubpopulations of T Cells in Animals Fed a diet containing different amounts of Vitamin D 20\xa0hours after infectionpercentage of all cd45+cellsas-vitdl-vitdh-vitd T Cells (Cd45+cd3+)11.25 (4/23.53)7.5 (1.1/18.50)10.70 (2.75/23.35)Regulatory T Cells (Cd45+Cd4+cd3+Cd25+Foxp3+)0.25 (0.04/0.93)0.05 (0.005/0.17)0.09 (0.015/0.5)Nk Cells (Cd45+Nk1.1Cd3−)2.25 (1.525/3.43)3 (0.95/4.4)1.3 (1.15/1.65)Inflammatory Monocytes (Cd45+Cd11B+ly6chighccr2+)28.90 (26.95/34.75)36.20 (25.9/40.85)27 (18.10/31.20)Monocytes (Cd45+Cd11B+ly6cintccr2−)35.35 (33.3/43.33)42.20 (31.4/47.3)34.40 (25.75/37.85)Granulocytes (Cd45+Cd11B+ly6g+Ccr2−)43.25 (28.85/51.58)26.20 (23/49.95)34.20 (28.60/54.40)\nadata are medians (25th/75th percentiles) determined by forward and side-scatter properties from the whole Brain of Animals (four or five Mice per group) of at least three separate experiments.']	N/A	N/A	[('CL_0000084', 'T cell', 49, 'T cells'), ('NCBITaxon_33208', 'Metazoa', 60, 'animals'), ('GO_0007631', 'feeding behavior', 68, 'fed'), ('CHEBI_27300', 'vitamin D', 111, 'vitamin D'), ('CL_0000084', 'T cell', 193, 'T cells'), ('PR_000001309', 'CD70 molecule', 202, 'CD45'), ('CL_0000232', 'erythrocyte', 260, 'Regulatory T cells'), ('GO_0065007', 'biological regulation', 260, 'Regulatory'), ('PR_000001309', 'CD70 molecule', 280, 'CD45'), ('PR_000001204', 'C-C chemokine receptor type 8', 285, 'CD4'), ('PR_000002030', 'alpha-type platelet-derived growth factor receptor', 293, 'CD25'), ('PR_000017653', 'zinc finger protein ZFPM2', 298, 'FoxP3'), ('CL_0000623', 'natural killer cell', 354, 'NK cells'), ('GO_0005634', 'nucleus', 354, 'NK'), ('PR_000001309', 'CD70 molecule', 364, 'CD45'), ('PR_000011120', 'neurofilament medium polypeptide', 369, 'NK1'), ('PR_000005170', 'CD37 molecule', 373, '1CD3'), ('CL_0000174', 'steroid hormone secreting cell', 423, 'Inflammatory monocytes'), ('PR_000001309', 'CD70 molecule', 447, 'CD45'), ('PR_000001309', 'CD70 molecule', 452, 'CD11b'), ('CL_0000576', 'monocyte', 525, 'Monocytes'), ('PR_000001309', 'CD70 molecule', 536, 'CD45'), ('PR_000001309', 'CD70 molecule', 541, 'CD11b'), ('CL_0002062', 'type I pneumocyte', 614, 'Granulocytes'), ('PR_000001309', 'CD70 molecule', 628, 'CD45'), ('PR_000001309', 'CD70 molecule', 633, 'CD11b'), ('PR_000001204', 'C-C chemokine receptor type 8', 644, 'CCR2'), ('UBERON_0000955', 'brain', 812, 'brain'), ('NCBITaxon_33208', 'Metazoa', 821, 'animals'), ('NCBITaxon_10088', 'Mus <genus>', 843, 'mice')]
PMC4302429	1/2015	S124-PMC4302429	['l-vitd low Vitamin D supplementation; s-vitd, standard Vitamin D supplementation; h-vitd, high Vitamin D supplementation.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 11, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 55, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 95, 'vitamin D')]
PMC4302429	1/2015	S138-PMC4302429	['filled circles, standard Vitamin D (s-vitd) diet-Fed Mice (Vitamin D3 concentration 1,500\xa0iu/kg Food); filled squares, low Vitamin D (l-vitd) diet-Fed Mice (Vitamin D3 concentration less than the detection level); filled triangles, high Vitamin D (h-vitd) diet-Fed Mice (Vitamin D3 concentration 75,000\xa0iu/kg Food).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 25, 'vitamin D'), ('GO_0007631', 'feeding behavior', 49, 'fed'), ('NCBITaxon_10088', 'Mus <genus>', 53, 'mice'), ('CHEBI_33279', 'vitamin D5', 59, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 59, 'vitamin D3'), ('CHEBI_33290', 'food', 96, 'food'), ('CHEBI_27300', 'vitamin D', 123, 'vitamin D'), ('GO_0007631', 'feeding behavior', 147, 'fed'), ('NCBITaxon_10088', 'Mus <genus>', 151, 'mice'), ('CHEBI_33279', 'vitamin D5', 157, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 157, 'vitamin D3'), ('CHEBI_27300', 'vitamin D', 237, 'vitamin D'), ('GO_0007631', 'feeding behavior', 261, 'fed'), ('NCBITaxon_10088', 'Mus <genus>', 265, 'mice'), ('CHEBI_33279', 'vitamin D5', 271, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 271, 'vitamin D3'), ('CHEBI_33290', 'food', 309, 'food')]
PMC4302429	1/2015	S149-PMC4302429	['filled circles, standard Vitamin D (s-vitd) diet-Fed Mice (Vitamin D3 concentration 1,500\xa0iu/kg Food); filled squares, low Vitamin D (l-vitd) diet-Fed Mice (Vitamin D3 concentration under detection level); filled triangles, high Vitamin D (h-vitd) diet-Fed Mice (Vitamin D3 concentration 75,000\xa0iu/kg Food).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 25, 'vitamin D'), ('GO_0007631', 'feeding behavior', 49, 'fed'), ('NCBITaxon_10088', 'Mus <genus>', 53, 'mice'), ('CHEBI_33279', 'vitamin D5', 59, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 59, 'vitamin D3'), ('CHEBI_33290', 'food', 96, 'food'), ('CHEBI_27300', 'vitamin D', 123, 'vitamin D'), ('GO_0007631', 'feeding behavior', 147, 'fed'), ('NCBITaxon_10088', 'Mus <genus>', 151, 'mice'), ('CHEBI_33279', 'vitamin D5', 157, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 157, 'vitamin D3'), ('CHEBI_27300', 'vitamin D', 229, 'vitamin D'), ('GO_0007631', 'feeding behavior', 253, 'fed'), ('NCBITaxon_10088', 'Mus <genus>', 257, 'mice'), ('CHEBI_33279', 'vitamin D5', 263, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 263, 'vitamin D3'), ('CHEBI_33290', 'food', 301, 'food')]
PMC4302429	1/2015	S164-PMC4302429	['for example, Activated Human T- and B-Cells can convert the inactive intermediate of Vitamin D (also known as 25-Hydroxyvitamin D or 25(Oh)D) to active 1,25(Oh)2D in vitro [35], and this locally produced 1,25(Oh)2D acts on Immune Cells in an autocrine or Paracrine fashion [36].']	N/A	N/A	[('CL_0002627', 'mature astrocyte', 13, 'activated'), ('NCBITaxon_9606', 'Homo sapiens', 23, 'human'), ('CL_0000918', 'Tc2 cell', 29, 'T- ...'), ('CL_0000236', 'B cell', 36, 'B-cells'), ('CHEBI_27300', 'vitamin D', 85, 'vitamin D'), ('CHEBI_62218', '23,24-dihydrocucurbitacin D', 110, '25-hydroxyvitamin D'), ('CHEBI_72805', '2-alkyl-sn-glycero-3-phosphocholine', 136, 'OH)D'), ('CHEBI_82784', 'PVP38-Ag NP', 152, '1,25(OH)2D'), ('CHEBI_82784', 'PVP38-Ag NP', 204, '1,25(OH)2D'), ('CL_0000738', 'leukocyte', 223, 'immune cells'), ('UBERON_0002405', 'immune system', 223, 'immune'), ('GO_0038001', 'paracrine signaling', 255, 'paracrine')]
PMC4302429	1/2015	S181-PMC4302429	['to clarify the activity of Vitamin D against m. tuberculosis , liu and colleagues [41] observed that activation of the toll-like receptor Tlr1/2 by a lipoprotein extracted from m. tuberculosis reduced the viability of Intracellular m. tuberculosis in Human Monocytes and Macrophages, concomitant with an increased Expression of the vitamin D receptors and of Cyp27B1 (the enzyme that produces 1,25(Oh)2D) in these cells.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 27, 'vitamin D'), ('PR_000001155', 'Toll-like receptor 4', 138, 'TLR1'), ('GO_0005622', 'intracellular anatomical structure', 218, 'intracellular'), ('NCBITaxon_9606', 'Homo sapiens', 251, 'human'), ('CL_0000576', 'monocyte', 257, 'monocytes'), ('CL_0000235', 'macrophage', 271, 'macrophages'), ('GO_0010467', 'gene expression', 314, 'expression'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 340, 'D'), ('PR_000006101', 'cytochrome P450 1A1', 359, 'CYP27B1'), ('CHEBI_37983', 'sulfur-35 atom', 393, '1'), ('CHEBI_17996', 'chloride', 394, ','), ('CHEBI_66212', "5,7,3',4'-tetrahydroxy-2'-(3,3-dimethylallyl)isoflavone", 395, '25(OH)2D')]
PMC4302429	1/2015	S183-PMC4302429	['activated Vitamin D (1,25(Oh)2D) bound to the Monocyte Vitamin D receptors and then was able to act as a transcription factor leading to the induction of Cathelicidin, a potent Antimicrobial protein [42], and the promotion of Phagocytosis and Intracellular Killing [41,43,44].']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 10, 'vitamin D'), ('CHEBI_82784', 'PVP38-Ag NP', 21, '1,25(OH)2D'), ('CL_0000576', 'monocyte', 46, 'monocyte'), ('CHEBI_27300', 'vitamin D', 55, 'vitamin D'), ('PR_000006009', 'alpha-catulin', 154, 'cathelicidin'), ('CHEBI_65381', 'albizoside C', 177, 'antimicrobial'), ('GO_0006909', 'phagocytosis', 226, 'phagocytosis'), ('GO_0005622', 'intracellular anatomical structure', 243, 'intracellular'), ('GO_0035556', 'intracellular signal transduction', 243, 'intracellular killing')]
PMC4302429	1/2015	S199-PMC4302429	['moreover, anti-inflammatory Il-10 release [52] was significantly increased in Mice dying in the acute phase and Fed a diet containing a high Vitamin D3 concentration compared with Mice dying in the acute phase and Fed a diet containing low or standard Vitamin D concentrations.']	N/A	N/A	[('PR_000001470', 'interleukin-28B', 28, 'IL-10'), ('NCBITaxon_10088', 'Mus <genus>', 78, 'mice'), ('GO_0007631', 'feeding behavior', 112, 'fed'), ('CHEBI_33229', 'vitamin (role)', 141, 'vitamin'), ('CHEBI_29238', 'tritium atom', 149, 'D3'), ('PR_000001177', 'D(2) dopamine receptor', 149, 'D3'), ('NCBITaxon_10088', 'Mus <genus>', 180, 'mice'), ('GO_0007631', 'feeding behavior', 214, 'fed'), ('CHEBI_27300', 'vitamin D', 252, 'vitamin D')]
PMC4303849	1/2015	S3-PMC4303849	['the hormonal form and most active Metabolite of Vitamin D is Calcitriol.']	N/A	N/A	[('CHEBI_39382', 'flufenoxuron', 34, 'metabolite'), ('CHEBI_27300', 'vitamin D', 48, 'vitamin D'), ('CHEBI_17823', 'calcitriol', 61, 'calcitriol')]
PMC4303849	1/2015	S9-PMC4303849	['Vitamin D Synthesis and Metabolism\nuvb radiation from sunlight initiates Vitamin D (vd) Biosynthesis in the skin by Bioconverting 7-Dehydrocholesterol to Previtamin D3, which is thermally isomerized to vd3.']	N/A	N/A	[('CHEBI_28384', 'vitamin K', 0, 'Vitamin D'), ('GO_0042357', 'thiamine diphosphate metabolic process', 0, 'Vitamin D Synthesis ... Metabolism'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 0, 'Vitamin D'), ('CHEBI_27300', 'vitamin D', 73, 'vitamin D'), ('GO_0042368', 'vitamin D biosynthetic process', 73, 'vitamin D ... biosynthesis'), ('GO_0008218', 'bioluminescence', 116, 'bioconverting'), ('CHEBI_17500', '7alpha-hydroxycholesterol', 130, '7-dehydrocholesterol'), ('PR_000014709', 'neuroserpin', 154, 'previtamin D3'), ('CHEBI_29238', 'tritium atom', 165, 'D3')]
PMC4303849	1/2015	S27-PMC4303849	['Calcitriol biological effects\nCalcitriol actions are mediated through the Vitamin D receptor (vdr), a high-affinity ligand-activated transcription factor.']	N/A	N/A	[('CHEBI_17823', 'calcitriol', 0, 'Calcitriol'), ('CHEBI_17823', 'calcitriol', 30, 'Calcitriol'), ('CHEBI_27300', 'vitamin D', 74, 'vitamin D')]
PMC4329404	10/2014	S2-PMC4329404	['methods\nin utero and early-Life Vitamin D deficiency was achieved using a Vitamin D-deficient diet for female Mice during the third Trimester of Pregnancy and Lactation.']	N/A	N/A	[('UBERON_0000104', 'life cycle', 27, 'life'), ('CHEBI_27300', 'vitamin D', 32, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 74, 'vitamin D'), ('NCBITaxon_10088', 'Mus <genus>', 110, 'mice'), ('GO_0009294', 'DNA mediated transformation', 132, 'trimester'), ('GO_0007565', 'female pregnancy', 145, 'pregnancy'), ('GO_0007595', 'lactation', 159, 'lactation')]
PMC4329404	10/2014	S3-PMC4329404	['offspring were weaned onto a Vitamin D-deficient or Vitamin D-replete diet, and exposure to Intranasal House Dust Mite (hdm) or saline was commenced from day 3 of Life for up to 6\xa0weeks, when Airway hyper-responsiveness (ahr), Airway inflammation and remodelling were assessed.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 29, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 52, 'vitamin D'), ('UBERON_0008337', 'inguinal part of abdomen', 92, 'intranasal'), ('CHEBI_16136', 'hydrogen sulfide', 103, 'house dust'), ('CHEBI_46662', 'mineral', 114, 'mite'), ('NCBITaxon_10088', 'Mus <genus>', 114, 'mite'), ('UBERON_0000104', 'life cycle', 163, 'life'), ('UBERON_0001005', 'respiratory airway', 192, 'airway'), ('UBERON_0001005', 'respiratory airway', 227, 'airway')]
PMC4329404	10/2014	S4-PMC4329404	['results\nneonatal Mice that had in utero and early-Life Vitamin D deficiency had significantly increased Pulmonary cd3+Cd4+T1St2+cells and reduced Cd4+il-10+cells.']	N/A	N/A	[('NCBITaxon_10088', 'Mus <genus>', 17, 'mice'), ('UBERON_0000104', 'life cycle', 50, 'life'), ('CHEBI_27300', 'vitamin D', 55, 'vitamin D'), ('UBERON_0002048', 'lung', 104, 'pulmonary'), ('PR_000001204', 'C-C chemokine receptor type 8', 118, 'CD4'), ('PR_000016585', 'tripeptidyl-peptidase 1', 122, 'T1ST2'), ('PR_000001204', 'C-C chemokine receptor type 8', 146, 'CD4')]
PMC4329404	10/2014	S6-PMC4329404	['ahr in hdm-exposed Mice was unaffected by Vitamin D status.']	N/A	N/A	[('NCBITaxon_10088', 'Mus <genus>', 19, 'mice'), ('CHEBI_27300', 'vitamin D', 42, 'vitamin D')]
PMC4329404	10/2014	S7-PMC4329404	['introduction of Vitamin D into the diet at weaning resulted in a significant reduction in Serum Ige levels, reduced Pulmonary Eosinophilia and Peri-Bronchiolar collagen deposition.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 16, 'vitamin D'), ('UBERON_0001977', 'blood serum', 90, 'serum'), ('GO_0071743', 'IgE immunoglobulin complex, circulating', 96, 'IgE'), ('UBERON_0002048', 'lung', 116, 'pulmonary'), ('CL_0000771', 'eosinophil', 126, 'eosinophilia'), ('UBERON_0001789', 'outer nuclear layer of retina', 143, 'peri'), ('UBERON_0002186', 'bronchiole', 148, 'bronchiolar')]
PMC4329404	10/2014	S27-PMC4329404	['treatment of Murine Cd4+T Cells with Vitamin D promotes Il-10 Gene Expression (21) and protein (22), while treatment of Human Cd4+T Cells with Vitamin D also results in Il-10 secretion (23).']	N/A	N/A	[('NCBITaxon_39107', 'Murinae', 13, 'murine'), ('CL_0000476', 'thyrotroph', 20, 'CD4 ...'), ('PR_000001204', 'C-C chemokine receptor type 8', 20, 'CD4'), ('CL_0000084', 'T cell', 24, 'T cells'), ('CHEBI_27300', 'vitamin D', 37, 'vitamin D'), ('PR_000001470', 'interleukin-28B', 56, 'IL-10'), ('GO_0010467', 'gene expression', 62, 'gene expression'), ('SO_0000704', 'gene', 62, 'gene'), ('NCBITaxon_9606', 'Homo sapiens', 120, 'human'), ('PR_000001204', 'C-C chemokine receptor type 8', 126, 'CD4'), ('CL_0000084', 'T cell', 130, 'T cells'), ('CHEBI_27300', 'vitamin D', 143, 'vitamin D'), ('PR_000001470', 'interleukin-28B', 169, 'IL-10')]
PMC4329404	10/2014	S29-PMC4329404	['as diet is the only source of Vitamin D for rodents (without a contribution from ultraviolet light), we used a Vitamin D-deficient diet to alter vitamin d status.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 30, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 111, 'vitamin D')]
PMC4329404	10/2014	S34-PMC4329404	['female balb/c Mice were Mated and, from day-16 Gestation, were either Fed a Vitamin D-deficient Chow (special diets services, uk) or remained on a regular diet throughout Pregnancy and Lactation.']	N/A	N/A	[('NCBITaxon_10088', 'Mus <genus>', 14, 'mice'), ('GO_0007618', 'mating', 24, 'mated'), ('GO_0007565', 'female pregnancy', 47, 'gestation'), ('GO_0007631', 'feeding behavior', 70, 'fed'), ('CHEBI_27300', 'vitamin D', 76, 'vitamin D'), ('CHEBI_33290', 'food', 96, 'chow'), ('GO_0007565', 'female pregnancy', 171, 'pregnancy'), ('GO_0007595', 'lactation', 185, 'lactation')]
PMC4329404	10/2014	S35-PMC4329404	['Vitamin D deficiency is achieved within 4\xa0weeks of Feeding a Vitamin D-deficient diet (29).']	N/A	N/A	[('CHEBI_28384', 'vitamin K', 0, 'Vitamin D'), ('GO_0007631', 'feeding behavior', 51, 'feeding'), ('CHEBI_27300', 'vitamin D', 61, 'vitamin D')]
PMC4329404	10/2014	S40-PMC4329404	['caption (fig): figure 1\n\nearly-Life Vitamin D insufficiency has no effect on Airway resistance in pups at 6\xa0weeks of age.']	N/A	N/A	[('UBERON_0000104', 'life cycle', 31, 'life'), ('CHEBI_27300', 'vitamin D', 36, 'vitamin D'), ('UBERON_0001005', 'respiratory airway', 77, 'airway')]
PMC4329404	10/2014	S42-PMC4329404	['Pregnant female balb/c Mice were Fed a Vitamin D-deficient diet from day-16 Gestation or remained on a normal Chow diet.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 0, 'Pregnant'), ('NCBITaxon_10088', 'Mus <genus>', 23, 'mice'), ('GO_0007631', 'feeding behavior', 33, 'fed'), ('CHEBI_27300', 'vitamin D', 39, 'vitamin D'), ('GO_0007565', 'female pregnancy', 76, 'gestation'), ('CHEBI_33290', 'food', 110, 'chow')]
PMC4329404	10/2014	S44-PMC4329404	['pups were weaned at 3\xa0weeks of age and either Fed a Vitamin D-deficient diet or a normal Chow diet.']	N/A	N/A	[('GO_0007631', 'feeding behavior', 46, 'fed'), ('CHEBI_27300', 'vitamin D', 52, 'vitamin D'), ('CHEBI_33290', 'food', 89, 'chow')]
PMC4329404	10/2014	S46-PMC4329404	['+ represents Vitamin D intake and - represents a lack of Vitamin D. data are expressed as mean and sem, n \xa0=\xa04–7.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 13, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 57, 'vitamin D')]
PMC4329404	10/2014	S68-PMC4329404	['results\n\nVitamin D insufficiency skews towards a Pulmonary th2 phenotype and reduces Il-10+T Regulatory Cells in Pregnant females\nPregnant female balb/c Mice received a Vitamin D-deficient diet from day-16 Gestation and throughout Lactation for a total of 4\xa0weeks to induce Vitamin D insufficiency (fig.1a) (29).']	N/A	N/A	[('CHEBI_28384', 'vitamin K', 9, 'Vitamin D'), ('UBERON_0002048', 'lung', 49, 'pulmonary'), ('PR_000001470', 'interleukin-28B', 85, 'IL-10'), ('CL_0000902', 'induced T-regulatory cell', 91, 'T regulatory cells'), ('GO_0065007', 'biological regulation', 93, 'regulatory'), ('GO_0007565', 'female pregnancy', 113, 'pregnant'), ('GO_0007565', 'female pregnancy', 130, 'Pregnant'), ('NCBITaxon_10088', 'Mus <genus>', 153, 'mice'), ('CHEBI_27300', 'vitamin D', 169, 'vitamin D'), ('GO_0007565', 'female pregnancy', 206, 'gestation'), ('GO_0007595', 'lactation', 231, 'lactation'), ('CHEBI_27300', 'vitamin D', 274, 'vitamin D')]
PMC4329404	10/2014	S72-PMC4329404	['Vitamin D insufficiency in early Life does not alter ahr in neonatal Mice exposed to hdm\nearly-Life Vitamin D insufficiency did not affect Airway resistance in pbs- or hdm-exposed pups at 6\xa0weeks of age (fig.1a–c).']	N/A	N/A	[('CHEBI_28384', 'vitamin K', 0, 'Vitamin D'), ('UBERON_0000104', 'life cycle', 33, 'life'), ('NCBITaxon_10088', 'Mus <genus>', 69, 'mice'), ('UBERON_0000104', 'life cycle', 95, 'life'), ('CHEBI_27300', 'vitamin D', 100, 'vitamin D'), ('UBERON_0001005', 'respiratory airway', 139, 'airway')]
PMC4329404	10/2014	S73-PMC4329404	['Lung compliance was also unaffected by Vitamin D status (data not shown).']	N/A	N/A	[('UBERON_0002048', 'lung', 0, 'Lung'), ('CHEBI_27300', 'vitamin D', 39, 'vitamin D')]
PMC4329404	10/2014	S74-PMC4329404	['Vitamin D supplementation after weaning reduces Pulmonary Eosinophilia\ninflammation was determined in Mice following 6\xa0weeks of Allergen exposure and Ingestion of either a normal or Vitamin D-deficient diet.']	N/A	N/A	[('CHEBI_28384', 'vitamin K', 0, 'Vitamin D'), ('UBERON_0002048', 'lung', 48, 'pulmonary'), ('CL_0000771', 'eosinophil', 58, 'eosinophilia'), ('NCBITaxon_10088', 'Mus <genus>', 102, 'mice'), ('CHEBI_50904', 'allergen', 128, 'allergen'), ('GO_0007631', 'feeding behavior', 150, 'ingestion'), ('CHEBI_27300', 'vitamin D', 182, 'vitamin D')]
PMC4329404	10/2014	S75-PMC4329404	['Lung eosinophilia was highest in pups after in utero and early-Life insufficiency, and this was significantly reduced when pups were supplemented with Vitamin D at weaning (fig.2b).']	N/A	N/A	[('UBERON_0002048', 'lung', 0, 'Lung'), ('UBERON_0000104', 'life cycle', 63, 'life'), ('CHEBI_27300', 'vitamin D', 151, 'vitamin D')]
PMC4329404	10/2014	S77-PMC4329404	['Eosinophils in the Bal (fig.2a) and total numbers of Inflammatory Cells in both the Bal and Lung were unaffected by Vitamin D status (fig.2a,b).']	N/A	N/A	[('CL_0000771', 'eosinophil', 0, 'Eosinophils'), ('UBERON_0006378', 'strand of vibrissa hair', 19, 'BAL'), ('CL_0000902', 'induced T-regulatory cell', 53, 'inflammatory cells'), ('UBERON_0006378', 'strand of vibrissa hair', 84, 'BAL'), ('UBERON_0002048', 'lung', 92, 'lung'), ('CHEBI_27300', 'vitamin D', 116, 'vitamin D')]
PMC4329404	10/2014	S79-PMC4329404	['Pregnant female balb/c Mice were either Fed a Vitamin D-deficient diet from day-16 Gestation or remained on a normal Chow diet.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 0, 'Pregnant'), ('NCBITaxon_10088', 'Mus <genus>', 23, 'mice'), ('GO_0007631', 'feeding behavior', 40, 'fed'), ('CHEBI_27300', 'vitamin D', 46, 'vitamin D'), ('GO_0007565', 'female pregnancy', 83, 'gestation'), ('CHEBI_33290', 'food', 117, 'chow')]
PMC4329404	10/2014	S80-PMC4329404	['pups were exposed to house dust Mite (hdm) or pbs and weaned on to either a Vitamin D-deficient diet or a normal Chow at 3\xa0weeks of age.']	N/A	N/A	[('CHEBI_46662', 'mineral', 32, 'mite'), ('CHEBI_27300', 'vitamin D', 76, 'vitamin D'), ('CHEBI_33290', 'food', 113, 'chow')]
PMC4329404	10/2014	S82-PMC4329404	['+ represents Vitamin D intake; - represents a lack of Vitamin D. Lung sections stained with Haematoxylin and eosin from hdm-exposed pups with in utero vitamin d insufficiency (c).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 13, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 54, 'vitamin D'), ('UBERON_0002048', 'lung', 65, 'Lung'), ('CHEBI_51686', 'haematoxylin', 92, 'haematoxylin')]
PMC4329404	10/2014	S83-PMC4329404	['postweaning Vitamin D insufficiency (left) and Postweaning Vitamin D sufficiency (right) are shown.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 12, 'vitamin D'), ('GO_0007569', 'cell aging', 47, 'postweaning'), ('CHEBI_27300', 'vitamin D', 59, 'vitamin D')]
PMC4329404	10/2014	S92-PMC4329404	['a Vitamin D-replete diet from 3\xa0weeks of age for a further 3\xa0weeks did not alter this phenotype.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 2, 'vitamin D')]
PMC4329404	10/2014	S93-PMC4329404	['caption (fig): figure 3\n\nin utero and early-Life Vitamin D insufficiency skews towards a th2 environment and reduces T Regulatory Cells in the Lungs of pups.']	N/A	N/A	[('UBERON_0000104', 'life cycle', 44, 'life'), ('CHEBI_27300', 'vitamin D', 49, 'vitamin D'), ('CL_0000902', 'induced T-regulatory cell', 117, 'T regulatory cells'), ('GO_0065007', 'biological regulation', 119, 'regulatory'), ('UBERON_0002048', 'lung', 143, 'lungs')]
PMC4329404	10/2014	S94-PMC4329404	['Pregnant female balb/c Mice were Fed a Vitamin D-deficient diet from day-16 Gestation or remained on a normal Chow diet.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 0, 'Pregnant'), ('NCBITaxon_10088', 'Mus <genus>', 23, 'mice'), ('GO_0007631', 'feeding behavior', 33, 'fed'), ('CHEBI_27300', 'vitamin D', 39, 'vitamin D'), ('GO_0007565', 'female pregnancy', 76, 'gestation'), ('CHEBI_33290', 'food', 110, 'chow')]
PMC4329404	10/2014	S96-PMC4329404	['pups were weaned at 3\xa0weeks of age and either Fed a Vitamin D-deficient diet or a normal Chow.']	N/A	N/A	[('GO_0007631', 'feeding behavior', 46, 'fed'), ('CHEBI_27300', 'vitamin D', 52, 'vitamin D'), ('CHEBI_33290', 'food', 89, 'chow')]
PMC4329404	10/2014	S99-PMC4329404	['+ represents Vitamin D intake; - represents a lack of Vitamin D. data are expressed as box and whisker plots; horizontal bar represents median, n \xa0=\xa04–6.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 13, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 54, 'vitamin D')]
PMC4329404	10/2014	S106-PMC4329404	['Pregnant female balb/c Mice were Fed a Vitamin D-deficient diet from day-16 Gestation or remained on a normal Chow diet.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 0, 'Pregnant'), ('NCBITaxon_10088', 'Mus <genus>', 23, 'mice'), ('GO_0007631', 'feeding behavior', 33, 'fed'), ('CHEBI_27300', 'vitamin D', 39, 'vitamin D'), ('GO_0007565', 'female pregnancy', 76, 'gestation'), ('CHEBI_33290', 'food', 110, 'chow')]
PMC4329404	10/2014	S108-PMC4329404	['pups were weaned at 3\xa0weeks of age and either Fed a Vitamin D-deficient diet or a normal Chow.']	N/A	N/A	[('GO_0007631', 'feeding behavior', 46, 'fed'), ('CHEBI_27300', 'vitamin D', 52, 'vitamin D'), ('CHEBI_33290', 'food', 89, 'chow')]
PMC4329404	10/2014	S111-PMC4329404	['+ represents Vitamin D intake; - represents a lack of Vitamin D. data are expressed as box and whisker plots; horizontal bar represents median, n \xa0=\xa09–16 combined from 2 experiments.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 13, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 54, 'vitamin D')]
PMC4329404	10/2014	S114-PMC4329404	['the skew in numbers of Th2 Cells in pups exposed to in utero and early-Life Vitamin D insufficiency was not evident in the level of Pulmonary th2 cytokines Il-13, Il-5 or Il-4 (fig.4b).']	N/A	N/A	[('CL_0000546', 'T-helper 2 cell', 23, 'Th2 cells'), ('UBERON_0000104', 'life cycle', 71, 'life'), ('CHEBI_27300', 'vitamin D', 76, 'vitamin D'), ('UBERON_0002048', 'lung', 132, 'pulmonary'), ('PR_000001470', 'interleukin-28B', 156, 'IL-13'), ('PR_000001470', 'interleukin-28B', 163, 'IL-5'), ('PR_000001470', 'interleukin-28B', 171, 'IL-4')]
PMC4329404	10/2014	S117-PMC4329404	['s2) were not influenced by Vitamin D status.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 27, 'vitamin D')]
PMC4329404	10/2014	S120-PMC4329404	['in utero and early-Life Vitamin D insufficiency did not alter Lung collagen content in hdm-exposed pups.']	N/A	N/A	[('UBERON_0000104', 'life cycle', 19, 'life'), ('CHEBI_27300', 'vitamin D', 24, 'vitamin D'), ('UBERON_0002048', 'lung', 62, 'lung')]
PMC4329404	10/2014	S123-PMC4329404	['caption (fig): figure 5\n\nintroduction of dietary Vitamin D after an in utero and early-Life insufficiency reduces house dust mite (hdm)-induced Lung collagen.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 49, 'vitamin D'), ('UBERON_0000104', 'life cycle', 87, 'life'), ('UBERON_0002048', 'lung', 144, 'lung')]
PMC4329404	10/2014	S124-PMC4329404	['Pregnant female balb/c Mice were Fed a Vitamin D-deficient diet from day-16 Gestation or remained on a normal Chow diet.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 0, 'Pregnant'), ('NCBITaxon_10088', 'Mus <genus>', 23, 'mice'), ('GO_0007631', 'feeding behavior', 33, 'fed'), ('CHEBI_27300', 'vitamin D', 39, 'vitamin D'), ('GO_0007565', 'female pregnancy', 76, 'gestation'), ('CHEBI_33290', 'food', 110, 'chow')]
PMC4329404	10/2014	S126-PMC4329404	['pups were weaned at 3\xa0weeks of age and either Fed a Vitamin D-deficient diet or a normal Chow.']	N/A	N/A	[('GO_0007631', 'feeding behavior', 46, 'fed'), ('CHEBI_27300', 'vitamin D', 52, 'vitamin D'), ('CHEBI_33290', 'food', 89, 'chow')]
PMC4329404	10/2014	S130-PMC4329404	['Lung sections stained with Sirius Red (d); + represents Vitamin D intake; - represents a lack of Vitamin D. data are expressed as box and whisker plots; horizontal bar represents median, n \xa0=\xa09–16 combined from 2 experiments.']	N/A	N/A	[('UBERON_0002048', 'lung', 0, 'Lung'), ('CHEBI_34957', 'S-(1,2-Dichlorovinyl)glutathione', 27, 'Sirius red'), ('CHEBI_27300', 'vitamin D', 56, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 97, 'vitamin D')]
PMC4329404	10/2014	S134-PMC4329404	['moreover, offspring from Vitamin D insufficient females exposed to hdm and Fed a Vitamin D-deficient diet had increased Pulmonary Eosinophilia, Th2 Cells and reduced Cd4+Il-10+Regulatory Cells.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 25, 'vitamin D'), ('GO_0007631', 'feeding behavior', 75, 'fed'), ('CHEBI_27300', 'vitamin D', 81, 'vitamin D'), ('UBERON_0002048', 'lung', 120, 'pulmonary'), ('CL_0000771', 'eosinophil', 130, 'eosinophilia'), ('CL_0000546', 'T-helper 2 cell', 144, 'Th2 cells'), ('PR_000001204', 'C-C chemokine receptor type 8', 166, 'CD4'), ('PR_000001470', 'interleukin-28B', 170, 'IL-10'), ('CL_0000232', 'erythrocyte', 176, 'regulatory cells'), ('GO_0065007', 'biological regulation', 176, 'regulatory')]
PMC4329404	10/2014	S136-PMC4329404	['introduction of Vitamin D after in utero and early-Life deficiency lowered disease severity in hdm-exposed neonatal Mice by reducing Eosinophilic inflammation, Airway Remodelling and serum Ige levels.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 16, 'vitamin D'), ('UBERON_0000104', 'life cycle', 51, 'life'), ('NCBITaxon_10088', 'Mus <genus>', 116, 'mice'), ('CL_0000771', 'eosinophil', 133, 'eosinophilic'), ('GO_0003313', 'heart rudiment development', 160, 'airway remodelling'), ('UBERON_0001005', 'respiratory airway', 160, 'airway'), ('GO_0071743', 'IgE immunoglobulin complex, circulating', 189, 'IgE')]
PMC4329404	10/2014	S142-PMC4329404	['despite establishment of Vitamin D-replete and Vitamin D-deficient Mice through 5\xa0weeks of dietary manipulation of parent Mice before breeding, and from Birth of offspring until Adulthood, Ovalbumin exposure did not impact Lung function in offspring.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 25, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 47, 'vitamin D'), ('NCBITaxon_10088', 'Mus <genus>', 67, 'mice'), ('NCBITaxon_10088', 'Mus <genus>', 122, 'mice'), ('GO_0007567', 'parturition', 153, 'birth'), ('UBERON_0000113', 'post-juvenile adult stage', 178, 'adulthood'), ('CHEBI_83268', 'oxathiapiprolin', 189, 'ovalbumin'), ('PR_000012086', 'homeobox protein OTX2', 189, 'ovalbumin'), ('UBERON_0002048', 'lung', 223, 'lung')]
PMC4329404	10/2014	S170-PMC4329404	['supplementation of dietary Vitamin D postweaning resulted in significantly higher Il-10+Tregs in hdm-exposed pups.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 27, 'vitamin D'), ('PR_000001470', 'interleukin-28B', 82, 'IL-10'), ('CL_0000909', 'CD8-positive, alpha-beta memory T cell', 88, 'Tregs')]
PMC4329745	10/2014	S3-PMC4329745	['Serum 25-Hydroxy Vitamin D levels were measured in all participants after recruiting their demographic and anthropometric data and past medical histories.']	N/A	N/A	[('UBERON_0001977', 'blood serum', 0, 'Serum'), ('CHEBI_43141', '3-hydroxypropoxy group', 6, '25-hydroxy'), ('CHEBI_27300', 'vitamin D', 17, 'vitamin D')]
PMC4329745	10/2014	S5-PMC4329745	['results:\nthe prevalence of Vitamin D deficiency was 69%; mild, moderate and severe degrees were seen in %10.4, %38.3, and %20.3 respectively.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 27, 'vitamin D')]
PMC4329745	10/2014	S20-PMC4329745	['exclusion criteria included chronic illness, history of cancer, Pregnancy or Lactation, malabsorption syndrome or gastric disorders, Metabolic bone disease, Renal or Hepatic failure, recent history of therapeutic Vitamin D consumption or osteoporosis treatment.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 64, 'pregnancy'), ('GO_0007595', 'lactation', 77, 'lactation'), ('GO_0008152', 'metabolic process', 133, 'metabolic'), ('UBERON_0002113', 'kidney', 157, 'renal'), ('UBERON_0002107', 'liver', 166, 'hepatic'), ('CHEBI_27300', 'vitamin D', 213, 'vitamin D')]
PMC4329745	10/2014	S42-PMC4329745	['overall, 418 of the participants had Vitamin D levels less than 50 nmol/l, the prevalence of Vitamin D deficiency was therefore 78%; insufficiency was detected in 43 patients (8%), deficiency in 103 (19.1%) cases, and severe deficiency in 315 women (58.6.%).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 37, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 93, 'vitamin D')]
PMC4329745	10/2014	S44-PMC4329745	['the prevalence of Vitamin D deficiency in different age, menopausal and bmi groups is shown intable 2.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 18, 'vitamin D')]
PMC4329745	10/2014	S45-PMC4329745	['all variables were separately entered in the univariable model of logistic and were compared between Vitamin D sufficiency and Vitamin D deficiency group.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 101, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 127, 'vitamin D')]
PMC4329745	10/2014	S53-PMC4329745	['babbreviations: nl, normal (vitd > 35 ngr/ml); insuf, Vitamin D insufficiency (35 < vitd < 25); def, Vitamin D deficiency (vitd < 25 ngr/ml); sev def, severe Vitamin D deficiency (vitd < 12.5 ngr/ml); bmi, body mass index.']	N/A	N/A	[('CHEBI_28384', 'vitamin K', 54, 'Vitamin D'), ('CHEBI_28384', 'vitamin K', 101, 'Vitamin D'), ('CHEBI_27300', 'vitamin D', 158, 'vitamin D')]
PMC4329745	10/2014	S75-PMC4329745	['in a study performed among 1210 males and females in tehran in 2004, the median level of Vitamin D was 20.65 nmol/l and the prevalence of deficiency (Vitamin D < 35 nmol/l) was 81.1%.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 89, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 150, 'vitamin D')]
PMC4349447	3/2015	S275-PMC4349447	['the new candidates for inclusion in the final model included maternal smoking in the last trimester, Vitamin C intake and a household chemical score.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 101, 'vitamin C')]
PMC4363193	3/2015	S71-PMC4363193	['Gestation and Lactation diets: Cu, 38\xa0mg; fe, 70\xa0mg; Mn, 62\xa0mg; zn, 80\xa0mg; i, 0.6\xa0mg; Se, 0.2\xa0mg; Vitamin A, 10000\xa0iu; Vitamin D3, 1000\xa0iu; Vitamin E, 100\xa0iu; Vitamin K, 2\xa0mg; Vitamin B12, 15\xa0μg; riboflavin, 5\xa0mg; Nicotinic Acid, 12\xa0mg; Pantothenic Acid, 10\xa0mg; Choline Chloride, 500\xa0mg; Biotin, 200\xa0μg; Folic Acid, 5\xa0mg; vitamin b1, 2\xa0mg and Vitamin B6, 3\xa0mg.\nweaner diet: Cu, 175\xa0mg; Fe, 140\xa0mg; Mn, 47\xa0mg; zn, 120\xa0mg; i, 0.6\xa0mg; Se, 0.3\xa0mg; Vitamin A, 6000\xa0iu; Vitamin D3, 1000\xa0iu; Vitamin E, 100\xa0iu; Vitamin K, 4\xa0mg; Vitamin B12, 15\xa0μg; riboflavin, 2\xa0mg; Nicotinic Acid, 12\xa0mg; Pantothenic Acid, 10\xa0mg; Choline Chloride, 250\xa0mg; vitamin B1, 2\xa0mg; Vitamin B6, 3\xa0mg; and endox, 60\xa0mg.\nfinisher diet: Cu, 100\xa0mg; Fe, 40\xa0mg; Mn, 31\xa0mg; zn, 80\xa0mg; i, 0.3\xa0mg; Se, 0.2\xa0mg; Vitamin A, 2000\xa0iu; Vitamin D3, 500\xa0iu; Vitamin E, 40\xa0iu; Vitamin K, 4\xa0mg; Vitamin B12, 15\xa0μg; riboflavin, 2\xa0mg; Nicotinic Acid, 12\xa0mg; Pantothenic Acid, 10\xa0mg; vitamin b1, 2\xa0mg and Vitamin B6, 3\xa0mg.\ncsynthetic amino acids.']	N/A	N/A	[('GO_0006266', 'DNA ligation', 0, 'Gestation'), ('GO_0007595', 'lactation', 14, 'lactation'), ('CHEBI_17996', 'chloride', 31, 'Cu'), ('CHEBI_25614', 'nylons', 53, 'Mn'), ('CHEBI_37972', 'phosphorus-32 atom', 86, 'Se'), ('CHEBI_27300', 'vitamin D', 98, 'vitamin A'), ('CHEBI_33279', 'vitamin D5', 119, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 119, 'vitamin D3'), ('CHEBI_27300', 'vitamin D', 140, 'vitamin E'), ('CHEBI_27300', 'vitamin D', 159, 'vitamin K'), ('CHEBI_33279', 'vitamin D5', 176, 'vitamin B12'), ('PR_000004738', 'class E basic helix-loop-helix protein 22', 184, 'B12'), ('CHEBI_44557', 'nitrilotriacetic acid', 214, 'nicotinic acid'), ('CHEBI_7916', 'pantothenic acid', 237, 'pantothenic acid'), ('CHEBI_133341', 'choline chloride', 262, 'choline chloride'), ('CHEBI_15956', 'biotin', 288, 'Biotin'), ('CHEBI_30751', 'formic acid', 304, 'Folic acid'), ('CHEBI_33237', 'vitamin D4', 343, 'vitamin B6'), ('CHEBI_17996', 'chloride', 374, 'Cu'), ('CHEBI_33290', 'food', 386, 'Fe'), ('CHEBI_25614', 'nylons', 398, 'Mn'), ('CHEBI_37972', 'phosphorus-32 atom', 432, 'Se'), ('CHEBI_27300', 'vitamin D', 444, 'vitamin A'), ('PR_000004370', 'asialoglycoprotein receptor 2', 452, 'A'), ('CHEBI_33279', 'vitamin D5', 464, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 464, 'vitamin D3'), ('CHEBI_27300', 'vitamin D', 485, 'vitamin E'), ('CHEBI_27300', 'vitamin D', 504, 'vitamin K'), ('CHEBI_33279', 'vitamin D5', 521, 'vitamin B12'), ('PR_000004738', 'class E basic helix-loop-helix protein 22', 529, 'B12'), ('CHEBI_44557', 'nitrilotriacetic acid', 559, 'nicotinic acid'), ('CHEBI_7916', 'pantothenic acid', 582, 'pantothenic acid'), ('CHEBI_133341', 'choline chloride', 607, 'choline chloride'), ('PR_000004693', 'Bcl-2-like protein 10', 641, 'B1'), ('CHEBI_33237', 'vitamin D4', 651, 'vitamin B6'), ('CHEBI_17996', 'chloride', 702, 'Cu'), ('CHEBI_33290', 'food', 714, 'Fe'), ('CHEBI_25614', 'nylons', 725, 'Mn'), ('CHEBI_37972', 'phosphorus-32 atom', 758, 'Se'), ('CHEBI_27300', 'vitamin D', 770, 'vitamin A'), ('CHEBI_33279', 'vitamin D5', 790, 'vitamin D3'), ('PR_000001177', 'D(2) dopamine receptor', 798, 'D3'), ('CHEBI_27300', 'vitamin D', 810, 'vitamin E'), ('CHEBI_27300', 'vitamin D', 828, 'vitamin K'), ('CHEBI_33279', 'vitamin D5', 845, 'vitamin B12'), ('PR_000004738', 'class E basic helix-loop-helix protein 22', 853, 'B12'), ('CHEBI_44557', 'nitrilotriacetic acid', 883, 'nicotinic acid'), ('CHEBI_7916', 'pantothenic acid', 906, 'pantothenic acid'), ('CHEBI_33237', 'vitamin D4', 952, 'vitamin B6')]
PMC4377870	3/2015	S66-PMC4377870	['antioxidants including Vitamin C, Vitamin E, Flavonoids and Carotenoids are abundantly present in fruits and vegetables, as well as nuts, vegetable oils, cocoa, red wine and green tea.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 23, 'vitamin C'), ('CHEBI_27300', 'vitamin D', 34, 'vitamin E'), ('CHEBI_72544', 'flavonoids', 45, 'flavonoids'), ('CHEBI_50815', 'norgestimate', 60, 'carotenoids')]
PMC4377870	3/2015	S68-PMC4377870	['Α-Tocopherol is a form of Vitamin E, which helps maintain integrity of Membrane Fatty Acids, by inhibiting Lipid peroxidation [22].']	N/A	N/A	[('CHEBI_27725', 'butin', 0, 'α-tocopherol'), ('CHEBI_27300', 'vitamin D', 26, 'vitamin E'), ('GO_0016020', 'membrane', 71, 'membrane'), ('CHEBI_35366', 'fatty acid', 80, 'fatty acids'), ('CHEBI_18059', 'lipid', 107, 'lipid')]
PMC4377870	3/2015	S91-PMC4377870	['[67] reported that in knock out Mice unable to synthesize Vitamin C, Vitamin C supplementation was able to prevent smoke induced emphysema and also to restore damaged Lung Tissue and decrease oxidative stress caused by smoke induced emphysema.']	N/A	N/A	[('NCBITaxon_10088', 'Mus <genus>', 32, 'mice'), ('CHEBI_27300', 'vitamin D', 58, 'vitamin C'), ('CHEBI_27300', 'vitamin D', 69, 'vitamin C'), ('UBERON_0002048', 'lung', 167, 'lung'), ('UBERON_0000479', 'tissue', 172, 'tissue')]
PMC4377870	3/2015	S96-PMC4377870	['Vitamin E\nthe Vitamin E family comprises of 4 Tocopherols and 4 Tocotrienols, with the most plentiful in the diet or in Tissues being Α-Tocopherol and γ-Tocopherol [70].']	N/A	N/A	[('CHEBI_28384', 'vitamin K', 0, 'Vitamin E'), ('CHEBI_27300', 'vitamin D', 14, 'vitamin E'), ('CHEBI_27013', 'tocopherol', 46, 'tocopherols'), ('CHEBI_33257', 'secondary amide', 64, 'tocotrienols'), ('UBERON_0000479', 'tissue', 120, 'tissues'), ('CHEBI_27725', 'butin', 134, 'α-tocopherol'), ('CHEBI_27013', 'tocopherol', 153, 'tocopherol')]
PMC4377870	3/2015	S107-PMC4377870	['in the women’s health study ( n = 38,597), the risk of developing chronic Lung disease over a 10 year supplementation period was reduced by 10% in women using Vitamin E supplements (600 iu on alternate days) [87].']	N/A	N/A	[('UBERON_0002048', 'lung', 74, 'lung'), ('CHEBI_27300', 'vitamin D', 159, 'vitamin E')]
PMC4377870	3/2015	S115-PMC4377870	['however, the addition of Vitamin C to the system had inflammatory actions, with increased production of pro-inflammatory cytokines, combined with reduced production of il-10 and Tgf-Β.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 25, 'vitamin C'), ('PR_000000046', 'TGF-beta', 178, 'TGF-β')]
PMC4377870	3/2015	S143-PMC4377870	['activated Vitamin D also decreases the Expression of rhinovirus receptors in Endothelial Cell cultures and pbmc’s [113].']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 10, 'vitamin D'), ('GO_0010467', 'gene expression', 39, 'expression'), ('CL_0000115', 'endothelial cell', 77, 'endothelial cell'), ('UBERON_0001986', 'endothelium', 77, 'endothelial')]
PMC4377879	3/2015	S204-PMC4377879	['supplementation with multivitamins (Vitamin B Complex, Vitamin C and Vitamin E) also significantly decreases the risk of adverse Pregnancy outcomes among hiv-infected women [76].']	N/A	N/A	[('CHEBI_75427', 'deuterated fatty acid', 36, 'vitamin B complex'), ('CHEBI_27300', 'vitamin D', 55, 'vitamin C'), ('CHEBI_27300', 'vitamin D', 69, 'vitamin E'), ('GO_0007565', 'female pregnancy', 129, 'pregnancy')]
PMC4377879	3/2015	S267-PMC4377879	['other success stories include the fortification of Sugar with Vitamin A in central america.']	N/A	N/A	[('CHEBI_24870', 'ion', 51, 'sugar'), ('CHEBI_27300', 'vitamin D', 62, 'vitamin A')]
PMC4377888	3/2015	S67-PMC4377888	['[54] report a 20% reduction in Nephron number in Adult Rats Born to mothers that were Fed a Vitamin A deficient diet during 3 weeks prior to Pregnancy, throughout Pregnancy up until day 21 of Gestation.']	N/A	N/A	[('UBERON_0001285', 'nephron', 31, 'nephron'), ('UBERON_0007023', 'adult organism', 49, 'adult'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 55, 'rats'), ('GO_0007567', 'parturition', 60, 'born'), ('GO_0007631', 'feeding behavior', 86, 'fed'), ('CHEBI_27300', 'vitamin D', 92, 'vitamin A'), ('GO_0007565', 'female pregnancy', 141, 'pregnancy'), ('GO_0007565', 'female pregnancy', 163, 'pregnancy'), ('GO_0007565', 'female pregnancy', 192, 'gestation')]
PMC4380518	9/2014	S4-PMC4380518	['75% of black and 19% of white women were Vitamin D deficient in the first Trimester.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 41, 'vitamin D'), ('GO_0009294', 'DNA mediated transformation', 74, 'trimester')]
PMC4380518	9/2014	S12-PMC4380518	['this substudy includes women enrolled from brigham and women’s hospital, a high-risk tertiary Perinatal center in boston, ma who had complete exposure (pnv use) and outcome data (Vitamin D status at two time points during Pregnancy).']	N/A	N/A	[('GO_0036268', 'swimming', 94, 'perinatal'), ('UBERON_0012101', 'perinatal stage', 94, 'perinatal'), ('CHEBI_27300', 'vitamin D', 179, 'vitamin D'), ('GO_0007565', 'female pregnancy', 222, 'pregnancy')]
PMC4380518	9/2014	S24-PMC4380518	['we then performed multivariable logistic regression models to estimate adjusted associations of pnv use and Vitamin D deficiency.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 108, 'vitamin D')]
PMC4380518	9/2014	S25-PMC4380518	['we subsequently stratified by race/ethnicity and obesity status to examine whether pnv was associated with Vitamin D deficiency in high risk groups.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 107, 'vitamin D')]
PMC4380518	9/2014	S31-PMC4380518	['at the earlier time point, 34.5 % of women had Vitamin D levels < 50 nmol/l; at the later time point, 29.1% did.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 47, 'vitamin D')]
PMC4383226	2/2015	S67-PMC4383226	['relative risk of malaria infection after standard vaccination and Vitamin A supplementation among children 6–59 months of age\ndoi: http://dx.doi.org/10.7554/elife.03925.005type of immunizationno.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 66, 'vitamin A')]
PMC4383226	2/2015	S74-PMC4383226	['adjusted relative risk of malaria infection according to different features of Vitamin A supplementation and Bcg vaccination\n(liu et al., 2012;world health organization, 2012).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 79, 'vitamin A'), ('CHEBI_33250', 'atom', 109, 'BCG')]
PMC4383226	2/2015	S158-PMC4383226	['eligible subjects for our analysis included children 6–59 months of age who, during survey interviews, provided Blood samples for malaria screening and had their history of vaccination and Vitamin A supplementation documented based on health records.']	N/A	N/A	[('UBERON_0000178', 'blood', 112, 'blood'), ('CHEBI_27300', 'vitamin D', 189, 'vitamin A')]
PMC4383226	2/2015	S179-PMC4383226	["identification of vaccination and Vitamin A supplementation history\ninformation regarding children's vaccination and Vitamin A supplementation history was ascertained from health card data recorded during the survey interview."]	N/A	N/A	[('CHEBI_27300', 'vitamin D', 34, 'vitamin A'), ('CHEBI_27300', 'vitamin D', 117, 'vitamin A')]
PMC4383226	2/2015	S184-PMC4383226	['for Vitamin A supplementations, data were recorded regarding the date of last dose received and use of the Vitamin Supplement during the 6 months prior to the survey interview.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 4, 'vitamin A'), ('CHEBI_33229', 'vitamin (role)', 107, 'vitamin'), ('CHEBI_16158', 'steroid sulfate', 115, 'supplement')]
PMC4383575	1/2015	S131-PMC4383575	['caption (table-wrap): table 3\n\ndietary predictors in adjusted associations with bulky dna adduct levels.predictor n mra(95% ci) p -valuemeat donenessnormal2521.00 (reference)well-done980.93 (0.77, 1.13)0.47processed meat (per 1 g/day)low1491.00 (reference)middle1581.15 (0.97, 1.37)0.11high1371.15 (0.94, 1.40)0.17dietary supplementssome3921.00 (reference)none481.03 (0.78, 1.36)0.82dairy products (per 1 g/day)4541.00 (1.00, 1.00)0.06low1421.00 (reference)middle1531.10 (0.92, 1.32)0.31high1591.21 (1.00, 1.46)0.05fruits with Vitamin C (per 1 g/day)4531.00 (1.00, 1.00)0.06low1471.00 (reference)middle1570.88 (0.74, 1.04)0.13high1490.83 (0.70, 0.99)0.04healthy dietary score (0–7 no units)4550.93 (0.88, 0.98)0.008low1061.00 (reference)middle2460.85 (0.71, 1.01)0.06high1030.78 (0.63, 0.96)0.02mean ratios (mrs) (95% cis) represent the proportional differences in bulky dna adduct levels ( n /108nucleotides) associated with a 1-unit increase in continuous variables, and for the categorical variables the mr and 95% cis are relative to the referent group.aadjusted for country, Maternal smoking (no, yes), and Prepregnancy bmi (kg/m2).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 527, 'vitamin C'), ('GO_0007618', 'mating', 1080, 'maternal'), ('GO_0007565', 'female pregnancy', 1112, 'prepregnancy')]
PMC4392531	3/2015	S73-PMC4392531	['in Pregnant women who consumed less than 65 mg of Vitamin C per day, this percentage during the second Trimester and increased risk of these complications was 70%.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 3, 'pregnant'), ('CHEBI_27300', 'vitamin D', 50, 'vitamin C'), ('GO_0009294', 'DNA mediated transformation', 103, 'trimester')]
PMC4392553	3/2015	S39-PMC4392553	['furthermore, many other biologically active Molecules, including Serotonin, melatonin, Melanin, Epinephrine, Dopamine, Thyroid hormone, Folate, coenzyme q10, Vitamin K, and Vitamin E, depend on the shikimate pathway Metabolites as precursors.']	N/A	N/A	[('CHEBI_36357', 'polyatomic entity', 44, 'molecules'), ('CHEBI_28790', 'serotonin', 65, 'serotonin'), ('CHEBI_25179', 'melanins', 87, 'melanin'), ('CHEBI_48509', 'triflic anhydride', 96, 'epinephrine'), ('CHEBI_18243', 'dopamine', 109, 'dopamine'), ('UBERON_0002046', 'thyroid gland', 119, 'thyroid'), ('CHEBI_30863', '5-azaorotic acid', 136, 'folate'), ('CHEBI_27300', 'vitamin D', 158, 'vitamin K'), ('CHEBI_27300', 'vitamin D', 173, 'vitamin E'), ('CHEBI_25212', 'metabolite', 216, 'metabolites')]
PMC4392553	3/2015	S267-PMC4392553	['[50] furthermore, gamma-glutamyl carboxylase, a Liver enzyme that Metabolizes Oxalate, is catalyzed by Vitamin K, which depends on the shikimate pathway.']	N/A	N/A	[('UBERON_0002107', 'liver', 48, 'liver'), ('GO_0008152', 'metabolic process', 66, 'metabolizes'), ('CHEBI_16162', 'o-orsellinate', 78, 'oxalate'), ('CHEBI_27300', 'vitamin D', 103, 'vitamin K')]
PMC4396835	1/2015	S4-PMC4396835	['results\nthe collapsed group of children with asd had significantly lower Vitamin D levels ( m \u2009=\u200924.0 nm, sd \u2009=\u200919.6) as compared with their siblings ( m \u2009=\u200931.9 nm, sd \u2009=\u200927.7), according to a paired samples t-test ( p \u2009=\u20090.013).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 73, 'vitamin D')]
PMC4396835	1/2015	S6-PMC4396835	['all children with african/middle east background, both the children with asd and their non-asd siblings, had Vitamin D deficiency.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 109, 'vitamin D')]
PMC4396835	1/2015	S19-PMC4396835	['the distribution of the Vitamin D Receptor in Human Brain has since been established [15].']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 24, 'vitamin D'), ('PR_000001683', 'vasopressin V2 receptor', 24, 'vitamin D receptor'), ('NCBITaxon_9606', 'Homo sapiens', 46, 'human'), ('UBERON_0000955', 'brain', 52, 'brain')]
PMC4396835	1/2015	S41-PMC4396835	['inclusion criteria for the children with asd were: (1) having been diagnosed with asd without a known cause according to clinical/Neurological assessments, such as rett syndrome, fragile x and tuberous sclerosis during preschool age; (2) having a non-asd sibling aged 4\xa0years or older; and (3) parents giving consent to assessment of Vitamin D status and Cmv-infection status (for a separate study) of the asd and non-asd affected siblings at Birth from dried Blood Spots.']	N/A	N/A	[('UBERON_0001016', 'nervous system', 130, 'neurological'), ('CHEBI_27300', 'vitamin D', 334, 'vitamin D'), ('NCBITaxon_10088', 'Mus <genus>', 355, 'CMV'), ('GO_0007567', 'parturition', 443, 'birth'), ('UBERON_0001969', 'blood plasma', 460, 'blood spots')]
PMC4396835	1/2015	S62-PMC4396835	['they were diagnosed with childhood autism combined with intellectual disability and had previously been included in prevalence studies of autism in children with somali background and their mothers in a Vitamin D study [26,28,29].']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 203, 'vitamin D')]
PMC4405493	4/2015	S5-PMC4405493	['competitive enzymatic Vitamin D assays were performed on banked Plasma specimens and Pregnancy outcomes were collected after Delivery.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 22, 'vitamin D'), ('PR_000006444', 'diacylglycerol kinase delta', 30, 'D'), ('UBERON_0001969', 'blood plasma', 64, 'plasma'), ('GO_0007565', 'female pregnancy', 85, 'pregnancy'), ('GO_0007567', 'parturition', 125, 'delivery')]
PMC4405493	4/2015	S6-PMC4405493	['logistic regression was performed on patients stratified by Plasma Vitamin D concentration and the following combined clinical outcomes: Preeclampsia, Preterm Delivery, Intrauterine growth restriction, Gestational diabetes, and Spontaneous Abortion.']	N/A	N/A	[('UBERON_0001969', 'blood plasma', 60, 'plasma'), ('CHEBI_27300', 'vitamin D', 67, 'vitamin D'), ('GO_0007128', 'meiotic prophase I', 137, 'preeclampsia'), ('GO_0007565', 'female pregnancy', 151, 'preterm'), ('GO_0007567', 'parturition', 159, 'delivery'), ('UBERON_0022293', 'reproductive gland secretion', 169, 'intrauterine'), ('GO_0007565', 'female pregnancy', 202, 'gestational'), ('GO_0035042', 'fertilization, exchange of chromosomal proteins', 228, 'spontaneous abortion')]
PMC4405493	4/2015	S8-PMC4405493	['seventy percent of our study population was Vitamin D insufficient with a Serum concentration less than 30 ng/ml (mean Serum concentration 27.6 ng/ml, range 13-71.6 ng/ml).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 44, 'vitamin D'), ('UBERON_0001977', 'blood serum', 74, 'serum'), ('UBERON_0001977', 'blood serum', 119, 'serum')]
PMC4405493	4/2015	S11-PMC4405493	['there was no association between Vitamin D deficiency and composite adverse Pregnancy outcomes with an adjusted odds ratio of 1.01 ( p value 0.738, 95% confidence intervals 0.961-1.057).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 33, 'vitamin D'), ('GO_0007565', 'female pregnancy', 76, 'pregnancy')]
PMC4405493	4/2015	S45-PMC4405493	['Plasma preparation and Vitamin D elisa\nmaternal Blood was collected by venipuncture in vacutainer edta-containing tubes at 5 to 12 weeks Gestational age and the date of the Blood draw was recorded.']	N/A	N/A	[('UBERON_0001969', 'blood plasma', 0, 'Plasma'), ('CHEBI_27300', 'vitamin D', 23, 'vitamin D'), ('UBERON_0000178', 'blood', 48, 'blood'), ('GO_0007565', 'female pregnancy', 137, 'gestational'), ('UBERON_0000178', 'blood', 173, 'blood')]
PMC4405493	4/2015	S48-PMC4405493	['samples were aliquoted into multiple tubes and stored at -140°c.total 25-Oh Vitamin D concentrations (ng/ml) were quantified in patient Plasma samples by competitive enzymatic linked immunosorption assay (catalog #dz688a, diazyme laboratories, poway, ca).']	N/A	N/A	[('CHEBI_86198', '1,2-di-[(11Z)-eicosenoyl]-sn-glycero-3-phosphocholine', 70, '25-OH'), ('CHEBI_27300', 'vitamin D', 76, 'vitamin D'), ('UBERON_0001969', 'blood plasma', 136, 'plasma')]
PMC4405493	4/2015	S50-PMC4405493	['briefly, 25-Oh Vitamin D was dissociated from its Serum transporter by Acetonitrile extraction.']	N/A	N/A	[('CHEBI_86198', '1,2-di-[(11Z)-eicosenoyl]-sn-glycero-3-phosphocholine', 9, '25-OH'), ('CHEBI_27300', 'vitamin D', 15, 'vitamin D'), ('UBERON_0001977', 'blood serum', 50, 'serum'), ('CHEBI_38472', 'acetonitrile', 71, 'acetonitrile')]
PMC4405493	4/2015	S51-PMC4405493	['Serum 25-Oh Vitamin D activated the enzyme beta-galactosidase and its substrate Chlorophenol Red-beta-d galactopyranoside, producing a colorimetric reaction product (Chlorophenol red) detectable at 560nm by microplate reader (synergy ht, biotek, winooski, va).']	N/A	N/A	[('UBERON_0001977', 'blood serum', 0, 'Serum'), ('CHEBI_86198', '1,2-di-[(11Z)-eicosenoyl]-sn-glycero-3-phosphocholine', 6, '25-OH'), ('CHEBI_27300', 'vitamin D', 12, 'vitamin D'), ('CHEBI_36113', '3-hydroxy-2-phenylchromenylium', 80, 'chlorophenol red'), ('CHEBI_23150', 'chlorophenol', 166, 'chlorophenol')]
PMC4405493	4/2015	S52-PMC4405493	['the amount of Chlorophenol Red was directly proportional to Serum 25-Oh Vitamin D concentration.']	N/A	N/A	[('CHEBI_36113', '3-hydroxy-2-phenylchromenylium', 14, 'chlorophenol red'), ('UBERON_0001977', 'blood serum', 60, 'serum'), ('CHEBI_86198', '1,2-di-[(11Z)-eicosenoyl]-sn-glycero-3-phosphocholine', 66, '25-OH'), ('CHEBI_27300', 'vitamin D', 72, 'vitamin D')]
PMC4405493	4/2015	S54-PMC4405493	['assay quality control was assessed by measuring 25-Oh Vitamin D concentrations of assay controls run in parallel with patient samples.']	N/A	N/A	[('CHEBI_86198', '1,2-di-[(11Z)-eicosenoyl]-sn-glycero-3-phosphocholine', 48, '25-OH'), ('CHEBI_27300', 'vitamin D', 54, 'vitamin D')]
PMC4405493	4/2015	S56-PMC4405493	['assay controls were 2 factory-supplied Serum specimens containing approximately 24.4 ng/ml and 43.4 ng/ml 25-Oh Vitamin D (#dz688a-con, Diazyme; exact concentrations were lot-specific) as measured by an alternative elisa strategy (immunodiagnostic systems, scottsdale, az).']	N/A	N/A	[('UBERON_0001977', 'blood serum', 39, 'serum'), ('CHEBI_86198', '1,2-di-[(11Z)-eicosenoyl]-sn-glycero-3-phosphocholine', 106, '25-OH'), ('CHEBI_27300', 'vitamin D', 112, 'vitamin D'), ('CHEBI_4495', 'diazoxide', 136, 'Diazyme')]
PMC4405493	4/2015	S60-PMC4405493	['Plasma Vitamin D diazyme Vitamin D immunoassay performed comparably to lc/ms mass spectrometry.']	N/A	N/A	[('UBERON_0001969', 'blood plasma', 0, 'Plasma'), ('CHEBI_27300', 'vitamin D', 7, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 25, 'vitamin D')]
PMC4405493	4/2015	S88-PMC4405493	['when actual Plasma Vitamin D concentrations were determined for the 235 patients included in the final analysis, technical reproducibility among replicates was assessed by calculating the coefficient of variation (cv) among calibrators, controls, and samples.']	N/A	N/A	[('UBERON_0001969', 'blood plasma', 12, 'plasma'), ('CHEBI_27300', 'vitamin D', 19, 'vitamin D')]
PMC4405493	4/2015	S90-PMC4405493	['ten percent of our study population was Vitamin D deficient with a Serum concentration less than 20 ng/ml (50 nmol/l); 60% were vitamin D insufficient (Serum concentrations between 20–29 ng/ml or 50–74 nmol/l); and 30% of our study population were Vitamin D sufficient with Serum concentrations above 30 ng/ml (75 nmol/l) (table 2).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 40, 'vitamin D'), ('UBERON_0001977', 'blood serum', 67, 'serum'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 136, 'D'), ('UBERON_0001977', 'blood serum', 152, 'serum'), ('CHEBI_27300', 'vitamin D', 248, 'vitamin D'), ('UBERON_0001977', 'blood serum', 274, 'serum')]
PMC4405493	4/2015	S91-PMC4405493	['none of our patients were classifiable as severely Vitamin D deficient (<10 ng/ml or 25 nmol/l).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 51, 'vitamin D')]
PMC4405493	4/2015	S92-PMC4405493	['the mean Serum 25-Oh Vitamin D concentration for our study population was 27.6 ng/ml (range 13–71.6 ng/ml).10.1371/journal.pone.0123763.t001\n\ncaption (table-wrap): table 1\nfrequency of clinical outcomes compared to national and global epidemiology.Pregnancy outcome n (% of 235 total)comorbiditiespredicted population us (%)frequencies global (%)madigan 2014 (%) none 176 (75%)-------- Preeclampsia 19 (8%)5 Preterm Deliveries3–10% [22,24–26]2–17% [20,23]3% spontaneous Preterm Delivery 10 (4%)2 iugr, 1 Gdm11.3% [27]9.6% [28]9% iugr 9 (4%)--8.6% [29]3–7% [30]0.6% gdm 5 (2%)--4.6–9.2% [33]4.1–27.5% [36]4% spontaneous Abortion 16 (7%)--8–20% [37,38]6%\niugr, Intrauterine growth restriction; gdm, Gestational diabetes mellitus.10.1371/journal.pone.0123763.t002\n\ncaption (table-wrap): table 2\ndemographics of the study population by Vitamin D classification.totalvitamin D sufficient (>30 ng/ml)Vitamin D insufficient (21–29 ng/ml)Vitamin D deficient (<20 ng/ml)p value**n = 235 (%)n = 70 (30%)n = 141 (60%)n = 24 (10%) age (years) *24.3 ± 4.424.5 ± 4.224.6 ± 4.522.5 ± 3.70.08 Gestational age at analysis (days) *62.2 ± 29.761.8 ± 13.762.2 ± 36.963.0 ± 11.20.99 n (% of 235)n (% of 70)n (% of 141)n (% of 24)p value ** race 0.03 caucasian 183 (77.9)57 (81.4)114 (80.9)12 (50) african american 16 (6.8)3 (4.3)10 (7.1)3 (12.5) asian 6 (2.6)1 (1.4)3 (2.1)2 (8.3) other 30 (12.8)9 (12.9)14 (9.9)7 (29.2) body mass index 0.36 <25 111 (47.2)39 (55.7)62 (44)10 (41.7) 25–30 82 (34.9)21 (30.0)50 (35.5)11 (45.8) >30 42 (17.9)10 (14.3)29 (20.5)3 (12.5) season 0.22 winter 89 (37.9)22 (31.4)61 (43.3)6 (25.0) spring 45 (19.1)16 (22.9)25 (17.7)4 (16.6) summer 53 (22.6)20 (28.6)26 (18.4)7 (29.2) fall 48 (20.4)12 (17.1)29 (20.6)7 (29.2) mode of delivery 0.41 Vaginal 155 (66.0)47 (67.1)95 (67.4)13 (54.2) cesarean section 63 (26.8)18 (25.7)36 (25.5)9 (37.5) iufd or sab 17 (7.2)5 (7.1)10 (7.1)2 (8.3) duty status 0.12 active duty 83 (35.3)22 (31.4)48 (34.0)13 (54.2) dependent 152 (64.6)48 (68.6)93 (66.0)11 (45.8) tobacco use 0.67 yes 15 (6.4)3 (4.3)10 (7.1)2 (8.3) no 220 (93.6)67 (95.7)131 (92.9)22 (91.7)\n*expressed in mean ± standard deviation\n**, p value calculated by analysis of variance for continuous variables and chi-square analysis for categorical variables\niufd, Intrauterine fetal demise; sab, spontaneous Abortion.']	N/A	N/A	[('UBERON_0001977', 'blood serum', 9, 'serum'), ('CHEBI_86198', '1,2-di-[(11Z)-eicosenoyl]-sn-glycero-3-phosphocholine', 15, '25-OH'), ('CHEBI_27300', 'vitamin D', 21, 'vitamin D'), ('GO_0007565', 'female pregnancy', 248, 'Pregnancy'), ('GO_0007128', 'meiotic prophase I', 386, 'Preeclampsia'), ('GO_0007565', 'female pregnancy', 408, 'preterm'), ('GO_0007567', 'parturition', 416, 'deliveries3'), ('GO_0007565', 'female pregnancy', 470, 'preterm'), ('GO_0007567', 'parturition', 478, 'delivery'), ('PR_000007939', 'glial fibrillary acidic protein', 504, 'GDM11'), ('GO_0007569', 'cell aging', 619, 'abortion'), ('UBERON_0022293', 'reproductive gland secretion', 659, 'intrauterine'), ('GO_0007565', 'female pregnancy', 697, 'gestational'), ('CHEBI_27300', 'vitamin D', 832, 'vitamin D'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 870, 'D'), ('PR_000006444', 'diacylglycerol kinase delta', 870, 'D'), ('CHEBI_28384', 'vitamin K', 894, 'Vitamin D'), ('CHEBI_28384', 'vitamin K', 930, 'Vitamin D'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 930, 'Vitamin D'), ('GO_0007565', 'female pregnancy', 1077, 'Gestational'), ('UBERON_0000970', 'eye', 1748, 'Vaginal'), ('UBERON_0022293', 'reproductive gland secretion', 2266, 'intrauterine'), ('GO_0007569', 'cell aging', 2310, 'abortion')]
PMC4405493	4/2015	S98-PMC4405493	['statistical associations between Vitamin D categorization and demographic variables are depicted intable 2.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 33, 'vitamin D')]
PMC4405493	4/2015	S100-PMC4405493	['the distribution of clinical outcomes among the Vitamin D categories is depicted intable 3.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 48, 'vitamin D')]
PMC4405493	4/2015	S101-PMC4405493	['study population percentages and with medians and ranges of Vitamin D measured in Plasma were calculated.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 60, 'vitamin D'), ('UBERON_0001969', 'blood plasma', 82, 'plasma')]
PMC4405493	4/2015	S102-PMC4405493	['preeclampsia was sub-stratified into severe, early onset preeclampsia and mild, late-onset preeclampsia.10.1371/journal.pone.0123763.t003\n\ncaption (table-wrap): table 3\nPlasma Vitamin D concentrations in women according to clinical outcome.n (% of 235 total)median Vitamin D concentration in ng/ml (range) no complications 176 (75)27.4 (13.0–71.6) all complications 59 (25)26.5 (13.2–42.3) Preeclampsia 19 (8)26.5 (16.1–35.9) severe, early onset 5 (2)27.1 (18.0–33.8) mild, late onset 14 (6)27.7 (16.1–35.9) spontaneous Preterm Delivery 10 (4)28.4 (19.9–42.3) iugr 9 (4)27.0 (16.6–38.8) gdm 5 (2)22.2 (20.5–31.9) spontaneous abortion 16 (7)25.1 (13.2–38.8)\niugr, Intrauterine growth restriction; gdm, Gestational diabetes mellitus.']	N/A	N/A	[('UBERON_0001969', 'blood plasma', 169, 'Plasma'), ('CHEBI_27300', 'vitamin D', 176, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 265, 'vitamin D'), ('PR_000006444', 'diacylglycerol kinase delta', 273, 'D'), ('GO_0007128', 'meiotic prophase I', 390, 'Preeclampsia'), ('GO_0007128', 'meiotic prophase I', 520, 'Preterm'), ('GO_0007567', 'parturition', 528, 'delivery'), ('UBERON_0022293', 'reproductive gland secretion', 663, 'intrauterine'), ('GO_0007565', 'female pregnancy', 701, 'gestational')]
PMC4405493	4/2015	S103-PMC4405493	['Plasma Vitamin D concentrations were subdivided into 3 categories based on the institution of medicine and Endocrine society criteria for Vitamin D categorization: sufficient (>30ng/ml [75nmol/l]), insufficient (21-29ng/ml [50-75nmol/l], or deficient [<50nmol/l).']	N/A	N/A	[('UBERON_0001969', 'blood plasma', 0, 'Plasma'), ('CHEBI_27300', 'vitamin D', 7, 'vitamin D'), ('UBERON_0005063', 'left ventricular compact myocardium', 107, 'Endocrine'), ('CHEBI_27300', 'vitamin D', 138, 'vitamin D')]
PMC4405493	4/2015	S106-PMC4405493	['there was no association between Vitamin D deficiency in the first trimester and adverse Pregnancy outcomes with an adjusted odds ratio of 1.01 ( p value 0.738, 95% ci 0.947–1.164).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 33, 'vitamin D'), ('GO_0007565', 'female pregnancy', 89, 'pregnancy')]
PMC4405493	4/2015	S108-PMC4405493	['there was no association between first Trimester Vitamin D levels and subsequent development of combined complications, or complications sub-stratified into preeclampsia, Gestational diabetes, Preterm Delivery, Intrauterine growth restriction (iugr), or spontaneous Abortion when each outcome was evaluated individually (table 5).']	N/A	N/A	[('GO_0009294', 'DNA mediated transformation', 39, 'trimester'), ('CHEBI_27300', 'vitamin D', 49, 'vitamin D'), ('GO_0007565', 'female pregnancy', 171, 'gestational'), ('GO_0007565', 'female pregnancy', 193, 'preterm'), ('GO_0007567', 'parturition', 201, 'delivery'), ('UBERON_0022293', 'reproductive gland secretion', 211, 'intrauterine'), ('GO_0007569', 'cell aging', 266, 'abortion')]
PMC4405493	4/2015	S110-PMC4405493	['there was no association between first Trimester Vitamin D levels and subsequent development of composite adverse Pregnancy complications (including Preeclampsia [severe, early onset or mild, late onset], Gestational diabetes, Preterm Delivery, growth restriction, or spontaneous Abortion (combined outcomes; p > 0.05 intable 5).']	N/A	N/A	[('GO_0009294', 'DNA mediated transformation', 39, 'trimester'), ('CHEBI_27300', 'vitamin D', 49, 'vitamin D'), ('GO_0007565', 'female pregnancy', 114, 'pregnancy'), ('GO_0007128', 'meiotic prophase I', 149, 'preeclampsia'), ('GO_0007565', 'female pregnancy', 205, 'gestational'), ('GO_0007565', 'female pregnancy', 227, 'preterm'), ('GO_0007567', 'parturition', 235, 'delivery'), ('GO_0007569', 'cell aging', 280, 'abortion')]
PMC4405493	4/2015	S130-PMC4405493	['there are two forms of Vitamin D in the body: Vitamin D2 and Vitamin D3.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 23, 'vitamin D'), ('CHEBI_28934', 'vitamin D2', 46, 'vitamin D2'), ('PR_000017299', 'VIP peptides', 46, 'vitamin D2'), ('CHEBI_33279', 'vitamin D5', 61, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 61, 'vitamin D3')]
PMC4405493	4/2015	S132-PMC4405493	['the Liver converts both forms of Vitamin D to 25-Oh Vitamin D, which is the specific Metabolite measured to determine Vitamin D status.']	N/A	N/A	[('UBERON_0002107', 'liver', 4, 'liver'), ('CHEBI_27300', 'vitamin D', 33, 'vitamin D'), ('CHEBI_86198', '1,2-di-[(11Z)-eicosenoyl]-sn-glycero-3-phosphocholine', 46, '25-OH'), ('CHEBI_27300', 'vitamin D', 52, 'vitamin D'), ('CHEBI_39382', 'flufenoxuron', 85, 'metabolite'), ('CHEBI_27300', 'vitamin D', 118, 'vitamin D')]
PMC4407379	4/2015	S51-PMC4407379	['caption (table-wrap): table 2\n\ncomposition of basal and test diets (af basis)itembasalcsoy ingredient, %\u2003corn97.0567.97\u2003extruded corn/soybeans--30.00\u2003Dicalcium Phosphate1.220.85\u2003limestone0.730.511\u2003Sodium Chloride0.400.28\u2003Vitamin and Mineral premix10.600.42composition analysis2\u2003cp, %8.2911.33\u2003crude fat, %3.234.09\u2003crude fiber, %1.451.72\u2003ash, %3.082.91\u2003total lysine, %0.240.58\n1provided the following per kilogram of basal diet: Vitamin A, 7,716\xa0iu; Vitamin D3, 1,929\xa0iu; Vitamin E, 39\xa0iu; Vitamin B12, 0.04\xa0mg; riboflavin, 12\xa0mg; niacin, 58\xa0mg; Pantothenic Acid, 31\xa0mg, copper, 35\xa0mg; iron, 350\xa0mg; Iodine, 4\xa0mg; Manganese 120\xa0mg; zinc, 300\xa0mg, Selenium, 0.3\xa0mg.\n2proximate analysis of diets was performed by sgs north america (brookings, sd).']	N/A	N/A	[('CHEBI_4509', 'diclofenac sodium', 150, 'Dicalcium phosphate1'), ('CHEBI_70124', "(2'S)-Hydroxy-(11S,12R)-dihydrostemofoline, (rel)-", 197, 'Sodium chloride0'), ('CHEBI_33229', 'vitamin (role)', 221, 'Vitamin'), ('CHEBI_46662', 'mineral', 233, 'mineral'), ('CHEBI_27300', 'vitamin D', 428, 'vitamin A'), ('CHEBI_33279', 'vitamin D5', 449, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 449, 'vitamin D3'), ('CHEBI_27300', 'vitamin D', 471, 'vitamin E'), ('CHEBI_33279', 'vitamin D5', 489, 'vitamin B12'), ('PR_000004481', 'V-type proton ATPase subunit B, kidney isoform', 489, 'vitamin B12'), ('CHEBI_7916', 'pantothenic acid', 545, 'pantothenic acid'), ('CHEBI_24859', 'iodine atom', 599, 'iodine'), ('CHEBI_33351', 'seaborgium atom', 613, 'manganese'), ('CHEBI_27568', 'selenium atom', 645, 'selenium')]
PMC4407379	4/2015	S102-PMC4407379	['caption (table-wrap): table 3\n\ncomposition of Lactation diets (af basis)itemdietcontrolproductoil ingredient, %\u2003corn67.28--57.69\u2003Soybean meal, 47%29.15--30.95\u2003extruded corn-soybeans--96.45--\u2003Soy oil----7.8\u2003Dicalcium Phosphate1.501.401.50\u2003limestone1.221.301.21\u2003salt0.500.500.50\u2003Vitamin and Trace Mineral premix10.350.350.35calculated analysis\u2003cp, %19.1018.5019.20\u2003crude fat, %3.5011.0011.00\u2003Ca, %0.840.840.84\u2003total p, %0.700.650.69\u2003available p, %0.390.390.39\u2003total lysine, %1.041.021.07\u2003sid lysine, %0.900.930.93\u2003sid lysine: mcal me2.762.542.54\n1the Vitamin and Trace Mineral premix provided the following (per kg of diet): Vitamin A, 11,000\xa0iu; Vitamin D3, 2,756\xa0iu; Vitamin E, 55\xa0iu; Vitamin B12, 55\xa0μg; Vitamin K, 4.4\xa0mg riboflavin, 9.9\xa0mg; Pantothenic Acid, 33\xa0mg; niacin, 55\xa0mg; Choline, 495\xa0mg; Pyridoxine, 2.2\xa0mg; Folic Acid, 1.65\xa0mg; Thiamine, 1.1\xa0mg; Biotin, 220\xa0μg; i, 2.2\xa0mg; zn, 150\xa0mg; Fe, 124\xa0μg; Mn, 40\xa0mg; Cu, 14.9\xa0mg; and Se, 0.3\xa0mg.\n\ncaption (table-wrap): table 4\n\ncomposition analysis of Lactation diets (af basis)1itembatch 1abatch 2acontrolproductoilcontrolproductoil proximate analysis2\u2003cp, %17.0519.5818.9315.7218.8518.28\u2003crude fat, %2.608.589.342.858.379.14\u2003crude fiber, %2.253.002.841.992.391.92\u2003ash, %3.703.614.853.744.464.08lysine3\u2003total lysine, %0.941.010.950.951.051.00\n1diets were mixed and prepared at u of minnesota sroc.']	N/A	N/A	[('GO_0007595', 'lactation', 46, 'lactation'), ('CHEBI_36945', 'sulfaniumyl group', 129, 'Soybean'), ('CHEBI_27922', 'sorbose', 191, 'Soy'), ('CHEBI_4509', 'diclofenac sodium', 206, 'Dicalcium phosphate1'), ('CHEBI_33229', 'vitamin (role)', 277, 'Vitamin'), ('CHEBI_73721', '5,8-tetradecadienal', 289, 'trace mineral'), ('CHEBI_32588', 'potassium chloride', 390, 'Ca'), ('CHEBI_33229', 'vitamin (role)', 549, 'vitamin'), ('CHEBI_73721', '5,8-tetradecadienal', 561, 'trace mineral'), ('CHEBI_27300', 'vitamin D', 623, 'vitamin A'), ('CHEBI_33279', 'vitamin D5', 645, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 645, 'vitamin D3'), ('CHEBI_27300', 'vitamin D', 667, 'vitamin E'), ('CHEBI_33279', 'vitamin D5', 685, 'vitamin B12'), ('CHEBI_27300', 'vitamin D', 705, 'vitamin K'), ('CHEBI_7916', 'pantothenic acid', 743, 'pantothenic acid'), ('CHEBI_15354', 'choline', 783, 'choline'), ('CHEBI_16410', 'pyridoxamine', 800, 'pyridoxine'), ('CHEBI_30751', 'formic acid', 820, 'folic acid'), ('CHEBI_26948', 'vitamin B1', 841, 'thiamine'), ('CHEBI_15956', 'biotin', 859, 'biotin'), ('CHEBI_33290', 'food', 898, 'Fe'), ('CHEBI_25614', 'nylons', 910, 'Mn'), ('CHEBI_17996', 'chloride', 921, 'Cu'), ('CHEBI_37972', 'phosphorus-32 atom', 938, 'Se'), ('GO_0007595', 'lactation', 1006, 'lactation')]
PMC4410595	4/2015	S82-PMC4410595	['child visited is older than 6\xa0months, ill, and with green or yellow muac (≥115\xa0mm)\nif the child is ill, the spk gives recommendations on Feeding during illness, checks the mother child protection card – which contains records of immunisations - and asks about deworming, Iron and Vitamin A supplementation, then, together with the mother, she makes a plan to visit the auxiliary nurse midwife, anganwadi, or the most appropriate local health facility.']	N/A	N/A	[('GO_0007631', 'feeding behavior', 137, 'feeding'), ('CHEBI_24870', 'ion', 271, 'iron'), ('CHEBI_27300', 'vitamin D', 280, 'vitamin A')]
PMC4417995	4/2015	S18-PMC4417995	['this Compound subsequently activates the Vitamin D receptor (vdr), Regulating the Expression of Genes involved in Calcium Metabolism, Proliferation, differentiation, Apoptosis, and Adaptive Immunity [9].']	N/A	N/A	[('CHEBI_36357', 'polyatomic entity', 5, 'compound'), ('CHEBI_27300', 'vitamin D', 41, 'vitamin D'), ('GO_0065007', 'biological regulation', 67, 'regulating'), ('GO_0010467', 'gene expression', 82, 'expression'), ('SO_0000704', 'gene', 96, 'genes'), ('CHEBI_22313', 'alkaline earth metal atom', 114, 'calcium'), ('GO_0018884', 'carbazole metabolic process', 114, 'calcium metabolism'), ('GO_0008283', 'cell proliferation', 134, 'proliferation'), ('GO_0006915', 'apoptotic process', 166, 'apoptosis'), ('GO_0051866', 'general adaptation syndrome', 181, 'adaptive immunity')]
PMC4417995	4/2015	S19-PMC4417995	['individuals with higher phototypes, whose Melanin functions as a natural sunblock, those who extensively use sunblocks, those who stay primarily indoors, and those living at high latitudes show a reduced Vitamin D Synthesis [10].']	N/A	N/A	[('CHEBI_25179', 'melanins', 42, 'melanin'), ('CHEBI_27300', 'vitamin D', 204, 'vitamin D'), ('GO_0031151', 'histone methyltransferase activity (H3-K79 specific)', 212, 'D synthesis')]
PMC4417995	4/2015	S73-PMC4417995	['as a matter of fact, patients with low Vitamin D (<10\u2009ng/ml) or with very high Vitamin D Serum levels (>54\u2009ng/ml) had significantly higher Ige levels than healthy Individuals (40–50\u2009ng/ml).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 39, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 79, 'vitamin D'), ('UBERON_0001977', 'blood serum', 89, 'serum'), ('GO_0071743', 'IgE immunoglobulin complex, circulating', 139, 'IgE'), ('NCBITaxon_1', 'root', 163, 'individuals')]
PMC4417995	4/2015	S74-PMC4417995	['consequent correction of Serum concentrations of Vitamin D reduced Ige level significantly.']	N/A	N/A	[('UBERON_0001977', 'blood serum', 25, 'serum'), ('CHEBI_27300', 'vitamin D', 49, 'vitamin D'), ('GO_0071743', 'IgE immunoglobulin complex, circulating', 67, 'IgE')]
PMC4417995	4/2015	S137-PMC4417995	['in 2008 a double-blind randomized controlled trial in children with winter-related ad was performed [60] utilizing a regimen of 1,000\u2009iu/day of Vitamin D for one month during the winter.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 144, 'vitamin D')]
PMC4417995	4/2015	S139-PMC4417995	['four of the five children who received Vitamin D improved, whereas only one of the six children in the control group improved.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 39, 'vitamin D')]
PMC4417995	4/2015	S144-PMC4417995	['clinical improvement was assessed by scorad, which decreased significantly at 60 days in the groups receiving Vitamin D or e or both Vitamins.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 110, 'vitamin D'), ('CHEBI_33277', 'gamma-tocotrienol', 133, 'vitamins')]
PMC4417995	4/2015	S146-PMC4417995	['30 patients received Vitamin D 1,600\u2009iu/day and 30 patients received placebo.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 21, 'vitamin D')]
PMC4417995	4/2015	S156-PMC4417995	['[66] carried out a study in which 20 out of 95 patients were selected for Vitamin D supplementation (2000\u2009iu of oral Cholecalciferol daily); 25(Oh)D mean concentrations were very low, between 4 and 15\u2009ng/ml.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 74, 'vitamin D'), ('CHEBI_52550', 'theopalauamide', 117, 'cholecalciferol'), ('CHEBI_72805', '2-alkyl-sn-glycero-3-phosphocholine', 144, 'OH)D')]
PMC4417995	4/2015	S159-PMC4417995	["after 3 months of supplementation most patients' Vitamin D levels switched from <10\u2009ng/ml to 10–20\u2009ng/ml."]	N/A	N/A	[('CHEBI_27300', 'vitamin D', 49, 'vitamin D')]
PMC4417995	4/2015	S172-PMC4417995	['before heliotherapy, 17 of 23 patients had Vitamin D deficiency; after 2 weeks of therapy, only 4 patients remained deficient.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 43, 'vitamin D')]
PMC4417995	4/2015	S175-PMC4417995	['of these, 16 were Vitamin D deficient and underwent 15 sessions of narrowband uvb.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 18, 'vitamin D')]
PMC4417995	4/2015	S176-PMC4417995	['this therapy resulted in a significant increase in Serum Vitamin D levels.']	N/A	N/A	[('UBERON_0001977', 'blood serum', 51, 'serum'), ('CHEBI_27300', 'vitamin D', 57, 'vitamin D')]
PMC4427001	4/2015	S27-PMC4427001	['cutaneous Vitamin D Synthesis is Modulated by several factors including skin pigmentation, clothing, Melanin concentration, latitude, climate type, and season [16].']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 10, 'vitamin D'), ('GO_0042368', 'vitamin D biosynthetic process', 10, 'vitamin D synthesis'), ('GO_0065007', 'biological regulation', 33, 'modulated'), ('CHEBI_25179', 'melanins', 101, 'melanin')]
PMC4427001	4/2015	S91-PMC4427001	['the Pancreatic Β Cells Express both Vitamin D Receptor and Enzyme 1 α -hydroxylase which enables them to produce 1,25(Oh)2D locally [17].']	N/A	N/A	[('CL_0000173', 'pancreatic D cell', 4, 'pancreatic β cells'), ('UBERON_0001264', 'pancreas', 4, 'pancreatic'), ('GO_0010467', 'gene expression', 23, 'express'), ('CHEBI_27300', 'vitamin D', 36, 'vitamin D'), ('PR_000001683', 'vasopressin V2 receptor', 36, 'vitamin D receptor'), ('PR_000006894', 'ER degradation-enhancing alpha-mannosidase-like protein 3', 59, 'enzyme 1'), ('CHEBI_82784', 'PVP38-Ag NP', 113, '1,25(OH)2D')]
PMC4427001	4/2015	S101-PMC4427001	['nearly 50% of Pregnant women were Vitamin D deficient in september while it was 82% in december.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 14, 'pregnant'), ('CHEBI_27300', 'vitamin D', 34, 'vitamin D')]
PMC4427001	4/2015	S110-PMC4427001	['given the high overall prevalence of Vitamin D deficiency, we did not find any statistically significant difference in 25(Oh)D levels between woman with gdm diagnosed by who criteria and controls during Pregnancy.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 37, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 119, '25(OH)D'), ('PR_000010220', 'mannose-binding protein C', 121, '('), ('PR_000013502', 'parvalbumin alpha', 124, ')D'), ('GO_0007565', 'female pregnancy', 203, 'pregnancy')]
PMC4427001	4/2015	S112-PMC4427001	['[25] reported higher prevalence of severe Vitamin D deficiency (≤12.5\u2009nmol/l) in gdm than in normoglycaemic Pregnancies in 741 iranian women.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 42, 'vitamin D'), ('GO_0007565', 'female pregnancy', 108, 'pregnancies')]
PMC4438660	3/2015	S75-PMC4438660	['in addition, a high proportion of these women did not meet the dri for Vitamin A (65.3%), Vitamin D (99.1%), magnesium (82.8%), calcium (53.6%), iron (87.2%), zinc (78.9%), and Folate (98.1%).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 71, 'vitamin A'), ('CHEBI_27300', 'vitamin D', 90, 'vitamin D'), ('CHEBI_30863', '5-azaorotic acid', 177, 'folate')]
PMC4448820	5/2015	S175-PMC4448820	['physiologic barrier function is not markedly affected by either Vitamin A or zinc.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 64, 'vitamin A')]
PMC4448820	5/2015	S206-PMC4448820	['● Vitamin D: mechanisms of Vitamin D–mediated inhibition of Nf-Κb Signaling include:\n○ inhibition of v-rel Avian Reticuloendotheliosis Viral Oncogene Homolog ( rel) transcription by competitive binding of vdr/rxr binding to the rel Promoter (121),\n○ induction of I Κ Bα (122) and inhibition of I Κ Bα Degradation (123), and\n○ hyperactivation of Nf-Κb occurs in vdr knockout Mice (124).']	N/A	N/A	[('CHEBI_28384', 'vitamin K', 2, 'Vitamin D'), ('CHEBI_27300', 'vitamin D', 27, 'vitamin D'), ('GO_0038060', 'nitric oxide-cGMP-mediated signaling pathway', 60, 'NF-κB signaling'), ('GO_0071159', 'NF-kappaB complex', 60, 'NF-κB'), ('PR_000011111', 'N-terminal EF-hand calcium-binding protein 3', 60, 'NF-κB'), ('NCBITaxon_33208', 'Metazoa', 107, 'avian'), ('PR_000013999', 'rapamycin-insensitive companion of mTOR', 113, 'reticuloendotheliosis viral oncogene homolog'), ('NCBITaxon_1', 'root', 135, 'viral'), ('SO_0000467', 'post_translationally_regulated_by_protein_stability', 135, 'viral oncogene'), ('SO_0000853', 'homologous_region', 150, 'homolog'), ('SO_0000167', 'promoter', 232, 'promoter'), ('PR_000008988', 'interleukin-1 family member 5', 263, 'I κ Bα'), ('GO_0042432', 'indole biosynthetic process', 294, 'I ... Bα degradation'), ('PR_000008988', 'interleukin-1 family member 5', 294, 'I κ Bα'), ('GO_0071159', 'NF-kappaB complex', 345, 'NF-κB'), ('PR_000011111', 'N-terminal EF-hand calcium-binding protein 3', 345, 'NF-κB'), ('NCBITaxon_10088', 'Mus <genus>', 374, 'mice')]
PMC4448820	5/2015	S235-PMC4448820	['the Mouse and Human Foxp3 Promoters also contain functional Vitamin D response elements (vdres) (141,142).']	N/A	N/A	[('NCBITaxon_10088', 'Mus <genus>', 4, 'mouse'), ('NCBITaxon_9606', 'Homo sapiens', 14, 'human'), ('PR_000007620', 'forkhead box protein E3', 20, 'FOXP3'), ('SO_0000167', 'promoter', 26, 'promoters'), ('CHEBI_27300', 'vitamin D', 60, 'vitamin D')]
PMC4448820	5/2015	S348-PMC4448820	['Hypomethylation Of Hepatic Dna occurs in response to Vitamin A treatment in Rats (204), and hypermethylation of long Interspersed Element (line) 1 is found in peripheral Blood White Cells of Vitamin A–deficient children (205).']	N/A	N/A	[('GO_0033526', 'tetrapyrrole biosynthetic process from glutamate', 0, 'Hypomethylation of ... DNA'), ('UBERON_0002107', 'liver', 19, 'hepatic'), ('CHEBI_27300', 'vitamin D', 53, 'vitamin A'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 76, 'rats'), ('SO_0002006', 'zinc_repressed_element', 117, 'interspersed element'), ('CL_0000081', 'blood cell', 170, 'blood white cells'), ('UBERON_0000178', 'blood', 170, 'blood'), ('CHEBI_27300', 'vitamin D', 191, 'vitamin A'), ('PR_000004370', 'asialoglycoprotein receptor 2', 199, 'A')]
PMC4448820	5/2015	S364-PMC4448820	['the Generation Of the Bioactive Form of Vitamin A is under tight Control.']	N/A	N/A	[('GO_0045184', 'establishment of protein localization', 4, 'generation of ... bioactive form'), ('CHEBI_51870', 'boryl group', 22, 'bioactive'), ('CHEBI_27300', 'vitamin D', 40, 'vitamin A'), ('GO_0007601', 'visual perception', 40, 'vitamin A'), ('GO_0065007', 'biological regulation', 65, 'control')]
PMC4448820	5/2015	S376-PMC4448820	['Histone Acetylation Controls Cathelicidin Gene Expression by Vitamin D in Keratinocytes (219).']	N/A	N/A	[('CHEBI_15358', 'histone', 0, 'Histone'), ('GO_0034729', 'histone H3-K79 methylation', 0, 'Histone acetylation'), ('PR_000027594', 'histone H3', 0, 'Histone'), ('GO_0065007', 'biological regulation', 20, 'controls'), ('CHEBI_3364', 'Canthiumine', 29, 'cathelicidin'), ('PR_000006009', 'alpha-catulin', 29, 'cathelicidin'), ('GO_0010467', 'gene expression', 42, 'gene expression'), ('SO_0000704', 'gene', 42, 'gene'), ('CHEBI_27300', 'vitamin D', 61, 'vitamin D'), ('CL_0000312', 'keratinocyte', 74, 'keratinocytes')]
PMC4448820	5/2015	S382-PMC4448820	['like Vitamin A, the Generation and Degradation Of the Bioactive Form Of Vitamin D is under tight Control.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 5, 'vitamin A'), ('PR_000004370', 'asialoglycoprotein receptor 2', 13, 'A'), ('GO_0007565', 'female pregnancy', 20, 'generation ...'), ('GO_0051625', 'epinephrine uptake', 35, 'degradation of ... form of vitamin D'), ('CHEBI_51870', 'boryl group', 54, 'bioactive'), ('CHEBI_27300', 'vitamin D', 72, 'vitamin D'), ('GO_0065007', 'biological regulation', 97, 'control')]
PMC4448820	5/2015	S383-PMC4448820	['the Promoter region of Cyp27B1 , the enzyme responsible for 1,25(Oh)2D generation, is demethylated, and Histones associated with the Promoter deacetylated in response to Vitamin D treatment in Mouse Kidney Proximal Tubule-derived Mouse Cortical Tubular Cells and the Human Embryonic Kidney–derived cell line 293f (222).']	N/A	N/A	[('SO_0000167', 'promoter', 4, 'promoter'), ('PR_000006101', 'cytochrome P450 1A1', 23, 'CYP27B1'), ('CHEBI_37958', 'dye', 60, '1,'), ('CHEBI_66212', "5,7,3',4'-tetrahydroxy-2'-(3,3-dimethylallyl)isoflavone", 62, '25(OH)2D'), ('CHEBI_15358', 'histone', 104, 'histones'), ('PR_000043452', 'core histone', 104, 'histones'), ('SO_0000167', 'promoter', 133, 'promoter'), ('CHEBI_27300', 'vitamin D', 170, 'vitamin D'), ('NCBITaxon_10088', 'Mus <genus>', 193, 'mouse'), ('UBERON_0004134', 'proximal tubule', 199, 'kidney proximal tubule'), ('NCBITaxon_10088', 'Mus <genus>', 230, 'mouse'), ('CL_0002364', 'cortical thymic epithelial cell', 236, 'cortical tubular cells'), ('UBERON_0004106', 'crus of ear', 236, 'cortical tubular'), ('NCBITaxon_9606', 'Homo sapiens', 267, 'human'), ('CL_0002321', 'embryonic cell (metazoa)', 273, 'embryonic ...'), ('UBERON_0000922', 'embryo', 273, 'embryonic'), ('UBERON_0002113', 'kidney', 283, 'kidney')]
PMC4448820	5/2015	S408-PMC4448820	['in addition, Single Nucleotide Polymorphisms in the Tnf Gene and tnf secretion from pbmcs of elderly subjects who are supplemented with Vitamin E were tested.']	N/A	N/A	[('SO_0000694', 'SNP', 13, 'single nucleotide polymorphisms'), ('PR_000016482', 'tumor necrosis factor receptor superfamily member 18', 52, 'TNF'), ('SO_0000704', 'gene', 56, 'gene'), ('CHEBI_27300', 'vitamin D', 136, 'vitamin E')]
PMC4448820	5/2015	S459-PMC4448820	['● Nutrient Sequestration limiting access to pathogens or to limit oxidative damage:\n○ iron\n○ zinc\nfor example, Vitamin D binding protein has multiple functions:\n\n○ it binds 95% of Vitamin D in Plasma,\n○ acts as a Macrophage-Activating factor and Neutrophil chemoattractant, and\n○ participates in the classical and alternative complement activation pathways (115).']	N/A	N/A	[('CHEBI_33284', 'nutrient', 2, 'Nutrient'), ('GO_0006735', 'NADH regeneration', 2, 'Nutrient sequestration'), ('CHEBI_27300', 'vitamin D', 111, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 180, 'vitamin D'), ('UBERON_0001969', 'blood plasma', 193, 'plasma'), ('CL_0000235', 'macrophage', 213, 'macrophage'), ('GO_0051519', 'activation of bipolar cell growth', 223, '-activating'), ('CL_0000775', 'neutrophil', 246, 'neutrophil')]
PMC4448820	5/2015	S469-PMC4448820	['c. case study: Vitamin A and the apr.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 15, 'vitamin A')]
PMC4448820	5/2015	S547-PMC4448820	['a brief overview of the basics of Vitamin A is provided in text box 20 .']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 34, 'vitamin A'), ('PR_000004370', 'asialoglycoprotein receptor 2', 42, 'A')]
PMC4448820	5/2015	S548-PMC4448820	['caption (boxed-text): text box 20\u2003\nbasics of Vitamin A: biology and assessment\n\n● primary causes of vad include:\n○ poor Intake/Food insecurity [the limited availability/accessibility of either Animal source (preformed) Vitamin A or alternative sources of Vitamin A] and\n○ poor absorption (e.g., Fat Malabsorption).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 45, 'vitamin A'), ('GO_0007631', 'feeding behavior', 120, 'intake'), ('CHEBI_33290', 'food', 127, 'food'), ('NCBITaxon_33208', 'Metazoa', 193, 'animal'), ('CHEBI_27300', 'vitamin D', 219, 'vitamin A'), ('PR_000004370', 'asialoglycoprotein receptor 2', 227, 'A'), ('CHEBI_27300', 'vitamin D', 255, 'vitamin A'), ('GO_0046660', 'female sex differentiation', 295, 'fat malabsorption')]
PMC4448820	5/2015	S554-PMC4448820	['● more quantitative assessment techniques include the following:\n○ dose-response tests that indicate the adequacy of Liver stores and isotope-dilution tests that reflect the amount of Vitamin A stored in the Liver.']	N/A	N/A	[('UBERON_0002107', 'liver', 117, 'liver'), ('CHEBI_27300', 'vitamin D', 184, 'vitamin A'), ('UBERON_0002107', 'liver', 208, 'liver')]
PMC4448820	5/2015	S1036-PMC4448820	['● in a follow-up of 5430 children randomly assigned to receive Vitamin A supplementation early in Life (i.e., maternal supplementation or during the first 6 mo of infancy), supplementation with Vitamin A was not associated with a decreased risk of asthma or lower forced Expiratory volume in 1 s to forced vital capacity (fev1:fvc) ratios at 9–23 y of age (576).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 63, 'vitamin A'), ('UBERON_0000104', 'life cycle', 98, 'life'), ('CHEBI_27300', 'vitamin D', 194, 'vitamin A'), ('GO_0010467', 'gene expression', 271, 'expiratory')]
PMC4448820	5/2015	S1226-PMC4448820	['nutrients considered in detail include iron, Vitamin A, Vitamin D, Vitamin B-12, zinc, and Folate (supplemental table 9).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 45, 'vitamin A'), ('CHEBI_27300', 'vitamin D', 56, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 67, 'vitamin B'), ('PR_000000037', 'BMP receptor type-2', 75, 'B'), ('PR_000003777', 'adiponectin', 77, '12'), ('CHEBI_30863', '5-azaorotic acid', 91, 'folate')]
PMC4448820	5/2015	S1446-PMC4448820	['the epidemiology of vad was discussed in the wg 2 review and indicators of Vitamin A have been reviewed extensively (bond review) (30).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 75, 'vitamin A')]
PMC4448820	5/2015	S1449-PMC4448820	['○ Retinol is Homeostatically Regulated and is not a good indicator of status when there are adequate Liver stores of Vitamin A (770).']	N/A	N/A	[('CHEBI_27810', 'resorcinol', 2, 'Retinol'), ('GO_0048872', 'homeostasis of number of cells', 13, 'homeostatically'), ('GO_0065007', 'biological regulation', 29, 'regulated'), ('UBERON_0002107', 'liver', 101, 'liver'), ('CHEBI_27300', 'vitamin D', 117, 'vitamin A')]
PMC4452099	6/2015	S2-PMC4452099	['the 1stof june 1985, which was the date of issue of the new ministerial order cancelling mandatory fortification of Margarine with Vitamin D in denmark, served as a reference point separating the studied population into various exposure groups.']	N/A	N/A	[('CHEBI_6784', 'mestranol', 116, 'margarine'), ('CHEBI_27300', 'vitamin D', 131, 'vitamin D')]
PMC4452099	6/2015	S24-PMC4452099	['in denmark, it was mandatory to add Vitamin D to all Margarine products in a distinct time period: from january1961 to june 1985.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 36, 'vitamin D'), ('CHEBI_6784', 'mestranol', 53, 'margarine')]
PMC4452099	6/2015	S25-PMC4452099	['the amount of Vitamin D added to Margarine was low (1.25 μg per 100 g of Margarine).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 14, 'vitamin D'), ('CHEBI_6784', 'mestranol', 33, 'margarine'), ('CHEBI_6784', 'mestranol', 73, 'margarine')]
PMC4452099	6/2015	S32-PMC4452099	['the 1stof june 1985—date of issue of the new ministerial order on Margarine cancelling obligatory fortification of Margarine with Vitamin D in denmark—served as a reference point separating the studied population into exposure, washout and non-exposure groups.']	N/A	N/A	[('CHEBI_6784', 'mestranol', 66, 'margarine'), ('CHEBI_6784', 'mestranol', 115, 'margarine'), ('CHEBI_27300', 'vitamin D', 130, 'vitamin D')]
PMC4452099	6/2015	S75-PMC4452099	['discussion\nmandatory fortification of Margarine with Vitamin D has been applied during various time periods since the 1930’s in the scandinavian countries [20].']	N/A	N/A	[('CHEBI_6784', 'mestranol', 38, 'margarine'), ('CHEBI_27300', 'vitamin D', 53, 'vitamin D')]
PMC4452099	6/2015	S85-PMC4452099	['the amount of Vitamin D added to Margarine was 1.25 μg per 100g [20].']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 14, 'vitamin D'), ('CHEBI_6784', 'mestranol', 33, 'margarine')]
PMC4452099	6/2015	S94-PMC4452099	['still, the infants’ Vitamin D intake from the fortified Margarine could not be higher than 0.40–0.55 μg per Person per day, as calculated above.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 20, 'vitamin D'), ('CHEBI_6784', 'mestranol', 56, 'margarine'), ('NCBITaxon_10088', 'Mus <genus>', 108, 'person')]
PMC4452099	6/2015	S110-PMC4452099	['supporting information\n\ncaption (supplementary-material): s1 table\nslopes (95% ci) for linear increase in t1d incidence for Individuals Born during various periods of Gestational exposure to Vitamin D fortification by age at t1d diagnosis.']	N/A	N/A	[('NCBITaxon_1', 'root', 124, 'individuals'), ('GO_0007567', 'parturition', 136, 'born'), ('GO_0007565', 'female pregnancy', 167, 'gestational'), ('CHEBI_27300', 'vitamin D', 191, 'vitamin D')]
PMC4452099	6/2015	S113-PMC4452099	['caption (supplementary-material): s2 table\nslopes (95% ci) for linear increase in t1d incidence for Individuals during various periods of first Postnatal year exposure to Vitamin D fortification by age at t1d diagnosis.']	N/A	N/A	[('NCBITaxon_1', 'root', 100, 'individuals'), ('GO_0007567', 'parturition', 144, 'postnatal'), ('CHEBI_27300', 'vitamin D', 171, 'vitamin D')]
PMC4453242	5/2015	S37-PMC4453242	["the ventralizing factor Sonic Hedgehog (Shh; 100 ng/ml) along with the caudalizing factor Retinoic Acid (0.1 μm) were used to initially pattern Neuroepithelial Cells; Glial differentiation medium (gdm; dulbecco's modified eagle's medium (dmem)/f12, b27 without Vitamin A, n1, mem-Neaa, Camp, Biotin, 60 ng/ml Triiodothyronine, 10 ng/ml Platelet-Derived Growth Factor (Pdgf)-aa, Insulin-Like Growth Factor (Igf)1 and Neurotrophin (Nt)3) was used for further differentiation."]	N/A	N/A	[('PR_000014841', 'sonic hedgehog protein', 24, 'sonic hedgehog'), ('PR_000014841', 'sonic hedgehog protein', 40, 'SHH'), ('CHEBI_26536', 'retinoic acid', 90, 'retinoic acid'), ('CL_0000513', 'cardiac muscle myoblast', 144, 'neuroepithelial cells'), ('CL_0000125', 'glial cell', 167, 'glial'), ('CHEBI_27300', 'vitamin D', 261, 'vitamin A'), ('CHEBI_32145', 'sodium hydroxide', 280, 'NEAA'), ('CHEBI_17489', "3',5'-cyclic AMP", 286, 'cAMP'), ('CHEBI_15956', 'biotin', 292, 'biotin'), ('CHEBI_26982', 'threo-3-methylmalic acid', 309, 'triiodothyronine'), ('CL_0000233', 'platelet', 336, 'platelet'), ('PR_000009208', 'protein Jumonji', 336, 'platelet-derived growth factor'), ('PR_000012490', 'platelet-derived growth factor subunit A', 368, 'PDGF'), ('PR_000045358', 'insulin family protein', 378, 'insulin'), ('PR_000009751', 'lymphoid enhancer-binding factor 1', 386, 'like growth factor ...'), ('PR_000008927', 'interferon kappa', 406, 'IGF ... 1'), ('PR_000011459', 'neurotrophin-3', 416, 'neurotrophin ...'), ('PR_000011468', 'netrin-G2', 430, 'NT ... 3')]
PMC4466139	6/2015	S5-PMC4466139	['maternal country of origin, skin phototype, Vitamin D dietary intake and supplementation during Pregnancy were recorded.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 44, 'vitamin D'), ('GO_0007565', 'female pregnancy', 96, 'pregnancy')]
PMC4466139	6/2015	S34-PMC4466139	['data on maternal Vitamin D supplementation during the whole Pregnancy and during the last month of Pregnancy, including doses, duration and type of integration were collected.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 17, 'vitamin D'), ('GO_0007565', 'female pregnancy', 60, 'pregnancy'), ('GO_0007565', 'female pregnancy', 99, 'pregnancy')]
PMC4466139	6/2015	S37-PMC4466139	['Vitamin D measurements\nwe rated Vitamin D levels (nmol/l) in neonatal Blood Spots (nbs) collected in the first three days of Life for neonatal Metabolic screening.']	N/A	N/A	[('CHEBI_28384', 'vitamin K', 0, 'Vitamin D'), ('CHEBI_27300', 'vitamin D', 32, 'vitamin D'), ('UBERON_0001969', 'blood plasma', 70, 'blood spots'), ('UBERON_0000104', 'life cycle', 125, 'life'), ('GO_0008152', 'metabolic process', 143, 'metabolic')]
PMC4466139	6/2015	S64-PMC4466139	['analyzing only migrant subjects, both newborns and mothers had Vitamin D deficiency (<50 nmol/l) respectively in 97.9% and 89.7%.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 63, 'vitamin D')]
PMC4466139	6/2015	S65-PMC4466139	['considering values ≥50 nmol/l as Vitamin D sufficiency (iom criteria), among newborns, 33.3% showed insufficiency and 52.1% a deficiency.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 33, 'vitamin D')]
PMC4466139	6/2015	S66-PMC4466139	['mothers had Vitamin D insufficiency in 42.9% and deficiency in 27.7%.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 12, 'vitamin D')]
PMC4466139	6/2015	S67-PMC4466139	['migrant’s newborns and mothers had a Vitamin D deficiency in 76.2% and 48.4%, respectively.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 37, 'vitamin D')]
PMC4466139	6/2015	S77-PMC4466139	['data on Vitamin D supplementation and dietary intake in Pregnancy are reported intable 3.10.1371/journal.pone.0129586.t003\n\ncaption (table-wrap): table 3\nmaternal Vitamin D supplementation and dietary intake during Pregnancy in italian and migrants.supplementationall (533)italian (342)migrant (191)p value n (%) 283/486 (58.2%)213 (68.9%)70 (39.5%)<0.0001 last month n (%) 255/483 (52.8%)193 (62.9%)62 (35.2%)<0.0001 duration of supplementation (days) 185.7±75.14191.8±74.6167.6±74.40.01 Vitamin D intake from supplementation (iu/die) 398±52400.47\xa0±61.19394.37±44.360.01 diet questionnaires analyzed n (%) 450/533 (84.4%)298 (66.2%)152 (33.8%)- Vitamin D intake from diet (iu/die) 136±68128±64152±680.0003\ndata are expressed as frequencies or as mean±sd and number (%).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 8, 'vitamin D'), ('GO_0007565', 'female pregnancy', 56, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 163, 'vitamin D'), ('GO_0007565', 'female pregnancy', 215, 'pregnancy'), ('CHEBI_28384', 'vitamin K', 489, 'Vitamin D'), ('CHEBI_28384', 'vitamin K', 646, 'Vitamin D')]
PMC4466139	6/2015	S79-PMC4466139	['the average daily Vitamin D intake was 398±52 iu/d.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 18, 'vitamin D')]
PMC4466139	6/2015	S81-PMC4466139	['all mothers ‘supplemented’ with Vitamin D had 25Ohd values higher than ‘not supplemented’ (p<0.0001) and the same was recorded in their newborns (p<0.0001) (table 4).10.1371/journal.pone.0129586.t004\n\ncaption (table-wrap): table 4\ncomparison between Vitamin D levels (25Ohd) in newborns and mothers supplemented or not supplemented with Vitamin D.25Ohd levels (nmol/l)snot sp valuenewborns 33.9±19.719.4±14.9<0.0001 mothers 44.6±20.729.7±16.7<0.0001 25Ohd levels (nmol/l) in the last monthsnot sp valuenewborns 34.6±19.719.4±14.9<0.0001 mothers 45.4±20.429.7±16.7<0.0001\ndata are expressed as mean±sd.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 32, 'vitamin D'), ('CHEBI_72652', "7,2'-dihydroxy-4'-methoxyisoflavan-4-ylium cation", 46, '25OHD'), ('CHEBI_27300', 'vitamin D', 250, 'vitamin D'), ('CHEBI_72652', "7,2'-dihydroxy-4'-methoxyisoflavan-4-ylium cation", 268, '25OHD'), ('CHEBI_27300', 'vitamin D', 337, 'vitamin D'), ('CHEBI_72652', "7,2'-dihydroxy-4'-methoxyisoflavan-4-ylium cation", 347, '25OHD'), ('CHEBI_72652', "7,2'-dihydroxy-4'-methoxyisoflavan-4-ylium cation", 450, '25OHD')]
PMC4476607	1/2015	S144-PMC4476607	['in Rodent models of fasd, Pregnant females given Nutrients high in antioxidant properties (e.g., Vitamin C, Vitamin E, Omega-3 Fatty Acids) during the time they also are given Alcohol, Give Birth to offspring with reduced oxidative stress and cell loss, and fewer behavioral impairments (brocardo et al.']	N/A	N/A	[('NCBITaxon_33208', 'Metazoa', 3, 'rodent'), ('GO_0007565', 'female pregnancy', 26, 'pregnant'), ('CHEBI_33284', 'nutrient', 49, 'nutrients'), ('CHEBI_27300', 'vitamin D', 97, 'vitamin C'), ('CHEBI_27300', 'vitamin D', 108, 'vitamin E'), ('CHEBI_75862', 'alpha-D-rhamnofuranose', 119, 'omega-3 fatty acids'), ('CHEBI_30879', 'alcohol', 176, 'alcohol'), ('GO_0007631', 'feeding behavior', 185, 'give'), ('GO_0007567', 'parturition', 190, 'birth')]
PMC4477503	6/2015	S143-PMC4477503	['in addition, conditions like rickets and osteomalacia are caused by a deficiency or impaired Metabolism Of Calcium, Phosphorus, or Vitamin D. osteomalacia occurs in mature Camels and is characterized by general weakness and lameness, stiffness, emaciation and easy fracturing with permanent recumbency and eventual death occurring in the final stages.']	N/A	N/A	[('GO_0051238', 'sequestering of metal ion', 93, 'metabolism of calcium'), ('CHEBI_35885', 'secondary phosphine', 116, 'phosphorus'), ('GO_0046903', 'secretion', 116, 'phosphorus'), ('CHEBI_27300', 'vitamin D', 131, 'vitamin D'), ('NCBITaxon_33208', 'Metazoa', 172, 'camels')]
PMC4488777	5/2015	S35-PMC4488777	['in Serum, Vitamin D is transported by Vitamin D-Binding Protein (Vdbp) to the Liver and Metabolized to an active form of 25-Hydroxycalciferol (25[Oh] D) [9].']	N/A	N/A	[('UBERON_0001977', 'blood serum', 3, 'serum'), ('CHEBI_27300', 'vitamin D', 10, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 38, 'vitamin D'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 38, 'vitamin D-binding protein'), ('PR_000017279', 'testis-specific basic protein Y 1', 65, 'VDBP'), ('UBERON_0002107', 'liver', 78, 'liver'), ('GO_0008152', 'metabolic process', 88, 'metabolized'), ('CHEBI_69445', '1-methyluracil', 121, '25-hydroxycalciferol'), ('CHEBI_15643', '(6R)-6-(L-erythro-1,2-dihydroxypropyl)-7,8-dihydro-6H-pterin', 143, '25[OH] D')]
PMC4488777	5/2015	S37-PMC4488777	['its chemical structure resembles Steroid hormones and it acts likewise via Nuclear receptor (Vdr, Vitamin D Receptor).']	N/A	N/A	[('CHEBI_35341', 'steroid', 33, 'steroid'), ('GO_0005634', 'nucleus', 75, 'nuclear'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 93, 'VDR'), ('CHEBI_27300', 'vitamin D', 98, 'vitamin D'), ('PR_000001683', 'vasopressin V2 receptor', 98, 'vitamin D receptor')]
PMC4488777	5/2015	S43-PMC4488777	['caption (fig): figure 1\n\nthe role of Vitamin D in the Reproductive System (after: grzechocinska b, dabrowski fa, cyganek a, wielgos m. the role of Vitamin D in impaired fertility treatment [2]).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 37, 'vitamin D'), ('GO_0000003', 'reproduction', 54, 'reproductive'), ('UBERON_0000990', 'reproductive system', 54, 'reproductive system'), ('CHEBI_27300', 'vitamin D', 147, 'vitamin D')]
PMC4488777	5/2015	S46-PMC4488777	['under the key words “Vitamin D, fertility”, 129 articles were found in the pubmed database, for “Vitamin D, infertility”, another 106 were located (march 15th, 2015).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 21, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 97, 'vitamin D')]
PMC4488777	5/2015	S62-PMC4488777	['caption (fig): figure 2\n\nthe effects and causes of Vitamin D deficiency in women with pcos (after: grzechocinska b, dabrowski fa, cyganek a, wielgos m. the role of Vitamin D in impaired fertility treatment.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 51, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 164, 'vitamin D')]
PMC4488777	5/2015	S86-PMC4488777	['the concentration of Vitamin D and Ca+2Were not dependent on Menstrual Cycle phase.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 21, 'vitamin D'), ('CHEBI_3258', 'CB3717', 35, 'Ca+2were'), ('GO_0044850', 'menstrual cycle', 61, 'menstrual cycle')]
PMC4488777	5/2015	S99-PMC4488777	['in a recent study, Serum levels of Vitamin D, Steroid hormones, Shbg and Ovarian reserve markers were determined in 73 non-obese, healthy, Parous women.']	N/A	N/A	[('UBERON_0001977', 'blood serum', 19, 'serum'), ('CHEBI_27300', 'vitamin D', 35, 'vitamin D'), ('CHEBI_35341', 'steroid', 46, 'steroid'), ('PR_000014843', 'protein shisa-3', 64, 'SHBG'), ('UBERON_0000992', 'ovary', 73, 'ovarian'), ('UBERON_0003983', 'conus arteriosus', 139, 'parous')]
PMC4488777	5/2015	S142-PMC4488777	['caption (fig): figure 3\n\nthe influence of Vitamin D on the activity and the morphology of Sperm (after: grzechocinska b, dabrowski fa, cyganek a, wielgos m. the role of Vitamin D in impaired fertility treatment [2]).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 42, 'vitamin D'), ('CL_0000019', 'sperm', 90, 'sperm'), ('CHEBI_27300', 'vitamin D', 169, 'vitamin D')]
PMC4488777	5/2015	S149-PMC4488777	['final Live-Birth rates were 31% among Vitamin D-deficient recipients, compared with 59% among Vitamin D-replete recipients.']	N/A	N/A	[('GO_0016042', 'lipid catabolic process', 6, 'live-birth'), ('CHEBI_27300', 'vitamin D', 38, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 94, 'vitamin D')]
PMC4499946	7/2015	S0-PMC4499946	['maternal Vitamin D supplementation during Pregnancy and Lactation to promote infant growth in dhaka, bangladesh (mdig trial): study protocol for a randomized controlled trial\n\nabstract\n\nbackground\nVitamin d Regulates bone Mineral Metabolism and Skeletal Development.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 9, 'vitamin D'), ('GO_0007565', 'female pregnancy', 42, 'pregnancy'), ('GO_0007595', 'lactation', 56, 'lactation'), ('CHEBI_33229', 'vitamin (role)', 197, 'Vitamin'), ('GO_0065007', 'biological regulation', 207, 'regulates'), ('CHEBI_46662', 'mineral', 222, 'mineral'), ('GO_0008152', 'metabolic process', 230, 'metabolism'), ('GO_0001501', 'skeletal system development', 245, 'skeletal development'), ('UBERON_0004288', 'skeleton', 245, 'skeletal')]
PMC4499946	7/2015	S3-PMC4499946	['methods/design\nthe maternal Vitamin D for infant growth study is a randomized, placebo-controlled, dose-ranging trial of maternal Vitamin D supplementation during Pregnancy and Lactation in dhaka, bangladesh.']	N/A	N/A	[('CHEBI_28384', 'vitamin K', 28, 'Vitamin D'), ('CHEBI_27300', 'vitamin D', 130, 'vitamin D'), ('GO_0007565', 'female pregnancy', 163, 'pregnancy'), ('GO_0007595', 'lactation', 177, 'lactation')]
PMC4499946	7/2015	S25-PMC4499946	['in the absence of maternal Vitamin D supplementation, Postnatal infant 25(Oh)D concentration was low in the Neonatal Period, but gradually increased over the first several months of Life (unpublished observations).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 27, 'vitamin D'), ('GO_0007567', 'parturition', 54, 'postnatal'), ('CHEBI_71657', 'versiconol acetate', 71, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 71, '25(OH ... D'), ('UBERON_0007221', 'neonate stage', 108, 'neonatal period'), ('UBERON_0000104', 'life cycle', 182, 'life')]
PMC4499946	7/2015	S32-PMC4499946	['maternal mean 25(Oh)D was significantly higher at Delivery after receiving Vitamin D versus placebo (134 vs. 39 nmol/l; p< 0.001; n = 133).']	N/A	N/A	[('CHEBI_71657', 'versiconol acetate', 14, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 14, '25(OH ... D'), ('GO_0007567', 'parturition', 50, 'delivery'), ('CHEBI_27300', 'vitamin D', 75, 'vitamin D')]
PMC4499946	7/2015	S33-PMC4499946	['there was a parallel difference in Cord 25(Oh)D (103 nmol/l in Vitamin D group vs. 39 nmol/l in placebo group; p< 0.001; n = 132) [16].']	N/A	N/A	[('UBERON_0002240', 'spinal cord', 35, 'cord'), ('CHEBI_71657', 'versiconol acetate', 40, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 40, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 63, 'vitamin D')]
PMC4499946	7/2015	S43-PMC4499946	['methods/design\nthe maternal Vitamin D for infant Growth (mdig) trial is randomized, placebo-controlled, dose-ranging trial of maternal Vitamin D supplementation during Pregnancy and Lactation to improve infant linear growth in dhaka, bangladesh (clinicaltrials.gov identifier nct01924013).']	N/A	N/A	[('CHEBI_28384', 'vitamin K', 28, 'Vitamin D'), ('GO_0006099', 'tricarboxylic acid cycle', 49, 'Growth'), ('CHEBI_27300', 'vitamin D', 135, 'vitamin D'), ('GO_0007565', 'female pregnancy', 168, 'pregnancy'), ('GO_0007595', 'lactation', 182, 'lactation')]
PMC4499946	7/2015	S92-PMC4499946	['participants, investigators, field personnel, study laboratory staff, and data analysts are blinded to Vitamin D or placebo group allocation.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 103, 'vitamin D')]
PMC4499946	7/2015	S107-PMC4499946	['the Vitamin E content of each tablet is 2.8 mg/wk (about 0.4 mg/day), which is far below recommended dietary allowances for Pregnancy (15 mg/day) and Lactation (19 mg/day)\n\ncaption (table-wrap): table 2\n\nVitamin D3Content of custom-made trial tablets, based on postproduction coated tablet content analysis by high-performance liquid chromatographyalabel claimcholecalciferol content (% label claim)batch 1b(november 2013)batch 2 (april 2014)batch 3 (june 2014)4200 iu106 %103 %101 %16,800 iu105 %101 %102 %28,000 iu102 %101 %99 %\namodified united states pharmacopeia method, as reported by the manufacturer (toronto institute of Pharmaceutical technology, toronto, on, canada).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 4, 'vitamin E'), ('GO_0007565', 'female pregnancy', 124, 'pregnancy'), ('GO_0007595', 'lactation', 150, 'lactation'), ('CHEBI_33229', 'vitamin (role)', 204, 'Vitamin'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 204, 'Vitamin D3content'), ('CHEBI_52217', 'pharmaceutical', 630, 'Pharmaceutical')]
PMC4499946	7/2015	S123-PMC4499946	['supplemental Calcium and/or Vitamin D not prescribed by the study protocol are prohibited during the intervention phase of the trial.']	N/A	N/A	[('CHEBI_22313', 'alkaline earth metal atom', 13, 'calcium'), ('CHEBI_27300', 'vitamin D', 28, 'vitamin D')]
PMC4499946	7/2015	S126-PMC4499946	['visit schedule\nfollowing enrollment and randomization of Pregnant women at 17–24 weeks of Gestation, weekly supplementation (Vitamin D or placebo) occurs throughout the Prenatal period and during the first 6 months Postpartum.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 57, 'pregnant'), ('GO_0007565', 'female pregnancy', 90, 'gestation'), ('CHEBI_27300', 'vitamin D', 125, 'vitamin D'), ('GO_0007565', 'female pregnancy', 169, 'prenatal'), ('GO_0007565', 'female pregnancy', 215, 'postpartum')]
PMC4499946	7/2015	S144-PMC4499946	['dietary intake of Vitamin D, Calcium, Phosphorus, and phytates are assessed among participants (mothers) at enrollment and 6 months Postpartum using a customized, focused Food frequency questionnaire.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 18, 'vitamin D'), ('CHEBI_22313', 'alkaline earth metal atom', 29, 'calcium'), ('CHEBI_35885', 'secondary phosphine', 38, 'phosphorus'), ('GO_0007565', 'female pregnancy', 132, 'postpartum'), ('CHEBI_33290', 'food', 171, 'food')]
PMC4499946	7/2015	S244-PMC4499946	['subgroup and interaction analyses will be based on the following covariates: ga at Birth, infant sex, maternal baseline Vitamin D status, maternal height, and maternal supplement adherence.']	N/A	N/A	[('GO_0007567', 'parturition', 83, 'birth'), ('CHEBI_27300', 'vitamin D', 120, 'vitamin D')]
PMC4499946	7/2015	S270-PMC4499946	['in previous Prenatal Vitamin D supplementation trials in dhaka, we used regular monitoring of maternal Urinary Ca:cr ratio as a screening measure for Vitamin D toxicity [16,40].']	N/A	N/A	[('GO_0007565', 'female pregnancy', 12, 'prenatal'), ('CHEBI_27300', 'vitamin D', 21, 'vitamin D'), ('UBERON_0001088', 'urine', 103, 'urinary'), ('CHEBI_32588', 'potassium chloride', 111, 'Ca'), ('CHEBI_27300', 'vitamin D', 150, 'vitamin D')]
PMC4499946	7/2015	S297-PMC4499946	['serial specimen collection and frequent clinical follow-up will enable a range of secondary objectives to be addressed, including tests of mechanistic hypotheses (e.g., mediation of the beneficial Vitamin D supplement effect on Skeletal length by pth suppression) and assessments of the effects of the intervention on infant morbidity (in particular, the incidence of acute Respiratory infections in the first 6 months after Birth).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 197, 'vitamin D'), ('UBERON_0004288', 'skeleton', 228, 'skeletal'), ('UBERON_0001004', 'respiratory system', 374, 'respiratory'), ('GO_0007567', 'parturition', 425, 'birth')]
PMC4514967	12/2014	S57-PMC4514967	['three notable examples involve tryptophan, Vitamin A, and the Short-Chain Fatty Acid (scfa) products of Gut microbial Fermentation Of dietary Glycans.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 43, 'vitamin A'), ('CHEBI_26666', 'short-chain fatty acid', 62, 'short-chain fatty acid'), ('UBERON_0001555', 'digestive tract', 104, 'gut'), ('GO_0009566', 'fertilization', 118, 'fermentation of'), ('CHEBI_33366', 'copper group element atom', 142, 'glycans')]
PMC4516377	6/2015	S15-PMC4516377	['method\nthe survey was carried out by searching the pubmed, science direct and scielo (scientific electronic library online) databases for articles published between 2001 and june 2014, using the combined english terms "children" and "Calcium" or "children" and "Vitamin D," each associated with the descriptors "obesity", "adiposity" or "body fat" for both bases (fig.']	N/A	N/A	[('CHEBI_22313', 'alkaline earth metal atom', 234, 'calcium'), ('CHEBI_27300', 'vitamin D', 262, 'vitamin D')]
PMC4516377	6/2015	S23-PMC4516377	['results\nthe search resulted in 216 studies on the subject (91 resulting from the search with the descriptor "calcium" and 125 with the descriptor "Vitamin D").']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 147, 'vitamin D')]
PMC4516377	6/2015	S40-PMC4516377	['among the children, 84.4% did not achieve sufficient levels of Vitamin D and 17.6% were deficient.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 63, 'vitamin D')]
PMC4516377	6/2015	S41-PMC4516377	['girls had higher levels of Vitamin D than boys.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 27, 'vitamin D')]
PMC4555116	7/2015	S5-PMC4555116	['energy, Macronutrients, and key Micronutrients: Long-Chain Omega-3 Fatty Acids, Folate, Vitamin B6, Vitamin B12, Calcium, Vitamin D and iron were examined.']	N/A	N/A	[('CHEBI_33839', 'macromolecule', 8, 'macronutrients'), ('CHEBI_33839', 'macromolecule', 32, 'micronutrients'), ('CHEBI_15904', 'long-chain fatty acid', 48, 'long-chain omega-3 fatty acids'), ('CHEBI_30863', '5-azaorotic acid', 80, 'folate'), ('CHEBI_33237', 'vitamin D4', 88, 'vitamin B6'), ('CHEBI_33279', 'vitamin D5', 100, 'vitamin B12'), ('CHEBI_22313', 'alkaline earth metal atom', 113, 'calcium'), ('CHEBI_27300', 'vitamin D', 122, 'vitamin D')]
PMC4555116	7/2015	S110-PMC4555116	['overall, the ffq provided a similar estimate of energy, Macronutrients and key Micronutrients: Folate, Vitamin B6, Vitamin B12, Vitamin D and iron between groups.']	N/A	N/A	[('CHEBI_33839', 'macromolecule', 56, 'macronutrients'), ('CHEBI_33839', 'macromolecule', 79, 'micronutrients'), ('CHEBI_30863', '5-azaorotic acid', 95, 'folate'), ('CHEBI_33237', 'vitamin D4', 103, 'vitamin B6'), ('CHEBI_33279', 'vitamin D5', 115, 'vitamin B12'), ('PR_000004481', 'V-type proton ATPase subunit B, kidney isoform', 115, 'vitamin B12'), ('CHEBI_27300', 'vitamin D', 128, 'vitamin D')]
PMC4555116	7/2015	S150-PMC4555116	['the ffq provided a similar estimate of dietary Intake between pre-Pregnant and non-Pregnant groups for energy, Macronutrients, and key Micronutrients Long-Chain Omega-3 Fatty Acids, Folate, Vitamin B6, Vitamin B12, Vitamin D and iron.']	N/A	N/A	[('GO_0007631', 'feeding behavior', 47, 'intake'), ('GO_0007565', 'female pregnancy', 66, 'pregnant'), ('GO_0007565', 'female pregnancy', 83, 'pregnant'), ('CHEBI_33839', 'macromolecule', 111, 'macronutrients'), ('CHEBI_33839', 'macromolecule', 135, 'micronutrients'), ('CHEBI_27610', 'cyclohexa-2,5-diene-1-carbonyl-CoA', 150, 'long-chain omega'), ('CHEBI_35366', 'fatty acid', 169, 'fatty acids'), ('CHEBI_30863', '5-azaorotic acid', 182, 'folate'), ('CHEBI_33237', 'vitamin D4', 190, 'vitamin B6'), ('CHEBI_33279', 'vitamin D5', 202, 'vitamin B12'), ('CHEBI_27300', 'vitamin D', 215, 'vitamin D')]
PMC4586449	10/2015	S231-PMC4586449	['this was combined with lower intakes of calcium, magnesium, iron, Vitamin C, Folate, and most Micronutrients (all p < 0.0001).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 66, 'vitamin C'), ('CHEBI_30863', '5-azaorotic acid', 77, 'folate'), ('CHEBI_33839', 'macromolecule', 94, 'micronutrients')]
PMC4586450	10/2015	S250-PMC4586450	['only 18% of children consumed supplements containing Vitamin D at age 1.5 years, falling to 11% at age 3.5 years.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 53, 'vitamin D')]
PMC4586450	10/2015	S526-PMC4586450	['low intakes of Vitamin D were common throughout childhood.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 15, 'vitamin D')]
PMC4586451	10/2015	S191-PMC4586451	['other maternal dietary factors tested but not associated after full adjustment: energy, Carbohydrate, protein, fat, calcium, Potassium, Retinol, Vitamin D, Folate, N-3 Fatty Acids, milk, meat, fish, fruit, and vegetables.']	N/A	N/A	[('CHEBI_16730', 'chloramphenicol 3-acetate', 88, 'carbohydrate'), ('CHEBI_22314', 'alkali metal atom', 125, 'potassium'), ('CHEBI_26536', 'retinoic acid', 136, 'retinol'), ('CHEBI_27300', 'vitamin D', 145, 'vitamin D'), ('CHEBI_30863', '5-azaorotic acid', 156, 'folate'), ('CHEBI_30256', 'thiocarbonyl group', 164, 'n-3'), ('CHEBI_35366', 'fatty acid', 168, 'fatty acids')]
PMC4586451	10/2015	S202-PMC4586451	['other maternal dietary factors tested but not associated after full adjustment: Carbohydrate, protein, fat, fiber, calcium, Sodium, phosphorus, zinc, iron, Retinol, Carotene, riboflavin, Thiamin, Niacin, Vitamin C, Vitamin D, Vitamin E, and N-3 Fatty Acids.']	N/A	N/A	[('CHEBI_16730', 'chloramphenicol 3-acetate', 80, 'carbohydrate'), ('CHEBI_52632', 'potassium-39 atom', 124, 'sodium'), ('CHEBI_26536', 'retinoic acid', 156, 'retinol'), ('CHEBI_23042', 'carotene', 165, 'carotene'), ('CHEBI_26948', 'vitamin B1', 187, 'thiamin'), ('CHEBI_7542', 'neurotensin', 196, 'niacin'), ('CHEBI_27300', 'vitamin D', 204, 'vitamin C'), ('CHEBI_27300', 'vitamin D', 215, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 226, 'vitamin E'), ('CHEBI_35418', 'N-acetylneuraminate', 241, 'n-3 fatty acids')]
PMC4591978	10/2015	S23-PMC4591978	['Vitamin D increases Igf-1 and Igfbp-3 production [14]; Vitamin E improves Insulin sensitivity [15]; and Retinoic Acid [16] and Vitamin d [17] each stimulate Hpl production in Trophoblast Cells of healthy Human Placentas.']	N/A	N/A	[('CHEBI_28384', 'vitamin K', 0, 'Vitamin D'), ('PR_000008929', 'interferon-related developmental regulator 1', 20, 'IGF-1'), ('GO_0036336', 'dendritic cell migration', 30, 'IGFBP-3'), ('PR_000008940', 'intraflagellar transport protein 88', 30, 'IGFBP-3'), ('CHEBI_27300', 'vitamin D', 55, 'vitamin E'), ('PR_000045358', 'insulin family protein', 74, 'insulin'), ('CHEBI_26536', 'retinoic acid', 104, 'retinoic acid'), ('CHEBI_33229', 'vitamin (role)', 127, 'vitamin'), ('PR_000008800', 'heat shock protein HSP 90-beta', 157, 'hPL'), ('CL_0000351', 'trophoblast cell', 175, 'trophoblast cells'), ('UBERON_0000088', 'trophoblast', 175, 'trophoblast'), ('NCBITaxon_9606', 'Homo sapiens', 204, 'human'), ('UBERON_0001987', 'placenta', 210, 'placentas')]
PMC4591978	10/2015	S32-PMC4591978	['the mm also included Vitamin A (770 μg Retinol equivalents), Vitamin D (5 μg), Vitamin E (15 mg), Thiamin (1.4 mg), riboflavin (1.4 mg), niacin (1.4 mg), Vitamin B12(2.5 mg), Vitamin B6(1.9 mg), Vitamin C (85 mg), zinc (12 mg), Iodine (220 μg), copper (1000 μg), and Selenium (60 μg).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 21, 'vitamin A'), ('CHEBI_26536', 'retinoic acid', 39, 'retinol'), ('CHEBI_27300', 'vitamin D', 61, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 79, 'vitamin E'), ('CHEBI_26948', 'vitamin B1', 98, 'thiamin'), ('CHEBI_33279', 'vitamin D5', 154, 'vitamin B12'), ('CHEBI_33237', 'vitamin D4', 175, 'vitamin B6'), ('CHEBI_27300', 'vitamin D', 195, 'vitamin C'), ('CHEBI_24859', 'iodine atom', 228, 'iodine'), ('CHEBI_27568', 'selenium atom', 267, 'selenium')]
PMC4595656	10/2015	S34-PMC4595656	['these changes do not persist if young Animals are Fed a Vitamin D replete diet at Birth but persist if they remain on a Vitamin D deficient diet for the first 3 weeks of Life (féron et al.,2005).']	N/A	N/A	[('NCBITaxon_33208', 'Metazoa', 38, 'animals'), ('GO_0007631', 'feeding behavior', 50, 'fed'), ('CHEBI_27300', 'vitamin D', 56, 'vitamin D'), ('GO_0007567', 'parturition', 82, 'birth'), ('CHEBI_27300', 'vitamin D', 120, 'vitamin D'), ('UBERON_0000104', 'life cycle', 170, 'life')]
PMC4595656	10/2015	S140-PMC4595656	['finally, there are no cross-sectional studies to date in young children on hippocampal function such as Memory Formation and Retrieval, and spatial Navigation as a function of their Vitamin D intake.']	N/A	N/A	[('GO_0051017', 'actin filament bundle assembly', 104, 'memory formation ... retrieval'), ('GO_0009647', 'skotomorphogenesis', 148, 'navigation'), ('CHEBI_27300', 'vitamin D', 182, 'vitamin D')]
PMC4598849	10/2015	S75-PMC4598849	['second, 25(Oh)D levels at Birth cannot represent the Vitamin D status in early Pregnancy.']	N/A	N/A	[('CHEBI_71657', 'versiconol acetate', 8, '25(OH)D'), ('GO_0007567', 'parturition', 26, 'birth'), ('CHEBI_27300', 'vitamin D', 53, 'vitamin D'), ('GO_0007565', 'female pregnancy', 79, 'pregnancy')]
PMC4600246	10/2015	S22-PMC4600246	['in a 3-year, double-blind, placebo-controlled trial, vitamin k1(along with Vitamin D) significantly delayed the deterioration of Arterial elasticity37in 181 Postmenopausal women.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 75, 'vitamin D'), ('UBERON_0001637', 'artery', 129, 'arterial'), ('GO_0007595', 'lactation', 157, 'postmenopausal')]
PMC4600246	10/2015	S38-PMC4600246	['the trial included 181 Postmenopausal women who were given (1) a placebo, (2) a supplement containing Minerals and Vitamin D, or (3) the same supplement with the addition of Vitamin K1.']	N/A	N/A	[('GO_0007595', 'lactation', 23, 'postmenopausal'), ('CHEBI_46751', 'quinolizidine', 102, 'minerals'), ('CHEBI_27300', 'vitamin D', 115, 'vitamin D'), ('PR_000004483', 'V-type proton ATPase subunit C 1', 174, 'vitamin K1')]
PMC4600246	10/2015	S40-PMC4600246	['there was no significant difference between the Vitamin D and Mineral group without Vitamin K and the placebo group.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 48, 'vitamin D'), ('CHEBI_46662', 'mineral', 62, 'mineral'), ('CHEBI_27300', 'vitamin D', 84, 'vitamin K')]
PMC4617437	9/2015	S18-PMC4617437	['Food Consumption was assessed with a semi-quantitative Food frequency questionnaire (ffq), referring to the last Gestational quarter, with 29 Food items and obtained by simplifying a 80-item ffq, validated by sichieri and everhart.28to this simplification, we performed a secondary analysis of the database employed in the elaboration of the original ffq, using stepwise regression to explain 95.0% of variance for the following Nutrients: energy, Carbohydrates, Lipids, saturated Fatty Acids, monounsaturated and polyunsaturated fats, Cholesterol, Calcium and Vitamin C.c\nthe Birth weight information came from medical records.']	N/A	N/A	[('CHEBI_33290', 'food', 0, 'Food'), ('GO_0007631', 'feeding behavior', 0, 'Food consumption'), ('CHEBI_33290', 'food', 55, 'food'), ('GO_0007565', 'female pregnancy', 113, 'gestational'), ('CHEBI_33290', 'food', 142, 'food'), ('CHEBI_33284', 'nutrient', 429, 'nutrients'), ('CHEBI_16646', 'carbohydrate', 448, 'carbohydrates'), ('CHEBI_18059', 'lipid', 463, 'lipids'), ('CHEBI_35366', 'fatty acid', 481, 'fatty acids'), ('CHEBI_16113', 'cholesterol', 536, 'cholesterol'), ('CHEBI_22313', 'alkaline earth metal atom', 549, 'calcium'), ('CHEBI_27300', 'vitamin D', 561, 'vitamin C'), ('PR_000004900', 'complement C3', 569, 'C'), ('GO_0007567', 'parturition', 577, 'birth')]
PMC4624803	10/2015	S1-PMC4624803	['material\nUmbilical Cord Blood samples collected at Birth from 202 children later diagnosed with attention deficit/hyperactivity disorder were analysed for Vitamin D content and compared with 202 matched controls.']	N/A	N/A	[('UBERON_0002331', 'umbilical cord', 9, 'Umbilical cord'), ('UBERON_0000178', 'blood', 24, 'blood'), ('GO_0007567', 'parturition', 51, 'birth'), ('CHEBI_27300', 'vitamin D', 155, 'vitamin D')]
PMC4624803	10/2015	S43-PMC4624803	['analysis of Vitamin D concentration\nquantitative analyses of Cord Sera were conducted using a triple quadrupole linear ion trap mass spectrometer (qtrap 5500; ab sciex, foster city, ca, usa) coupled to a liquid chromatography system (uflcxr, shimadzu corporation, kyoto, japan; lc/ms/ms).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 12, 'vitamin D'), ('UBERON_0002240', 'spinal cord', 61, 'cord'), ('UBERON_0001977', 'blood serum', 66, 'sera')]
PMC4624803	10/2015	S53-PMC4624803	['2011/724)\n\nstatistical analyses\nthe wilcoxon matched-pairs signed-rank test was used to compare the Vitamin D concentrations between children with adhd and matched control children.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 100, 'vitamin D')]
PMC4624803	10/2015	S55-PMC4624803	['anova analyses were performed concerning differences in the means for Vitamin D in children with adhd compared to control children, stratified for all cases and for children with a mother Born in sweden.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 70, 'vitamin D'), ('GO_0007567', 'parturition', 188, 'born')]
PMC4624803	10/2015	S60-PMC4624803	['quartiles of Vitamin D levels were also analysed.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 13, 'vitamin D')]
PMC4624803	10/2015	S69-PMC4624803	['no difference between Vitamin D levels was detected when the adhd group (n = 202) was compared with the control group (n = 202, p = 0.43) (fig 1).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 22, 'vitamin D')]
PMC4624803	10/2015	S71-PMC4624803	['the or for an increase by one unit (ng/ml) in the Vitamin D concentration was 0.99 (95% ci: 0.96–1.01).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 50, 'vitamin D')]
PMC4624803	10/2015	S73-PMC4624803	['no association between a value below this threshold and adhd could be detected (or: 1.13; 95% ci: 0.69–1.83); nor could an association between a Vitamin D value below the 10thpercentile (5.84 ng/ml) and adhd be detected (or: 1.14; 95% ci: 0.56–2.34).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 145, 'vitamin D')]
PMC4624803	10/2015	S77-PMC4624803	['in the conditional multivariable regression analysis, only maternal age and smoking had a p- value less than 0.20, so the final conditional logistic regression model was performed with maternal age, maternal smoking, two seasonal periods of Birth and Vitamin D levels as independent variables.']	N/A	N/A	[('GO_0007567', 'parturition', 241, 'birth'), ('CHEBI_27300', 'vitamin D', 251, 'vitamin D')]
PMC4624803	10/2015	S79-PMC4624803	['box plot of Vitamin D concentrations in Serum at Birth for Individuals with adhd compared with matched controls.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 12, 'vitamin D'), ('UBERON_0001977', 'blood serum', 40, 'serum'), ('GO_0007567', 'parturition', 49, 'birth'), ('NCBITaxon_1', 'root', 59, 'individuals')]
PMC4624803	10/2015	S80-PMC4624803	['the Vitamin D concentrations are measured in ng/ml.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 4, 'vitamin D')]
PMC4624803	10/2015	S82-PMC4624803	['the difference is non-significant when tested with wilcoxon’s signed rank test.10.1371/journal.pone.0140164.t002\n\ncaption (table-wrap): table 2\ndescriptive data concerning Vitamin D levels (ng/ml) among different subgroups.all childrencontrolschildren with adhdnmean (sd)nmean (sd)nmean (sd)gender:boys34014.77 (7.95)16115.40 (8.27)17914.21 (7.64)girls6414.08 (7.55)4113.68 (7.78)2314.80 (7.23)season of Birth:january-march6910.41 (6.02)3211.17 (6.68)379.74 (5.40)april-june8914.55 (7.29)4914.01 (6.90)4015.22 (7.79)july-september9020.81 (9.07)3722.55 (10.10)5319.60 (8.15)september-december15613.06 (5.98)8413.83 (6.37)7212.16 (5.39)maternal smoking:no25615.52 (8.56)13316.20 (8.91)12314.79 (8.12)yes13213.07 (6.35)6112.64 (6.02)7113.44 (6.63)maternal age (years):<201012.30 (5.31)410.36 (2.58)613.6 (6.46)20–249612.46 (6.80)3812.47 (6.93)5812.46 (6.77)25–2914115.83 (8.39)7217.03 (9.07)6914.56 (7.47)30–349115.77 (8.81)5216.07 (8.65)3915.38 (9.13)35–393514.71 (6.50)1913.46 (5.39)1616.19 (7.53)> = 401513.21 (7.03)910.32 (5.97)617.56 (6.60)maternal bmi:<18.5411.24 (7.01)39.70 (7.72)115.86(0.0)18.5–24.97515.94 (7.48)3915.89 (7.30)3616.01 (7.77)25.0–29.93014.66 (7.98)1417.68 (8.11)1612.02 (7.08)> = 301213.04 (7.26)415.26 (8.82)811.93 (6.73)10.1371/journal.pone.0140164.t003\n\ncaption (table-wrap): table 3\ndifference in Vitamin D levels (ng/ml) for children with adhd and control children, stratified for the mother’s country of Birth.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 172, 'vitamin D'), ('GO_0007567', 'parturition', 404, 'birth'), ('CHEBI_27300', 'vitamin D', 1323, 'vitamin D'), ('GO_0007567', 'parturition', 1432, 'birth')]
PMC4624803	10/2015	S86-PMC4624803	['no other study of Vitamin D levels in children, with a prospective or pseudo-prospective design, has previously been performed.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 18, 'vitamin D')]
PMC4624803	10/2015	S87-PMC4624803	['in a study from qatar, Vitamin D in Serum was determined in 1331 adhd children age 5–18 years and in the same number of controls.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 23, 'vitamin D'), ('UBERON_0001977', 'blood serum', 36, 'serum')]
PMC4632418	10/2015	S29-PMC4632418	['the following keywords were used in the search: “Vitamin D” or “Cholecalciferol” or “25-Hydroxyvitamin D” or “25(Oh)d” in combination with “Gestational diabetes”.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 49, 'vitamin D'), ('CHEBI_52550', 'theopalauamide', 64, 'cholecalciferol'), ('CHEBI_62218', '23,24-dihydrocucurbitacin D', 85, '25-hydroxyvitamin D'), ('CHEBI_30778', 'gallic acid', 110, '25(OH)'), ('GO_0007565', 'female pregnancy', 140, 'gestational')]
PMC4632418	10/2015	S40-PMC4632418	['if the or and 95% confidence intervals (ci) were not available for meta-analysis, these data were calculated by a 2 × 2 table using the number of Vitamin D deficiency cases in the gdm and control group compared with the total number of participants in both groups.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 146, 'vitamin D')]
PMC4632418	10/2015	S53-PMC4632418	['of those, 39 reviews and 16 studies aiming at Vitamin D supplementation were excluded.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 46, 'vitamin D')]
PMC4632418	10/2015	S63-PMC4632418	['seven different criteria were used to diagnose gdm and five assay techniques were used to measure Serum 25(Oh)D level.nutrients-07-05398-t001_table 1\n\ncaption (table-wrap): table 1\n\ncharacteristics of observational studies included in this meta-analysis.author and yearlocationstudy typeparticipants( n )gdm( n )gdm criteria *assay methodmean 25(Oh)D nmol/l (sd)prevalencesignificantadjustments**gdmngtmaghbooli (2008) [22]irancross-sectional57952c&cria16.5(10.4)22.9(18.3)70.60%yesa, bclifton-bligh (2008) [23]australiacross-sectional30781adpslc–ms48.6(24.9)55.3(23.3)48%yesa, b, czhang (2008) [24]usnested-case-control17157adaelisa60.4(21.22)75.13(24.21)19.80%yesa, b, c, dfarrant (2009) [16]indiacross-sectional55939c&cria49.3(31.2)46.4(30.9)66%noa, b, e, fsoheilykhah (2010) [25]irancase-control16554c&celisa24.01(20.62)32.2(35.74)78.40%yesnrbaker (2012) [15]usnested-case-control18060nddglc–ms97.0(29.0)86.0(22.0)7.20%yesa, b, e, hmakgoba (2011) [26]ukcase-control24890wholc–ms47.2(26.7)47.6 (26.7)58.80%noa, b, c, d, e, gparlea (2012) [27]canadanested-case-control337118nddgclia56.3(19.4)62.0(21.6)nryesh, ifernandez-alonso (2012) [28]spaincross-sectional46636adaeclianrnr23.40%nrnrparildar (2013) [29]turkeycase-control12244iadpsgclia48.67(23.21)57.16(24.96)43.40%nonrwang (2012) [30]chinanested-case-control400200adaelisa22.4(10.7)25.9(12.3)96.25%yesa, d, jburris (2012) [31]uscross-sectional115568adaclianrnr33.10%nra, b, c, e, h, k, l, m, n, o, p, tperez-ferre (2012) [32]spaincross-sectional26649adaclianrnr59.02%nra, c, d, gzuhur (2013) [33]turkeycross-sectional402234iadpsgeclia30.8(16.3)36.0(16.2)84.30%yesa, b, d, gbener (2013) [34]qatariprospective cohort1873260whorianrnr48.40%nrnrlacroix (2014) [35]canadacross-sectional65554iadpsglc–ms57.5(17.2)63.5(18.9)26.70%yesa, c, d, e, g, r, s, t, umcmanus (2014) [36]canadacase-control7336cdaria77.3(24.3)93.2(19.2)6.85%yesa, bpark (2014) [37]koreaprospective cohort52323c&ceclia49.4(19.4)48(24.8)88.90%noa, b, e, h, g, varnold (2015) [38]usnested-case-control652135adalc–ms59.7(23.5)66.6(22)25.61%yesa, b, c, d, epleskacova (2015) [39]czechcase-control7647whoeiasa28(3.76)31.85(4.62)94.7%nob\nnote: nr, not reported; prevalence: prevalence of Vitamin D deficiency; significant: significant difference in Serum 25(Oh)d between Gestational diabetes mellitus (gdm) & normal Glucose tolerance (ngt).']	N/A	N/A	[('UBERON_0001977', 'blood serum', 98, 'serum'), ('CHEBI_71657', 'versiconol acetate', 104, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 104, '25(OH)D'), ('CHEBI_71657', 'versiconol acetate', 343, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 2203, 'vitamin D'), ('UBERON_0001977', 'blood serum', 2264, 'serum'), ('CHEBI_30778', 'gallic acid', 2270, '25(OH)'), ('GO_0007565', 'female pregnancy', 2286, 'gestational'), ('CHEBI_17234', 'glucose', 2331, 'glucose')]
PMC4632418	10/2015	S66-PMC4632418	['**, adjustments a: age; b: body mass index (bmi); c: ethnicity; d: family history of type 2 diabetes mellitus (t2dm); e: season; f: socio-economic status; g: previous history of gdm; h: Gestational age; i: maternal weight; j: Triglyceride (Tg); k: education; l: marital status; m: smoking; n: Pregnancy weight gain; o: physical activity; p: dietary intake of fish and calcium; q: trimester; r: Vitamin D lifestyle score; s: Parathyroid hormone (pth); t: parity; u: waist circumference; v: Vitamin D intake.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 186, 'gestational'), ('CHEBI_17855', 'triglyceride', 226, 'triglyceride'), ('CHEBI_17855', 'triglyceride', 240, 'TG'), ('GO_0007565', 'female pregnancy', 293, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 394, 'vitamin D'), ('UBERON_0001132', 'parathyroid gland', 424, 'parathyroid'), ('CHEBI_27300', 'vitamin D', 489, 'vitamin D')]
PMC4632418	10/2015	S79-PMC4632418	['caption (fig): figure 2\n\nmeta-analysis of the association between Vitamin D deficiency and risk of Gestational diabetes mellitus (gdm).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 66, 'vitamin D'), ('GO_0007565', 'female pregnancy', 99, 'gestational')]
PMC4632418	10/2015	S112-PMC4632418	['first, 1,25(Oh)2D3, the active form of Vitamin D, Regulates circulating Glucose levels by binding to Vitamin D Receptor of Pancreatic β-Cell and Modulating Insulin secretion [41,42].']	N/A	N/A	[('CHEBI_72779', '11-trans-LTE4', 7, '1,25(OH)2D3'), ('CHEBI_27300', 'vitamin D', 39, 'vitamin D'), ('GO_0065007', 'biological regulation', 50, 'regulates'), ('CHEBI_17234', 'glucose', 72, 'glucose'), ('CHEBI_27300', 'vitamin D', 101, 'vitamin D'), ('PR_000001683', 'vasopressin V2 receptor', 101, 'vitamin D receptor'), ('UBERON_0001264', 'pancreas', 123, 'pancreatic'), ('CL_0000622', 'acinar cell', 135, '-cell'), ('GO_0065007', 'biological regulation', 145, 'modulating'), ('PR_000045358', 'insulin family protein', 156, 'insulin')]
PMC4632423	10/2015	S46-PMC4632423	['Plasma samples were used to measure levels of Vitamin A, Vitamin E and Cholesterol by high performance liquid chromatography; copper, zinc, and selenium by inductively coupled Plasma mass spectrometry (agilent technologies, stockport, cheshire, uk sk8 3gr); and 25 Hydroxyvitamin D (25(Oh)D) by tandem mass spectrometry (waters acquity; uplc and tqd, hertfordshire, uk wd6 3sz).']	N/A	N/A	[('UBERON_0001969', 'blood plasma', 0, 'Plasma'), ('CHEBI_27300', 'vitamin D', 46, 'vitamin A'), ('PR_000004370', 'asialoglycoprotein receptor 2', 54, 'A'), ('CHEBI_27300', 'vitamin D', 57, 'vitamin E'), ('CHEBI_16113', 'cholesterol', 71, 'cholesterol'), ('UBERON_0001969', 'blood plasma', 176, 'plasma'), ('CHEBI_67828', 'rel-(3aR,4S,6aS,7R,9aR,10aS)-10a-Hydroxy-7-isopropyl-1,4,9a-trimethyl-4,5,6,6a,7,8,9,9a,10,10a-decahydro-3aH-dicyclopenta[a,d]cycloocten-3-one', 262, '25 hydroxyvitamin D'), ('CHEBI_71657', 'versiconol acetate', 283, '25(OH)D')]
PMC4632423	10/2015	S81-PMC4632423	['eighty percent of very severely obese women did not meet the rni for Vitamin K, Vitamins D and e, Thiamine and fibre; 95% of very severely obese and lean women did not meet the rni for iron and Folate.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 69, 'vitamin K'), ('CHEBI_27300', 'vitamin D', 80, 'vitamins D'), ('CHEBI_26948', 'vitamin B1', 98, 'thiamine'), ('CHEBI_30863', '5-azaorotic acid', 194, 'folate')]
PMC4645901	8/2014	S1-PMC4645901	['in our paediatrics department in a major london hospital, we audited the number of babies with low Vitamin D levels attending our prolonged jaundice clinic.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 99, 'vitamin D')]
PMC4645901	8/2014	S3-PMC4645901	['the gp would receive a letter which included a 14-page guideline on Vitamin D supplementation.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 68, 'vitamin D')]
PMC4645901	8/2014	S5-PMC4645901	['those babies that were either Vitamin D deficient or insufficient were identified.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 30, 'vitamin D')]
PMC4645901	8/2014	S23-PMC4645901	['[3]\nin our paediatrics department in a major london teaching hospital, we tested Vitamin D levels in babies who attended the prolonged jaundice clinic.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 81, 'vitamin D')]
PMC4645901	8/2014	S29-PMC4645901	['on average those with lighter Skin complexions will gain enough Vitamin D from exposure to just half an hour each day for two to three days each week.']	N/A	N/A	[('UBERON_0000014', 'zone of skin', 30, 'skin'), ('CHEBI_27300', 'vitamin D', 64, 'vitamin D')]
PMC4645901	8/2014	S31-PMC4645901	['in such times, Vitamin D status is relied upon dietary intake and body stores.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 15, 'vitamin D')]
PMC4645901	8/2014	S40-PMC4645901	['then, we identified those babies that were either Vitamin D deficient or insufficient (less than 25 and 50 nmol/l respectively).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 50, 'vitamin D')]
PMC4645901	8/2014	S47-PMC4645901	['at the time of the study, Pregnancy supplementation products that could be purchased over the counter in the uk provided either 200 or 400 units of Vitamin D daily.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 26, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 148, 'vitamin D')]
PMC4645901	8/2014	S49-PMC4645901	['mothers of babies who attended the clinic were notified of the low Vitamin D levels in their child and a letter with guidelines on prescribing Medications for Vitamin D deficiency was posted to their general practitioner (gp).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 67, 'vitamin D'), ('CHEBI_25441', 'mycothiols', 143, 'medications'), ('CHEBI_27300', 'vitamin D', 159, 'vitamin D')]
PMC4645901	8/2014	S50-PMC4645901	['when we followed up on the uptake of the Vitamin D prescriptions, only 38% had been taking the correct dose of Medication (figure 2).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 41, 'vitamin D'), ('CHEBI_60211', 'compound Z', 111, 'medication')]
PMC4645901	8/2014	S81-PMC4645901	['moreover, by the time of the re-audit all over the counter Vitamin Supplements in the uk provided the same 400 units daily of Vitamin D instead of the lower 200 unit daily dose.']	N/A	N/A	[('CHEBI_33229', 'vitamin (role)', 59, 'vitamin'), ('CHEBI_33341', 'titanium atom', 67, 'supplements'), ('CHEBI_27300', 'vitamin D', 126, 'vitamin D')]
PMC4661480	10/2015	S13-PMC4661480	['medications taken during Pregnancy included Amoxicillin-clavulanate, Acetaminophen with codeine, Vitamin D, and Prenatal Vitamins.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 25, 'pregnancy'), ('CHEBI_2676', 'amoxicillin', 44, 'amoxicillin'), ('CHEBI_15343', 'acetaldehyde', 69, 'acetaminophen'), ('CHEBI_27300', 'vitamin D', 97, 'vitamin D'), ('GO_0007565', 'female pregnancy', 112, 'prenatal'), ('CHEBI_33277', 'gamma-tocotrienol', 121, 'vitamins')]
PMC4673623	11/2015	S35-PMC4673623	['the control diet and hf-hed provided the same amount of Vitamin B-12 (33\xa0 μ g/kg) and Choline Chloride (1200\xa0ppm).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 56, 'vitamin B'), ('PR_000017269', 'ventral anterior homeobox 2', 56, 'vitamin B-12'), ('CHEBI_133341', 'choline chloride', 86, 'choline chloride')]
PMC4673623	11/2015	S37-PMC4673623	['the Sugar-containing Beverage (kool aid) contained no Folate, Choline, betaine, Vitamin B-12, or amino Acids.']	N/A	N/A	[('CHEBI_24870', 'ion', 4, 'sugar'), ('CHEBI_75861', 'arsenopyrite', 21, 'beverage'), ('CHEBI_30863', '5-azaorotic acid', 54, 'folate'), ('CHEBI_15354', 'choline', 62, 'choline'), ('CHEBI_27300', 'vitamin D', 80, 'vitamin B'), ('PR_000017269', 'ventral anterior homeobox 2', 80, 'vitamin B-12'), ('CHEBI_37527', 'acid', 103, 'acids')]
PMC4673623	11/2015	S111-PMC4673623	['maternal obesity alters circulating concentrations of Methyl-Nutrients\nmaternal and Fetal Blood concentrations of Vitamin B-12 were depleted in the hf-hed group as compared with the control group.']	N/A	N/A	[('CHEBI_33837', 'conjugated protein', 54, 'methyl-nutrients'), ('UBERON_0000922', 'embryo', 84, 'fetal'), ('UBERON_0000178', 'blood', 90, 'blood'), ('CHEBI_27300', 'vitamin D', 114, 'vitamin B'), ('PR_000017269', 'ventral anterior homeobox 2', 114, 'vitamin B-12')]
PMC4673623	11/2015	S121-PMC4673623	['like Vitamin B-12, betaine is a lipotrope and its use would be augmented under conditions of a Lipid load.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 5, 'vitamin B'), ('PR_000017269', 'ventral anterior homeobox 2', 5, 'vitamin B-12'), ('CHEBI_18059', 'lipid', 95, 'lipid')]
PMC4684854	12/2015	S42-PMC4684854	['terms searched included Gestational Vitamin D, Pregnancy and Vitamin D, fetus and Vitamin D, nutrition in Pregnancy, as well as pediatric health and Vitamin D. relevant references found in these publications were also searched in order to glean pertinent information.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 24, 'gestational'), ('CHEBI_27300', 'vitamin D', 36, 'vitamin D'), ('GO_0007565', 'female pregnancy', 47, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 61, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 82, 'vitamin D'), ('GO_0007565', 'female pregnancy', 106, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 149, 'vitamin D')]
PMC4685088	12/2015	S152-PMC4685088	['these include Rosiglitazone (106,107), Hepatocyte Growth Factor (Hgf) (108), b-naphthoflavone (109), arginyl-glutamine as well as Docosahexaenoic Acid (110), and a combination of Vitamin A and Retinoic Acid (111).']	N/A	N/A	[('CHEBI_8875', 'Rizatriptan benzoate', 14, 'rosiglitazone'), ('CL_0000182', 'hepatocyte', 39, 'hepatocyte'), ('PR_000008550', '3-hydroxyisobutyryl-CoA hydrolase, mitochondrial', 39, 'hepatocyte growth factor'), ('PR_000008530', 'hairy/enhancer-of-split related with YRPW motif-like protein', 65, 'HGF'), ('CHEBI_36003', 'decenoic acid', 130, 'docosahexaenoic acid'), ('CHEBI_27300', 'vitamin D', 179, 'vitamin A'), ('CHEBI_26536', 'retinoic acid', 193, 'retinoic acid')]
PMC4689556	12/2015	S27-PMC4689556	['methods\n\nstudy setting and subjects\nthis was a follow up study of the offspring of 180 women who took part in an ethnically stratified, parallel group, randomised controlled trial of Vitamin D supplementation in Pregnancy at st mary’s hospital london, a university-affiliated hospital Antenatal clinic, between april and november 2007.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 183, 'vitamin D'), ('GO_0007565', 'female pregnancy', 212, 'pregnancy'), ('GO_0007567', 'parturition', 285, 'antenatal'), ('UBERON_0001760', 'frontal sinus', 285, 'antenatal')]
PMC4689556	12/2015	S49-PMC4689556	['primary and secondary outcomes\nthe primary outcome of the trial was 25(Oh) Vitamin D level at Birth, and has been reported elsewhere [28].']	N/A	N/A	[('CHEBI_30778', 'gallic acid', 68, '25(OH)'), ('CHEBI_27300', 'vitamin D', 75, 'vitamin D'), ('GO_0007567', 'parturition', 94, 'birth')]
PMC4689556	12/2015	S110-PMC4689556	['effect of Prenatal Vitamin D supplementation on healthcare utilisation\nthere was no significant difference in the primary outcome measure, total unscheduled healthcare utilisation, between treatment groups (fig 2).']	N/A	N/A	[('GO_0007565', 'female pregnancy', 10, 'prenatal'), ('CHEBI_27300', 'vitamin D', 19, 'vitamin D')]
PMC4689556	12/2015	S111-PMC4689556	['mean difference between control and daily Vitamin D supplementation in ln transformed total costs was—0.02 (95%ci -0.47, 0.50); adjusted mean difference 0.07 (95%ci -0.48, 0.62).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 42, 'vitamin D')]
PMC4689556	12/2015	S112-PMC4689556	['for bolus Vitamin D supplementation versus controls the mean difference was -0.46 (95%ci-0.97, 0.06); adjusted mean difference -0.34 (95%ci -0.90, 0.22).10.1371/journal.pone.0145303.g002\n\ncaption (fig): fig 2\neffect of Prenatal Vitamin D randomisation on total healthcare utilisation in the first three years of Life.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 10, 'vitamin D'), ('GO_0007565', 'female pregnancy', 219, 'prenatal'), ('CHEBI_27300', 'vitamin D', 228, 'vitamin D'), ('UBERON_0000104', 'life cycle', 312, 'life')]
PMC4689556	12/2015	S117-PMC4689556	['daily Vitamin D versus control.ncontrol*ndaily*mean difference (95% ci)pnadjusted**mean difference (95% ci)ptotal cost†311176.14 (437.03, 3165.29)361187.97 (441.42, 3197.10)1.02 (-1.60, 1.65)0.95531.07 (-1.62, 1.86)0.81all visits†311130.03 (419.90, 3041.18)361118.79 (407.48, 3071.74)-1.01 (-1.65, 1.60)0.95531.02 (-1.70, 1.79)0.93prescription cost†3125.28 (4.06, 157.60)3635.52 (11.59, 108.85)1.40 (-1.49, 2.94)0.36531.65 (-1.43, 3.90)0.25year 1 cost†31287.15 (38.09, 2164.62)36383.75 (86.49, 1702.75)1.34 (-1.75, 3.16)0.50531.67 (-1.58, 4.39)0.30year 2 cost31247 (103, 607)36248 (123, 487)-0.92---year 3 cost31239 (103, 552)36212 (96, 463)-0.57---primary care cost†31387.61 (145.47, 1032.77)36450.39 (242.26, 837.15)1.15 (-1.28, 1.72)0.47531.34 (-1.16, 2.05)0.20secondary care cost31632 (206, 1853)36368 (155, 1502)-0.42---wheeze cost310 (0, 0)360 (0, 0)-0.71---cough cost310 (0, 36)360 (0, 36)-0.26---urti cost31180 (36, 324)36150 (54, 234)-0.78---lrti cost310 (0, 0)360 (0, 0)-0.75---bronchiolitis cost310 (0, 0)360 (0, 0)-0.89---overall resp cost†31170.72 (27.39, 1064.22)36141.17 (27.11, 735.10)-1.21 (-3.16, 2.14)0.69---Food allergy cost310 (0, 0)360 (0, 0)-0.35---eczema cost310 (0, 88)360 (0, 36)-0.62---\nurti (Upper Respiratory Tract infection), lrti (Lower Respiratory Tract infection).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 6, 'vitamin D'), ('CHEBI_33290', 'food', 1127, 'Food'), ('UBERON_0001557', 'upper respiratory tract', 1220, 'Upper respiratory tract'), ('UBERON_0009567', 'nail of pedal digit', 1262, 'Lower'), ('UBERON_0000065', 'respiratory tract', 1268, 'respiratory tract')]
PMC4689556	12/2015	S121-PMC4689556	['bolus Vitamin D versus control.ncontrol*nbolus*mean difference (95% ci)pnadjusted**mean difference (95% ci)ptotal cost†311176.14 (437.03, 3165.29)31742.48 (257.24, 2413.08)-1.58 (-2.63, 1.06)0.0849-1.40 (-2.45, 1.24)0.23all visit costs†311130.03 (419.90, 3041.18)32706.27 (239.85, 2079.74)1.60 (-2.69, 1.05)0.0849-1.43 (-2.53, 1.23)0.21all prescription cost†3125.28 (4.06, 157.60)3222.42 (4.85, 103.54)1.12 (-2.61, 2.08)0.79491.23 (-1.95, 3.00)0.63year 1 cost†31287.15 (38.09, 2164.62)32223.63 (62.80, 796.32)1.28 (-2.97, 1.82)0.56491.02 (-2.36, 2.46)0.96year 2 cost31247 (103, 607)32202 (101, 603)-0.75---year 3 cost31239 (103, 552)32142 (36, 333)-0.04---primary care cost†31387.61 (145.47, 1032.77)32383.75 (169.02, 871.32)1.02 (-1.60, 1.55)0.95491.01 (-1.57, 1.60)0.98secondary care cost31632 (206, 1853)32313 (0, 848)-0.04---wheeze visit cost310 (0, 0)320 (0, 0)-0.22---cough visit cost310 (0, 36)320 (0, 36)-0.59---urti visit cost31180 (36, 324)32108 (72, 255)-0.91---lrti visit cost310 (0, 0)320 (0, 36)-0.31---Bronchiolitis visit cost310 (0, 0)320 (0, 0)-0.59---overall resp cost†31170.72 (27.39, 1064.22)32137.00 (15.96, 1176.15)-1.25 (-3.42, 2.20)0.66---Food allergy cost310 (0, 0)320 (0, 0)-1.00---eczema cost310 (0, 88)320 (0, 36)-0.77---\nurti (Upper Respiratory Tract infection), lrti (Lower Respiratory Tract infection).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 6, 'vitamin D'), ('PR_000006444', 'diacylglycerol kinase delta', 14, 'D'), ('UBERON_0002186', 'bronchiole', 1017, 'Bronchiolitis'), ('CHEBI_33290', 'food', 1163, 'Food'), ('UBERON_0001557', 'upper respiratory tract', 1256, 'Upper respiratory tract'), ('UBERON_0004905', 'articulation', 1298, 'Lower respiratory tract')]
PMC4689556	12/2015	S125-PMC4689556	['combined Vitamin D versus control.ncontrol*ncombined*mean differencepnadjusted**mean differenceptotal cost†311176.14 (437.03, 3165.29)68953.37 (333.62, 2724.39)-1.23 (-1.92, 1.27)0.3684-1.17 (-1.90, 1.39)0.52all visit cost†311130.03 (419.90, 3041.18)68897.85 (311.06, 2591.52)-1.27 (-1.95, 1.25)0.3184-1.21 (-1.97, 1.35)0.45all prescription cost†3125.28 (4.06, 157.60)6828.50 (7.32, 111.05)1.14 (-1.70, 2.18)0.70841.34 (-1.49, 2.66)0.41year 1 total cost†31287.15 (38.09, 2164.62)68298.87 (74.44, 1199.91)1.04 (-1.93, 2.08)0.91841.25 (-1.70, 2.63)0.56year 2 total cost31247 (103, 607)68244 (108, 558)-0.81---year 3 total cost31239 (103, 552)68168 (60, 430)-0.14---primary care visit cost†31387.61 (145.47, 1032.77)68415.72 (202.35, 854.06)1.07 (-1.32, 1.52)0.70841.16 (-1.25, 1.67)0.42secondary care visit cost31632 (206, 1853)68316 (103, 1050)-0.11---wheeze visit cost310 (0,0)680 (0, 0)-0.37---cough visit cost310 (0, 36)680 (0, 36)-0.33---urti visit cost31180 (36, 324)68130 (72, 252)-0.82---lrti visit cost310 (0, 0)680 (0, 24)-0.68---bronchiolitis visit cost310 (0, 0)680 (0, 0)-0.70---overall resp cost†31170.72 (27.39, 1064.22)68138.38 (347.23, 1107.65)-1.23 (2.92, 1.93)0.64---Food allergy cost310 (0, 0)680 (0, 0)-0.50---eczema cost310 (0, 88)680 (0, 36)-0.90---\nurti (Upper Respiratory Tract infection), lrti (Lower Respiratory Tract infection).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 9, 'vitamin D'), ('CHEBI_33290', 'food', 1184, 'Food'), ('UBERON_0001557', 'upper respiratory tract', 1277, 'Upper respiratory tract'), ('UBERON_0004905', 'articulation', 1319, 'Lower respiratory tract')]
PMC4689556	12/2015	S128-PMC4689556	['effect of Prenatal Vitamin D supplementation on need for prescription Medications\nprescribing data were also dichotomized according to whether any prescription was made in the first three years of Life.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 10, 'prenatal'), ('CHEBI_27300', 'vitamin D', 19, 'vitamin D'), ('CHEBI_25441', 'mycothiols', 70, 'medications'), ('UBERON_0000104', 'life cycle', 197, 'life')]
PMC4689556	12/2015	S135-PMC4689556	['association between Prenatal or Postnatal Vitamin D level and healthcare utilisation\nof the 99 offspring with complete e-hr data, Cord levels of 25(Oh)D were available for 79, and 25(Oh)D levels at age three years for 65.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 20, 'prenatal'), ('GO_0007567', 'parturition', 32, 'postnatal'), ('CHEBI_27300', 'vitamin D', 42, 'vitamin D'), ('UBERON_0002240', 'spinal cord', 130, 'cord'), ('CHEBI_71657', 'versiconol acetate', 145, '25(OH)D'), ('CHEBI_71657', 'versiconol acetate', 180, '25(OH)D'), ('PR_000005506', 'Cbp/p300-interacting transactivator 2', 180, '25('), ('PR_000006444', 'diacylglycerol kinase delta', 186, 'D')]
PMC4689556	12/2015	S156-PMC4689556	['maternal Serum 25(Oh) Vitamin D levels in that trial were higher at randomization, and rose to a higher level in the supplemented groups—from ~60 to ~100 nmol/l; compared to ~26 to ~40 nmol/l in our trial.']	N/A	N/A	[('UBERON_0001977', 'blood serum', 9, 'serum'), ('CHEBI_30778', 'gallic acid', 15, '25(OH)'), ('CHEBI_27300', 'vitamin D', 22, 'vitamin D')]
PMC4690051	12/2015	S87-PMC4690051	['median dietary intake of Vitamin D during the second trimester for the whole cohort was 177 iu (range 13.3–772).nutrients-07-05499-t001_table 1\n\ncaption (table-wrap): table 1\n\ncharacteristics of the mothers at enrollment and the children at 2-year assessment (cv2; n = 1020).n %insurance\u2003other insurance48947.9\u2003medicaid, medicare53152.1education\u2003hs diploma or lower56755.6\u2003college or higher degree45344.4marital status\u2003cohabitation60158.9\u2003single41941.1pre-Pregnancy bmi, kg/m2\u2003underweight454.4\u2003normal39738.9\u2003overweight24023.5\u2003obese33833.1alcohol use, yes868.4tobacco use, yes858.3total Pregnancies1\u2003130930.3\u20032–559458.2\u2003>511711.5gestational 25(Oh)D\u2003<20 ng/dl42541.7\u200320.00–29.99 ng/dl44043.1\u2003≥30 ng/dl15515.2 meansd Weeks Of Gestation38.91.725(Oh)D, ng/dl22.38.5maternal age, years26.65.5maternal total iq96.216.4birth weight, z -score0.050.95birth length, z -score0.531.28head circumference, z -score−0.031.34child age at cv2 assessment, months25.01.5cognitive scaled score29.62.6receptive language scaled score29.52.9expressive language scaled score29.92.7\n1includes current Pregnancy and previously completed term and pre-term Pregnancies;2as assessed at 2-year exam (cv2).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 25, 'vitamin D'), ('GO_0007565', 'female pregnancy', 456, 'Pregnancy'), ('GO_0007565', 'female pregnancy', 586, 'Pregnancies1'), ('CHEBI_71657', 'versiconol acetate', 640, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 646, 'D'), ('GO_0016055', 'Wnt signaling pathway', 714, 'Weeks of Gestation38'), ('CHEBI_33010', 'chromide(1-)', 741, '(OH)D'), ('GO_0007565', 'female pregnancy', 1075, 'pregnancy'), ('GO_0007565', 'female pregnancy', 1128, 'pregnancies')]
PMC4690051	12/2015	S100-PMC4690051	['dietary intake of Vitamin D was not associated with scaled scores or mid-Gestational 25(Oh)D levels.nutrients-07-05499-t002_table 2\n\ncaption (table-wrap): table 2\n\nscaled developmental scores by selective characteristics ( n = 1020).Cognitivereceptive languageexpressive languagemeansd p1meansd p1meansd p1race<0.0001<0.0001<0.0001\u2003african-american8.82.28.62.39.32.3\u2003european-american11.02.711.13.111.03.1insurance<0.0001<0.0001<0.0001\u2003other insurance10.42.810.53.110.73.0\u2003medicaid, medicare8.82.18.62.39.22.2education<0.0001<0.0001<0.0001\u2003hs diploma or lower8.92.18.72.49.32.2\u2003college or higher degree10.42.810.53.110.73.0marital status<0.0001<0.0001<0.0001\u2003cohabitation10.12.710.13.010.32.9\u2003single8.82.28.62.39.32.3pre-Pregnancy bmi, kg/m20.00010.00010.0001\u2003under weight9.72.29.92.99.92.6\u2003normal9.92.79.93.110.42.9\u2003overweight9.52.39.42.710.02.6\u2003obese9.22.69.02.79.42.4alcohol use0.00240.0020.007\u2003no9.52.59.42.89.82.6\u2003yes10.33.010.73.610.63.1tobacco use<0.0006<0.0006<0.0006\u2003no9.62.69.62.910.02.7\u2003yes8.72.08.52.78.82.6total Pregnancies0.00060.0290.0028\u2003110.02.99.83.010.32.7\u20032–59.52.49.52.99.82.8\u2003>58.82.28.82.39.42.2gestational diabetes0.100.220.14\u2003missing8.32.19.72.59.71.2\u2003no9.52.69.52.99.92.7\u2003yes10.02.69.93.010.32.9pre-eclampsia0.0670.0230.19\u2003missing9.02.29.62.59.81.6\u2003no9.62.69.62.910.02.7\u2003yes9.12.28.82.49.52.6delivery0.00210.1020.024\u2003pre-term8.82.28.92.99.32.8\u2003full term9.62.69.52.910.02.7gestational 25(oh)d<0.0001<0.0001<0.0001\u2003<20 ng/dl9.12.48.92.59.42.4\u200320.00–29.99 ng/dl9.82.89.73.010.22.9\u2003≥30 ng/dl10.12.410.53.210.42.6\n1p -value for comparison among the subgroups ( i.e.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 18, 'vitamin D'), ('GO_0007565', 'female pregnancy', 73, 'gestational'), ('CHEBI_71657', 'versiconol acetate', 85, '25(OH)D'), ('PR_000009880', 'Lon protease, mitochondrial', 85, '25 ... OH ... D'), ('GO_0050802', 'circadian sleep/wake cycle, sleep', 233, 'CognitiveReceptive'), ('GO_0007565', 'female pregnancy', 721, 'Pregnancy'), ('GO_0006412', 'translation', 1025, 'Pregnancies0'), ('CHEBI_37972', 'phosphorus-32 atom', 1410, '25')]
PMC4690051	12/2015	S115-PMC4690051	['Expression of Vitamin D Receptors (vdr) in Mammalian Brain occurs as early as day 12 of Gestation, then increases throughout Pregnancy [40].']	N/A	N/A	[('GO_0010467', 'gene expression', 0, 'Expression'), ('CHEBI_27300', 'vitamin D', 14, 'vitamin D'), ('PR_000002025', 'T-cell surface glycoprotein CD1a', 22, 'D receptors'), ('NCBITaxon_40674', 'Mammalia', 43, 'mammalian'), ('UBERON_0000955', 'brain', 53, 'brain'), ('GO_0007565', 'female pregnancy', 88, 'gestation'), ('GO_0007565', 'female pregnancy', 125, 'pregnancy')]
PMC4691762	12/2015	S3-PMC4691762	['methods nd analysis\ninfants (n=3012) who are fully Breastfed and not receiving Vitamin D supplementation will be recruited at the time of their first immunisation, from council-led immunisation clinics throughout metropolitan melbourne, australia.']	N/A	N/A	[('GO_0007567', 'parturition', 51, 'breastfed'), ('CHEBI_27300', 'vitamin D', 79, 'vitamin D')]
PMC4691762	12/2015	S5-PMC4691762	['secondary outcomes are Food Sensitisation (positive skin prick test), number of lower Respiratory infections (through hospital linkage), moderately-severe and persistent eczema (by history and examination) and Vitamin D deficiency (Serum Vitamin D <50\u2005nmol/l) at age 12\u2005months.']	N/A	N/A	[('CHEBI_33290', 'food', 23, 'food'), ('GO_0007416', 'synapse assembly', 23, 'food sensitisation'), ('UBERON_0001004', 'respiratory system', 86, 'respiratory'), ('CHEBI_27300', 'vitamin D', 210, 'vitamin D'), ('UBERON_0001977', 'blood serum', 232, 'serum'), ('CHEBI_27300', 'vitamin D', 238, 'vitamin D')]
PMC4691762	12/2015	S21-PMC4691762	['the trial will be conducted and reported according to consort16guidelines with the cost-effectiveness analysis conducted and reported according to cheers guidelines.17\n\nsetting and participants\nthe trial will be conducted in 6–8\u2005week old breast Fed infants not already receiving Vitamin D supplementation.']	N/A	N/A	[('GO_0007631', 'feeding behavior', 245, 'fed'), ('CHEBI_27300', 'vitamin D', 279, 'vitamin D')]
PMC4691762	12/2015	S30-PMC4691762	['exclusion criteria : infants with the following will be excluded: already receiving Vitamin D supplementation, Born premature (<37\u2005weeks)/low Birth weight (<2500\u2005g), multiple Births, poor health due to a current or past significant disease state or congenital abnormality or infants on medication that interfere with Vitamin D Metabolism.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 84, 'vitamin D'), ('GO_0007567', 'parturition', 111, 'born'), ('GO_0007567', 'parturition', 142, 'birth'), ('GO_0007567', 'parturition', 175, 'births'), ('CHEBI_27300', 'vitamin D', 317, 'vitamin D'), ('GO_0018977', '1,1,1-trichloro-2,2-bis-(4-chlorophenyl)ethane metabolic process', 325, 'D metabolism')]
PMC4691762	12/2015	S38-PMC4691762	['a daily dose of 400\u2005iu administered from around 4\u2005weeks of age was sufficient to increase Vitamin D levels to ≥50\u2005nmol/l in 98% of infants by 3\u2005months of age.19\n\ncompliance\nwe have developed an iphone application to remind study participants to give their infant the study Medication and to monitor dosing compliance.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 90, 'vitamin D'), ('CHEBI_60211', 'compound Z', 273, 'medication')]
PMC4691762	12/2015	S77-PMC4691762	['newborn screening (guthrie) card : consent will be obtained at recruitment to access guthrie cards to undertake assessment of Vitamin D levels at Birth.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 126, 'vitamin D'), ('GO_0007567', 'parturition', 146, 'birth')]
PMC4691762	12/2015	S88-PMC4691762	['statistical analysis\noutcomes will be compared between the Vitamin D and the placebo groups using an intention-to-treat analysis.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 59, 'vitamin D')]
PMC4691762	12/2015	S115-PMC4691762	['the Vitamin D receptor is widely Expressed in the Immune System including T Cells.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 4, 'vitamin D'), ('GO_0010467', 'gene expression', 33, 'expressed'), ('UBERON_0002405', 'immune system', 50, 'immune system'), ('CL_0000084', 'T cell', 74, 'T cells')]
PMC4719746	1/2016	S79-PMC4719746	['no change in the proportion using Vitamin D supplements was observed among the other ethnic groups (table\xa01).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 34, 'vitamin D')]
PMC4719746	1/2016	S86-PMC4719746	['caption (table-wrap): table 2\n\ndescriptive Vitamin D at inclusion (Gestational week 15) and at Gestational week 28.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 43, 'vitamin D'), ('GO_0007565', 'female pregnancy', 67, 'gestational'), ('GO_0007565', 'female pregnancy', 95, 'gestational')]
PMC4719746	1/2016	S88-PMC4719746	['1\n\nproportions of participants with levels of 25(Oh)D 12-\u2009<\u200925\xa0nmol/l and <12\xa0nmol/l at Gestational week 15 and 28\nin early Pregnancy, the values of 25(Oh)D differed between the ethnic groups and remained significant after adjustment for age, parity, season, education and intake of Vitamin D supplements (table\xa03).']	N/A	N/A	[('CHEBI_71657', 'versiconol acetate', 46, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 46, '25(OH ... D'), ('GO_0007565', 'female pregnancy', 88, 'gestational'), ('GO_0007565', 'female pregnancy', 124, 'pregnancy'), ('CHEBI_71657', 'versiconol acetate', 149, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 149, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 283, 'vitamin D')]
PMC4719746	1/2016	S93-PMC4719746	['caption (table-wrap): table 3\n\nlinear regression analysis with Vitamin D [25(Oh)D] at inclusion and Gestational week 28 as dependant variablesat inclusionat Gestational week 28univariate analysismultiple analysisunivariate analysismultiple analysisn\u2009=\u2009735, r2adj.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 63, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 74, '25(OH)D'), ('GO_0007565', 'female pregnancy', 100, 'gestational'), ('GO_0007565', 'female pregnancy', 157, 'gestational')]
PMC4719746	1/2016	S98-PMC4719746	['mean 25(Oh)D values were −17 (95 % ci: −23, −11), −10 (−16, −2.9) and −12 (−20, −3.1) nmol/l lower in south asians, middle easterners and sub-saharan africans compared with western europeans after adjustments for Gestational week at inclusion, age, parity, season, education and Vitamin D supplements (table\xa03).']	N/A	N/A	[('CHEBI_71657', 'versiconol acetate', 5, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 5, '25(OH ... D'), ('GO_0007565', 'female pregnancy', 213, 'gestational'), ('CHEBI_27300', 'vitamin D', 279, 'vitamin D')]
PMC4729160	1/2016	S43-PMC4729160	['the questionnaires included questions regarding the Pregnant such as:age; Gestational age; parity; whether use the Vitamin A supplements; Pregnant women drinkers defined as pregnant women who drink Alcohol during the past 12\xa0months; education levels of the Pregnant ; whether received college or university education; annual income of the Pregnant women rmb(yuan) was divided into four levels: <10,000,10,000–20,000,20,000–30,000, >\u2009=\u200930,000; smoking habit was divided into three categories: non-smoker without passive smoking, non-smoker with passive smoking,smokers.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 52, 'pregnant'), ('GO_0007565', 'female pregnancy', 74, 'gestational'), ('CHEBI_27300', 'vitamin D', 115, 'vitamin A'), ('GO_0007565', 'female pregnancy', 138, 'pregnant'), ('CHEBI_30879', 'alcohol', 198, 'alcohol'), ('GO_0007565', 'female pregnancy', 257, 'pregnant'), ('GO_0007565', 'female pregnancy', 339, 'pregnant')]
PMC4729160	1/2016	S73-PMC4729160	['Pregnant women with Vitamin A supplements compared with without Vitamin A supplements was significant difference ( f \u2009=\u20098.67, p \u2009=\u20090.00).']	N/A	N/A	[('GO_0007565', 'female pregnancy', 0, 'Pregnant'), ('CHEBI_27300', 'vitamin D', 20, 'vitamin A'), ('CHEBI_27300', 'vitamin D', 64, 'vitamin A')]
PMC4729160	1/2016	S88-PMC4729160	['the level of Vitamin A was 1.63\xa0μmol/l and vad was 5.3\xa0%.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 13, 'vitamin A')]
PMC4764019	1/2016	S19-PMC4764019	['a few years after the publication of that work, hyppönen et al6reported an 88% reduction in incidence of dm1 developing prior to age 31 years in a 1967 finnish birth cohort, for infants receiving 2000 iu vitamin d3per day, relative to members of the same Birth cohort receiving no Vitamin D. in addition, infants in the same study clinically suspected of having rickets exhibited a 3-fold increase in incidence of dm1 relative to nonrachitic infants.']	N/A	N/A	[('GO_0007567', 'parturition', 255, 'birth'), ('CHEBI_27300', 'vitamin D', 281, 'vitamin D')]
PMC4765528	12/2015	S110-PMC4765528	['using Vitamin D receptor polymorphisms as an example, dennison et al .']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 6, 'vitamin D')]
PMC4770602	1/2016	S2-PMC4770602	['materials and methods:\nin this randomized controlled trial, in 2012, 140 nulliparous Pregnant women in two groups received supplementation with 600 iu/day of Vitamin D or supplementation free of Vitamin D at 16 week Gestation until the Delivery.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 85, 'pregnant'), ('CHEBI_27300', 'vitamin D', 158, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 195, 'vitamin D'), ('GO_0007565', 'female pregnancy', 216, 'gestation'), ('GO_0007567', 'parturition', 236, 'delivery')]
PMC4770602	1/2016	S28-PMC4770602	['Pregnant women at less than 16 week Gestation from outpatient clinics at “shahid beheshti” hospital were eligible if they did not have any sign of Vitamin D deficiency, did not using Aspirin and had no diagnosis of chronic hypertension, Gestational diabetes, Renal disease or systemic lupus erythematus.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 0, 'Pregnant'), ('GO_0007565', 'female pregnancy', 36, 'gestation'), ('CHEBI_27300', 'vitamin D', 147, 'vitamin D'), ('CHEBI_2904', 'atenolol', 183, 'aspirin'), ('GO_0007565', 'female pregnancy', 237, 'gestational'), ('UBERON_0002113', 'kidney', 259, 'renal')]
PMC4770602	1/2016	S32-PMC4770602	['case group included 70 Pregnant women who received supplementation with 600 iu daily of Vitamin D at 16 week Gestation until Labor, also, in control group, 70 Pregnant women received daily supplementation free of Vitamin D and followed through Pregnancy to Labor process.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 23, 'pregnant'), ('CHEBI_27300', 'vitamin D', 88, 'vitamin D'), ('GO_0007565', 'female pregnancy', 109, 'gestation'), ('GO_0007612', 'learning', 125, 'labor'), ('GO_0007565', 'female pregnancy', 159, 'pregnant'), ('CHEBI_27300', 'vitamin D', 213, 'vitamin D'), ('GO_0007565', 'female pregnancy', 244, 'pregnancy'), ('GO_0007612', 'learning', 257, 'labor')]
PMC4784858	3/2016	S54-PMC4784858	['in its first version, 24 Nutrients were considered: protein, total Carbohydrate, dietary fibre, total fat, polyunsaturated Fatty Acids, Saturated Fatty Acids, Cholesterol, Vitamin A, Thiamin, riboflavin, niacin, vitamin B6, Folate, Vitamin B12, Vitamin C, Vitamin D and Vitamin E, calcium, iron, magnesium, Phosphorus, potassium, sodium and zinc [15].']	N/A	N/A	[('CHEBI_33284', 'nutrient', 25, 'nutrients'), ('CHEBI_16730', 'chloramphenicol 3-acetate', 67, 'carbohydrate'), ('CHEBI_35366', 'fatty acid', 123, 'fatty acids'), ('CHEBI_26604', 'santonin', 136, 'saturated fatty acids'), ('CHEBI_16113', 'cholesterol', 159, 'cholesterol'), ('CHEBI_27300', 'vitamin D', 172, 'vitamin A'), ('CHEBI_26948', 'vitamin B1', 183, 'thiamin'), ('CHEBI_51231', 'DAPI', 220, 'B6'), ('CHEBI_30863', '5-azaorotic acid', 224, 'folate'), ('CHEBI_33279', 'vitamin D5', 232, 'vitamin B12'), ('CHEBI_27300', 'vitamin D', 245, 'vitamin C'), ('CHEBI_27300', 'vitamin D', 256, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 270, 'vitamin E'), ('CHEBI_35885', 'secondary phosphine', 307, 'phosphorus')]
PMC4785305	3/2016	S62-PMC4785305	['the study Medications will be stored at the aub-mc pharmacy, and placebo and/or Vitamin D pills will be dispensed in boxes.']	N/A	N/A	[('CHEBI_25441', 'mycothiols', 10, 'medications'), ('CHEBI_27300', 'vitamin D', 80, 'vitamin D')]
PMC4785305	3/2016	S70-PMC4785305	['each tablet can be either a placebo or a 10\u2005000\u2005iu Vitamin D (Cholecalciferol), provided by europharm.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 51, 'vitamin D'), ('CHEBI_52550', 'theopalauamide', 62, 'cholecalciferol')]
PMC4785305	3/2016	S82-PMC4785305	['aub-mc clinical chemistry laboratory partakes in the quality assurance, evaluation and accreditation by the college of american pathologists43and is a participant in the Vitamin D external quality assurance surveillance (deqas) programme.44\n\ncaption (table-wrap): table\xa01\n\ntrial events and outcomes measurestrial event and outcomes measures11–13\u2005weeks (screening visit)15–18\u2005weeks (visit 1)20\u2005weeks24–28\u2005weeks28–32\u2005weeks (visit 2)37–42\u2005weeks delivery (visit 3)1\u2005month post Partum (visit 4)maternal height✓maternal weight, Blood pressure✓✓✓maternal health and diet assessment✓✓✓maternal 25(Oh)D, crea, ca×××maternal Cell count, ph, mg, alb, Tsh, 1,25(Oh)2D×pth××maternal Glucose (1\u2005h)✓maternal 24\u2005h (or spot) Urine collection for calcium and creatinine××maternal Vitamin D Binding Protein××maternal Genetic pathways of Vitamin D Metabolism×fetal us:\nCrown -Rump✓fetal us:\nFemur length\nabdominal circumference\nHead circumference\nbiparietal diameter✓newborn weight, length, Knee to Heel length apgar score✓Placental weight×Placental studies×newborn 25(Oh)D, ca, pth (Cord Blood)×newborn Genetic pathways of Vitamin D Metabolism×infant bone/fat mass×infant weight and length✓infant health and diet assessment✓\n✓test performed for clinical purpose.']	N/A	N/A	[('CHEBI_28384', 'vitamin K', 170, 'Vitamin D'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 170, 'Vitamin D'), ('GO_0007567', 'parturition', 473, 'partum'), ('UBERON_0000178', 'blood', 522, 'blood'), ('CHEBI_71657', 'versiconol acetate', 586, '25(OH)D'), ('CL_0000573', 'retinal cone cell', 615, 'cell'), ('CHEBI_17855', 'triglyceride', 640, 'TSH'), ('CHEBI_17996', 'chloride', 646, ','), ('CHEBI_66212', "5,7,3',4'-tetrahydroxy-2'-(3,3-dimethylallyl)isoflavone", 647, '25(OH)2D'), ('CHEBI_17234', 'glucose', 670, 'glucose'), ('UBERON_0001088', 'urine', 708, 'urine'), ('CHEBI_27300', 'vitamin D', 762, 'vitamin D'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 762, 'vitamin D binding protein'), ('SO_0000704', 'gene', 798, 'genetic'), ('CHEBI_27300', 'vitamin D', 818, 'vitamin D'), ('GO_0042359', 'vitamin D metabolic process', 818, 'vitamin D metabolism'), ('UBERON_0002943', 'lingual gyrus', 849, 'crown -rump✓'), ('UBERON_0000981', 'femur', 871, 'Femur'), ('UBERON_0000033', 'head', 908, 'Head'), ('UBERON_0001465', 'knee', 971, 'knee'), ('UBERON_0015875', 'heel', 979, 'heel'), ('UBERON_0001987', 'placenta', 1003, 'Placental'), ('UBERON_0001987', 'placenta', 1020, 'Placental'), ('CHEBI_71657', 'versiconol acetate', 1046, '25(OH)D'), ('UBERON_0009472', 'axilla', 1064, 'cord blood'), ('SO_0000704', 'gene', 1084, 'genetic'), ('CHEBI_27300', 'vitamin D', 1104, 'vitamin D'), ('GO_0042359', 'vitamin D metabolic process', 1104, 'vitamin D metabolism')]
PMC4785305	3/2016	S97-PMC4785305	['allergy to any component of Vitamin D formulation.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 28, 'vitamin D')]
PMC4785305	3/2016	S98-PMC4785305	['c. first visit\nduring the first visit at 15–18\u2005weeks ga, a questionnaire will be administered to collect maternal information on parity, demographics, smoking and alcohol history, exercise, previous medical problems, medications, dietary calcium and Vitamin D intake, in addition to relevant paternal information.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 250, 'vitamin D')]
PMC4785305	3/2016	S99-PMC4785305	['Pregnant women will be randomised early in their second Trimester to one of two Vitamin D doses as discussed above.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 0, 'Pregnant'), ('GO_0009294', 'DNA mediated transformation', 56, 'trimester'), ('CHEBI_27300', 'vitamin D', 80, 'vitamin D')]
PMC4785305	3/2016	S109-PMC4785305	['in addition, Blood tests at Delivery include Genetic studies such as Vitamin D Genes polymorphism and rna Expression of Vitamin D polymorphisms.']	N/A	N/A	[('UBERON_0000178', 'blood', 13, 'blood'), ('GO_0007567', 'parturition', 28, 'delivery'), ('SO_0000704', 'gene', 45, 'genetic'), ('CHEBI_27300', 'vitamin D', 69, 'vitamin D'), ('SO_0000704', 'gene', 79, 'genes'), ('GO_0010467', 'gene expression', 106, 'expression'), ('CHEBI_27300', 'vitamin D', 120, 'vitamin D')]
PMC4785305	3/2016	S118-PMC4785305	['the low-dose group will receive 10\u2005000\u2005iu Vitamin D weekly, equivalent to 700\u2005iu daily.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 42, 'vitamin D')]
PMC4785305	3/2016	S119-PMC4785305	['the high-dose group will receive 20\u2005000\u2005iu Vitamin D weekly, equivalent to 2850\u2005iu daily.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 43, 'vitamin D')]
PMC4785305	3/2016	S121-PMC4785305	['this computation takes into consideration that all groups will be taking additional 200\u2005iu Vitamin D daily from their Prenatal Vitamin Pills, thus increasing the final Vitamin D intake approximately to 900\u2005iu/day in the low-dose group and 3050\u2005iu/day in the high-dose group.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 91, 'vitamin D'), ('GO_0007565', 'female pregnancy', 118, 'prenatal'), ('CHEBI_33229', 'vitamin (role)', 127, 'vitamin'), ('CHEBI_35710', 'pinane', 135, 'pills'), ('CHEBI_27300', 'vitamin D', 168, 'vitamin D')]
PMC4811441	3/2016	S42-PMC4811441	['during these periods, chosen to capture the seasonality of Vitamin D status, all Pregnant women registering at the Antenatal Care within the study areas were eligible for inclusion.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 59, 'vitamin D'), ('GO_0007565', 'female pregnancy', 81, 'pregnant'), ('GO_0007608', 'sensory perception of smell', 115, 'antenatal care')]
PMC4811441	3/2016	S88-PMC4811441	['in model 2, Vitamin D status was fixed and only baseline 25(Oh)D was included.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 12, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 57, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 63, 'D')]
PMC4829940	5/2016	S0-PMC4829940	['25-Hydroxyvitamin D in Pregnancy and Genome wide Cord Blood Dna Methylation in two Pregnancy cohorts (moba and alspac)\n\nabstract:author-highlightshighlights\n\nPregnancy Vitamin D and Cord Blood Dna Methylation compared in 1416 infants.']	N/A	N/A	[('CHEBI_27844', "2',3'-cyclic AMP", 0, '25-Hydroxyvitamin D'), ('GO_0007565', 'female pregnancy', 23, 'pregnancy'), ('SO_0001026', 'genome', 37, 'genome'), ('UBERON_0002240', 'spinal cord', 49, 'cord'), ('UBERON_0000178', 'blood', 54, 'blood'), ('GO_0006306', 'DNA methylation', 60, 'DNA methylation'), ('GO_0007565', 'female pregnancy', 83, 'pregnancy'), ('GO_0007565', 'female pregnancy', 158, 'Pregnancy'), ('CHEBI_27300', 'vitamin D', 168, 'vitamin D'), ('UBERON_0002240', 'spinal cord', 182, 'cord'), ('UBERON_0000178', 'blood', 187, 'blood'), ('GO_0006306', 'DNA methylation', 193, 'DNA methylation')]
PMC4829940	5/2016	S11-PMC4829940	['a number of different Tissues Express the Vitamin D Receptor ( Vdr ), which acts as a transcriptional factor after binding of 1,25(Oh)2D and Heterodimerisation with Retinoic x Receptor ( rxr ).']	N/A	N/A	[('UBERON_0000479', 'tissue', 22, 'tissues'), ('GO_0010467', 'gene expression', 30, 'express'), ('CHEBI_27300', 'vitamin D', 42, 'vitamin D'), ('PR_000001683', 'vasopressin V2 receptor', 42, 'vitamin D receptor'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 63, 'VDR'), ('CHEBI_82784', 'PVP38-Ag NP', 126, '1,25(OH)2D'), ('GO_0031058', 'positive regulation of histone modification', 141, 'heterodimerisation'), ('CHEBI_26537', 'retinoid', 165, 'retinoic'), ('PR_000014377', 'ryanodine receptor 1', 165, 'retinoic'), ('PR_000014368', 'RuvB-like 1', 176, 'receptor')]
PMC4843009	4/2016	S28-PMC4843009	['the Vitamin D receptor (vdr) and Vitamin D Metabolizing enzymes are Expressed widely in Cerebral structures including Prefrontal Cortex, hippocampus, Cingulate Gyrus, Thalamus, Hypothalamus, and Substantia Nigra46.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 4, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 33, 'vitamin D'), ('GO_0043181', 'vacuolar sequestering', 33, 'vitamin D metabolizing'), ('GO_0010467', 'gene expression', 68, 'expressed'), ('UBERON_0001893', 'telencephalon', 88, 'cerebral'), ('UBERON_0000451', 'prefrontal cortex', 118, 'prefrontal cortex'), ('UBERON_0002967', 'cingulate gyrus', 150, 'cingulate gyrus'), ('UBERON_0001897', 'dorsal plus ventral thalamus', 167, 'thalamus'), ('UBERON_0001898', 'hypothalamus', 177, 'hypothalamus'), ('UBERON_0006114', 'lateral occipital cortex', 195, 'substantia nigra46')]
PMC4843009	4/2016	S53-PMC4843009	['Nh4Cl treatment and the Vitamin D deficient diet normalized the Plasma Pai-1 levels (fig.']	N/A	N/A	[('CHEBI_63016', 'nonyl phenoxypolyethoxylethanol', 0, 'NH4Cl'), ('CHEBI_27300', 'vitamin D', 24, 'vitamin D'), ('UBERON_0001969', 'blood plasma', 64, 'plasma'), ('PR_000012319', 'paired box protein Pax-7', 71, 'Pai-1')]
PMC4843009	4/2016	S57-PMC4843009	['3b)\nbehavioral studies were performed with untreated control wild-type Mice (control), Nh4Cl treated wt Mice and Nh4Cl treated kl/kl Mice (Nh4Cl) under regular diet as well as wt Mice and kl/kl Mice under a Vitamin D deficient diet (lvd).']	N/A	N/A	[('NCBITaxon_10088', 'Mus <genus>', 71, 'mice'), ('CHEBI_63016', 'nonyl phenoxypolyethoxylethanol', 87, 'NH4Cl'), ('NCBITaxon_10088', 'Mus <genus>', 104, 'mice'), ('CHEBI_63016', 'nonyl phenoxypolyethoxylethanol', 113, 'NH4Cl'), ('NCBITaxon_10088', 'Mus <genus>', 133, 'mice'), ('CHEBI_63016', 'nonyl phenoxypolyethoxylethanol', 139, 'NH4Cl'), ('NCBITaxon_10088', 'Mus <genus>', 179, 'mice'), ('NCBITaxon_10088', 'Mus <genus>', 194, 'mice'), ('CHEBI_27300', 'vitamin D', 207, 'vitamin D')]
PMC4843009	4/2016	S148-PMC4843009	['the Mice had access to either tap Water or a Solution of Nh4Cl in tap Water (280\u2009mm) ad libitum and were Fed either a standard Chow diet (altromin c1000) or a Vitamin D deficient diet (altromin c1017).']	N/A	N/A	[('NCBITaxon_10088', 'Mus <genus>', 4, 'mice'), ('CHEBI_15377', 'water', 34, 'water'), ('CHEBI_75958', 'solution', 45, 'solution'), ('CHEBI_63016', 'nonyl phenoxypolyethoxylethanol', 57, 'NH4Cl'), ('CHEBI_15377', 'water', 70, 'water'), ('GO_0007631', 'feeding behavior', 105, 'fed'), ('CHEBI_33290', 'food', 127, 'chow'), ('CHEBI_27300', 'vitamin D', 159, 'vitamin D')]
PMC4846845	4/2016	S160-PMC4846845	['circulating Vitamin D is converted to 1,25-Dihydroxyvitamin D (25-Ohd), and can be further converted into its hormonal form, 1,25(Oh)2D.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 12, 'vitamin D'), ('CHEBI_67472', '15-epi-lupulin B', 38, '1,25-dihydroxyvitamin D'), ('CHEBI_72765', 'verruculogen', 63, '25-OHD'), ('CHEBI_72698', '(2R)-trihomocitric acid', 129, '(OH)2D')]
PMC4856298	5/2016	S234-PMC4856298	['/ none of the study participants that were given the advice to contact an official facility, followed up on this advice.jivitaa2012 study design: cross-sectional / purpose of study: post-analysis of utilization for a pilot study nested within a rct / research methods: data collection / location: bangladesh / health care setting: rural (19 unions of gaidbandha and rangpur districts) / target population: Pregnant women and newborns / size: 500 and >16,000 Births emergency medical response system : labor notification system to ensure the presence of nurses at Birth to collect Placentas and Cord Blood / communication and support : mobile birth notification allowing newborns to be reached for the provision of a Vitamin A dose direct two-way communication337/611 of the total number of "near miss" events used a mobile phone.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 406, 'Pregnant'), ('GO_0007567', 'parturition', 458, 'births'), ('GO_0007567', 'parturition', 563, 'birth'), ('UBERON_0001987', 'placenta', 580, 'placentas'), ('UBERON_0009472', 'axilla', 594, 'cord blood'), ('CHEBI_27300', 'vitamin D', 716, 'vitamin A')]
PMC4859539	5/2016	S2-PMC4859539	['Blood samples were obtained during yearly visits from 133 children, ages 2–7, whose mothers had participated in a Pregnancy Vitamin D supplementation rct.']	N/A	N/A	[('UBERON_0000178', 'blood', 0, 'Blood'), ('GO_0007565', 'female pregnancy', 114, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 124, 'vitamin D')]
PMC4859539	5/2016	S17-PMC4859539	['offspring of mothers enrolled in an nichd Pregnancy Vitamin D supplementation trial (results of which were previously published [21,22]) were seen in follow-up from ages 2–7 years during a three-year study period.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 42, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 52, 'vitamin D')]
PMC4859539	5/2016	S20-PMC4859539	['materials and methods\n\nsubjects\nthe offspring of mothers who had participated in an nichd, irb-approved Vitamin D supplementation study during Pregnancy (hr#10727; ctrc protocol #670; n = 350) were invited back for yearly follow-up beginning at 2 years of age.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 104, 'vitamin D'), ('GO_0007565', 'female pregnancy', 143, 'pregnancy')]
PMC4859539	5/2016	S48-PMC4859539	['using the institute of medicine’s definition of sufficiency (total circulating 25(Oh)D ≥20 ng/ml (50 nmol/l) [25], the cohort also was divided into two groups based on child’s current Vitamin D status, with those with 25(Oh)D concentrations <20 ng/ml (50.0 nmol/l) defined as deficient.']	N/A	N/A	[('CHEBI_71657', 'versiconol acetate', 79, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 79, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 184, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 218, '25(OH)D')]
PMC4859539	5/2016	S52-PMC4859539	['results\n\ncohort\nwhile 194 children had participated in the follow-up study (55% of the original cohort participating in the Vitamin D Pregnancy study), 133 (38%) had a Blood sample obtained at the time of the study visit and thus, were able to have Cathelicidin measured.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 124, 'vitamin D'), ('GO_0007565', 'female pregnancy', 134, 'pregnancy'), ('UBERON_0000178', 'blood', 168, 'blood'), ('CHEBI_3364', 'Canthiumine', 249, 'cathelicidin')]
PMC4859539	5/2016	S57-PMC4859539	["of infections in the last year [median (range)]1.0 (0.0–5.0)child’s daily Vitamin D intake at time of visit (iu/day)1205.3 ± 109.8 (17.1–512.5)child's 25(Oh)D at time of visit (ng/ml)127.2 ± 9.4 (8.3–61.5)child's Vitamin D status at time of visit\xa0\xa0\xa0\xa0\xa0sufficient (≥20 ng/ml) [n (%)]106 (79.7)\xa0\xa0\xa0\xa0deficient (<20 ng/ml) [n (%)]27 (20.3)total circulating 25(Oh)D (ng/ml) at Birth122.8 ± 9.8 (3.6–47.8)maternal 25(Oh)D (ng/ml) within 1 month prior to Delivery139.2 ± 15.0 (10.0–78.6)maternal 25(Oh)D area under curve, Pregnancy visits 3–71153.1 ± 44.6 (50.1–251.4)\n1mean±std (range)\n\nstudy outcomes\nthe median Cathelicidin concentration for the entire cohort was 28.1 ng/ml, ranging from 5.6 to 3368.6 ng/ml."]	N/A	N/A	[('CHEBI_27300', 'vitamin D', 74, 'vitamin D'), ('CHEBI_72805', '2-alkyl-sn-glycero-3-phosphocholine', 154, 'OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 157, 'D'), ('CHEBI_27300', 'vitamin D', 213, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 351, '25(OH)D'), ('PR_000009880', 'Lon protease, mitochondrial', 351, '25 ... OH ... D'), ('GO_0042750', 'hibernation', 370, 'birth122'), ('CHEBI_71657', 'versiconol acetate', 406, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 406, '25(OH)D'), ('GO_0030324', 'lung development', 446, 'delivery139'), ('CHEBI_71657', 'versiconol acetate', 487, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 487, '25(OH)D'), ('GO_0007565', 'female pregnancy', 513, 'pregnancy'), ('CHEBI_3364', 'Canthiumine', 605, 'cathelicidin')]
PMC4859539	5/2016	S80-PMC4859539	['when dividing the cohort by Vitamin D sufficiency status for additional analyses, Vitamin D deficiency was defined as <20 ng/ml (<50 nmol/l)).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 28, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 82, 'vitamin D')]
PMC4859539	5/2016	S81-PMC4859539	['in Vitamin D deficient children, there were no statistically significant differences between Cathelicidin concentration among the races/ethnicities or by gender.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 3, 'vitamin D'), ('CHEBI_3364', 'Canthiumine', 93, 'cathelicidin'), ('PR_000006009', 'alpha-catulin', 93, 'cathelicidin')]
PMC4859539	5/2016	S121-PMC4859539	['of the original cohort of mothers participating in this Vitamin D supplementation trial, 55% of the children were available for follow-up, and of those, 68% of those who came for follow-up (38% of the original cohort) were able to have a Blood sample obtained at the time of the visit.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 56, 'vitamin D'), ('UBERON_0000178', 'blood', 238, 'blood')]
PMC4861121	5/2016	S9-PMC4861121	['adherence to all seven Food pyramid guidelines was less than 1% overall, and less than 1% of participants met all four Micronutrient guidelines on Vitamin D, Folate, calcium and iron Intake around the time of Pregnancy.']	N/A	N/A	[('CHEBI_33290', 'food', 23, 'food'), ('CHEBI_33962', 'mu4-sulfido-quadro-tetracopper(6+)', 119, 'micronutrient'), ('CHEBI_27300', 'vitamin D', 147, 'vitamin D'), ('CHEBI_30863', '5-azaorotic acid', 158, 'folate'), ('GO_0007631', 'feeding behavior', 183, 'intake'), ('GO_0007565', 'female pregnancy', 209, 'pregnancy')]
PMC4861121	5/2016	S34-PMC4861121	['this included Folic Acid intake of 400\u2005µg or more per day, Vitamin D intake of 10\u2005µg or more per day, Calcium of 1000\u2005mg or more per day and iron Intake of 14\u2005mg or more per day.']	N/A	N/A	[('CHEBI_30751', 'formic acid', 14, 'folic acid'), ('CHEBI_27300', 'vitamin D', 59, 'vitamin D'), ('CHEBI_22313', 'alkaline earth metal atom', 102, 'calcium'), ('GO_0007631', 'feeding behavior', 146, 'intake')]
PMC4864049	1/2016	S347-PMC4864049	['the levels of Vitamin D are low in populations living in overcast areas that have low sun exposure.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 14, 'vitamin D')]
PMC4889866	5/2016	S8-PMC4889866	['there was no relationship between maternal and Cord Blood Vitamin D status with infectious diseases during infancy.']	N/A	N/A	[('UBERON_0002240', 'spinal cord', 47, 'cord'), ('UBERON_0000178', 'blood', 52, 'blood'), ('CHEBI_27300', 'vitamin D', 58, 'vitamin D')]
PMC4889866	5/2016	S57-PMC4889866	['association between Serum Vitamin D level and binary outcomes (bronchiolitis, pneumonia, croup, infectious enteritis, and Urinary Tract infection) was analyzed by using logistic regression.']	N/A	N/A	[('UBERON_0001977', 'blood serum', 20, 'serum'), ('CHEBI_27300', 'vitamin D', 26, 'vitamin D'), ('UBERON_0001553', 'medial tarsal artery', 122, 'urinary tract')]
PMC4889866	5/2016	S86-PMC4889866	['Cord Blood Vitamin D level was also not correlated with any of the infectious disorders by 12 months of age.']	N/A	N/A	[('UBERON_0000948', 'heart', 0, 'Cord'), ('UBERON_0000178', 'blood', 5, 'blood'), ('CHEBI_27300', 'vitamin D', 11, 'vitamin D')]
PMC4891833	6/2016	S163-PMC4891833	['in Serum samples collected at endline, ferritin and Transferrin Receptor as markers of iron status, Retinol Binding Protein as a marker of Vitamin A status, and c-Reactive Protein (Crp) and Alpha-1 Acid Glycoprotein (agp) as markers of inflammation will be measured.']	N/A	N/A	[('UBERON_0001977', 'blood serum', 3, 'serum'), ('PR_000001679', 'trace amine-associated receptor 5', 52, 'transferrin receptor'), ('CHEBI_26536', 'retinoic acid', 100, 'retinol'), ('PR_000014009', 'regulating synaptic membrane exocytosis protein 1', 100, 'retinol binding protein'), ('CHEBI_27300', 'vitamin D', 139, 'vitamin A'), ('PR_000014009', 'regulating synaptic membrane exocytosis protein 1', 163, 'reactive protein'), ('PR_000005890', 'crooked neck-like protein 1', 181, 'CRP'), ('PR_000001183', 'alpha-1A adrenergic receptor', 190, 'alpha-1 acid glycoprotein'), ('CHEBI_15369', 'actinomycin', 198, 'acid glycoprotein')]
PMC4896250	4/2016	S1249-PMC4896250	['concluson: foki vdr polymorphism determine Vitamin D status in children with Food allergy.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 43, 'vitamin D'), ('CHEBI_33290', 'food', 77, 'food')]
PMC4896250	4/2016	S2796-PMC4896250	['and Vitamin D supplement in recent 3 months.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 4, 'vitamin D')]
PMC4896250	4/2016	S3007-PMC4896250	['we used Serum Vitamin D levels from the korea national health and nutrition examination surveys during the period corresponding to fia.']	N/A	N/A	[('UBERON_0001977', 'blood serum', 8, 'serum'), ('CHEBI_27300', 'vitamin D', 14, 'vitamin D')]
PMC4896250	4/2016	S3010-PMC4896250	['results: the number of cases of fia was 2,851, and Serum Vitamin D levels were obtained in 15,368 Persons from 2011 to 2013.']	N/A	N/A	[('UBERON_0001977', 'blood serum', 51, 'serum'), ('CHEBI_27300', 'vitamin D', 57, 'vitamin D'), ('NCBITaxon_10088', 'Mus <genus>', 98, 'persons')]
PMC4896250	4/2016	S3012-PMC4896250	['for all age groups of <20, 20-59, and ≥60 years, serum Vitamin D levels were significantly higher in region 2 than in region 1.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 55, 'vitamin D')]
PMC4896250	4/2016	S3014-PMC4896250	['Serum Vitamin D level in region 1 was higher than that in region 2 for both males and females.']	N/A	N/A	[('UBERON_0001977', 'blood serum', 0, 'Serum'), ('CHEBI_27300', 'vitamin D', 6, 'vitamin D')]
PMC4896250	4/2016	S3554-PMC4896250	['data on sunlight exposure and maternal Vitamin D supplementation was also collected .']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 39, 'vitamin D')]
PMC4896250	4/2016	S3555-PMC4896250	['results\nprevalence of Vitamin D deficiency when using 20 ng/ml cut-off, was 24 % (95% ci 14.9%-32.0%).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 22, 'vitamin D')]
PMC4896250	4/2016	S3556-PMC4896250	['a further 32% of the infants had insufficient levels of Vitamin D and 45% of the infants were replete.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 56, 'vitamin D')]
PMC4896250	4/2016	S3557-PMC4896250	['there were no cases of secondary hyperparathyroidism with Vitamin D level above 40ng/ml and one case had an elevated pth with Vitamin D level above 30ng/ml.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 58, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 126, 'vitamin D')]
PMC4896250	4/2016	S3559-PMC4896250	['only four mothers received Vitamin D supplementation during breastfeeding and all their infants were Vitamin D replete.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 27, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 101, 'vitamin D')]
PMC4896250	4/2016	S4155-PMC4896250	['results: there were no differences in Vitamin D levels between the mild or moderate ad and severe ad groups.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 38, 'vitamin D')]
PMC4896250	4/2016	S4487-PMC4896250	['Serum 25-Hydroxy Vitamin D3 (25-Oh Vitamin D) levels were measured and compared between the two groups.']	N/A	N/A	[('UBERON_0001977', 'blood serum', 0, 'Serum'), ('CHEBI_43141', '3-hydroxypropoxy group', 6, '25-hydroxy'), ('CHEBI_33279', 'vitamin D5', 17, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 17, 'vitamin D3'), ('CHEBI_86198', '1,2-di-[(11Z)-eicosenoyl]-sn-glycero-3-phosphocholine', 29, '25-OH'), ('CHEBI_27300', 'vitamin D', 35, 'vitamin D')]
PMC4896250	4/2016	S4489-PMC4896250	['results: Serum 25-Oh Vitamin D levels in asthmatic patients (16.63 ± 4.20 ng/ml) were significantly (p<0.05) lower than that in healthy controls (24.24 ± 6.76 ng/ml).']	N/A	N/A	[('UBERON_0001977', 'blood serum', 9, 'Serum'), ('CHEBI_86198', '1,2-di-[(11Z)-eicosenoyl]-sn-glycero-3-phosphocholine', 15, '25-OH'), ('CHEBI_27300', 'vitamin D', 21, 'vitamin D')]
PMC4896250	4/2016	S5547-PMC4896250	['results: in all age groups, Vitamin A and Vitamin D values of females were significantly lower than those of males (p<0.05).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 28, 'vitamin A'), ('CHEBI_27300', 'vitamin D', 42, 'vitamin D')]
PMC4896250	4/2016	S5549-PMC4896250	['due to Vitamin A, Vitamin D, Vitamin E, Vitamin B12 and Folic Acid, no statistically significant difference was detected among astmatic levels of patients enrolled in the study (p>0.05).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 7, 'vitamin A'), ('CHEBI_27300', 'vitamin D', 18, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 29, 'vitamin E'), ('CHEBI_33279', 'vitamin D5', 40, 'vitamin B12'), ('CHEBI_30751', 'formic acid', 56, 'folic acid')]
PMC4896250	4/2016	S6529-PMC4896250	['methods: we performed a randomized, placebo controlled trial in Adult subjects meeting the research criteria for crs, with low Serum Vitamin D levels (<40 ng/ml), and having no contraindications to Vitamin D therapy.']	N/A	N/A	[('UBERON_0007023', 'adult organism', 64, 'adult'), ('UBERON_0001977', 'blood serum', 127, 'serum'), ('CHEBI_27300', 'vitamin D', 133, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 198, 'vitamin D')]
PMC4896250	4/2016	S6530-PMC4896250	['subjects were randomized to receive Vitamin D (n=12) or placebo (n=12) for 12 weeks in addition to their standard regimen.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 36, 'vitamin D')]
PMC4896250	4/2016	S6533-PMC4896250	['results: the levels of Vitamin D in the Serum were elevated in the Vitamin D group and unchanged in the placebo group.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 23, 'vitamin D'), ('UBERON_0001977', 'blood serum', 40, 'serum'), ('CHEBI_27300', 'vitamin D', 67, 'vitamin D')]
PMC4896250	4/2016	S7534-PMC4896250	['in addition, there was no significant association between Vitamin D level and the presence of pediatrician-confirmed ad on the day of survey ( p value = 0.195).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 58, 'vitamin D')]
PMC4896250	4/2016	S8296-PMC4896250	['subsequently, patients with Vitamin D deficiency received 2000 i.u.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 28, 'vitamin D')]
PMC4896250	4/2016	S8299-PMC4896250	['results\nseventeen patients (27%) were found to have Vitamin D levels lower than 30 ng/ml, considered to be insufficient.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 52, 'vitamin D')]
PMC4896250	4/2016	S8301-PMC4896250	['patients with Vitamin D insufficiency had an average number of medical visits for Respiratory infections the previous year of 3.94, while after Vitamin D supplementation the average was 2.17.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 14, 'vitamin D'), ('UBERON_0001004', 'respiratory system', 82, 'respiratory'), ('CHEBI_27300', 'vitamin D', 144, 'vitamin D')]
PMC4896250	4/2016	S8592-PMC4896250	['tests (cbc with differential, Ige, Serum zinc, Vitamin D, Food Allergens tests of spt or specific Ige), scorad and weight and height were collected.']	N/A	N/A	[('GO_0071743', 'IgE immunoglobulin complex, circulating', 30, 'IgE'), ('UBERON_0001977', 'blood serum', 35, 'serum'), ('CHEBI_27300', 'vitamin D', 47, 'vitamin D'), ('CHEBI_33290', 'food', 58, 'food'), ('CHEBI_33663', 'cyclic hydrocarbon', 63, 'allergens'), ('GO_0071743', 'IgE immunoglobulin complex, circulating', 98, 'IgE')]
PMC4897157	5/2016	S101-PMC4897157	['Vitamin D passes to the fetus through the Placenta; 25-Hydroxy-Vitamin D concentrations in Umbilical Cord Blood at the time of Delivery range from 68% to 108% of maternal levels15).']	N/A	N/A	[('CHEBI_28384', 'vitamin K', 0, 'Vitamin D'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 0, 'Vitamin D'), ('UBERON_0001987', 'placenta', 42, 'placenta'), ('CHEBI_70487', '(-)-sanguinolignan C', 52, '25-hydroxy-'), ('CHEBI_27300', 'vitamin D', 63, 'vitamin D'), ('UBERON_0002331', 'umbilical cord', 91, 'umbilical cord'), ('UBERON_0000178', 'blood', 106, 'blood'), ('GO_0007567', 'parturition', 127, 'delivery')]
PMC4903143	5/2016	S112-PMC4903143	['reduced Gastrointestinal absorption of magnesium occurs in the face of Vitamin D deficiency.']	N/A	N/A	[('UBERON_0005409', 'alimentary part of gastrointestinal system', 8, 'gastrointestinal'), ('CHEBI_27300', 'vitamin D', 71, 'vitamin D')]
PMC4908484	6/2016	S4-PMC4908484	['pretreatment with Calcitriol (the active form of Vitamin D) reduced cellular injury induced by exposure to catalytic iron.']	N/A	N/A	[('CHEBI_17823', 'calcitriol', 18, 'calcitriol'), ('CHEBI_27300', 'vitamin D', 49, 'vitamin D')]
PMC4908484	6/2016	S17-PMC4908484	['Gestational Vitamin D deficiency induces long‐lasting alterations in the Brain structure, including changes in volume, Cell Proliferation and reduced Expression of Nerve growth factors, glia‐Derived Neurotrophic Factor, and Neurotrophins 3 and 4 (eyles et\xa0al.2003; tetich et\xa0al.2004; cui et\xa0al.2007).']	N/A	N/A	[('GO_0007565', 'female pregnancy', 0, 'Gestational'), ('CHEBI_27300', 'vitamin D', 12, 'vitamin D'), ('UBERON_0000955', 'brain', 73, 'brain'), ('GO_0008283', 'cell proliferation', 119, 'cell proliferation'), ('GO_0010467', 'gene expression', 150, 'expression'), ('UBERON_0001021', 'nerve', 164, 'nerve'), ('PR_000006860', 'transcription factor E4F1', 191, 'derived neurotrophic factor'), ('PR_000011459', 'neurotrophin-3', 224, 'neurotrophins 3'), ('PR_000017527', 'YEATS domain-containing protein 4', 244, '4')]
PMC4908484	6/2016	S90-PMC4908484	['(a) dose–response study of Vitamin D (0.01–100\xa0nmol/l) on viability ofbe(2)m17 cells.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 27, 'vitamin D')]
PMC4910255	6/2016	S19-PMC4910255	['for example, 38\xa0% of Pregnant women have iron deficiency leading to anaemia [5] and 15\xa0% have Vitamin A deficiency causing night blindness and increasing the risk of infection [6,7].']	N/A	N/A	[('GO_0007565', 'female pregnancy', 21, 'pregnant'), ('CHEBI_27300', 'vitamin D', 94, 'vitamin A')]
PMC4910255	6/2016	S93-PMC4910255	['[25]individual873 children Born in the trial were subsequently randomised to receive Postnatal multiple Micronutrients or Iron and Vitamin A supplements69\xa0days until Birthiron 60\xa0mg; no supplements on sundaysvit a, Thiamine, riboflavin, niacin, vit b6, Folic Acid, vit b12, vit c, vit d3, vit e, iron, magnesium, zinc; no supplements taken on sundays24.1birthweight in mmn, 2981\xa0g; birthweight in control, 2977\xa0gsga in mmn, 10.1\xa0%; sga in control, 11.8\xa0% Gestation in mmn, 39.5\xa0weeks; Gestation in control, 39.6\xa0weeksnepal janakpurosrin et al.']	N/A	N/A	[('GO_0007567', 'parturition', 27, 'born'), ('GO_0007567', 'parturition', 85, 'postnatal'), ('CHEBI_33839', 'macromolecule', 104, 'micronutrients'), ('CHEBI_24870', 'ion', 122, 'iron'), ('CHEBI_27300', 'vitamin D', 131, 'vitamin A'), ('GO_0007567', 'parturition', 166, 'birthIron'), ('CHEBI_26948', 'vitamin B1', 215, 'thiamine'), ('CHEBI_30751', 'formic acid', 253, 'folic acid'), ('GO_0006266', 'DNA ligation', 455, 'Gestation'), ('GO_0007565', 'female pregnancy', 485, 'gestation')]
PMC4910255	6/2016	S98-PMC4910255	['it contained Vitamin A 800\xa0μg, Thiamine 1.4\xa0mg, riboflavin 1.4\xa0mg, niacin 18\xa0mg, Vitamin B6 1.9\xa0mg, Folic Acid 400\xa0μg, Vitamin B12 2.6\xa0μg, Vitamin C 70\xa0mg, Vitamin D 5\xa0μg, Vitamin E 10\xa0mg, copper 2\xa0mg, Iodine 150\xa0μg, iron 30\xa0mg, Selenium 65\xa0μg, and zinc 15\xa0mg [33].']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 13, 'vitamin A'), ('CHEBI_26948', 'vitamin B1', 31, 'thiamine'), ('CHEBI_33237', 'vitamin D4', 81, 'vitamin B6'), ('CHEBI_30751', 'formic acid', 100, 'folic acid'), ('CHEBI_33279', 'vitamin D5', 119, 'vitamin B12'), ('PR_000004738', 'class E basic helix-loop-helix protein 22', 127, 'B12'), ('CHEBI_27300', 'vitamin D', 139, 'vitamin C'), ('PR_000004900', 'complement C3', 147, 'C'), ('CHEBI_27300', 'vitamin D', 156, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 172, 'vitamin E'), ('CHEBI_24859', 'iodine atom', 202, 'iodine'), ('CHEBI_27568', 'selenium atom', 229, 'selenium')]
PMC4910255	6/2016	S100-PMC4910255	['the supplement used in nepal sarlahi contained Micronutrients in similar doses (with 60\xa0mg iron), plus magnesium and Vitamin K, but no Selenium or Iodine [34].']	N/A	N/A	[('CHEBI_33839', 'macromolecule', 47, 'micronutrients'), ('CHEBI_27300', 'vitamin D', 117, 'vitamin K'), ('CHEBI_27568', 'selenium atom', 135, 'selenium'), ('CHEBI_24859', 'iodine atom', 147, 'iodine')]
PMC4910255	6/2016	S191-PMC4910255	['mean Cognitive scores were a little lower for the mmn group compared to iron, Folic Acid and Vitamin A (universal nonverbal Intelligence test score, –2.4; 95\xa0% ci, –4.6 to –0.2).']	N/A	N/A	[('GO_0050890', 'cognition', 5, 'cognitive'), ('CHEBI_30751', 'formic acid', 78, 'folic acid'), ('CHEBI_27300', 'vitamin D', 93, 'vitamin A'), ('GO_0036155', 'acylglycerol acyl-chain remodeling', 124, 'Intelligence')]
PMC4910734	6/2015	S58-PMC4910734	['the other members of the aldh superfamily participate in converting an Aldehyde intermediate to an Acid product in various Metabolic pathways, including the Biosynthesis of the Retinoic Acid form of Vitamin A, the oxidation of Long-Chain Fatty Aldehydes, and the Metabolism Of several Amino Acids as well as glutamate, Γ-Aminobutyric Acid (Gaba), and inositol.']	N/A	N/A	[('CHEBI_17478', 'aldehyde', 71, 'aldehyde'), ('CHEBI_37527', 'acid', 99, 'acid'), ('GO_0008152', 'metabolic process', 123, 'metabolic'), ('GO_0009057', 'macromolecule catabolic process', 157, 'biosynthesis'), ('CHEBI_26536', 'retinoic acid', 177, 'retinoic acid'), ('GO_0019401', 'alditol biosynthetic process', 186, 'acid'), ('CHEBI_27300', 'vitamin D', 199, 'vitamin A'), ('CHEBI_25095', 'L-lysine derivative', 227, 'long-chain fatty aldehydes'), ('GO_0019429', 'fluorene catabolic process', 263, 'metabolism of ... amino acids'), ('CHEBI_33867', 'idonates', 285, 'amino acids'), ('CHEBI_37079', '2-methylacetoacetic acid', 319, 'γ-aminobutyric acid'), ('CHEBI_16865', 'gamma-aminobutyric acid', 340, 'GABA')]
PMC4910734	6/2015	S232-PMC4910734	['other Aldehyde Micronutrients include inositol and the Retinal form of Vitamin A.']	N/A	N/A	[('CHEBI_17478', 'aldehyde', 6, 'aldehyde'), ('CHEBI_33839', 'macromolecule', 15, 'micronutrients'), ('UBERON_0000966', 'retina', 55, 'retinal'), ('CHEBI_27300', 'vitamin D', 71, 'vitamin A')]
PMC4910734	6/2015	S246-PMC4910734	['finally, the dietary reference intake for Retinol, in the form of mercury-free cod Liver oil that also includes essential Fatty Acids and Vitamin D, should be included for most.']	N/A	N/A	[('CHEBI_26536', 'retinoic acid', 42, 'retinol'), ('UBERON_0002107', 'liver', 83, 'liver'), ('CHEBI_35366', 'fatty acid', 122, 'fatty acids'), ('CHEBI_27300', 'vitamin D', 138, 'vitamin D')]
PMC4921626	6/2016	S29-PMC4921626	['information regarding total iron, bioavailable Iron, and Vitamin C content of the menu can be found elsewhere [16].']	N/A	N/A	[('CHEBI_24870', 'ion', 47, 'iron'), ('CHEBI_27300', 'vitamin D', 57, 'vitamin C')]
PMC4923982	5/2016	S26-PMC4923982	['these factors included bmi, smoking, Vitamin C (which enhances iron absorption), and calcium (which inhibits it).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 37, 'vitamin C')]
PMC4923982	5/2016	S48-PMC4923982	['Preconceptional dietary covariates included quintiles of saturated fat, polyunsaturated fat, dietary fiber, Cholesterol, Vitamin C, Glycemic index, Glycemic load, and daily servings of red/processed meat.']	N/A	N/A	[('GO_0019230', 'proprioception', 0, 'Preconceptional'), ('CHEBI_16113', 'cholesterol', 108, 'cholesterol'), ('CHEBI_27300', 'vitamin D', 121, 'vitamin C'), ('GO_0006096', 'glycolytic process', 132, 'glycemic'), ('GO_0006096', 'glycolytic process', 148, 'glycemic')]
PMC4929134	8/2016	S54-PMC4929134	['Plasma concentrations of Retinol, 25(Oh)D, cobalamin, Folic Acid, Transferrin receptor, ferritin, and thyroglobulin were measured to assess child Vitamin A, d, and b12, Folate, iron, and Iodine status.']	N/A	N/A	[('UBERON_0001969', 'blood plasma', 0, 'Plasma'), ('CHEBI_26536', 'retinoic acid', 25, 'retinol'), ('CHEBI_71657', 'versiconol acetate', 34, '25(OH)D'), ('CHEBI_30751', 'formic acid', 54, 'folic acid'), ('PR_000016293', 'protein-glutamine gamma-glutamyltransferase 2', 66, 'transferrin'), ('CHEBI_27300', 'vitamin D', 146, 'vitamin A'), ('CHEBI_30863', '5-azaorotic acid', 169, 'folate'), ('CHEBI_24859', 'iodine atom', 187, 'iodine')]
PMC4930210	7/2016	S5-PMC4930210	['25(Oh)D2, 25(Oh)D3, and 3-Epi-25(Oh)D3) were identified in all of the 537 Plasma samples;3-Epi-25(Oh)D3Contributed 5% of the total Vitamin D. the median (iqr) total 25(Oh)D (D2+d3) was 92.7 (30.4) nmol/l and 20% of women had 25(Oh)D concentration < 75 nmol/l.']	N/A	N/A	[('CHEBI_77765', '2,4,6-trihydroxybenzophenone(1-)', 0, '25(OH)D2'), ('CHEBI_62946', 'ammonium sulfate', 10, '25(OH)D3'), ('CHEBI_76959', '19-HEPE', 24, '3-epi-'), ('CHEBI_62946', 'ammonium sulfate', 30, '25(OH)D3'), ('UBERON_0001969', 'blood plasma', 74, 'plasma'), ('CHEBI_86390', '3-pyridylacetic acid', 89, '3-epi-25(OH)D3contributed'), ('CHEBI_27300', 'vitamin D', 131, 'vitamin D'), ('CHEBI_30778', 'gallic acid', 165, '25(OH)'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 171, 'D'), ('CHEBI_37987', 'Cy3 dye', 174, 'D2'), ('CHEBI_71657', 'versiconol acetate', 225, '25(OH)D')]
PMC4930210	7/2016	S6-PMC4930210	['the median (iqr) reported Vitamin D intake from diet and supplements was 600 (472) iu/day.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 26, 'vitamin D')]
PMC4930210	7/2016	S41-PMC4930210	['the major source for Vitamin D was from the supplements; this data was obtained from the questionnaire that has been previously described in detail [15].']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 21, 'vitamin D')]
PMC4930210	7/2016	S54-PMC4930210	['all extreme values of Vitamin D (>4000, which is the upper limit recommended intake) were reviewed by reviewing the actual siq.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 22, 'vitamin D'), ('PR_000006444', 'diacylglycerol kinase delta', 30, 'D')]
PMC4930210	7/2016	S57-PMC4930210	['no participants took a separate Vitamin D supplement through a prescription, although a Prenatal supplement would have been recommended by their physician.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 32, 'vitamin D'), ('GO_0007565', 'female pregnancy', 88, 'prenatal')]
PMC4930210	7/2016	S61-PMC4930210	['measurement of Vitamin D status\nmaternal Blood was collected at each clinic visit by a certified phlebotomist.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 15, 'vitamin D'), ('UBERON_0000178', 'blood', 41, 'blood')]
PMC4930210	7/2016	S67-PMC4930210	['the prevalence rates of Vitamin D deficiency and insufficiency in women were estimated as percentages with 95% confidence interval (ci).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 24, 'vitamin D')]
PMC4930210	7/2016	S69-PMC4930210	['the prevalence rates of Vitamin D insufficiency with and without the epimer were compared using mcnemar’s chi-square test.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 24, 'vitamin D')]
PMC4930210	7/2016	S72-PMC4930210	['as reported dietary and supplemental Vitamin D intakes were not normally distributed, the natural log transformation of the skewed variables was used for the test.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 37, 'vitamin D')]
PMC4930210	7/2016	S75-PMC4930210	['again, as the dependent variables (dietary and supplemental Vitamin D intakes) and independent variables (25(Oh)D3And 3-Epi-25(Oh)d3) were not normally distributed, the natural log transformation of the skewed variables was used for the test.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 60, 'vitamin D'), ('CHEBI_76945', 'manool', 106, '25(OH)D3and'), ('PR_000036846', 'class II olfactory receptor', 106, '25(OH)D3and'), ('CHEBI_76351', 'benzyl trimethylsilyl ether', 118, '3-epi-25(OH')]
PMC4930210	7/2016	S78-PMC4930210	['≥ 75 nmol/l) as a function of reported Vitamin D intake, adjusted for the same covariates (odds ratios and their corresponding 95% cis).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 39, 'vitamin D')]
PMC4930210	7/2016	S88-PMC4930210	['the median (iqr) overall reported Intake of Vitamin D (iu) from the combined (24-hour Recall + siq) was 568 (404) for the first trimester, 600 (472) for the second trimester, and 634 (516) for the third trimester (table 3).10.1371/journal.pone.0157262.t003\n\ncaption (table-wrap): table 3\ndistribution of reported dietary Vitamin D intake (iu/day) in the first, second, and third trimesters of Pregnancy in a longitudinal cohort of Pregnant women and their infants in alberta, canada.trimesternmean ± sdmin to maxmedian (25thto 75th) first trimester supplement intake398451 ± 5300 to 4250320 (200 to 400)dietary intakes113185 ± 1465 to 840165 (71 to 264)overall intakesa112704 ± 55432 to 4482568 (407 to 810) second trimester supplement intake537590 ± 6900 to 8400400 (250 to 544)dietary intakes528218 ± 1730 to 1350175 (98 to 298)overall intakesa526812 ± 72238 to 9209600 (449 to 921) third trimester supplement intake493634 ± 6800 to 5427400 (250 to 689)dietary intakes471236 ± 1930 to 1633192 (105 to 321)overall Intakesa469872 ± 69528 to 3790634 (469 to 985)\naoverall intakes: supplements + diet; the repeated measures anova showed no significant difference in log transformed mean Vitamin D intake from diet (24 hour recall) (p = 0.13), but a significant difference in log transformed mean intake from Supplement across all trimesters (p<0.001), resulting in a significant difference in total Vitamin D intake across all trimesters (p = 0.004).']	N/A	N/A	[('GO_0007631', 'feeding behavior', 34, 'intake'), ('CHEBI_27300', 'vitamin D', 44, 'vitamin D'), ('GO_0060033', 'anatomical structure regression', 86, 'recall'), ('CHEBI_28384', 'vitamin K', 321, 'Vitamin D'), ('GO_0007565', 'female pregnancy', 393, 'Pregnancy'), ('GO_0007565', 'female pregnancy', 431, 'Pregnant'), ('GO_0042332', 'gravitaxis', 1015, 'intakesa469872'), ('CHEBI_27300', 'vitamin D', 1185, 'vitamin D'), ('CHEBI_16158', 'steroid sulfate', 1306, 'supplement'), ('CHEBI_27300', 'vitamin D', 1397, 'vitamin D')]
PMC4930210	7/2016	S92-PMC4930210	['third) (p<0.001), resulting in a significant increase in total reported Vitamin D intake from trimester one to trimester three (p = 0.004).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 72, 'vitamin D')]
PMC4930210	7/2016	S93-PMC4930210	['fifty-four percent of Pregnant women reported taking 600 and higher iu/day of Vitamin D through their diet and supplements in the second Trimester of Pregnancy; maternal characteristics were not different between those who reported taking <600 iu/day Vitamin D vs .']	N/A	N/A	[('GO_0007565', 'female pregnancy', 22, 'pregnant'), ('CHEBI_27300', 'vitamin D', 78, 'vitamin D'), ('GO_0009294', 'DNA mediated transformation', 137, 'trimester'), ('GO_0007565', 'female pregnancy', 150, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 251, 'vitamin D')]
PMC4930210	7/2016	S110-PMC4930210	['the relationship between 25(Oh)D and 3-epi-25(oh)D3And Vitamin D intake are shown infig 2a and 2b.']	N/A	N/A	[('CHEBI_71657', 'versiconol acetate', 25, '25(OH)D'), ('PR_000006317', 'mRNA-decapping enzyme 1A', 49, 'D3and'), ('CHEBI_27300', 'vitamin D', 55, 'vitamin D')]
PMC4930210	7/2016	S120-PMC4930210	['women with Plasma concentration of <75 nmol/l reported Consuming less Vitamin D (diet + supplements) compared to those with Plasma concentration ≥ 75 nmol/l (median (iqr): 492 (320) iu/day vs .']	N/A	N/A	[('UBERON_0001969', 'blood plasma', 11, 'plasma'), ('GO_0007631', 'feeding behavior', 55, 'consuming'), ('CHEBI_27300', 'vitamin D', 70, 'vitamin D'), ('UBERON_0001969', 'blood plasma', 124, 'plasma')]
PMC4930210	7/2016	S130-PMC4930210	['there are few natural sources of Vitamin D in the Food supply: primarily fatty fish, beef Liver, and Egg Yolk [7].']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 33, 'vitamin D'), ('CHEBI_33290', 'food', 50, 'food'), ('UBERON_0002107', 'liver', 90, 'liver'), ('UBERON_0007378', 'egg yolk', 101, 'egg yolk')]
PMC4930210	7/2016	S131-PMC4930210	['in north america, the main dietary source of Vitamin D is through fortified dairy and dietary supplements [23,24].']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 45, 'vitamin D')]
PMC4930210	7/2016	S169-PMC4930210	['fifty percent of women who were classified as Vitamin D insufficient (<75 nmol/l) consumed the rda from both diet and supplements.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 46, 'vitamin D')]
PMC4934634	11/2015	S2-PMC4934634	['rates of Vitamin D deficiency during Pregnancy remain high worldwide.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 9, 'vitamin D'), ('GO_0007565', 'female pregnancy', 37, 'pregnancy')]
PMC4934634	11/2015	S16-PMC4934634	['Vitamin D deficiency is common among women in the united states with 35% of women between 20 and 49 years of age having Vitamin D concentrations below 50 nmol/l (the iom cut-off for Vitamin D sufficiency) [4].']	N/A	N/A	[('CHEBI_28384', 'vitamin K', 0, 'Vitamin D'), ('CHEBI_27300', 'vitamin D', 120, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 182, 'vitamin D')]
PMC4934634	11/2015	S41-PMC4934634	['once bound to Vitamin D, vdr can form a heterodimer with Retinoid-X Receptor and bind to response elements on Promoter Regions Of Dna leading to changes in the transcription of specific target Genes.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 14, 'vitamin D'), ('CHEBI_26537', 'retinoid', 57, 'retinoid'), ('PR_000001658', 'prostaglandin E2 receptor EP2 subtype', 57, 'retinoid-x receptor'), ('SO_0001187', 'pseudouridylation_guide_snoRNA', 110, 'promoter regions of DNA'), ('SO_0000704', 'gene', 193, 'genes')]
PMC4934634	11/2015	S78-PMC4934634	['other Reproductive outcomes, including Ovarian stimulation, Fertilization rates, or markers of Embryo quality were not affected by varying Vitamin D concentrations or race.']	N/A	N/A	[('GO_0000003', 'reproduction', 6, 'reproductive'), ('UBERON_0000992', 'ovary', 39, 'ovarian'), ('GO_0009566', 'fertilization', 60, 'fertilization'), ('UBERON_0000922', 'embryo', 95, 'embryo'), ('CHEBI_27300', 'vitamin D', 139, 'vitamin D')]
PMC4934634	11/2015	S83-PMC4934634	['all women receiving the weekly supplement reached Vitamin D sufficiency as assessed by both iom and Endocrine society cut-offs (25(Oh)D) = 47.65 ± 1.11 ng/ml) at the end of the study.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 50, 'vitamin D'), ('UBERON_0005063', 'left ventricular compact myocardium', 100, 'Endocrine'), ('CHEBI_71657', 'versiconol acetate', 128, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 128, '25(OH ... D')]
PMC4934634	11/2015	S84-PMC4934634	['the population in the study represented a homogenous population of women with Vitamin D insufficiency at baseline (15.81 ± 5.94 ng/ml).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 78, 'vitamin D')]
PMC4934634	11/2015	S88-PMC4934634	['the control diet includes sunflower seed oil for cooking, a sunflower oil based spread, and a daily supplement drink without Vitamin D, epa or Dha.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 125, 'vitamin D'), ('CHEBI_17874', 'dihydrozeatin', 143, 'DHA')]
PMC4934634	11/2015	S92-PMC4934634	['when separated into ethnic groups, frequencies of Vitamin D deficiency are highest in african americans (75%), followed by mexican-americans (42%) and non-hispanic whites (9%) [4].']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 50, 'vitamin D')]
PMC4934634	11/2015	S95-PMC4934634	['the current rda for Vitamin D is 600 iu/day for both non-Pregnant females of Reproductive age and Pregnant/Lactating females according to iom recommendations (table 2).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 20, 'vitamin D'), ('GO_0007565', 'female pregnancy', 57, 'pregnant'), ('GO_0000003', 'reproduction', 77, 'reproductive'), ('GO_0007565', 'female pregnancy', 98, 'pregnant'), ('GO_0007594', 'puparial adhesion', 107, 'lactating')]
PMC4934634	11/2015	S107-PMC4934634	['these changes induced by Vitamin D would dampen the Adaptive Immune System while optimizing the innate Immune’s function to kill pathogens aiding the maternal body to protect against microbial insults and establish an environment of fetal tolerance.healthcare-03-01097-t002_table 2\n\ncaption (table-wrap): table 2\n\nVitamin D recommended intakes.ageiomendocrine societyaustralian nhmrc **whordauldaily requirementulaiulrni0–6 months400 iu (10 μg) *1000 iu (25 μg)400–1000 iu2000 iu (50 μg)200 iu (5 μg)1000 iu (25 μg)200 iu (5 μg)7–12 months400 iu (10 μg) *1500 iu (38 μg)400–1000 iu2000 iu (50 μg)200 iu (5 μg)1000 iu (25 μg)200 iu (5 μg)1–3 years600 iu (15 μg)2500 iu (63μg)600–1000 iu4000 iu (100 μg)200 iu (5 μg)3200 iu (80 μg)200 iu (5 μg)4–8 years600 iu (15 μg)3000 iu (75 μg)600–1000 iu4000 iu (100 μg)200 iu (5 μg)3200 iu (80 μg)200 iu (5 μg)Pregnancy/lactation14–18 years600 iu (15 μg)4000 iu (100 μg)600–1000 iu4000 iu (100 μg)200–400 iu3200 iu (80 μg)200 iu (5 μg)19–50 years600 iu (15 μg)4000 iu (100 μg)1500–2000 iu10,000 iu (250 μg)200–400 iu3200 iu (80 μg)200 iu (5 μg)\n* adequate intake (ai); ** national health and medical research council.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 25, 'vitamin D'), ('GO_0019825', 'oxygen binding', 52, 'adaptive immune'), ('UBERON_0002405', 'immune system', 61, 'immune system'), ('UBERON_0002405', 'immune system', 103, 'immune'), ('CHEBI_28384', 'vitamin K', 314, 'Vitamin D'), ('GO_0007565', 'female pregnancy', 848, 'Pregnancy')]
PMC4934634	11/2015	S117-PMC4934634	['after nine weeks of supplementation of Vitamin D or placebo, the Vitamin D supplemented group had reductions in Serum Insulin, fasting Plasma Glucose levels, high sensitivity c-Reactive Protein (Hs-Crp), and Blood pressure compared to the placebo group.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 39, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 65, 'vitamin D'), ('UBERON_0001977', 'blood serum', 112, 'serum'), ('PR_000045358', 'insulin family protein', 118, 'insulin'), ('UBERON_0001969', 'blood plasma', 135, 'plasma'), ('CHEBI_17234', 'glucose', 142, 'glucose'), ('PR_000004806', 'bromodomain-containing protein 2', 176, '-reactive protein'), ('PR_000006060', 'CWF19-like protein 1', 195, 'hs-CRP'), ('UBERON_0000178', 'blood', 208, 'blood')]
PMC4934634	11/2015	S121-PMC4934634	['after six weeks, there was a significant increase in Serum 25(Oh)D in the Vitamin D group (+18.51 ± 20.46 ng/ml).']	N/A	N/A	[('UBERON_0001977', 'blood serum', 53, 'serum'), ('CHEBI_71657', 'versiconol acetate', 59, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 59, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 74, 'vitamin D')]
PMC4934634	11/2015	S134-PMC4934634	['according to endocrine society cut-offs (table 1), the biweekly high dose group was able to achieve sufficiency in 62.5% of subjects, the high dose monthly group had 39.5% of subjects while 11.4% of subjects in the low dose (200 iu/day) had sufficient Vitamin D levels.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 252, 'vitamin D')]
PMC4934634	11/2015	S135-PMC4934634	['there was a dose response decrease in the rise of Serum Insulin and homa-ir with increasing Vitamin D supplementation.']	N/A	N/A	[('UBERON_0001977', 'blood serum', 50, 'serum'), ('PR_000045358', 'insulin family protein', 56, 'insulin'), ('CHEBI_27300', 'vitamin D', 92, 'vitamin D')]
PMC4934634	11/2015	S148-PMC4934634	['when the culture media was supplemented with Vitamin D in hypoxic conditions (used to stimulate the production and secretion of pro-inflammatory cytokines), Placental Tissue from preeclamptic Pregnancies Secreted significantly lower concentrations of hypoxia-induced Antiangiogenic factor, Sflt-1, and had diminished il-6 production compared to Preeclamptic Placentas cultured without vitamin D supplementation [57].']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 45, 'vitamin D'), ('UBERON_0001987', 'placenta', 157, 'placental'), ('UBERON_0000479', 'tissue', 167, 'tissue'), ('GO_0007565', 'female pregnancy', 192, 'pregnancies'), ('GO_0046903', 'secretion', 204, 'secreted'), ('CHEBI_76219', 'fluorogen', 267, 'antiangiogenic'), ('PR_000014793', 'inactive tyrosine-protein kinase PRAG1', 290, 'sFlt-1'), ('PR_000017511', "5'-3' exoribonuclease 1", 320, '6'), ('GO_0007565', 'female pregnancy', 345, 'preeclamptic'), ('UBERON_0001987', 'placenta', 358, 'placentas'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 393, 'D')]
PMC4934634	11/2015	S193-PMC4934634	['women were asked to avoid use of Vitamin D supplements and were randomized at 27 weeks Gestation to receive 800 iu/day Vitamin D2Until Delivery, a single oral bolus of 200,000 iu Vitamin D3, or no intervention [75].']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 33, 'vitamin D'), ('GO_0007565', 'female pregnancy', 87, 'gestation'), ('CHEBI_72701', '2-oxopimelate(2-)', 119, 'vitamin D2until'), ('GO_0007567', 'parturition', 135, 'delivery'), ('CHEBI_33279', 'vitamin D5', 179, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 179, 'vitamin D3')]
PMC4934634	11/2015	S215-PMC4934634	['after the one month, there was a significant improvement in clinical severity of winter-related atopic dermatitis in the Vitamin D group compared to placebo.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 121, 'vitamin D')]
PMC4934634	11/2015	S232-PMC4934634	['out of 1070 patients with Serum Vitamin D levels > 50 ng/ml, 15% (165) of patients presented with hypercalcemia.']	N/A	N/A	[('UBERON_0001977', 'blood serum', 26, 'serum'), ('CHEBI_27300', 'vitamin D', 32, 'vitamin D')]
PMC4934634	11/2015	S236-PMC4934634	['five out of fifteen over-the-counter Vitamin D supplements in the united states were found to have amounts of Vitamin D outside a 90%–120% variability range of the stated quantity on the bottle [84].']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 37, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 110, 'vitamin D')]
PMC4934634	11/2015	S238-PMC4934634	['common Gene polymorphisms in 7-Dehydrocholesterol reductase, Cyp2Ri, and Vitamin D binding protein were found to significantly alter Serum 25(Oh)D levels [85].']	N/A	N/A	[('SO_0000704', 'gene', 7, 'gene'), ('CHEBI_17500', '7alpha-hydroxycholesterol', 29, '7-dehydrocholesterol'), ('PR_000006101', 'cytochrome P450 1A1', 61, 'CYP2RI'), ('CHEBI_27300', 'vitamin D', 73, 'vitamin D'), ('UBERON_0001977', 'blood serum', 133, 'serum'), ('CHEBI_71657', 'versiconol acetate', 139, '25(OH)D')]
PMC4934634	11/2015	S243-PMC4934634	[', supplemented a cohort of Vitamin D deficient women with varying doses of Vitamin D3: 4000 iu/day, 2000 iu/day, or 400 iu/day starting at 12–16 weeks of Gestation to Delivery [87].']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 27, 'vitamin D'), ('CHEBI_33279', 'vitamin D5', 75, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 75, 'vitamin D3'), ('GO_0007565', 'female pregnancy', 154, 'gestation'), ('GO_0007567', 'parturition', 167, 'delivery')]
PMC4934634	11/2015	S264-PMC4934634	['recommendations for the upper limit for Vitamin D intake ranges from 3200 to 10,000 iu (table 2).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 40, 'vitamin D')]
PMC4934634	11/2015	S283-PMC4934634	['in addition, the amount of Vitamin D in the supplement was threefold higher than what was listed on the label.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 27, 'vitamin D')]
PMC4934634	11/2015	S293-PMC4934634	['using nhanes data, 78% of women of Childbearing age did not meet the ear for Vitamin D ( n = 3210) [102].']	N/A	N/A	[('GO_0007129', 'homologous chromosome pairing at meiosis', 35, 'childbearing'), ('CHEBI_27300', 'vitamin D', 77, 'vitamin D')]
PMC4937150	2/2016	S30-PMC4937150	['composition and Nutrient content of the experimental dietcontrolbetaineingredient, g/kgcorn370370wheat300300bran8080soybean meal170170lignocelluloses3030cahpo42020soybean oil88premix*2020betaine03digestible energy, mj/kg13.113.1calculated compositioncrude protein, %1515crude fiber, %4.54.5calcium, %0.840.84phosphorous, %0.650.65\n* the premix contains (per kg): Vitamin A: 240,000 iu; Vitamin D3: 60,000 iu; Vitamin E: 720 iu; Vitamin K3: 30 mg; vitamin B1: 30 mg; Vitamin B2: 120 mg; Vitamin B6: 60 mg; Vitamin B12: 360 mg; Niacin: 600 mg; Pantothenic Acid: 300 mg; Folic Acid: 6 mg; Manganese Sulphate: 1.0 g; Zinc Oxide: 2.5 g; Iron Sulphate: 4.0 g; Copper Sulphate: 4.0 g; Sodium Selenite: 6 mg; calcium: 150 g; Phosphorus: 15 g; Sodium Chloride: 40 g.) , and those in betaine group (n = 6) were Fed with diet supplemented with 3 g/kg betaine Hydrochloride of 98% purity (skystone feed co., ltd., yixing, china) throughout the whole pregancy stage.']	N/A	N/A	[('CHEBI_33284', 'nutrient', 16, 'nutrient'), ('CHEBI_27300', 'vitamin D', 363, 'vitamin A'), ('PR_000004370', 'asialoglycoprotein receptor 2', 371, 'A'), ('CHEBI_33279', 'vitamin D5', 386, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 386, 'vitamin D3'), ('CHEBI_27300', 'vitamin D', 409, 'vitamin E'), ('CHEBI_33237', 'vitamin D4', 428, 'vitamin K3'), ('PR_000009481', 'keratin, type II cytoskeletal 5', 436, 'K3'), ('PR_000004693', 'Bcl-2-like protein 10', 455, 'B1'), ('CHEBI_33279', 'vitamin D5', 466, 'vitamin B2'), ('PR_000004693', 'Bcl-2-like protein 10', 474, 'B2'), ('CHEBI_33237', 'vitamin D4', 486, 'vitamin B6'), ('CHEBI_33279', 'vitamin D5', 505, 'vitamin B12'), ('PR_000004738', 'class E basic helix-loop-helix protein 22', 513, 'B12'), ('CHEBI_7542', 'neurotensin', 526, 'niacin'), ('CHEBI_7916', 'pantothenic acid', 542, 'pantothenic acid'), ('CHEBI_30751', 'formic acid', 568, 'folic acid'), ('CHEBI_37509', 'organoammonium phosphate', 586, 'manganese sulphate'), ('CHEBI_33110', 'diarsane', 613, 'zinc oxide'), ('CHEBI_5975', 'iron chelate', 632, 'iron sulphate'), ('CHEBI_16573', 'carbonyl sulfide', 654, 'copper sulphate'), ('CHEBI_77773', 'sodium selenide', 678, 'sodium selenite'), ('CHEBI_35885', 'secondary phosphine', 717, 'phosphorus'), ('CHEBI_26710', 'sodium chloride', 735, 'sodium chloride'), ('GO_0007631', 'feeding behavior', 801, 'fed'), ('CHEBI_17883', 'hydrogen chloride', 848, 'hydrochloride')]
PMC4944244	7/2016	S5-PMC4944244	['a total of 396 respondents (99\xa0% response rate) aged 18–40 years completed self–administered and guided questionnaire (characteristics and risk factors), validated semi-quantitative Food frequency questionnaire for Vitamin D in malaysia (ffq Vitamin D/my), anthropometric measures (weight and height), Blood test for Serum 25(Oh)D, skin measurement using mexameter (mx 18) and fitzpatrick skin type chart measurement (fstcm).']	N/A	N/A	[('CHEBI_33290', 'food', 182, 'food'), ('CHEBI_27300', 'vitamin D', 215, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 242, 'vitamin D'), ('UBERON_0000178', 'blood', 302, 'blood'), ('UBERON_0001977', 'blood serum', 317, 'serum'), ('CHEBI_33010', 'chromide(1-)', 325, '(OH)D')]
PMC4944244	7/2016	S46-PMC4944244	['respondents were given written informed consent and they were asked to complete the guided self-administered questionnaire on socio-demographic characteristics, risk factors and the validated semi-quantitative Food frequency questionnaire (ffq Vitamin D/my).']	N/A	N/A	[('CHEBI_33290', 'food', 210, 'food'), ('CHEBI_27300', 'vitamin D', 244, 'vitamin D')]
PMC4944244	7/2016	S47-PMC4944244	['the validated ffq contained Food fortified with Vitamin D, natural Food rich with Vitamin D and dietary supplement [17].']	N/A	N/A	[('CHEBI_33290', 'food', 28, 'food'), ('CHEBI_27300', 'vitamin D', 48, 'vitamin D'), ('CHEBI_33290', 'food', 67, 'food'), ('CHEBI_27300', 'vitamin D', 82, 'vitamin D')]
PMC4944244	7/2016	S48-PMC4944244	['meanwhile, recommended Nutrient intakes (rni) for Vitamin D among malaysians was defined as\u2009≥\u2009200\xa0iu/day.']	N/A	N/A	[('CHEBI_33284', 'nutrient', 23, 'Nutrient'), ('CHEBI_27300', 'vitamin D', 50, 'vitamin D')]
PMC4944244	7/2016	S51-PMC4944244	['the questionnaire included age, gender, ethnicity, smoking, educational status, Antenatal history, previous medical, surgical, obstetrics and gynecology history, sun protection score, length of time exposed to sunlight (minutes per week) and ffq Vitamin D/my.']	N/A	N/A	[('GO_0007567', 'parturition', 80, 'antenatal'), ('CHEBI_27300', 'vitamin D', 246, 'vitamin D')]
PMC4944244	7/2016	S69-PMC4944244	['results\na total of 396 respondents (99\xa0% response rate) aged 18–40 years completed the questionnaire, skin test measurement using fstcm and mx 18, anthropometric measurement, and Blood test for Vitamin D. the mean\u2009±\u2009sd age of the respondents was 28.06\u2009±\u20094.09\xa0years.']	N/A	N/A	[('UBERON_0000178', 'blood', 179, 'blood'), ('CHEBI_27300', 'vitamin D', 194, 'vitamin D')]
PMC4944244	7/2016	S76-PMC4944244	['the crude or (95%ci) for Intake of Vitamin D from Food was 0.998 (0.997,0.999) with p value 0.042.']	N/A	N/A	[('GO_0007631', 'feeding behavior', 25, 'intake'), ('CHEBI_27300', 'vitamin D', 35, 'vitamin D'), ('CHEBI_33290', 'food', 50, 'food')]
PMC4944244	7/2016	S78-PMC4944244	['the selected independent variables ( p<0.25) were age, ethnicity, education level, household income per month, household number, weeks of Pregnancy, number of children/parity, fitzpatrick classification, Melanin index, sun protection score, Vitamin D intake from Food (iu/day), Vitamin D intake from Food and supplement (iu/day), and the level of Vitamin D in Foods and supplements (iu/day).']	N/A	N/A	[('GO_0007565', 'female pregnancy', 138, 'pregnancy'), ('CHEBI_25179', 'melanins', 204, 'melanin'), ('CHEBI_27300', 'vitamin D', 241, 'vitamin D'), ('CHEBI_33290', 'food', 263, 'food'), ('CHEBI_27300', 'vitamin D', 278, 'vitamin D'), ('CHEBI_33290', 'food', 300, 'food'), ('CHEBI_27300', 'vitamin D', 347, 'vitamin D'), ('CHEBI_33290', 'food', 360, 'foods')]
PMC4944244	7/2016	S81-PMC4944244	['meanwhile, only Vitamin D intake from meals was selected as the p value was lower.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 16, 'vitamin D')]
PMC4944244	7/2016	S83-PMC4944244	['caption (table-wrap): table 3\n\ncombination of descriptive and simple logistic regression analysis to show the relationship between risk factors and hypovitaminosis d ( n \u2009=\u2009396)variableserum 25(Oh)D <50\xa0nmol/l n\u2009(%) mean\u2009±\u2009sd median (iqr)Serum 25(Oh)D ≥50\xa0nmol/l n\u2009(%) mean\u2009±\u2009sd median (iqr)crude or (95 % ci) p valueage(year)c27.91\u2009±\u20093.9529.47\u2009±\u20095.070.91(0.84, 0.99)0.026ethnic groupscmalay296 (96.40)11 (3.60)22.42(9.63, 52.21)<0.001chinese24 (54.50)20 (45.5)1.00indian32 (91.40)3 (8.60)8.89(2.36, 33.40)0.001others6 (60.00)4 (40.00)1.25(0.31, 5.06)0.754education levelcprimary11 (68.80)5 (31.20)1.00secondary136 (91.30)13 (8.70)4.75(1.43, 15.80)0.011tertiary211 (91.30)20 (8.70)4.80(1.52, 15.18)0.008working statusworking275 (91.40)26 (8.60)1.000.252not working83 (87.40)12 (12.60)0.65(0.32, 1.35)household income per monthc3500 (2800,5000)3750 (2500,5250)1.00(1.00, 1.00)0.060household Membersc3 (2,4)3 (2,5)0.90(0.75, 1.07)0.225weeks of Pregnancy at first Antenatal visitc10.0 (8.0,12.0)11.5 (8.0,12.0)0.89(0.77,1.02)0.100parityc0 (0,1)1 (0,1)0.79(0.61, 1.03)0.083last child Birth≤ 2\xa0years111 (89.50)13 (10.50)0.86(0.43,1.75)0.686>2 yearsa247 (90.80)25 (9.20)1.00breastfeedingyes36 (87.80)5 (12.20)0.74(0.27,2.01)0.552nob322 (90.70)33 (9.30)1.00bmi before Pregnant (kg/m2)22.76 (20.00,26.25)22.15 (19.75,26.58)1.02(0.96,1.09)0.499weight at first Antenatal visit (Kg)57.85 (49.30,68.54)57.03 (51.49,65.61)1.01(0.98,1.03)0.569fitzpatrick classificationcskin type i-ii83 (80.60)20 (19.40)1.00skin type iii163 (94.20)10 (5.80)3.93(1.76,8.77)0.001skin type iv-vi112 (93.30)8 (6.70)3.37(1.42,8.03)0.006melanin indices (using mexameter)(0-999.000)306.17 (254.17,373.67)242.83 (181.08, 354.00)1.01(1.00,1.01)0.006sun protection score(0-8)c5 (4,5)3.5 (1,5)1.77(1.42,2.21)<0.001total of respondents exposed to sunlight (10\xa0am-2\xa0pm)yes201 (90.10)22 (9.90)1.00no157 (90.80)16 (9.20)1.07(0.55,2.11)0.836the length of time exposed to sunlight (minutes in week)35 (0,150)55 (0,210)1.00(1.00,1.00)0.570intake of Vitamin D from Food (iu/day)c197.51 (122.70,332.05)263.81 (142.90,460.55)1.00(1.00,1.00)0.042intake of Vitamin D from Food and supplements (iu/day)215.080 (132.93,361.98)302.135 (147.89,515.74)1.00(1.00,1.00)0.064the level of Vitamin D in Foods and supplements (iu/day)<200\xa0iu/day165 (92.70)13 (7.30)1.64(0.82,3.32)0.165≥200\xa0iu/day193 (88.50)25 (11.50)1.00\nor odds ratio, ci confidence interval\np values have been derived from wald tests\narespondents with last child Birth more than 2\xa0years and respondents who did not have previous child (primid)\nbrespondents who did not Breastfeed during Pregnancy and those who did not have children.']	N/A	N/A	[('CHEBI_71657', 'versiconol acetate', 191, '25(OH)D'), ('PR_000012046', 'oxysterol-binding protein-related protein 11', 194, 'OH ... D'), ('UBERON_0001977', 'blood serum', 238, 'Serum'), ('CHEBI_71657', 'versiconol acetate', 244, '25(OH)D'), ('PR_000012046', 'oxysterol-binding protein-related protein 11', 247, 'OH ... D'), ('PR_000010433', 'makorin-3', 890, 'membersc3'), ('GO_0007565', 'female pregnancy', 942, 'pregnancy'), ('GO_0007567', 'parturition', 961, 'antenatal'), ('GO_0007567', 'parturition', 1080, 'birth'), ('GO_0007565', 'female pregnancy', 1261, 'pregnant'), ('GO_0007567', 'parturition', 1351, 'antenatal'), ('UBERON_0001465', 'knee', 1368, 'kg'), ('CHEBI_27300', 'vitamin D', 2001, 'vitamin D'), ('CHEBI_33290', 'food', 2016, 'food'), ('CHEBI_27300', 'vitamin D', 2104, 'vitamin D'), ('PR_000006444', 'diacylglycerol kinase delta', 2112, 'D'), ('CHEBI_33290', 'food', 2119, 'food'), ('CHEBI_27300', 'vitamin D', 2227, 'vitamin D'), ('CHEBI_33290', 'food', 2240, 'foods'), ('GO_0007567', 'parturition', 2468, 'birth'), ('GO_0007596', 'blood coagulation', 2574, 'breastfeed'), ('GO_0007565', 'female pregnancy', 2592, 'pregnancy')]
PMC4944244	7/2016	S102-PMC4944244	['[21] reported that the prevalence of Vitamin D deficiency (Serum 25(Oh)D <25\xa0nmol/l) among Pregnant women in tehran was 70.6\xa0% and the prevalence of severe Vitamin D deficiency (Serum 25(Oh)D <12.5\xa0nmol/l) was 28.8\xa0%.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 37, 'vitamin D'), ('UBERON_0001977', 'blood serum', 59, 'serum'), ('CHEBI_71657', 'versiconol acetate', 65, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 65, '25(OH ... D'), ('GO_0007565', 'female pregnancy', 91, 'pregnant'), ('CHEBI_27300', 'vitamin D', 156, 'vitamin D'), ('UBERON_0001977', 'blood serum', 178, 'serum'), ('CHEBI_71657', 'versiconol acetate', 184, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 184, '25(OH ... D')]
PMC4944244	7/2016	S117-PMC4944244	['predictors of low Vitamin D among the third trimester Pregnant women were they did not take Milk that has been fortified with Vitamin D (or 11:42; 95\xa0% ci: 3.12–41.86), did not take Antenatal Vitamin Supplements (or 9.70; 95\xa0% ci: 2.28–41.19) and had low Vitamin D level in the first trimester (or 10.58; 95\xa0% ci: 2.89–38.80).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 18, 'vitamin D'), ('GO_0007565', 'female pregnancy', 54, 'pregnant'), ('UBERON_0001913', 'milk', 92, 'milk'), ('CHEBI_27300', 'vitamin D', 126, 'vitamin D'), ('GO_0007567', 'parturition', 182, 'antenatal'), ('CHEBI_33229', 'vitamin (role)', 192, 'vitamin'), ('CHEBI_33341', 'titanium atom', 200, 'supplements'), ('CHEBI_27300', 'vitamin D', 255, 'vitamin D')]
PMC4944244	7/2016	S176-PMC4944244	['high-income families provided better outdoor activities for school teenagers, better Antenatal care facilities for Pregnant women, consumed balanced diet and could afford Vitamin D supplements for their older People.']	N/A	N/A	[('GO_0007567', 'parturition', 85, 'antenatal'), ('GO_0007565', 'female pregnancy', 115, 'pregnant'), ('CHEBI_27300', 'vitamin D', 171, 'vitamin D'), ('NCBITaxon_10088', 'Mus <genus>', 209, 'people')]
PMC4944244	7/2016	S182-PMC4944244	['none of the Antenatal history associated with Vitamin D status.']	N/A	N/A	[('GO_0007567', 'parturition', 12, 'antenatal'), ('CHEBI_27300', 'vitamin D', 46, 'vitamin D')]
PMC4944244	7/2016	S215-PMC4944244	['meanwhile, the institute of medicine [40] reported that the recommended dietary allowance (rda) of Vitamin D for Pregnant mothers is 600\xa0iu/day.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 99, 'vitamin D'), ('GO_0007565', 'female pregnancy', 113, 'pregnant')]
PMC4944244	7/2016	S231-PMC4944244	['abbreviations\nffq Vitamin D/my, validated semi-quantitative Food frequency questionnaire for Vitamin D in malaysia; fstcm, fitzpatrick skin type chart measurement; iqr, interquartile range; mi, Melanin indices; mx, mexameter; sd, standard deviation\n\npubmed central:']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 18, 'vitamin D'), ('CHEBI_33290', 'food', 60, 'food'), ('CHEBI_27300', 'vitamin D', 93, 'vitamin D'), ('CHEBI_25179', 'melanins', 194, 'melanin')]
PMC4949006	7/2016	S140-PMC4949006	['major dietary sources of Vitamin D are fatty fish (salmon), Egg Yolks, fortified Milk, Margarine, yogurt, and orange juice.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 25, 'vitamin D'), ('UBERON_0005079', 'eggshell', 60, 'egg yolks'), ('UBERON_0001913', 'milk', 81, 'milk'), ('CHEBI_6784', 'mestranol', 87, 'margarine')]
PMC4949006	7/2016	S171-PMC4949006	['vegan diets can be low in b12, riboflavin, Vitamin D, Calcium, and Long-Chain N-3 Fats if not properly supplemented.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 43, 'vitamin D'), ('CHEBI_22313', 'alkaline earth metal atom', 54, 'calcium'), ('CHEBI_15904', 'long-chain fatty acid', 67, 'long-chain n-3 fats')]
PMC4969253	8/2016	S0-PMC4969253	['vitamin a-Retinoid Signaling in Pulmonary Development and disease\n\nabstract\nRetinoic Acid (ra), the active form of Vitamin A, Regulates key developmental processes in multiple Organs.']	N/A	N/A	[('CHEBI_26537', 'retinoid', 10, 'retinoid'), ('GO_0023051', 'regulation of signaling', 19, 'signaling'), ('GO_0060021', 'roof of mouth development', 32, 'pulmonary development'), ('UBERON_0002048', 'lung', 32, 'pulmonary'), ('CHEBI_28592', 'ricinoleic acid', 76, 'Retinoic acid'), ('CHEBI_27300', 'vitamin D', 115, 'vitamin A'), ('GO_0065007', 'biological regulation', 126, 'regulates'), ('UBERON_0000062', 'organ', 176, 'organs')]
PMC4969253	8/2016	S56-PMC4969253	['in the Adult Lung, Vitamin A deficiency results in marked changes in the Respiratory Epithelium, including necrotizing Tracheobronchiolitis and squamous metaplasias (transformation of a Respiratory pseudostratifed into a skin-like Stratified Epithelium).']	N/A	N/A	[('UBERON_0007023', 'adult organism', 7, 'adult'), ('UBERON_0002048', 'lung', 13, 'lung'), ('CHEBI_27300', 'vitamin D', 19, 'vitamin A'), ('UBERON_0004802', 'respiratory tract epithelium', 73, 'respiratory epithelium'), ('UBERON_0008426', 'transverse foramen of atlas', 119, 'tracheobronchiolitis'), ('UBERON_0001004', 'respiratory system', 186, 'respiratory'), ('UBERON_0000486', 'multilaminar epithelium', 231, 'stratified epithelium')]
PMC4969253	8/2016	S57-PMC4969253	['once Vitamin A levels were restored to normality, these changes were reversed.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 5, 'vitamin A')]
PMC4969253	8/2016	S64-PMC4969253	['there was no significant difference in the outcomes based on standard vs higher doses of Vitamin A.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 89, 'vitamin A')]
PMC4969253	8/2016	S68-PMC4969253	['for example, Vitamin A-deficient Adult Rats exposed to aerosolized Methacholine have an increase in total Pulmonary resistance compared to control Rats.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 13, 'vitamin A'), ('UBERON_0007023', 'adult organism', 33, 'adult'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 39, 'rats'), ('CHEBI_6805', 'methacycline', 67, 'methacholine'), ('UBERON_0002048', 'lung', 106, 'pulmonary'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 147, 'rats')]
PMC4969253	8/2016	S75-PMC4969253	['mild maternal Vitamin A deficiency in Pregnant Rats resulted in changes in the composition of the Extracellular Matrix of the Lung in Adult offspring; these Mice showed increased collagen and decreased elastin deposition in the Lungs.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 14, 'vitamin A'), ('GO_0007565', 'female pregnancy', 38, 'pregnant'), ('NCBITaxon_9986', 'Oryctolagus cuniculus', 47, 'rats'), ('GO_0031012', 'extracellular matrix', 98, 'extracellular matrix'), ('UBERON_0002048', 'lung', 126, 'lung'), ('UBERON_0007023', 'adult organism', 134, 'adult'), ('NCBITaxon_10088', 'Mus <genus>', 157, 'mice'), ('UBERON_0002048', 'lung', 228, 'lungs')]
PMC4969253	8/2016	S81-PMC4969253	['aberrant Airway sm phenotype with increased and ectopic Expression of sm markers is found in Embryos from mothers exposed to a short developmental window of Vitamin A deficiency.']	N/A	N/A	[('UBERON_0001005', 'respiratory airway', 9, 'airway'), ('GO_0010467', 'gene expression', 56, 'expression'), ('UBERON_0000922', 'embryo', 93, 'embryos'), ('CHEBI_27300', 'vitamin D', 157, 'vitamin A')]
PMC4969253	8/2016	S94-PMC4969253	['abbreviations\nra, Retinoic Acid; rars, Retinoic Acid Receptors; rxr, Retinoid x Receptor; sm, Smooth Muscle; vad, Vitamin A deficiency\n\npubmed central:']	N/A	N/A	[('CHEBI_26536', 'retinoic acid', 18, 'retinoic acid'), ('CHEBI_26536', 'retinoic acid', 39, 'retinoic acid'), ('PR_000001245', 'rhodopsin', 39, 'retinoic acid receptors'), ('CHEBI_26537', 'retinoid', 69, 'retinoid'), ('PR_000000124', 'ribosomal protein S6 kinase beta-2', 69, 'retinoid'), ('PR_000014368', 'RuvB-like 1', 80, 'receptor'), ('UBERON_0001135', 'smooth muscle tissue', 94, 'smooth muscle'), ('CHEBI_27300', 'vitamin D', 114, 'vitamin A')]
PMC4971719	8/2016	S10-PMC4971719	['for every one unit increase in Vitamin D in early Pregnancy, the average decrease in the mean bdi score was .14 units.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 31, 'vitamin D'), ('GO_0007565', 'female pregnancy', 50, 'pregnancy')]
PMC4971719	8/2016	S20-PMC4971719	['Vitamin D is obtained by Ingestion of Vitamin D-containing foods or produced endogenously by the skin after exposure to ultraviolet b sunlight.']	N/A	N/A	[('CHEBI_28384', 'vitamin K', 0, 'Vitamin D'), ('GO_0007631', 'feeding behavior', 25, 'ingestion'), ('CHEBI_27300', 'vitamin D', 38, 'vitamin D')]
PMC4971719	8/2016	S56-PMC4971719	['all participating women were taking Prenatal Vitamins, which typically contain approximately 400\xa0iu Vitamin D [39].']	N/A	N/A	[('GO_0007565', 'female pregnancy', 36, 'prenatal'), ('CHEBI_33277', 'gamma-tocotrienol', 45, 'vitamins'), ('CHEBI_27300', 'vitamin D', 100, 'vitamin D')]
PMC4971719	8/2016	S88-PMC4971719	['using a generalized linear models (ancova) approach we entered winter and Vitamin D at visit 1 into the model as predictors of the Bdi score at visit 1 (study entry), at 34–36 weeks Gestation and at 6–8 weeks Postpartum.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 74, 'vitamin D'), ('PR_000004717', "transcription factor TFIIIB component B''", 131, 'BDI'), ('GO_0007565', 'female pregnancy', 182, 'gestation'), ('GO_0007565', 'female pregnancy', 209, 'postpartum')]
PMC4971719	8/2016	S89-PMC4971719	['we used repeated measures anova to fit the Vitamin D level at baseline and in late Pregnancy to the square root of the Bdi score at visits 1, 2, 3, and 5, adjusting for “winter”, baseline bdi, baseline Vitamin D and most recent Vitamin D. we transformed the bdi by its square root to correct for skewed (non-normal) distribution.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 43, 'vitamin D'), ('GO_0007565', 'female pregnancy', 83, 'pregnancy'), ('PR_000004717', "transcription factor TFIIIB component B''", 119, 'BDI'), ('CHEBI_27300', 'vitamin D', 202, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 228, 'vitamin D')]
PMC4971719	8/2016	S91-PMC4971719	['to compare outcomes according to Vitamin D sufficiency versus insufficiency in our population, we performed a secondary analysis selecting a Vitamin D level of\u2009≥\u200920\xa0ng/ml at enrollment ( n \u2009=\u200998) as our reference group and <20\xa0ng/ml ( n \u2009=\u200919) as our “low vitamin group.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 33, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 141, 'vitamin D')]
PMC4971719	8/2016	S99-PMC4971719	['we evaluated the association of Vitamin D levels at visits 1 and 3 with “winter”, using fisher’s exact test.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 32, 'vitamin D')]
PMC4971719	8/2016	S100-PMC4971719	['we used descriptive statistics to compare characteristics of the reference group and the “low Vitamin D” group.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 94, 'vitamin D')]
PMC4971719	8/2016	S116-PMC4971719	['1\n\nconsort diagram\nparticipants characteristics were stratified by possible Vitamin D deficiency (25 (Oh) D <20\xa0ng/ml) for descriptive purposes (table\xa01).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 76, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 98, '25 (OH) D'), ('PR_000006444', 'diacylglycerol kinase delta', 106, 'D')]
PMC4971719	8/2016	S117-PMC4971719	['the mean Vitamin D level for the aggregate study population was 28.17\xa0ng/ml+/− 8.25 and 3.1.84\xa0ng/ml +/− 10.63at 12–20 weeks and 34–36 weeks respectively.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 9, 'vitamin D')]
PMC4971719	8/2016	S119-PMC4971719	['Vitamin D levels drawn in winter were significantly lower than Vitamin D levels drawn during other seasons (mean Vitamin D =29.0 +/− 8.2 versus 26.5 +/− 7.6, p \u2009<\u20090.05).']	N/A	N/A	[('CHEBI_28384', 'vitamin K', 0, 'Vitamin D'), ('CHEBI_27300', 'vitamin D', 63, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 113, 'vitamin D')]
PMC4971719	8/2016	S121-PMC4971719	['standard deviation, bmi body-mass index,a\u2009=\u2009statistically significant\nbstudent’s t -test\ncmann-whitney test\ndfisher’s exact test\nas previously discussed, we selected a Vitamin D level\u2009≥\u200920\xa0ng/ml ( n \u2009=\u200998) for our reference group and <20\xa0ng/ml ( n \u2009=\u200919) for our “low Vitamin D” group for sub-analysis.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 168, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 268, 'vitamin D')]
PMC4971719	8/2016	S124-PMC4971719	['the frequency of Vitamin D <20\xa0ng/ml at 12–20 versus 34–36 weeks was 16\xa0% and 12\xa0% of our total population.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 17, 'vitamin D')]
PMC4971719	8/2016	S131-PMC4971719	['we next performed repeated measures analysis, evaluating for association of the most recent Vitamin D value with the bdi score adjusting for winter, baseline bdi score, most recent bdi score, most recent dha level and group assignment.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 92, 'vitamin D')]
PMC4971719	8/2016	S135-PMC4971719	['when evaluating “low Vitamin D” as a categorical variable, there was no association seen between Vitamin D level at 12–20 weeks and Bdi score at that time ( p \u2009=\u20090.11) or with Postpartum bdi score ( p \u2009=\u20090.97).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 21, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 97, 'vitamin D'), ('PR_000004717', "transcription factor TFIIIB component B''", 132, 'BDI'), ('GO_0007565', 'female pregnancy', 176, 'postpartum')]
PMC4971719	8/2016	S139-PMC4971719	['there was no association between low Vitamin D and Postpartum bdi scores in the regression analysis.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 37, 'vitamin D'), ('GO_0007565', 'female pregnancy', 51, 'postpartum')]
PMC4971719	8/2016	S147-PMC4971719	['low Vitamin D levels (at any time point) were not significantly associated with higher Postpartum depression symptom scores.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 4, 'vitamin D'), ('GO_0007565', 'female pregnancy', 87, 'postpartum')]
PMC4973215	8/2016	S1-PMC4973215	['study design:\nCord Blood Vitamin D levels were measured in 438 infants (276 black and 162 white).']	N/A	N/A	[('UBERON_0000948', 'heart', 14, 'Cord'), ('UBERON_0000178', 'blood', 19, 'blood'), ('CHEBI_27300', 'vitamin D', 25, 'vitamin D')]
PMC4973215	8/2016	S2-PMC4973215	['multivariable logistic regression models were used to evaluate associations between maternal characteristics, Vitamin D status and sga.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 110, 'vitamin D')]
PMC4973215	8/2016	S4-PMC4973215	['black infants had 3.6 greater adjusted odds (95% confidence interval (ci): 2.4, 5.6) of Vitamin D deficiency when compared with white infants.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 88, 'vitamin D')]
PMC4973215	8/2016	S5-PMC4973215	['black infants with Vitamin D deficiency had 2.4 greater adjusted odds (95% ci: 1.0, 5.8) of sga.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 19, 'vitamin D')]
PMC4973215	8/2016	S27-PMC4973215	['for categorical analysis of Vitamin D levels, we used cutoff values of: sufficient (⩾50\u2009nmol\u2009l−1) and deficient (<50\u2009nmol\u2009l−1).28,29,30,31\n\nstatistical analysis\ndistributions of continuous variables were evaluated for normality graphically using histogram and box plots and are described using means and s.d.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 28, 'vitamin D')]
PMC4973215	8/2016	S36-PMC4973215	['results\nof the 506 non-hispanic white and black infants, 438 with available data on Vitamin D status, bmi at Delivery, Prenatal Vitamin use and pre-eclampsia/Pregnancy-induced hypertension (pih) history were included in final analyses.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 84, 'vitamin D'), ('GO_0007567', 'parturition', 109, 'delivery'), ('GO_0007565', 'female pregnancy', 119, 'prenatal'), ('CHEBI_33229', 'vitamin (role)', 128, 'vitamin'), ('GO_0007565', 'female pregnancy', 158, 'pregnancy')]
PMC4973215	8/2016	S44-PMC4973215	['after adjusting for medicaid status, bmi at Delivery and Prenatal vitamin use, black infants had a 3.6 greater odds (95% confidence interval (ci): 2.4, 5.6) of having Vitamin D deficiency compared with white infants (table 2).']	N/A	N/A	[('GO_0007567', 'parturition', 44, 'delivery'), ('GO_0007565', 'female pregnancy', 57, 'prenatal'), ('CHEBI_27300', 'vitamin D', 167, 'vitamin D')]
PMC4973215	8/2016	S46-PMC4973215	['for every 5-unit increase in maternal bmi, infants had a 1.2 greater odds (95% ci: 1.1, 1.4) of Vitamin D deficiency (table 2).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 96, 'vitamin D')]
PMC4973215	8/2016	S47-PMC4973215	['the predicted probabilities of Vitamin D deficiency, based on significant predictors in the multivariable regression model, are shown infigure 2.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 31, 'vitamin D')]
PMC4976416	7/2016	S28-PMC4976416	['in which 96 atopic dermatitis patients were treated with either placebo or oral Vitamin E (400 ie/day) for 8 months.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 80, 'vitamin E')]
PMC4976416	7/2016	S38-PMC4976416	['mirak consists of natural spring Water, valconic earth, and Vitamin E cream.']	N/A	N/A	[('CHEBI_15377', 'water', 33, 'water'), ('CHEBI_27300', 'vitamin D', 60, 'vitamin E')]
PMC4976416	7/2016	S43-PMC4976416	['[2829]\n\nWound Healing\nVitamin E along with zinc and Vitamin C, is included in oral therapies for pressure ulcers and burns.']	N/A	N/A	[('GO_0060396', 'growth hormone receptor signaling pathway', 8, 'Wound healing'), ('CHEBI_28384', 'vitamin K', 22, 'Vitamin E'), ('PR_000017279', 'testis-specific basic protein Y 1', 22, 'Vitamin E'), ('CHEBI_27300', 'vitamin D', 52, 'vitamin C')]
PMC4976416	7/2016	S47-PMC4976416	['[33]\nin a randomized, double-bind, placebo-controlled trial, a combination of oral Proanthocyanidin plus Vitamin A, C, and e was assessed in 60 phillipino females with bilateral Epidermal melasma.']	N/A	N/A	[('CHEBI_26267', 'proanthocyanidin', 83, 'proanthocyanidin'), ('CHEBI_27300', 'vitamin D', 105, 'vitamin A'), ('CHEBI_18245', 'carboxylato group', 116, 'C'), ('UBERON_0007376', 'outer epithelium', 178, 'epidermal')]
PMC4976416	7/2016	S56-PMC4976416	['[38]\n\nacne vulgaris\nin one of the studies conducted in a series of 98 patients, the emphasis was based on the correction of the defective Keratinization of Sebaceous Follicles with a combination of Vitamin E and Vitamin C.[39] this was seen to prevent the formation of comedones, thus depriving the propionibacterium acnes of a culture medium.']	N/A	N/A	[('GO_0031424', 'keratinization', 138, 'keratinization'), ('UBERON_0010308', 'os opticus', 156, 'sebaceous follicles'), ('CHEBI_27300', 'vitamin D', 198, 'vitamin E'), ('CHEBI_27300', 'vitamin D', 212, 'vitamin C')]
PMC4976416	7/2016	S66-PMC4976416	['he received 800 iu oral Vitamin E daily and applied the Vitamin (50 iu per ml) to the ulcerated Fingers twice daily.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 24, 'vitamin E'), ('CHEBI_33229', 'vitamin (role)', 56, 'vitamin'), ('UBERON_0002389', 'manual digit', 96, 'fingers')]
PMC4976416	7/2016	S72-PMC4976416	['[53] most of the over-the-counter antiaging creams contain 0.5%–1% of Vitamin E.\none of the most popular applications of Vitamin E is the treatment of burns, surgical scars, and wounds.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 70, 'vitamin E'), ('CHEBI_27300', 'vitamin D', 121, 'vitamin E')]
PMC4979151	8/2016	S96-PMC4979151	['Prenatal Vitamin D supplementation and T and B Cell Activation pathways\nwithin each intervention group, comparisons were made between Genes from unstimulated and Stimulated Lymphocytes.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 0, 'Prenatal'), ('CHEBI_27300', 'vitamin D', 9, 'vitamin D'), ('CL_0000909', 'CD8-positive, alpha-beta memory T cell', 39, 'T ...'), ('GO_0050909', 'sensory perception of taste', 39, 'T ...'), ('CL_0000236', 'B cell', 45, 'B cell'), ('GO_0042113', 'B cell activation', 45, 'B cell activation'), ('SO_0000704', 'gene', 134, 'genes'), ('CL_0002651', 'endothelial cell of venous sinus of spleen', 162, 'stimulated'), ('CL_0000542', 'lymphocyte', 173, 'lymphocytes')]
PMC4979151	8/2016	S124-PMC4979151	['active Vitamin D can inhibit in vitro Proliferation and Differentiation Of B Cells into Plasma Cells as well as Antibody Production [23,24].']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 7, 'vitamin D'), ('GO_0007565', 'female pregnancy', 38, 'proliferation ...'), ('GO_0030154', 'cell differentiation', 56, 'differentiation of ... cells ... cells'), ('CL_0000236', 'B cell', 75, 'B cells'), ('CL_0000786', 'plasma cell', 88, 'plasma cells'), ('GO_0002376', 'immune system process', 112, 'antibody production'), ('GO_0042571', 'immunoglobulin complex, circulating', 112, 'antibody')]
PMC4982007	8/2016	S4-PMC4982007	['methods\nexposures considered were maternal bmi, height and weight, Micronutrient status (Vitamins D, B12, Folate and iron) and Macronutrient intakes (Carbohydrate, protein and fat).']	N/A	N/A	[('CHEBI_33962', 'mu4-sulfido-quadro-tetracopper(6+)', 67, 'micronutrient'), ('CHEBI_27300', 'vitamin D', 89, 'vitamins D'), ('CHEBI_27778', 'abequose', 101, 'B12'), ('CHEBI_30863', '5-azaorotic acid', 106, 'folate'), ('CHEBI_33937', 'macronutrient', 127, 'macronutrient'), ('CHEBI_16730', 'chloramphenicol 3-acetate', 150, 'carbohydrate')]
PMC4982007	8/2016	S42-PMC4982007	['eligibility criteria, search strategy and identification of literature\nour exposure of interest was maternal nutritional status during Pregnancy: bmi, height and weight; status or intake of selected single Micronutrients (Vitamins D, b1, b6, b12 and Folate) and iron and dietary intake of Macronutrients (Carbohydrate, protein and fat).']	N/A	N/A	[('GO_0007565', 'female pregnancy', 135, 'pregnancy'), ('CHEBI_33839', 'macromolecule', 206, 'micronutrients'), ('CHEBI_27300', 'vitamin D', 222, 'vitamins D'), ('CHEBI_30863', '5-azaorotic acid', 250, 'folate'), ('CHEBI_33839', 'macromolecule', 289, 'macronutrients'), ('CHEBI_16730', 'chloramphenicol 3-acetate', 305, 'carbohydrate')]
PMC4982007	8/2016	S47-PMC4982007	['caption (table-wrap): table 1\n\nlist of mesh terms and the text word terms used for exposure and outcomeexposure: maternal nutritional status during Pregnancyoutcome: childhood and adolescent Cognitive functionmesh termstext word termsmesh termstext word terms“exp body weight/or exp body mass index/or exp anthropometry/or exp body size/or exp Skinfold thickness/or exp nutrition assessment/or exp nutritional status/or exp mothers/or exp Pregnancy/or exp malnutrition/or exp diet vegetarian/or exp haemoglobin/or Pregnancy complications/or exp anemia/or exp Folic Acid/or exp Folic Acid deficiency/or exp Vitamin B12 deficiency/or exp ferritin/or exp iron, dietary/or exp Cholecalciferol/or exp Pyridoxine/or exp Vitamin B Complex/or exp riboflavin/or exp Thiamine/or exp Vitamin D/”“maternal nutrition or maternal anthropometry or Pregnancy nutrition or Antenatal nutrition or intrauterine nutrition or Gestational nutrition or maternal undernutrition or Prenatal nutrition or maternal bmi or maternal Micronutrients or vegan mothers or vegetarian mothers or Macrobiotic mothers or maternal Folate or maternal Folic Acid or maternal Vitamin B12 or maternal cobalamin or maternal Vitamin D or 25 Hydoxy Vitamin D or maternal Cholecaliciferol or maternal haemoglobin or maternal iron or maternal b Vitamins or maternal vitamin b1 or maternal vitamin b6 or maternal Vitamin B9 or maternal b Vitamins or maternal anaemia or maternal diet”“exp child/or exp Child Development/or exp adolescent/or exp neurobehavioral manifestations/or exp child, preschool/or exp Cognition, physiology/or exp attention/or exp Memory, Long-Term/or exp Memory, short-term/or exp Memory/or exp intelligence tests/or exp psycho motor performance/or exp child psychology/or exp Decision Making/or exp psychometrics/or exp intelligence/or exp mental competence/or exp Cognition/or exp motor skills/or exp Language Development/or exp Learning/or exp Verbal Learning/or exp Problem Solving/or exp perception/or exp Thinking/or exp executive function/or exp function/or exp Human development/or exp adolescent development/or exp speech/or exp mental Processes/Cognitive function or intelligence or iq or executive function or Psychomotor Development or cognitive performance or Cognition or educational attainment or Cognitive ability or Cognitive deficits or intellectual ability or Learning or Memory or Language Development.']	N/A	N/A	[('GO_0006606', 'protein import into nucleus', 148, 'pregnancyOutcome'), ('GO_0050890', 'cognition', 191, 'cognitive'), ('UBERON_0009007', 'superficial inguinal lymph node', 344, 'skinfold'), ('GO_0007565', 'female pregnancy', 439, 'pregnancy'), ('GO_0007565', 'female pregnancy', 514, 'pregnancy'), ('CHEBI_30751', 'formic acid', 559, 'folic acid'), ('CHEBI_30751', 'formic acid', 577, 'folic acid'), ('CHEBI_83324', 'pent-2-enoyl-CoA(4-)', 606, 'vitamin b12'), ('PR_000004480', 'V-type proton ATPase catalytic subunit A', 606, 'vitamin b12'), ('CHEBI_52550', 'theopalauamide', 673, 'cholecalciferol'), ('CHEBI_16410', 'pyridoxamine', 696, 'pyridoxine'), ('CHEBI_49976', 'zinc dichloride', 714, 'vitamin b'), ('GO_0032991', 'protein-containing complex', 724, 'complex'), ('CHEBI_26948', 'vitamin B1', 757, 'thiamine'), ('CHEBI_27300', 'vitamin D', 773, 'vitamin D'), ('GO_0007565', 'female pregnancy', 833, 'pregnancy'), ('GO_0007567', 'parturition', 856, 'antenatal'), ('GO_0007565', 'female pregnancy', 905, 'gestational'), ('GO_0007565', 'female pregnancy', 957, 'prenatal'), ('CHEBI_33839', 'macromolecule', 1004, 'micronutrients'), ('CHEBI_64709', 'organic acid', 1061, 'macrobiotic'), ('CHEBI_30863', '5-azaorotic acid', 1093, 'folate'), ('CHEBI_30751', 'formic acid', 1112, 'folic acid'), ('CHEBI_83324', 'pent-2-enoyl-CoA(4-)', 1135, 'vitamin b12'), ('PR_000004677', 'breast cancer anti-estrogen resistance protein 3', 1143, 'b12'), ('CHEBI_27300', 'vitamin D', 1181, 'vitamin D'), ('CHEBI_45557', 'sec-butyl group', 1194, '25 hydoxy'), ('CHEBI_27300', 'vitamin D', 1204, 'vitamin D'), ('CHEBI_17937', 'L-rhamnono-1,4-lactone', 1226, 'cholecaliciferol'), ('CHEBI_33277', 'gamma-tocotrienol', 1298, 'vitamins'), ('CHEBI_33229', 'vitamin (role)', 1365, 'vitamin'), ('PR_000017209', 'utrophin', 1365, 'vitamin b9'), ('CHEBI_33277', 'gamma-tocotrienol', 1390, 'vitamins'), ('GO_0001410', 'chlamydospore formation', 1454, 'child development'), ('GO_0050890', 'cognition', 1559, 'cognition'), ('GO_0007613', 'memory', 1605, 'memory'), ('GO_0007616', 'long-term memory', 1613, 'long-term'), ('GO_0007613', 'memory', 1630, 'memory'), ('GO_0007613', 'memory', 1656, 'memory'), ('GO_0016045', 'detection of bacterium', 1752, 'decision making'), ('GO_0050890', 'cognition', 1841, 'cognition'), ('GO_0060132', 'prolactin secreting cell development', 1878, 'language development'), ('GO_0007612', 'learning', 1906, 'learning'), ('GO_0008355', 'olfactory learning', 1922, 'verbal learning'), ('GO_0008283', 'cell proliferation', 1945, 'problem solving'), ('GO_0007596', 'blood coagulation', 1986, 'thinking'), ('NCBITaxon_9606', 'Homo sapiens', 2044, 'human'), ('GO_0007565', 'female pregnancy', 2120, 'processes'), ('GO_0050890', 'cognition', 2130, 'Cognitive'), ('GO_0030324', 'lung development', 2196, 'psychomotor development'), ('GO_0050890', 'cognition', 2248, 'cognition'), ('GO_0050890', 'cognition', 2287, 'cognitive'), ('GO_0050890', 'cognition', 2308, 'cognitive'), ('GO_0007612', 'learning', 2354, 'learning'), ('GO_0007613', 'memory', 2366, 'memory'), ('GO_0060132', 'prolactin secreting cell development', 2376, 'language development')]
PMC4982007	8/2016	S119-PMC4982007	['maternal Vitamin D (table\xa03)\nall three studies were conducted in developed populations and were observational [20–22].']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 9, 'vitamin D')]
PMC4982007	8/2016	S122-PMC4982007	['all the studies assessed Serum Vitamin D concentration using stored samples collected during the second or third trimester.']	N/A	N/A	[('UBERON_0001977', 'blood serum', 25, 'serum'), ('CHEBI_27300', 'vitamin D', 31, 'vitamin D')]
PMC4982007	8/2016	S272-PMC4982007	['for example children of mothers with normal Vitamin D status scored 0.1-0.2 sd higher in Mental and Psychomotor Development tests compared to children of deficient mothers [22].']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 44, 'vitamin D'), ('GO_0007613', 'memory', 89, 'mental ...'), ('GO_0030324', 'lung development', 100, 'psychomotor development')]
PMC4988030	8/2016	S103-PMC4988030	['participants were classified as compliant with dietary guidelines if they met minimum daily intake for fiber (28\xa0g), calcium (1300\xa0mg for women 18\xa0years of age and 1000\xa0mg for women\u2009≥\u200919\xa0years of age), Folate (600 mcg), iron (27\xa0mg), Vitamin C (80\xa0mg for women 18\xa0years of age and 85\xa0mg for women\u2009≥\u200919\xa0years of age), Vitamin D (5 mcg), and Choline (450\xa0mg) or did not exceed the maximum daily intake for total dietary fat (35\xa0% of total energy), saturated fat (10\xa0% of total energy), Cholesterol (300\xa0mg), and sodium (1500\xa0mg for african american women).']	N/A	N/A	[('CHEBI_30863', '5-azaorotic acid', 202, 'folate'), ('CHEBI_27300', 'vitamin D', 234, 'vitamin C'), ('CHEBI_27300', 'vitamin D', 317, 'vitamin D'), ('CHEBI_15354', 'choline', 340, 'choline'), ('CHEBI_16113', 'cholesterol', 484, 'cholesterol')]
PMC4989298	8/2016	S339-PMC4989298	['notes on Vitamin D Metabolism\nexposure to sunlight is the main source of Vitamin D: ultraviolet b rays induce the production of Cholecalciferol (Vitamin D3) in the skin, and it is then hydroxylated to 25-Hydroxyvitamin D3 (25 [Oh] D) in the Liver.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 9, 'vitamin D'), ('GO_0008152', 'metabolic process', 19, 'metabolism'), ('CHEBI_27300', 'vitamin D', 73, 'vitamin D'), ('CHEBI_52550', 'theopalauamide', 128, 'cholecalciferol'), ('CHEBI_33279', 'vitamin D5', 145, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 145, 'vitamin D3'), ('CHEBI_63991', '15-epi-lipoxin B4', 201, '25-hydroxyvitamin D3'), ('CHEBI_15643', '(6R)-6-(L-erythro-1,2-dihydroxypropyl)-7,8-dihydro-6H-pterin', 223, '25 [OH] D'), ('UBERON_0002107', 'liver', 241, 'liver')]
PMC4989298	8/2016	S341-PMC4989298	['1,25[Oh]2D3 is activated by binding to the Vitamin D receptor and with subsequent Regulation Of Gene Expression.']	N/A	N/A	[('CHEBI_64115', '(1S,2R)-5-methoxy-1-methyl-2-(propylamino)tetralin hydrochloride', 2, '25[OH]2D3'), ('CHEBI_27300', 'vitamin D', 43, 'vitamin D'), ('GO_0010468', 'regulation of gene expression', 82, 'regulation of gene expression'), ('SO_0000704', 'gene', 96, 'gene')]
PMC4989298	8/2016	S342-PMC4989298	['other sources of Vitamin D are foods, especially fatty fish and dairy products, and administered supplements.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 17, 'vitamin D')]
PMC4989298	8/2016	S343-PMC4989298	['there is currently no common definition of the threshold below which Vitamin D deficiency begins.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 69, 'vitamin D')]
PMC4990268	8/2016	S300-PMC4990268	['as a result, any routine Antenatal supplementation with Vitamin A is typically provided on a regular (daily or weekly) basis that is limited to the current recommended daily allowances (770 micrograms daily or 2,600 iu)[104].']	N/A	N/A	[('GO_0007567', 'parturition', 25, 'antenatal'), ('CHEBI_27300', 'vitamin D', 56, 'vitamin A')]
PMC4990268	8/2016	S301-PMC4990268	['evidence: the first cluster randomized rct was done in a population in rural, southern nepal with a high prevalence of low Vitamin A-intake and poor Vitamin a status[105].']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 123, 'vitamin A'), ('CHEBI_33229', 'vitamin (role)', 149, 'vitamin')]
PMC4990268	8/2016	S308-PMC4990268	['the trial in ghana compared 25000 iu (weekly) of Retinol against placebo among 207,781 women aged 15–45 in rural, central ghana, an area without significant Vitamin A deficiency among women[106].']	N/A	N/A	[('CHEBI_26536', 'retinoic acid', 49, 'retinol'), ('CHEBI_27300', 'vitamin D', 157, 'vitamin A')]
PMC4990268	8/2016	S311-PMC4990268	['the trial in bangladesh included 59,666 Pregnancies randomized to Vitamin A (7,000 μg), Β-Carotene (42 mg), or placebo from the first Trimester through 12 weeks post-Partum[107].']	N/A	N/A	[('GO_0007565', 'female pregnancy', 40, 'pregnancies'), ('CHEBI_27300', 'vitamin D', 66, 'vitamin A'), ('CHEBI_28064', 'cyanidin 3-O-rutinoside', 88, 'β-carotene'), ('GO_0009294', 'DNA mediated transformation', 134, 'trimester'), ('GO_0007567', 'parturition', 166, 'partum')]
PMC4990268	8/2016	S312-PMC4990268	['this population had evidence of significant Vitamin A deficiency, with night blindness rates during Pregnancy approaching 10%.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 44, 'vitamin A'), ('GO_0007565', 'female pregnancy', 100, 'pregnancy')]
PMC4990268	8/2016	S313-PMC4990268	['relative risks for total mortality in the Vitamin A and Beta Carotene groups were 1.15 (95% ci: 0.75–1.76) and 1.21 (95% ci: 0.81–1.81), respectively versus Placebo[107].']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 42, 'vitamin A'), ('CHEBI_51438', 'D-isoascorbic acid', 56, 'beta carotene'), ('CHEBI_26130', 'biological pigment', 157, 'placebo')]
PMC4990268	8/2016	S353-PMC4990268	['among hiv negative women, hazard ratios for the groups who received both maternal and newborn Vitamin A, maternal Vitamin alone, and newborn supplementation alone relative to placebo for both were 1.28 (95% ci: 0.83–1.98), 1.27 (95% ci: 0.82–1.97), and 1.18 (0.76–1.83), respectively[120].']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 94, 'vitamin A'), ('CHEBI_33229', 'vitamin (role)', 114, 'vitamin')]
PMC4990268	8/2016	S428-PMC4990268	['antenatal Vitamin A///// when given to night-blind Pregnant women, infant mortality is ↓d Postnatal Vitamin A 10% or greater ↓ in infant mortality to 6 months of age in areas with endemic Vitamin A deficiency [119,121,123]Iodine ↓ Cognitive disability; universal coverage could prevent ~18m cases of Cognitive impairment/ year [129]balanced protein-energy supplementation up to ~30%↓?, rct evidence underpowered [132,135]up to ~40%↓ in populations with significant malnutrition [132,135]/ up to 30%↓ in populations with significant malnutrition [133,135]expected knock-on effects on stuntingeffectiveness estimate assumes 100% coverage.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 10, 'vitamin A'), ('GO_0007565', 'female pregnancy', 51, 'pregnant'), ('GO_0007567', 'parturition', 90, 'Postnatal'), ('CHEBI_27300', 'vitamin D', 100, 'vitamin A'), ('CHEBI_27300', 'vitamin D', 188, 'vitamin A'), ('CHEBI_31719', 'ipriflavone', 222, 'Iodine'), ('CHEBI_24870', 'ion', 229, '↓'), ('GO_0050890', 'cognition', 231, 'cognitive'), ('GO_0050890', 'cognition', 300, 'cognitive')]
PMC4990280	8/2016	S60-PMC4990280	['isocratic reverse-phase hplc and uv detection were used to analyze concentrations of Plasma Retinol/Vitamin A (shimadzu corporation, kyoto, japan).']	N/A	N/A	[('UBERON_0001969', 'blood plasma', 85, 'plasma'), ('CHEBI_26536', 'retinoic acid', 92, 'retinol'), ('CHEBI_27300', 'vitamin D', 100, 'vitamin A')]
PMC4990280	8/2016	S61-PMC4990280	['the mean inter-day coefficient of variation was <5% for stfr, ferritin, Folate, Vitamin B12,zn, Vitamin A, and crp and <8% for hepcidin.']	N/A	N/A	[('CHEBI_30863', '5-azaorotic acid', 72, 'folate'), ('CHEBI_33279', 'vitamin D5', 80, 'vitamin B12'), ('PR_000004481', 'V-type proton ATPase subunit B, kidney isoform', 80, 'vitamin B12'), ('CHEBI_27300', 'vitamin D', 96, 'vitamin A')]
PMC4990280	8/2016	S102-PMC4990280	['Zinc and Vitamin A deficiencies were present in 8% and 6.2% children respectively (s2 table).']	N/A	N/A	[('CHEBI_27377', "Unsym-bis(4'-chlorophenyl)ethylene", 0, 'Zinc'), ('CHEBI_27300', 'vitamin D', 9, 'vitamin A')]
PMC4992225	8/2016	S6-PMC4992225	['a total of 169 participants were assigned to the two groups of Placebo and Vitamin D through block randomization design.']	N/A	N/A	[('CHEBI_26130', 'biological pigment', 63, 'placebo'), ('CHEBI_27300', 'vitamin D', 75, 'vitamin D')]
PMC4992225	8/2016	S14-PMC4992225	['while, the Vitamin D group had greater reduction in depression scores than the control group at 38–40 weeks of Gestation ( p \u2009=\u20090.01) also, at 4 and 8 weeks after Birth ( p \u2009<\u20090.001).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 11, 'vitamin D'), ('GO_0007565', 'female pregnancy', 111, 'gestation'), ('GO_0007567', 'parturition', 163, 'birth')]
PMC4992225	8/2016	S31-PMC4992225	['in Human body, the most important source of Vitamin D is the skin where 7-Dehydrocholesterol is converted to Vitamin D3In response to uv exposure.']	N/A	N/A	[('NCBITaxon_9606', 'Homo sapiens', 3, 'human'), ('CHEBI_27300', 'vitamin D', 44, 'vitamin D'), ('CHEBI_17500', '7alpha-hydroxycholesterol', 72, '7-dehydrocholesterol'), ('CHEBI_33229', 'vitamin (role)', 109, 'vitamin D3in'), ('PR_000017209', 'utrophin', 109, 'vitamin D3in')]
PMC4992225	8/2016	S32-PMC4992225	['both cutaneous production and dietary Consumption of Vitamin D must undergo two hydroxylations in the body for activation.']	N/A	N/A	[('GO_0007631', 'feeding behavior', 38, 'consumption'), ('CHEBI_27300', 'vitamin D', 53, 'vitamin D')]
PMC4992225	8/2016	S34-PMC4992225	['however, 25-Hydroxyvitamin D requires an additional hydroxylation in the Kidneys to form the biologically active form of Vitamin D, 1, 25(Oh) 2D.']	N/A	N/A	[('CHEBI_62218', '23,24-dihydrocucurbitacin D', 9, '25-hydroxyvitamin D'), ('UBERON_0002113', 'kidney', 73, 'kidneys'), ('CHEBI_27300', 'vitamin D', 121, 'vitamin D'), ('CHEBI_66212', "5,7,3',4'-tetrahydroxy-2'-(3,3-dimethylallyl)isoflavone", 135, '25(OH) 2D')]
PMC4992225	8/2016	S41-PMC4992225	['the special Nuclear receptors for 1, 25-Dihydroxyvitamin D and also essential enzymes for Hydroxylation Of Vitamin D are found in the Central Nervous System.']	N/A	N/A	[('GO_0005634', 'nucleus', 12, 'nuclear'), ('CHEBI_67472', '15-epi-lupulin B', 34, '1, 25-dihydroxyvitamin D'), ('CHEBI_36836', '3beta-hydroxy steroid', 90, 'hydroxylation'), ('GO_0044101', '(R)-citramalyl-CoA lyase activity', 90, 'hydroxylation of vitamin D'), ('CHEBI_27300', 'vitamin D', 107, 'vitamin D'), ('UBERON_0001017', 'central nervous system', 134, 'central nervous system')]
PMC4992225	8/2016	S85-PMC4992225	['the Vitamin D measurements were all done in one laboratory in shiraz.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 4, 'vitamin D')]
PMC4992225	8/2016	S102-PMC4992225	['also, other study protocol measures for this group were similar to the Vitamin D group.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 71, 'vitamin D')]
PMC4992225	8/2016	S110-PMC4992225	['in the strata, each eligible Pregnant woman was assigned in the control or the Vitamin D groups using block randomization strategy.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 29, 'pregnant'), ('CHEBI_27300', 'vitamin D', 79, 'vitamin D')]
PMC4992225	8/2016	S127-PMC4992225	['the remaining 169 participants were assigned to the control or Vitamin D groups with a block randomization design, and they were referred to the laboratory to provide Blood sample.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 63, 'vitamin D'), ('UBERON_0000178', 'blood', 167, 'blood')]
PMC4992225	8/2016	S187-PMC4992225	['in a study by hovsepian et al., in men and women with average age of 41.4\xa0years in isfahan, 45\xa0% of men and 52.4\xa0% of women had Vitamin D concentrations lower than 20\xa0ng/ml ([52]).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 128, 'vitamin D')]
PMC4992225	8/2016	S191-PMC4992225	['in a study by hashempoor et al., in tehran, 67.1\xa0% of the men and women had Vitamin D concentrations lower than 25\xa0ng/ml [55].']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 76, 'vitamin D')]
PMC4992225	8/2016	S199-PMC4992225	['in their study used a dosage of 14,000\xa0iu Vitamin D supplement per week, equal to 2000\xa0iu per day, started at 27–30 weeks of Gestation.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 42, 'vitamin D'), ('GO_0007565', 'female pregnancy', 125, 'gestation')]
PMC4992225	8/2016	S200-PMC4992225	['of total, 89\xa0% achieved Vitamin D concentration of higher than 20\xa0ng/ml and 56\xa0% achieved Vitamin D concentration of higher than 32\xa0ng/ml [57].']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 24, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 90, 'vitamin D')]
PMC4992225	8/2016	S202-PMC4992225	['gave 2000\xa0iu of Vitamin D per day to non-Pregnant women in form of oral drops for 105\xa0days.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 16, 'vitamin D'), ('GO_0007565', 'female pregnancy', 41, 'pregnant')]
PMC4992225	8/2016	S227-PMC4992225	['in our study, nearly 70\xa0% of the mothers had Vitamin D deficiency.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 45, 'vitamin D')]
PMC4992225	8/2016	S233-PMC4992225	['unplanned Pregnancy was more frequent in the Vitamin D group than the control group.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 10, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 45, 'vitamin D')]
PMC4992225	8/2016	S243-PMC4992225	['in another study, 20,000 and 40,000\xa0iu Vitamin D per week were given to the obese and overweight People for one year.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 39, 'vitamin D'), ('NCBITaxon_10088', 'Mus <genus>', 97, 'people')]
PMC4992225	8/2016	S250-PMC4992225	['the essential enzymes for Vitamin D hydroxylation are found in the Brain that can produce Calcitriol.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 26, 'vitamin D'), ('UBERON_0000955', 'brain', 67, 'brain'), ('CHEBI_17823', 'calcitriol', 90, 'calcitriol')]
PMC4992225	8/2016	S265-PMC4992225	['as, in the two subgroups, the depression scores were not significantly lower in Vitamin D group compared to control group at 38–40 weeks.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 80, 'vitamin D')]
PMC4993554	8/2016	S103-PMC4993554	['the majority of women (62%, n=248) did not identify Liver as a high source of Vitamin A, among a list including cheese and sweet potato.']	N/A	N/A	[('UBERON_0002107', 'liver', 52, 'liver'), ('CHEBI_27300', 'vitamin D', 78, 'vitamin A')]
PMC4993554	8/2016	S119-PMC4993554	['the highest level of awareness was for Vitamin A (56.3%, n=225) and the lowest for Vitamin D (17.5%, n=70).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 39, 'vitamin A'), ('PR_000004370', 'asialoglycoprotein receptor 2', 47, 'A'), ('CHEBI_27300', 'vitamin D', 83, 'vitamin D'), ('PR_000006444', 'diacylglycerol kinase delta', 91, 'D')]
PMC4993554	8/2016	S169-PMC4993554	['they also varied in their ability to identify Foods containing high levels of key Nutrients (namely, Omega-3 Fatty Acids, iron, Vitamin A, and Iodine).']	N/A	N/A	[('CHEBI_33290', 'food', 46, 'foods'), ('CHEBI_33284', 'nutrient', 82, 'nutrients'), ('CHEBI_75862', 'alpha-D-rhamnofuranose', 101, 'omega-3 fatty acids'), ('CHEBI_27300', 'vitamin D', 128, 'vitamin A'), ('CHEBI_24859', 'iodine atom', 143, 'iodine')]
PMC4997301	9/2016	S39-PMC4997301	['the Nutrients in the sq-Lns for infants (20 g/d) were energy (118 kcal), protein (2.6 g), fat (9.6 g), Linoleic Acid (4.46 g), Α-Linolenic Acid (0.58 g), Vitamin A (400 μg Retinol equivalents), Thiamin (0.3 mg), riboflavin (0.4 mg), niacin (4 mg), Vitamin B-6 (0.3 mg), Vitamin B-12 (0.5 μg), Vitamin C (30 mg), Vitamin D (5 μg), Vitamin E (6 mg), Vitamin K (30 μg), Folic Acid (80 μg), Pantothenic Acid (1.8 mg), iron (6 mg), zinc (8 mg), copper (0.34 mg), calcium (280 mg), Phosphorus (190 mg), potassium (200 mg), magnesium (40 mg), Selenium (20 μg), Iodine (90 μg), and Manganese (1.2 mg).']	N/A	N/A	[('CHEBI_33284', 'nutrient', 4, 'nutrients'), ('UBERON_0000029', 'lymph node', 24, 'LNS'), ('CHEBI_30881', 'xanthine-8-carboxylic acid', 103, 'linoleic acid'), ('CHEBI_86354', '2-hydroxyacrylic acid', 127, 'α-linolenic acid'), ('CHEBI_27300', 'vitamin D', 154, 'vitamin A'), ('CHEBI_26536', 'retinoic acid', 172, 'retinol'), ('CHEBI_26948', 'vitamin B1', 194, 'thiamin'), ('CHEBI_52970', 'ubiquinol-6', 248, 'vitamin B-6'), ('CHEBI_85855', 'diacylglycerol 46:7', 270, 'vitamin B-12'), ('PR_000004770', 'Polycomb complex protein BMI-1', 278, 'B-12'), ('CHEBI_27300', 'vitamin D', 293, 'vitamin C'), ('CHEBI_27300', 'vitamin D', 312, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 330, 'vitamin E'), ('CHEBI_27300', 'vitamin D', 348, 'vitamin K'), ('CHEBI_30751', 'formic acid', 367, 'folic acid'), ('CHEBI_7916', 'pantothenic acid', 387, 'pantothenic acid'), ('CHEBI_35885', 'secondary phosphine', 476, 'phosphorus'), ('CHEBI_27568', 'selenium atom', 536, 'selenium'), ('CHEBI_24859', 'iodine atom', 554, 'iodine'), ('CHEBI_33351', 'seaborgium atom', 574, 'manganese')]
PMC4997421	8/2016	S28-PMC4997421	['outcomes: the main outcome variable was Vitamin A status as assessed by Serum Retinol concentrations.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 40, 'vitamin A'), ('UBERON_0001977', 'blood serum', 72, 'serum'), ('CHEBI_26536', 'retinoic acid', 78, 'retinol')]
PMC4997421	8/2016	S31-PMC4997421	['for the multivariate models, we dichotomized Vitamin A status into insufficient (<1.05) and sufficient (>1.05).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 45, 'vitamin A')]
PMC4997421	8/2016	S37-PMC4997421	['study participants’ dietary Intake of Vitamin A in Retinol activity equivalents (rae, mcg) per day was the main measure of Vitamin A intake [17].']	N/A	N/A	[('GO_0007631', 'feeding behavior', 28, 'intake'), ('CHEBI_27300', 'vitamin D', 38, 'vitamin A'), ('CHEBI_27810', 'resorcinol', 51, 'Retinol'), ('CHEBI_27300', 'vitamin D', 123, 'vitamin A')]
PMC4997421	8/2016	S66-PMC4997421	['for the multivariate model, a backward selection method was used to determine the best subset of variables associated with Vitamin A insufficiency.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 123, 'vitamin A')]
PMC4997421	8/2016	S77-PMC4997421	['the overall prevalence of Vitamin A insufficiency (>0.7–1.05) was 3.5%.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 26, 'vitamin A')]
PMC4997421	8/2016	S80-PMC4997421	['the proportion of Individuals who were Vitamin A deficient or insufficient increased as poverty status increased (table 2).']	N/A	N/A	[('NCBITaxon_1', 'root', 18, 'individuals'), ('CHEBI_27300', 'vitamin D', 39, 'vitamin A')]
PMC4997421	8/2016	S102-PMC4997421	['the primary cause of Vitamin A deficiency is inadequate dietary intake, especially with diets that are of poor quality or diversity.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 21, 'vitamin A')]
PMC4997421	8/2016	S103-PMC4997421	['vitamin a is a fat-soluble Vitamin that can be obtained from the diet in two forms, preformed Vitamin A or pro-Vitamin A Compounds.']	N/A	N/A	[('CHEBI_33229', 'vitamin (role)', 27, 'vitamin'), ('CHEBI_27300', 'vitamin D', 94, 'vitamin A'), ('CHEBI_27300', 'vitamin D', 111, 'vitamin A'), ('CHEBI_36357', 'polyatomic entity', 121, 'compounds')]
PMC4997421	8/2016	S104-PMC4997421	['preformed Vitamin A includes Retinol which can be found in Animal sources such as dairy products, fish, meat, and eggs and comprises up to 70% of the daily Vitamin A intake in the united states [30].']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 10, 'vitamin A'), ('CHEBI_26536', 'retinoic acid', 29, 'retinol'), ('NCBITaxon_33208', 'Metazoa', 59, 'animal'), ('CHEBI_27300', 'vitamin D', 156, 'vitamin A')]
PMC4997421	8/2016	S105-PMC4997421	['pro-Vitamin A Compounds are precursors for Retinol and include Β-Carotene, Α-Carotene, and β-cryptoxanthin [2].']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 4, 'vitamin A'), ('CHEBI_36357', 'polyatomic entity', 14, 'compounds'), ('CHEBI_26536', 'retinoic acid', 43, 'retinol'), ('CHEBI_28064', 'cyanidin 3-O-rutinoside', 63, 'β-carotene'), ('CHEBI_28061', 'alpha-D-galactose', 75, 'α-carotene')]
PMC4997421	8/2016	S107-PMC4997421	['pro-Vitamin A Compounds provide more than 30% of the daily Vitamin A intake in the united states [2].']	N/A	N/A	[('CHEBI_35586', '1H-purine', 4, 'vitamin A compounds'), ('CHEBI_27300', 'vitamin D', 59, 'vitamin A')]
PMC4997567	8/2016	S9-PMC4997567	['raising the standard of living, level of education, housings, and dietary supplementation of Vitamin D to the Pregnant women and infants are the Solution.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 93, 'vitamin D'), ('GO_0007565', 'female pregnancy', 110, 'pregnant'), ('CHEBI_75958', 'solution', 145, 'solution')]
PMC4997567	8/2016	S16-PMC4997567	["patients and methods\na total of 250 consecutive children with Vitamin D deficient Rachitic Bow Legs or Genu Varus, being 130 males and 120 females, between 2 - 4 years of age, together with 250 non-rachitic controls of the same age group, out of a total number of 1900 children with other types of rickets, other Rachitic deformity presentations, and other children's orthopaedic diseases, being 1000 males and 900 females, of similar and different ages, presented to the orthopaedic outpatient clinic of the national institute of Neuromotor System of imbaba, egypt, between september 2014 to september 2015, were enrolled in the study."]	N/A	N/A	[('CHEBI_27300', 'vitamin D', 62, 'vitamin D'), ('UBERON_0000323', 'late embryo', 82, 'rachitic bow legs'), ('UBERON_0004084', 'genital labium', 103, 'genu varus'), ('UBERON_0000387', 'meniscus', 313, 'rachitic'), ('UBERON_0027225', 'noradrenergic system', 531, 'Neuromotor System')]
PMC4997567	8/2016	S19-PMC4997567	['inclusion criteria\nthe cases were children between 2 - 4 years of age with history, clinical, laboratory, and radiographic findings of Vitamin D deficiency rickets causing bow Legs or Genu Varus, not receiving therapeutic doses of Vitamin D, with no history of prematurity, and not suffering any form of Renal, Liver, Cardiac, bone (excluding rickets) disease or any form of chronic infection.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 135, 'vitamin D'), ('UBERON_0000978', 'leg', 176, 'legs'), ('UBERON_0004084', 'genital labium', 184, 'genu varus'), ('CHEBI_27300', 'vitamin D', 231, 'vitamin D'), ('UBERON_0002113', 'kidney', 304, 'renal'), ('UBERON_0002107', 'liver', 311, 'liver'), ('UBERON_0000948', 'heart', 318, 'cardiac')]
PMC4997567	8/2016	S21-PMC4997567	['exclusion criteria\nchildren younger than 2 years and older than 4 years of age, with no history, clinical, laboratory, and radiographic findings of Vitamin D deficiency rickets, or rachitic but with no Bow Legs or Genu varus, receiving therapeutic doses of Vitamin D, history of prematurity, and suffering any form of Renal, Liver, Cardiac, bone (excluding rickets) disease or any form of chronic infection were rejected.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 148, 'vitamin D'), ('UBERON_0000160', 'intestine', 202, 'bow legs'), ('UBERON_2001304', 'vagal ganglion 3', 214, 'genu'), ('CHEBI_27300', 'vitamin D', 257, 'vitamin D'), ('UBERON_0002113', 'kidney', 318, 'renal'), ('UBERON_0002107', 'liver', 325, 'liver'), ('UBERON_0000948', 'heart', 332, 'cardiac')]
PMC4997567	8/2016	S25-PMC4997567	['maternal questionnaire\nthe mothers of all children were inquired about the number of Pregnancies, the intervals between Pregnancies, maternal nutrition, and Calcium and Vitamin D supplementation during Pregnancy.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 85, 'pregnancies'), ('GO_0007565', 'female pregnancy', 120, 'pregnancies'), ('CHEBI_22313', 'alkaline earth metal atom', 157, 'calcium'), ('CHEBI_27300', 'vitamin D', 169, 'vitamin D'), ('GO_0007565', 'female pregnancy', 202, 'pregnancy')]
PMC4997567	8/2016	S28-PMC4997567	['nutritional data included type of milk Fed during infancy, dietary calcium intake, and Calcium and Vitamin D supplementation.']	N/A	N/A	[('GO_0007631', 'feeding behavior', 39, 'fed'), ('CHEBI_22313', 'alkaline earth metal atom', 87, 'calcium'), ('CHEBI_27300', 'vitamin D', 99, 'vitamin D')]
PMC4997567	8/2016	S30-PMC4997567	['laboratory biochemical findings\nSerum calcium, phosphorus, alkaline phosphatase, and active Vitamin D 1,25(Oh)2D levels were measured by the standard methods.']	N/A	N/A	[('UBERON_0001977', 'blood serum', 32, 'Serum'), ('CHEBI_27300', 'vitamin D', 92, 'vitamin D'), ('CHEBI_37958', 'dye', 102, '1,'), ('CHEBI_66212', "5,7,3',4'-tetrahydroxy-2'-(3,3-dimethylallyl)isoflavone", 104, '25(OH)2D'), ('PR_000005450', 'chromatin accessibility complex protein 1', 110, '2D')]
PMC4997567	8/2016	S31-PMC4997567	['1,25(Oh)2D is the product of both Liver and Renal Hydroxylation of Vitamin D3Which is the most active Metabolite of Vitamin D. its standard Serum level ranges from 20 - 60 ng/dl.']	N/A	N/A	[('CHEBI_66212', "5,7,3',4'-tetrahydroxy-2'-(3,3-dimethylallyl)isoflavone", 2, '25(OH)2D'), ('UBERON_0002107', 'liver', 34, 'liver'), ('UBERON_0002113', 'kidney', 44, 'renal'), ('GO_0044444', 'cytoplasmic part', 50, 'hydroxylation'), ('CHEBI_83360', 'N-lignoceroylsphingosine-1-phosphocholine', 67, 'vitamin D3which'), ('CHEBI_39382', 'flufenoxuron', 102, 'metabolite'), ('CHEBI_27300', 'vitamin D', 116, 'vitamin D'), ('UBERON_0001977', 'blood serum', 140, 'serum')]
PMC4997567	8/2016	S40-PMC4997567	["the incidence of Vitamin D deficient Rachitic Genu Varus was 13.1% of the children's orthopaedic diseases in the national institute of Neuromotor System of egypt, with 6.8% of the total being males and 6.3% females, i.e ."]	N/A	N/A	[('CHEBI_27300', 'vitamin D', 17, 'vitamin D'), ('UBERON_0001910', 'medial forebrain bundle', 37, 'rachitic genu varus'), ('UBERON_0027225', 'noradrenergic system', 135, 'Neuromotor System')]
PMC4997567	8/2016	S41-PMC4997567	['52% of the Vitamin D deficient Rachitic Genu varus group being males and 48% females (table 1 ).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 11, 'vitamin D'), ('UBERON_0001944', 'pretectal region', 31, 'rachitic genu ...')]
PMC4997567	8/2016	S42-PMC4997567	['all children in the current study had both Vitamin D deficiency and Genu Varus deformity secondary to it.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 43, 'vitamin D'), ('UBERON_0004084', 'genital labium', 68, 'genu varus')]
PMC4997567	8/2016	S57-PMC4997567	['all the 250 cases (100%) received Calcium and Vitamin D supplementations during infancy, and also all the controls.']	N/A	N/A	[('CHEBI_22313', 'alkaline earth metal atom', 34, 'calcium'), ('CHEBI_27300', 'vitamin D', 46, 'vitamin D')]
PMC4997567	8/2016	S69-PMC4997567	['the current prospective study was concerned of the incidence of Vitamin D deficient Rachitic Genu Varus in the egyptian preschool children; which is the rate of occurrence of new cases.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 64, 'vitamin D'), ('UBERON_0001910', 'medial forebrain bundle', 84, 'rachitic genu varus')]
PMC4997567	8/2016	S96-PMC4997567	['summary\negyptian young children have a high incidence of Vitamin D deficient rickets causing Genu varus deformity.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 57, 'vitamin D'), ('UBERON_2001304', 'vagal ganglion 3', 93, 'genu')]
PMC4997567	8/2016	S97-PMC4997567	['a prospective study was made with 250 consecutive children between 2 - 4 years of age (130 males & 120 females) suffering Vitamin D deficient Rachitic Genu varus, together with 250 non-rachitic controls of the same age group, out of a total number of 1900 children (1000 males & 900 females) who presented to the orthopaedic outpatient clinic in the national institute of Neuromotor System of imbaba, egypt between september 2014 to september 2015.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 122, 'vitamin D'), ('UBERON_0001762', 'turbinate bone', 142, 'rachitic genu'), ('UBERON_0027225', 'noradrenergic system', 372, 'Neuromotor System')]
PMC4997567	8/2016	S100-PMC4997567	['the incidence of Vitamin D deficient Rachitic Genu Varus was slightly greater in males (6.8%) than that in females (6.3%).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 17, 'vitamin D'), ('UBERON_0001910', 'medial forebrain bundle', 37, 'rachitic genu varus')]
PMC4997567	8/2016	S102-PMC4997567	['conclusion\nnutritional Vitamin D deficiency rickets, causing Rachitic Genu Varus deformity, is a multi-factorial condition comprising beside nutritional Vitamin D deficiency, environmental and lifestyle factors.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 23, 'vitamin D'), ('UBERON_0001910', 'medial forebrain bundle', 61, 'rachitic genu varus'), ('CHEBI_27300', 'vitamin D', 153, 'vitamin D')]
PMC4998950	4/2016	S30-PMC4998950	['caption (table-wrap): table 2\nodds ratios (ors) and 95% confidence intervals (cis) for autism spectrum disorder (asd), with and without comorbid intellectual disability, in relation to lifetime maternal history of diagnosed Vitamin D deficiencyvitamin D deficiencycasesor (95% ci)aor (95% ci)bor (95% ci)call asd\u2003no98591.00 (ref)1.00 (ref)1.00 (ref)\u2003yes232.20 (1.35–3.58)1.70 (1.03–2.79)1.78 (1.08–2.92)asd with intellectual disability\u2003no24631.00 (ref)1.00 (ref)1.00 (ref)\u2003yes135.08 (2.53–10.20)3.55 (1.76–7.18)2.51 (1.22–5.16)asd without intellectual disability\u2003no73961.00 (ref)1.00 (ref)1.00 (ref)\u2003yes101.23 (0.67–2.28)0.99 (0.52–1.87)1.28 (0.68–2.42)\nadjusted for year of Birth and gender.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 224, 'vitamin D'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 252, 'D'), ('GO_0007567', 'parturition', 675, 'birth')]
PMC4998950	4/2016	S41-PMC4998950	['no cases of Vitamin D deficiency were recorded before the Birth Of a Child.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 12, 'vitamin D'), ('GO_0007596', 'blood coagulation', 58, 'birth of ... child')]
PMC5014971	8/2016	S66-PMC5014971	['fortified dairy products were the Vitamin D source recommended by most respondents, followed by green leafy vegetables, fatty fish, fortified cereals, and Vitamin D supplements and multivitamins.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 34, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 155, 'vitamin D')]
PMC5014971	8/2016	S70-PMC5014971	['more than half of the respondents indicated that they never (32.7%) or rarely (23.8%) screen their Pregnant patients for Vitamin D; about one in four always (12.9%) or often (12.9%) screen.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 99, 'pregnant'), ('CHEBI_27300', 'vitamin D', 121, 'vitamin D')]
PMC5014971	8/2016	S75-PMC5014971	['a majority of the responding physicians agreed that alcohol abuse (79.2%) and african american race (51.5%) were risk factors for Vitamin D insufficiency.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 130, 'vitamin D')]
PMC5014971	8/2016	S84-PMC5014971	['the most common answer for Vitamin D supplementation dose given to a Pregnant woman with no sign of Vitamin D insufficiency was 1,000\u2009iu/day (41.6%), followed by 400\u2009iu/day (22.8%) and 600\u2009iu/day (20.8%).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 27, 'vitamin D'), ('GO_0007565', 'female pregnancy', 69, 'pregnant'), ('CHEBI_27300', 'vitamin D', 100, 'vitamin D')]
PMC5017622	9/2016	S106-PMC5017622	['according to fao [22] the Food groups included in the wdds include Starchy staples, dark green leafy vegetables, other Vitamin A rich fruits and vegetables, other fruits and vegetables, Organ meat, meat and fish, eggs, Legumes nuts and seeds, Milk and Milk products.']	N/A	N/A	[('CHEBI_33290', 'food', 26, 'food'), ('CHEBI_26738', 'sphingenine', 67, 'starchy'), ('CHEBI_27300', 'vitamin D', 119, 'vitamin A'), ('UBERON_0000062', 'organ', 186, 'organ'), ('NCBITaxon_7955', 'Danio rerio', 219, 'legumes'), ('UBERON_0001913', 'milk', 243, 'milk'), ('UBERON_0001913', 'milk', 252, 'milk')]
PMC5024513	9/2016	S8-PMC5024513	['pooled analysis of Individual means as a percentage of uk dietary reference intakes showed intakes of Vitamin D (34.8\xa0% ci 0–83.1) to be significantly below recommendations ( p \u2009=\u20090.05).']	N/A	N/A	[('NCBITaxon_1', 'root', 19, 'individual'), ('CHEBI_27300', 'vitamin D', 102, 'vitamin D')]
PMC5024513	9/2016	S31-PMC5024513	['a higher proportion of adolescent girls also had intakes of key Vitamins and Minerals below the lower reference Nutrient intake level than Adult women, including Vitamin A, riboflavin, Vitamin B12, Folate, iron, calcium, magnesium, potassium, zinc and Iodine.']	N/A	N/A	[('CHEBI_33277', 'gamma-tocotrienol', 64, 'vitamins'), ('CHEBI_46751', 'quinolizidine', 77, 'minerals'), ('CHEBI_33284', 'nutrient', 112, 'nutrient'), ('UBERON_0007023', 'adult organism', 139, 'adult'), ('CHEBI_27300', 'vitamin D', 162, 'vitamin A'), ('CHEBI_33279', 'vitamin D5', 185, 'vitamin B12'), ('CHEBI_30863', '5-azaorotic acid', 198, 'folate'), ('CHEBI_24859', 'iodine atom', 252, 'iodine')]
PMC5024513	9/2016	S192-PMC5024513	['intake of Vitamin D and Serum Selenium status were identified as being significantly low in pooled analysis of included studies.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 10, 'vitamin D'), ('UBERON_0001977', 'blood serum', 24, 'serum'), ('CHEBI_27568', 'selenium atom', 30, 'selenium')]
PMC5028238	10/2016	S79-PMC5028238	['subsequently, levels of 7-Dehydrocholesterol would increase allowing more available 7-Dehydrocholesterol to be converted to Vitamin D upon exposure to ultraviolet b light.']	N/A	N/A	[('CHEBI_17500', '7alpha-hydroxycholesterol', 24, '7-dehydrocholesterol'), ('CHEBI_17500', '7alpha-hydroxycholesterol', 84, '7-dehydrocholesterol'), ('CHEBI_27300', 'vitamin D', 124, 'vitamin D')]
PMC5028238	10/2016	S82-PMC5028238	['historically, there would have been an evolutionary pressure to maximize the small amount of sunlight available for Vitamin D Production in northern climates due to lower sunlight exposure.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 116, 'vitamin D'), ('GO_0071611', 'granulocyte colony-stimulating factor production', 116, 'vitamin D production')]
PMC5028238	10/2016	S88-PMC5028238	['typically, 7-Dehydrocholesterol can be converted into either Cholesterol or Vitamin D (Cholecalciferol).']	N/A	N/A	[('CHEBI_17500', '7alpha-hydroxycholesterol', 11, '7-dehydrocholesterol'), ('CHEBI_16113', 'cholesterol', 61, 'cholesterol'), ('CHEBI_27300', 'vitamin D', 76, 'vitamin D'), ('CHEBI_52550', 'theopalauamide', 87, 'cholecalciferol')]
PMC5029029	9/2016	S47-PMC5029029	['in addition to the biochemical tests (targeted at ckd), we progressively added iron status, B12, and 25-Oh Vitamin D to the routine monthly tests; Vitamins and iron supplements were employed on the basis of the biochemical results.']	N/A	N/A	[('CHEBI_27778', 'abequose', 92, 'B12'), ('CHEBI_86198', '1,2-di-[(11Z)-eicosenoyl]-sn-glycero-3-phosphocholine', 101, '25-OH'), ('CHEBI_27300', 'vitamin D', 107, 'vitamin D'), ('CHEBI_33277', 'gamma-tocotrienol', 147, 'vitamins')]
PMC5035678	4/2016	S17-PMC5035678	['Vitamin D (25-Hydroxy Vitamin D, or 25Ohd) is a fat-soluble Vitamin with Skeletal and non-Skeletal functions.']	N/A	N/A	[('CHEBI_28384', 'vitamin K', 0, 'Vitamin D'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 0, 'Vitamin D'), ('CHEBI_43141', '3-hydroxypropoxy group', 11, '25-hydroxy'), ('CHEBI_27300', 'vitamin D', 22, 'vitamin D'), ('CHEBI_72652', "7,2'-dihydroxy-4'-methoxyisoflavan-4-ylium cation", 36, '25OHD'), ('CHEBI_33229', 'vitamin (role)', 60, 'vitamin'), ('UBERON_0004288', 'skeleton', 73, 'skeletal'), ('UBERON_0004288', 'skeleton', 90, 'skeletal')]
PMC5035678	4/2016	S39-PMC5035678	['we excluded those women using Assisted Reproductive techniques (n = 1) or those with a history of high dose Vitamin D consumption during the previous 3 months (n = 1).']	N/A	N/A	[('GO_0000380', 'alternative mRNA splicing, via spliceosome', 30, 'assisted reproductive'), ('CHEBI_27300', 'vitamin D', 108, 'vitamin D')]
PMC5035678	4/2016	S40-PMC5035678	['the selected women were randomly assigned to receive either Vitamin D in the intervention group (i) or no supplementation in the control group (c).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 60, 'vitamin D')]
PMC5035678	4/2016	S47-PMC5035678	['we excluded the subjects with sufficient basal Serum Vitamin D in group i initially, and in group c at the end of trial.']	N/A	N/A	[('UBERON_0001977', 'blood serum', 47, 'serum'), ('CHEBI_27300', 'vitamin D', 53, 'vitamin D')]
PMC5035678	4/2016	S48-PMC5035678	['after excluding the patients with sufficient basal Vitamin D, the remaining participants in group i were instructed to take 200,000 iu Vitamin D3 for each of the first two days, and then 50,000 iu per week thereafter, up to 700,000 iu in total.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 51, 'vitamin D'), ('CHEBI_33279', 'vitamin D5', 135, 'vitamin D3'), ('PR_000001177', 'D(2) dopamine receptor', 143, 'D3')]
PMC5035678	4/2016	S94-PMC5035678	['the subject continued Vitamin D supplementation as specified in the study protocol.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 22, 'vitamin D')]
PMC5035678	4/2016	S131-PMC5035678	['(29) on 179 women with gdm, plasma Glucose level and homa-ir were compared in two groups receiving high dose (5000 iu daily) and low dose (400 iu daily) Vitamin D supplementation.']	N/A	N/A	[('CHEBI_17234', 'glucose', 35, 'glucose'), ('CHEBI_27300', 'vitamin D', 153, 'vitamin D')]
PMC5039809	10/2016	S15-PMC5039809	['different dietary sources yield different forms of Vitamin A.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 51, 'vitamin A')]
PMC5039809	10/2016	S16-PMC5039809	['specifically, Plant sources contain provitamin a Carotenoids, of which the most common is Β-Carotene, and Animal sources provide preformed Vitamin A, such as Retinoids and Retinyl Esters (5).']	N/A	N/A	[('NCBITaxon_33208', 'Metazoa', 14, 'plant'), ('CHEBI_50815', 'norgestimate', 49, 'carotenoids'), ('CHEBI_28064', 'cyanidin 3-O-rutinoside', 90, 'β-carotene'), ('NCBITaxon_33208', 'Metazoa', 106, 'animal'), ('CHEBI_27300', 'vitamin D', 139, 'vitamin A'), ('CHEBI_26537', 'retinoid', 158, 'retinoids'), ('CHEBI_26523', 'reactive oxygen species', 172, 'retinyl esters')]
PMC5039809	10/2016	S49-PMC5039809	['maternal Vitamin D status was determined from Serum 25-Hydroxyvitamin D concentrations.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 9, 'vitamin D'), ('UBERON_0001977', 'blood serum', 46, 'serum'), ('CHEBI_62218', '23,24-dihydrocucurbitacin D', 52, '25-hydroxyvitamin D')]
PMC5039809	10/2016	S77-PMC5039809	['the use of Vitamin A supplements was comparable for women included in this analysis and other women in the Sws cohort (table 1).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 11, 'vitamin A'), ('PR_000015683', 'type 2 lactosamine alpha-2,3-sialyltransferase', 107, 'SWS')]
PMC5045784	10/2016	S27-PMC5045784	['we measured 25(Oh)D levels, a combination of 25(Oh)D2And 25(Oh)D3, which represent the best analytes for overall Vitamin D status11using diasorin liaison (diasorin, stillwater, mn, usa), which uses a chemiluminescence immunoassay12to determine Plasma concentrations of 25(Oh)D. for quality control, the laboratory used the us national institute of standards and technology level 1.']	N/A	N/A	[('CHEBI_71657', 'versiconol acetate', 12, '25(OH)D'), ('CHEBI_76948', 'ent-manool', 45, '25(OH)D2and'), ('CHEBI_62946', 'ammonium sulfate', 57, '25(OH)D3'), ('CHEBI_27300', 'vitamin D', 113, 'vitamin D'), ('UBERON_0001969', 'blood plasma', 244, 'plasma'), ('CHEBI_71657', 'versiconol acetate', 269, '25(OH)D'), ('PR_000003010', 'moesin isoform 1', 271, '(OH ... D')]
PMC5045784	10/2016	S82-PMC5045784	['for example, for exclusively Human Milk-Fed infants with fortification of Human milk fortifier that contains Vitamin D, we additionally provide 200 units per day.']	N/A	N/A	[('NCBITaxon_9606', 'Homo sapiens', 29, 'human'), ('UBERON_0001913', 'milk', 35, 'milk'), ('GO_0007631', 'feeding behavior', 40, 'fed'), ('NCBITaxon_9606', 'Homo sapiens', 74, 'human'), ('CHEBI_27300', 'vitamin D', 109, 'vitamin D')]
PMC5051327	9/2016	S21-PMC5051327	['furthermore, we compared the rate of Birth asphyxia in women with Vitamin D deficiency and non-deficiency in early Pregnancy.']	N/A	N/A	[('GO_0007567', 'parturition', 37, 'birth'), ('CHEBI_27300', 'vitamin D', 66, 'vitamin D'), ('GO_0007565', 'female pregnancy', 115, 'pregnancy')]
PMC5051327	9/2016	S29-PMC5051327	['Vitamin D analysis\nVenous Serum samples were collected at enrolment between february 1994 and june 1995 at a mean of 12\u2005weeks of Gestation, centrifuged and stored at −80°c until analysis of 25-Oh Vitamin D. 25-Oh Vitamin D levels were measured in nmol/l.']	N/A	N/A	[('CHEBI_28384', 'vitamin K', 0, 'Vitamin D'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 0, 'Vitamin'), ('UBERON_0001638', 'vein', 19, 'Venous'), ('UBERON_0001977', 'blood serum', 26, 'serum'), ('GO_0007565', 'female pregnancy', 129, 'gestation'), ('CHEBI_86198', '1,2-di-[(11Z)-eicosenoyl]-sn-glycero-3-phosphocholine', 190, '25-OH'), ('CHEBI_27300', 'vitamin D', 196, 'vitamin D'), ('CHEBI_86198', '1,2-di-[(11Z)-eicosenoyl]-sn-glycero-3-phosphocholine', 207, '25-OH'), ('CHEBI_27300', 'vitamin D', 213, 'vitamin D')]
PMC5051327	9/2016	S34-PMC5051327	['we performed a logistic regression analysis and used emergency caesarean Delivery due to suspected fetal distress as the dependent variable and Vitamin D level, and smoking habits and parity as independent variables.']	N/A	N/A	[('GO_0007567', 'parturition', 73, 'delivery'), ('CHEBI_27300', 'vitamin D', 144, 'vitamin D')]
PMC5051327	9/2016	S39-PMC5051327	['in the crude analysis, the mean 25-Oh Vitamin D levels in women undergoing caesarean Delivery due to suspected asphyxia was 43.6±18\u2005nmol/l, which was comparable to controls, 48.6±19\u2005nmol/l (p=0.1).']	N/A	N/A	[('CHEBI_86198', '1,2-di-[(11Z)-eicosenoyl]-sn-glycero-3-phosphocholine', 32, '25-OH'), ('CHEBI_27300', 'vitamin D', 38, 'vitamin D'), ('GO_0007567', 'parturition', 85, 'delivery')]
PMC5051327	9/2016	S40-PMC5051327	['in the adjusted analysis, controlling for nulliparity and smoking, Vitamin D levels were significantly lower in cases versus controls (p=0.04).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 67, 'vitamin D')]
PMC5051327	9/2016	S43-PMC5051327	['*logistic regression analysis including nulliparity, smoking and Vitamin D level.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 65, 'vitamin D')]
PMC5051327	9/2016	S46-PMC5051327	['the rate of Birth asphyxia was more than doubled in women with Vitamin D deficiency as compared to non-deficient women in crude and adjusted analysis (or=2.4, 95% ci 1.1 to 5.7 and or=2.9, 95% ci 1.2\xa0to 7.0, respectively).']	N/A	N/A	[('GO_0007567', 'parturition', 12, 'birth'), ('CHEBI_27300', 'vitamin D', 63, 'vitamin D')]
PMC5051327	9/2016	S48-PMC5051327	['the proportion of Pregnant women with Vitamin D deficiency (<50\u2005nmol/l) in the whole population was 70% during winter/spring season (december–may) and 36% during summer season.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 18, 'pregnant'), ('CHEBI_27300', 'vitamin D', 38, 'vitamin D')]
PMC5051327	9/2016	S49-PMC5051327	['caption (table-wrap): table\xa02\n\ncharacteristics in relation to maternal Vitamin D levels in the whole study group25-Oh Vitamin D<50\u2005nmol/l≥ 50\u2005nmol/lsignificance of difference (p)Vitamin D deficiencynot deficiencyn=95n=78 maternal characteristics \u2003age (years)29.15.330.24.40.1\u2003height (cm)163.25.9166.37.10.02\u2003body mass index (kg/m2)23.74.122.93.60.2\u2003nulliparous (n)4244.2%4355.1%0.2\u2003smoker (n)1818.9%1721.8%0.6 mode of Delivery \u2003vaginal spontaneous (n)5254.7%4659.0%0.6\u2003vaginal assisted (n)33.2%79.0%0.2\u2003caesarean section (n)4042.1%2532.1%0.2\u2003cs due to suspected fetal distress (n)3334.7%2025.6%0.2 neonatal outcome \u2003Gestational age (days)273.019.1278.914.60.02\u2003Preterm Delivery (n)1313.7%45.1%0.06\u2003Birth weight (g)3323.58193447.56780.3\u2003sga (n)1111.6%56.4%0.2\u20035\u2005min apgar score <7 (n)66.3%22.6%0.3\u2003Umbilical Artery ph7.200.097.230.070.1\u2003Umbilical Vein ph7.280.097.300.080.4\u2003Umbilical Cord ph ≤7.152021.1%810.3%0.06\u2003Birth asphyxia2324.2%911.5%0.03\nmean and sd or number and percentages are given.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 71, 'vitamin D'), ('CHEBI_86030', 'O-(hydroxyhexadecanoyl)carnitine', 114, '-OH'), ('CHEBI_27300', 'vitamin D', 118, 'vitamin D'), ('CHEBI_28384', 'vitamin K', 178, 'Vitamin D'), ('GO_0007567', 'parturition', 418, 'delivery'), ('GO_0007565', 'female pregnancy', 616, 'Gestational'), ('GO_0007128', 'meiotic prophase I', 661, 'Preterm'), ('GO_0007567', 'parturition', 669, 'delivery'), ('GO_0007567', 'parturition', 698, 'Birth'), ('UBERON_0001310', 'umbilical artery', 797, 'Umbilical artery'), ('UBERON_0002066', 'umbilical vein', 836, 'Umbilical vein'), ('UBERON_0002331', 'umbilical cord', 873, 'Umbilical cord'), ('GO_0007567', 'parturition', 914, 'Birth')]
PMC5054480	9/2016	S30-PMC5054480	['the patient was taking Prenatal Vitamins daily, Vitamin D tablets (1000 iu), and Calcium Carbonate tablets as needed.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 23, 'prenatal'), ('CHEBI_33277', 'gamma-tocotrienol', 32, 'vitamins'), ('CHEBI_27300', 'vitamin D', 48, 'vitamin D'), ('CHEBI_3311', 'calcium carbonate', 81, 'calcium carbonate')]
PMC5054480	9/2016	S34-PMC5054480	['pth was measured at 29.3 pmol/l, Vitamin D levels were normal, and bilateral nephrocalcinosis was detected, along with a large Renal staghorn calculus without hydronephrosis.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 33, 'vitamin D'), ('UBERON_0002113', 'kidney', 127, 'renal')]
PMC5062906	10/2016	S28-PMC5062906	['dietary Vitamin D is converted in the Liver to the inactive Metabolite 25-Hydroxyvitamin D, 25(Oh)D, before being converted in the Kidney to the active Metabolite 1,25(Oh)2D.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 8, 'vitamin D'), ('UBERON_0002107', 'liver', 38, 'liver'), ('CHEBI_39382', 'flufenoxuron', 60, 'metabolite'), ('CHEBI_62218', '23,24-dihydrocucurbitacin D', 71, '25-hydroxyvitamin D'), ('CHEBI_71657', 'versiconol acetate', 92, '25(OH)D'), ('UBERON_0002113', 'kidney', 131, 'kidney'), ('CHEBI_39382', 'flufenoxuron', 152, 'metabolite'), ('CHEBI_66212', "5,7,3',4'-tetrahydroxy-2'-(3,3-dimethylallyl)isoflavone", 165, '25(OH)2D')]
PMC5062906	10/2016	S34-PMC5062906	['among females 12–44\xa0years of age, 28\xa0% of Pregnant/Lactating females and 37\xa0% of non-Pregnant/non-Lactating females are at risk of Vitamin D inadequacy [15].']	N/A	N/A	[('GO_0007565', 'female pregnancy', 42, 'pregnant'), ('GO_0007594', 'puparial adhesion', 51, 'lactating'), ('GO_0007565', 'female pregnancy', 85, 'pregnant'), ('GO_0007594', 'puparial adhesion', 98, 'lactating'), ('CHEBI_27300', 'vitamin D', 131, 'vitamin D')]
PMC5062906	10/2016	S35-PMC5062906	['the active Vitamin D Metabolite 1,25(Oh)2D has both Genomic and non-Genomic functions.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 11, 'vitamin D'), ('CHEBI_39382', 'flufenoxuron', 21, 'metabolite'), ('CHEBI_17996', 'chloride', 33, ','), ('CHEBI_66212', "5,7,3',4'-tetrahydroxy-2'-(3,3-dimethylallyl)isoflavone", 34, '25(OH)2D'), ('SO_0001026', 'genome', 52, 'genomic'), ('SO_0001026', 'genome', 68, 'genomic')]
PMC5062906	10/2016	S36-PMC5062906	['primarily, 1,25(Oh)2D functions by binding to the Vitamin D receptor (vdr) and initiating Gene Expression changes via Genomic vdr response elements.']	N/A	N/A	[('CHEBI_37958', 'dye', 11, '1,'), ('CHEBI_66212', "5,7,3',4'-tetrahydroxy-2'-(3,3-dimethylallyl)isoflavone", 13, '25(OH)2D'), ('CHEBI_27300', 'vitamin D', 50, 'vitamin D'), ('GO_0010467', 'gene expression', 90, 'gene expression'), ('SO_0000704', 'gene', 90, 'gene'), ('SO_0001026', 'genome', 118, 'genomic')]
PMC5062906	10/2016	S56-PMC5062906	['to maximize the robustness of phenotypic response to Vitamin D deficiency, we used collaborative cross (cc) inbred Mouse strains (cc001/unc and cc011/unc [30]).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 53, 'vitamin D'), ('NCBITaxon_10088', 'Mus <genus>', 115, 'mouse')]
PMC5062906	10/2016	S75-PMC5062906	['depletion was not complete despite being on diet lacking Vitamin D for more than 11\xa0weeks.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 57, 'vitamin D')]
PMC5062906	10/2016	S81-PMC5062906	['a dietary treatments are indicated in middle block : con (ain-93g), lvd (lacking Vitamin D), standard Chow (teklad 8604).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 81, 'vitamin D'), ('CHEBI_33290', 'food', 102, 'chow')]
PMC5062906	10/2016	S84-PMC5062906	['b illustration of crosses used in paternal transmission of Genomes exposed to Vitamin D depletion ( highlighted region depicts direct exposure), developmental timepoints and cell types tested ( parentheses ).']	N/A	N/A	[('SO_0001026', 'genome', 59, 'genomes'), ('CHEBI_27300', 'vitamin D', 78, 'vitamin D')]
PMC5062906	10/2016	S102-PMC5062906	['standard error of the mean\neffect of maternal Vitamin D deficiency on Development Of G1And G2Offspring were evaluated by body weight, body composition (percent fat and lean mass), Testes weight, and mature Sperm count.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 46, 'vitamin D'), ('GO_0048264', 'determination of ventral identity', 70, 'development of G1and G2offspring'), ('UBERON_0000473', 'testis', 180, 'testes'), ('CL_0000019', 'sperm', 206, 'sperm')]
PMC5062906	10/2016	S161-PMC5062906	['4\n\nmaternal Vitamin D deficiency perturbs Dna Methylation at Imprinted regions in Adult g1 Soma (Liver) and germline (Sperm).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 12, 'vitamin D'), ('GO_0006306', 'DNA methylation', 42, 'DNA methylation'), ('GO_0071514', 'genetic imprinting', 61, 'imprinted'), ('UBERON_0007023', 'adult organism', 82, 'adult'), ('GO_0044297', 'cell body', 91, 'soma'), ('UBERON_0002107', 'liver', 97, 'liver'), ('CL_0000019', 'sperm', 118, 'sperm')]
PMC5062906	10/2016	S194-PMC5062906	['5\n\nGrandmaternal Vitamin D deficiency perturbs Dna Methylation at Imprinted regions in Adult g2male Soma (Liver) and germline (Sperm).']	N/A	N/A	[('GO_0000050', 'urea cycle', 3, 'Grandmaternal'), ('CHEBI_27300', 'vitamin D', 17, 'vitamin D'), ('GO_0006306', 'DNA methylation', 47, 'DNA methylation'), ('GO_0071514', 'genetic imprinting', 66, 'imprinted'), ('UBERON_0007023', 'adult organism', 87, 'adult'), ('GO_0044297', 'cell body', 100, 'soma'), ('UBERON_0002107', 'liver', 106, 'liver'), ('CL_0000019', 'sperm', 127, 'sperm')]
PMC5062906	10/2016	S201-PMC5062906	['not significant\n\nVitamin D-dependent epimutations are unstable in the Soma and do not reflect transcriptional state\nto determine the developmental timing of Vitamin D-dependent Dna Methylation changes in g2adult Liver, and thus investigate the mode of inheritance, we assayed Dna Methylation levels at the h19/igf2 , Dlk1/Meg3 , snrpn , and Grb10 Domains in g2neonatal (pnd9) Liver.']	N/A	N/A	[('CHEBI_28384', 'vitamin K', 17, 'Vitamin D'), ('GO_0044297', 'cell body', 70, 'soma'), ('CHEBI_27300', 'vitamin D', 157, 'vitamin D'), ('GO_0006306', 'DNA methylation', 177, 'DNA methylation'), ('UBERON_0002107', 'liver', 212, 'liver'), ('GO_0006306', 'DNA methylation', 276, 'DNA methylation'), ('PR_000006549', 'doublesex- and mab-3-related transcription factor C2', 317, 'Dlk1'), ('PR_000010229', 'membrane-bound transcription factor site-1 protease', 322, 'Meg3'), ('PR_000008210', 'glutathione peroxidase 1', 341, 'Grb10'), ('SO_0000417', 'polypeptide_domain', 347, 'domains'), ('UBERON_0002107', 'liver', 376, 'liver')]
PMC5062906	10/2016	S276-PMC5062906	['7a, which provides the overall profile of Vitamin D-related methylation changes between control and lvd groups for each cell type and generation regardless of statistical significance.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 42, 'vitamin D')]
PMC5062906	10/2016	S321-PMC5062906	['cc001 and cc011 g0dams were Fed either control diet (con, ain-93g #110700, 1000\xa0iu/kg of Vitamin D3, dyets inc., pa) or diet lacking Vitamin D (lvd, modified ain-93g diet #119266, 0\xa0iu/kg of Vitamin D3, dyets inc., pa).']	N/A	N/A	[('GO_0007631', 'feeding behavior', 28, 'fed'), ('CHEBI_33279', 'vitamin D5', 89, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 89, 'vitamin D3'), ('CHEBI_27300', 'vitamin D', 133, 'vitamin D'), ('CHEBI_33279', 'vitamin D5', 191, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 191, 'vitamin D3')]
PMC5062906	10/2016	S323-PMC5062906	['this treatment window ensures depletion of Vitamin D before Conception and throughout early Development Of the Offspring.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 43, 'vitamin D'), ('GO_0007620', 'copulation', 60, 'conception'), ('GO_0098754', 'detoxification', 92, 'development of ... offspring')]
PMC5064894	10/2016	S22-PMC5064894	['in Rsv-Infected Human Airway Epithelial Cells, Vitamin D induces Iκβα, an Nf-Κb Inhibitor, in Airway Epithelium and decreases Rsv induction of inflammatory Genes [7].']	N/A	N/A	[('NCBITaxon_10088', 'Mus <genus>', 3, 'RSV'), ('GO_0007631', 'feeding behavior', 7, 'infected'), ('NCBITaxon_9606', 'Homo sapiens', 16, 'human'), ('CL_0000069', 'branched duct epithelial cell', 22, 'airway epithelial cells'), ('UBERON_0003209', 'blood nerve barrier', 22, 'airway epithelial'), ('CHEBI_27300', 'vitamin D', 47, 'vitamin D'), ('PR_000008988', 'interleukin-1 family member 5', 65, 'Iκβα'), ('GO_0071159', 'NF-kappaB complex', 74, 'NF-κB'), ('PR_000011111', 'N-terminal EF-hand calcium-binding protein 3', 74, 'NF-κB'), ('CHEBI_35222', 'inhibitor', 80, 'inhibitor'), ('UBERON_0010305', 'subdivision of conjunctiva', 94, 'airway epithelium'), ('NCBITaxon_10088', 'Mus <genus>', 126, 'RSV'), ('SO_0000704', 'gene', 156, 'genes')]
PMC5064894	10/2016	S29-PMC5064894	['in a trial in japan, school children randomized to 1200\xa0iu/day of Vitamin D compared to placebo had a significantly decreased risk of developing laboratory-proven influenza a (rr 0.58, 95\xa0% ci 0.34, 0.99) but not influenza b (rr 1.39, 95\xa0% ci 0.90-2.15) [22].']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 66, 'vitamin D')]
PMC5064894	10/2016	S33-PMC5064894	['in this study, Pregnant women in london, england were randomized at 27\xa0weeks Gestation to receive either no Vitamin D, 800\xa0iu Ergocalciferol daily until Delivery, or a single bolus of 200,000\xa0iu Cholecalciferol.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 15, 'pregnant'), ('GO_0007565', 'female pregnancy', 77, 'gestation'), ('CHEBI_27300', 'vitamin D', 108, 'vitamin D'), ('CHEBI_4910', 'etomidate', 126, 'ergocalciferol'), ('GO_0007567', 'parturition', 153, 'delivery'), ('CHEBI_52550', 'theopalauamide', 195, 'cholecalciferol')]
PMC5064894	10/2016	S40-PMC5064894	['in south asia, biochemical Vitamin D deficiency is common among women and young infants [26].']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 27, 'vitamin D')]
PMC5064894	10/2016	S41-PMC5064894	['our study in dhaka is being conducted in a population known to have a high prevalence of Vitamin D deficiency as well as high incidence of early infant Respiratory infection morbidity and mortality [27–29].']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 89, 'vitamin D'), ('UBERON_0001004', 'respiratory system', 152, 'respiratory')]
PMC5064894	10/2016	S46-PMC5064894	['methods\n\ndesign\nthe mdig trial is a randomized placebo-controlled dose-ranging trial of maternal Vitamin D supplementation during Pregnancy and Lactation to improve infant linear growth in dhaka, bangladesh.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 97, 'vitamin D'), ('GO_0007565', 'female pregnancy', 130, 'pregnancy'), ('GO_0007595', 'lactation', 144, 'lactation')]
PMC5064894	10/2016	S61-PMC5064894	['interventions and randomization\na full description of the intervention groups along with the rationale for choice of Vitamin D dosages may be found in the methods paper describing the mdig trial [30].']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 117, 'vitamin D')]
PMC5064894	10/2016	S62-PMC5064894	['three intervention groups are receiving weekly Prenatal Vitamin D supplementation of 4200\xa0iu/week, 16,800\xa0iu/week, or 28,000\xa0iu/week respectively given as a single weekly dose beginning in the 2ndtrimester of Pregnancy.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 47, 'prenatal'), ('CHEBI_27300', 'vitamin D', 56, 'vitamin D'), ('GO_0007565', 'female pregnancy', 209, 'pregnancy')]
PMC5064894	10/2016	S76-PMC5064894	['participants, investigators, field personnel, study lab staff and data analysts are blinded to Vitamin D or placebo group allocation.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 95, 'vitamin D')]
PMC5064894	10/2016	S184-PMC5064894	['secondary analyses will include comparing aggregated “high-dose” Vitamin D groups (16,800\xa0iu/week (group c) and 28,000\xa0iu/week (group d)) versus low/no Vitamin D groups (4200\xa0iu/week (group b) and placebo (group a)) to optimize power for detecting smaller differences.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 65, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 152, 'vitamin D')]
PMC5073870	10/2016	S126-PMC5073870	['for Perinatal Care, services include a maternity incentive of npr 500 for women who go to government (and certain participating private) health facilities for institutional Delivery, and Postnatal visits by fchvs to distribute Vitamin A and iron-Folate.']	N/A	N/A	[('GO_0036356', 'cyclic 2,3-diphosphoglycerate synthetase activity', 4, 'perinatal care'), ('UBERON_0012101', 'perinatal stage', 4, 'perinatal'), ('GO_0007567', 'parturition', 173, 'delivery'), ('GO_0007567', 'parturition', 187, 'postnatal'), ('CHEBI_27300', 'vitamin D', 227, 'vitamin A'), ('PR_000004370', 'asialoglycoprotein receptor 2', 235, 'A'), ('CHEBI_30863', '5-azaorotic acid', 246, 'folate')]
PMC5084016	10/2016	S4-PMC5084016	['this particularly applies to Docosahexaenoic Acid (Dha), Iron, Iodine, Calcium, Folic Acid, and Vitamin D, also in the italian population.']	N/A	N/A	[('CHEBI_36003', 'decenoic acid', 29, 'docosahexaenoic acid'), ('CHEBI_17874', 'dihydrozeatin', 51, 'DHA'), ('CHEBI_24870', 'ion', 57, 'iron'), ('CHEBI_24859', 'iodine atom', 63, 'iodine'), ('CHEBI_22313', 'alkaline earth metal atom', 71, 'calcium'), ('CHEBI_30751', 'formic acid', 80, 'folic acid'), ('CHEBI_27300', 'vitamin D', 96, 'vitamin D')]
PMC5084016	10/2016	S116-PMC5084016	['Vitamin D\nthe term Vitamin D comprises the two main molecular species that share vitamin activity: Cholecalciferol (Vitamin D3, derived from Cholesterol and synthesized by the Animal Organisms) and Ergocalciferol (Vitamin D2, derived from Ergosterol, found in vegetables).']	N/A	N/A	[('CHEBI_28384', 'vitamin K', 0, 'Vitamin D'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 0, 'Vitamin D'), ('CHEBI_27300', 'vitamin D', 19, 'vitamin D'), ('CHEBI_52550', 'theopalauamide', 99, 'cholecalciferol'), ('CHEBI_33279', 'vitamin D5', 116, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 116, 'vitamin D3'), ('CHEBI_16113', 'cholesterol', 141, 'cholesterol'), ('NCBITaxon_33208', 'Metazoa', 176, 'animal'), ('NCBITaxon_1', 'root', 183, 'organisms'), ('CHEBI_4910', 'etomidate', 198, 'ergocalciferol'), ('CHEBI_28934', 'vitamin D2', 214, 'vitamin D2'), ('PR_000017299', 'VIP peptides', 214, 'vitamin D2'), ('CHEBI_16933', 'ergosterol', 239, 'ergosterol')]
PMC5084016	10/2016	S124-PMC5084016	['high amounts of Vitamin D are contained in cod Liver oil.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 16, 'vitamin D'), ('UBERON_0002107', 'liver', 47, 'liver')]
PMC5084016	10/2016	S193-PMC5084016	['Folic Acid, iron, zinc, Calcium, Vitamin C, and Vitamin D (in addition to energy and protein), are the main Micronutrients for which the requirement physiologically increases during Pregnancy and Lactation.']	N/A	N/A	[('CHEBI_30751', 'formic acid', 0, 'Folic acid'), ('CHEBI_22313', 'alkaline earth metal atom', 24, 'calcium'), ('CHEBI_27300', 'vitamin D', 33, 'vitamin C'), ('CHEBI_27300', 'vitamin D', 48, 'vitamin D'), ('CHEBI_33839', 'macromolecule', 108, 'micronutrients'), ('GO_0007565', 'female pregnancy', 182, 'pregnancy'), ('GO_0007595', 'lactation', 196, 'lactation')]
PMC5084016	10/2016	S212-PMC5084016	['this particularly applies to Dha, iron, Iodine, Calcium, Folic Acid, and Vitamin D (table 4).']	N/A	N/A	[('CHEBI_17874', 'dihydrozeatin', 29, 'DHA'), ('CHEBI_24859', 'iodine atom', 40, 'iodine'), ('CHEBI_22313', 'alkaline earth metal atom', 48, 'calcium'), ('CHEBI_30751', 'formic acid', 57, 'folic acid'), ('CHEBI_27300', 'vitamin D', 73, 'vitamin D')]
PMC5084041	10/2016	S8-PMC5084041	['determinants of Vitamin D deficiency at t1 were of non-north european origin, and had less sun exposure, lower Vitamin D intake and lower age.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 16, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 111, 'vitamin D')]
PMC5084041	10/2016	S11-PMC5084041	['the overall prevalence of Vitamin D deficiency was low but common among women Born in africa and asia.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 26, 'vitamin D'), ('GO_0007567', 'parturition', 78, 'born')]
PMC5084041	10/2016	S15-PMC5084041	['one of these areas of interest is Vitamin D status during Pregnancy.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 34, 'vitamin D'), ('GO_0007565', 'female pregnancy', 58, 'pregnancy')]
PMC5084041	10/2016	S16-PMC5084041	['the Pregnant woman’s Vitamin D status determines the Vitamin D status of her newborn infant [1].']	N/A	N/A	[('GO_0007565', 'female pregnancy', 4, 'pregnant'), ('CHEBI_27300', 'vitamin D', 21, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 53, 'vitamin D')]
PMC5084041	10/2016	S34-PMC5084041	['determinants of Vitamin D deficiency in the first trimester of Pregnancy and of changes in Vitamin D status during Pregnancy were identified.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 16, 'vitamin D'), ('GO_0007565', 'female pregnancy', 63, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 91, 'vitamin D'), ('GO_0007565', 'female pregnancy', 115, 'pregnancy')]
PMC5084041	10/2016	S48-PMC5084041	['at both time-points, participants answered a questionnaire regarding sun exposure (sun-Seeking behaviour and clothing style); recent travel <35° n, intake of Foods rich in Vitamin D (Milk and oily fish at t1 with the addition of Margarine, yoghurt and sour Milk in t3) [22]; supplement use; and background characteristics not included in the medical charts (education level and country of Birth).']	N/A	N/A	[('GO_0007568', 'aging', 86, '-seeking'), ('CHEBI_33290', 'food', 158, 'foods'), ('CHEBI_27300', 'vitamin D', 172, 'vitamin D'), ('UBERON_0001913', 'milk', 183, 'milk'), ('CHEBI_6784', 'mestranol', 229, 'margarine'), ('UBERON_0001913', 'milk', 257, 'milk'), ('GO_0007567', 'parturition', 389, 'birth')]
PMC5084041	10/2016	S63-PMC5084041	['statistical analysis\nrisk factors for Vitamin D deficiency (25(Oh)D <30 nmol/l) [26] were analysed using a multivariable logistic regression analysis.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 38, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 60, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 66, 'D')]
PMC5084041	10/2016	S65-PMC5084041	['the 25(Oh)D concentration was adjusted to the predicted yearly mean 25(Oh)D of the function, in order to account for seasonality in Vitamin D status.']	N/A	N/A	[('CHEBI_71657', 'versiconol acetate', 4, '25(OH)D'), ('CHEBI_71657', 'versiconol acetate', 68, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 132, 'vitamin D')]
PMC5084041	10/2016	S71-PMC5084041	['data collected at t3 were used as appropriate (season, recent travel to <35° n, dietary intake of Vitamin D and Vitamin D supplement use).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 98, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 112, 'vitamin D')]
PMC5084041	10/2016	S72-PMC5084041	['dietary Intake of Vitamin D at t3 also included Margarine, yoghurt and sour Milk at t3 (not included in the questionnaire at t1).']	N/A	N/A	[('GO_0007631', 'feeding behavior', 8, 'intake'), ('CHEBI_27300', 'vitamin D', 18, 'vitamin D'), ('CHEBI_6784', 'mestranol', 48, 'margarine'), ('UBERON_0001913', 'milk', 76, 'milk')]
PMC5084041	10/2016	S74-PMC5084041	['subgroup analyses of the variables relating to Vitamin D deficiency and season-corrected 25(Oh)D change were performed for women Born in africa and asia, using the same models.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 47, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 89, '25(OH)D'), ('PR_000009880', 'Lon protease, mitochondrial', 89, '25 ... OH ... D'), ('GO_0007567', 'parturition', 129, 'born')]
PMC5084041	10/2016	S76-PMC5084041	['also, 25(Oh)D at t1 and tobacco use at t1 were considered as confounders in the regression analysis of season-corrected change in 25(Oh)D.\ncontinuous variables were bmi (kg/m2), Gestational weight gain, dietary Vitamin D intake and age.']	N/A	N/A	[('CHEBI_71657', 'versiconol acetate', 6, '25(OH)D'), ('CHEBI_72805', '2-alkyl-sn-glycero-3-phosphocholine', 133, 'OH)D'), ('GO_0007565', 'female pregnancy', 178, 'gestational'), ('CHEBI_27300', 'vitamin D', 211, 'vitamin D')]
PMC5084041	10/2016	S77-PMC5084041	['categorical variables were season (december–february, march–may, june–august, september–november), Vitamin D supplement use (any dose and frequency: no/yes), origin (defined as country of Birth, categorized as north europe, america, continental europe, africa and asia), recent travel to a southern latitude (<35° n within six months of Blood sampling: no/yes), sun-seeking behaviour (preference for sun, both sun and shade or shade in sunny weather), clothing style when sunny (often, seldom or never exposes more skin than Face and Hands to the sun in warm weather), parity (0, 1, 2, ≥3 children), education level (primary, secondary, university), employment (unemployed, fulltime, part time, parental leave) and tobacco use (any: no/yes).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 99, 'vitamin D'), ('GO_0007567', 'parturition', 188, 'birth'), ('UBERON_0000178', 'blood', 337, 'blood'), ('UBERON_0001456', 'face', 525, 'face'), ('UBERON_0002398', 'manus', 534, 'hands')]
PMC5084041	10/2016	S125-PMC5084041	['at t1, 43% used a Supplement containing Vitamin D, including multivitamins and 77% reported taking some Supplement (not only Vitamin D containing).']	N/A	N/A	[('CHEBI_16158', 'steroid sulfate', 18, 'supplement'), ('CHEBI_27300', 'vitamin D', 40, 'vitamin D'), ('CHEBI_16158', 'steroid sulfate', 104, 'supplement'), ('CHEBI_27300', 'vitamin D', 125, 'vitamin D')]
PMC5084041	10/2016	S126-PMC5084041	['at t3, 42% used Vitamin D containing supplements and 61% in total reported some supplement use.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 16, 'vitamin D')]
PMC5084734	5/2016	S53-PMC5084734	['one option is fortification or Biofortification of staple Foods, which can increase intake of certain key Nutrients such as iron, zinc and Vitamin A.']	N/A	N/A	[('GO_0008150', 'biological_process', 31, 'biofortification'), ('GO_0007631', 'feeding behavior', 58, 'foods'), ('CHEBI_33284', 'nutrient', 106, 'nutrients'), ('CHEBI_27300', 'vitamin D', 139, 'vitamin A')]
PMC5085625	9/2016	S17-PMC5085625	['Vitamin D3 is transported to the Liver from the skin and Intestines by Vitamin D-Binding Protein (Dbp) [7].']	N/A	N/A	[('CHEBI_33237', 'vitamin D4', 0, 'Vitamin D3'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 0, 'Vitamin D3'), ('UBERON_0002107', 'liver', 33, 'liver'), ('UBERON_0000160', 'intestine', 57, 'intestines'), ('CHEBI_27300', 'vitamin D', 71, 'vitamin D'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 71, 'vitamin D-binding protein'), ('PR_000006317', 'mRNA-decapping enzyme 1A', 98, 'DBP')]
PMC5085625	9/2016	S20-PMC5085625	['the most active form of Vitamin D, 1,25-Dihydroxy-Vitamin D, is synthesized in Kidneys, as well as in other Tissues and cells, e.g., Parathyroid Glands, Prostate, Macrophages, Immune and Reproductive Cells [8].']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 24, 'vitamin D'), ('CHEBI_67771', 'Xestoproxamine C, (rel)-', 35, '1,25-dihydroxy-'), ('CHEBI_27300', 'vitamin D', 50, 'vitamin D'), ('UBERON_0002113', 'kidney', 79, 'kidneys'), ('UBERON_0000479', 'tissue', 108, 'tissues'), ('UBERON_0001132', 'parathyroid gland', 133, 'parathyroid glands'), ('UBERON_0002367', 'prostate gland', 153, 'prostate'), ('CL_0000235', 'macrophage', 163, 'macrophages'), ('CL_0000738', 'leukocyte', 176, 'immune ...'), ('UBERON_0002405', 'immune system', 176, 'immune'), ('CL_0000683', 'ependymoglial cell', 187, 'reproductive cells'), ('GO_0000003', 'reproduction', 187, 'reproductive')]
PMC5085625	9/2016	S154-PMC5085625	['a certified reference material (nist standard reference material (srm) 972) was used for Vitamin D measurement.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 89, 'vitamin D')]
PMC5085625	9/2016	S173-PMC5085625	['it would be necessary to get detailed information on Vitamin D and Calcium intake, as well as on patients’ habits (outdoor activities and sunbathing).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 53, 'vitamin D'), ('CHEBI_22313', 'alkaline earth metal atom', 67, 'calcium')]
PMC5089547	11/2016	S187-PMC5089547	['these were childhood anemia [61], maternal hookworm infection [62], and Vitamin A deficiency [63].']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 72, 'vitamin A')]
PMC5100620	10/2016	S41-PMC5100620	['the three types of Micronutrient supplements were capsules containing either: (i) 30\u2009mg of iron (Fumarate) and 400\u2009μg Folic Acid (fe30f); or (ii) 60\u2009mg iron and 400\u2009μg Folic Acid (fe60f); or (iii) multiple Micronutrients (mms)16containing 30\u2009mg of iron, 400\u2009μg of Folic Acid, 800\u2009μg of re Vitamin A (retinyl Acetate), 200 iu of Vitamin D (D3), 10\u2009mg of Vitamin E (α-Tocopherol Acetate), 70\u2009mg of Vitamin C, 1.4\u2009mg of vitamin B1(Thiamine Mononitrate), 1.4\u2009mg of Vitamin B2(riboflavin), 18\u2009mg of niacin, 1.9\u2009mg of Vitamin B6(Pyridoxine Hydrochloride), 2.6\u2009μg of Vitamin B12(Cyanocobalamin), 15\u2009mg of zinc (Sulphate), 2\u2009mg of copper (Sulphate), 65\u2009μg of Selenium (Sodium Selenite) and 150\u2009μg of Iodine (Potassium Iodide).']	N/A	N/A	[('CHEBI_33962', 'mu4-sulfido-quadro-tetracopper(6+)', 19, 'micronutrient'), ('CHEBI_16136', 'hydrogen sulfide', 97, 'fumarate'), ('CHEBI_30751', 'formic acid', 118, 'folic acid'), ('CHEBI_30751', 'formic acid', 168, 'folic acid'), ('CHEBI_33839', 'macromolecule', 206, 'micronutrients'), ('CHEBI_30751', 'formic acid', 264, 'folic acid'), ('CHEBI_27300', 'vitamin D', 289, 'vitamin A'), ('PR_000004370', 'asialoglycoprotein receptor 2', 297, 'A'), ('CHEBI_30089', 'acetate', 308, 'acetate'), ('CHEBI_27300', 'vitamin D', 328, 'vitamin D'), ('CHEBI_29238', 'tritium atom', 339, 'D3'), ('CHEBI_27300', 'vitamin D', 353, 'vitamin E'), ('CHEBI_27013', 'tocopherol', 366, 'tocopherol acetate'), ('CHEBI_27300', 'vitamin D', 396, 'vitamin C'), ('PR_000004693', 'Bcl-2-like protein 10', 425, 'B1'), ('CHEBI_9561', 'thiopental sodium', 428, 'thiamine mononitrate'), ('CHEBI_33279', 'vitamin D5', 461, 'vitamin B2'), ('CHEBI_33237', 'vitamin D4', 512, 'vitamin B6'), ('CHEBI_16410', 'pyridoxamine', 523, 'pyridoxine'), ('CHEBI_17883', 'hydrogen chloride', 534, 'hydrochloride'), ('CHEBI_33279', 'vitamin D5', 560, 'vitamin B12'), ('PR_000004481', 'V-type proton ATPase subunit B, kidney isoform', 560, 'vitamin B12'), ('CHEBI_38845', 'profenofos', 572, 'cyanocobalamin'), ('CHEBI_16189', 'sulfate', 604, 'sulphate'), ('CHEBI_16189', 'sulfate', 631, 'sulphate'), ('CHEBI_27568', 'selenium atom', 651, 'selenium'), ('CHEBI_77773', 'sodium selenide', 661, 'sodium selenite'), ('CHEBI_24859', 'iodine atom', 692, 'iodine'), ('CHEBI_8346', 'potassium iodide', 700, 'potassium iodide')]
PMC5118763	12/2016	S3-PMC5118763	['Plasma concentrations of Vitamin B-12, Folate, ferritin, and zinc were analyzed before the start of Micronutrient supplementation (week 14) and at week 30 of Pregnancy in 641 randomly selected women.']	N/A	N/A	[('UBERON_0001969', 'blood plasma', 0, 'Plasma'), ('CHEBI_27300', 'vitamin D', 25, 'vitamin B'), ('PR_000017269', 'ventral anterior homeobox 2', 25, 'vitamin B-12'), ('CHEBI_30863', '5-azaorotic acid', 39, 'folate'), ('CHEBI_33962', 'mu4-sulfido-quadro-tetracopper(6+)', 100, 'micronutrient'), ('GO_0007565', 'female pregnancy', 158, 'pregnancy')]
PMC5118763	12/2016	S6-PMC5118763	['results: at week 30 of Pregnancy, women in the mmn group had higher geometric mean concentrations of Vitamin B-12 than women in the fe60f group (119 compared with 101 pmol/l, respectively); no other differences in effectiveness of Micronutrient and Food regimens were observed.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 23, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 101, 'vitamin B'), ('PR_000017269', 'ventral anterior homeobox 2', 101, 'vitamin B-12'), ('CHEBI_33962', 'mu4-sulfido-quadro-tetracopper(6+)', 231, 'micronutrient'), ('CHEBI_33290', 'food', 249, 'food')]
PMC5118763	12/2016	S41-PMC5118763	['Plasma Vitamin B-12 and Folate were determined simultaneously by using an ria (simultrac-snb; mp biomedicals).']	N/A	N/A	[('UBERON_0001969', 'blood plasma', 0, 'Plasma'), ('CHEBI_27300', 'vitamin D', 7, 'vitamin B'), ('PR_000017269', 'ventral anterior homeobox 2', 7, 'vitamin B-12'), ('CHEBI_30863', '5-azaorotic acid', 24, 'folate')]
PMC5118763	12/2016	S91-PMC5118763	['the mean Plasma Vitamin B-12 concentration was significantly higher among women in the mmn regimen at week 30 of Pregnancy, but no other significant differences were observed in Plasma concentrations of Folate, ferritin, and zinc between the different Micronutrient supplementation regimens (table 2).']	N/A	N/A	[('UBERON_0001969', 'blood plasma', 9, 'plasma'), ('CHEBI_27300', 'vitamin D', 16, 'vitamin B'), ('PR_000017269', 'ventral anterior homeobox 2', 16, 'vitamin B-12'), ('GO_0007565', 'female pregnancy', 113, 'pregnancy'), ('UBERON_0001969', 'blood plasma', 178, 'plasma'), ('CHEBI_30863', '5-azaorotic acid', 203, 'folate'), ('CHEBI_33962', 'mu4-sulfido-quadro-tetracopper(6+)', 252, 'micronutrient')]
PMC5118763	12/2016	S102-PMC5118763	['caption (fig): figure 2\n\nlowess curves of associations between total numbers of capsules Consumed from week 14 to 30 of Pregnancy and maternal Plasma concentrations of Vitamin B-12 (a), Folate (b), ferritin (c), and zinc (d) at week 30 of Pregnancy, by Micronutrient supplementation type.']	N/A	N/A	[('GO_0007631', 'feeding behavior', 89, 'consumed'), ('GO_0007565', 'female pregnancy', 120, 'pregnancy'), ('UBERON_0001969', 'blood plasma', 143, 'plasma'), ('CHEBI_27300', 'vitamin D', 168, 'vitamin B'), ('CHEBI_30863', '5-azaorotic acid', 186, 'folate'), ('GO_0007565', 'female pregnancy', 239, 'pregnancy'), ('CHEBI_33962', 'mu4-sulfido-quadro-tetracopper(6+)', 253, 'micronutrient')]
PMC5118763	12/2016	S108-PMC5118763	['furthermore, there were no significant differences in Vitamin B-12 concentration between tertiles of capsule intake within any of the Micronutrient supplementation types ( table 3 ).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 54, 'vitamin B'), ('PR_000017269', 'ventral anterior homeobox 2', 54, 'vitamin B-12'), ('CHEBI_33962', 'mu4-sulfido-quadro-tetracopper(6+)', 134, 'micronutrient')]
PMC5118763	12/2016	S109-PMC5118763	['caption (table-wrap): table 3\n\nPlasma Vitamin B-12 concentrations at week 30 of Pregnancy by tertile of capsule Intake and Micronutrient supplementation type in a selected sample of rural bangladeshi women participating in the minimat trial1micronutrient typelowest tertile (6–65 capsules)middle tertile (66–99 capsules)highest tertile (100–157 capsules)fe30f \u2003n 605465\u2003mean,2pmol/l103 (88, 120)120 (87, 141)101 (87, 119)\u2003unadjusted mean difference3reference0.15 (−0.08, 0.38)−0.01 (−0.23, 0.21)\u2003adjusted mean difference4reference0.23 (−0.01, 0.47)0.02 (−0.22, 0.25)fe60f \u2003n 676561\u2003mean,2pmol/l94 (81, 109)112 (96, 130)98 (85, 116)\u2003unadjusted mean difference3reference0.17 (−0.04, 0.39)0.05 (−0.17, 0.26)\u2003adjusted mean difference4reference0.18 (−0.04, 0.40)−0.00 (−0.23, 0.22)mmn \u2003n 526967\u2003mean,2pmol/l103 (87, 119)124 (108, 143)128 (111, 147)\u2003unadjusted mean difference3reference0.19 (−0.01, 0.40)0.22 (0.02, 0.43)*\u2003adjusted mean difference4reference0.16 (−0.05, 0.38)0.15 (−0.07, 0.37)\ndata were analyzed by using general linear models.']	N/A	N/A	[('UBERON_0001969', 'blood plasma', 31, 'Plasma'), ('CHEBI_27300', 'vitamin D', 38, 'vitamin B'), ('PR_000017269', 'ventral anterior homeobox 2', 38, 'vitamin B-12'), ('GO_0007565', 'female pregnancy', 80, 'pregnancy'), ('GO_0007631', 'feeding behavior', 112, 'intake'), ('CHEBI_33962', 'mu4-sulfido-quadro-tetracopper(6+)', 123, 'micronutrient')]
PMC5118763	12/2016	S157-PMC5118763	['at week 30 of Pregnancy, Plasma Vitamin B-12 concentrations were significantly higher among the women in the mmn group.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 14, 'pregnancy'), ('UBERON_0001969', 'blood plasma', 25, 'plasma'), ('CHEBI_27300', 'vitamin D', 32, 'vitamin B'), ('PR_000017269', 'ventral anterior homeobox 2', 32, 'vitamin B-12')]
PMC5119728	11/2016	S49-PMC5119728	['christian, 2010 [43]rct, 676 children followed to age of 7 to 9 years.Pregnant women were randomly allocatedto receive daily Iron/Folic Acid (400 ug), Iron/Folic Acid/zinc, or multiple Micronutrients containing these plus 11 other Micronutrients, or placebo (Vitamin A only) groups from early Pregnancy to 3 months Postpartum.beneficial.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 70, 'Pregnant'), ('CHEBI_24870', 'ion', 125, 'iron'), ('CHEBI_30751', 'formic acid', 130, 'folic acid'), ('CHEBI_24870', 'ion', 151, 'iron'), ('CHEBI_30751', 'formic acid', 156, 'folic acid'), ('CHEBI_33839', 'macromolecule', 185, 'micronutrients'), ('CHEBI_33839', 'macromolecule', 231, 'micronutrients'), ('CHEBI_27300', 'vitamin D', 259, 'vitamin A'), ('GO_0007565', 'female pregnancy', 293, 'pregnancy'), ('GO_0007565', 'female pregnancy', 315, 'postpartum')]
PMC5129897	10/2016	S114-PMC5129897	['an 8-week clinical trial of 50,000 iu/wk of Vitamin D or placebo was conducted on patients with mdd in iran from october to december 2014.77baseline 25(Oh)D concentrations were 23 ± 15\xa0nmol/l in the placebo group and 35 ± 23\xa0nmol/l in the vitamin d group.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 44, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 149, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 155, 'D')]
PMC5129897	10/2016	S115-PMC5129897	['at the end of 8weeks, the concentrations were 21 ± 10\xa0nmol/l and 85 ± 23\xa0nmol/l, respectively, and the beck depression inventory total score decreased by 3.2 ± 1.6 in the placebo group and 8.0 ± 1.6 in the Vitamin D group.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 206, 'vitamin D')]
PMC5134748	11/2017	S7-PMC5134748	['there are significant differences between the two groups in all Micronutrient including Folic Acid, iron, Vitamin C, Vitamin B6, Vitamin B12 and zinc (p<0.001).']	N/A	N/A	[('CHEBI_33962', 'mu4-sulfido-quadro-tetracopper(6+)', 64, 'micronutrient'), ('CHEBI_30751', 'formic acid', 88, 'folic acid'), ('CHEBI_27300', 'vitamin D', 106, 'vitamin C'), ('CHEBI_33237', 'vitamin D4', 117, 'vitamin B6'), ('CHEBI_33279', 'vitamin D5', 129, 'vitamin B12')]
PMC5134748	11/2017	S59-PMC5134748	['values are given as number (%) ϰ2testfood items, portion per daycase group (n=331)control group (n=331)p valuevegetables0.012\xa0\xa0(<3 parts)282 (85.2)253 (76.4)\xa0\xa0(3-5 parts)49 (14.8)77 (23.3)\xa0\xa0(>5 parts)0 (0)1 (0.3)Fruits0.055\xa0\xa0(<2 parts)152 (45.9)122 (36.9)\xa0\xa0(2-4 parts)169 (51.1)195 (58.9)\xa0\xa0(>4 parts)10 (3)14 (4.2)breads and cereals<0.001\xa0\xa0(<6 parts)129 (39)88 (26.6)\xa0\xa0(6-11 parts)199 (60.1)208 (62.8)\xa0\xa0(>11 parts)3 (0.9)35 (10.6)meat and beans0.004\xa0\xa0(<2parts)268 (81.0)232 (70.1)\xa0\xa0(2-3 parts)63 (19.0)98 (29.6)\xa0\xa0(>3 parts)0 (0)1 (0.3)Dairy products<0.001\xa0\xa0(<2 parts)173 (52.3)120 (36.3)\xa0\xa0(2-3 parts)151 (45.6)190 (57.4)\xa0\xa0(>3 parts)7 (2.1)21 (6.3)Fats and oils0.019\xa0\xa0(<55 g)77 (23.3)50 (15.1)\xa0\xa0(55-66 g)113 (34.1)114 (34.4)\xa0\xa0(>66 g)141 (42.6)167 (50.5)\nin addition, there are significant differences between the two groups in terms of all Micronutrient factors including Folic Acid, iron, Vitamin C, Vitamin B6, Vitamin B12 and zinc (table 3).']	N/A	N/A	[('UBERON_0002281', 'vestibular membrane of cochlear duct', 212, 'Fruits0'), ('CHEBI_4323', 'Daphnoline', 535, 'Dairy'), ('CHEBI_33250', 'atom', 647, 'Fats'), ('CHEBI_33962', 'mu4-sulfido-quadro-tetracopper(6+)', 839, 'micronutrient'), ('CHEBI_30751', 'formic acid', 871, 'folic acid'), ('CHEBI_27300', 'vitamin D', 889, 'vitamin C'), ('CHEBI_33237', 'vitamin D4', 900, 'vitamin B6'), ('CHEBI_33279', 'vitamin D5', 912, 'vitamin B12')]
PMC5134748	11/2017	S63-PMC5134748	['for the women Consuming the Micronutrients or of spontaneous Abortion was significant in Acid Folic (0.986, 0.984-0.988), iron (0.868, 0.837-0.900), Vitamin C (0.949, 0.928-0.971), Vitamin B6 (0.096, 0.064-0.144), Vitamin B12 (0.129, 0.076-0.218), and zinc (0.288, 0.237-0.349).']	N/A	N/A	[('GO_0007631', 'feeding behavior', 14, 'consuming'), ('CHEBI_33839', 'macromolecule', 28, 'micronutrients'), ('GO_0007569', 'cell aging', 61, 'abortion'), ('CHEBI_37527', 'acid', 89, 'acid'), ('CHEBI_5054', 'Fibrin', 94, 'folic'), ('CHEBI_27300', 'vitamin D', 149, 'vitamin C'), ('CHEBI_33237', 'vitamin D4', 181, 'vitamin B6'), ('CHEBI_33279', 'vitamin D5', 214, 'vitamin B12'), ('PR_000004481', 'V-type proton ATPase subunit B, kidney isoform', 214, 'vitamin B12')]
PMC5146866	12/2016	S2-PMC5146866	['methods\namerican academy of pediatrics (aap) defined levels (ng/ml) were utilized to categorize the Vitamin D status in cb samples as deficient (5–15), insufficient (16–20), and sufficient (21–100).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 100, 'vitamin D')]
PMC5146866	12/2016	S8-PMC5146866	['we did not find an association between the Vitamin D status at Birth and pre-discharge clinical characteristics of the neonates.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 43, 'vitamin D'), ('GO_0007567', 'parturition', 63, 'birth')]
PMC5146866	12/2016	S14-PMC5146866	['the Drug and therapeutics committee of the lawson wilkins pediatric endocrine society classified Vitamin D levels\u2009<\u20095\xa0ng/ml in children as severely deficient, 5–15\xa0ng/ml as deficient, and 15–20\xa0ng/ml as insufficient [9].']	N/A	N/A	[('CHEBI_23888', 'drug', 4, 'Drug'), ('CHEBI_27300', 'vitamin D', 97, 'vitamin D')]
PMC5146866	12/2016	S17-PMC5146866	['a cb Vitamin D level\u2009≤\u200920\xa0ng/ml was detected in 84% of african american and 22% of white infants Born in florida [11], 55% of infants from the mixed ethnic population in belgium [12], and 55.5% of infants Born to italian women and 77.3% of the immigrant mothers in italy from latin, asian and african countries [13].']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 5, 'vitamin D'), ('GO_0007567', 'parturition', 97, 'born'), ('GO_0007567', 'parturition', 205, 'born')]
PMC5146866	12/2016	S32-PMC5146866	['samples proceed and testing procedure\nleftover samples in lavender top edta (Ethylenediaminetetraacetic Acid) tubes from routine collection of cb for identification of Blood type in all infants born in the hospital were used to test for Vitamin D levels.']	N/A	N/A	[('CHEBI_42191', 'ethylenediaminetetraacetic acid', 77, 'ethylenediaminetetraacetic acid'), ('UBERON_0000178', 'blood', 168, 'blood'), ('CHEBI_27300', 'vitamin D', 237, 'vitamin D')]
PMC5146866	12/2016	S38-PMC5146866	['tested levels of Calcidiol [25(Oh)D] and Vitamin D components, including the Ergocalciferol (Vitamin D2) and Cholecalciferol (Vitamin D3) were Expressed in ng/ml.']	N/A	N/A	[('CHEBI_17933', 'calcidiol', 17, 'calcidiol'), ('CHEBI_71657', 'versiconol acetate', 28, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 41, 'vitamin D'), ('CHEBI_4910', 'etomidate', 77, 'ergocalciferol'), ('CHEBI_28934', 'vitamin D2', 93, 'Vitamin D2'), ('PR_000017279', 'testis-specific basic protein Y 1', 93, 'Vitamin D2'), ('CHEBI_52550', 'theopalauamide', 109, 'cholecalciferol'), ('CHEBI_33237', 'vitamin D4', 126, 'Vitamin D3'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 126, 'Vitamin D3'), ('GO_0010467', 'gene expression', 143, 'expressed')]
PMC5146866	12/2016	S57-PMC5146866	['characteristics of Umbilical Cord Blood Vitamin D status\ncb levels of Vitamin D were classified as deficient, insufficient, and sufficient in 95 (38.9%, 95%ci 33.0–44.8), 79 (29.8%, 95%ci 24.3–35.3), and 91 (34.3%, 95%ci 28.6–40) infants, respectively.']	N/A	N/A	[('UBERON_0002331', 'umbilical cord', 19, 'umbilical cord'), ('UBERON_0000178', 'blood', 34, 'blood'), ('CHEBI_27300', 'vitamin D', 40, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 70, 'vitamin D')]
PMC5146866	12/2016	S58-PMC5146866	['the mean and 95% ci of mean of cb Vitamin D levels in infants defined with sufficient, insufficient, and deficient levels was 27.3\xa0ng/ml (26–28.5), 17.8\xa0ng/ml (17.4–18.1), and 11.6\xa0ng/ml (11–12.2), respectively.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 34, 'vitamin D')]
PMC5146866	12/2016	S59-PMC5146866	['as shown in table\xa01, mothers of infants with deficient and insufficient level of Vitamin D in cb were younger and had a greater number of Pregnancies as compared to mothers of infants with sufficient level of [25(Oh)D].']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 81, 'vitamin D'), ('GO_0007565', 'female pregnancy', 138, 'pregnancies'), ('CHEBI_71657', 'versiconol acetate', 210, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 210, '25(OH ... D')]
PMC5146866	12/2016	S62-PMC5146866	['the highest prevalence of Vitamin D deficiency was recorded in cb of infants Born to black mothers (61.8%) and Vitamin D sufficiency in infants Born to white mothers (46.5%).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 26, 'vitamin D'), ('GO_0007567', 'parturition', 77, 'born'), ('CHEBI_27300', 'vitamin D', 111, 'vitamin D'), ('GO_0007567', 'parturition', 144, 'born')]
PMC5146866	12/2016	S63-PMC5146866	['caption (table-wrap): table 1\n\nmaternal demographics and clinical characteristics with respect to cb Vitamin D statusparametricvitamin D status p valuedeficiency n \u2009=\u200995insufficiency n \u2009=\u200979sufficiency n \u2009=\u200991age (years)30.6+/−5.7(29.4–31.8)29.9+/−5.1(28.8–31.1)32.6+/−5.3(31.5–33.8)<0.01medicaid/uninsured16.0%(9.9–24.7)8.8%(4.3–16.9)6.7%(3.1–13.6)0.09weight at Birth (pounds)175+/−41(167–183)172+/−34(165–180)174+/−39(166–182)0.89multiple Gestation1.1%(0.002–0.06)1.3%(0.002–0.07)3.3%(0.11–0.09)0.47nulliparity (%)27.7%(19.6–37.4)38.8%(28.8–49.7)36.3%(27.1–46.5)0.26first gravidity (%)21.3%(9.1–23.5)26.3%(14.7–32.8)31.9%(6.9–20.4)0.56gravidity (number)3.4+/−2.4(2.9–3.9)2.8+/−1.9(2.3–3.2)2.4+/−1.3(2.1–2.6)<0.01gestational age38.9+/−1.3(38.6–39.1)39.2+/−1.2(38.9–39.5)39.0+/−1.3(38.7–39.3)0.15winter season Deliveries14.9%(9.1–23.5)22.5%(14.7–32.8)12.1%(6.9–20.4)0.17cesarean section32.9%(24.3–42.9)35.0%(25.5–45.9)41.8%(32.2–52.1)0.44vitamins supplementation66.0%(60.3–78.5)77.5%(67.2–85.3)67.0%(56.9–75.8)0.20iron supplementation8.5%(4.4–15.9)3.8%(1.3–10.5)2.2%(0.6–7.7)0.15thyroid medications9.6%(5.1–17.2)8.8%(4.3–16.9)8.8%(4.5–16.4)0.98substance abuse (smoking/alcohol/Drugs)3.2%(1.1–8.9)5.0%(2.0–12.2)6.6%(3.1–13.6)0.56morbidities during Pregnancy21.3%(14.2–30.6)26.3%(17.9–36.8)23.1%(15.6–32.7)0.74diabetes10.6%(5.9–18.5)12.5%(6.9–21.5)7.7%(3.8–15.1)0.57\ndata presented as mean or proportion (%) with 95% confidence interval\n\ncaption (fig): fig.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 101, 'vitamin D'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 135, 'D'), ('GO_0007567', 'parturition', 363, 'birth'), ('GO_0007565', 'female pregnancy', 441, 'gestation1'), ('GO_0060179', 'male mating behavior', 810, 'deliveries14'), ('CHEBI_23888', 'drug', 1177, 'drugs'), ('GO_0007565', 'female pregnancy', 1247, 'pregnancy21')]
PMC5146866	12/2016	S65-PMC5146866	['chi-square test statistics were used to compare cb vitamin status defined as deficient, insufficient and sufficient with respect to maternal race/ethnicity\n\nfactors associated with cb Vitamin D status\nmaternal race/ethnicity, age and gravidity were included in the multiple regression models to identify factors associated with detection of Vitamin D deficiency (model 1) and insufficiency (model 2) in infants’ cb.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 184, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 341, 'vitamin D')]
PMC5146866	12/2016	S68-PMC5146866	['when the same variables were included in each race/ethnic group (table\xa02), the risk for detection of Vitamin D deficiency in cb of infants was associated with black, asian and hispanic race/ethnicity of the mothers.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 101, 'vitamin D')]
PMC5146866	12/2016	S71-PMC5146866	['caption (table-wrap): table 2\n\ncontribution of maternal characteristics in development of cb Vitamin D deficiency and insufficiencyvariablescb Vitamin D statusinsufficiencydeficiencyβ +/−std.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 93, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 143, 'vitamin D')]
PMC5146866	12/2016	S75-PMC5146866	['cb Vitamin D status: deficiency ( n \u2009=\u200995), insufficiency ( n \u2009=\u200979), sufficient ( n \u2009=\u200991)\n\nneonatal characteristics and cb Vitamin D status\namong the 265 infants in this study, 6.4% were Born at Gestational age between 37 and 34\xa0weeks and 1.9% from multiple Gestations.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 3, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 125, 'vitamin D'), ('GO_0007567', 'parturition', 189, 'born'), ('GO_0007565', 'female pregnancy', 197, 'gestational'), ('GO_0007565', 'female pregnancy', 260, 'gestations')]
PMC5146866	12/2016	S77-PMC5146866	['we found no significant difference in the clinical characteristics of the infants with regards to their cb Vitamin D level (table\xa03).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 107, 'vitamin D')]
PMC5146866	12/2016	S103-PMC5146866	['we did not find a difference between the maternal weight at Delivery and occurrence of Vitamin D deficiency/insufficiency in infants at Birth.']	N/A	N/A	[('GO_0007567', 'parturition', 60, 'delivery'), ('CHEBI_27300', 'vitamin D', 87, 'vitamin D'), ('GO_0007567', 'parturition', 136, 'birth')]
PMC5155676	12/2016	S2-PMC5155676	['design:\nwithin-randomization-group analysis of participants in the maternal Vitamin D osteoporosis study trial of Vitamin D supplementation in Pregnancy.']	N/A	N/A	[('CHEBI_28384', 'vitamin K', 76, 'Vitamin D'), ('CHEBI_27300', 'vitamin D', 114, 'vitamin D'), ('GO_0007565', 'female pregnancy', 143, 'pregnancy')]
PMC5155676	12/2016	S9-PMC5155676	['results:\n25(Oh)D at 34 weeks of Gestation was higher in the women randomized to Vitamin D (mean [sd], 67.7 [21.3] nmol/l) compared with placebo (43.1 [22.5] nmol/l; p< .001).']	N/A	N/A	[('CHEBI_71657', 'versiconol acetate', 9, '25(OH)D'), ('GO_0007565', 'female pregnancy', 32, 'gestation'), ('CHEBI_27300', 'vitamin D', 80, 'vitamin D')]
PMC5155676	12/2016	S25-PMC5155676	['materials and methods\n\nthe maternal Vitamin D osteoporosis study (mavidos)\nthe mavidos study is a multicenter, double-blind, randomized, placebo-controlled trial of Vitamin D supplementation in Pregnancy.']	N/A	N/A	[('CHEBI_28384', 'vitamin K', 36, 'Vitamin D'), ('CHEBI_27300', 'vitamin D', 165, 'vitamin D'), ('GO_0007565', 'female pregnancy', 194, 'pregnancy')]
PMC5155676	12/2016	S32-PMC5155676	['women with known Metabolic bone disease, Renal stones, hyperparathyroidism or hypercalciuria, those taking medication known to interfere with fetal growth, fetal anomalies on ultrasonography, and women already using more than 400 iu/d Vitamin D supplementation were excluded.']	N/A	N/A	[('GO_0008152', 'metabolic process', 17, 'metabolic'), ('UBERON_0002113', 'kidney', 41, 'renal'), ('CHEBI_27300', 'vitamin D', 235, 'vitamin D')]
PMC5155676	12/2016	S33-PMC5155676	['a screening Blood sample was obtained and analyzed on the local nhs platform (all 3 laboratories [southampton, oxford, and sheffield] participate in Vitamin D external quality assessment scheme Vitamin D quality assurance system [http://www.deqas.org/]).']	N/A	N/A	[('UBERON_0000178', 'blood', 12, 'blood'), ('CHEBI_28384', 'vitamin K', 149, 'Vitamin D'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 149, 'Vitamin D'), ('CHEBI_27300', 'vitamin D', 194, 'vitamin D')]
PMC5155676	12/2016	S37-PMC5155676	['all participants received standard Antenatal care and could continue self-administration of dietary supplements containing up to 400 iu/d Vitamin D.\n\nmaternal assessments during Pregnancy\nbefore commencing the study Medication, and again at 34 weeks of Gestation, the women attended the research center for a detailed assessment of diet (including supplement use), lifestyle (smoking, physical activity participation, employment), and health (past medical history, current medication use) using interviewer-led questionnaires.']	N/A	N/A	[('GO_0007567', 'parturition', 35, 'antenatal'), ('CHEBI_27300', 'vitamin D', 138, 'vitamin D'), ('GO_0007565', 'female pregnancy', 178, 'pregnancy'), ('CHEBI_60211', 'compound Z', 216, 'medication'), ('GO_0007565', 'female pregnancy', 253, 'gestation')]
PMC5155676	12/2016	S54-PMC5155676	['the cut-point of 50 nmol/l as the definition for Vitamin D replete status was chosen to reflect the iom guidelines (5).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 49, 'vitamin D')]
PMC5155676	12/2016	S58-PMC5155676	['finally, in sensitivity analysis, we excluded women who reported having taken any additional Vitamin D-containing Supplements within 90 days of the late Pregnancy Blood sampling.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 93, 'vitamin D'), ('CHEBI_33341', 'titanium atom', 114, 'supplements'), ('GO_0007565', 'female pregnancy', 153, 'pregnancy'), ('UBERON_0000178', 'blood', 163, 'blood')]
PMC5155676	12/2016	S63-PMC5155676	['there were no significant differences in baseline characteristics between women randomized to placebo and Vitamin D supplementation (table 1).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 106, 'vitamin D')]
PMC5155676	12/2016	S68-PMC5155676	['maternal characteristics at baseline according to randomization groupplacebo1000-iu/d Cholecalciferoln422407Gestation (wk), mean (sd)15.9 (1.5)15.9 (1.5)maternal age (y), mean (sd)30.7 (5.4)30.7 (5.0)nulliparous (%)44.842.7current smoker (%)7.77.7bmi (kg/m2), median (iqr)25.4 (22.7–29.7)24.6 (22.2–28.6)height (cm), mean (sd)165.6 (6.6)165.5 (6.3)white ethnicity (%)94.895.625(Oh)D (nmol/l), median (iqr)44.4 (33.2–57.0)45.7 (34.3–57.8)\n\nmaternal 25(Oh)D status at 34 weeks of Gestation by randomization group\nmaternal 25(Oh)D at 34 weeks of Gestation was greater in the women randomized to Cholecalciferol (mean 67.7 nmol/l [sd 21.3 nmol/l]) compared with the placebo group (mean 43.1 nmol/l [sd 22.5 nmol/l], p< .0001); 83.3% of women randomized to Cholecalciferol achieved Vitamin D replete status at 34 weeks of Gestation (>50 nmol/l) compared with 35.6% in the placebo group ( p< .001).']	N/A	N/A	[('CHEBI_52815', 'cresyl violet', 86, 'Cholecalciferoln422407Gestation'), ('CHEBI_33010', 'chromide(1-)', 377, '(OH)D'), ('CHEBI_72805', '2-alkyl-sn-glycero-3-phosphocholine', 451, 'OH)D'), ('GO_0007565', 'female pregnancy', 478, 'gestation'), ('CHEBI_71657', 'versiconol acetate', 520, '25(OH)D'), ('GO_0007565', 'female pregnancy', 543, 'gestation'), ('CHEBI_52550', 'theopalauamide', 592, 'cholecalciferol'), ('CHEBI_52550', 'theopalauamide', 752, 'cholecalciferol'), ('CHEBI_27300', 'vitamin D', 777, 'vitamin D'), ('GO_0007565', 'female pregnancy', 817, 'gestation')]
PMC5155676	12/2016	S71-PMC5155676	['in both treatment groups, the proportion of women who were Vitamin D replete at 34 weeks of Gestation was lower in those who Delivered in winter (table 2).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 59, 'vitamin D'), ('GO_0007565', 'female pregnancy', 92, 'gestation'), ('GO_0007567', 'parturition', 125, 'delivered')]
PMC5155676	12/2016	S93-PMC5155676	['sensitivity analyses\nas participants were permitted to continue taking daily Vitamin D supplements containing up to 400 iu, in the sensitivity analysis we excluded 229 women (n = 117 randomized to Cholecalciferol) who reported taking other Vitamin D containing dietary supplements at the late Pregnancy interview.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 77, 'vitamin D'), ('CHEBI_52550', 'theopalauamide', 197, 'cholecalciferol'), ('CHEBI_27300', 'vitamin D', 240, 'vitamin D'), ('GO_0007565', 'female pregnancy', 293, 'pregnancy')]
PMC5155676	12/2016	S94-PMC5155676	['similarly, 81.0% of women randomized to Cholecalciferol were Vitamin D replete at 34 weeks of Gestation, compared with 29.4% of women randomized to placebo ( p< .001).']	N/A	N/A	[('CHEBI_52550', 'theopalauamide', 40, 'cholecalciferol'), ('CHEBI_27300', 'vitamin D', 61, 'vitamin D'), ('GO_0007565', 'female pregnancy', 94, 'gestation')]
PMC5167470	12/2016	S45-PMC5167470	['a strict monitoring and biochemical follow-up of Pregnant women taking high doses of Vitamins A and D significantly minimizes the risk for developing adverse events.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 49, 'pregnant'), ('CHEBI_27300', 'vitamin D', 85, 'vitamins A'), ('PR_000004370', 'asialoglycoprotein receptor 2', 94, 'A'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 100, 'D'), ('PR_000006444', 'diacylglycerol kinase delta', 100, 'D')]
PMC5223368	12/2016	S137-PMC5223368	['the seasonal variation of 25-Hydroxy Vitamin D concentration was high in summer [28,29], and the sunlight exposure in summer provided 80% of total annual intake of Vitamin D [28].']	N/A	N/A	[('CHEBI_43141', '3-hydroxypropoxy group', 26, '25-hydroxy'), ('CHEBI_27300', 'vitamin D', 37, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 164, 'vitamin D')]
PMC5264377	7/2016	S52-PMC5264377	['Vitamin D level measurements\nff 25(Oh)D3 levels were assessed with a chemiluminescent immunoassay (elecsys total Vitamin D -roche diagnostics, brazil) at the laboratory of molecular and translational endocrinology, department of medicine, paulista school of medicine, federal university of são paulo (unifesp/epm), são paulo, brazil.']	N/A	N/A	[('CHEBI_28384', 'vitamin K', 0, 'Vitamin D'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 0, 'Vitamin D'), ('CHEBI_62946', 'ammonium sulfate', 32, '25(OH)D3'), ('PR_000029655', '28S rRNA (cytosine-C(5))-methyltransferase', 32, '25(OH)D3'), ('CHEBI_27300', 'vitamin D', 113, 'vitamin D')]
PMC5264377	7/2016	S79-PMC5264377	['patients with ff 25(Oh)D3 deficiency were heavier than their counterparts with higher levels of Vitamin D (64.1±12.1 kg vs. 60.7± 10.5 kg, p<0.01,table 1andfigure 3).']	N/A	N/A	[('CHEBI_62946', 'ammonium sulfate', 17, '25(OH)D3'), ('PR_000029655', '28S rRNA (cytosine-C(5))-methyltransferase', 17, '25(OH)D3'), ('CHEBI_27300', 'vitamin D', 96, 'vitamin D')]
PMC5295046	12/2016	S63-PMC5295046	['at the same clinic visit, maternal cigarette smoking, alcohol drinking, and physical activities were assessed using a questionnaire while maternal Blood was collected for analysis of plasma Vitamin D and Folate concentrations.']	N/A	N/A	[('UBERON_0000178', 'blood', 147, 'blood'), ('CHEBI_27300', 'vitamin D', 190, 'vitamin D'), ('CHEBI_30863', '5-azaorotic acid', 204, 'folate')]
PMC5310660	1/2017	S40-PMC5310660	['the biologically active form of Vitamin D is generated in the skin during exposure to uv radiation from sunlight, and its levels follow a seasonal distribution.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 32, 'vitamin D'), ('PR_000006444', 'diacylglycerol kinase delta', 40, 'D')]
PMC5310660	1/2017	S49-PMC5310660	['the Vitamin D acts as an immunomodulator by inhibiting the Proliferation Of the T Cells, shifting the T-Cell population toward noninflammatory T Helper 2 (th2) and T-Regulatory Cells, and suppressing the transcription of Genes encoding key th1 pro-inflammatory cytokines [18].']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 4, 'vitamin D'), ('GO_0008283', 'cell proliferation', 59, 'proliferation of ... T cells'), ('CL_0000084', 'T cell', 80, 'T cells'), ('CL_0000084', 'T cell', 102, 'T-cell'), ('PR_000016293', 'protein-glutamine gamma-glutamyltransferase 2', 143, 'T helper'), ('CL_0000901', 'Tr1 cell', 164, 'T-regulatory cells'), ('GO_0065007', 'biological regulation', 166, 'regulatory'), ('SO_0000704', 'gene', 221, 'genes')]
PMC5318550	2/2017	S58-PMC5318550	['these sd scores were constructed based on distributions in the generation r cohort.17\n\nassessment of Vitamin D status in maternal mid-Pregnancy and Cord Blood Plasma samples\ntotal Vitamin D was reported as the sum of 25-Hydroxyvitamin D2 (25ohd2) and 25-Hydroxyvitamin D3 (25ohd3) species measured in maternal Plasma and Cord Blood samples using a modification of a method previously described.18in mid-Pregnancy (mean 20.6\u2005weeks; sd 1.0, iqr 1.14), Venous Blood samples were collected and directly after Delivery (mean Gestational duration 39.8\u2005weeks; sd 1.8, iqr 2.0), midwives or obstetricians collected Cord Blood from the Umbilical Vein.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 101, 'vitamin D'), ('GO_0007565', 'female pregnancy', 134, 'pregnancy'), ('UBERON_0002240', 'spinal cord', 148, 'cord'), ('UBERON_0000178', 'blood', 153, 'blood'), ('UBERON_0001969', 'blood plasma', 159, 'plasma'), ('CHEBI_27300', 'vitamin D', 180, 'vitamin D'), ('CHEBI_86319', '25-hydroxyvitamin D2', 217, '25-hydroxyvitamin D2'), ('PR_000002019', 'MHC class II histocompatibility antigen beta chain DRB1', 235, 'D2'), ('CHEBI_63991', '15-epi-lipoxin B4', 251, '25-hydroxyvitamin D3'), ('UBERON_0001969', 'blood plasma', 310, 'plasma'), ('UBERON_0002240', 'spinal cord', 321, 'cord'), ('UBERON_0000178', 'blood', 326, 'blood'), ('GO_0007565', 'female pregnancy', 403, 'pregnancy'), ('UBERON_0001638', 'vein', 450, 'venous'), ('UBERON_0000178', 'blood', 457, 'blood'), ('GO_0007567', 'parturition', 505, 'delivery'), ('GO_0007565', 'female pregnancy', 520, 'gestational'), ('UBERON_0002240', 'spinal cord', 607, 'cord'), ('UBERON_0000178', 'blood', 612, 'blood'), ('UBERON_0002066', 'umbilical vein', 627, 'umbilical vein')]
PMC5318550	2/2017	S85-PMC5318550	['next, the following variables were added stepwise to this basic model; (2) sociodemographic factors and maternal iq; (3) child Birth weight and Gestational duration; (4) maternal mid-Pregnancy and Cord Blood Vitamin D Plasma concentrations; (5) maternal nutritional intake; (6) maternal exposure to fever during Pregnancy; and (7) child relative age in class.']	N/A	N/A	[('GO_0007567', 'parturition', 127, 'birth'), ('GO_0007565', 'female pregnancy', 144, 'gestational'), ('GO_0007565', 'female pregnancy', 183, 'pregnancy'), ('UBERON_0002240', 'spinal cord', 197, 'cord'), ('UBERON_0000178', 'blood', 202, 'blood'), ('CHEBI_27300', 'vitamin D', 208, 'vitamin D'), ('UBERON_0001969', 'blood plasma', 218, 'plasma'), ('GO_0007565', 'female pregnancy', 312, 'pregnancy')]
PMC5318550	2/2017	S110-PMC5318550	["caption (table-wrap): table\xa02\n\nchange of the association between child's season of Birth and iq at age 6\u2005years with stepwise addition of covariates (n=6034)\xa0child iq at age 6\u2005yearsseason of Birthadjusted forbasic model: child gender and age at iq assessmentmodel 2: +maternal sociodemographic characteristicsmodel 3: +maternal iqmodel 4: +maternal nutritional Intake and one-carbon biomarkersmodel 5: +child relative age in class and season at iq assessmentmodel 6: +Vitamin D Plasma levelsmodel 7: +Gestational duration and Birth weightmodel 8: +fever during Pregnancy and crp levelsspringβ (95% ci) p value−1.24 (−2.31 to −0.17) 0.02−1.14 (−2.17 to −0.12) 0.03−0.87 (−1.87 to 0.14) 0.09−0.86 (−1.87 to 0.14) 0.09−0.75 (−1.91 to 0.40) 0.20−0.68 (−1.89 to 0.52) 0.27−0.59 (−1.80 to 0.61) 0.33−0.57 (−1.78 to 0.64) 0.35summer\xa0 referencereferencereferencereferencereferencereferencereferencereference autumnβ (95% ci) p value−0.52 (−1.56 to 0.51) 0.32−0.75 (−1.74 to 0.24) 0.14−0.63 (−1.60 to 0.34) 0.20−0.64 (−1.61 to 0.34) 0.20−0.53 (−2.25 to 1.18) 0.54−0.66 (−2.41 to 1.09) 0.46−0.63 (−2.37 to 1.12) 0.48−0.63 (−2.37 to 1.12) 0.48winterβ (95% ci) p value−0.84 (−1.93 to 0.26) 0.13−0.89 (−1.94 to 0.15) 0.09−0.66 (−1.69 to 0.36) 0.21−0.71 (−1.74 to 0.32) 0.18−0.76 (−2.28 to 0.77) 0.33−0.84 (−2.47 to 0.79) 0.31−0.76 (−2.39 to 0.86) 0.36−0.75 (−2.38 to 0.88) 0.37seasonal trendβ (95% ci) p value−0.40 (−0.74 to −0.07) 0.02−0.36 (−0.68 to −0.04) 0.03−0.27 (−0.58 to 0.05) 0.10−0.27 (0.59 to 0.05) 0.10−0.23 (−0.55 to 0.10) 0.18−0.18 (−0.53 to 0.17) 0.31−0.15 (−0.50 to 0.20) 0.39−0.14 (−0.49 to 0.21) 0.42effect estimate change of seasonal trend (%) reference 10.032.532.542.555.062.565.0r2(change)*0.0200.0880.0360.0030.0010.0010.010.001p value<0.001<0.001<0.001<0.0010.020.02<0.0010.001\nresults from linear regression analyses."]	N/A	N/A	[('GO_0007567', 'parturition', 83, 'birth'), ('GO_0007608', 'sensory perception of smell', 190, 'birthAdjusted'), ('GO_0007631', 'feeding behavior', 360, 'intake'), ('CHEBI_27300', 'vitamin D', 467, 'vitamin D'), ('UBERON_0001969', 'blood plasma', 477, 'plasma'), ('GO_0007565', 'female pregnancy', 500, 'gestational'), ('GO_0007567', 'parturition', 525, 'birth'), ('GO_0007565', 'female pregnancy', 560, 'pregnancy')]
PMC5318550	2/2017	S135-PMC5318550	['we did not observe a meaningful effect of maternal nutritional intake, Vitamin D status or maternal exposure to fever during Pregnancy on the association between child season of Birth and iq.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 71, 'vitamin D'), ('GO_0007565', 'female pregnancy', 125, 'pregnancy'), ('GO_0007567', 'parturition', 178, 'birth')]
PMC5322422	2/2017	S0-PMC5322422	['Vitamin K deficiency presenting in an infant with an anterior Mediastinal mass: a case report and review of the literature\n\nabstract\nwe report a case of a 1-month-old infant with spontaneous Thymic hemorrhage secondary to severe Vitamin K deficiency.']	N/A	N/A	[('CHEBI_28384', 'vitamin K', 0, 'Vitamin K'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 0, 'Vitamin K'), ('UBERON_0005452', 'hepatic cord', 62, 'Mediastinal'), ('UBERON_0002370', 'thymus', 191, 'thymic'), ('CHEBI_27300', 'vitamin D', 229, 'vitamin K')]
PMC5322422	2/2017	S5-PMC5322422	['the coagulopathy resolved with administration of Vitamin K, and a biopsy confirmed the anterior Mediastinal mass was due to spontaneous Thymic hemorrhage.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 49, 'vitamin K'), ('UBERON_0003728', 'mediastinum', 96, 'mediastinal'), ('UBERON_0002370', 'thymus', 136, 'thymic')]
PMC5322422	2/2017	S7-PMC5322422	['introduction\nVitamin K deficiency bleeding (vkdb), formerly known as hemorrhagic disease of the newborn, is a Coagulopathy infants acquire due to insufficient Vitamin K stores.']	N/A	N/A	[('CHEBI_28384', 'vitamin K', 13, 'Vitamin K'), ('GO_0050817', 'coagulation', 110, 'coagulopathy'), ('CHEBI_27300', 'vitamin D', 159, 'vitamin K')]
PMC5322422	2/2017	S22-PMC5322422	['the infant did not receive Vitamin K prophylaxis at Birth, though his mother was taking oral Vitamin K, a Prenatal Vitamin, and herbal supplements daily.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 27, 'vitamin K'), ('GO_0007567', 'parturition', 52, 'birth'), ('CHEBI_27300', 'vitamin D', 93, 'vitamin K'), ('GO_0007565', 'female pregnancy', 106, 'prenatal'), ('CHEBI_33229', 'vitamin (role)', 115, 'vitamin')]
PMC5322422	2/2017	S35-PMC5322422	['the patient received three iv doses of Vitamin K, packed Red Blood Cells (60\u2009ml/kg total), fresh frozen Plasma (15\u2009ml/kg), and Platelets (15\u2009ml/kg).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 39, 'vitamin K'), ('CL_0000232', 'erythrocyte', 57, 'red blood cells'), ('UBERON_0000178', 'blood', 61, 'blood'), ('UBERON_0001969', 'blood plasma', 104, 'plasma'), ('CL_0000233', 'platelet', 127, 'platelets')]
PMC5322422	2/2017	S57-PMC5322422	['third, infant Production Of Vitamin K is reduced secondary to immature or altered Gut flora [3].']	N/A	N/A	[('GO_0040010', 'positive regulation of growth rate', 14, 'production of vitamin K'), ('CHEBI_27300', 'vitamin D', 28, 'vitamin K'), ('UBERON_0001555', 'digestive tract', 82, 'gut')]
PMC5322422	2/2017	S58-PMC5322422	['lastly, Vitamin K content in Breast Milk (1\u2009 μ g/l) is significantly lower (60\u2009 μ g/l) than found in formula [4].']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 8, 'vitamin K'), ('UBERON_0001348', 'brown adipose tissue', 29, 'breast milk')]
PMC5322422	2/2017	S68-PMC5322422	['surveillance programs in different countries, including the british isles, sweden, switzerland, and germany, demonstrate that the im injection of 1\u2009mg of Vitamin K is more effective at preventing late vkdb than when given by the Oral route [8].']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 154, 'vitamin K'), ('UBERON_0000165', 'mouth', 229, 'oral')]
PMC5322422	2/2017	S74-PMC5322422	['in each case, parents had declined intramuscular Vitamin K prophylaxis.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 49, 'vitamin K')]
PMC5322422	2/2017	S76-PMC5322422	['a confirmed case fulfills the following diagnostic criteria [8]: (1) elevation of the prothrombin time (pt) ≥ 4 times the laboratory limit of normal; (2) normal or elevated Platelet count, normal Fibrinogen, and absent Fibrin degradation products (excludes disseminated intravascular Coagulation); and (3) pt returning to normal after Vitamin K administration.']	N/A	N/A	[('CL_0000233', 'platelet', 173, 'platelet'), ('GO_0005577', 'fibrinogen complex', 196, 'fibrinogen'), ('CHEBI_5054', 'Fibrin', 219, 'fibrin'), ('GO_0050817', 'coagulation', 284, 'coagulation'), ('CHEBI_27300', 'vitamin D', 335, 'vitamin K')]
PMC5332602	3/2017	S51-PMC5332602	['caption (fig): fig\xa02\xa0\n\nconcentrations of protein (a), albumin (b), Glucose (c), Selenium (d), Vitamin A (e), and Vitamin E (f) in the Serum of protein-deficient and -sufficient Hifm/Hrv-infected Pigs measured at experiment termination.']	N/A	N/A	[('CHEBI_17234', 'glucose', 67, 'glucose'), ('CHEBI_27568', 'selenium atom', 80, 'selenium'), ('CHEBI_27300', 'vitamin D', 94, 'vitamin A'), ('CHEBI_27300', 'vitamin D', 113, 'vitamin E'), ('UBERON_0001977', 'blood serum', 134, 'serum'), ('PR_000008563', 'histidine triad nucleotide-binding protein 3', 177, 'HIFM'), ('NCBITaxon_10088', 'Mus <genus>', 182, 'HRV'), ('NCBITaxon_10088', 'Mus <genus>', 195, 'pigs')]
PMC5332602	3/2017	S52-PMC5332602	['concentrations of protein, Albumin, and Glucose in the Serum of protein-deficient and -sufficient Hifm/Hrv-infected Pigs ( n = 10/group) were determined at marshfield labs (marshfield, wi), and Selenium, Vitamin A and E concentrations in the Serum of protein-deficient and -sufficient hifm/hrv-infected Pigs ( n = 8/group) were measured at the diagnostic center for population and Animal health (michigan state university, east lansing, mi) by high-performance liquid chromatography.']	N/A	N/A	[('PR_000005908', 'alpha-crystallin B chain', 27, 'albumin'), ('CHEBI_17234', 'glucose', 40, 'glucose'), ('UBERON_0001977', 'blood serum', 55, 'serum'), ('PR_000008563', 'histidine triad nucleotide-binding protein 3', 98, 'HIFM'), ('NCBITaxon_10088', 'Mus <genus>', 103, 'HRV'), ('NCBITaxon_10088', 'Mus <genus>', 116, 'pigs'), ('CHEBI_27568', 'selenium atom', 194, 'selenium'), ('CHEBI_27300', 'vitamin D', 204, 'vitamin A'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 218, 'E'), ('UBERON_0001977', 'blood serum', 242, 'serum'), ('NCBITaxon_10088', 'Mus <genus>', 303, 'pigs'), ('NCBITaxon_33208', 'Metazoa', 381, 'Animal')]
PMC5332602	3/2017	S279-PMC5332602	['the frequencies of cell populations in flow cytometry and Serum Glucose, protein, albumin, Lps, Vitamin A ands E, and Selenium levels were compared among groups with the kruskal-wallis rank sum and mann-whitney (nonparametric) tests.']	N/A	N/A	[('UBERON_0001977', 'blood serum', 58, 'serum'), ('CHEBI_17234', 'glucose', 64, 'glucose'), ('CHEBI_16412', 'lipopolysaccharide', 91, 'LPS'), ('CHEBI_27300', 'vitamin D', 96, 'vitamin A'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 111, 'E'), ('CHEBI_27568', 'selenium atom', 118, 'selenium')]
PMC5340372	3/2017	S120-PMC5340372	['C3-Epi-25(Oh)D has lower affinity for the Vitamin D receptor, thus it own lower bio-function than 25(Oh)d in vivo.']	N/A	N/A	[('CHEBI_72865', '(5Z,8Z,11Z)-icosatrienoic acid', 0, 'C3-epi-25(OH)D'), ('CHEBI_27300', 'vitamin D', 42, 'vitamin D'), ('CHEBI_30778', 'gallic acid', 98, '25(OH)')]
PMC5340372	3/2017	S124-PMC5340372	['Expression of Cathelicidin, an Antimicrobial peptide, can be augmented by Lung Epithelial Cells under the stimulation of Vitamin D [48].']	N/A	N/A	[('GO_0010467', 'gene expression', 0, 'Expression'), ('PR_000006009', 'alpha-catulin', 14, 'cathelicidin'), ('CHEBI_65381', 'albizoside C', 31, 'antimicrobial'), ('CL_0000082', 'epithelial cell of lung', 74, 'lung epithelial cells'), ('UBERON_0000115', 'lung epithelium', 74, 'lung epithelial'), ('CHEBI_27300', 'vitamin D', 121, 'vitamin D')]
PMC5351212	3/2017	S31-PMC5351212	['for instance, Vitamin D interferes with pro-inflammatory transcription factors and signaling pathways, Regulates the Expression of pro-inflammatory enzymes, and Modulates cytokine Gene Expression, Protein Production, and signaling.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 14, 'vitamin D'), ('GO_0065007', 'biological regulation', 103, 'regulates'), ('GO_0010467', 'gene expression', 117, 'expression'), ('GO_0065007', 'biological regulation', 161, 'modulates'), ('GO_0010467', 'gene expression', 180, 'gene expression'), ('SO_0000704', 'gene', 180, 'gene'), ('GO_0007599', 'hemostasis', 197, 'protein production')]
PMC5351212	3/2017	S32-PMC5351212	['more specifically, Vitamin D inhibits the production Of pro-inflammatory Cytokines such as Il-6 or Tnf-Alpha in Monocytes via the inhibition of P38 Map kinase [29], and it downregulates the Expression of Il-6 mrna [30].']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 19, 'vitamin D'), ('GO_0007608', 'sensory perception of smell', 53, 'of ...'), ('GO_0000900', 'translation repressor activity, mRNA regulatory element binding', 73, 'cytokines'), ('PR_000001470', 'interleukin-28B', 91, 'IL-6'), ('PR_000000134', 'tumor necrosis factor alpha', 99, 'TNF-alpha'), ('CL_0000576', 'monocyte', 112, 'monocytes'), ('PR_000005409', 'chromodomain-helicase-DNA-binding protein 3', 144, 'p38 MAP'), ('GO_0010467', 'gene expression', 190, 'expression'), ('PR_000001470', 'interleukin-28B', 204, 'IL-6')]
PMC5351212	3/2017	S149-PMC5351212	['cytokines in the Plasma of dams and in the fetal Brain Tissue and Vitamin D Metabolites in maternal Blood were analyzed using a 2\u2009×\u20092 (mia\u2009×\u2009vitdtreatment) anova as well.']	N/A	N/A	[('UBERON_0001969', 'blood plasma', 17, 'plasma'), ('UBERON_0000955', 'brain', 49, 'brain'), ('UBERON_0000479', 'tissue', 55, 'tissue'), ('CHEBI_27300', 'vitamin D', 66, 'vitamin D'), ('CHEBI_25212', 'metabolite', 76, 'metabolites'), ('UBERON_0000178', 'blood', 100, 'blood')]
PMC5351212	3/2017	S159-PMC5351212	['1\n\nelevated plus maze behaviors in juvenile offspring who were exposed to Prenatal Immune challenge (pol) or Prenatal Vitamin D treatment (vitd).']	N/A	N/A	[('GO_0007565', 'female pregnancy', 74, 'prenatal'), ('UBERON_0002405', 'immune system', 83, 'immune'), ('GO_0007565', 'female pregnancy', 109, 'prenatal'), ('CHEBI_27300', 'vitamin D', 118, 'vitamin D')]
PMC5351212	3/2017	S171-PMC5351212	['2\n\nsocial approach behavior in juvenile offspring who were exposed to Prenatal Immune challenge (pol) or Prenatal Vitamin D treatment (vitd).']	N/A	N/A	[('GO_0007565', 'female pregnancy', 70, 'prenatal'), ('UBERON_0002405', 'immune system', 79, 'immune'), ('GO_0007565', 'female pregnancy', 105, 'prenatal'), ('CHEBI_27300', 'vitamin D', 114, 'vitamin D')]
PMC5351212	3/2017	S183-PMC5351212	['3\n\nmarble burying behavior in juvenile offspring who were exposed to Prenatal Immune challenge (pol) or Prenatal Vitamin D treatment (vitd).']	N/A	N/A	[('GO_0007565', 'female pregnancy', 69, 'prenatal'), ('UBERON_0002405', 'immune system', 78, 'immune'), ('GO_0007565', 'female pregnancy', 104, 'prenatal'), ('CHEBI_27300', 'vitamin D', 113, 'vitamin D')]
PMC5351212	3/2017	S194-PMC5351212	['4\n\nacquisition of Fear Memory, association with context and fear Memory behavior in juvenile offspring who were exposed to Prenatal Immune challenge (pol) or Prenatal Vitamin D treatment (vitd).']	N/A	N/A	[('GO_0007631', 'feeding behavior', 18, 'fear'), ('GO_0007613', 'memory', 23, 'memory'), ('GO_0007613', 'memory', 65, 'memory'), ('GO_0007565', 'female pregnancy', 123, 'prenatal'), ('UBERON_0002405', 'immune system', 132, 'immune'), ('GO_0007565', 'female pregnancy', 158, 'prenatal'), ('CHEBI_27300', 'vitamin D', 167, 'vitamin D')]
PMC5351212	3/2017	S222-PMC5351212	['Vitamin D Metabolite levels\nthere was no main effect of 1,25Ohd or Poly(I:C) treatment on maternal levels of either the major Circulatory form of Vitamin D 25ohd or its inactive Metabolite 24,25ohd when measured 4\xa0h after exposure; 25Ohd and 24,25Ohd concentrations (nm) in each group were as follows: con/veh 29.7\u2009±\u20097.4, 21.2\u2009±\u20095.5, con/vitd40.3\u2009±\u200911.0, 27.2\u2009±\u20096.7, pol/veh 35.3\u2009±\u200911.4, 20.3\u2009±\u20098.2, and pol/vitd36.8\u2009±\u20098.8, 23.6\u2009±\u20094.1; ( p \u2009>\u20090.1).']	N/A	N/A	[('CHEBI_28384', 'vitamin K', 0, 'Vitamin D'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 0, 'Vitamin D'), ('CHEBI_39382', 'flufenoxuron', 10, 'metabolite'), ('CHEBI_72652', "7,2'-dihydroxy-4'-methoxyisoflavan-4-ylium cation", 58, '25OHD'), ('CHEBI_77358', 'CDP-dipalmitoyl-sn-glycerol', 67, 'poly(I:C'), ('UBERON_0001009', 'circulatory system', 126, 'circulatory'), ('CHEBI_27300', 'vitamin D', 146, 'vitamin D'), ('CHEBI_39382', 'flufenoxuron', 178, 'metabolite'), ('CHEBI_72652', "7,2'-dihydroxy-4'-methoxyisoflavan-4-ylium cation", 232, '25OHD'), ('CHEBI_72652', "7,2'-dihydroxy-4'-methoxyisoflavan-4-ylium cation", 245, '25OHD')]
PMC5368580	4/2017	S12-PMC5368580	['supplementation was reflected in fasting, 24-h postdose samples for riboflavin and Vitamin B-6.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 83, 'vitamin B'), ('PR_000017255', 'Vang-like protein 1', 83, 'vitamin B-6')]
PMC5368580	4/2017	S67-PMC5368580	['the outcomes were concentrations of Thiamin (Vitamin B-1; free Thiamin + Thiamin monophosphate + Thiamin pyrophosphate), riboflavin (Vitamin B-2; riboflavin + fad), niacin (Vitamin B-3; Nicotinamide), Vitamin B-6 (Pyridoxal), Vitamin B-12, Vitamin A (Retinol + β-Carotene), and Vitamin E (Α-Tocopherol), and fat-adjusted Vitamins A (vitamin afat; Retinol + Β-Carotene per gram of milk fat) and e (Vitamin Efat; Α-Tocopherol, the active form of Vitamin E, per gram of milk fat) in Breast Milk.']	N/A	N/A	[('CHEBI_26948', 'vitamin B1', 36, 'thiamin'), ('CHEBI_27300', 'vitamin D', 45, 'vitamin B'), ('PR_000004480', 'V-type proton ATPase catalytic subunit A', 45, 'vitamin B-1'), ('CHEBI_26948', 'vitamin B1', 63, 'thiamin'), ('CHEBI_26948', 'vitamin B1', 73, 'thiamin'), ('CHEBI_26948', 'vitamin B1', 97, 'thiamin'), ('CHEBI_27300', 'vitamin D', 133, 'vitamin B'), ('PR_000017279', 'testis-specific basic protein Y 1', 133, 'vitamin B-2'), ('CHEBI_27300', 'vitamin D', 173, 'vitamin B'), ('PR_000017269', 'ventral anterior homeobox 2', 173, 'vitamin B-3'), ('CHEBI_17154', 'nicotinamide', 186, 'nicotinamide'), ('CHEBI_27300', 'vitamin D', 201, 'vitamin B'), ('CHEBI_17310', 'pyridoxal', 214, 'pyridoxal'), ('CHEBI_27300', 'vitamin D', 226, 'vitamin B'), ('CHEBI_27300', 'vitamin D', 240, 'vitamin A'), ('CHEBI_26536', 'retinoic acid', 251, 'retinol'), ('CHEBI_23042', 'carotene', 263, 'carotene'), ('CHEBI_27300', 'vitamin D', 278, 'vitamin E'), ('CHEBI_27725', 'butin', 289, 'α-tocopherol'), ('CHEBI_27300', 'vitamin D', 321, 'vitamins A'), ('CHEBI_26536', 'retinoic acid', 347, 'retinol'), ('CHEBI_28064', 'cyanidin 3-O-rutinoside', 357, 'β-carotene'), ('CHEBI_85367', '2-epi-5-epi-valiolone 7-phosphate', 397, 'vitamin Efat'), ('CHEBI_27725', 'butin', 411, 'α-tocopherol'), ('CHEBI_27300', 'vitamin D', 444, 'vitamin E'), ('UBERON_0001348', 'brown adipose tissue', 480, 'breast milk')]
PMC5368580	4/2017	S69-PMC5368580	['logarithmic transformations were performed on riboflavin, niacin, Vitamin B-6, Vitamin A, vitamin afat, Vitamin efat, fat, and the square root transformation Vitamin E to normalize the skewed data.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 66, 'vitamin B'), ('CHEBI_27300', 'vitamin D', 79, 'vitamin A'), ('CHEBI_33229', 'vitamin (role)', 104, 'vitamin'), ('CHEBI_27300', 'vitamin D', 158, 'vitamin E')]
PMC5368580	4/2017	S70-PMC5368580	['no Transformation was needed for Thiamin and Vitamin B-12.']	N/A	N/A	[('GO_0005992', 'trehalose biosynthetic process', 3, 'transformation'), ('CHEBI_26948', 'vitamin B1', 33, 'thiamin'), ('CHEBI_27300', 'vitamin D', 45, 'vitamin B'), ('PR_000017269', 'ventral anterior homeobox 2', 45, 'vitamin B-12')]
PMC5368580	4/2017	S91-PMC5368580	['bmq, Breast-Milk-quality; bv, b-Vitamin Complex; mn, Micronutrient; vd, Vitamin D.\n\ndifferences between aliquots i, ii, and iii within a day.']	N/A	N/A	[('UBERON_0000310', 'breast', 5, 'Breast'), ('UBERON_0001913', 'milk', 12, 'Milk'), ('CHEBI_75192', 'thallium(I) acetate', 32, 'vitamin complex'), ('CHEBI_33962', 'mu4-sulfido-quadro-tetracopper(6+)', 53, 'micronutrient'), ('CHEBI_27300', 'vitamin D', 72, 'vitamin D')]
PMC5368580	4/2017	S94-PMC5368580	['when compared with the full-Breast aliquot iii, aliquot i was significantly lower in concentrations of Niacin, fat, vitamin afat, and Vitamin efat, whereas aliquot ii was significantly higher for Thiamin and Vitamins A, e, afat, and efat.']	N/A	N/A	[('UBERON_0000310', 'breast', 28, 'breast'), ('CHEBI_7542', 'neurotensin', 103, 'niacin'), ('CHEBI_33229', 'vitamin (role)', 134, 'vitamin'), ('CHEBI_26948', 'vitamin B1', 196, 'thiamin'), ('CHEBI_27300', 'vitamin D', 208, 'vitamins A')]
PMC5368580	4/2017	S103-PMC5368580	['a, Vitamin A; afat, Vitamin A adjusted for milk fat; b1, Thiamin; b2, riboflavin; b3, niacin (Nicotinamide); b6, Vitamin B-6; B12, Vitamin B-12; e, Vitamin E; efat, Vitamin E adjusted for milk fat; fat, milk fat.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 3, 'vitamin A'), ('CHEBI_27300', 'vitamin D', 20, 'vitamin A'), ('CHEBI_26948', 'vitamin B1', 57, 'thiamin'), ('CHEBI_17154', 'nicotinamide', 94, 'nicotinamide'), ('CHEBI_27300', 'vitamin D', 113, 'vitamin B'), ('PR_000000037', 'BMP receptor type-2', 121, 'B'), ('CHEBI_27778', 'abequose', 126, 'B12'), ('CHEBI_27300', 'vitamin D', 131, 'vitamin B'), ('PR_000017269', 'ventral anterior homeobox 2', 131, 'vitamin B-12'), ('CHEBI_27300', 'vitamin D', 148, 'vitamin E'), ('CHEBI_27300', 'vitamin D', 165, 'vitamin E')]
PMC5368580	4/2017	S107-PMC5368580	['caption (table-wrap): table 2\n\ncircadian variations in Breast-Milk concentrations for Thiamin, riboflavin, niacin, fat, and Vitamins B-6, b-12, a, and e for days 1–31vitamin or fat, %time (24 h)2n thiaminriboflavinniacinvitamin b-6vitamin b-12vitamin avitamin efatvitamin afatvitamin efatday 1\u20030800–08591785*70*8294121809790101103\u20030900–09593953942126341199811710191\u20031000–1059129113310210374*13811910594105\u20031100–11591010183122106146*981019681116\u20031200–12596118*169*75116618410787108116\u20031300–13591110096799411710711211410883\u20031400–1459910395166131137*117*142*123*96101\u20031500–15598115101731061191201051338289\u20031600–16591285121112889411910193132108\u20031700–17599108102991077571871088293\u20031800–18599818611792*162146136112107111\u20031900–19597107153125136*1469010596185109\u20032000–215920103111881051261219611112782\u20032200–23591212413193113105126828912290\u20030000–015912987911269*7569*83*78*8093\u20030200–03591196*79*50*67*59*6982808190\u20030400–055910108*1461026763*109*818012895\u20030600–0759976*61*80*71*10887849092108\u2003daily median318713734.326586.914548.845.158.429.4182\u2003variance due to Circadian fluctuation, %3.72.13.03.08.65.45.58.7<0.5<0.5\u2003variance due to between-subject variability, %81.886.373.776.854.656.748.018.767.258.4\u2003variance due to within-subject variability, %14.511.623.320.236.837.946.572.632.841.6day 2\u20030800–08591790*69*697692126118*96120109\u20030900–09597100159*116105*55981231118890\u20031000–1059886127*8586145132130120*118104\u20031100–115910107*167*97127*54119113100112118\u20031200–12591297*136*103*119*13199*125*11187114\u20031300–13594117220155128172*2109310620368\u20031400–1459811010610078132120*113*131*9181\u20031500–1559101121131151288514610310412998\u20031600–165910888090*108156113*147*10092110\u20031700–17591011095115931181199910413478\u20031800–1859410511915482891071171298280\u20031900–195987668679112310111679155112\u20032000–2159161119710185729294969286\u20032200–2359179310010910310010179103102119\u20030000–01591094*788059*8476*77*64*110127\u20030200–03591082*62*66*1118969*87*76*84113\u20030400–05595113125108*11372111707415584\u20030600–07591374*76*75*1147478*918391*85\u2003daily median317916045.122912614653.242.355.732.3190\u2003variance due to Circadian fluctuation, %3.46.63.15.53.26.86.915.4<0.5<0.5\u2003variance due to between-subject variability, %85.379.679.174.549.966.151.88.467.746.9\u2003variance due to within-subject variability, %11.313.817.819.946.927.241.276.232.353.1day 3\u20030800–08591686*61*9669*88911071068588\u20030900–0959799167*978361107135119100113\u20031000–10598101972*105228*1029610712910886\u20031100–115910107476*88134*8276908993111\u20031200–1259899*188*168*210*125*139*131*101142*102\u20031300–135911132*288*78*283*84114118106115*93\u20031400–1459695114117183*86142*100*77153*137*\u20031500–155914118*133140*107118*125*111117*101107\u20031600–16596837081*11112411412010472108\u20031700–17597116151103102*1311908910118897\u20031800–1859910794162126132881011129397\u20031900–1959612112112311710112371939776\u20032000–2159169471*878283881089810098\u20032200–2359178962*12680*11388979789105\u20030000–0159497*57*6654*617886858095\u20030200–0359998*86108*77*61*75809710483\u20030400–05591083*42*85*64*98648788100116\u20030600–0759980*41*92*94*126*71*8370*72126*\u2003daily median317316664.719321414560.241.956.037.9172\u2003variance due to Circadian fluctuation, %8.840.56.223.93.95.82.07.0<0.50.9\u2003variance due to between-subject variability, %70.030.582.459.366.959.548.123.964.359.9\u2003variance due to within-subject variability, %21.229.011.416.829.234.849.969.135.439.2\nvalues are relative medians (%) compared with the daily median unless otherwise indicated.']	N/A	N/A	[('UBERON_0000310', 'breast', 55, 'breast'), ('UBERON_0001913', 'milk', 62, 'milk'), ('CHEBI_26948', 'vitamin B1', 86, 'thiamin'), ('CHEBI_27300', 'vitamin D', 124, 'vitamins B'), ('GO_0051216', 'cartilage development', 1052, 'circadian'), ('GO_0051216', 'cartilage development', 2063, 'circadian'), ('GO_0051216', 'cartilage development', 3076, 'circadian')]
PMC5368580	4/2017	S112-PMC5368580	['fat, milk fat; Vitamin afat, Vitamin A adjusted for milk fat; vitamin efat, Vitamin E adjusted for milk fat.']	N/A	N/A	[('CHEBI_33229', 'vitamin (role)', 15, 'Vitamin'), ('CHEBI_27300', 'vitamin D', 29, 'vitamin A'), ('CHEBI_27300', 'vitamin D', 76, 'vitamin E')]
PMC5368580	4/2017	S114-PMC5368580	['vitamin A (μg/100 ml); vitamin afat(nmol/g milk fat); Thiamin, riboflavin, niacin, and Vitamin B-6 (μg/l); Vitamin B-12 (ng/l); Vitamin E (μg/10 ml); Vitamin Efat(nmol/g milk fat); fat (g/l).']	N/A	N/A	[('PR_000004370', 'asialoglycoprotein receptor 2', 8, 'A'), ('CHEBI_26948', 'vitamin B1', 54, 'thiamin'), ('CHEBI_27300', 'vitamin D', 87, 'vitamin B'), ('PR_000017255', 'Vang-like protein 1', 87, 'vitamin B-6'), ('CHEBI_27300', 'vitamin D', 107, 'vitamin B'), ('PR_000017269', 'ventral anterior homeobox 2', 107, 'vitamin B-12'), ('CHEBI_27300', 'vitamin D', 128, 'vitamin E'), ('CHEBI_85367', '2-epi-5-epi-valiolone 7-phosphate', 150, 'vitamin Efat')]
PMC5368580	4/2017	S126-PMC5368580	['Thiamin, riboflavin, and Vitamins B-6, a, and afatconcentrations in Breast Milk were significantly increased when Supplements were consumed ( figure 3 ), with median increases >180% (riboflavin and Vitamin B-6) and 120–130% (Thiamin and Vitamins A and afat) compared with the median baseline value of day 1.']	N/A	N/A	[('CHEBI_9544', 'thiethylperazine', 0, 'Thiamin'), ('CHEBI_27300', 'vitamin D', 25, 'vitamins B'), ('PR_000000037', 'BMP receptor type-2', 34, 'B'), ('UBERON_0000310', 'breast', 68, 'breast'), ('UBERON_0001913', 'milk', 75, 'milk'), ('CHEBI_33341', 'titanium atom', 114, 'supplements'), ('CHEBI_27300', 'vitamin D', 198, 'vitamin B'), ('PR_000017255', 'Vang-like protein 1', 198, 'vitamin B-6'), ('CHEBI_26948', 'vitamin B1', 225, 'thiamin'), ('CHEBI_27300', 'vitamin D', 237, 'vitamins A')]
PMC5368580	4/2017	S135-PMC5368580	['a, Vitamin A; afat, Vitamin A adjusted for milk fat; b1, Thiamin; b2, riboflavin; b3, niacin (Nicotinamide); b6, Vitamin B-6; B12, Vitamin B-12; e, Vitamin E; efat, Vitamin E adjusted for milk fat; fat, milk fat.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 3, 'vitamin A'), ('CHEBI_27300', 'vitamin D', 20, 'vitamin A'), ('CHEBI_26948', 'vitamin B1', 57, 'thiamin'), ('CHEBI_17154', 'nicotinamide', 94, 'nicotinamide'), ('CHEBI_27300', 'vitamin D', 113, 'vitamin B'), ('PR_000000037', 'BMP receptor type-2', 121, 'B'), ('CHEBI_27778', 'abequose', 126, 'B12'), ('CHEBI_27300', 'vitamin D', 131, 'vitamin B'), ('PR_000017269', 'ventral anterior homeobox 2', 131, 'vitamin B-12'), ('CHEBI_27300', 'vitamin D', 148, 'vitamin E'), ('CHEBI_27300', 'vitamin D', 165, 'vitamin E')]
PMC5368580	4/2017	S149-PMC5368580	['no significant differences were observed for Thiamin and Vitamins B-12, afat, efat, and a ( table 4 ).']	N/A	N/A	[('CHEBI_26948', 'vitamin B1', 45, 'thiamin'), ('CHEBI_27300', 'vitamin D', 57, 'vitamins B'), ('PR_000004770', 'Polycomb complex protein BMI-1', 66, 'B-12')]
PMC5368580	4/2017	S158-PMC5368580	['fat, milk fat; vitamin afat, Vitamin A adjusted for fat; vitamin efat, Vitamin E adjusted for fat.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 29, 'vitamin A'), ('CHEBI_27300', 'vitamin D', 71, 'vitamin E')]
PMC5372327	3/2017	S26-PMC5372327	['rickets is caused by insufficient Vitamin D supply resulting in the lack of sufficient Calcium and Phosphate for bone mineralization at the Growth Plates [11].']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 34, 'vitamin D'), ('CHEBI_22313', 'alkaline earth metal atom', 87, 'calcium'), ('CHEBI_18367', 'phosphate(3-)', 99, 'phosphate'), ('UBERON_0002516', 'epiphyseal plate', 140, 'growth plates')]
PMC5372327	3/2017	S36-PMC5372327	['Immune Cells Express Vitamin D Receptor (vdr) and respond to Vitamin D [22,23].']	N/A	N/A	[('CL_0000129', 'microglial cell', 0, 'Immune cells'), ('GO_0010467', 'gene expression', 13, 'express'), ('CHEBI_27300', 'vitamin D', 21, 'vitamin D'), ('PR_000001683', 'vasopressin V2 receptor', 21, 'vitamin D receptor'), ('CHEBI_27300', 'vitamin D', 61, 'vitamin D')]
PMC5372327	3/2017	S37-PMC5372327	['on Innate Immunity, Vitamin D inhibits the Expression of pattern-recognition receptors, induces Autophagy in Macrophages and induces endogenous Antimicrobial peptides, such as cathelicidin.']	N/A	N/A	[('GO_0045087', 'innate immune response', 3, 'innate immunity'), ('CHEBI_27300', 'vitamin D', 20, 'vitamin D'), ('GO_0010467', 'gene expression', 43, 'expression'), ('GO_0006914', 'autophagy', 96, 'autophagy'), ('CL_0000235', 'macrophage', 109, 'macrophages'), ('CHEBI_65381', 'albizoside C', 144, 'antimicrobial')]
PMC5372327	3/2017	S38-PMC5372327	['on Adaptive Immunity, for example, Vitamin D acts by Regulating the Release Of pro-inflammatory Cytokines From Mononuclear Cells and inhibits T-Cell Proliferation through decreased th1 cytokine secretion [24–26].']	N/A	N/A	[('GO_0051866', 'general adaptation syndrome', 3, 'adaptive immunity'), ('CHEBI_27300', 'vitamin D', 35, 'vitamin D'), ('GO_0065007', 'biological regulation', 53, 'regulating'), ('GO_0071867', 'response to monoamine', 68, 'release of ... cytokines from ... cells'), ('CL_0000226', 'single nucleate cell', 111, 'mononuclear cells'), ('GO_0031097', 'medial cortex', 111, 'mononuclear'), ('CL_0000084', 'T cell', 142, 'T-cell'), ('GO_0042098', 'T cell proliferation', 142, 'T-cell proliferation')]
PMC5372327	3/2017	S88-PMC5372327	['the families received a study diary to record treatment compliance prospectively and empty Vitamin D bottles are collected at follow-up visits.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 91, 'vitamin D')]
PMC5372327	3/2017	S120-PMC5372327	['in the group receiving 30\xa0μg of Vitamin D we expect a decrease from 12 to 9 infections during the 24-month study period.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 32, 'vitamin D')]
PMC5372327	3/2017	S130-PMC5372327	['we are collecting used Vitamin D bottles to evaluate the amount of Vitamin D left after each cycle.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 23, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 67, 'vitamin D')]
PMC5372327	3/2017	S131-PMC5372327	['these data, and parentally kept diaries on the use of Vitamin D are used to evaluate the compliance in Vitamin D intake.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 54, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 103, 'vitamin D')]
PMC5372933	3/2017	S28-PMC5372933	['canadian sample\nparticipants in the canadian sample were enrolled as part of a randomized control trial from june 2010 through march 2013, investigating the efficacy of three doses of maternal Perinatal Vitamin D to improve infant 25-Hydroxyvitamin D concentrations at 8 weeks Postpartum; results are published elsewhere [13].']	N/A	N/A	[('GO_0036268', 'swimming', 193, 'perinatal'), ('UBERON_0012101', 'perinatal stage', 193, 'perinatal'), ('CHEBI_27300', 'vitamin D', 203, 'vitamin D'), ('CHEBI_62218', '23,24-dihydrocucurbitacin D', 231, '25-hydroxyvitamin D'), ('GO_0007565', 'female pregnancy', 277, 'postpartum')]
PMC5379504	4/2017	S92-PMC5379504	['caption (table-wrap): table 2\n\nFeeding practice, Micronutrient supplementation and morbidity related characteristics of study participants, dabat district, northwest ethiopia, 2015characteristicsfrequencypercentfeeding during Pregnancy\u2003less than before/usual35660.6\u2003as usual22137.6\u2003greater than usual/extra foods101.7prenatal Iron-Folate supplementation\u2003yes30852.5\u2003no27947.5colostrum\u2003given to the child32455.2\u2003discarded26344.8ever breastfeeding\u2003yes58499.5\u2003no30.5initiation of breastfeeding\u2003early initiation33357.0\u2003late initiation25143.0exclusive breastfeeding\u2003yes36161.5\u2003no22638.5pre-lacteal Feeding\u2003yes13723.3\u2003no45076.7complementary Feeding initiation\u2003early initiation10918.6\u2003timely initiation31453.5\u2003lately initiation16427.9bottle Feeding in the previous 24\xa0h\u2003yes406.8\u2003no54793.2dietary diversity score\u2003<\xa04 Food groups56295.7\u2003≥\xa04 Food groups254.3maternal vitamin a supplementation\u2003yes14524.7\u2003no44275.3history of fever in the previous 2\xa0weeks\u2003yes23740.4\u2003no35059.6history of diarrheal disease in the previous 2\xa0weeks\u2003yes14324.4\u2003no44475.6child Vitamin A supplementation in the previous 12\xa0months\u2003yes46378.9\u2003no12421.1\n\ncaption (table-wrap): table 3\n\nenvironmental health related characteristics of the households, dabat district, northwest ethiopia, 2015characteristicsfrequencypercent (%)source of drinking Water\u2003safe sourcea21236.1\u2003unsafe sourceb37563.9water treatment habit\u2003not at all55093.7\u2003sometimes233.9\u2003always142.4availability of latrine71.9\u2003yes16528.1\u2003no42271.9waste disposal\u2003appropriatec7412.6\u2003inappropriated51387.4hand washing habit after toilet\u2003not at all7112.1\u2003sometimes11118.9\u2003always40569\napiped, protected well and spring Water\nbunprotected well, spring and surface Water\nccollected by municipality, buried and burned\nddumped in street/open space, compound and river\nthe prevalence of stunting and wasting among children aged 6–24\xa0months were 58.1% [95% ci; 50.3, 65.9%] and 17.0% [95% ci; 11.1, 22.9%], respectively.']	N/A	N/A	[('GO_0007631', 'feeding behavior', 31, 'Feeding'), ('CHEBI_33962', 'mu4-sulfido-quadro-tetracopper(6+)', 49, 'micronutrient'), ('GO_0007565', 'female pregnancy', 226, 'pregnancy'), ('CHEBI_24870', 'ion', 326, 'iron'), ('CHEBI_30863', '5-azaorotic acid', 331, 'folate'), ('GO_0007631', 'feeding behavior', 592, 'feeding'), ('GO_0007631', 'feeding behavior', 634, 'feeding'), ('GO_0007631', 'feeding behavior', 733, 'feeding'), ('CHEBI_33290', 'food', 808, 'food'), ('CHEBI_33290', 'food', 831, 'food'), ('CHEBI_27300', 'vitamin D', 1042, 'vitamin A'), ('PR_000004370', 'asialoglycoprotein receptor 2', 1050, 'A'), ('CHEBI_15377', 'water', 1305, 'water'), ('CHEBI_15377', 'water', 1633, 'water'), ('CHEBI_15377', 'water', 1677, 'water')]
PMC5381088	4/2017	S112-PMC5381088	['fertile women in norway are reported to have an intake of fibre, Vitamin D, Folate and iron below recommended amounts [16].']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 65, 'vitamin D'), ('CHEBI_30863', '5-azaorotic acid', 76, 'folate')]
PMC5384134	4/2017	S202-PMC5384134	['Vitamin A for treating measles in children) with the rest addressing risk factor questions (e.g.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 0, 'vitamin A')]
PMC5385921	4/2017	S17-PMC5385921	['autistic traits were based on parental ratings of the social responsiveness scale (srs), which quantifies behavioural features related to Cognition, Social Communication and autistic mannerisms.14compared with Individuals who were Vitamin D sufficient (25ohd concentrations >50 nmol/l), those who were deficient (25ohd <25 nmol/l) had significantly higher (more impaired) srs scores.']	N/A	N/A	[('GO_0050890', 'cognition', 138, 'cognition'), ('GO_0016445', 'somatic diversification of immunoglobulins', 149, 'social communication'), ('NCBITaxon_1', 'root', 210, 'individuals'), ('CHEBI_27300', 'vitamin D', 231, 'vitamin D')]
PMC5385921	4/2017	S70-PMC5385921	['to remove the effect of family relatedness in the sample, we removed one of each pair of siblings, prioritising siblings with valid Vitamin D measurements from both mid-Gestation and Cord Serum to maximise sample size.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 132, 'vitamin D'), ('GO_0007565', 'female pregnancy', 169, 'gestation'), ('UBERON_0002240', 'spinal cord', 183, 'cord'), ('UBERON_0001977', 'blood serum', 188, 'serum')]
PMC5385921	4/2017	S72-PMC5385921	['we compared full models in which we included the Vitamin D predictor and parental and offspring demographic variables with nested models that did not include the Vitamin D predictor.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 49, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 162, 'vitamin D')]
PMC5385921	4/2017	S75-PMC5385921	['significance of the Vitamin D predictor was tested by comparing the fit of the full model with the fit of the reduced model, thereby considering that the penalty that is involved in the firth correction is the same for the full and the nested model to make the two models directly comparable.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 20, 'vitamin D')]
PMC5385921	4/2017	S88-PMC5385921	['in total, 4334 children and their mothers were available with measures of Vitamin D concentrations drawn from maternal Blood at mid-Gestation or drawn from Cord Blood at time of Birth as well as data on the srs and asd status.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 74, 'vitamin D'), ('UBERON_0000178', 'blood', 119, 'blood'), ('GO_0007565', 'female pregnancy', 132, 'gestation'), ('UBERON_0002240', 'spinal cord', 156, 'cord'), ('UBERON_0000178', 'blood', 161, 'blood'), ('GO_0007567', 'parturition', 178, 'birth')]
PMC5385921	4/2017	S118-PMC5385921	['the prevalence of Vitamin D deficiency was high in this cohort (17% of the mothers had mid-Gestational 25Ohd concentrations <25 nmol/l).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 18, 'vitamin D'), ('GO_0007565', 'female pregnancy', 91, 'gestational'), ('CHEBI_72652', "7,2'-dihydroxy-4'-methoxyisoflavan-4-ylium cation", 103, '25OHD')]
PMC5387760	11/2016	S36-PMC5387760	['multivitamin supplements included 20 mg Thiamin, 20 mg riboflavin, 25 mg Vitamin B6, 100 mg niacin, 50 µg Vitamin B12, 500 mg Vitamin C, 30 mg Vitamin E and 0·8 mg Folic Acid.']	N/A	N/A	[('CHEBI_26948', 'vitamin B1', 40, 'thiamin'), ('CHEBI_33237', 'vitamin D4', 73, 'vitamin B6'), ('CHEBI_33279', 'vitamin D5', 106, 'vitamin B12'), ('CHEBI_27300', 'vitamin D', 126, 'vitamin C'), ('CHEBI_27300', 'vitamin D', 143, 'vitamin E'), ('CHEBI_30751', 'formic acid', 164, 'folic acid')]
PMC5396145	10/2016	S197-PMC5396145	['for absolute mean Intakes, women in the ‘white bread and coffee’ cluster had the lowest intake of energy and all Nutrients, while those in the ‘meat and potatoes’ cluster had the highest absolute mean intakes of energy and most Macronutrients except total N‐3 highly unsaturated Fatty Acids and fibre and the highest absolute mean intakes of most Micronutrients except Magnesium, Carotene, Folate, Vitamins C and D (table3).']	N/A	N/A	[('GO_0007631', 'feeding behavior', 18, 'intakes'), ('CHEBI_33284', 'nutrient', 113, 'nutrients'), ('CHEBI_33839', 'macromolecule', 228, 'macronutrients'), ('31', 'ACACA (human)', 256, 'n'), ('CHEBI_35366', 'fatty acid', 279, 'fatty acids'), ('CHEBI_33839', 'macromolecule', 347, 'micronutrients'), ('CHEBI_22313', 'alkaline earth metal atom', 369, 'magnesium'), ('CHEBI_23042', 'carotene', 380, 'carotene'), ('CHEBI_30863', '5-azaorotic acid', 390, 'folate'), ('CHEBI_27300', 'vitamin D', 398, 'vitamins C'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 413, 'D')]
PMC5396145	10/2016	S198-PMC5396145	['women in the ‘fruit and vegetables’ cluster had the highest absolute mean Intakes of Docosahexaenoic Acid (Dha), Eicosapentaenoic Acid (Epa) and total n‐3 highly unsaturated Fatty Acids, fibre, Magnesium, Carotene, Folate, Vitamin C and D (table3).']	N/A	N/A	[('GO_0007631', 'feeding behavior', 74, 'intakes'), ('CHEBI_36003', 'decenoic acid', 85, 'docosahexaenoic acid'), ('CHEBI_17874', 'dihydrozeatin', 107, 'DHA'), ('CHEBI_36003', 'decenoic acid', 113, 'eicosapentaenoic acid'), ('CHEBI_34733', 'EPN', 136, 'EPA'), ('CHEBI_35366', 'fatty acid', 174, 'fatty acids'), ('CHEBI_22313', 'alkaline earth metal atom', 194, 'magnesium'), ('CHEBI_23042', 'carotene', 205, 'carotene'), ('CHEBI_30863', '5-azaorotic acid', 215, 'folate'), ('CHEBI_27300', 'vitamin D', 223, 'vitamin C'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 237, 'D')]
PMC5405075	4/2017	S61-PMC5405075	['(75)denmark 2009–2010623 mother–child pairs recruited from copsac2010cohort study double-blinded Placebo\u2009+\u2009400\u2009iu ( n \u2009=\u2009308)Cholecalciferol 2,400\u2009+\u2009400\u2009iu ( n \u2009=\u2009315)581/3\u2009yearsmothers: 24\u2009weeks of Gestation to 1\u2009week after deliveryincrease in maternal Serum vitd level in treatment group (mean sd at randomization vs Postpartum: 31 vs 43; control group 31 vs 29)mean group difference 13 [95% ci 11–16, p \u2009<\u20090.001]persistent wheeze, asthma, urti, lrti, episodes of Lung symptoms, spt, specific igeno significant reduction in the risk of persistent wheezing per 4\u2009ng/ml increase in maternal Serum Vitamin D level (hr: 0.86, 95% ci 0.89–0.99 p \u2009=\u20090.03)reduced number of troublesome Lung episodes (irr: 0.83, 95% ci 0.71–0.97 p \u2009=\u20090.02)upregulation or Airway Immune profile (principal component analysis p \u2009=\u20090.04)no effect on additional end pointslitonjua et al.']	N/A	N/A	[('CHEBI_8246', 'Pirbuterol acetate', 97, 'Placebo'), ('CHEBI_16113', 'cholesterol', 125, 'Cholecalciferol'), ('GO_0007565', 'female pregnancy', 199, 'gestation'), ('UBERON_0001977', 'blood serum', 254, 'serum'), ('GO_0007565', 'female pregnancy', 319, 'postpartum'), ('UBERON_0002048', 'lung', 466, 'lung'), ('UBERON_0001977', 'blood serum', 591, 'serum'), ('CHEBI_27300', 'vitamin D', 597, 'vitamin D'), ('UBERON_0002048', 'lung', 681, 'lung'), ('UBERON_0001005', 'respiratory airway', 750, 'airway'), ('UBERON_0002405', 'immune system', 757, 'immune')]
PMC5405075	4/2017	S66-PMC5405075	['recruited 623 unselected women who were randomized to receive either 2,800 or 400\u2009iu (as part of routine care) of Vitamin D daily from 24\u2009weeks of Gestation until the first Postpartum week.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 114, 'vitamin D'), ('GO_0007565', 'female pregnancy', 147, 'gestation'), ('GO_0007565', 'female pregnancy', 173, 'postpartum')]
PMC5410409	4/2017	S55-PMC5410409	['supplementation with Vitamin A and Vitamin C during Pregnancy had no preventive effect on the development Of Wheezing in the child [7].']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 21, 'vitamin A'), ('CHEBI_27300', 'vitamin D', 35, 'vitamin C'), ('GO_0007565', 'female pregnancy', 52, 'pregnancy'), ('GO_0001503', 'ossification', 106, 'of wheezing')]
PMC5417583	5/2017	S108-PMC5417583	['Wheat is deficient in lysine/isoleucine, Rice in protein and Vitamin A, Millet or sorghum deficient in protein.']	N/A	N/A	[('NCBITaxon_10088', 'Mus <genus>', 0, 'Wheat'), ('NCBITaxon_33208', 'Metazoa', 41, 'rice'), ('CHEBI_27300', 'vitamin D', 61, 'vitamin A'), ('NCBITaxon_10088', 'Mus <genus>', 72, 'millet')]
PMC5418719	5/2017	S2-PMC5418719	['of these, 52 infants were eligible and received 800\xa0iu/day Vitamin D from 2\xa0weeks of age.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 59, 'vitamin D')]
PMC5418719	5/2017	S17-PMC5418719	['responses to different doses of Vitamin D supplementation and monitored supplementation of Vitamin D with serial measurement of 25 (Oh)D concentrations are limited in vlbw within a month after Birth.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 32, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 91, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 128, '25 (OH)D'), ('GO_0007567', 'parturition', 193, 'birth')]
PMC5418719	5/2017	S24-PMC5418719	['study protocol\nat Birth, Serum calcium, phosphorus, alkaline phosphatase and 25(Oh)D concentrations were obtained from Cord Blood samples before Vitamin D supplementation was started.']	N/A	N/A	[('GO_0007567', 'parturition', 18, 'birth'), ('UBERON_0001977', 'blood serum', 25, 'serum'), ('CHEBI_71657', 'versiconol acetate', 77, '25(OH)D'), ('UBERON_0002240', 'spinal cord', 119, 'cord'), ('UBERON_0000178', 'blood', 124, 'blood'), ('CHEBI_27300', 'vitamin D', 145, 'vitamin D')]
PMC5418719	5/2017	S25-PMC5418719	['early Vitamin D supplements (sunny d, gmp laboratories of america, inc., anaheim, ca, usa) were initiated at 14\xa0days after Birth at a dose of 800\xa0iu/day through an orogastric tube just before feeds, if infants were tolerating trophic feeds.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 6, 'vitamin D'), ('GO_0007567', 'parturition', 123, 'birth')]
PMC5418719	5/2017	S28-PMC5418719	['after receiving 100\xa0m\xa0l/kg per day of enteral Feedings, fortified Human Milk (including 82\xa0mg calcium, 45\xa0mg Phosphorus and 100\xa0iu Vitamin D per 100\xa0ml) or a Mineral-fortified preterm formula (including 115\xa0mg calcium, 62\xa0mg Phosphorus and 66\xa0iu Vitamin D per 100\xa0ml) were used for nutritional care.']	N/A	N/A	[('GO_0007631', 'feeding behavior', 46, 'feedings'), ('NCBITaxon_9606', 'Homo sapiens', 66, 'human'), ('UBERON_0001913', 'milk', 72, 'milk'), ('CHEBI_35885', 'secondary phosphine', 109, 'phosphorus'), ('CHEBI_27300', 'vitamin D', 131, 'vitamin D'), ('CHEBI_46662', 'mineral', 158, 'mineral'), ('CHEBI_35885', 'secondary phosphine', 225, 'phosphorus'), ('CHEBI_27300', 'vitamin D', 246, 'vitamin D')]
PMC5418719	5/2017	S36-PMC5418719	['secondary outcomes included Vitamin D toxicity profile: Serum levels of calcium, phosphorus, alkaline phosphatase, the proportion of Vitamin D excess and Parathyroid hormone (pth) at 32\xa0weeks pma; hypercalciuria (Urine calcium to creatinine ratio [uca/ucr]\u2009>\u20090.8\xa0mg/mg) or nephrocalcinosis at 36\xa0weeks pma.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 28, 'vitamin D'), ('UBERON_0001977', 'blood serum', 56, 'serum'), ('CHEBI_27300', 'vitamin D', 133, 'vitamin D'), ('UBERON_0001132', 'parathyroid gland', 154, 'parathyroid'), ('UBERON_0001088', 'urine', 213, 'urine')]
PMC5418719	5/2017	S40-PMC5418719	['data on maternal age, Gestational diabetes mellitus, Antenatal Steroid use, histologic chorioamnionitis, maternal education, Birth during Vitamin D synthetizing period, Gestational age, Birth weight, small Gestational age, sex, type of Delivery, and apgar scores at 1 and 5\xa0min were retrieved for each infant.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 22, 'gestational'), ('GO_0007567', 'parturition', 53, 'antenatal'), ('CHEBI_35341', 'steroid', 63, 'steroid'), ('GO_0007567', 'parturition', 125, 'birth'), ('CHEBI_27300', 'vitamin D', 138, 'vitamin D'), ('GO_0007565', 'female pregnancy', 169, 'gestational'), ('GO_0007567', 'parturition', 186, 'birth'), ('GO_0007565', 'female pregnancy', 206, 'gestational'), ('GO_0007567', 'parturition', 236, 'delivery')]
PMC5418719	5/2017	S53-PMC5418719	['of these, 2 infants died before 2\xa0weeks of age; consent was refused by 2 parents and withdrawn after decision by 5 parents shortly; 5 infants were intolerant of trophic feeds and Vitamin D. thus, a total of 52 infants were eligible and completed the intervention after parents provided informed consent.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 179, 'vitamin D')]
PMC5418719	5/2017	S56-PMC5418719	['among the study groups at baseline, the number of cases of Vitamin D deficiency and insufficiency were 20 (41%) and 24 (49%), respectively, while after Vitamin D supplementation, the number of cases of Vitamin D deficiency and insufficiency were 0 (0%) and 9 (21%) at 36\u2009±\u20091\xa0weeks pma.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 59, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 152, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 202, 'vitamin D')]
PMC5418719	5/2017	S57-PMC5418719	['five infants (10%) had sufficient 25(Oh)D levels in range of 30.1–80\xa0ng/ml at Birth, and 31 infants (72%) at 36\u2009±\u20091\xa0weeks pma achieved sufficient 25(Oh)D levels after Vitamin D supplementation.']	N/A	N/A	[('CHEBI_71657', 'versiconol acetate', 34, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 34, '25(OH ... D'), ('GO_0007567', 'parturition', 78, 'birth'), ('CHEBI_71657', 'versiconol acetate', 146, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 146, '25(OH ... D'), ('CHEBI_27300', 'vitamin D', 167, 'vitamin D')]
PMC5418719	5/2017	S71-PMC5418719	['caption (table-wrap): table 1\n\ndemographic characteristicscharacteristicsall patients( n \u2009=\u200952)Cord 25(Oh)D concentrations <10\xa0ng/ml ( n \u2009=\u200920)Cord 25(Oh)D concentrations ≥10\xa0ng/ml ( n \u2009=\u200929)maternal age, years34.3\u2009±\u20093.432.4\u2009±\u20093.133.8\u2009±\u20094.0gdm6 (12%)5 (25%)1 (3%)*preeclampsia4 (8%)0 (0%)3 (10%)antenatal Steroid44 (85%)19 (95%)22 (79%)histological chorioamnionitis33 (64%)11 (55%)21 (72%)completed college38 (73)13 (65%)24 (83%)Birth during Vitamin D Synthesizing period30 (58%)7 (35%)20 (69%)†Gestational age (weeks)27.1\u2009±\u20092.527.5\u2009±\u20092.526.8\u2009±\u20092.6small Gestational age8 (15%)2 (10%)5 (17%)Birth weight (g)971.2\u2009±\u2009252.41045.5\u2009±\u2009271.8933.5\u2009±\u2009203.6birth length (cm)34.1\u2009±\u20093.534.3\u2009±\u20093.434.1\u2009±\u20093.6birth Head circumference (cm)24.6\u2009±\u20092.224.8\u2009±\u20092.324.5\u2009±\u20092.2male sex26 (50%)7 (35%)16 (55%)cesarean section40 (77%)18 (90%)20 (71%)apgar score at 5\xa0min5.1\u2009±\u20091.55.3\u2009±\u20091.74.9\u2009±\u20091.3rds47 (90%)17 (85%)27 (96%)pda35 (67%)15 (79%)19 (66%)Nec3 (6%)0 (0%)2 (7%)culture-proven sepsis17 (33%)5 (26%)11 (38%)bpd (≥ moderate)25 (48%)7 (37%)16 (55%)rop (≥ stage 2)24 (46%)8 (40%)14 (50%)ivh (≥ grade 2)6 (12%)4 (20%)2 (7%)Breast Milk with/without formula38 (73%)13 (65%)22 (76%)exclusively fortified Breast Milk13 (25%)5 (25%)8 (28%)ventilation days (d)24.1\u2009±\u200918.420.9\u2009±\u200918.120.9\u2009±\u200918.1hospital days (d)85.5\u2009±\u200933.277.6\u2009±\u200924.886.6\u2009±\u200928.3tpn days (d)47.1\u2009±\u200932.537.2\u2009±\u200922.747.2\u2009±\u200922.4\ndata are presented as n (%), median (range), or mean\u2009±\u2009sd\ngdm Gestational diabetes mellitus, rds Respiratory Distress syndrome, pda patent Ductus Arteriosus, nec necrotizing enterocolitis, bpd bronchopulmonary dysplasia, rop retinopathy of prematurity, Ivh Intraventricular hemorrhage, tpn total parenteral nutrition\n*p \u2009=\u20090.035 for the difference between cord 25(Oh)D concentrations\u2009<\u200910\xa0ng/ml vs. ≥ 10\xa0ng/ml\n†p \u2009=\u20090.023 for the difference between Cord 25(Oh)D concentrations\u2009<\u200910\xa0ng/ml vs. ≥ 10\xa0ng/ml\nall neonates received 800\xa0iu 25(Oh)D per day from first 2\xa0weeks of age.']	N/A	N/A	[('CHEBI_33252', 'atomic nucleus', 95, 'Cord'), ('UBERON_0000948', 'heart', 95, 'Cord'), ('CHEBI_71657', 'versiconol acetate', 100, '25(OH)D'), ('PR_000005506', 'Cbp/p300-interacting transactivator 2', 100, '25'), ('PR_000012046', 'oxysterol-binding protein-related protein 11', 103, 'OH ... D'), ('CHEBI_33252', 'atomic nucleus', 143, 'Cord'), ('UBERON_0000948', 'heart', 143, 'Cord'), ('CHEBI_71657', 'versiconol acetate', 148, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 148, '25(OH ... D'), ('CHEBI_75977', '(S)-2-hydroxyhexadecanoic acid', 305, 'steroid44'), ('GO_0007567', 'parturition', 429, 'Birth'), ('CHEBI_27300', 'vitamin D', 442, 'vitamin D'), ('GO_0031319', 'detection of cAMP', 450, 'D synthesizing'), ('GO_0007565', 'female pregnancy', 495, 'Gestational'), ('GO_0007565', 'female pregnancy', 554, 'gestational'), ('GO_0007567', 'parturition', 590, 'Birth'), ('UBERON_0000033', 'head', 699, 'head'), ('PR_000011111', 'N-terminal EF-hand calcium-binding protein 3', 924, 'NEC3'), ('UBERON_0013538', 'Brodmann (1909) area 7', 1101, 'Breast milk'), ('UBERON_0013558', 'Brodmann (1909) area 27', 1179, 'breast milk13'), ('GO_0007565', 'female pregnancy', 1423, 'gestational'), ('UBERON_0003495', 'respiratory system arteriole', 1458, 'respiratory distress'), ('UBERON_0002254', 'thyroglossal duct', 1500, 'ductus arteriosus'), ('UBERON_2005050', 'palatocerebral artery', 1614, 'IVH'), ('UBERON_0006250', 'infundibular recess of 3rd ventricle', 1618, 'intraventricular'), ('CHEBI_71657', 'versiconol acetate', 1722, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 1722, '25(OH)D'), ('UBERON_0002240', 'spinal cord', 1810, 'cord'), ('CHEBI_33010', 'chromide(1-)', 1817, '(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 1821, 'D'), ('CHEBI_71657', 'versiconol acetate', 1893, '25(OH)D'), ('PR_000011614', 'opioid growth factor receptor', 1896, 'OH)D')]
PMC5418719	5/2017	S72-PMC5418719	['we checked Serum Vitamin D at Birth, 32\u2009±\u20091\xa0weeks pma and 36\u2009±\u20091\xa0weeks pma.']	N/A	N/A	[('UBERON_0001977', 'blood serum', 11, 'serum'), ('CHEBI_27300', 'vitamin D', 17, 'vitamin D'), ('GO_0007567', 'parturition', 30, 'birth')]
PMC5418719	5/2017	S74-PMC5418719	['after the Vitamin D supplementation, the Serum 25(Oh)D status at discharge in the two groups converged into increasing 25(Oh)D concentrations.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 10, 'vitamin D'), ('UBERON_0001977', 'blood serum', 41, 'serum'), ('CHEBI_71657', 'versiconol acetate', 47, '25(OH)D'), ('CHEBI_71657', 'versiconol acetate', 119, '25(OH)D')]
PMC5418719	5/2017	S76-PMC5418719	['the proportion of infants with Vitamin D sufficiency was lower in those with cord 25(Oh)D concentrations\u2009<\u200910\xa0ng/ml than in those with cord 25(Oh)D concentrations\u2009≥\u200910\xa0ng/ml at 36\u2009±\u20091\xa0weeks Pma (65% vs. 88%; p \u2009=\u20090.12; table\xa02).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 31, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 82, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 82, '25(OH)D'), ('CHEBI_71657', 'versiconol acetate', 140, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 140, '25(OH)D'), ('CHEBI_34913', 'Phenbenzamine hydrochloride', 190, 'PMA')]
PMC5418719	5/2017	S81-PMC5418719	['the two infants of the three infants with nephrocalcinosis were not related with both excessive amounts of Vitamin D and an increased uca/ucr at 36\u2009±\u20091\xa0weeks pma.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 107, 'vitamin D')]
PMC5418719	5/2017	S82-PMC5418719	['one of the three infants with exceeding level of Vitamin D had both nephrocalcinosis on a Renal ultrasound and increased uca/ucr\u2009>\u20090.8.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 49, 'vitamin D'), ('UBERON_0002113', 'kidney', 90, 'renal')]
PMC5418719	5/2017	S83-PMC5418719	['the three infants in the Cord 25(Oh)D concentrations\u2009≥\u200910\xa0ng/ml group had a Vitamin D excess (85.5, 94 and 97.2\xa0ng/ml) at 36\u2009±\u20091\xa0weeks pma.']	N/A	N/A	[('UBERON_0002240', 'spinal cord', 25, 'cord'), ('CHEBI_71657', 'versiconol acetate', 30, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 30, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 76, 'vitamin D')]
PMC5418719	5/2017	S115-PMC5418719	['daily maternal (2000\xa0iu) and infant (800\xa0iu) Vitamin D supplementation attained a Serum 25(Oh)D\u2009>\u200930\xa0ng/ml in 80% of study infants at 4\xa0months of age.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 45, 'vitamin D'), ('UBERON_0001977', 'blood serum', 82, 'serum'), ('CHEBI_71657', 'versiconol acetate', 88, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 88, '25(OH)D')]
PMC5424337	10/2016	S87-PMC5424337	['overall, Vitamins were considered beneficial, including Prenatal Vitamins (88.3\xa0%), multivitamins (81.6\xa0%), Vitamin C (66.1\xa0%), Vitamin E (65.2\xa0%), and Vitamin D (68.1\xa0%).']	N/A	N/A	[('CHEBI_33277', 'gamma-tocotrienol', 9, 'vitamins'), ('GO_0007565', 'female pregnancy', 56, 'prenatal'), ('CHEBI_33277', 'gamma-tocotrienol', 65, 'vitamins'), ('CHEBI_27300', 'vitamin D', 108, 'vitamin C'), ('CHEBI_27300', 'vitamin D', 128, 'vitamin E'), ('CHEBI_27300', 'vitamin D', 152, 'vitamin D')]
PMC5426325	4/2017	S6-PMC5426325	['the risk of fractures was increased among both girls and boys who were Born before the Vitamin D fortification terminated in 1985 (rate ratio (rr) exposed v .']	N/A	N/A	[('GO_0007567', 'parturition', 71, 'born'), ('CHEBI_27300', 'vitamin D', 87, 'vitamin D')]
PMC5426325	4/2017	S10-PMC5426325	['there was no interaction between season of Birth and Vitamin D availability in relation to fracture risk.']	N/A	N/A	[('GO_0007567', 'parturition', 43, 'birth'), ('CHEBI_27300', 'vitamin D', 53, 'vitamin D')]
PMC5426325	4/2017	S39-PMC5426325	['vertical lines indicate the timing of the cohorts around the Vitamin D fortification termination date (31 may 1985).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 61, 'vitamin D')]
PMC5426325	4/2017	S115-PMC5426325	['for both girls and boys, there was no interaction between season of Birth and the exposure to Vitamin D fortification in relation to overall fracture risk (girls: p 0·23; boys: p 0·44).']	N/A	N/A	[('GO_0007567', 'parturition', 68, 'birth'), ('CHEBI_27300', 'vitamin D', 94, 'vitamin D')]
PMC5426325	4/2017	S149-PMC5426325	['furthermore, from the danish dietary habit survey from 1985, the median Vitamin D intake was 2·8 µg/d among women aged 23–50 years(61).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 72, 'vitamin D')]
PMC5436890	5/2017	S58-PMC5436890	['guidelines included imci chart booklet, iycf guideline, guidelines for deworming and Vitamin A distribution and the basic nns nutrition training manual.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 85, 'vitamin A')]
PMC5436890	5/2017	S103-PMC5436890	['one uh&fwc and one community clinic had none of the listed equipment,table 2.10.1371/journal.pone.0178121.t002\n\ncaption (table-wrap): table 2\nstructural readiness of health facilities—availability of equipment, supplements, guidelines and record keeping registers.upazila health complex, n = 11union health & family welfare centres, n = 14community clinics, n = 12 antenatal care rooms \u2003weighing scales111212\u2003stadiometers5411\u2003Blood Pressure monitor10109\u2003stethoscope101112\u2003tape measure465\u2003thermometer6511\u2003picture cards with maternal danger signs587\u2003Iron and Folic Acid supplement111410\u2003Calcium supplement746\u2003basic nns nutrition training manual132\u2003record keeping register/reporting forms61110\u2003facilities with >5 items of equipment8811\u2003facilities with none of the above listed equipment010 imcia-nutrition corners/areas for the management of sick children \u2003weighing scales745\u2003stadiometers643\u2003infantometer422\u2003tape measure (mid-upper Arm circumference)436\u2003growth charts703\u2003imciachart booklet642\u2003guidelines for deworming210\u2003guidelines for Vitamin A distribution411\u2003basic nns nutrition training manual301\u2003iycfbguidelines200\u2003record keeping register/reporting forms864\u2003facilities with >5 items of equipment401\u2003facilities with none of the above listed equipment175\naimci = integrated management of childhood illness\nbiycf = infant and young child Feeding\nless than half (43%) of the imci-nutrition corners/areas for management of sick children had weighing scales and approximately one third had infantometers, tape measures and growth monitoring cards.']	N/A	N/A	[('UBERON_0003061', 'blood island', 426, 'Blood pressure'), ('CHEBI_24870', 'ion', 548, 'Iron'), ('CHEBI_30751', 'formic acid', 557, 'folic acid'), ('CHEBI_31341', 'calcium dihydroxide', 585, 'Calcium'), ('UBERON_0001460', 'arm', 929, 'arm'), ('CHEBI_27300', 'vitamin D', 1033, 'vitamin A'), ('GO_0007631', 'feeding behavior', 1337, 'feeding')]
PMC5444625	5/2017	S52-PMC5444625	['preventive services include immunization (free for children under 5 years of age), deworming, and Vitamin A supplementation.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 98, 'vitamin A')]
PMC5444625	5/2017	S185-PMC5444625	['seven Food groups were included: cereals, roots and tubers; legumes and nuts; dairy products (milk, yogurt, and cheese); meat products (meat, poultry, and offal) and fish; eggs; fruits and vegetables rich in Vitamin A; and other fruits and vegetables.']	N/A	N/A	[('CHEBI_33290', 'food', 6, 'food'), ('CHEBI_27300', 'vitamin D', 208, 'vitamin A')]
PMC5452160	4/2017	S91-PMC5452160	['marginal Vitamin A status was defined as rbp < 1.32 µmol/l [31].']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 9, 'vitamin A')]
PMC5474873	6/2017	S18-PMC5474873	['the main source of Vitamin D for Humans is from its dermal synthesis by exposure to sunlight (11,12), which provides up to 90% in the form of Vitamin D3 (Cholecalciferol) with the remainder coming from Food in the form of Vitamin D3 or Vitamin D2 (Ergocalciferol) (6,9,13,14).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 19, 'vitamin D'), ('NCBITaxon_9606', 'Homo sapiens', 33, 'humans'), ('CHEBI_33279', 'vitamin D5', 142, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 142, 'vitamin D3'), ('CHEBI_52550', 'theopalauamide', 154, 'cholecalciferol'), ('CHEBI_33290', 'food', 202, 'food'), ('CHEBI_33279', 'vitamin D5', 222, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 222, 'vitamin D3'), ('CHEBI_28934', 'vitamin D2', 236, 'vitamin D2'), ('PR_000017299', 'VIP peptides', 236, 'vitamin D2'), ('CHEBI_4910', 'etomidate', 248, 'ergocalciferol')]
PMC5474873	6/2017	S19-PMC5474873	['in order to convert 7-Dehydrocholesterol to pre-Vitamin D3, the skin is penetrated by solar ultraviolet b radiation (wavelength between 290 and 315\u2009nm), which then is isomerized by heat to Vitamin D3 before being carried, bound to Vitamin D-binding protein, to the Liver where it is converted into the main Metabolite 25-Hydroxyvitamin D3.']	N/A	N/A	[('CHEBI_17500', '7alpha-hydroxycholesterol', 20, '7-dehydrocholesterol'), ('CHEBI_33279', 'vitamin D5', 48, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 48, 'vitamin D3'), ('CHEBI_33279', 'vitamin D5', 189, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 189, 'vitamin D3'), ('CHEBI_27300', 'vitamin D', 231, 'vitamin D'), ('UBERON_0002107', 'liver', 265, 'liver'), ('CHEBI_39382', 'flufenoxuron', 307, 'metabolite'), ('CHEBI_63991', '15-epi-lipoxin B4', 318, '25-hydroxyvitamin D3'), ('PR_000001177', 'D(2) dopamine receptor', 336, 'D3')]
PMC5485024	3/2017	S90-PMC5485024	['furthermore, there was a difference in mean Intake of Vitamin D, Omega‐3 and Omega‐6 Fatty Acids across tertiles of dietary tac (table1).']	N/A	N/A	[('GO_0007631', 'feeding behavior', 44, 'intake'), ('CHEBI_27300', 'vitamin D', 54, 'vitamin D'), ('CHEBI_30823', 'oleate', 65, 'omega'), ('CHEBI_37972', 'phosphorus-32 atom', 71, '3'), ('CHEBI_30823', 'oleate', 77, 'omega'), ('CHEBI_52026', 'amorpha-4,11-diene', 83, '6'), ('CHEBI_35366', 'fatty acid', 85, 'fatty acids')]
PMC5489519	6/2017	S4-PMC5489519	['milk from Vitamin D deficient mothers showed high levels of Trail (Α and β) proteins compared to milk from Vitamin D replete women.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 10, 'vitamin D'), ('PR_000001949', 'tumor necrosis factor ligand superfamily member 4', 60, 'TRAIL'), ('PR_000006000', 'carboxy-terminal domain RNA polymerase II polypeptide A small phosphatase 2', 67, 'α'), ('CHEBI_27300', 'vitamin D', 107, 'vitamin D')]
PMC5489519	6/2017	S12-PMC5489519	['various factors such as less sunlight exposure due to indoor activity during the day or use of sunscreen, darker skin pigmentation, and health conditions such as Pregnancy and obesity result in Vitamin D deficiency in People6.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 162, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 194, 'vitamin D'), ('NCBITaxon_10088', 'Mus <genus>', 218, 'people6')]
PMC5489519	6/2017	S48-PMC5489519	['Serum samples collected from fifteen nursing mothers’ were measured for 25(Oh)D levels to evaluate Vitamin D status in mother groups as described in methods.']	N/A	N/A	[('UBERON_0001977', 'blood serum', 0, 'Serum'), ('CHEBI_71657', 'versiconol acetate', 72, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 78, 'D'), ('CHEBI_27300', 'vitamin D', 99, 'vitamin D')]
PMC5489519	6/2017	S53-PMC5489519	['Milk samples from Vitamin D sufficient and deficient mother groups containing an equal amount of protein (50\u2009µg) were subjected to western blot analysis for Trail Expression using a specific anti-Trail Antibody.']	N/A	N/A	[('UBERON_0001913', 'milk', 0, 'Milk'), ('CHEBI_27300', 'vitamin D', 18, 'vitamin D'), ('PR_000001949', 'tumor necrosis factor ligand superfamily member 4', 157, 'TRAIL'), ('GO_0010467', 'gene expression', 163, 'expression'), ('PR_000001949', 'tumor necrosis factor ligand superfamily member 4', 196, 'TRAIL'), ('GO_0042571', 'immunoglobulin complex, circulating', 202, 'antibody')]
PMC5489519	6/2017	S72-PMC5489519	['caption (fig): figure 3\n\nwestern blot analysis for Vitamin D [1,25(Oh)2D] Regulation Of Trail Isoforms Expression in normal Human breast Epithelial Cells.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 51, 'vitamin D'), ('CHEBI_37958', 'dye', 62, '1,'), ('CHEBI_66212', "5,7,3',4'-tetrahydroxy-2'-(3,3-dimethylallyl)isoflavone", 64, '25(OH)2D'), ('GO_0010468', 'regulation of gene expression', 74, 'regulation of ... expression'), ('PR_000001949', 'tumor necrosis factor ligand superfamily member 4', 88, 'TRAIL'), ('SO_0001060', 'sequence_variant', 94, 'isoforms'), ('NCBITaxon_9606', 'Homo sapiens', 124, 'human'), ('CL_0000066', 'epithelial cell', 137, 'epithelial cells'), ('UBERON_0000483', 'epithelium', 137, 'epithelial')]
PMC5489519	6/2017	S80-PMC5489519	['hme-1 cells were treated with Vitamin D [1,25(Oh)2D] at 0, 5 and 20\u2009nm for 24\u2009h. total rna isolated from these cells was subjected to real-time rt-pcr analysis for Trail mrna Expression as described.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 30, 'vitamin D'), ('CHEBI_37958', 'dye', 41, '1,'), ('CHEBI_66212', "5,7,3',4'-tetrahydroxy-2'-(3,3-dimethylallyl)isoflavone", 43, '25(OH)2D'), ('PR_000001949', 'tumor necrosis factor ligand superfamily member 4', 164, 'TRAIL'), ('GO_0010467', 'gene expression', 175, 'expression')]
PMC5489519	6/2017	S117-PMC5489519	['the collection of Breast Milk and Serum samples from women participating in an nichd-sponsored study of Vitamin D supplementation during Lactation was carried out by the approved guidelines.']	N/A	N/A	[('UBERON_0001348', 'brown adipose tissue', 18, 'breast milk'), ('UBERON_0001977', 'blood serum', 34, 'serum'), ('CHEBI_27300', 'vitamin D', 104, 'vitamin D'), ('GO_0007595', 'lactation', 137, 'lactation')]
PMC5489519	6/2017	S118-PMC5489519	['all subjects were taking a Prenatal Vitamin with 400\u2009iu of Vitamin D. Blood samples were collected by venipuncture at the time of the study visit; then placed in a Serum separator tube, centrifuged, and Serum stored at −20\u2009°c until later analysis.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 27, 'prenatal'), ('CHEBI_33229', 'vitamin (role)', 36, 'vitamin'), ('CHEBI_27300', 'vitamin D', 59, 'vitamin D'), ('UBERON_0000178', 'blood', 70, 'Blood'), ('UBERON_0001977', 'blood serum', 164, 'serum'), ('UBERON_0001977', 'blood serum', 203, 'serum')]
PMC5489519	6/2017	S127-PMC5489519	['western blot analysis\ntotal protein content of the Milk samples from Vitamin D sufficient and deficient women and hme-1 cells stimulated with 0–20\u2009nm of vitamin d [1,25(Oh)2D]48,49was measured using the bradford protein assay method (bio-rad, hercules, ca).']	N/A	N/A	[('UBERON_0001913', 'milk', 51, 'milk'), ('CHEBI_27300', 'vitamin D', 69, 'vitamin D'), ('CHEBI_17996', 'chloride', 165, ','), ('CHEBI_66212', "5,7,3',4'-tetrahydroxy-2'-(3,3-dimethylallyl)isoflavone", 166, '25(OH)2D')]
PMC5504744	7/2017	S30-PMC5504744	['caption (table-wrap): table 1\n\ningredients and calculated Nutrient composition of the Gestation diet1itemgestation dietingredients, % as-Fed\u2003barley25.0\u2003oat20.0\u2003dried sugar Beet pulp14.3\u2003Wheat bran10.0\u2003soybean meal5.7\u2003dried Apple pomace5.6\u2003dried whole Maize Plant5.0\u2003Animal fat (70% lard and 30 % tallow)3.0\u2003linseed meal2.0\u2003potato protein2.0\u2003rapeseed meal2.0\u2003molasses2.0\u2003Dicalcium Phosphate1.16\u2003Calcium Carbonate0.75\u2003Sodium Chloride0.56\u2003pellan20.40\u2003Vitamin-Mineral premix30.40\u2003Amino acids4, %\u2003\u2003l-lysine Hcl0.08\u2003\u2003l-threonine0.06calculated composition, % dm\u2003dry matter, % of wet weight88.35\u2003total ash7.20\u2003Ether extract6.80\u2003crude protein15.10\u2003digestible energy, mj/kg dm13.70\n1in the arg group, the pellets were top dressed with 25 gl-Arginine Hcl/(sow·d), and in the ctrl group, the pellets were top dressed with 43 gl-alanine/(sow·d)\n2binder that aids in pellet formation (mikro-technik, gmbh & co. kg, germany)\n3contains: Vitamin A: 2,000,000 u/kg; Vitamin D3: 200,000 u/kg; Vitamin E: 10 g/kg; i: 137.4 mg/kg; Mn: 5 g/kg; Cu: 1.75 g/kg; zn: 1.4 g/kg; Se: 50 mg/kg\n4calculated amino acid composition, g/kg dm: alanine: 6.42; arginine: 8.51; aspartate plus asparagine: 12.70; cystine: 3.15; glutamate plus glutamine: 27.50; glycine: 6.54; histidine: 3.42; isoleucine: 5.74; leucine: 10.72; lysine: 7.90; methionine: 2.46; phenylalanine: 7.00; proline: 9.59; serine: 6.73; threonine: 6.30; tryptophan: 1.83; tyrosine: 5.03; valine: 7.38\n\ndata and Tissue sample collection at farrowing\nat the end of farrowing, litter characteristics including the number of piglets Born alive and stillborn and their individual body weights were recorded.']	N/A	N/A	[('CHEBI_33284', 'nutrient', 58, 'nutrient'), ('GO_0007565', 'female pregnancy', 86, 'gestation'), ('GO_0007631', 'feeding behavior', 137, 'fed'), ('NCBITaxon_33208', 'Metazoa', 172, 'beet'), ('NCBITaxon_10088', 'Mus <genus>', 186, 'Wheat'), ('NCBITaxon_33208', 'Metazoa', 223, 'apple'), ('NCBITaxon_40674', 'Mammalia', 251, 'maize'), ('NCBITaxon_10088', 'Mus <genus>', 257, 'plant5'), ('NCBITaxon_33208', 'Metazoa', 266, 'Animal'), ('CHEBI_4509', 'diclofenac sodium', 370, 'Dicalcium phosphate1'), ('CHEBI_553473', 'ceftizoxime', 394, 'Calcium carbonate0'), ('CHEBI_70124', "(2'S)-Hydroxy-(11S,12R)-dihydrostemofoline, (rel)-", 416, 'Sodium chloride0'), ('CHEBI_33229', 'vitamin (role)', 448, 'Vitamin'), ('CHEBI_46662', 'mineral', 456, 'mineral'), ('CHEBI_29318', 'aminyl', 476, 'Amino'), ('CHEBI_17883', 'hydrogen chloride', 502, 'HCl0'), ('CHEBI_25698', 'ether', 602, 'Ether'), ('CHEBI_22654', 'asparagine derivative', 731, 'arginine'), ('CHEBI_17883', 'hydrogen chloride', 740, 'HCl'), ('CHEBI_27300', 'vitamin D', 921, 'vitamin A'), ('CHEBI_33279', 'vitamin D5', 948, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 948, 'vitamin D3'), ('CHEBI_27300', 'vitamin D', 974, 'vitamin E'), ('CHEBI_25614', 'nylons', 1010, 'Mn'), ('CHEBI_17996', 'chloride', 1022, 'Cu'), ('CHEBI_37972', 'phosphorus-32 atom', 1051, 'Se'), ('UBERON_0000479', 'tissue', 1444, 'tissue'), ('GO_0007567', 'parturition', 1562, 'born')]
PMC5510234	7/2017	S75-PMC5510234	['five randomized, Placebo-controlled studies were included, among which four focused on Antenatal Vitamin A supplementation, in of 3033 hiv-infected women.']	N/A	N/A	[('CHEBI_26130', 'biological pigment', 17, 'placebo'), ('GO_0007567', 'parturition', 87, 'antenatal'), ('CHEBI_27300', 'vitamin D', 97, 'vitamin A')]
PMC5510234	7/2017	S77-PMC5510234	['the included studies were conducted in zimbabwe, south africa, malawi and tanzania, and rates of Vitamin A deficiency were 31-51%.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 97, 'vitamin A')]
PMC5513133	7/2017	S35-PMC5513133	['Calcitriol can also Modulate Immune function through a rapid action pathway by binding to receptors on the Plasma Membrane when the active hormone is synthesized in situ by several extra-Renal Tissues, namely Macrophages, Endothelium, cells in the Prostate, and Keratinocytes, as all of them Express the Vitamin D receptor [25].']	N/A	N/A	[('CHEBI_17823', 'calcitriol', 0, 'Calcitriol'), ('GO_0065007', 'biological regulation', 20, 'modulate'), ('UBERON_0002405', 'immune system', 29, 'immune'), ('GO_0005886', 'plasma membrane', 107, 'plasma membrane'), ('UBERON_0001228', 'renal papilla', 187, 'renal tissues'), ('CL_0000235', 'macrophage', 209, 'macrophages'), ('UBERON_0001986', 'endothelium', 222, 'endothelium'), ('UBERON_0002367', 'prostate gland', 248, 'prostate'), ('CL_0000312', 'keratinocyte', 262, 'keratinocytes'), ('GO_0010467', 'gene expression', 292, 'express'), ('CHEBI_27300', 'vitamin D', 304, 'vitamin D')]
PMC5513133	7/2017	S49-PMC5513133	['syncytial Trophoblasts responsible for invading the Uterine Wall for fetal Implantation also Express active Cyp27B1, in addition to Vitamin D Receptor (Vdr), Vitamin D Binding Protein (Vdbp), 25-hydroxylase, and 24-hydroxlyase.']	N/A	N/A	[('UBERON_0000088', 'trophoblast', 10, 'trophoblasts'), ('UBERON_0000459', 'uterine wall', 52, 'uterine wall'), ('GO_0007566', 'embryo implantation', 75, 'implantation'), ('GO_0010467', 'gene expression', 93, 'express'), ('PR_000006101', 'cytochrome P450 1A1', 108, 'CYP27B1'), ('CHEBI_27300', 'vitamin D', 132, 'vitamin D'), ('PR_000001683', 'vasopressin V2 receptor', 132, 'vitamin D receptor'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 152, 'VDR'), ('CHEBI_27300', 'vitamin D', 158, 'vitamin D'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 158, 'vitamin D binding protein'), ('PR_000017279', 'testis-specific basic protein Y 1', 185, 'VDBP')]
PMC5513133	7/2017	S93-PMC5513133	['search terms: (Preeclampsia or pre-eclampsia) and (Vitamin D or hypovitaminosis D or 1,25 Dihydroxyvitamin D or (Vitamin D and (supplementation or supplement)) or Dihydroxyvitamin D or 25 Hydroxyvitamin D).']	N/A	N/A	[('GO_0007128', 'meiotic prophase I', 15, 'preeclampsia'), ('CHEBI_27300', 'vitamin D', 51, 'vitamin D'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 80, 'D'), ('CHEBI_67469', '15-hydroxyajubractin C', 85, '1,25 dihydroxyvitamin D'), ('CHEBI_27300', 'vitamin D', 113, 'vitamin D'), ('CHEBI_27481', 'rhodexin A', 163, 'dihydroxyvitamin D'), ('CHEBI_37972', 'phosphorus-32 atom', 185, '25'), ('CHEBI_67825', '17beta,21beta-epoxyhopan-3-one', 188, 'hydroxyvitamin D')]
PMC5513133	7/2017	S119-PMC5513133	['there was an adjusted or of 0.72 (95% ci 0.58–0.92) in women with Vitamin D intake of 10–15\xa0μg/d from supplementation of Vitamin D alone when compared with no supplementation.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 66, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 121, 'vitamin D')]
PMC5513133	7/2017	S126-PMC5513133	['caption (table-wrap): table 2\n\ncharacteristics of included reportsauthor, location, yeardesignsubjectstime of Vitamin D measurementcross-sectional studies\u2003august et al., usa, 1992 [88]cross-sectional11 – women with pe3rd trimester9 – chronic Htn12 – normotensive Pregnant controls\u2003fernandez- alonzo et al., spain, 2012 [97]cross-sectional466 – Pregnant women (7 had pe)1st Trimester\u2003pena hr, et al.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 110, 'vitamin D'), ('PR_000008832', 'histatin-3', 242, 'HTN12'), ('GO_0007565', 'female pregnancy', 263, 'pregnant'), ('GO_0007565', 'female pregnancy', 344, 'pregnant'), ('GO_0009294', 'DNA mediated transformation', 373, 'trimester')]
PMC5513133	7/2017	S183-PMC5513133	['there was no statistical evidence of interaction between Pigf and Vitamin D ( p \xa0=\xa00.54) [14].']	N/A	N/A	[('PR_000012702', 'GPI ethanolamine phosphate transferase 3', 57, 'PIGF'), ('CHEBI_27300', 'vitamin D', 66, 'vitamin D')]
PMC5513133	7/2017	S193-PMC5513133	['after adjusting for covariates, Vitamin D insufficiency and deficiency were not significantly associated with pe (aor\xa0=\xa01.1 95% ci: 0.6–2.0; aor\xa0=\xa01.4 95% ci: 0.7–3.0, respectively) [96].']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 32, 'vitamin D')]
PMC5513133	7/2017	S228-PMC5513133	['rcts reviewed in this article were not able to study Vitamin D supplementation independently of calcium and/or other multivitamin/Micronutrient supplementation.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 53, 'vitamin D'), ('CHEBI_33962', 'mu4-sulfido-quadro-tetracopper(6+)', 130, 'micronutrient')]
PMC5513133	7/2017	S230-PMC5513133	['in trials with an intervention of Vitamin D without Calcium, women who received Vitamin D supplements had a statistically nonsignificant lower risk of pre-eclampsia than those receiving no intervention or placebo (8.9% versus 15.5%; risk ratio (rr) 0.52; 95% ci 0.25 to 1.05; low quality) with no adverse outcomes [105].']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 34, 'vitamin D'), ('CHEBI_22313', 'alkaline earth metal atom', 52, 'calcium'), ('CHEBI_27300', 'vitamin D', 80, 'vitamin D')]
PMC5513133	7/2017	S245-PMC5513133	['the doses of Vitamin D supplements in the studies reviewed ranged from 400 to 2500\xa0iu daily [91].']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 13, 'vitamin D')]
PMC5513133	7/2017	S252-PMC5513133	['in the vdaart, frequency of pe among Pregnant women with a high risk for atopic disease was not lower when a supplementation of 4400\xa0iu Vitamin D daily was given in early Pregnancy (10–18\xa0weeks).']	N/A	N/A	[('GO_0007565', 'female pregnancy', 37, 'pregnant'), ('CHEBI_27300', 'vitamin D', 136, 'vitamin D'), ('GO_0007565', 'female pregnancy', 171, 'pregnancy')]
PMC5513133	7/2017	S257-PMC5513133	['studies reported varying degrees of risk for clinical subtypes of pe among women with low Vitamin D levels [79,90].']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 90, 'vitamin D')]
PMC5521778	7/2017	S0-PMC5521778	['inhibition of Pulmonary Β-Carotene 15, 15’-oxygenase Expression by Glucocorticoid involves Pparα\n\nabstract\nΒ-Carotene 15,15’-oxygenase (bco1) catalyzes the first step in the conversion of dietary Provitamin A Carotenoids to Vitamin A.']	N/A	N/A	[('UBERON_0002048', 'lung', 14, 'pulmonary'), ('CHEBI_68219', 'aspergillusene B', 24, 'β-carotene 15, 15’-'), ('GO_0010467', 'gene expression', 53, 'expression'), ('CHEBI_24261', 'glucocorticoid', 67, 'glucocorticoid'), ('PR_000013057', 'peroxisome proliferator-activated receptor delta', 91, 'PPARα'), ('CHEBI_68219', 'aspergillusene B', 107, 'β-carotene 15,15’-'), ('CHEBI_70584', 'Pulicatin A', 196, 'provitamin A'), ('CHEBI_50815', 'norgestimate', 209, 'carotenoids'), ('CHEBI_27300', 'vitamin D', 224, 'vitamin A')]
PMC5521778	7/2017	S14-PMC5521778	['Bco1 catalyzes the symmetrical (central) cleavage of the Β-Carotene Molecule to produce two Molecules of Retinaldehyde (Retinal), which can then be oxidized to a transcriptionally active form, Retinoic Acid (ra) [1], or be reduced to Retinol (Vitamin A) [2].']	N/A	N/A	[('CHEBI_22918', 'branched-chain amino acid', 0, 'BCO1'), ('CHEBI_28064', 'cyanidin 3-O-rutinoside', 57, 'β-carotene'), ('CHEBI_36357', 'polyatomic entity', 68, 'molecule'), ('CHEBI_36357', 'polyatomic entity', 92, 'molecules'), ('CHEBI_17173', 'D-ribulose', 105, 'retinaldehyde'), ('CHEBI_26536', 'retinoic acid', 120, 'retinal'), ('CHEBI_26536', 'retinoic acid', 193, 'retinoic acid'), ('CHEBI_26536', 'retinoic acid', 234, 'retinol'), ('CHEBI_27300', 'vitamin D', 243, 'vitamin A')]
PMC5521778	7/2017	S20-PMC5521778	['in Mammals, Pulmonary Vitamin A is accumulated in Lipid Interstitial Cells (Lipofibroblasts) located in the Periacinar fetal Lung during late Gestation and is mobilized during the Perinatal burst in Air Sac (Alveolar) remodeling and differentiation [12].']	N/A	N/A	[('NCBITaxon_40674', 'Mammalia', 3, 'mammals'), ('UBERON_0002048', 'lung', 12, 'pulmonary'), ('CHEBI_27300', 'vitamin D', 22, 'vitamin A'), ('CHEBI_18059', 'lipid', 50, 'lipid'), ('CL_0002295', 'type-6 epithelial cell of thymus', 50, 'lipid interstitial cells'), ('UBERON_0005169', 'interstitial tissue', 56, 'interstitial'), ('CL_0000057', 'fibroblast', 76, 'lipofibroblasts'), ('UBERON_0001179', 'peritoneal cavity', 108, 'periacinar'), ('UBERON_0002048', 'lung', 125, 'lung'), ('GO_0007565', 'female pregnancy', 142, 'gestation'), ('GO_0036268', 'swimming', 180, 'perinatal'), ('UBERON_0012101', 'perinatal stage', 180, 'perinatal'), ('UBERON_0001005', 'respiratory airway', 199, 'air sac'), ('UBERON_0003215', 'alveolus', 208, 'alveolar')]
PMC5521778	7/2017	S23-PMC5521778	['neonatal or Antenatal Vitamin A supplementation either for preterm infants or Vitamin A deficient Pregnant women improves Vitamin A status and Pulmonary function and mitigates chronic Lung disease [16,17].']	N/A	N/A	[('GO_0007567', 'parturition', 12, 'antenatal'), ('CHEBI_27300', 'vitamin D', 22, 'vitamin A'), ('CHEBI_27300', 'vitamin D', 78, 'vitamin A'), ('GO_0007565', 'female pregnancy', 98, 'pregnant'), ('CHEBI_27300', 'vitamin D', 122, 'vitamin A'), ('UBERON_0002048', 'lung', 143, 'pulmonary'), ('UBERON_0002048', 'lung', 184, 'lung')]
PMC5521778	7/2017	S26-PMC5521778	['Bco1-mediated Β-Carotene cleavage also serves as a back-up pathway for Vitamin A Synthesis when Vitamin A intake is insufficient.']	N/A	N/A	[('CHEBI_22918', 'branched-chain amino acid', 0, 'BCO1'), ('PR_000004693', 'Bcl-2-like protein 10', 0, 'BCO1'), ('CHEBI_28064', 'cyanidin 3-O-rutinoside', 14, 'β-carotene'), ('CHEBI_27300', 'vitamin D', 71, 'vitamin A'), ('GO_0035238', 'vitamin A biosynthetic process', 71, 'vitamin A synthesis'), ('CHEBI_27300', 'vitamin D', 96, 'vitamin A')]
PMC5524288	7/2017	S4-PMC5524288	['free Vitamin D supplements were offered and the treatment goal was ≥40 ng/ml.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 5, 'vitamin D')]
PMC5524288	7/2017	S33-PMC5524288	['additionally, obstetrical health care providers received education regarding the potential health impact of low Vitamin D status via continuing medical education (cme) and nurses provided Vitamin D education and standard recommendations for improving Vitamin D status using supplements to obstetrical (ob) patients at the initial visit.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 112, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 188, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 251, 'vitamin D')]
PMC5524288	7/2017	S35-PMC5524288	['new ob patients were offered a free bottle of bio-tech pharmacal, inc. (fayetteville, ar) Vitamin D supplements (5000 iu per capsule) at their first visit and personalized dosing recommendations were provided based on the result of their initial 25(Oh)D test using an algorithm of existing dose-response data [11].']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 90, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 246, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 246, '25(OH)D')]
PMC5524288	7/2017	S90-PMC5524288	['there were no cases of Vitamin D toxicity based on elevated Serum calcium levels (≥11 mg/dl).10.1371/journal.pone.0180483.g004\n\ncaption (fig): fig 4\nPreterm Birth rates among women with low initial 25(Oh)D concentrations (<40 ng/ml at ≤20 weeks), comparing those with concentrations ≥40 ng/ml vs. those with concentrations <40 ng/ml on a follow-up test.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 23, 'vitamin D'), ('UBERON_0001977', 'blood serum', 60, 'serum'), ('GO_0007128', 'meiotic prophase I', 149, 'Preterm'), ('GO_0007567', 'parturition', 157, 'birth'), ('CHEBI_71657', 'versiconol acetate', 198, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 198, '25(OH)D')]
PMC5537904	7/2017	S3-PMC5537904	['Prenatal Vitamin D intake was assessed with diet recalls and questionnaires, and offspring body composition was measured via air displacement plethysmography at Birth and 5 months.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 0, 'Prenatal'), ('CHEBI_27300', 'vitamin D', 9, 'vitamin D'), ('GO_0007567', 'parturition', 161, 'birth')]
PMC5537904	7/2017	S13-PMC5537904	['maternal 25(Oh)D freely crosses the Placenta and is the only source of Vitamin D available to the developing fetus [3].']	N/A	N/A	[('CHEBI_71657', 'versiconol acetate', 9, '25(OH)D'), ('UBERON_0001987', 'placenta', 36, 'placenta'), ('CHEBI_27300', 'vitamin D', 71, 'vitamin D')]
PMC5537904	7/2017	S39-PMC5537904	['assessment of maternal Vitamin D intake\nprospective data on Vitamin D intake from Food and dietary supplements was collected from early Pregnancy through 5 months Postnatally.']	N/A	N/A	[('CHEBI_28384', 'vitamin K', 23, 'Vitamin D'), ('CHEBI_27300', 'vitamin D', 60, 'vitamin D'), ('CHEBI_33290', 'food', 82, 'food'), ('GO_0007565', 'female pregnancy', 136, 'pregnancy'), ('GO_0007565', 'female pregnancy', 163, 'postnatally')]
PMC5537904	7/2017	S56-PMC5537904	['daily Vitamin D from dietary supplements was combined with daily Vitamin D from Food sources to estimate total oral intake of Vitamin D in Pregnancy.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 6, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 65, 'vitamin D'), ('CHEBI_33290', 'food', 80, 'food'), ('CHEBI_27300', 'vitamin D', 126, 'vitamin D'), ('GO_0007565', 'female pregnancy', 139, 'pregnancy')]
PMC5537904	7/2017	S63-PMC5537904	['mothers were asked to specify “other Supplements” (e.g., Vitamin D, Probiotics), and provide starting date, stopping date, and doses per week for all infant Supplements.']	N/A	N/A	[('CHEBI_33341', 'titanium atom', 37, 'supplements'), ('CHEBI_27300', 'vitamin D', 57, 'vitamin D'), ('CHEBI_26346', 'prostaglandins J', 68, 'probiotics'), ('CHEBI_33341', 'titanium atom', 157, 'supplements')]
PMC5537904	7/2017	S94-PMC5537904	['mother-offspring dyads were eligible for the analyses if offspring were Born ≥37 weeks Gestation, had 25(Oh)D measured in Cord Blood, and had at least one of the following: complete data on maternal Intake of Vitamin D during Pregnancy from Food and dietary supplements, body composition measured at Birth, or body composition measured Postnatally.']	N/A	N/A	[('GO_0007567', 'parturition', 72, 'born'), ('GO_0007565', 'female pregnancy', 87, 'gestation'), ('CHEBI_71657', 'versiconol acetate', 102, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 102, '25(OH ... D'), ('UBERON_0002240', 'spinal cord', 122, 'cord'), ('UBERON_0000178', 'blood', 127, 'blood'), ('GO_0007631', 'feeding behavior', 199, 'intake'), ('CHEBI_27300', 'vitamin D', 209, 'vitamin D'), ('GO_0007565', 'female pregnancy', 226, 'pregnancy'), ('CHEBI_33290', 'food', 241, 'food'), ('GO_0007567', 'parturition', 300, 'birth'), ('GO_0007565', 'female pregnancy', 336, 'postnatally')]
PMC5537904	7/2017	S112-PMC5537904	['results\ncomplete data were available for 305 dyads for the Vitamin D intake analysis, 605 dyads for the neonatal analysis, and 348 dyads for the Postnatal analysis (figure 1).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 59, 'vitamin D'), ('GO_0007567', 'parturition', 145, 'postnatal')]
PMC5537904	7/2017	S138-PMC5537904	['use of infant Supplements that contained Vitamin D was not associated with body size or composition at 5 months (data not shown).']	N/A	N/A	[('CHEBI_33341', 'titanium atom', 14, 'supplements'), ('CHEBI_27300', 'vitamin D', 41, 'vitamin D')]
PMC5537904	7/2017	S167-PMC5537904	['for every 100 iu/day increase in Vitamin D from Food sources or dietary supplements, we observed a 0.6 nmol/l increase in Cord Blood 25(Oh)D. this is a substantially smaller increase than the 2.5 nmol/l increase per 100 iu/day benchmark that has been used to guide Vitamin D supplementation [62].']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 33, 'vitamin D'), ('CHEBI_33290', 'food', 48, 'food'), ('UBERON_0002240', 'spinal cord', 122, 'cord'), ('UBERON_0000178', 'blood', 127, 'blood'), ('CHEBI_71657', 'versiconol acetate', 133, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 139, 'D'), ('CHEBI_27300', 'vitamin D', 265, 'vitamin D')]
PMC5539754	8/2017	S19-PMC5539754	['the physiological response to sunlight exposure, beyond that of Vitamin D Production, includes Regulation Of biological Circadian and Circannual Rhythms, Control of circulating melatonin, as well as Production Of Nitric Oxide, a vasodilator, and beta-endorphins which promote a feeling of Well-Being [11–13].']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 64, 'vitamin D'), ('GO_0071611', 'granulocyte colony-stimulating factor production', 64, 'vitamin D production'), ('GO_0043523', 'regulation of neuron apoptotic process', 95, 'regulation of ... circadian ... circannual rhythms'), ('GO_0065007', 'biological regulation', 154, 'control'), ('GO_0000050', 'urea cycle', 199, 'production of nitric oxide'), ('CHEBI_16480', 'nitric oxide', 213, 'nitric oxide'), ('GO_0007129', 'homologous chromosome pairing at meiosis', 289, 'well-being')]
PMC5539754	8/2017	S106-PMC5539754	['furthermore, no interaction effect was observed between season and Vitamin D with regards to Glucose Homeostasis.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 67, 'vitamin D'), ('CHEBI_17234', 'glucose', 93, 'glucose'), ('GO_0042593', 'glucose homeostasis', 93, 'glucose homeostasis')]
PMC5546866	8/2017	S20-PMC5546866	['these include Dhcr7 encoding 7-Dehydrocholesterol (7-Dhc) reductase; Cyp2R1 and Cyp24A1 encoding 25-hydroxylase and 24-hydroxylase, respectively; and gc encoding Vitamin D binding protein (vdp).']	N/A	N/A	[('PR_000006474', 'ATP-dependent RNA helicase A', 14, 'DHCR7'), ('CHEBI_17500', '7alpha-hydroxycholesterol', 29, '7-dehydrocholesterol'), ('CHEBI_17759', 'cholesta-5,7-dien-3beta-ol', 51, '7-DHC'), ('PR_000006110', 'cytochrome P450 27, mitochondrial', 69, 'CYP2R1'), ('PR_000006101', 'cytochrome P450 1A1', 80, 'CYP24A1'), ('CHEBI_27300', 'vitamin D', 162, 'vitamin D')]
PMC5546866	8/2017	S28-PMC5546866	['materials and methods\n\nthe maternal Vitamin d osteoporosis study\nthe maternal Vitamin d osteoporosis study is a multicenter, double-blind, randomized, placebo-controlled trial of Vitamin D supplementation in Pregnancy.']	N/A	N/A	[('CHEBI_33229', 'vitamin (role)', 36, 'Vitamin'), ('CHEBI_33229', 'vitamin (role)', 78, 'Vitamin'), ('CHEBI_27300', 'vitamin D', 179, 'vitamin D'), ('GO_0007565', 'female pregnancy', 208, 'pregnancy')]
PMC5546866	8/2017	S35-PMC5546866	['women with known Metabolic bone disease, Renal stones, hyperparathyroidism or hypercalciuria, those taking medication known to interfere with fetal growth, fetal anomalies on ultrasonography, and women already using >400 iu/d Vitamin D supplementation were excluded.']	N/A	N/A	[('GO_0008152', 'metabolic process', 17, 'metabolic'), ('UBERON_0002113', 'kidney', 41, 'renal'), ('CHEBI_27300', 'vitamin D', 226, 'vitamin D')]
PMC5546866	8/2017	S42-PMC5546866	['all participants received standard Antenatal care and could continue self-administration of dietary supplements containing up to 400 iu/d Vitamin D.\n\nmaternal assessments during Pregnancy\nprior to commencing the study Medication and again at 34 weeks of Gestation, the women attended the research center for a detailed assessment of diet (including supplement use), lifestyle (smoking, physical activity participation, employment), and health (medical history, current medication use) using interviewer-led questionnaires.']	N/A	N/A	[('GO_0007567', 'parturition', 35, 'antenatal'), ('CHEBI_27300', 'vitamin D', 138, 'vitamin D'), ('GO_0007565', 'female pregnancy', 178, 'pregnancy'), ('CHEBI_60211', 'compound Z', 218, 'medication'), ('GO_0007565', 'female pregnancy', 254, 'gestation')]
PMC5546866	8/2017	S65-PMC5546866	['in addition, in women randomized to Cholecalciferol, we assessed the relationship between the Snps and the change in Vitamin D using the residuals of 25(Oh)D at 34 weeks of Gestation Regressed on 25(Oh)D at 14 weeks of Gestation as the outcome.']	N/A	N/A	[('CHEBI_52550', 'theopalauamide', 36, 'cholecalciferol'), ('SO_0000694', 'SNP', 94, 'SNPs'), ('CHEBI_27300', 'vitamin D', 117, 'vitamin D'), ('CHEBI_30778', 'gallic acid', 150, '25(OH)'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 156, 'D'), ('GO_0007565', 'female pregnancy', 173, 'gestation'), ('GO_0060033', 'anatomical structure regression', 183, 'regressed'), ('CHEBI_71657', 'versiconol acetate', 196, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 202, 'D'), ('GO_0007565', 'female pregnancy', 219, 'gestation')]
PMC5546866	8/2017	S71-PMC5546866	['we also undertook sensitivity analysis in which women who reported having taken any additional Vitamin D–containing Supplements within 90 days of the late-Pregnancy Blood sampling were excluded.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 95, 'vitamin D'), ('CHEBI_33341', 'titanium atom', 116, 'supplements'), ('GO_0007565', 'female pregnancy', 155, 'pregnancy'), ('UBERON_0000178', 'blood', 165, 'blood')]
PMC5546866	8/2017	S116-PMC5546866	['sensitivity analysis\nas the women were allowed to continue taking Vitamin D supplements containing up to 400 iu/d, in sensitivity analyses, we included only women who were not taking additional Vitamin D–containing supplements at 34 weeks of Gestation (n = 224, 67.7%).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 66, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 194, 'vitamin D'), ('GO_0007565', 'female pregnancy', 242, 'gestation')]
PMC5576167	8/2017	S8-PMC5576167	['other common supplements used were iron, Calcium and Vitamin D (88.8, 81.6, and 41%, respectively).']	N/A	N/A	[('CHEBI_22313', 'alkaline earth metal atom', 41, 'calcium'), ('CHEBI_27300', 'vitamin D', 53, 'vitamin D')]
PMC5576167	8/2017	S18-PMC5576167	['Folic Acid was the most common type of dietary supplement use (95.9%; n \xa0=\xa094), followed by iron, Calcium and Vitamin D (88.8, 81.6, and 41%, respectively).']	N/A	N/A	[('CHEBI_30751', 'formic acid', 0, 'Folic acid'), ('CHEBI_22313', 'alkaline earth metal atom', 98, 'calcium'), ('CHEBI_27300', 'vitamin D', 110, 'vitamin D')]
PMC5576377	8/2017	S150-PMC5576377	['newborns will be given the routine vaccinations, weights taken and Prenatal and Vitamin A provided including all the relevant services as outlined in the ehc package.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 67, 'prenatal'), ('CHEBI_27300', 'vitamin D', 80, 'vitamin A')]
PMC5580292	9/2017	S32-PMC5580292	['caption (table-wrap): table 1\n\nnutrition formulation of basic dietingredients%Nutrient%corn67.83digestible energy, mj/kga13.42soybean meal23dry matter87.09rapeseed meal3crude protein17.02wheat midding3crude fat3.98cahpo41.5calcium0.85limestone1.0phosphorus0.64salt0.3lysine0.92lysine0.10met0.27trace element premixb0.25vintamin premixc0.02\naall of the data were analyzed value except digestible energy which was calculated using Swine nrc(2012) values\nbprovided the following amounts per kilogram of diet: Fe (Feso4·7h2o), 50\xa0mg; Cu (Cuso4·5H2O), 5\xa0mg; mn (Mnso4·H2O), 5\xa0mg; zn (Znso4·7H2O), 50\xa0mg; i (ki), 0.35\xa0mg; Se (Nase2O3), 0.15\xa0mg\ncprovided the following amounts per kilogram of diet: Vitamin A, 3000\xa0iu; Vitamin D3, 610\xa0iu; Vitamin E, 20\xa0iu; Vitamin B2, 5\xa0mg; Vitamin B12, 0.021\xa0mg; Biotin, 0.1\xa0mg; Pantothenic Acid, 10\xa0mg; Nicotinic Acid, 15\xa0mg\n\nsample collection\nat the end of the trial, eighteen Pigs (six from each dietary treatment) weighing about 111.8\xa0kg (sd 2.08\xa0kg) were selected to collect Tissue samples.']	N/A	N/A	[('CHEBI_33284', 'nutrient', 78, 'Nutrient'), ('NCBITaxon_33208', 'Metazoa', 429, 'swine'), ('CHEBI_30808', 'iron trichloride', 506, 'Fe ('), ('CHEBI_32588', 'potassium chloride', 510, 'FeSO4·'), ('CHEBI_37987', 'Cy3 dye', 530, 'Cu ('), ('CHEBI_15773', 'cyclohexylamine', 534, 'CuSO4·5H2O'), ('CHEBI_63625', 'tenofovir (anhydrous)', 557, 'MnSO4·H2O'), ('CHEBI_10049', 'XTP', 579, 'ZnSO4'), ('CHEBI_15377', 'water', 585, '7H2O'), ('CHEBI_33292', 'fuel', 616, 'Se ('), ('CHEBI_32906', 'gibberellin A24', 620, 'NaSe2O3'), ('CHEBI_27300', 'vitamin D', 692, 'vitamin A'), ('CHEBI_33279', 'vitamin D5', 712, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 712, 'vitamin D3'), ('CHEBI_27300', 'vitamin D', 732, 'vitamin E'), ('CHEBI_33279', 'vitamin D5', 750, 'vitamin B2'), ('PR_000004481', 'V-type proton ATPase subunit B, kidney isoform', 750, 'vitamin B2'), ('CHEBI_33279', 'vitamin D5', 768, 'vitamin B12'), ('PR_000004481', 'V-type proton ATPase subunit B, kidney isoform', 768, 'vitamin B12'), ('CHEBI_15956', 'biotin', 791, 'biotin'), ('CHEBI_7916', 'pantothenic acid', 807, 'pantothenic acid'), ('CHEBI_44557', 'nitrilotriacetic acid', 832, 'nicotinic acid'), ('NCBITaxon_10088', 'Mus <genus>', 907, 'pigs'), ('UBERON_0000479', 'tissue', 1008, 'tissue')]
PMC5587553	9/2017	S53-PMC5587553	['childhood nutritional supplements included iron (25 interventions), zinc (23), Folic Acid (18), Lipid/fat (13), calcium (14), Vitamin A (14), Vitamin B2(13), protein (11), and Vitamins B1, B3, B12(9).']	N/A	N/A	[('CHEBI_30751', 'formic acid', 79, 'folic acid'), ('CHEBI_18059', 'lipid', 96, 'lipid'), ('CHEBI_27300', 'vitamin D', 126, 'vitamin A'), ('CHEBI_33279', 'vitamin D5', 142, 'vitamin B2'), ('PR_000004481', 'V-type proton ATPase subunit B, kidney isoform', 142, 'vitamin B2'), ('CHEBI_33277', 'gamma-tocotrienol', 176, 'vitamins'), ('PR_000002190', 'RAC-alpha serine/threonine-protein kinase', 176, 'vitamins B1'), ('PR_000004680', 'breast carcinoma-amplified sequence 3', 189, 'B3'), ('PR_000004738', 'class E basic helix-loop-helix protein 22', 193, 'B12')]
PMC5587553	9/2017	S54-PMC5587553	['antenatal nutritional supplements given to mothers during Pregnancy included zinc (15), iron (10), Vitamin A (10), Vitamins b1, b2, b3, b12(10), Vitamin C (9), and Iodine and Selenium (8).']	N/A	N/A	[('GO_0007565', 'female pregnancy', 58, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 99, 'vitamin A'), ('CHEBI_33277', 'gamma-tocotrienol', 115, 'vitamins'), ('CHEBI_27300', 'vitamin D', 145, 'vitamin C'), ('CHEBI_24859', 'iodine atom', 164, 'iodine'), ('CHEBI_27568', 'selenium atom', 175, 'selenium')]
PMC5623264	9/2017	S21-PMC5623264	['oral supplementation with Vitamin A, low-dose calcium, zinc, multiple Micronutrient (mmn)\xa0supplements, nutritional education and preventive Antimalarials decreased the risk of lbw.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 26, 'vitamin A'), ('CHEBI_33962', 'mu4-sulfido-quadro-tetracopper(6+)', 70, 'micronutrient'), ('CHEBI_22580', 'anthraquinone', 140, 'antimalarials')]
PMC5623264	9/2017	S75-PMC5623264	['vitamin a with other Micronutrients (Iron\xa0+\xa0Folate) versus Micronutrient supplements without Vitamin A significantly reduced lbw by 33%, but did not affect ptb.']	N/A	N/A	[('CHEBI_33839', 'macromolecule', 21, 'micronutrients'), ('CHEBI_24870', 'ion', 37, 'iron'), ('CHEBI_30863', '5-azaorotic acid', 44, 'folate'), ('CHEBI_33962', 'mu4-sulfido-quadro-tetracopper(6+)', 59, 'micronutrient'), ('CHEBI_27300', 'vitamin D', 93, 'vitamin A')]
PMC5634602	10/2017	S43-PMC5634602	['infants were randomized to receive either 400 iu or 800 iu of Vitamin D3Enterally with the initiation of enteral Feedings in addition to parenteral mvi while on parenteral nutrition and enteral Vitamin D from Breast Milk and Human milk fortifier or preterm formula.']	N/A	N/A	[('CHEBI_64356', 'pregabalin', 62, 'vitamin D3enterally'), ('PR_000017299', 'VIP peptides', 62, 'vitamin D3enterally'), ('GO_0007631', 'feeding behavior', 113, 'feedings'), ('CHEBI_27300', 'vitamin D', 194, 'vitamin D'), ('UBERON_0001348', 'brown adipose tissue', 209, 'breast milk'), ('NCBITaxon_9606', 'Homo sapiens', 225, 'human')]
PMC5634602	10/2017	S46-PMC5634602	['all Vitamin D formulations were prepared and dispensed by a research pharmacist who was independent of the study.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 4, 'vitamin D')]
PMC5634602	10/2017	S68-PMC5634602	['after 4 weeks of Vitamin D3Supplementation in addition to dietary Vitamin D intake, median 25(Oh)D3Levels increased in both groups (84.6 vs. 105.3 nmol/l for 400 vs. 800 iu/day respectively), with significantly greater improvement in the higher dose group (p = 0.048).']	N/A	N/A	[('CHEBI_52915', 'phosphatediyl group', 17, 'vitamin D3supplementation'), ('CHEBI_27300', 'vitamin D', 66, 'vitamin D'), ('CHEBI_51924', 'ethyl 2-cyanoacetoacetate', 91, '25(OH)D3levels')]
PMC5634602	10/2017	S78-PMC5634602	['mean calcium (mg/dl) levels were not different at any time point during supplementation with 400 or 800 iu of Vitamin D.\n\ndietary Vitamin D intake\nVitamin D intake from diet was calculated for subjects by week of study.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 110, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 130, 'vitamin D'), ('CHEBI_28384', 'vitamin K', 147, 'Vitamin D')]
PMC5634602	10/2017	S80-PMC5634602	['no significant trends were associated with season of Birth or with pth level (measured at 4 and 8 weeks) at any study time point.10.1371/journal.pone.0185950.t004\n\ncaption (table-wrap): table 4\nweekly dietary Vitamin D intake by group.Vitamin D intakeiu/day400 iu800 iup-valuenmedianiqrnmedianiqr week 1 16233116161261170.046 week 2 16267109162891960.75 week 3 16327154163511420.99 week 4 16357186163291900.64 week 5 15399244143132660.44 week 6 14455174102452200.11 week 7 114122919238950.04 week 8 938035073391340.17\n\nresults for infants <1200 grams at Birth\nas some of the smallest and youngest patients to be enrolled in a Vitamin D trial, infants in the study <1200 grams at Birth were evaluated for 25(Oh)D3Status and response to supplementation regardless of supplementation group, and compared to the larger infants in the study.']	N/A	N/A	[('GO_0007567', 'parturition', 53, 'birth'), ('CHEBI_27300', 'vitamin D', 209, 'vitamin D'), ('CHEBI_28384', 'vitamin K', 235, 'Vitamin D'), ('GO_0007567', 'parturition', 554, 'birth'), ('CHEBI_27300', 'vitamin D', 626, 'vitamin D'), ('GO_0007567', 'parturition', 679, 'birth'), ('CHEBI_77726', '1-decanoyl-sn-glycero-3-phosphocholine', 704, '25(OH)D3status'), ('PR_000006770', 'cytoplasmic dynein 1 heavy chain 1', 710, 'D3status')]
PMC5634602	10/2017	S82-PMC5634602	['our group of preterm infants at Birth had suboptimal Vitamin D status with the median of both groups demonstrating levels below 75 nmol/l.']	N/A	N/A	[('GO_0007567', 'parturition', 32, 'birth'), ('CHEBI_27300', 'vitamin D', 53, 'vitamin D')]
PMC5634602	10/2017	S117-PMC5634602	['in a case series of 7 children aged 0.7–4.2 years, kara et al report Intake between 66,000 and 800,000 iu daily for periods of up to two months in an erroneously produced fish oil product containing 800,000 iu of Vitamin D/dose.']	N/A	N/A	[('GO_0007631', 'feeding behavior', 69, 'intake'), ('CHEBI_27300', 'vitamin D', 213, 'vitamin D')]
PMC5634602	10/2017	S138-PMC5634602	['conclusions\nadministration of 400 or 800 iu of Vitamin D3Improves Vitamin D status at 4 weeks as compared to Cord levers in high risk infants <32 weeks ega at Delivery.']	N/A	N/A	[('CHEBI_16094', 'thiosulfate(2-)', 47, 'vitamin D3improves'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 47, 'vitamin D3improves'), ('CHEBI_27300', 'vitamin D', 66, 'vitamin D'), ('UBERON_0002240', 'spinal cord', 109, 'cord'), ('GO_0007567', 'parturition', 159, 'delivery')]
PMC5638722	8/2017	S39-PMC5638722	['fresh Serum samples protected from light were analyzed for Vitamin D levels in the biochemistry laboratory.']	N/A	N/A	[('UBERON_0001977', 'blood serum', 6, 'serum'), ('CHEBI_27300', 'vitamin D', 59, 'vitamin D')]
PMC5638722	8/2017	S40-PMC5638722	['the level of Cord Blood Vitamin D was measured by using a direct competitive chemiluminescent immunoassay (elecsys; roche diagnostics, mannheim, germany).']	N/A	N/A	[('UBERON_0002240', 'spinal cord', 13, 'cord'), ('UBERON_0000178', 'blood', 18, 'blood'), ('CHEBI_27300', 'vitamin D', 24, 'vitamin D')]
PMC5638722	8/2017	S44-PMC5638722	['the preterm infants were categorized according to their Cord Blood Vitamin D levels.']	N/A	N/A	[('UBERON_0002240', 'spinal cord', 56, 'cord'), ('UBERON_0000178', 'blood', 61, 'blood'), ('CHEBI_27300', 'vitamin D', 67, 'vitamin D')]
PMC5638722	8/2017	S62-PMC5638722	['using variables significant on univariate analyses, (Gestational age at Birth, Birth weight, cord-Blood Vitamin D level) multivariable logistic regression analysis was done for determining the risk of eos and los.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 53, 'gestational'), ('GO_0007567', 'parturition', 72, 'birth'), ('GO_0007567', 'parturition', 79, 'birth'), ('UBERON_0000178', 'blood', 98, 'blood'), ('CHEBI_27300', 'vitamin D', 104, 'vitamin D')]
PMC5638722	8/2017	S83-PMC5638722	['there were no significant difference between the Cord Blood Vitamin D level and culture-proven sepsis.']	N/A	N/A	[('UBERON_0009472', 'axilla', 49, 'cord blood'), ('CHEBI_27300', 'vitamin D', 60, 'vitamin D')]
PMC5638722	8/2017	S86-PMC5638722	['using variables significant on univariate analyses, (Gestational age at Birth, Birth weight, cord-Blood Vitamin D level) multivariable logistic regression analysis was done for determining the risk of eos and los.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 53, 'gestational'), ('GO_0007567', 'parturition', 72, 'birth'), ('GO_0007567', 'parturition', 79, 'birth'), ('UBERON_0000178', 'blood', 98, 'blood'), ('CHEBI_27300', 'vitamin D', 104, 'vitamin D')]
PMC5638722	8/2017	S115-PMC5638722	['premature deliveries are also found to be increased in case of Gestational Vitamin D insufficiency22).']	N/A	N/A	[('GO_0007565', 'female pregnancy', 63, 'gestational'), ('CHEBI_27300', 'vitamin D', 75, 'vitamin D')]
PMC5638722	8/2017	S124-PMC5638722	['first of all, none of the mothers were checked for their Serum Vitamin D levels before Delivery.']	N/A	N/A	[('UBERON_0001977', 'blood serum', 57, 'serum'), ('CHEBI_27300', 'vitamin D', 63, 'vitamin D'), ('GO_0007567', 'parturition', 87, 'delivery')]
PMC5659607	10/2017	S28-PMC5659607	['vdaart Vitamin D intervention\nthe women were randomized 1:1, between 10–18 weeks of Gestation, to a daily intake of 4,000 iu vitamin d3plus a multivitamin containing 400 iu Vitamin D3Or a matching placebo tablet plus a multivitamin containing 400 iu Vitamin D3, i.e.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 7, 'vitamin D'), ('GO_0007565', 'female pregnancy', 84, 'gestation'), ('CHEBI_76020', 'poly[d(TTC)]', 173, 'vitamin D3or'), ('PR_000025569', 'amyloid-beta precursor protein sequence variant T714I (human)', 173, 'vitamin D3or'), ('CHEBI_33279', 'vitamin D5', 250, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 250, 'vitamin D3')]
PMC5659607	10/2017	S34-PMC5659607	['exclusion criteria were Gestational age >26thweek, any endocrine, Cardiovascular, or Nephrological disorders or Vitamin D intake >600 iu/day[8].']	N/A	N/A	[('GO_0007565', 'female pregnancy', 24, 'gestational'), ('UBERON_0004535', 'cardiovascular system', 66, 'cardiovascular'), ('UBERON_0001288', 'loop of Henle', 85, 'nephrological'), ('CHEBI_27300', 'vitamin D', 112, 'vitamin D')]
PMC5659607	10/2017	S42-PMC5659607	['there was no interaction between the Vitamin D and Pufa interventions on risk of asthma/recurrent wheeze[16].']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 37, 'vitamin D'), ('CHEBI_8102', 'phenylmethanesulfonyl fluoride', 51, 'PUFA')]
PMC5659607	10/2017	S65-PMC5659607	['third, we cross-classified the women using 25(Oh)D level at randomization (above or below 30 ng/ml) combined with the assigned treatment (Vitamin D or placebo).']	N/A	N/A	[('CHEBI_71657', 'versiconol acetate', 43, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 43, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 138, 'vitamin D')]
PMC5659607	10/2017	S66-PMC5659607	['for the secondary end-points, we performed analyses of the effect of the intervention (Vitamin D vs. placebo).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 87, 'vitamin D')]
PMC5659607	10/2017	S95-PMC5659607	['there was no such association for women with 25(Oh)D level ≥30ng/ml randomized to Placebo or women with 25(Oh)D level <30ng/ml randomized to Vitamin D ( table 3 ).']	N/A	N/A	[('CHEBI_71657', 'versiconol acetate', 45, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 45, '25(OH)D'), ('CHEBI_26130', 'biological pigment', 82, 'placebo'), ('CHEBI_71657', 'versiconol acetate', 104, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 104, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 141, 'vitamin D')]
PMC5659607	10/2017	S96-PMC5659607	['an exploratory analysis of the primary end-point, asthma/recurrent wheeze, including the third Vitamin D trial by goldring et al.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 95, 'vitamin D')]
PMC5659607	10/2017	S100-PMC5659607	['analyzing total Ige level as a continuous variable yielded similar results (data not shown).10.1371/journal.pone.0186657.t004\n\ncaption (table-wrap): table 4\nindividual study results in vdaart and copsac2010and combined analyses of the effect of Vitamin D vs. placebo on the secondary end-points at age 0–3.']	N/A	N/A	[('GO_0071743', 'IgE immunoglobulin complex, circulating', 16, 'IgE'), ('CHEBI_27300', 'vitamin D', 245, 'vitamin D')]
PMC5659607	10/2017	S109-PMC5659607	['using a poisson regression model, we found no effect on the risk of developing one or more lrti in the combined analysis of the Vitamin D intervention: or = 0.94 (0.65 to 1.37), p = 0.76 (table 4), i2= 63%, p = 0.10.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 128, 'vitamin D')]
PMC5659607	10/2017	S119-PMC5659607	['the vdaart and copsac2010trials used different doses of Vitamin D, initiated the supplementation at different Pregnancy stages ranging from 10 to 26 weeks of Gestation, and enrolled pregnant women with divergent 25(Oh)D levels at entry into the trials.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 56, 'vitamin D'), ('GO_0007565', 'female pregnancy', 110, 'pregnancy'), ('GO_0007565', 'female pregnancy', 158, 'gestation'), ('CHEBI_71657', 'versiconol acetate', 212, '25(OH)D'), ('PR_000009880', 'Lon protease, mitochondrial', 212, '25 ... OH ... D')]
PMC5664622	9/2017	S3-PMC5664622	['data on Vitamin D Consumption (collected with the use of Food frequency questionnaire) and lifestyle factors were taken.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 8, 'vitamin D'), ('GO_0007631', 'feeding behavior', 18, 'consumption'), ('CHEBI_33290', 'food', 57, 'Food')]
PMC5664622	9/2017	S4-PMC5664622	['both, maternal and Umbilical Cord Blood concentrations of Vitamin D were higher in the summer group as compared to the winter group (mean 22.2 ± 6.5 ng/ml vs. 16.5 ± 8.2 ng/ml ( p< 0.001), respectively for the mothers and 31.3 ± 9.4 ng/ml vs. 22.7 ± 11.0 ng/ml ( p< 0.0001), respectively for the neonates).']	N/A	N/A	[('UBERON_0002331', 'umbilical cord', 19, 'umbilical cord'), ('UBERON_0000178', 'blood', 34, 'blood'), ('CHEBI_27300', 'vitamin D', 58, 'vitamin D')]
PMC5664622	9/2017	S30-PMC5664622	['the lower detection threshold for Vitamin D is 4.0 ng/ml.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 34, 'vitamin D')]
PMC5664622	9/2017	S31-PMC5664622	['Vitamin D Consumption was evaluated on the basis of the frequency of the Consumption of main dietary sources (fish, eggs, Milk, and Margarine —obligatorily supplemented with Vitamin D in poland), and supplements of Vitamin D. a Food frequency questionnaire, validated at the institute of Food and nutrition, was used to assess the quantity of Food consumed by the subjects.']	N/A	N/A	[('CHEBI_28384', 'vitamin K', 0, 'Vitamin D'), ('GO_0007631', 'feeding behavior', 10, 'consumption'), ('GO_0007631', 'feeding behavior', 73, 'consumption'), ('UBERON_0001913', 'milk', 122, 'milk'), ('CHEBI_6784', 'mestranol', 132, 'margarine'), ('CHEBI_27300', 'vitamin D', 174, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 215, 'vitamin D'), ('CHEBI_33290', 'food', 228, 'Food'), ('CHEBI_33290', 'food', 288, 'Food'), ('CHEBI_33290', 'food', 343, 'food')]
PMC5664622	9/2017	S40-PMC5664622	['simple linear regression was used to analyze Venous versus Cord Blood Vitamin D concentration.']	N/A	N/A	[('UBERON_0001638', 'vein', 45, 'venous'), ('UBERON_0002240', 'spinal cord', 59, 'cord'), ('UBERON_0000178', 'blood', 64, 'blood'), ('CHEBI_27300', 'vitamin D', 70, 'vitamin D')]
PMC5664622	9/2017	S44-PMC5664622	['roc curves were used to predict neonatal levels on the basis of maternal levels of Vitamin D.\n\n3.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 83, 'vitamin D')]
PMC5664622	9/2017	S51-PMC5664622	['out of the total, the recommended level of Vitamin D concentration was found in 11% of the women (figure 1).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 43, 'vitamin D')]
PMC5664622	9/2017	S53-PMC5664622	['Umbilical Cord Blood by season\nmean Umbilical Cord Blood Vitamin D concentration was 27.0 ± 11.1 ng/ml, and was lower among neonates born in winter as compared to summer (22.7 ± 11.2 ng/ml vs. 31.3 ± 9.4 ng/ml, respectively) ( p< 0.0001).']	N/A	N/A	[('UBERON_0002331', 'umbilical cord', 0, 'Umbilical Cord'), ('UBERON_0000178', 'blood', 15, 'Blood'), ('UBERON_0002331', 'umbilical cord', 36, 'umbilical cord'), ('UBERON_0000178', 'blood', 51, 'blood'), ('CHEBI_27300', 'vitamin D', 57, 'vitamin D')]
PMC5664622	9/2017	S60-PMC5664622	['maternal vs. Umbilical Cord Blood\nUmbilical Cord Blood Vitamin D concentration was higher as compared to maternal levels in all of the investigated cases (figure 2).']	N/A	N/A	[('UBERON_0002331', 'umbilical cord', 13, 'Umbilical Cord'), ('UBERON_0000178', 'blood', 28, 'Blood'), ('UBERON_0002331', 'umbilical cord', 34, 'Umbilical cord'), ('UBERON_0000178', 'blood', 49, 'blood'), ('CHEBI_27300', 'vitamin D', 55, 'vitamin D')]
PMC5664622	9/2017	S66-PMC5664622	['mean concentration among women who supplemented their diet with single-component Vitamin D preparations (mean content: 25 µg) increased by 6.3 ng/ml (95% ci = [1.77, 10.84]) as compared to non-users of Supplements ( p< 0.01), while Cord Blood levels were higher by 12.1 ng/ml (95% ci = [6.06, 18.19]) ( p< 0.001).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 81, 'vitamin D'), ('CHEBI_33341', 'titanium atom', 202, 'supplements'), ('UBERON_0002240', 'spinal cord', 232, 'cord'), ('UBERON_0000178', 'blood', 237, 'blood')]
PMC5664622	9/2017	S70-PMC5664622	['mean Vitamin D concentration in Cord Blood was lower by 4.8 ng/ml (95% ci = [−9.41, −0.28]) in neonates Born to mothers aged <30 years as compared to ≥30 years ( p< 0.05).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 5, 'vitamin D'), ('UBERON_0009472', 'axilla', 32, 'cord blood'), ('GO_0007567', 'parturition', 104, 'born')]
PMC5664622	9/2017	S71-PMC5664622	['dietary intake of Vitamin D (without supplementation) by Pregnant women was significantly below recommendations (median 2.1 µg/day) and was not significantly associated with Blood Vitamin D levels.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 18, 'vitamin D'), ('GO_0007565', 'female pregnancy', 57, 'pregnant'), ('UBERON_0000178', 'blood', 174, 'blood'), ('CHEBI_27300', 'vitamin D', 180, 'vitamin D')]
PMC5664622	9/2017	S120-PMC5664622	['in our study, Vitamin D intake was not connected with education or age (data not presented).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 14, 'vitamin D')]
PMC5679631	11/2017	S2-PMC5679631	['infant and maternal Vitamin D supplement use was ascertained via questionnaires.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 20, 'vitamin D')]
PMC5679631	11/2017	S6-PMC5679631	['the association between Vitamin D exposure and prevalence or abundance of a specific bacterial group or species was analyzed using logistic or linear regression, respectively.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 24, 'vitamin D')]
PMC5679631	11/2017	S8-PMC5679631	['and levels of maternal Vitamin D supplementation and maternal 25-Hydroxyvitamin D quintiles, respectively.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 23, 'vitamin D'), ('CHEBI_62218', '23,24-dihydrocucurbitacin D', 62, '25-hydroxyvitamin D')]
PMC5679631	11/2017	S40-PMC5679631	['maternal Vitamin D supplement use\nmaternal Vitamin D intake through use of multivitamin supplements containing Vitamin D was calculated as previously described [14].']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 9, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 43, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 111, 'vitamin D')]
PMC5679631	11/2017	S43-PMC5679631	['infant Vitamin D supplement use\nVitamin D supplementation of the infant was categorized as yes or no.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 7, 'vitamin D'), ('CHEBI_28384', 'vitamin K', 32, 'Vitamin D')]
PMC5679631	11/2017	S44-PMC5679631	['thirty-seven children received a Vitamin A-d supplement and were included in the group of Vitamin D supplemented children.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 33, 'vitamin A'), ('CHEBI_27300', 'vitamin D', 90, 'vitamin D')]
PMC5679631	11/2017	S62-PMC5679631	['statistical analyses\nthe association between Vitamin D exposure and prevalence or exposure and abundance of specific groups or species (log10cfu/g wet weight Faeces) only in infants who were colonized with the bacteria under study was analyzed using logistic or linear regression, respectively.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 45, 'vitamin D'), ('UBERON_0001988', 'feces', 158, 'faeces')]
PMC5679631	11/2017	S64-PMC5679631	['in the analysis regarding supplementation of the infant, both bottle Fed and combination Fed (bottle and Breast Milk) children were excluded because commercial formulas contain Vitamin d and the amount of Vitamin D supplementation would vary depending on the volume of formula consumed.']	N/A	N/A	[('GO_0007631', 'feeding behavior', 69, 'fed'), ('GO_0007631', 'feeding behavior', 89, 'fed'), ('UBERON_0000310', 'breast', 105, 'breast'), ('UBERON_0001913', 'milk', 112, 'milk'), ('CHEBI_33229', 'vitamin (role)', 177, 'vitamin'), ('CHEBI_27300', 'vitamin D', 205, 'vitamin D')]
PMC5679631	11/2017	S65-PMC5679631	['the analyses regarding maternal Vitamin D supplementation and maternal 25(Oh)D quintiles were performed on the entire population because the exposure of interest was Prenatal, i .']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 32, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 71, '25(OH)D'), ('GO_0007565', 'female pregnancy', 166, 'prenatal')]
PMC5679631	11/2017	S71-PMC5679631	['the categorical variables, quintiles of maternal 25(Oh)D and amount of maternal Vitamin D supplementation, were transformed into interval variables to conduct the tests for interaction, as well as the tests for linear trend performed with linear regression.']	N/A	N/A	[('CHEBI_71657', 'versiconol acetate', 49, '25(OH)D'), ('PR_000009880', 'Lon protease, mitochondrial', 49, '25 ... OH ... D'), ('CHEBI_27300', 'vitamin D', 80, 'vitamin D')]
PMC5679631	11/2017	S83-PMC5679631	['table 1depicts the numbers of participants according to: Vitamin D supplement administration to the infant, maternal use of multivitamin supplements containing Vitamin D, and maternal 25(Oh)D quintiles and other characteristics.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 57, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 160, 'vitamin D'), ('CHEBI_72805', '2-alkyl-sn-glycero-3-phosphocholine', 187, 'OH)D')]
PMC5679631	11/2017	S86-PMC5679631	['finally, there was an expected difference among the quintiles in terms of season of Blood sampling in that the higher quintiles included a lower percentage of mothers giving blood during the winter season and a higher percentage in the summer.10.1371/journal.pone.0188011.t001\n\ncaption (table-wrap): table 1\ncharacteristics of the study population (n = 913).maternal multivitamin supplementation containing Vitamin D (n = 913)maternal Plasma 25(Oh)D nmol/l (n = 892)infant Vitamin D supplementation§(n = 616)none< 10 μg≥ 10 μgq 1q 2q 3q 4q 5yesno7.7–27.3#27.4–37.3#37.4–47.8#47.9–59.9#60.0–126.4#n = 350n = 144n = 41921.4 (4.3)&32.3 (2.9)&43.0 (3.2)&53.3 (3.5)&71.9 (10.9)&n = 441n = 165n (%)n (%)n (%)n (%)n (%)n (%)n (%)n (%)n (%)n (%) mode and place of Delivery Vaginal / home171 (48.9)71 (49.3)188 (44.9)80 (44.9)87 (48.6)80 (44.7)92 (51.7)78 (43.8)245 (55.6)93 (56.3)Vaginal / hospital137 (39.1)56 (38.9)174 (41.5)68 (38.2)74 (41.3)77 (43.0)63 (35.4)78 (43.8)157 (35.6)58 (35.2)c-section / hospital36 (10.3)12 (8.3)47 (11.2)21 (11.8)15 (8.4)19 (10.6)21 (11.8)18 (10.1)39 (8.8)14 (8.5)missing6 (1.7)5 (3.5)10 (2.4)9 (5.1)3 (1.7)3 (1.7)2 (1.1)4 (2.2)00 number of siblings none130 (37.1)68 (47.2)166 (39.6)71 (39.9)71 (39.7)73 (40.8)83 (46.7)61 (34.3)185 (42)46 (27.9)1153 (43.7)51 (35.4)197 (47.0)79 (44.4)79 (44.1)82 (45.8)72 (40.4)77 (43.2)189 (42.8)76 (46.1)2 or more66 (18.9)25 (17.4)56 (13.4)28 (15.7)28 (15.6)24 (13.4)23 (12.9)40 (22.5)66 (15)43 (26)missing1 (0.3)0001 (0.6)0001 (0.2)0 recruitment group conventional233 (66.6)66 (45.8)322 (76.8)114 (64)117 (65.4)121 (67.6)129 (72.5)132 (74.2)298 (67.6)54 (32.7)alternative117 (33.4)78 (54.2)97 (23.2)64 (36)62 (34.6)58 (32.4)49 (27.5)46 (25.8)143 (32.4)111 (67.3) maternal Vitamin D quintile 1104 (29.7)30 (20.8)44 (10.5)64 (14.5)40 (24.2)283 (23.7)30 (20.8)66 (15.8)87 (19.7)38 (23)359 (16.9)25 (17.4)95 (22.7)88 (20)24 (14.5)460 (17.1)22 (15.3)96 (22.9)98 (22.2)28 (17)538 (10.9)30 (20.8)110 (26.2)96 (21.8)29 (17.7)missing6 (1.7)7 (4.9)8 (1.9)8 (1.8)6 (3.6) sex male196 (56)63 (43.8)200 (47.7)102 (57.3)87 (48.6)93 (52)78 (43.8)89 (50)219 (49.7)81 (49.1)female154 (44)81 (56.2)219 (52.3)76 (42.7)92 (51.4)86 (48)100 (56.2)89 (50)222 (50.3)84 (50.9) vaginitis (last month of Pregnancy) no319 (91.2)123 (85.4)372 (88.8)156 (87.6)161 (89.9)163 (91)162 (91)153 (86)409 (92.7)143 (86.7)yes25 (7.1)16 (11.1)37 (8.8)13 (7.3)15 (8.4)13 (7.3)14 (7.9)21 (11.8)32 (7.3)22 (13.3)missing6 (1.7)5 (3.5)10 (2.4)9 (5.1)3 (1.7)3 (1.7)2 (1.1)4 (2.2)00 mode of infant Feeding Breast Feeding243 (69.4)105 (72.9)268 (64.0)107 (60.1)125 (69.8)114 (63.7)128 (71.9)128 (71.9)bottle feeding80 (22.9)25 (17.4)103 (24.6)52 (29.2)39 (21.8)50 (27.9)29 (16.3)34 (19.1)combination feeding26 (7.4)14 (9.7)47 (11.2)19 (10.7)15 (8.4)15 (8.4)21 (11.8)15 (8.4)missing1 (0.3)01 (0.2)00001 (0.6) season of maternal Blood sampling winter89 (50)69 (38.6)49 (27.4)41 (23)22 (12.4)spring54 (30.3)51 (28.5)46 (25.7)31 (17.4)16 (8.9)summer8 (4.5)23 (12.8)40 (22.3)66 (37.1)82 (46.1)autumn27 (15.2)36 (20.1)44 (24.6)40 (22.5)58 (32.6)\n§only Breast Fed children;\n#range;\n&mean (sd)\n\nmaternal 25(Oh)D and use of multivitamin supplements containing Vitamin D\nmaternal 25(Oh)D concentrations of the entire group ranged from 7.7 to 126.3 nmol/l with a mean of 44.3, sd 18.3 nmol/l.']	N/A	N/A	[('UBERON_0000178', 'blood', 84, 'blood'), ('CHEBI_27300', 'vitamin D', 407, 'vitamin D'), ('UBERON_0001969', 'blood plasma', 435, 'plasma'), ('CHEBI_71657', 'versiconol acetate', 442, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 442, '25(OH ... D'), ('CHEBI_28384', 'vitamin K', 473, 'Vitamin D'), ('PR_000006444', 'diacylglycerol kinase delta', 481, 'D'), ('GO_0007586', 'digestion', 756, 'Delivery'), ('UBERON_0000970', 'eye', 765, 'Vaginal'), ('UBERON_0000970', 'eye', 872, 'Vaginal'), ('CHEBI_28384', 'vitamin K', 1733, 'Vitamin D'), ('GO_0007565', 'female pregnancy', 2237, 'Pregnancy'), ('GO_0007631', 'feeding behavior', 2512, 'Feeding'), ('UBERON_0000310', 'breast', 2520, 'Breast'), ('GO_0070479', "nuclear-transcribed mRNA catabolic process, 5'-3' exonucleolytic nonsense-mediated decay", 2527, 'Feeding243'), ('UBERON_0000178', 'blood', 2840, 'Blood'), ('GO_0007567', 'parturition', 3059, 'breast'), ('UBERON_0000310', 'breast', 3059, 'breast'), ('GO_0007631', 'feeding behavior', 3066, 'fed'), ('CHEBI_71657', 'versiconol acetate', 3109, '25(OH)D'), ('PR_000009880', 'Lon protease, mitochondrial', 3109, '25 ... OH ... D'), ('CHEBI_27300', 'vitamin D', 3164, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 3183, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 3189, 'D')]
PMC5679631	11/2017	S87-PMC5679631	['the relationship between maternal 25(Oh)D and maternal use of multivitamin supplements containing Vitamin D is shown intable 2.']	N/A	N/A	[('CHEBI_71657', 'versiconol acetate', 34, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 34, '25(OH ... D'), ('CHEBI_27300', 'vitamin D', 98, 'vitamin D')]
PMC5679631	11/2017	S133-PMC5679631	['in a Mouse model of induced colitis, Vitamin D deficient Mice were shown to have decreased Colonic Antimicrobial activity (Angiogenin-4 protein) and higher levels of 16s rdna in Colonic Tissue (bacterial infiltration) compared to Vitamin D sufficient Mice [27].']	N/A	N/A	[('NCBITaxon_10088', 'Mus <genus>', 5, 'mouse'), ('CHEBI_27300', 'vitamin D', 37, 'vitamin D'), ('NCBITaxon_10088', 'Mus <genus>', 57, 'mice'), ('UBERON_0001155', 'colon', 91, 'colonic'), ('CHEBI_65381', 'albizoside C', 99, 'antimicrobial'), ('PR_000004123', 'adenomatous polyposis coli protein 2', 123, 'angiogenin-4'), ('UBERON_0001155', 'colon', 178, 'colonic'), ('UBERON_0000479', 'tissue', 186, 'tissue'), ('CHEBI_27300', 'vitamin D', 230, 'vitamin D'), ('NCBITaxon_10088', 'Mus <genus>', 251, 'mice')]
PMC5679631	11/2017	S150-PMC5679631	['(n = 45) for the analyses involving Vitamin D supplementation of the child or maternal Vitamin D quintile.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 36, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 87, 'vitamin D')]
PMC5682869	11/2017	S74-PMC5682869	['Calcium and Vitamin D\nthe main source of Calcium is milk and milk products (50%), cereals (11%) and vegetables (11%).']	N/A	N/A	[('CHEBI_31341', 'calcium dihydroxide', 0, 'Calcium'), ('CHEBI_27300', 'vitamin D', 12, 'vitamin D'), ('CHEBI_22313', 'alkaline earth metal atom', 41, 'calcium')]
PMC5682869	11/2017	S80-PMC5682869	['the main dietary sources of Vitamin D are cod Liver oil and fish.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 28, 'vitamin D'), ('UBERON_0002107', 'liver', 46, 'liver')]
PMC5685050	10/2014	S4-PMC5685050	["Vitamin D2(Ergocalciferol), from dietary sources or supplements, and Vitamin D3Are Metabolized in the Liver to 25-Hydroxyvitamin D (25(Oh)D), which is the major circulating form of Vitamin D and is used to determine an Individual's Vitamin D status[1]."]	N/A	N/A	[('CHEBI_28934', 'vitamin D2', 0, 'Vitamin D2'), ('PR_000017279', 'testis-specific basic protein Y 1', 0, 'Vitamin D2'), ('CHEBI_4910', 'etomidate', 11, 'ergocalciferol'), ('CHEBI_66036', "(2S)-2'-hydroxy-7,8,3',4',5'-pentamethoxyflavan", 69, 'vitamin D3are'), ('PR_000017209', 'utrophin', 69, 'vitamin D3are'), ('GO_0008152', 'metabolic process', 83, 'metabolized'), ('UBERON_0002107', 'liver', 102, 'liver'), ('CHEBI_62218', '23,24-dihydrocucurbitacin D', 111, '25-hydroxyvitamin D'), ('CHEBI_71657', 'versiconol acetate', 132, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 181, 'vitamin D'), ('NCBITaxon_1', 'root', 219, 'individual'), ('CHEBI_27300', 'vitamin D', 232, 'vitamin D')]
PMC5685050	10/2014	S6-PMC5685050	['many factors can alter Cutaneous Vitamin D Production such as Aging, skin pigmentation, sunscreen usage, time of the day, season and latitude5,7.']	N/A	N/A	[('GO_0050817', 'coagulation', 23, 'cutaneous'), ('CHEBI_27300', 'vitamin D', 33, 'vitamin D'), ('GO_0071611', 'granulocyte colony-stimulating factor production', 33, 'vitamin D production'), ('GO_0007568', 'aging', 62, 'aging')]
PMC5685050	10/2014	S8-PMC5685050	['People residing far from the equator are at an increased risk for Vitamin D deficiency due to decreased cutaneous Synthesis Of Vitamin D[9].']	N/A	N/A	[('NCBITaxon_10088', 'Mus <genus>', 0, 'People'), ('CHEBI_27300', 'vitamin D', 66, 'vitamin D'), ('GO_0030474', 'spindle pole body duplication', 114, 'synthesis of vitamin D'), ('CHEBI_27300', 'vitamin D', 127, 'vitamin D')]
PMC5685050	10/2014	S12-PMC5685050	['found that Vitamin D insufficiency is common in the sunny climate in saudi arabia[3].']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 11, 'vitamin D')]
PMC5685050	10/2014	S15-PMC5685050	['[12]conducted the largest-scale examination of Vitamin D status in thai population and reported a 45.2% prevalence rate of Vitamin D insufficiency, defined as Serum 25(Oh)D level\xa0<\xa030\xa0ng/ml (<75\xa0nmol/l) a 5.7% prevalence rate of Vitamin D deficiency, defined as Serum 25(Oh)D level <20\xa0ng/ml (<50\xa0nmol/l).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 47, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 123, 'vitamin D'), ('UBERON_0001977', 'blood serum', 159, 'serum'), ('CHEBI_71657', 'versiconol acetate', 165, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 165, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 229, 'vitamin D'), ('UBERON_0001977', 'blood serum', 262, 'serum'), ('CHEBI_71657', 'versiconol acetate', 268, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 268, '25(OH)D')]
PMC5685050	10/2014	S19-PMC5685050	['[14]assessed Vitamin D status in healthy thai elderly women and found that two-thirds had Vitamin D insufficiency and one-third had Vitamin D deficiency.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 13, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 90, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 132, 'vitamin D')]
PMC5685050	10/2014	S20-PMC5685050	['women living in a nursing home have a higher prevalence of Vitamin D deficiency than in free-living women, 39.8% compared to 30%, respectively[13].']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 59, 'vitamin D')]
PMC5685050	10/2014	S22-PMC5685050	['[15]evaluated Vitamin D status in a younger group of Premenopausal women found the prevalence of Vitamin D insufficiency to be 77.8%, which was as high as the rate found in elderly thai women living in nursing homes.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 14, 'vitamin D'), ('GO_0043277', 'apoptotic cell clearance', 53, 'premenopausal'), ('CHEBI_27300', 'vitamin D', 97, 'vitamin D')]
PMC5685050	10/2014	S24-PMC5685050	['[16]evaluated Vitamin D status in healthy young thai men and women (age 25–54 years) and found that the prevalence of Vitamin D deficiency was three-fold higher in females than in males (43.1% in females compared to 13.9% in males).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 14, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 118, 'vitamin D')]
PMC5685050	10/2014	S26-PMC5685050	['[17]demonstrated that 83.3% of Pregnant thai women, especially in the 1st Trimester of Pregnancy, had Vitamin D insufficiency but without association with adverse Pregnancy outcomes such as spontaneous Abortion, Gestational diabetes, cesarean section rate and Preterm labor.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 31, 'pregnant'), ('GO_0009294', 'DNA mediated transformation', 74, 'trimester'), ('GO_0007565', 'female pregnancy', 87, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 102, 'vitamin D'), ('GO_0007565', 'female pregnancy', 163, 'pregnancy'), ('GO_0007569', 'cell aging', 202, 'abortion'), ('GO_0007565', 'female pregnancy', 212, 'gestational'), ('GO_0007565', 'female pregnancy', 260, 'preterm')]
PMC5685050	10/2014	S27-PMC5685050	['they also demonstrated that Intake of Prenatal Vitamins at the Vitamin D dose of 400\xa0iu/day was sufficient to prevent Vitamin D deficiency but was not high enough to prevent Vitamin D insufficiency.']	N/A	N/A	[('GO_0007631', 'feeding behavior', 28, 'intake'), ('GO_0007565', 'female pregnancy', 38, 'prenatal'), ('CHEBI_33277', 'gamma-tocotrienol', 47, 'vitamins'), ('CHEBI_27300', 'vitamin D', 63, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 118, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 174, 'vitamin D')]
PMC5685050	10/2014	S32-PMC5685050	['caption (table-wrap): table\xa01\n\nsummary of Vitamin D status in thai peoplestudychailurkit et\xa0al.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 42, 'vitamin D')]
PMC5685050	10/2014	S42-PMC5685050	['Life style and environmental factors are the major factors that determine Vitamin D status in thai People.']	N/A	N/A	[('UBERON_0000104', 'life cycle', 0, 'Life'), ('CHEBI_27300', 'vitamin D', 74, 'vitamin D'), ('NCBITaxon_10088', 'Mus <genus>', 99, 'people')]
PMC5685050	10/2014	S45-PMC5685050	['also at increased risk for Vitamin D insufficiency are young thai People living in urban areas in thailand who have less leisure time and spend less time in the sunlight.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 27, 'vitamin D'), ('NCBITaxon_10088', 'Mus <genus>', 66, 'people')]
PMC5685050	10/2014	S46-PMC5685050	['furthermore, in thailand dairy products are not fortified with Vitamin D and very few Vitamin D-rich Foods are part of the thai diet.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 63, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 86, 'vitamin D'), ('CHEBI_33290', 'food', 101, 'foods')]
PMC5697969	12/2017	S141-PMC5697969	['compared with the standard mnch group, the nutrition-focused mnch group showed higher increases in the proportion of women who Consumed pulses, dairy, meat, eggs, and Vitamin A–rich fruit and vegetables (effect range: 17–38 pp).']	N/A	N/A	[('GO_0007631', 'feeding behavior', 127, 'consumed'), ('CHEBI_27300', 'vitamin D', 167, 'vitamin A')]
PMC5697969	12/2017	S147-PMC5697969	['caption (table-wrap): table 4\n\ndiversity and quantity of Food groups consumed during past 24 h by Pregnant women, by program group and survey round1baseline2endlinestandard mnchnutrition-focused mnchstandard mnchnutrition-focused mnchdifference-in-difference effect estimates3n 300300300300type of Food groups Consumed, %\u2003all Starchy staple foods100100100100—\u2003pulses37.734.737.065.729.3∗∗∗\u2003nuts and seeds3.71.63.73.01.4\u2003dairy40.334.339.367.033.7∗∗\u2003Flesh foods82.785.790.393.0−0.30\u2003\u2003meat23.020.716.030.717.0∗∗\u2003\u2003fish73.079.085.384.3−6.70\u2003eggs26.724.325.761.338.0∗∗∗\u2003dark-green leafy vegetables44.749.739.067.323.3∗\u2003other Vitamin A–rich fruit and vegetables28.0∗20.717.046.036.0∗∗∗\u2003other vegetables90.093.098.393.7−7.70∗\u2003other fruit62.7∗52.758.753.34.70number of Food groups Consumed, n 5.1 ± 1.445.0 ± 1.45.1 ± 1.36.5 ± 1.61.6∗∗∗consumed ≥5 Food groups, %67.060.765.088.730.0∗∗∗quantity of Food groups consumed, g\u2003all Starchy staple foods574 ± 210574 ± 225637 ± 399611 ± 276−26.3\u2003pulses89.9 ± 79.787.9 ± 77.8121 ± 96.9208 ± 12188.7∗∗∗\u2003nuts and seeds1.9 ± 10.93.8 ± 20.23.8 ± 14.62.6 ± 12.1−3.0\u2003dairy93.0 ± 17177.8 ± 14193.2 ± 137171 ± 15593.1∗∗\u2003Flesh foods89.6 ± 92.083.0 ± 91.7116 ± 120196 ± 18687.4∗∗\u2003\u2003meat22.2 ± 61.421.0 ± 57.723.1 ± 63.349.1 ± 11427.2∗∗\u2003\u2003fish67.4 ± 77.562.4 ± 73.197.9 ± 111151 ± 15158.1∗\u2003Eggs14.3 ± 32.112.9 ± 25.619.1 ± 36.337.7 ± 37.720.1∗∗\u2003dark-green leafy vegetables127 ± 185138 ± 174123 ± 145334 ± 272200∗∗∗\u2003other Vitamin A–rich fruit and vegetables36.3 ± 97.433.3 ± 91.826.6 ± 92.891.7 ± 17468.0∗∗\u2003other vegetables139 ± 111128 ± 112167 ± 129212 ± 14156.1∗∗\u2003other fruit185 ± 233∗∗131 ± 272141 ± 197160 ± 20172.4\n∗p< 0.05,∗∗p< 0.01,∗∗∗p< 0.001.']	N/A	N/A	[('CHEBI_33290', 'food', 57, 'food'), ('GO_0007565', 'female pregnancy', 98, 'pregnant'), ('CHEBI_33290', 'food', 298, 'food'), ('GO_0007631', 'feeding behavior', 310, 'consumed'), ('CHEBI_26738', 'sphingenine', 326, 'starchy'), ('UBERON_0007381', 'epidermal scale', 448, 'Flesh'), ('CHEBI_27300', 'vitamin D', 619, 'vitamin A'), ('CHEBI_33290', 'food', 760, 'food'), ('GO_0007631', 'feeding behavior', 772, 'consumed'), ('CHEBI_33290', 'food', 839, 'food'), ('CHEBI_33290', 'food', 888, 'food'), ('CHEBI_26738', 'sphingenine', 916, 'starchy'), ('UBERON_0007381', 'epidermal scale', 1143, 'Flesh'), ('CL_0002425', 'early T lineage precursor', 1308, 'Eggs14'), ('CHEBI_27300', 'vitamin D', 1439, 'vitamin A')]
PMC5706533	11/2017	S3-PMC5706533	['eligibility criteria for study selection \xa0trials of Prenatal Vitamin D supplementation with randomised allocation and control groups administered placebo, no Vitamin D, or Vitamin D ≤600 iu/day (or its equivalent), and published in a peer reviewed journal.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 52, 'prenatal'), ('CHEBI_27300', 'vitamin D', 61, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 158, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 172, 'vitamin D')]
PMC5706533	11/2017	S8-PMC5706533	['overall, Vitamin D increased mean Birth weight of 58.33 g (95% confidence interval 18.88 g to 97.78 g; 37 comparisons) and reduced the risk of small for Gestational age Births (risk ratio 0.60, 95% confidence interval 0.40 to 0.90; seven comparisons), but findings were not robust in sensitivity and subgroup analyses.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 9, 'vitamin D'), ('GO_0007567', 'parturition', 34, 'birth'), ('GO_0007565', 'female pregnancy', 153, 'gestational'), ('GO_0007567', 'parturition', 169, 'births')]
PMC5706533	11/2017	S23-PMC5706533	['eligibility criteria\nwe included trials of Prenatal Vitamin D supplementation in which\nsupplementation was Vitamin D given alone or in combination with a cointervention that was similar across multiple arms\nparticipants were Pregnant at enrolment or enrolled before Pregnancy and then followed-up in Pregnancy\nallocation into the parallel intervention groups at or after enrolment was randomised\nat least one trial group received placebo, no Vitamin D, or up to 600 iu/day (or a less frequent dose that would be about equivalent to 600 iu/day—for example, 4200 iu/week) during Pregnancy\nat least one of the articles describing the trial was a full text report published in a scientific journal or in another peer reviewed format.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 43, 'prenatal'), ('CHEBI_27300', 'vitamin D', 52, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 107, 'vitamin D'), ('GO_0007565', 'female pregnancy', 225, 'pregnant'), ('GO_0007565', 'female pregnancy', 266, 'pregnancy'), ('GO_0007565', 'female pregnancy', 300, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 442, 'vitamin D'), ('GO_0007565', 'female pregnancy', 577, 'pregnancy')]
PMC5706533	11/2017	S28-PMC5706533	['studies that met only the first two inclusion criteria were ineligible for inclusion in meta-analysis but were reviewed separately (that is, trials that had parallel but non-randomised intervention group assignment, trials with control arms administered Vitamin D dose >600 iu/day, or those whose results were not reported in a full text publication).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 254, 'vitamin D')]
PMC5706533	11/2017	S47-PMC5706533	['to facilitate comparisons, regular doses given less frequently than daily were converted to an equivalent daily dose (for example, 28000 iu/week = 4000 iu/day) and expressed as an “effective dose” (that is, intervention dose minus the Vitamin D dose in the control group in the same trial).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 235, 'vitamin D')]
PMC5706533	11/2017	S48-PMC5706533	['additional covariates included type of Vitamin D supplementation (d2 versus d3); geographical region based on who classification (africa, americas, south-east asia, europe, eastern mediterranean, and western pacific); and timing of initiation of supplementation (such as first, second, or third Trimester) among regular dose trials in which supplementation continued until Delivery.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 39, 'vitamin D'), ('GO_0009294', 'DNA mediated transformation', 295, 'trimester'), ('GO_0007567', 'parturition', 373, 'delivery')]
PMC5706533	11/2017	S61-PMC5706533	['from registry entries of eligible ongoing/planned trials, we extracted information (when available) on geographical location, study status (for example, completed but unpublished, ongoing, not yet started, status unknown), number of participants enrolled, recruitment start date, inclusion and exclusion criteria, details on Vitamin D supplementation dose, frequency and duration, cointerventions, and primary and secondary outcomes that investigators listed in the registry.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 325, 'vitamin D')]
PMC5706533	11/2017	S68-PMC5706533	['results\n\nliterature search results and study selection\namong 3810 articles identified from the literature search, 43 Prenatal Vitamin D trials were eligible for inclusion in meta-analyses based on data in 77 publications (fig 1; table a in appendix 5).']	N/A	N/A	[('GO_0007565', 'female pregnancy', 117, 'prenatal'), ('CHEBI_27300', 'vitamin D', 126, 'vitamin D')]
PMC5706533	11/2017	S71-PMC5706533	['caption (fig)\n\nfig 1 \xa0screening and selection of studies for systematic review and meta-analysis of Vitamin D supplementation during Pregnancy\n\ncharacteristics and quality of trials included in meta-analyses\nthe 43 eligible trials comprised 55 intervention-control arm comparisons and a total of 8406 enrolled women (table 1; tables a and b in Appendix 5).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 100, 'vitamin D'), ('GO_0007565', 'female pregnancy', 133, 'pregnancy'), ('UBERON_0001154', 'vermiform appendix', 344, 'appendix')]
PMC5706533	11/2017	S79-PMC5706533	['caption (table-wrap): table 1\n\ncharacteristics of Prenatal Vitamin D trials included in systematic review and meta-analyses.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 50, 'prenatal'), ('CHEBI_27300', 'vitamin D', 59, 'vitamin D')]
PMC5706533	11/2017	S85-PMC5706533	['caption (fig)\n\nfig 2 \xa0accumulation of Prenatal Vitamin D supplementation trials 1980-2024.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 38, 'prenatal'), ('CHEBI_27300', 'vitamin D', 47, 'vitamin D')]
PMC5706533	11/2017	S97-PMC5706533	['the 25(Oh)D response to supplemental Vitamin D was not enhanced in trial populations with low mean baseline 25(Oh)D (<30 nmol/l) (tables s1 and s2 in appendix 10).']	N/A	N/A	[('CHEBI_71657', 'versiconol acetate', 4, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 10, 'D'), ('CHEBI_27300', 'vitamin D', 37, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 108, '25(OH)D'), ('PR_000011614', 'opioid growth factor receptor', 111, 'OH'), ('PR_000006444', 'diacylglycerol kinase delta', 114, 'D')]
PMC5706533	11/2017	S100-PMC5706533	['caption (table-wrap): table 3\n\nweighted mean differences (wmd) from primary meta-analyses of effects of Vitamin D supplementation during Pregnancy on maternal and neonatal/infant outcomesoutcomestrialsintervention-control comparisonsparticipantswmd (intervention versus control) (95% ci)i2(%) maternal Serum 25(Oh)D concentration at/near Delivery (nmol/l)3242570632.91*(27.19 to 38.62)96*neonatal/infant Birth weight (g ) 3037527358.33*(18.88 to 97.78)43*Birth length (cm)192138990.19 (−0.08 to 0.47)62*Head circumference at Birth (cm)171837910.13 (−0.05 to 0.30)63*Cord Serum 25(Oh)D concentration (nmol/l)2028298827.73*(21.57 to 33.88)96*Gestational age at Birth (weeks)19233214−0.01 (−0.19 to 0.16)54*neonatal bone Mineral content (g)226901.09 (−0.64 to 2.81)0infant bone Mineral content (g)1252−43.00*(−67.25 to −18.75)0neonatal bone Mineral density (g/cm2)226900.00 (−0.003 to 0.004)0infant bone Mineral density (g/cm2)1252−0.04*(−0.06 to −0.03)0length at age 1 year (cm)222511.30*(0.54 to 2.06)40weight at age 1 year (g)22252290.62 (−5.04 to 586.29)47head circumference at age 1 year (cm)222480.09 (−0.28 to 0.45)0length for age z score at 1 year†231860.31 (−0.04 to 0.66)0weight for age z score at 1 year†231870.13 (−0.19 to 0.45)0head circumference for age z score at 1 year†231830.12 (−0.18 to 0.42)0\n*p<0.05.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 104, 'vitamin D'), ('GO_0007565', 'female pregnancy', 137, 'pregnancy'), ('UBERON_0001977', 'blood serum', 302, 'Serum'), ('CHEBI_71657', 'versiconol acetate', 308, '25(OH)D'), ('PR_000009880', 'Lon protease, mitochondrial', 308, '25 ... OH ... D'), ('GO_0007567', 'parturition', 338, 'delivery'), ('GO_0007567', 'parturition', 404, 'Birth'), ('GO_0007567', 'parturition', 455, 'Birth'), ('UBERON_0000033', 'head', 503, 'Head'), ('GO_0007567', 'parturition', 525, 'birth'), ('UBERON_0000948', 'heart', 566, 'Cord'), ('UBERON_0001977', 'blood serum', 571, 'serum'), ('CHEBI_71657', 'versiconol acetate', 577, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 583, 'D'), ('GO_0007565', 'female pregnancy', 640, 'Gestational'), ('GO_0007567', 'parturition', 659, 'birth'), ('CHEBI_46662', 'mineral', 718, 'mineral'), ('CHEBI_46662', 'mineral', 775, 'mineral'), ('CHEBI_46662', 'mineral', 838, 'mineral'), ('CHEBI_46662', 'mineral', 901, 'mineral')]
PMC5706533	11/2017	S103-PMC5706533	['pooled effect estimates therefore had wide confidence intervals except for caesarean section (for which there was evidence of no effect of Vitamin D), and 95% confidence intervals for all primary pooled estimates for maternal clinical outcomes except hypocalcaemia included the null (table 2).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 139, 'vitamin D')]
PMC5707701	11/2017	S64-PMC5707701	['after revision of questionnaires, Food records were entered in a database, and individual Intakes of Vitamin A, total Carotenoids, Retinol, Vitamin E, and α-Tocopherol were processed with a Food composition database created for this study that included data from chinese Food composition (cfc) tables 2004 & 2009 [45,46], the japanese Food composition (jfc) tables 2005 [47], and branded products and supplements from china.']	N/A	N/A	[('CHEBI_33290', 'food', 34, 'food'), ('GO_0007631', 'feeding behavior', 90, 'intakes'), ('CHEBI_27300', 'vitamin D', 101, 'vitamin A'), ('CHEBI_50815', 'norgestimate', 118, 'carotenoids'), ('CHEBI_26536', 'retinoic acid', 131, 'retinol'), ('CHEBI_27300', 'vitamin D', 140, 'vitamin E'), ('CHEBI_27013', 'tocopherol', 157, 'tocopherol'), ('CHEBI_33290', 'food', 190, 'food'), ('CHEBI_33290', 'food', 271, 'Food'), ('GO_0007601', 'visual perception', 271, 'Food'), ('CHEBI_33290', 'food', 335, 'Food')]
PMC5707701	11/2017	S189-PMC5707701	['conclusions\nthe total concentrations of Carotenoids (Β-Carotene and β-cryptoxanthin, lutein, Lycopene, and Zeaxanthin) and Vitamin E (as α- and Γ-Tocopherol) were studied in Human Milk from healthy chinese women.']	N/A	N/A	[('CHEBI_50815', 'norgestimate', 40, 'carotenoids'), ('CHEBI_28064', 'cyanidin 3-O-rutinoside', 53, 'β-carotene'), ('CHEBI_15948', 'lycopene', 93, 'lycopene'), ('CHEBI_27547', 'zeaxanthin', 107, 'zeaxanthin'), ('CHEBI_27300', 'vitamin D', 123, 'vitamin E'), ('CHEBI_27725', 'butin', 144, 'γ-tocopherol'), ('NCBITaxon_9606', 'Homo sapiens', 174, 'human'), ('UBERON_0001913', 'milk', 180, 'milk')]
PMC5716389	9/2017	S37-PMC5716389	['dietary sources of Vitamin A include whole Milk, Liver, eggs, dark colored fruits and vegetables [11].']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 19, 'vitamin A'), ('UBERON_0001913', 'milk', 43, 'milk'), ('UBERON_0002107', 'liver', 49, 'liver')]
PMC5724074	8/2017	S132-PMC5724074	['we will estimate the approximate weight in grams using the conversion table from the Food composition table for bangladesh (infs 2013) to calculate the equivalent weight of the raw Food and attainable calories.25we will combine all Consumed Food items in 10 groups as: (1) grains, white Roots and tubers; (2) pulses (beans, peas and lentils); (3) nuts and seeds; (4) dairy; (5) meat, poultry and fish; (6) eggs; (7) dark green leafy vegetables; (8) other Vitamin A-rich fruits and vegetables; (9) other vegetables; and (10) other fruits.']	N/A	N/A	[('CHEBI_33290', 'food', 85, 'Food'), ('CHEBI_33290', 'food', 181, 'food'), ('GO_0007631', 'feeding behavior', 232, 'consumed'), ('CHEBI_33290', 'food', 241, 'food'), ('UBERON_0002211', 'nerve root', 287, 'roots'), ('CHEBI_27300', 'vitamin D', 455, 'vitamin A')]
PMC5732505	12/2017	S8-PMC5732505	['of the study population, 97% were Vitamin D sufficient [25(Oh)D\u2009≥\u200950\xa0nmol/l].']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 34, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 56, '25(OH)D')]
PMC5732505	12/2017	S45-PMC5732505	['the quality and accuracy of the Serum 25(Oh)D analysis is validated on an ongoing basis by participation in the Vitamin D external quality assessment scheme (deqas, charing cross hospital, london, uk).']	N/A	N/A	[('UBERON_0001977', 'blood serum', 32, 'serum'), ('CHEBI_71657', 'versiconol acetate', 38, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 38, '25(OH ... D'), ('CHEBI_27300', 'vitamin D', 112, 'vitamin D')]
PMC5732505	12/2017	S66-PMC5732505	['we calculated the average daily intake of Vitamin D from supplementation during the last two months of Pregnancy.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 42, 'vitamin D'), ('GO_0007565', 'female pregnancy', 103, 'pregnancy')]
PMC5732505	12/2017	S87-PMC5732505	['p -values refer to differences between the groupsmaternal characteristics n non-gdm n gdm p valueage at Delivery (y)64231.4\xa0±\xa04.38132.7\xa0±\xa04.50.018level of educationa6325.0\xa0±\xa01.3794.7\xa0±\xa01.40.051parity6401.5\xa0±\xa00.7811.5\xa0±\xa00.70.275prepregnancy smoking, number of cigarettes daily6251.2\xa0±\xa03.7762.0\xa0±\xa04.60.064alcohol consumption before Pregnancy, portion/wk.6251.9\xa0±\xa02.0782.3\xa0±\xa03.50.755prepregnancy height (cm)642166.3\xa0±\xa06.081165.9\xa0±\xa05.40.398prepregnancy weight (kg)63163.5\xa0±\xa010.28172.1\xa0±\xa013.5<0.001prepregnancy bmi (kg/m2)63923.0\xa0±\xa03.58126.2\xa0±\xa04.8<0.001duration of Gestation at ogtt (wk)32326.3\xa0±\xa04.38025.9\xa0±\xa05.90.774duration of Gestation at Pregnancy Blood sampling (wk)64211.3\xa0±\xa01.98111.2\xa0±\xa02.20.089duration of Gestation at Delivery (wk)64240.2\xa0±\xa01.18140.1\xa0±\xa01.10.410pregnancy 25(Oh)D (nmol/l)64281.9\xa0±\xa019.58180.0\xa0±\xa021.20.417ucb 25(Oh)D (nmol/l)64280.1\xa0±\xa020.08178.4\xa0±\xa018.80.448supplemental Vitamin D intake during Pregnancy ( μ g/d)62115.5\xa0±\xa016.67613.5\xa0±\xa010.80.162cumulative Gestational weight gain atb(kg)0.093\u2003first measurement5801.7\xa0±\xa00.5741.6\xa0±\xa00.5\u200312th Gestational week5803.8\xa0±\xa01.0743.6\xa0±\xa01.1\u200320th Gestational week5806.3\xa0±\xa00.8746.2\xa0±\xa00.8\u200330th Gestational week5809.7\xa0±\xa00.5749.7\xa0±\xa00.4\u2003last measurement58013.8\xa0±\xa00.47413.7\xa0±\xa00.3\ngdm Gestational diabetes mellitus, 25(Oh)D 25-Hydroxy Vitamin D, ucb Umbilical cord Blood\nvalues are means ± sd\nascale from 1\u2009=\u2009lower secondary education to 6\u2009=\u2009first or second stage of tertiary education\nbvalues are adjusted for duration of Gestation\nindependent sample t-tests, mann-whitney u-tests, repeated measures anova or the pearson chi-square test, when appropriate, were applied to compare maternal characteristics between gdm and non-gdm mothers.']	N/A	N/A	[('GO_0007567', 'parturition', 104, 'delivery'), ('GO_0007565', 'female pregnancy', 330, 'pregnancy'), ('GO_0007565', 'female pregnancy', 560, 'gestation'), ('GO_0007565', 'female pregnancy', 624, 'gestation'), ('GO_0007565', 'female pregnancy', 637, 'pregnancy'), ('UBERON_0000178', 'blood', 647, 'blood'), ('GO_0007565', 'female pregnancy', 708, 'gestation'), ('GO_0007567', 'parturition', 721, 'delivery'), ('CHEBI_71657', 'versiconol acetate', 774, '25(OH)D'), ('CHEBI_63056', 'zinc cation', 826, '25(OH'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 832, 'D'), ('CHEBI_27300', 'vitamin D', 887, 'vitamin D'), ('GO_0007565', 'female pregnancy', 911, 'pregnancy'), ('GO_0007565', 'female pregnancy', 972, 'gestational'), ('GO_0007565', 'female pregnancy', 1055, 'gestational'), ('GO_0007565', 'female pregnancy', 1100, 'gestational'), ('GO_0007565', 'female pregnancy', 1145, 'gestational'), ('GO_0007565', 'female pregnancy', 1231, 'gestational'), ('CHEBI_71657', 'versiconol acetate', 1262, '25(OH)D'), ('CHEBI_62218', '23,24-dihydrocucurbitacin D', 1270, '25-hydroxy vitamin D'), ('UBERON_0007118', 'umbilicus', 1296, 'umbilical'), ('UBERON_0000178', 'blood', 1311, 'blood'), ('GO_0007565', 'female pregnancy', 1469, 'gestation')]
PMC5732505	12/2017	S90-PMC5732505	['prevalence of Vitamin D deficiency in non-gdm and gdm mothers were tested with fisher’s exact test.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 14, 'vitamin D')]
PMC5732505	12/2017	S95-PMC5732505	['the means and medians were similar in both Vitamin D concentrations.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 43, 'vitamin D')]
PMC5732505	12/2017	S98-PMC5732505	['results\nin the study population 97% were Vitamin D sufficient [25(Oh)D\u2009>\u200950\xa0nmol/l] in both mothers and newborns, while optimal Vitamin D status [25(Oh)D above 80\xa0nmol/l] was seen in 52% of the mothers and 45% of the newborns.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 41, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 63, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 69, 'D'), ('CHEBI_27300', 'vitamin D', 128, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 146, '25(OH)D'), ('PR_000006444', 'diacylglycerol kinase delta', 152, 'D')]
PMC5732505	12/2017	S111-PMC5732505	['1\n\nmaternal Vitamin D status and Gestational diabetes mellitus.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 12, 'vitamin D'), ('GO_0007565', 'female pregnancy', 33, 'gestational')]
PMC5732505	12/2017	S128-PMC5732505	['caption (table-wrap): table 2\n\nindependent effect of maternal factors on Birth sizeabirth weight (sds)Birth length (sds)Head circumference (sds)bponderal index (z-score)cmaternal factors np value p value p value p valueprepregnancy bmi 0.020 0.2010.3640.719\u2003underweight19−0.49\u2009±\u20090.17−0.36\u2009±\u20090.19−0.34\u2009±\u20090.22−0.12\u2009±\u20090.23\u2003normal weight494−0.30\u2009±\u20090.03−0.23\u2009±\u20090.04−0.14\u2009±\u20090.04−0.01\u2009±\u20090.05\u2003overweight117−0.13\u2009±\u20090.07−0.12\u2009±\u20090.08−0.04\u2009±\u20090.090.08\u2009±\u20090.09\u2003obese44−0.05\u2009±\u20090.12−0.01\u2009±\u20090.130.03\u2009±\u20090.140.08\u2009±\u20090.16gestational weight gain <0.0010.006 0.1860.505\u2003inadequate164−0.43\u2009±\u20090.06−0.37\u2009±\u20090.07−0.23\u2009±\u20090.07−0.05\u2009±\u20090.08\u2003adequate261−0.28\u2009±\u20090.05−0.20\u2009±\u20090.05−0.11\u2009±\u20090.06−0.02\u2009±\u20090.06\u2003excessive242−0.12\u2009±\u20090.05−0.09\u2009±\u20090.06−0.05\u2009±\u20090.060.07\u2009±\u20090.07prepregnancy smoking 0.021 0.2270.0930.173\u2003yes101−0.43\u2009±\u20090.08−0.30\u2009±\u20090.09−0.27\u2009±\u20090.10−0.13\u2009±\u20090.11\u2003no573−0.23\u2009±\u20090.03−0.18\u2009±\u20090.04−0.09\u2009±\u20090.040.03\u2009±\u20090.04maternal education0.9720.6700.7210.634\u2003higher513−0.26\u2009±\u20090.03−0.19\u2009±\u20090.04−0.11\u2009±\u20090.04−0.00\u2009±\u20090.05\u2003lower161−0.26\u2009±\u20090.06−0.23\u2009±\u20090.07−0.14\u2009±\u20090.080.04\u2009±\u20090.08parity <0.001<0.0010.0070.027 \u2003nullipara431−0.40\u2009±\u20090.04−0.32\u2009±\u20090.04−0.20\u2009±\u20090.05−0.05\u2009±\u20090.05\u2003secundipara185−0.03\u2009±\u20090.05−0.05\u2009±\u20090.06−0.03\u2009±\u20090.070.18\u2009±\u20090.07\u2003multipara580.04\u2009±\u20090.100.22\u2009±\u20090.110.17\u2009±\u20090.12−0.07\u2009±\u20090.13gestational diabetes mellitus0.0630.5590.3510.075\u2003yes76−0.10\u2009±\u20090.09−0.15\u2009±\u20090.10−0.02\u2009±\u20090.110.21\u2009±\u20090.12\u2003no598−0.28\u2009±\u20090.03−0.21\u2009±\u20090.03−0.13\u2009±\u20090.04−0.02\u2009±\u20090.04pregnancy 25(Oh)D concentration 0.010 0.0950.3980.236\u2003suboptimal (<80\xa0nmol/l)333−0.34\u2009±\u20090.04−0.26\u2009±\u20090.05−0.15\u2009±\u20090.05−0.04\u2009±\u20090.06\u2003optimal (≥80\xa0nmol/l)341−0.19\u2009±\u20090.04−0.15\u2009±\u20090.05−0.09\u2009±\u20090.050.05\u2009±\u20090.06ucb 25(Oh)D concentration0.1490.486 0.003 0.234\u2003suboptimal (<80\xa0nmol/l)369−0.22\u2009±\u20090.04−0.18\u2009±\u20090.04−0.02\u2009±\u20090.050.05\u2009±\u20090.05\u2003optimal (≥80\xa0nmol/l)305−0.31\u2009±\u20090.04−0.23\u2009±\u20090.05−0.24\u2009±\u20090.05−0.05\u2009±\u20090.06\n25(Oh)D 25-Hydroxy Vitamin D, ucb Umbilical Cord Blood\nvalues are adjusted mean\u2009±\u2009sem.']	N/A	N/A	[('GO_0007567', 'parturition', 73, 'birth'), ('GO_0007567', 'parturition', 102, 'Birth'), ('UBERON_0000033', 'head', 120, 'Head'), ('CHEBI_71657', 'versiconol acetate', 1405, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 1405, '25(OH)D'), ('CHEBI_71657', 'versiconol acetate', 1598, '25(OH)D'), ('CHEBI_72805', '2-alkyl-sn-glycero-3-phosphocholine', 1791, 'OH)D'), ('CHEBI_43141', '3-hydroxypropoxy group', 1796, '25-hydroxy'), ('CHEBI_27300', 'vitamin D', 1807, 'vitamin D'), ('UBERON_0002331', 'umbilical cord', 1822, 'umbilical cord'), ('UBERON_0000178', 'blood', 1837, 'blood')]
PMC5738092	12/2017	S3-PMC5738092	['we analyzed maternal and infant data from singletons (n = 14,506) Born during a double-masked, cluster-randomized, Placebo-controlled maternal Vitamin A or Β-Carotene supplementation trial in rural northwest bangladesh.']	N/A	N/A	[('GO_0007567', 'parturition', 66, 'born'), ('CHEBI_26130', 'biological pigment', 115, 'placebo'), ('CHEBI_27300', 'vitamin D', 143, 'vitamin A'), ('CHEBI_28064', 'cyanidin 3-O-rutinoside', 156, 'β-carotene')]
PMC5738092	12/2017	S26-PMC5738092	['the data reported in this analysis were collected during a field based study assessing the efficacy of weekly Antenatal Vitamin A or Β-Carotene versus placebo supplementation on maternal and infant mortality through 6 months of age from july 2001 to january 2007.']	N/A	N/A	[('GO_0007567', 'parturition', 110, 'antenatal'), ('CHEBI_27300', 'vitamin D', 120, 'vitamin A'), ('PR_000004370', 'asialoglycoprotein receptor 2', 128, 'A'), ('CHEBI_28064', 'cyanidin 3-O-rutinoside', 133, 'β-carotene')]
PMC5738092	12/2017	S31-PMC5738092	['Birth size measurements were added as part of a newborn, placebo-controlled, single-dose Vitamin A supplementation trial that was initiated among infants Born during the 2Ndhalf of the maternal trial [12].']	N/A	N/A	[('GO_0007567', 'parturition', 0, 'Birth'), ('CHEBI_27300', 'vitamin D', 89, 'vitamin A'), ('GO_0007567', 'parturition', 154, 'born'), ('UBERON_0003632', 'pedal digit 2', 170, '2ndhalf')]
PMC5738092	12/2017	S96-PMC5738092	['(muac, mid-upper arm circumference; hc, Head circumference; cc, chest circumference; m-muac, maternal muac; lsi, living standard index; anc, antenatal care visit; vit a, maternal Vitamin A supplementation; b-care, maternal Β-Carotene supplementation; male, infant’s sex as male).']	N/A	N/A	[('UBERON_0000033', 'head', 40, 'Head'), ('CHEBI_27300', 'vitamin D', 179, 'vitamin A'), ('CHEBI_28064', 'cyanidin 3-O-rutinoside', 223, 'β-carotene')]
PMC5738092	12/2017	S113-PMC5738092	['orange color indicating the weights of dependent variables (Birth size variables: weight, length, Head (hc), Chest (cc) and Arm (muac) circumferences) and the blue color indicating the weights of the predictors (maternal and infant factors: maternal age, parity, education, muac, Vitamin A sup.']	N/A	N/A	[('GO_0007567', 'parturition', 60, 'birth'), ('UBERON_0000033', 'head', 98, 'head'), ('UBERON_0001443', 'chest', 109, 'chest'), ('UBERON_0001460', 'arm', 124, 'arm'), ('CHEBI_27300', 'vitamin D', 280, 'vitamin A')]
PMC5741981	12/2018	S39-PMC5741981	['presented Drug classes were Paracetamol, nonsteroidal Anti-Inflammatory Drugs (Nsaids), Vitamins other than Folic Acid and Vitamin D, Drugs against a cold, Acid-suppressive medication, Antibiotics, antifungal medication, Drugs against nausea and vomiting (nvp), Sedatives/anxiolytics, anti-asthma medication, anti-diabetes medication, medication against high Blood pressure, and homeopathic medication.19\nFolic Acid and Vitamin D are Vitamins which are advised in the netherlands during Pregnancy.20therefore, women who only used these Vitamins were categorized as non-medication users.']	N/A	N/A	[('CHEBI_23888', 'drug', 10, 'drug'), ('CHEBI_46195', 'paracetamol', 28, 'paracetamol'), ('CHEBI_35472', 'anti-inflammatory drug', 54, 'anti-inflammatory drugs'), ('CHEBI_16039', 'ITP', 79, 'NSAIDs'), ('CHEBI_33277', 'gamma-tocotrienol', 88, 'vitamins'), ('CHEBI_30751', 'formic acid', 108, 'folic acid'), ('CHEBI_27300', 'vitamin D', 123, 'vitamin D'), ('CHEBI_23888', 'drug', 134, 'drugs'), ('CHEBI_37527', 'acid', 156, 'acid'), ('CHEBI_33282', 'antibacterial agent', 185, 'antibiotics'), ('CHEBI_23888', 'drug', 221, 'drugs'), ('CHEBI_46670', 'serpentine mineral', 262, 'sedatives'), ('UBERON_0000178', 'blood', 359, 'blood'), ('CHEBI_30751', 'formic acid', 405, 'Folic acid'), ('CHEBI_27300', 'vitamin D', 420, 'vitamin D'), ('CHEBI_33277', 'gamma-tocotrienol', 434, 'vitamins'), ('GO_0007565', 'female pregnancy', 487, 'pregnancy'), ('CHEBI_33277', 'gamma-tocotrienol', 536, 'vitamins')]
PMC5741981	12/2018	S70-PMC5741981	['of the respondents, 56 (48%) reported Folic Acid and/or Vitamin D use during Pregnancy.']	N/A	N/A	[('CHEBI_30751', 'formic acid', 38, 'folic acid'), ('CHEBI_27300', 'vitamin D', 56, 'vitamin D'), ('GO_0007565', 'female pregnancy', 77, 'pregnancy')]
PMC5758521	1/2018	S2-PMC5758521	['in a singleton Birth cohort (n\u2009=\u2009248), Vitamin A and e nutritional status in fetuses/newborns were assessed by Cord Plasma concentrations of Retinol, β-Carotene, Α- and γ-tocopherols.']	N/A	N/A	[('GO_0007567', 'parturition', 15, 'birth'), ('CHEBI_27300', 'vitamin D', 39, 'vitamin A'), ('UBERON_0002240', 'spinal cord', 111, 'cord'), ('UBERON_0001969', 'blood plasma', 116, 'plasma'), ('CHEBI_26536', 'retinoic acid', 141, 'retinol'), ('CHEBI_23042', 'carotene', 152, 'carotene'), ('CHEBI_16199', 'urea', 162, 'α-')]
PMC5758521	1/2018	S10-PMC5758521	['the common circulating forms of Vitamins A and E include Α- and γ-tocopherols for Vitamin E3, Retinol for Vitamin A, and Β-Carotene for Provitamin A4.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 32, 'vitamins A'), ('PR_000004480', 'V-type proton ATPase catalytic subunit A', 32, 'vitamins A'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 47, 'E'), ('CHEBI_16199', 'urea', 57, 'α-'), ('CHEBI_33237', 'vitamin D4', 82, 'vitamin E3'), ('PR_000017264', 'synaptic vesicle membrane protein VAT-1', 82, 'vitamin E3'), ('CHEBI_26536', 'retinoic acid', 94, 'retinol'), ('CHEBI_27300', 'vitamin D', 106, 'vitamin A'), ('CHEBI_28064', 'cyanidin 3-O-rutinoside', 121, 'β-carotene'), ('PR_000012529', 'PDZK1-interacting protein 1', 136, 'provitamin A4')]
PMC5758521	1/2018	S12-PMC5758521	['the major circulating form of Vitamin E is Α-Tocopherol, whereas Γ-Tocopherol is the most abundant form of Vitamin E in the diet in north america7.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 30, 'vitamin E'), ('CHEBI_27725', 'butin', 43, 'α-tocopherol'), ('CHEBI_27725', 'butin', 65, 'γ-tocopherol'), ('CHEBI_27300', 'vitamin D', 107, 'vitamin E')]
PMC5758521	1/2018	S33-PMC5758521	['for assessing Vitamin A and E nutritional status in fetuses/neonates, Retinol, Β-Carotene, Α-Tocopherol and Γ-Tocopherol in edta cord plasma specimens were measured by high-performance liquid chromatography (hplc)18.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 14, 'vitamin A'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 28, 'E'), ('CHEBI_26536', 'retinoic acid', 70, 'retinol'), ('CHEBI_28064', 'cyanidin 3-O-rutinoside', 79, 'β-carotene'), ('CHEBI_27725', 'butin', 91, 'α-tocopherol'), ('CHEBI_27725', 'butin', 108, 'γ-tocopherol')]
PMC5758844	12/2017	S56-PMC5758844	['the following biochemical assays were performed: full Blood count, Liver function tests, Renal function, total Cholesterol, high-density lipoprotein (hdl), low-density lipoprotein (ldl), Triglycerides, Glucose, Insulin, hba1c, Vitamin D, and crp.']	N/A	N/A	[('UBERON_0000178', 'blood', 54, 'blood'), ('UBERON_0002107', 'liver', 67, 'liver'), ('UBERON_0002113', 'kidney', 89, 'renal'), ('CHEBI_16113', 'cholesterol', 111, 'cholesterol'), ('CHEBI_17855', 'triglyceride', 187, 'triglycerides'), ('CHEBI_17234', 'glucose', 202, 'glucose'), ('PR_000045358', 'insulin family protein', 211, 'insulin'), ('CHEBI_27300', 'vitamin D', 227, 'vitamin D')]
PMC5784894	1/2018	S3-PMC5784894	['a Murine model was created in which Pregnant dams were either Vitamin D deficient or replete, and their offspring moved to a Vitamin D replete diet at weaning.']	N/A	N/A	[('NCBITaxon_39107', 'Murinae', 2, 'murine'), ('GO_0007565', 'female pregnancy', 36, 'pregnant'), ('CHEBI_27300', 'vitamin D', 62, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 125, 'vitamin D')]
PMC5784894	1/2018	S5-PMC5784894	['offspring of Vitamin D deplete Mice demonstrated lower bone mass in the non loaded Limb and reduced bone mass accrual in response to loading in both the Growing Skeleton and after Skeletal maturity.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 13, 'vitamin D'), ('NCBITaxon_10088', 'Mus <genus>', 31, 'mice'), ('UBERON_0002101', 'limb', 83, 'limb'), ('GO_0040007', 'growth', 153, 'growing'), ('UBERON_0004288', 'skeleton', 161, 'skeleton'), ('UBERON_0004288', 'skeleton', 180, 'skeletal')]
PMC5784894	1/2018	S22-PMC5784894	['we used c57bl/6 Mice to generate Vitamin D replete and deplete dams, who went on to deliver litters that remained on the maternal diet until weaning, mimicking the common situation of Vitamin D exposure in Humans.']	N/A	N/A	[('NCBITaxon_10088', 'Mus <genus>', 16, 'mice'), ('CHEBI_27300', 'vitamin D', 33, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 184, 'vitamin D'), ('NCBITaxon_9606', 'Homo sapiens', 206, 'humans')]
PMC5784894	1/2018	S35-PMC5784894	['after weaning onto the control diet Chow all Animals were Vitamin D replete when mechanically loaded at 10 and 18 weeks (fig 1).']	N/A	N/A	[('CHEBI_33290', 'food', 36, 'chow'), ('NCBITaxon_33208', 'Metazoa', 45, 'animals'), ('CHEBI_27300', 'vitamin D', 58, 'vitamin D')]
PMC5784894	1/2018	S92-PMC5784894	['(a) Trabecular region of loaded and non-loaded Tibias of early Life Vitamin D deficient and replete Mice aged 10 weeks.']	N/A	N/A	[('UBERON_0002363', 'dura mater', 4, 'trabecular'), ('UBERON_0000979', 'tibia', 47, 'tibias'), ('UBERON_0000104', 'life cycle', 63, 'life'), ('CHEBI_27300', 'vitamin D', 68, 'vitamin D'), ('NCBITaxon_10088', 'Mus <genus>', 100, 'mice')]
PMC5784894	1/2018	S93-PMC5784894	['(b) mid Cortical region of loaded and non-loaded Tibias of early Life Vitamin D deficient and deplete Mice aged 10 weeks.']	N/A	N/A	[('UBERON_0001851', 'cortex', 8, 'cortical'), ('UBERON_0000979', 'tibia', 49, 'tibias'), ('UBERON_0000104', 'life cycle', 65, 'life'), ('CHEBI_27300', 'vitamin D', 70, 'vitamin D'), ('NCBITaxon_10088', 'Mus <genus>', 102, 'mice')]
PMC5784894	1/2018	S94-PMC5784894	['(c) Trabecular region of loaded and non-loaded Tibias of early Life Vitamin D deficient and replete Mice aged 18 weeks.']	N/A	N/A	[('UBERON_0002363', 'dura mater', 4, 'trabecular'), ('UBERON_0000979', 'tibia', 47, 'tibias'), ('UBERON_0000104', 'life cycle', 63, 'life'), ('CHEBI_27300', 'vitamin D', 68, 'vitamin D'), ('NCBITaxon_10088', 'Mus <genus>', 100, 'mice')]
PMC5784894	1/2018	S95-PMC5784894	['(d) mid Cortical region of loaded and non-loaded Tibias of early Life Vitamin D deficient and deplete Mice aged 18 weeks.']	N/A	N/A	[('UBERON_0001851', 'cortex', 8, 'cortical'), ('UBERON_0000979', 'tibia', 49, 'tibias'), ('UBERON_0000104', 'life cycle', 65, 'life'), ('CHEBI_27300', 'vitamin D', 70, 'vitamin D'), ('NCBITaxon_10088', 'Mus <genus>', 102, 'mice')]
PMC5784894	1/2018	S124-PMC5784894	['in the loaded Bones in offspring of Vitamin D deplete dams, a larger volume of bone had higher strain with a larger difference at 18 weeks than at 10 weeks.']	N/A	N/A	[('UBERON_0001474', 'bone element', 14, 'bones'), ('CHEBI_27300', 'vitamin D', 36, 'vitamin D')]
PMC5784894	1/2018	S129-PMC5784894	['for non-loaded Bones at 10 weeks, stiffness and ultimate force (the force needed to break the bone) were higher in the offspring of Vitamin D-replete dams; whilst all offspring showed an increase in both parameters in response to loading, that increase was greater in the “replete” group.']	N/A	N/A	[('UBERON_0001474', 'bone element', 15, 'bones'), ('CHEBI_27300', 'vitamin D', 132, 'vitamin D')]
PMC5784894	1/2018	S139-PMC5784894	['in the younger (10 week) Mice studied there were baseline differences between the control and early Life deficiency group in Cortical bone with early Life Vitamin D deficient Mice having wider Bones with thinner Cortices.']	N/A	N/A	[('NCBITaxon_10088', 'Mus <genus>', 25, 'mice'), ('UBERON_0000104', 'life cycle', 100, 'life'), ('UBERON_0001851', 'cortex', 125, 'cortical'), ('UBERON_0000104', 'life cycle', 150, 'life'), ('CHEBI_27300', 'vitamin D', 155, 'vitamin D'), ('NCBITaxon_10088', 'Mus <genus>', 175, 'mice'), ('UBERON_0001474', 'bone element', 193, 'bones'), ('UBERON_0001851', 'cortex', 212, 'cortices')]
PMC5784894	1/2018	S150-PMC5784894	['there are no similar previous experiments of this nature (i.e combining Vitamin D depletion with mechanical loading) with which to compare our data.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 72, 'vitamin D')]
PMC5784894	1/2018	S155-PMC5784894	['at 28 days when supplemented with Vitamin D they maintained lower bmc and strength[31].']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 34, 'vitamin D')]
PMC5804088	2/2018	S17-PMC5804088	['Zinc and Vitamin A supplementation reduced clinical malaria episodes caused by p. falciparum in young children [8–10].']	N/A	N/A	[('CHEBI_27377', "Unsym-bis(4'-chlorophenyl)ethylene", 0, 'Zinc'), ('CHEBI_27300', 'vitamin D', 9, 'vitamin A')]
PMC5812027	2/2018	S89-PMC5812027	['1\n\nflow chart of the study inclusion\n\ncaption (table-wrap): table 1\n\ncharacteristics of the Pregnant women and their infants at Birthmeansdbirth weight (grams)a3542537.7birth length (cm)a502.3gestational age at Delivery (days)28012.4gestational age t1 (days)7613.8gestational age t3 (days)23412.9maternal s-25Ohd t1 (nmol/l)6424.4maternal s-25Ohd t3 (nmol/l)7534.4n (%)male gender of infanta976 (49.8)small for Gestational age (weight or length)93 (4.5)low Birth weight (<\u20092500\xa0g)58 (2.8)Preterm Delivery (<\u200937\xa0weeks)78 (3.8)spontaneous Preterm Delivery (<\u200937\xa0weeks)55 (2.7)Pregnancy loss97 (4.7)Intrauterine fetal death (≥\u200922\xa0weeks)9 (0.5)\nt1 first trimester, t3 third trimester, 25Ohd 25-Hydroxyvitamin D\nalive Born infants only\n\ncaption (table-wrap): table 2\n\nthe Pregnant women’s Vitamin D status in the first (t1) and third (t3) Trimester of Pregnancy, and their characteristics (mean or percent) grouped by 25Ohd concentration in (t1)t1 25Ohd (nmol/l)<\u20093030–49.950–74.975–99.9≥\u2009100n198291788565125%10.114.840.128.76.4bmi t1 (kg/m2)25.124.924.423.924.4age t1 (years)29.430.931.632.032.4born in sweden (%)14.154.683.387.893.5tobacco use t1 (%)6.84.64.04.61.6nulliparous t1 (%)34.842.042.643.142.7vitamin D supplement use t1 (%)10.628.245.256.662.9university level education (%)32.354.961.367.366.1small for Gestational age (%)5.74.25.34.14.0preterm Delivery (%)4.15.23.83.91.6low Birth weight (%)3.04.53.12.11.6pregnancy loss (%)6.35.64.55.10t3 25Ohd (nmol/l)<\u20093030–49.950–74.975–99.9≥\u2009100n163330473409443%9.018.226.022.524.4small for Gestational age (%)7.55.54.74.62.3preterm Delivery (%)4.31.23.62.21.6low Birth weight (%)4.30.32.71.21.4\nt1 first trimester, t3 third trimester, 25Ohd 25-hydroxyvitamin d\n\nBirth size and Preterm Delivery\nin total, 93 (4.5%) infants were Born sga.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 92, 'pregnant'), ('GO_0002211', 'behavioral defense response to insect', 128, 'birthMeanSDBirth'), ('GO_0007567', 'parturition', 211, 'delivery'), ('CHEBI_72652', "7,2'-dihydroxy-4'-methoxyisoflavan-4-ylium cation", 307, '25OHD'), ('CHEBI_72652', "7,2'-dihydroxy-4'-methoxyisoflavan-4-ylium cation", 341, '25OHD'), ('GO_0007565', 'female pregnancy', 411, 'gestational'), ('GO_0007567', 'parturition', 457, 'birth'), ('GO_0007128', 'meiotic prophase I', 488, 'Preterm'), ('GO_0007567', 'parturition', 496, 'delivery'), ('GO_0007565', 'female pregnancy', 537, 'preterm'), ('GO_0007567', 'parturition', 545, 'delivery'), ('GO_0007565', 'female pregnancy', 574, 'Pregnancy'), ('UBERON_0035108', 'temporalis fascia', 596, 'Intrauterine'), ('CHEBI_72652', "7,2'-dihydroxy-4'-methoxyisoflavan-4-ylium cation", 681, '25OHD'), ('CHEBI_62218', '23,24-dihydrocucurbitacin D', 687, '25-hydroxyvitamin D'), ('GO_0007567', 'parturition', 713, 'born'), ('GO_0007565', 'female pregnancy', 767, 'pregnant'), ('CHEBI_27300', 'vitamin D', 784, 'vitamin D'), ('GO_0009294', 'DNA mediated transformation', 834, 'trimester'), ('GO_0007565', 'female pregnancy', 847, 'pregnancy'), ('CHEBI_72652', "7,2'-dihydroxy-4'-methoxyisoflavan-4-ylium cation", 913, '25OHD'), ('CHEBI_72652', "7,2'-dihydroxy-4'-methoxyisoflavan-4-ylium cation", 943, '25OHD'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 1208, 'D'), ('GO_0007565', 'female pregnancy', 1311, 'gestational'), ('GO_0007567', 'parturition', 1353, 'delivery'), ('GO_0007567', 'parturition', 1384, 'birth'), ('CHEBI_72652', "7,2'-dihydroxy-4'-methoxyisoflavan-4-ylium cation", 1449, '25OHD'), ('GO_0007565', 'female pregnancy', 1539, 'gestational'), ('GO_0007567', 'parturition', 1581, 'delivery'), ('GO_0007567', 'parturition', 1612, 'birth'), ('CHEBI_72652', "7,2'-dihydroxy-4'-methoxyisoflavan-4-ylium cation", 1684, '25OHD'), ('GO_0007567', 'parturition', 1711, 'Birth'), ('GO_0007565', 'female pregnancy', 1726, 'preterm'), ('GO_0007567', 'parturition', 1734, 'delivery'), ('GO_0007567', 'parturition', 1776, 'born')]
PMC5812027	2/2018	S95-PMC5812027	['women with t3 25Ohd ≥\u2009100\xa0nmol/l had a lower or for sga (or\u2009=\u20090.32, p \u2009=\u20090.031) compared to those with Vitamin D deficiency (<\u200930\xa0nmol/l).']	N/A	N/A	[('CHEBI_72652', "7,2'-dihydroxy-4'-methoxyisoflavan-4-ylium cation", 14, '25OHD'), ('CHEBI_27300', 'vitamin D', 103, 'vitamin D')]
PMC5812027	2/2018	S96-PMC5812027	['women with t3 25Ohd concentrations ≥\u2009100\xa0nmol/l and 30–50\xa0nmol/l had lower or for lbw (or\u2009=\u20090.22, p \u2009=\u20090.046 and or\u2009=\u20090.07, p \u2009=\u20090.017, respectively), compared to Vitamin D deficiency.']	N/A	N/A	[('CHEBI_72652', "7,2'-dihydroxy-4'-methoxyisoflavan-4-ylium cation", 14, '25OHD'), ('CHEBI_27300', 'vitamin D', 163, 'vitamin D')]
PMC5812027	2/2018	S98-PMC5812027	['the results were not meaningfully affected by additional adjustment for tobacco use or Vitamin D supplementation or by excluding cases of preeclampsia (data not shown).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 87, 'vitamin D')]
PMC5812027	2/2018	S99-PMC5812027	['caption (table-wrap): table 3\n\nassociation between Vitamin D status in Pregnancy with Birth size and Pregnancy loss (adjusted logistic regression analysis)small for Gestational ageapreterm Delivery (<\u200937\xa0weeks)blow Birth weight (<\u20092500\xa0g)cpregnancy lossdorci 95%orci 95%orci 95%orci 95%t1 25Ohde\u2003continuous nmol/l1.0030.99–1.010.9960.99–1.010.9990.99–1.010.989*0.98–1.00\u2003\u2003<\u200930 (ref)1.01.01.01.0\u2003\u200330–49.91.0780.44–2.661.6470.63–4.332.5490.88–7.381.0300.44–2.41\u2003\u200350–74.91.6320.69–3.851.2600.47–3.362.2870.77–6.830.6880.29–1.62\u2003\u200375–99-91.2920.51–3.271.3320.48–3.731.6650.51–5.490.8090.33–1.96\u2003\u2003≥\u20091001.2940.38–4.420.5020.09–2.721.2550.22–7.270.000ft3 25Ohde\u2003\u2003<\u200930 (ref)1.01.01.0\u2003\u200330–49.90.7710.34–1.750.3020.08–1.140.071*0.01–0.63\u2003\u200350–74.90.6230.27–1.450.9330.31–2.790.5840.17–1.98\u2003\u200375–99-90.6570.27–1.610.6140.18–2.140.2370.06–1.01\u2003\u2003≥\u20091000.318*0.11–0.900.4460.11–1.760.215*0.05–0.97δ25ohdg\u2003\u2003large increase (≥\u200930\xa0nmol/l) (ref)1.01.01.0\u2003\u2003small increase (0–30\xa0nmol/l)2.564*1.16–5.672.905*1.01–8.343.1220.97–10.09\u2003\u2003decrease (<\u20090\xa0nmol/l)3.679**1.60–8.442.8940.95–8.854.722*1.37–16.28\nt1 first trimester, t3 third trimester, 25Ohd 25-Hydroxyvitamin D\n* p \u2009<\u20090.05 ** p \u2009<\u20090.01\namodels include 92 (t1) and 80 (t3 and δ25ohd) cases of small for Gestational age\nbmodels include 77 (t1) and 43 (t3 and δ25ohd) cases of Preterm Delivery\ncmodels include 57 (t1) and 31 (t3 and δ25ohd) cases of low Birth weight\ndmodels include 96 cases of Pregnancy loss\neadjusted for education, origin, season of Conception and bmi at t1.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 51, 'vitamin D'), ('GO_0007565', 'female pregnancy', 71, 'pregnancy'), ('GO_0007567', 'parturition', 86, 'birth'), ('GO_0007565', 'female pregnancy', 101, 'pregnancy'), ('GO_0007565', 'female pregnancy', 165, 'gestational'), ('GO_0007567', 'parturition', 189, 'delivery'), ('GO_0007567', 'parturition', 215, 'birth'), ('CHEBI_63058', '(2R,3S)-EHNA', 289, '25OHDe'), ('CHEBI_63058', '(2R,3S)-EHNA', 647, '25OHDe'), ('CHEBI_72652', "7,2'-dihydroxy-4'-methoxyisoflavan-4-ylium cation", 1116, '25OHD'), ('CHEBI_62218', '23,24-dihydrocucurbitacin D', 1122, '25-hydroxyvitamin D'), ('GO_0007565', 'female pregnancy', 1233, 'gestational'), ('GO_0019230', 'proprioception', 1305, 'preterm delivery'), ('GO_0007567', 'parturition', 1382, 'birth'), ('GO_0007565', 'female pregnancy', 1423, 'pregnancy'), ('GO_0007620', 'copulation', 1481, 'conception')]
PMC5812027	2/2018	S103-PMC5812027	['neither of these results changed after adjustment for tobacco use and Vitamin D supplementation at t3 or after excluding cases of Preeclampsia.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 70, 'vitamin D'), ('GO_0007128', 'meiotic prophase I', 130, 'preeclampsia')]
PMC5812027	2/2018	S117-PMC5812027	['supplements containing Vitamin D were used by 43% in t1 and 39% in t3- mainly multivitamins [19].']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 23, 'vitamin D')]
PMC5812027	2/2018	S135-PMC5812027	['also, Vitamin D supplements were used by almost half of the women but most (88%) used multivitamins containing 5–10\xa0μg of Vitamin D3.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 6, 'vitamin D'), ('CHEBI_33279', 'vitamin D5', 122, 'vitamin D3'), ('PR_000017299', 'VIP peptides', 122, 'vitamin D3')]
PMC5827025	2/2018	S12-PMC5827025	['the classical function of Vitamin D is Regulating Calcium and Phosphorus Homeostasis1.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 26, 'vitamin D'), ('GO_0065007', 'biological regulation', 39, 'regulating'), ('CHEBI_22313', 'alkaline earth metal atom', 50, 'calcium'), ('GO_0007129', 'homologous chromosome pairing at meiosis', 50, 'calcium ... homeostasis1'), ('CHEBI_35885', 'secondary phosphine', 62, 'phosphorus')]
PMC5827025	2/2018	S33-PMC5827025	['caption (table-wrap): table 1\n\ndemographic characteristics of 3598 mothers.demographic variablesgestational Vitamin D status1p -value2deficiencyinsufficiencysufficiencypregnant women [n (%)]1397 (38.83)1260 (35.02)941 (26.15)maternal age [years, n (%)]\xa0\xa0<25\xa0\xa025–34\xa0\xa0≥35220 (15.75)1131 (80.96)46 (3.29)194 (15.40)1022 (81.11)44 (3.49)147 (15.62)768 (81.61)26 (2.77)0.909maternal bmi [kg/m2, n (%)]\xa0\xa0underweight (<18.5)\xa0\xa0normal weight (18.5–22.9)\xa0\xa0overweight (≥23.0)333 (23.84)925 (66.21)139 (9.95)271 (21.51)859 (68.17)130 (10.32)168 (17.85)649 (68.97)124 (13.18)0.003season of Blood sample [n (%)]\xa0\xa0spring\xa0\xa0summer\xa0\xa0fall\xa0\xa0winter477 (34.14)311 (22.26)279 (19.97)330 (23.62)468 (37.14)271 (21.51)275 (21.83)246 (19.52)371 (39.43)225 (23.91)193 (20.51)152 (16.15)0.001periconceptional Multivitamin use [n (%)]\xa0\xa0no\xa0\xa0less than one month\xa0\xa0more than one month1220 (87.33)97 (6.94)80 (5.73)1033 (81.98)112 (8.89)115 (9.13)743 (78.96)81 (8.61)117 (12.43)<0.001family monthly income (rmb/yuan) [n (%)]\xa0\xa0low (<2000)\xa0\xa0middle (2000–3999)\xa0\xa0high (≥4000)611 (43.74)590 (42.23)196 (14.03)557 (44.21)516 (40.95)187 (14.84)432 (45.91)372 (39.53)137 (14.56)0.746parity [n(%)]\xa0\xa01 >11345 (96.87)60 (3.13)1238 (96.97)51 (3.03)927 (96.58)37 (3.42)0.854gestational week of Blood sample [w, n (%)]\xa0\xa0first-trimester (<13)\xa0\xa0second-trimester (13–27)519 (37.15)878 (62.85)444 (35.24)816 (64.76)337 (35.81)604 (64.19)0.575\n125(Oh)D < 20\u2009ng/ml for deficiency; 20\u2009≤\u200925(Oh)D < 30\u2009ng/ml for insufficiency; 25(Oh)D ≥ 30\u2009ng/ml for sufficiency.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 108, 'vitamin D'), ('UBERON_0000178', 'blood', 577, 'blood'), ('CHEBI_7025', 'mupirocin', 781, 'multivitamin'), ('UBERON_0000178', 'blood', 1247, 'blood'), ('CHEBI_84177', '14-HPDHE', 1391, '125(OH)D'), ('CHEBI_71657', 'versiconol acetate', 1432, '25(OH)D'), ('CHEBI_71657', 'versiconol acetate', 1470, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 1470, '25(OH)D')]
PMC5827025	2/2018	S60-PMC5827025	['caption (table-wrap): table 3\n\nassociation between demographic characteristics and the risk of Gestational Vitamin D deficiency based on multiple logistic regression analyses.parametercrude modelsadjusted models rr (95% ci ) p values rr (95% ci) p valuespre-Pregnancy bmi [kg/m2]1\xa0\xa0<18.51.25 (1.06, 1.47)0.0071.26 (1.07, 1.48)0.006\xa0\xa018.5–22.91.001.00\xa0\xa0≥23.00.84 (0.67, 1.05)0.1160.84 (0.67, 1.06)0.135season of Blood sample2\xa0\xa0spring1.001.00\xa0\xa0summer1.11 (0.93, 1.33)0.2601.12 (0.94, 1.34)0.211\xa0\xa0fall1.06 (0.88, 1.27)0.5551.05 (0.87, 1.27)0.601\xa0\xa0winter1.45 (1.21, 1.74)<0.0011.45 (1.21, 1.74)<0.001periconceptional Multivitamin use3\xa0\xa0no1.001.00\xa0\xa0less than one month0.69 (0.51, 0.94)0.0190.68 (0.50, 0.93)0.016\xa0\xa0more than one month0.72 (0.58, 0.89)0.0020.72 (0.58, 0.90)0.003\n1adjusted for maternal age, periconceptional Multivitamin use, and season of sampling.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 95, 'gestational'), ('CHEBI_27300', 'vitamin D', 107, 'vitamin D'), ('GO_0007565', 'female pregnancy', 258, 'pregnancy'), ('UBERON_0000178', 'blood', 411, 'blood'), ('CHEBI_7025', 'mupirocin', 613, 'multivitamin'), ('CHEBI_7025', 'mupirocin', 818, 'multivitamin')]
PMC5827025	2/2018	S63-PMC5827025	['association between Gestational Vitamin D status and the risk of Preterm Delivery\nthe association between Gestational Vitamin D status and the risk of Preterm Delivery was analyzed.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 20, 'gestational'), ('CHEBI_27300', 'vitamin D', 32, 'vitamin D'), ('GO_0007565', 'female pregnancy', 65, 'preterm'), ('GO_0007567', 'parturition', 73, 'delivery'), ('GO_0007565', 'female pregnancy', 106, 'gestational'), ('CHEBI_27300', 'vitamin D', 118, 'vitamin D'), ('GO_0007565', 'female pregnancy', 151, 'preterm'), ('GO_0007567', 'parturition', 159, 'delivery')]
PMC5827025	2/2018	S66-PMC5827025	['caption (table-wrap): table 4\n\ncrude and adjusted rrs for Preterm Delivery in different groups.parametergestational Vitamin D statussufficiencyinsufficiencydeficiencygestational week (week)39.3\u2009±\u20091.739.0\u2009±\u20091.5**38.6\u2009±\u20092.5**††Preterm Delivery [n (%)]25 (2.66)48 (3.81)115 (8.23)crude rr (95% ci )1.001.45 (0.89, 2.37)3.28 (2.12, 5.11)**adjusted rr (95% ci )11.002.07 (1.16, 3.71)*4.02 (2.33, 6.92)**††early Preterm Delivery [n (%)]29 (0.97)6 (0.49)34 (2.59)crude rr (95% ci )1.000.50 (0.18, 1.42)2.70 (1.29, 5.66)**††adjusted rr (95% ci )11.000.54 (0.19, 1.51)2.97 (1.41, 6.24)**††late Preterm Delivery [n (%)]216 (1.69)42 (3.32)81 (5.64)crude rr (95% ci )1.001.98 (1.11, 3.55)*3.62 (2.10, 6.23)**††adjusted rr (95% ci )11.002.09 (1.17, 3.74)*3.90 (2.26, 6.72)**††\n1adjusted for pre-Pregnancy bmi, maternal age, Periconceptional multivitamin use, and season of sampling.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 58, 'preterm'), ('GO_0007567', 'parturition', 66, 'delivery'), ('CHEBI_27300', 'vitamin D', 116, 'vitamin D'), ('GO_0007622', 'rhythmic behavior', 225, 'Preterm delivery'), ('GO_0019230', 'proprioception', 406, 'preterm delivery'), ('GO_0019230', 'proprioception', 585, 'preterm delivery'), ('GO_0007565', 'female pregnancy', 782, 'pregnancy'), ('GO_0007565', 'female pregnancy', 811, 'periconceptional')]
PMC5827025	2/2018	S69-PMC5827025	['the association between Gestational Vitamin D status and risk of early Preterm Delivery and late Preterm Delivery were then analyzed.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 24, 'gestational'), ('CHEBI_27300', 'vitamin D', 36, 'vitamin D'), ('GO_0007565', 'female pregnancy', 71, 'preterm'), ('GO_0007567', 'parturition', 79, 'delivery'), ('GO_0007565', 'female pregnancy', 97, 'preterm'), ('GO_0007567', 'parturition', 105, 'delivery')]
PMC5827025	2/2018	S142-PMC5827025	['Gestational Vitamin D status was divided into three groups according to following criteria: 25(Oh)D <20\u2009ng/ml for vdd, 20\u2009≤\u200925(Oh)D <30\u2009ng/ml for vitamin insufficiency (vdi), and 25(Oh)D ≥30\u2009ng/ml for Vitamin D sufficiency (vds)5,14.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 0, 'Gestational'), ('CHEBI_27300', 'vitamin D', 12, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 92, '25(OH)D'), ('PR_000005506', 'Cbp/p300-interacting transactivator 2', 92, '25'), ('PR_000012046', 'oxysterol-binding protein-related protein 11', 95, 'OH ... D'), ('CHEBI_33010', 'chromide(1-)', 126, '(OH)D'), ('CHEBI_71657', 'versiconol acetate', 179, '25(OH)D'), ('PR_000005506', 'Cbp/p300-interacting transactivator 2', 179, '25'), ('PR_000006444', 'diacylglycerol kinase delta', 185, 'D'), ('CHEBI_27300', 'vitamin D', 201, 'vitamin D')]
PMC5838372	3/2018	S5-PMC5838372	['Serum levels of Vitamin D, calcium, phosphorus and alkaline phosphatase in all subjects were measured.']	N/A	N/A	[('UBERON_0001977', 'blood serum', 0, 'Serum'), ('CHEBI_27300', 'vitamin D', 16, 'vitamin D')]
PMC5838372	3/2018	S6-PMC5838372	['the mothers and newborns were divided into groups based on their Vitamin D levels.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 65, 'vitamin D')]
PMC5838372	3/2018	S7-PMC5838372	['the relationship between Vitamin D levels and risk factors was analyzed.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 25, 'vitamin D')]
PMC5838372	3/2018	S8-PMC5838372	['results:\nmean ± standard deviation Vitamin D levels for the women and their infants were found to be 14.82±11.45 and 13.16±7.16 ng/ml, respectively.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 35, 'vitamin D')]
PMC5838372	3/2018	S9-PMC5838372	['the number of mothers and infants was significantly higher in the deficient group, and their mean Vitamin D levels significantly lower (9.02±1.34 and 8.80±1.06 ng/ml, respectively) (p<0.001, p<0.001).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 98, 'vitamin D')]
PMC5838372	3/2018	S14-PMC5838372	['a new Vitamin D support programme was launched for Pregnant women by the ministry of health in 2011.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 6, 'vitamin D'), ('GO_0007565', 'female pregnancy', 51, 'pregnant')]
PMC5838372	3/2018	S24-PMC5838372	['this program included free distribution of Supplements to provide 400 iu/day of Vitamin D. at the end of this program, the prevalence of rickets decreased in children under three years of age (14).']	N/A	N/A	[('CHEBI_33341', 'titanium atom', 43, 'supplements'), ('CHEBI_27300', 'vitamin D', 80, 'vitamin D')]
PMC5838372	3/2018	S25-PMC5838372	['after this success, a new nationwide Vitamin D support program was launched for Pregnant women by the ministry of health in 2011.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 37, 'vitamin D'), ('GO_0007565', 'female pregnancy', 80, 'pregnant')]
PMC5838372	3/2018	S26-PMC5838372	['this program included 1200 iu Vitamin D replacement daily to all Pregnant women from the first Trimester of Pregnancy until six months after Delivery (15).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 30, 'vitamin D'), ('GO_0007565', 'female pregnancy', 65, 'pregnant'), ('GO_0009294', 'DNA mediated transformation', 95, 'trimester'), ('GO_0007565', 'female pregnancy', 108, 'pregnancy'), ('GO_0007567', 'parturition', 141, 'delivery')]
PMC5838372	3/2018	S40-PMC5838372	['the mothers were divided into three groups according to daily Vitamin D intake; none, 400-600 iu/day and 1000-1200 Vitamin D iu/day.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 62, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 115, 'vitamin D')]
PMC5838372	3/2018	S56-PMC5838372	['the mean Vitamin D level for all women was 14.82±11.45 ng/ml.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 9, 'vitamin D')]
PMC5838372	3/2018	S59-PMC5838372	['the number of women was significantly higher in the deficient group (p<0.001), and their mean Vitamin D level was significantly lower (9.02±1.34 ng/ml) than insufficient (15.13±2.34 ng/ml) and sufficient groups (33.95±20.71 ng/ml) (p<0.001; seetable 2).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 94, 'vitamin D')]
PMC5838372	3/2018	S63-PMC5838372	['mean Vitamin D level was 13.16±7.16 ng/ml for the total group of infants.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 5, 'vitamin D')]
PMC5838372	3/2018	S66-PMC5838372	['infants were divided into three groups according to their Vitamin D levels.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 58, 'vitamin D')]
PMC5838372	3/2018	S68-PMC5838372	['mean Vitamin D level in the deficient group was 8.80±1.06 ng/ml and this level was significantly lower when compared to the insufficient (15.43±2.33 ng/ml) and sufficient groups (28.84±9.26 ng/ml; p<0.001).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 5, 'vitamin D')]
PMC5838372	3/2018	S71-PMC5838372	['mean Vitamin D levels of babies whose mothers wear covered clothing or not were 13.01 and 13.44 ng/ml, respectively.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 5, 'vitamin D')]
PMC5838372	3/2018	S73-PMC5838372	['mean Vitamin D level in infants whose mothers took no daily Vitamin D, in infants whose mothers took 400-<1000 iu and 1000-1200 iu daily were 12.13, 12.95 and 16.25 ng/ml, respectively.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 5, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 60, 'vitamin D')]
PMC5838372	3/2018	S75-PMC5838372	['also, we evaluated the infants according to mother’s Vitamin D status.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 53, 'vitamin D')]
PMC5838372	3/2018	S76-PMC5838372	['mean Vitamin D level in the infants of mothers who have deficient, insufficient and sufficient Vitamin D levels were 10.05±3.70 ng/ml, 13.06±4.09 ng/ml and 24.28±10.33 ng/ml, respectively (p<0.001) (table 4).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 5, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 95, 'vitamin D')]
PMC5838372	3/2018	S77-PMC5838372	['the pearson correlation between the mothers’ and their babies’ Vitamin D levels was significant (p<0.001) and the correlation coefficient was 0.63.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 63, 'vitamin D')]
PMC5838372	3/2018	S103-PMC5838372	['the proportion of Pregnant women who received 1000-1200 iu/day of Vitamin D was 14.4% and this low value was statistically significant.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 18, 'pregnant'), ('CHEBI_27300', 'vitamin D', 66, 'vitamin D')]
PMC5841533	2/2018	S23-PMC5841533	['the unimmap contains Vitamin A 800\u2009µg, Vitamin E 10\u2009mg, Vitamin D5Μg, Vitamin B11.4\u2009mg, vitamin B21.4\u2009mg, niacin 18\u2009mg, Vitamin B61.9\u2009mg, Vitamin B122.6\u2009µg, Folic Acid 400\u2009µg, Vitamin C 70\u2009mg, iron 30\u2009mg, zinc 15\u2009mg, copper 2\u2009mg, Selenium 65\u2009µg and Iodine 150\u2009µg.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 21, 'vitamin A'), ('CHEBI_27300', 'vitamin D', 39, 'vitamin E'), ('CHEBI_63629', 'tizanidine', 56, 'vitamin D5µg'), ('CHEBI_33237', 'vitamin D4', 70, 'vitamin B11'), ('PR_000004738', 'class E basic helix-loop-helix protein 22', 78, 'B11'), ('PR_000004693', 'Bcl-2-like protein 10', 96, 'B21'), ('CHEBI_33279', 'vitamin D5', 120, 'vitamin B61'), ('CHEBI_33237', 'vitamin D4', 138, 'vitamin B122'), ('CHEBI_30751', 'formic acid', 157, 'folic acid'), ('CHEBI_27300', 'vitamin D', 176, 'vitamin C'), ('CHEBI_27568', 'selenium atom', 230, 'selenium'), ('CHEBI_24859', 'iodine atom', 249, 'iodine')]
PMC5941617	5/2018	S5-PMC5941617	['an expert panel of the italian society of preventive and social pediatrics reviewed available literature focusing on randomized controlled trials of Vitamin D supplementation to provide a practical approach to Vitamin D supplementation for infants, children and adolescents.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 149, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 210, 'vitamin D')]
PMC5941617	5/2018	S13-PMC5941617	['once Previtamin D3Is synthesized in the skin, it can undergo also a Photoconversion to Lumisterol and Tachysterol, solar photoproducts inactive on Calcium Metabolism that are produced at times of prolonged exposure to solar uv-b radiation, to prevent sun-induced Vitamin D intoxication.']	N/A	N/A	[('PR_000014909', 'S-phase kinase-associated protein 2', 5, 'previtamin D3is'), ('GO_0007602', 'phototransduction', 68, 'photoconversion'), ('CHEBI_66555', 'laurinterol', 87, 'lumisterol'), ('CHEBI_26874', 'terpenol', 102, 'tachysterol'), ('GO_0050817', 'coagulation', 147, 'calcium'), ('GO_0008152', 'metabolic process', 155, 'metabolism'), ('CHEBI_27300', 'vitamin D', 263, 'vitamin D')]
PMC5941617	5/2018	S14-PMC5941617	['Vitamin D2And D3Are transported by Vitamin D binding protein to the Liver, where they are 25-hydroxylated by the Vitamin D-25-hydroxylase (Cyp2R1) to produce 25-Hydroxyvitamin D [25(Oh)D], the major circulating Vitamin D Metabolite which is used to evaluate individual Vitamin D status.']	N/A	N/A	[('CHEBI_67916', '2alpha,3beta,23-trihydroxylup-20(29)-en-28-oic acid', 0, 'Vitamin D2and D3are'), ('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 0, 'Vitamin D2and D3are'), ('CHEBI_27300', 'vitamin D', 35, 'vitamin D'), ('UBERON_0002107', 'liver', 68, 'liver'), ('CHEBI_27300', 'vitamin D', 113, 'vitamin D'), ('PR_000006110', 'cytochrome P450 27, mitochondrial', 139, 'CYP2R1'), ('CHEBI_62218', '23,24-dihydrocucurbitacin D', 158, '25-hydroxyvitamin D'), ('CHEBI_71657', 'versiconol acetate', 179, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 211, 'vitamin D'), ('CHEBI_39382', 'flufenoxuron', 221, 'metabolite'), ('CHEBI_27300', 'vitamin D', 269, 'vitamin D')]
PMC5941617	5/2018	S15-PMC5941617	['then 25(Oh)D reaches the Kidney, where it undergoes a further hydroxylation by 25(Oh)D-1α-hydroxylase (Cyp27B1) into 1,25-Dihydroxyvitamin D [1,25(Oh)2D or Calcitriol], the bioactive hormonal form of Vitamin D [2,4].']	N/A	N/A	[('CHEBI_71657', 'versiconol acetate', 5, '25(OH)D'), ('UBERON_0002113', 'kidney', 25, 'kidney'), ('CHEBI_71657', 'versiconol acetate', 79, '25(OH)D'), ('PR_000006101', 'cytochrome P450 1A1', 103, 'CYP27B1'), ('CHEBI_67472', '15-epi-lupulin B', 117, '1,25-dihydroxyvitamin D'), ('CHEBI_82784', 'PVP38-Ag NP', 142, '1,25(OH)2D'), ('CHEBI_17823', 'calcitriol', 156, 'calcitriol'), ('CHEBI_27300', 'vitamin D', 200, 'vitamin D')]
PMC5941617	5/2018	S18-PMC5941617	['Calcitriol acts synergistically with parathormone (pth) that acts in bone stimulating calcium absorption by the Osteoclasts, and in the Kidney where it promotes calcium reuptake in the Tubules, Phosphorus Excretion, and Vitamin D conversion into its active hormone form [2].']	N/A	N/A	[('CHEBI_17823', 'calcitriol', 0, 'Calcitriol'), ('CL_0000092', 'osteoclast', 112, 'osteoclasts'), ('UBERON_0002113', 'kidney', 136, 'kidney'), ('UBERON_0000025', 'tube', 185, 'tubules'), ('CHEBI_35885', 'secondary phosphine', 194, 'phosphorus'), ('GO_0007588', 'excretion', 205, 'excretion'), ('CHEBI_27300', 'vitamin D', 220, 'vitamin D')]
PMC5941617	5/2018	S99-PMC5941617	['in italy, few commercial Milks or yoghurts are supplemented with Vitamin D and/or Calcium.']	N/A	N/A	[('UBERON_0001913', 'milk', 25, 'milks'), ('CHEBI_27300', 'vitamin D', 65, 'vitamin D'), ('CHEBI_22313', 'alkaline earth metal atom', 82, 'calcium')]
PMC5941617	5/2018	S102-PMC5941617	['in the last years various organizations and societies [10,11,16–18,25,26,89] revised dietary reference values of Vitamin D in infants, children, and adolescents, as reported in table\xa05.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 113, 'vitamin D')]
PMC5941617	5/2018	S130-PMC5941617	['caption (table-wrap): table 6\n\nrisk factors for Vitamin D deficiency in the first year of Life• non-caucasian ethnicity with dark skin pigmentation• inadequate diets (i.e.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 48, 'vitamin D'), ('UBERON_0000104', 'life cycle', 90, 'life')]
PMC5941617	5/2018	S161-PMC5941617	['most of the studies evaluated daily Vitamin D supplementation at doses ranging from 200 to 1000\xa0iu/day [78,147–164].']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 36, 'vitamin D')]
PMC5941617	5/2018	S206-PMC5941617	['nutritional rickets is caused by Vitamin D deficiency and/or low Calcium intake in children.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 33, 'vitamin D'), ('CHEBI_22313', 'alkaline earth metal atom', 65, 'calcium')]
PMC5941617	5/2018	S215-PMC5941617	['subsequently, the clinical signs of Vitamin D deficiency (i.e.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 36, 'vitamin D')]
PMC5941617	5/2018	S245-PMC5941617	['moreover, Vitamin D stimulates Skeletal Calcium and Phosphorus and Renal calcium reabsorption.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 10, 'vitamin D'), ('UBERON_0004288', 'skeleton', 31, 'skeletal'), ('CHEBI_22313', 'alkaline earth metal atom', 40, 'calcium'), ('CHEBI_35885', 'secondary phosphine', 52, 'phosphorus'), ('GO_0006281', 'DNA repair', 67, 'renal'), ('UBERON_0002113', 'kidney', 67, 'renal')]
PMC5941617	5/2018	S246-PMC5941617	['besides the direct Regulation Of Calcium-Phosphorus Metabolism, Vitamin D also indirectly promotes bone mass accrual stimulating the Development Of Muscle Tissue [196–198].']	N/A	N/A	[('GO_0007565', 'female pregnancy', 19, 'regulation of'), ('CHEBI_30272', 'arsonium', 33, 'calcium-phosphorus'), ('GO_0050655', 'dermatan sulfate proteoglycan metabolic process', 33, 'calcium-phosphorus metabolism'), ('CHEBI_27300', 'vitamin D', 64, 'vitamin D'), ('GO_0001503', 'ossification', 133, 'development of muscle tissue'), ('UBERON_0002385', 'muscle tissue', 148, 'muscle tissue')]
PMC5941617	5/2018	S262-PMC5941617	['in 2010 a cochrane meta-analysis of 6 randomized controlled trials (rcts) [148,153,166,216–218] evaluated the effect of Vitamin D supplementation on bmd in healthy children and adolescents (age 8–17\xa0years, 541 subjects receiving Vitamin D and 343 receiving placebo) [219].']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 120, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 229, 'vitamin D')]
PMC5941617	5/2018	S266-PMC5941617	['this systematic review selected 1 prospective study [221], 3 cross-sectional studies [42,222,223], and 8 rcts of Vitamin D supplementation.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 113, 'vitamin D')]
PMC5941617	5/2018	S330-PMC5941617	['in a large french study Vitamin D deficiency was more frequent in 113 children with hiv than in 54 healthy controls [286].']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 24, 'vitamin D')]
PMC5941617	5/2018	S392-PMC5941617	['the lower intake of Vitamin D during early childhood increased the risk for disease persistence during the mild childhood [348].']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 20, 'vitamin D')]
PMC5941617	5/2018	S396-PMC5941617	['particularly, Vitamin D supplementation decreased ad severity and improved its symptoms and clinical signs.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 14, 'vitamin D')]
PMC5941617	5/2018	S447-PMC5941617	['regarding dose regimens, both oral doses of 2000\xa0iu/day of Vitamin D3And 50000\xa0iu/week of Vitamin D2For 6\xa0weeks were well-tolerated and superior to 2000\xa0iu/day of Vitamin D2In raising Serum 25(Oh)D concentration ibd patients with Vitamin D deficiency [410].']	N/A	N/A	[('CHEBI_61991', 'maltotriose trisaccharide', 59, 'vitamin D3and'), ('PR_000027594', 'histone H3', 59, 'vitamin D3and'), ('CHEBI_27364', 'zinc molecular entity', 90, 'vitamin D2for'), ('PR_000017209', 'utrophin', 90, 'vitamin D2for'), ('CHEBI_33229', 'vitamin (role)', 163, 'vitamin D2in'), ('PR_000017255', 'Vang-like protein 1', 163, 'vitamin D2in'), ('UBERON_0001977', 'blood serum', 184, 'serum'), ('CHEBI_71657', 'versiconol acetate', 190, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 190, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 230, 'vitamin D')]
PMC5941617	5/2018	S479-PMC5941617	['particularly, obese italian children and adolescents have high prevalence of Vitamin D deficiency and insufficiency [50,71,75,78–80,83,84,437,438].']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 77, 'vitamin D')]
PMC5941617	5/2018	S543-PMC5941617	['another italian study [498] examined 24 women (light and dark skinned) at full-term Pregnancy: 23 out of 24 women had Vitamin D deficiency.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 84, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 118, 'vitamin D')]
PMC5941617	5/2018	S544-PMC5941617	['similarly, both light and dark skinned babies showed Vitamin D deficiency at Birth.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 53, 'vitamin D'), ('GO_0007567', 'parturition', 77, 'birth')]
PMC5941617	5/2018	S575-PMC5941617	['studies with daily or weekly regimens\nin Vitamin D deficient infants younger than 2\xa0years, either 2000\xa0iu of Vitamin D2Or Vitamin D3Daily or 50000\xa0iu of Vitamin D2Weekly for 6\xa0weeks equally increased Serum 25(Oh)D levels [515].']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 41, 'vitamin D'), ('CHEBI_27329', 'xanthosine phosphate', 109, 'vitamin D2or'), ('PR_000017209', 'utrophin', 109, 'vitamin D2or'), ('CHEBI_63717', 'tenofovir disoproxil', 122, 'vitamin D3daily'), ('CHEBI_83468', 'isoproturon-monodemethyl', 153, 'vitamin D2weekly'), ('UBERON_0001977', 'blood serum', 200, 'serum'), ('CHEBI_71657', 'versiconol acetate', 206, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 206, '25(OH)D')]
PMC5941617	5/2018	S603-PMC5941617	['for treatment of Vitamin D deficiency in obese or ibd children see specific chapters.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 17, 'vitamin D')]
PMC5941617	5/2018	S652-PMC5941617	['treatment of nutritional rickets is based on the administration of Vitamin D (2000\xa0iu/day in patients aged less than 1\xa0year, 3000–6000\xa0iu/day in patients aged 1 to 12\xa0years and 6000\xa0iu/day in patients older than 12\xa0years for a minimum of 3\xa0months) and Calcium (30–75\xa0mg/kg/day of Elemental Calcium in 3 divided doses, starting at a higher dose and weaning down to the lower end of the range over 2–4\xa0weeks).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 67, 'vitamin D'), ('CHEBI_22313', 'alkaline earth metal atom', 252, 'calcium'), ('CHEBI_59794', 'dithioacetal', 280, 'elemental'), ('CHEBI_22313', 'alkaline earth metal atom', 290, 'calcium')]
PMC5941617	5/2018	S689-PMC5941617	['recommended Vitamin D intakes in patients with t1dm are the same as those for the healthy pediatric population.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 12, 'vitamin D')]
PMC5941617	5/2018	S723-PMC5941617	['we suggest to start Vitamin D supplementation at the beginning of Pregnancy and continue for the entire duration of Pregnancy and Lactation.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 20, 'vitamin D'), ('GO_0007565', 'female pregnancy', 66, 'pregnancy'), ('GO_0007565', 'female pregnancy', 116, 'pregnancy'), ('GO_0007595', 'lactation', 130, 'lactation')]
PMC5952272	5/2018	S21-PMC5952272	['Micronutrient supplementation includes Folic Acid tablets 3\u2009months before Pregnancy and 3\u2009months Postnatal, Vitamin A and D drops for infant starting from Birth until 12\u2009months, and Iron and Folic Acid tablets for Pregnant women 3\u2009months after Conception until 3\u2009months Postnatal.']	N/A	N/A	[('CHEBI_6956', 'Mitragynine', 0, 'Micronutrient'), ('CHEBI_30751', 'formic acid', 39, 'folic acid'), ('GO_0007565', 'female pregnancy', 74, 'pregnancy'), ('GO_0007567', 'parturition', 97, 'postnatal'), ('CHEBI_27300', 'vitamin D', 108, 'vitamin A'), ('CHEBI_52024', '4-(4-dihexadecylaminostyryl)-N-methylpyridium iodide', 122, 'D'), ('GO_0007567', 'parturition', 155, 'birth'), ('CHEBI_24870', 'ion', 182, 'iron'), ('CHEBI_30751', 'formic acid', 191, 'folic acid'), ('GO_0007565', 'female pregnancy', 214, 'pregnant'), ('GO_0007620', 'copulation', 244, 'conception'), ('GO_0007567', 'parturition', 270, 'postnatal')]
PMC5952272	5/2018	S78-PMC5952272	['immunity-related Micronutrients\n\nVitamins E and D\n\nPregnant women\nalmost 1 in every 5 women had Vitamin E deficiency.']	N/A	N/A	[('CHEBI_33839', 'macromolecule', 17, 'micronutrients'), ('CHEBI_27306', 'vitamin B6', 33, 'Vitamins E'), ('PR_000004483', 'V-type proton ATPase subunit C 1', 33, 'Vitamins E'), ('PR_000006444', 'diacylglycerol kinase delta', 48, 'D'), ('GO_0007565', 'female pregnancy', 51, 'Pregnant'), ('CHEBI_27300', 'vitamin D', 96, 'vitamin E')]
PMC5952272	5/2018	S83-PMC5952272	['an unsatisfying status was also observed for Vitamin D whose mean Serum level did not meet the reference value in any of the sub-groups, with more than two-thirds of the women being deficient.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 45, 'vitamin D'), ('UBERON_0001977', 'blood serum', 66, 'serum')]
PMC5952272	5/2018	S88-PMC5952272	['status of (a) Vitamin E and (b) Vitamin D in Pregnant women (18-43 years) by Trimester and province assessed through Serum levels.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 14, 'vitamin E'), ('CHEBI_27300', 'vitamin D', 32, 'vitamin D'), ('GO_0007565', 'female pregnancy', 45, 'pregnant'), ('GO_0009294', 'DNA mediated transformation', 77, 'trimester'), ('UBERON_0001977', 'blood serum', 117, 'serum')]
PMC5952272	5/2018	S89-PMC5952272	['reference levels – Vitamin D: deficient <25\u2009nmol/l, low <50\u2009nmol/l, sufficient >50\u2009nmol/l; Vitamin E: deficient <11.6\u2009μmol/l, low <16.2\u2009μmol/l, sufficient >16.2\u2009μmol/l.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 19, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 91, 'vitamin E')]
PMC5952272	5/2018	S90-PMC5952272	['lactating women\nthe average level of Vitamin E was adequate.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 37, 'vitamin E')]
PMC5952272	5/2018	S97-PMC5952272	['status of (a) Vitamin E and (b) Vitamin D in Lactating women (18-48 years) by province assessed through Serum levels.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 14, 'vitamin E'), ('CHEBI_27300', 'vitamin D', 32, 'vitamin D'), ('GO_0007594', 'puparial adhesion', 45, 'lactating'), ('UBERON_0001977', 'blood serum', 104, 'serum')]
PMC5952272	5/2018	S98-PMC5952272	['reference levels – Vitamin D: deficient <25\u2009nmol/l, low <50 nmol/l, sufficient >50 nmol/l; Vitamin E: deficient <11.6\u2009μmol/l, low <16.2\u2009μmol/l, sufficient >16.2\u2009μmol/l.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 19, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 91, 'vitamin E')]
PMC5952272	5/2018	S104-PMC5952272	['status of (a) Vitamin E and (b) Vitamin D status in children (6-59 months) by sex and province assessed through Plasma levels.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 14, 'vitamin E'), ('CHEBI_27300', 'vitamin D', 32, 'vitamin D'), ('UBERON_0001969', 'blood plasma', 112, 'plasma')]
PMC5952272	5/2018	S105-PMC5952272	['reference levels – Vitamin D: deficient <25\u2009nmol/l, low <50\u2009nmol/l, sufficient >50\u2009nmol/l; Vitamin E: deficient <11.6\u2009μmol/l, low <16.2\u2009μmol/l, sufficient >16.2\u2009μmol/l.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 19, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 91, 'vitamin E')]
PMC5952272	5/2018	S145-PMC5952272	['Brains of Individuals with asd display significantly lower concentrations of Serotonin compared with the Brains of non-autistic Individuals.35patrick and ames36proposed that Vitamin D (Calcitriol) activates the transcription of Serotonin-synthesizing Gene Tryptophan Hydroxylase 2 (Tph2) in the Brain and represses the transcription of Tph1 in Tissues outside the Blood-Brain barrier.']	N/A	N/A	[('UBERON_0000955', 'brain', 0, 'Brains'), ('NCBITaxon_1', 'root', 10, 'individuals'), ('CHEBI_28790', 'serotonin', 77, 'serotonin'), ('UBERON_0000955', 'brain', 105, 'brains'), ('NCBITaxon_1', 'root', 128, 'individuals'), ('CHEBI_27300', 'vitamin D', 174, 'vitamin D'), ('CHEBI_17823', 'calcitriol', 185, 'calcitriol'), ('CHEBI_28790', 'serotonin', 228, 'serotonin'), ('SO_0000704', 'gene', 251, 'gene'), ('PR_000016777', 'tau-tubulin kinase 1', 256, 'tryptophan hydroxylase 2'), ('PR_000016585', 'tripeptidyl-peptidase 1', 282, 'TPH2'), ('UBERON_0000955', 'brain', 295, 'brain'), ('PR_000016585', 'tripeptidyl-peptidase 1', 336, 'TPH1'), ('UBERON_0000479', 'tissue', 344, 'tissues'), ('UBERON_0000178', 'blood', 364, 'blood'), ('UBERON_0000955', 'brain', 370, 'brain')]
PMC5956785	5/2018	S17-PMC5956785	['Cytochrome P450 27B1 (Cyp27B1) is the enzyme required to synthesize 1,25-Dihydroxyvitamin D (1,25(Oh)2D), the active form of Vitamin D, from circulating 25-Hydroxyvitamin D (25(Oh)D).']	N/A	N/A	[('CHEBI_4056', 'cytochrome', 0, 'Cytochrome'), ('PR_000006139', 'cytochrome P450 4F12', 0, 'Cytochrome p450 27B1'), ('PR_000006101', 'cytochrome P450 1A1', 22, 'CYP27B1'), ('CHEBI_67472', '15-epi-lupulin B', 68, '1,25-dihydroxyvitamin D'), ('CHEBI_82784', 'PVP38-Ag NP', 93, '1,25(OH)2D'), ('CHEBI_27300', 'vitamin D', 125, 'vitamin D'), ('CHEBI_62218', '23,24-dihydrocucurbitacin D', 153, '25-hydroxyvitamin D'), ('CHEBI_71657', 'versiconol acetate', 174, '25(OH)D')]
PMC5956785	5/2018	S18-PMC5956785	['the actions of 1,25(Oh)2D are mediated by its binding to the Vitamin D receptor (vdr), a Nuclear transcription factor.']	N/A	N/A	[('CHEBI_82784', 'PVP38-Ag NP', 15, '1,25(OH)2D'), ('CHEBI_27300', 'vitamin D', 61, 'vitamin D'), ('GO_0005634', 'nucleus', 89, 'nuclear')]
PMC5956785	5/2018	S19-PMC5956785	['vdr then binds to the Vitamin D response element (vdre), a Genetic sequence located in the Promotor Region of Genes Regulated by Vitamin D [7–9].']	N/A	N/A	[('CHEBI_28384', 'vitamin K', 22, 'Vitamin D'), ('SO_0000704', 'gene', 59, 'genetic'), ('SO_0000167', 'promoter', 91, 'promotor region'), ('SO_0000704', 'gene', 110, 'genes'), ('GO_0065007', 'biological regulation', 116, 'regulated'), ('CHEBI_27300', 'vitamin D', 129, 'vitamin D')]
PMC5956785	5/2018	S39-PMC5956785	['medical subject heading (mesh) terms used for retrieval were “Vitamin D” and “juvenile arthritis”.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 62, 'vitamin D')]
PMC5956785	5/2018	S42-PMC5956785	['publication titles and abstracts were then screened for relevance to the subject of Vitamin D in children with idiopathic chronic arthritis as defined by jia, jca, or jra classification criteria [2,3,17].']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 84, 'vitamin D')]
PMC5956785	5/2018	S72-PMC5956785	['using the specified mesh search terms (Vitamin D and childhood arthritis), 386 reports (full-text articles, conference abstracts, and letters to the editor) were identified.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 39, 'vitamin D')]
PMC5956785	5/2018	S80-PMC5956785	['2001 39°n [40]jian\u2009=\u200910 (6f)13.1\u2009±\u20092.553.9\u2009±\u20098.5all patients were Vitamin D replete 25(Oh)D\u2009>\u200917.5\xa0nmol/l, most were measured between february to may.missouri, usa hillman et al.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 66, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 84, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 84, '25(OH ... D')]
PMC5956785	5/2018	S93-PMC5956785	['active disease or frequent flare-ups resulted in lower Vitamin D than non-active and no frequent flare-ups.control group 25(Oh)D 74.4\u2009±\u200928.0\xa0nmol/l p \u2009<\u20090.005.intake jia 164\u2009±\u200984\xa0iu/day control 160\u2009±\u200972\xa0iu/day.new delhi, india dey et al.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 55, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 121, '25(OH)D')]
PMC5956785	5/2018	S97-PMC5956785	['no correlation between disease activity, type of jia or Metabolites of Vitamin D.control n \u2009=\u200928 age, gender matched, hospitalized children 43.4\u2009±\u200940.7\xa0nmol/l.sao paulo, brazil munekata et al.']	N/A	N/A	[('CHEBI_25212', 'metabolite', 56, 'metabolites'), ('CHEBI_27300', 'vitamin D', 71, 'vitamin D')]
PMC5956785	5/2018	S102-PMC5956785	['2000 51°n [49]jca n \u2009=\u200934 (23f)9.2 (4.6–13.6)estimated from graph\xa045 (14.5–62.5)Vitamin D status was significantly lower in jca patients than age-matched controls before treatment, Steroid-treated children have low Vitamin D. all but three children received Corticosteroids.control group 25(Oh)D estimate 75\xa0nmol/l.florence, italy falcini et al.']	N/A	N/A	[('CHEBI_28384', 'vitamin K', 80, 'Vitamin D'), ('CHEBI_35341', 'steroid', 181, 'Steroid'), ('CHEBI_27300', 'vitamin D', 215, 'vitamin D'), ('CHEBI_50850', 'etabonate ester', 258, 'corticosteroids'), ('CHEBI_71657', 'versiconol acetate', 288, '25(OH)D'), ('PR_000008838', 'serine protease HTRA1', 288, '25(OH ... D')]
PMC5956785	5/2018	S114-PMC5956785	['2013 conference abstract 41°n [30]jia n \u2009=\u200940 (31)22.3 (4–63)10\u2009>\u200975\xa0nmol/l, 19 between 50 and 75\xa0nmol/l, 11\u2009<\u200920\xa0nmol/lprevalence of Vitamin D deficiency/insufficiency among jia patients is very high.antalya, turkey comak et al.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 134, 'vitamin D')]
PMC5956785	5/2018	S124-PMC5956785	['2012 60°n [37]jian\u2009=\u200950 (41)14.8 (7.0–18.7)53\xa0nmol/l (20–95\xa0nmol/l)62% sufficient, 24% insufficient and 14% deficient.52% taking Vitamin D supplement % of dri median and iqr 187 (57,331).saskatchewan, canada mcnally et al.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 129, 'vitamin D')]
PMC5956785	5/2018	S128-PMC5956785	['1993 40°n [42]jra n \u2009=\u200927 (23)2.9–1684.9\u2009±\u200911.0no difference in Vitamin D status between active and inactive groups.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 64, 'vitamin D')]
PMC5956785	5/2018	S166-PMC5956785	['above 33° latitude uvb radiation is not intense enough for the Cutaneous Synthesis Of Vitamin D all year long [63,64].']	N/A	N/A	[('GO_0050817', 'coagulation', 63, 'cutaneous'), ('GO_0030474', 'spindle pole body duplication', 73, 'synthesis of vitamin D'), ('CHEBI_27300', 'vitamin D', 86, 'vitamin D')]
PMC5956785	5/2018	S190-PMC5956785	['as latitude increases more studies report a difference in Vitamin D status between patients with active versus inactive disease in comparison to lower latitudes as illustrated in fig.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 58, 'vitamin D')]
PMC5956785	5/2018	S196-PMC5956785	['this is the amount of Vitamin D that is expected to be sufficient for 50% of the population [19].']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 22, 'vitamin D')]
PMC5956785	5/2018	S224-PMC5956785	['these patients were found to be Consuming significantly less Vitamin D and had less sun exposure compared to healthy controls [31].']	N/A	N/A	[('GO_0007631', 'feeding behavior', 32, 'consuming'), ('CHEBI_27300', 'vitamin D', 61, 'vitamin D')]
PMC5956785	5/2018	S246-PMC5956785	['the use of Vitamin D and Fish Oil during Pregnancy in case mothers was not significantly different from controls following covariate adjustments [80].']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 11, 'vitamin D'), ('CHEBI_34766', 'Furamizole', 25, 'fish oil'), ('GO_0007565', 'female pregnancy', 41, 'pregnancy')]
PMC5995352	6/2018	S1-PMC5995352	['an odense child cohort study\n\nabstract\n\nbackground and aim\nlong standing Vitamin D deficiency in children causes rickets with growth impairment.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 73, 'vitamin D')]
PMC5995352	6/2018	S24-PMC5995352	['in Pregnancy, an increase in the active Vitamin D Calcitriol (1,25(Oh)2D) ensures Calcium and Phosphate supply to the foetus.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 3, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 40, 'vitamin D'), ('CHEBI_17823', 'calcitriol', 50, 'calcitriol'), ('CHEBI_17996', 'chloride', 63, ','), ('CHEBI_66212', "5,7,3',4'-tetrahydroxy-2'-(3,3-dimethylallyl)isoflavone", 64, '25(OH)2D'), ('CHEBI_22313', 'alkaline earth metal atom', 82, 'calcium'), ('CHEBI_18367', 'phosphate(3-)', 94, 'phosphate')]
PMC5995352	6/2018	S25-PMC5995352	['in foetal Life, Parathyroid-Hormone-Related Protein (Pthrp) is the primary regulator of the Mineral Homeostasis and Bone Mineralization, which in the foetus is independent of maternal Vitamin D and occurs uncomplicated as long as sufficient Calcium and Phosphorous is supplied from the maternal circulation across the Placenta.']	N/A	N/A	[('UBERON_0000104', 'life cycle', 10, 'life'), ('PR_000012233', 'P antigen family member 4', 16, 'parathyroid-hormone-related protein'), ('UBERON_0001132', 'parathyroid gland', 16, 'parathyroid'), ('PR_000013439', 'prostate tumor-overexpressed gene 1 protein', 53, 'PTHrP'), ('CHEBI_46662', 'mineral', 92, 'mineral'), ('GO_0042592', 'homeostatic process', 100, 'homeostasis'), ('GO_0030282', 'bone mineralization', 116, 'bone mineralization'), ('CHEBI_27300', 'vitamin D', 184, 'vitamin D'), ('CHEBI_22313', 'alkaline earth metal atom', 241, 'calcium'), ('CHEBI_30207', 'phosphorus(.)', 253, 'phosphorous'), ('UBERON_0001987', 'placenta', 318, 'placenta')]
PMC5995352	6/2018	S26-PMC5995352	['this transport is independent of active Vitamin D [9,10].']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 40, 'vitamin D')]
PMC5995352	6/2018	S27-PMC5995352	['maternal 25Ohd crosses the Placenta and, as the Foetus has no endogenous synthesis of 25Ohd, maternal Vitamin D insufficiency during Pregnancy implies Vitamin D insufficiency in the new Born.']	N/A	N/A	[('CHEBI_72652', "7,2'-dihydroxy-4'-methoxyisoflavan-4-ylium cation", 9, '25OHD'), ('UBERON_0001987', 'placenta', 27, 'placenta'), ('UBERON_0000376', 'hindlimb stylopod', 48, 'foetus'), ('CHEBI_72652', "7,2'-dihydroxy-4'-methoxyisoflavan-4-ylium cation", 86, '25OHD'), ('CHEBI_27300', 'vitamin D', 102, 'vitamin D'), ('GO_0007565', 'female pregnancy', 133, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 151, 'vitamin D'), ('GO_0007567', 'parturition', 186, 'born')]
PMC5995352	6/2018	S60-PMC5995352	['time spent outdoors during Pregnancy and Vitamin D supplementation during Pregnancy was self-reported in a questionnaire at 28 weeks of Gestation.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 27, 'pregnancy'), ('CHEBI_27300', 'vitamin D', 41, 'vitamin D'), ('GO_0007565', 'female pregnancy', 74, 'pregnancy'), ('GO_0007565', 'female pregnancy', 136, 'gestation')]
PMC5995352	6/2018	S169-PMC5995352	['[45] observed no association between maternal 25Ohd sampled at 26–28 weeks Gestation and offspring length z-scores at 18 months in 596 children of mixed ethnicity from singapore with a lower rate of Vitamin D insufficiency (25%) and deficiency (6%) compared to our mothers (40% insufficient and 17% deficient).']	N/A	N/A	[('CHEBI_72652', "7,2'-dihydroxy-4'-methoxyisoflavan-4-ylium cation", 46, '25OHD'), ('GO_0007565', 'female pregnancy', 75, 'gestation'), ('CHEBI_27300', 'vitamin D', 199, 'vitamin D')]
PMC5995352	6/2018	S184-PMC5995352	['conclusion\nin a healthy child population with very few having Vitamin D deficiency, lower 25Ohd did not associate with reduced Leg length.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 62, 'vitamin D'), ('CHEBI_72652', "7,2'-dihydroxy-4'-methoxyisoflavan-4-ylium cation", 90, '25OHD'), ('UBERON_0000978', 'leg', 127, 'leg')]
PMC6011374	6/2018	S5-PMC6011374	['results\nmean Serum 25(Oh)D in all women was 68.1\u2009±\u200927.1\xa0nmol/l and 28% ( n \u2009=\u2009772) were considered Vitamin D deficient (<\u200950\xa0nmol/l).']	N/A	N/A	[('UBERON_0001977', 'blood serum', 13, 'serum'), ('CHEBI_71657', 'versiconol acetate', 19, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 19, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 99, 'vitamin D')]
PMC6011374	6/2018	S7-PMC6011374	['a 53% decreased risk for Gestational diabetes mellitus (gdm) was observed with high (>\u200981\xa0nmol/l) “standardised” Vitamin D status when compared to moderate-high (63–81\xa0nmol/l, arr, 0.47; 95% ci: 0.23, 0.96).']	N/A	N/A	[('GO_0007565', 'female pregnancy', 25, 'gestational'), ('CHEBI_27300', 'vitamin D', 113, 'vitamin D')]
PMC6011374	6/2018	S8-PMC6011374	['marginal sex-specific differences occurred between Vitamin D status and gdm: women carrying a female fetus had a 56% decreased risk for gdm in those with low-moderate levels of standardised Vitamin D (44–63\xa0nmol/l) compared to moderate-high levels (arr: 0.44; 95% ci: 0.20, 0.97), whilst in women carrying a male fetus, a 55% decreased risk of gdm was found with high standardised Vitamin D when compared to moderately-high Vitamin D, but this was not statistically significant (arr: 0.45; 95% ci: 0.15, 1.38).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 51, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 190, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 381, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 424, 'vitamin D')]
PMC6011374	6/2018	S20-PMC6011374	['studies focused on high-risk populations, for example, veiled, dark-skinned or obese women in australia and new zealand, report between 50 and 94% of women to be Vitamin D deficient [8–10].']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 162, 'vitamin D')]
PMC6011374	6/2018	S51-PMC6011374	['briefly, Vitamin D concentrations were standardized by taking the difference of 25(Oh)D concentration to the average 25(Oh)D concentration of the corresponding month.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 9, 'vitamin D'), ('CHEBI_71657', 'versiconol acetate', 80, '25(OH)D'), ('CHEBI_71657', 'versiconol acetate', 117, '25(OH)D')]
PMC6011374	6/2018	S54-PMC6011374	['potential confounders for Vitamin D status were assessed using linear modelling.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 26, 'vitamin D')]
PMC6011374	6/2018	S56-PMC6011374	['these analyses were also repeated but using the current definitions of Vitamin D deficiency: <\u200925, 25–50, 50–75 and\u2009>\u200975\xa0nmol/l in the non-standardised data [7].']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 71, 'vitamin D')]
PMC6011374	6/2018	S65-PMC6011374	['average hours of sunlight per day in adelaide from september 2005 to september 2008 were obtained from the australian government bureau of meteorology and compared against Serum Vitamin D measured in the women recruited in adelaide (fig.']	N/A	N/A	[('UBERON_0001977', 'blood serum', 172, 'serum'), ('CHEBI_27300', 'vitamin D', 178, 'vitamin D')]
PMC6011374	6/2018	S71-PMC6011374	['seasonal variation in Vitamin D followed a similar pattern to hours of sunlight although was slightly shifted.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 22, 'vitamin D')]
PMC6011374	6/2018	S76-PMC6011374	['using moderate-high as a reference (standardised Vitamin D 63–81\xa0nmol/l), there was no appreciable effect of having a low, low-moderate or high Vitamin D with the risk of developing any Pregnancy complication after adjusting for confounders.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 49, 'vitamin D'), ('CHEBI_27300', 'vitamin D', 144, 'vitamin D'), ('GO_0007565', 'female pregnancy', 186, 'pregnancy')]
PMC6011374	6/2018	S78-PMC6011374	['when women were categorised based on clinical definitions of Vitamin D deficiency and Serum 25(Oh)D between 50 and 75\xa0nmol/l used as the reference, no significant relationship between Vitamin D status and adverse Pregnancy outcome was found (table2).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 61, 'vitamin D'), ('UBERON_0001977', 'blood serum', 86, 'serum'), ('CHEBI_71657', 'versiconol acetate', 92, '25(OH)D'), ('PR_000008775', 'estradiol 17-beta-dehydrogenase 11', 92, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 184, 'vitamin D'), ('GO_0007565', 'female pregnancy', 213, 'pregnancy')]
PMC6011374	6/2018	S85-PMC6011374	['similar results were observed when Vitamin D status was based on clinical definitions of deficiency (additional file1: table s1).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 35, 'vitamin D')]
PMC6011374	6/2018	S104-PMC6011374	['the Placenta Expresses all the necessary components to convert 25(Oh)D to the active form and thus utilise active Vitamin D either locally or in a paracrine manner [45,47].']	N/A	N/A	[('UBERON_0001987', 'placenta', 4, 'placenta'), ('GO_0010467', 'gene expression', 13, 'expresses'), ('CHEBI_71657', 'versiconol acetate', 63, '25(OH)D'), ('CHEBI_27300', 'vitamin D', 114, 'vitamin D')]
PMC6011374	6/2018	S114-PMC6011374	['however, routine Vitamin D supplementation did not occur during the time period the women in the current study were recruited.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 17, 'vitamin D')]
PMC6011374	6/2018	S117-PMC6011374	['for example, active Vitamin D (1,25-Dihydroxyvitamin D3) is the principal hormone that Regulates calcium absorption within the Intestine [53] and is integral to maintaining Calcium Homeostasis.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 20, 'vitamin D'), ('CHEBI_63912', '19-hydroxyprostaglandin H2', 31, '1,25-dihydroxyvitamin D3'), ('PR_000001177', 'D(2) dopamine receptor', 53, 'D3'), ('GO_0065007', 'biological regulation', 87, 'regulates'), ('UBERON_0000160', 'intestine', 127, 'intestine'), ('GO_0055073', 'cadmium ion homeostasis', 173, 'calcium homeostasis')]
PMC6011374	6/2018	S124-PMC6011374	['adjusted relative risks (arr) of Pregnancy complications from any complication, preeclampsia (pe), Gestational hypertension (gh), Gestational diabetes mellitus (gdm), spontaeous preterm Birth (sptb) and small-for-Gestational age (sga) according to Vitamin D status and stratified by fetal sex.']	N/A	N/A	[('GO_0007565', 'female pregnancy', 33, 'pregnancy'), ('GO_0007565', 'female pregnancy', 99, 'gestational'), ('GO_0007565', 'female pregnancy', 130, 'gestational'), ('GO_0007567', 'parturition', 186, 'birth'), ('GO_0007565', 'female pregnancy', 213, 'gestational'), ('CHEBI_27300', 'vitamin D', 248, 'vitamin D')]
PMC6039335	7/2018	S252-PMC6039335	['Vitamin A\nrestricting Vitamin A intake increases imf deposition.']	N/A	N/A	[('PR_000017319', 'vacuolar protein sorting-associated protein 13A', 0, 'Vitamin A'), ('CHEBI_27300', 'vitamin D', 22, 'vitamin A')]
PMC6039335	7/2018	S257-PMC6039335	['a study of Angus-crossbred steers showed that Animals not supplemented with Vitamin A had higher ms and qg compared to Vitamin A-supplemented Animals [132].']	N/A	N/A	[('NCBITaxon_10088', 'Mus <genus>', 11, 'Angus'), ('NCBITaxon_33208', 'Metazoa', 46, 'animals'), ('CHEBI_27300', 'vitamin D', 76, 'vitamin A'), ('CHEBI_27300', 'vitamin D', 119, 'vitamin A'), ('NCBITaxon_33208', 'Metazoa', 142, 'animals')]
PMC6039335	7/2018	S258-PMC6039335	['the same authors reported that exclusion of a Vitamin A supplement induced hyperplasia in imf, but not in the Subcutaneous Fat Depot.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 46, 'vitamin A'), ('UBERON_0002190', 'subcutaneous adipose tissue', 110, 'subcutaneous fat depot')]
PMC6039335	7/2018	S259-PMC6039335	['the lack of Vitamin A supplementation also increased marbling compared with Vitamin A supplementation in a study of angus crossbred steers [133].']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 12, 'vitamin A'), ('CHEBI_27300', 'vitamin D', 76, 'vitamin A')]
PMC6039335	7/2018	S273-PMC6039335	['the cattle with a tt genotype (approximately 6.15%) that were not supplemented with Vitamin A had 22.9% greater imf compared with those with the cc genotype (approximately 4.95%).']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 84, 'vitamin A')]
PMC6039335	7/2018	S277-PMC6039335	['1,25-Dihydroxyvitamin D3(active form of Vitamin D) inhibits Preadipocyte differentiation [141] and suppresses Adipogenic Pparg Gene Expression in 3t3 l1 cells [142].']	N/A	N/A	[('CHEBI_86320', '1alpha,25-dihydroxyvitamin D2', 0, '1,25-Dihydroxyvitamin D3'), ('CHEBI_27300', 'vitamin D', 40, 'vitamin D'), ('CL_0002334', 'preadipocyte', 60, 'preadipocyte'), ('GO_0060612', 'adipose tissue development', 110, 'adipogenic'), ('PR_000013057', 'peroxisome proliferator-activated receptor delta', 121, 'PPARG'), ('GO_0010467', 'gene expression', 127, 'gene expression'), ('SO_0000704', 'gene', 127, 'gene')]
PMC6039335	7/2018	S292-PMC6039335	['in vivo studies showed increased marbling in response to dietary Vitamin C supplementation in beef cattle; dietary supplementation of Rumen-protected L-Ascorbic Acid-2-Phosphate during the final fattening period increased both ms and fat content in Carcasses of japanese black cattle [150].']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 65, 'vitamin C'), ('UBERON_0007365', 'rumen', 134, 'rumen'), ('CHEBI_30882', '2-oxoglutaramic acid', 150, 'l-ascorbic acid'), ('CHEBI_18367', 'phosphate(3-)', 168, 'phosphate'), ('UBERON_0008979', 'carcass', 249, 'carcasses')]
PMC6039335	7/2018	S293-PMC6039335	['supplementing Rumen-protected Vitamin C in a high sulfur diet increased the ms and the percentage of choice grade beef in angus cross steers [151].']	N/A	N/A	[('UBERON_0007365', 'rumen', 14, 'rumen'), ('CHEBI_27300', 'vitamin D', 30, 'vitamin C')]
PMC6043562	7/2018	S6-PMC6043562	['feno levels were lower with higher intakes of Prenatal Vitamin D (−16.15%, 95% ci: −20.38 to −2.88%), Folate from Foods (−3.86%, 95% ci: −8.33 to 0.83%) and N-3 Pufas (−9.21%, 95% ci −16.81 to −0.92%).']	N/A	N/A	[('GO_0007565', 'female pregnancy', 46, 'prenatal'), ('CHEBI_27300', 'vitamin D', 55, 'vitamin D'), ('CHEBI_30863', '5-azaorotic acid', 102, 'folate'), ('CHEBI_33290', 'food', 114, 'foods'), ('CHEBI_30256', 'thiocarbonyl group', 157, 'n-3'), ('CHEBI_86926', 'S a S b S', 161, 'PUFAs')]
PMC6043562	7/2018	S69-PMC6043562	['2), with a relatively flat dose-response at lower Vitamin D levels, and a decreasing linear slope from moderate to high Vitamin D levels.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 50, 'vitamin D'), ('CHEBI_28384', 'vitamin K', 120, 'Vitamin D')]
PMC6043562	7/2018	S72-PMC6043562	['the point estimate for Prenatal Vitamin E intake from Food and supplements combined was 6.94% (95% ci −2.36 to 12.24%) for the feno outcome (table\xa04), which was much larger than the Vitamin E estimate from diet alone (table\xa03).']	N/A	N/A	[('GO_0007565', 'female pregnancy', 23, 'prenatal'), ('CHEBI_27300', 'vitamin D', 32, 'vitamin E'), ('CHEBI_33290', 'food', 54, 'food'), ('CHEBI_27300', 'vitamin D', 182, 'vitamin E')]
PMC6043562	7/2018	S223-PMC6043562	['Prenatal maternal exposures of interest were residence-specific Air Pollutants (3rdtrimester bc or Pm2.5,) and Nutrient intakes (1stand 2ndtrimester averaged energy-adjusted dietary intakes of Vitamins D, c, and e, Β-Carotene, Folate, Choline, and N-3 and N-6 polyunsaturated Fatty Acids).']	N/A	N/A	[('GO_0007565', 'female pregnancy', 0, 'Prenatal'), ('CHEBI_35086', 'm-Benzenesulfonium diazonium chloride', 64, 'air'), ('CHEBI_26199', 'polyprenol', 68, 'pollutants'), ('CHEBI_8102', 'phenylmethanesulfonyl fluoride', 99, 'PM2'), ('CHEBI_33284', 'nutrient', 111, 'nutrient'), ('CHEBI_27300', 'vitamin D', 193, 'vitamins D'), ('CHEBI_28064', 'cyanidin 3-O-rutinoside', 215, 'β-carotene'), ('CHEBI_30863', '5-azaorotic acid', 227, 'folate'), ('CHEBI_15354', 'choline', 235, 'choline'), ('CHEBI_30256', 'thiocarbonyl group', 248, 'n-3'), ('CHEBI_18320', '1,4-dithiothreitol', 256, 'n-6'), ('CHEBI_35366', 'fatty acid', 276, 'fatty acids')]
PMC6043562	7/2018	S226-PMC6043562	['in our bkmr model specification, we grouped the exposures into 3 different groups, Vitamin E and Β-Carotene (group 1), all of the other Nutrients (group 2), and the air Pollutant (either Pm2.5orbc) exposure (group 3) and conducted hierarchical variable selection on these groups of exposures.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 83, 'vitamin E'), ('CHEBI_28660', '(-)-alpha-pinene', 97, 'β-Carotene'), ('CHEBI_33284', 'nutrient', 136, 'nutrients'), ('CHEBI_75260', 'penicillinate salt', 169, 'pollutant'), ('CHEBI_8102', 'phenylmethanesulfonyl fluoride', 187, 'PM2')]
PMC6056931	7/2018	S28-PMC6056931	['hence, not surprisingly, 31% and 13% of south african women of Reproductive age are anaemic [22] and Vitamin A deficient [18], respectively, while 68% of women are overweight or obese, and 46% hypertensive [22].']	N/A	N/A	[('GO_0000003', 'reproduction', 63, 'reproductive'), ('CHEBI_27300', 'vitamin D', 101, 'vitamin A')]
PMC6056931	7/2018	S204-PMC6056931	['the iron status indices, ferritin and Transferrin receptor, as well as the Vitamin A status indicator Retinol binding protein will be determined using the q-plex™ Human Micronutrient array (7-plex, quansys bioscience, logan, ut, usa) [69].']	N/A	N/A	[('PR_000016293', 'protein-glutamine gamma-glutamyltransferase 2', 38, 'transferrin'), ('CHEBI_27300', 'vitamin D', 75, 'vitamin A'), ('CHEBI_26536', 'retinoic acid', 102, 'retinol'), ('NCBITaxon_10088', 'Mus <genus>', 163, 'Human'), ('CHEBI_6956', 'Mitragynine', 169, 'Micronutrient')]
PMC6056931	7/2018	S238-PMC6056931	['data will then be screened by means of range checks and for outliers in total energy, protein, fat, Vitamin A and Vitamin C intake.']	N/A	N/A	[('CHEBI_27300', 'vitamin D', 100, 'vitamin A'), ('CHEBI_27300', 'vitamin D', 114, 'vitamin C')]
